<SEC-DOCUMENT>0000886163-24-000009.txt : 20240229
<SEC-HEADER>0000886163-24-000009.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229161614
ACCESSION NUMBER:		0000886163-24-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		24703870

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lgnd-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lgnd="http://www.ligand.com/20231231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="c-16" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-265">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-532">P1Y0M0D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-114" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-620">12.50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-115" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-621">2.08</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-878">http://www.ligand.com/20231231#NonCashChangeInEstimatedFairValueOfContingentValueRights</ix:nonNumeric><ix:nonNumeric contextRef="c-15" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="f-882">http://fasb.org/us-gaap/2023#GainLossOnInvestments</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-926">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-927">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-1191">P1Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="c-344" name="lgnd:ShareBasedCompensationInitialOfferingPeriod" id="f-1520">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>lgnd:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lgnd:right</xbrli:measure></xbrli:unit><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>lgnd:contract</xbrli:measure></xbrli:unit><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:BelowMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:AboveMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquityMethodInvestmentsAllocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquitySecuritiesAllocationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:DerivativeAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-27</xbrli:startDate><xbrli:endDate>2023-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-27</xbrli:startDate><xbrli:endDate>2023-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="pure"><xbrli:measure>lgnd:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:SoticlestatMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cvr"><xbrli:measure>lgnd:cvr</xbrli:measure></xbrli:unit><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">lgnd:NotesRepurchasedDuringCurrentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">lgnd:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">lgnd:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>lgnd:position</xbrli:measure></xbrli:unit><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>lgnd:agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgnd:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-31</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>lgnd:complaint</xbrli:measure></xbrli:unit><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.276%"><tr><td style="width:1.0%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.024%"><tr><td style="width:1.0%"/><td style="width:2.857%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33093</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><img src="lgnd-20231231_g1.jpg" alt="Logo_2023.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:284px"/></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.661%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">555 Heritage Drive, Suite 200</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Jupiter</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">33458</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">550-7500</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.482%"><tr><td style="width:1.0%"/><td style="width:36.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ndicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in Rule 12b-2 of the Exchange Act. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.547%"><tr><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-23">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;Filer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;Filer&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the Registrant&#8217;s voting and non-voting stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="f-29">0.9</ix:nonFraction> billion based on the last sales price of the Registrant&#8217;s Common Stock on the Nasdaq Global Market of the Nasdaq Stock Market LLC on June&#160;30, 2023. For purposes of this calculation, shares of Common Stock held by directors, officers and 10% stockholders known to the Registrant have been deemed to be owned by affiliates which should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant or that such person is controlled by or under common control with the Registrant.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;26, 2024, the Registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">17,705,287</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the Registrant&#8217;s 2024 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2023 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</span></div></ix:nonNumeric><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.766%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_16">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_19">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_799">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_799">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_22">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_25">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_28">45</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_34">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_37">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_37">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_40">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_52">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_52">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_55">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_55">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_124">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_124">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_127">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_127">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_133">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_127">95</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_139">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_139">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_142">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_142">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_145">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_145">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_148">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_148">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_151">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_151">100</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_157">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_157">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_160">Form 10-K - Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_157">101</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_163">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_163">105</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.170%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GLOSSARY OF TERMS AND ABBREVIATIONS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abbreviation</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$750.0 million aggregate principal amount of convertible senior unsecured notes due 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldeyra Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo Med, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter International, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BeiGene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BeiGene, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx Corp.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BLA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biologics license application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cGMP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Good Manufacturing Practice</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Note</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Convertible Promissory Note</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COPD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix Cardiovascular, Inc. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement, dated as of October 12, 2023, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein), and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CVR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent value right</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo Company, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dianomi Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DMF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Master File</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental, Social and Governance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extracellular matrix</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental Protection Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan, as amended and restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FSGS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Focal segmental glomerulosclerosis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's fiscal year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's fiscal year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's fiscal year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Generally accepted accounting principles in the United States</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GCSF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granulocyte-colony stimulating factor</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead Sciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HBV</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hepatitis B Virus</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma Pharmaceuticals PLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hovione</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hovione FarmCiencia, S.A.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intramuscular</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational New Drug</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liver targeting prodrug</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOLs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan, Inc. (n/k/a NVN Liquidation, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb Operations, Inc. (f/k/a OmniAb, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono Pharmaceutical Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orange Book</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Publication identifying drug products approved by the FDA based on safety and effectiveness</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PDUFA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue Repair</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The revolving credit facility under the Credit Agreement</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSU </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi SA</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selective Androgen Receptor Modulator</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor Pharmaceuticals, Inc., or RODES, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis, SA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix Pharmaceuticals, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SII</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serum Institute of India</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda Pharmaceuticals Company Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Act</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Tax Cuts and Jobs Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Actavis, LLC </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR-Beta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thyroid hormone receptor beta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis plc</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona Pharma plc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking Therapeutics</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong Medicine Research</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydus Cadila Healthcare, Ltd</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as those related to our future results of operations and financial position, royalties and milestones under license agreements, Captisol material sales, product development, and product regulatory filings and approvals, and the timing thereof, Ligand's status as a high-growth company, as well as other statements that are not historical. You should be aware that the occurrence of any of the events discussed under the caption &#8220;Risk Factors&#8221; could negatively affect our results of operations and financial condition and the trading price of our stock.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section&#160;21E of the Securities Exchange Act of 1934, as amended.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to &#8220;Ligand Pharmaceuticals Incorporated,&#8221; &#8220;Ligand,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Partner Information</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding partnered products and programs comes from information publicly released by our partners and licensees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Trademarks</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Annual Report on Form 10-K includes trademarks, trade names and service marks owned by us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ligand&#174;, BEPro&#8482;, Captisol&#174;, CyDex&#174;, LTP&#174;, LTP Technology&#174;, NITRICIL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and ZELSUVMI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">are protected under applicable intellectual property laws and are our property. All other trademarks, trade names and service marks including, but not limited to Pelican Expression Technology&#174;, PeliCRM&#174;, Pfenex Expression Technology&#174;, OmniAb&#174; Kyprolis&#174;, Evomela&#174;, Veklury&#174;, Livogiva&#174;, Bonteo&#174;, Zulresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Rylaze&#174;, VAXNEUVANCE&#8482;, Pneumosil&#174;, Minnebro&#174;, Baxdela&#174;, Nexterone&#174;, Noxafil&#174;, Duavee&#174;, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FILSPARI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the &#174;, &#8482; or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to such trademarks, trade names and service marks. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world&#8217;s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of three primary elements: royalties from commercialized products, sales of our Captisol material to partners, and contract revenue from license fees and milestones payments. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Strategy and Execution</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical royalty aggregator, focused on investing in differentiated late-stage assets and operating royalty-generating, infrastructure-light platform technologies. Since our transition to this business model in 2007, we have deployed over $1 billion of capital to build our diverse portfolio. Following the spin-offs of our OmniAb antibody discovery business in November 2022 and the Pelican Expression Technology subsidiary in September 2023, our strategy is to continue to expand our pipeline by aggregating royalty rights in mid- to late-stage development and commercial biopharma products, while maintaining a lean infrastructure and high-margin business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is highly differentiated from a traditional biotechnology company in several key ways. First, we have limited infrastructure requirements, enabling us to maintain relative high operating margins. Second, we can enable development over a broad range of therapeutic areas and can be strategic and balanced about the size of our investments to achieve a highly diversified portfolio. Third, our business model mitigates the high volatility associated with building a business around a single or small number of assets. With this approach, we have the ability to mitigate the impact of binary clinical outcomes in the biopharmaceutical industry, thereby facilitating cash flows that are more predictable. Finally, we can target the size of our investments to achieve appropriate risk management across the portfolio.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an organization, we bring a highly experienced team and financial strength to execute on our strategy. There is high demand for capital and low availability of structured capital in the segment of the biopharmaceutical market in which we operate, creating significant deal flow opportunity for Ligand. Unlike open-market equity investing, many of our investments take place under Confidential Disclosure Agreements (CDAs), allowing us access to in-depth, advantageous diligence materials. Our flexible investment structures are designed to mitigate risks, and also help accommodate different transaction structures based on our partners' goals. We believe our business model is highly scalable and has significant growth potential. We have assembled a talented, long-tenured team with deep industry relationships, investment experience and industry knowledge. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From a more tactical perspective, we execute our strategy using four key approaches: royalty monetization, M&amp;A, project finance, and platform investments. With royalty monetization, we purchase rights on existing royalty contracts that are owned by inventors, academic institutions or companies. There are advantages of royalty investing as a model since royalties 1) have minimal infrastructure, 2) are non-dilutive and 3) their cash flows are often protected in bankruptcy. In M&amp;A investments, we acquire companies with valuable assets or partnerships and realize the value of those assets by restructuring operations and/or partnering the assets. Ligand has a history of doing this successfully with deals such as:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pharmacopeia acquisition in 2008 which yielded Travere&#8217;s Filspari</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Metabasis acquisition in 2010 which contributed to the creation of Viking Therapeutics</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Vernalis acquisition in 2018 which yielded Verona&#8217;s ensifentrine</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pfenex acquisition in 2020 which yielded four of our major commercial programs &#8211; Vaxneuvance, Rylaze, Pneumosil, and Teriparatide as well as our equity interest in Primrose Bio</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Novan acquisition in 2023 which yielded Zelsuvmi</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Project finance involves the provision of development capital to fund late-stage clinical programs in return for royalty contracts that we negotiate, creating royalties on the future sales of those products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, with platform technology acquisitions, we look for platforms with high operating margins and existing licensing contracts and acquire these targets. The ideal platform will provide new royalties by operating those platforms, and it will be scalable and have broad applicability. Our Captisol business is an excellent example of a successful platform technology investment. </span></div><div><img src="lgnd-20231231_g2.jpg" alt="Investment tactics.jpg" style="height:363px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a specific set of criteria we use to assess potential investments. The first criteria is time to cash flow, as we seek products that are within a few years of regulatory approval and commercialization. Typically, this means we invest in Phase 3 assets, although we also evaluate opportunities to invest in Phase 2 assets. In terms of an asset's clinical profile, we are looking for strong data supporting both efficacy and safety, and products which will ultimately deliver significant value to patients and to the healthcare system. We also look for strong market exclusivity, which can be achieved through intellectual property and/or regulatory protections. Structural alignment with our counterparty and the marketer is also a key criteria of the investments we make. Ultimately, we look for assets with favorable risk-reward profiles, which have above average probability of technical and regulatory success and can be commercialized effectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><img src="lgnd-20231231_g3.jpg" alt="Investment criteria.jpg" style="height:357px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technologies</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a combination of research and acquisitions, we have created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider breadth of scientific innovation, more licensing opportunities and lower impact of individual patent expiry.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol Technology</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This unique technology has enabled several FDA-approved products, including Gilead&#8217;s Veklury, Amgen&#8217;s Kyprolis, Baxter International&#8217;s Nexterone, Acrotech Biopharma&#8217;s and CASI Pharmaceuticals&#8217; Evomela, Melinta Therapeutics&#8217; Baxdela and Sage Therapeutics&#8217; Zulresso. There are many Captisol-enabled products currently in various stages of development. We maintain a broad global patent portfolio for Captisol with the latest expiration date in 2035. Other patent applications covering methods of making Captisol, if issued, extend to 2041.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to solid Captisol powder, we offer our partners access to cGMP manufactured aqueous Captisol concentrate. This product offering was established in 2017 to reduce cycle time and increase Captisol production capacity for large-volume drug products. We maintain both Type IV and Type V drug master files (DMFs) with the FDA. These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs. We also have active DMFs in Japan, China and Canada. In 2023, royalties on commercial products using Captisol comprised over half of our total royalty revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HepDirect, LTP and BEPro Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HepDirect and LTP platforms are our proprietary liver-targeting prodrug technologies that can deliver many different chemical classes of drugs to the liver by using a chemical modification that renders an active pharmaceutical ingredient (API) biologically inactive until cleaved by a liver-specific enzyme. These technologies may improve the efficacy and/or safety of certain drugs and can be applied to marketed or new drug products to treat liver diseases or diseases caused by hemostasis imbalance of circulating molecules controlled by the liver. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BEPro technology platform is a next generation prodrug technology distinct from HepDirect and LTP prodrug technologies, expanding use to non-liver related diseases. BEPro is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles. Ligand has demonstrated benefits in cell penetration and oral, intravenous and inhaled pharmacokinetics with BEPro-enabled nucleotide analogs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SUREtechnology Platform (owned by Selexis)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired economic rights to various SURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform programs from Selexis. The SURE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pelican Expression Technology (owned by Primrose Bio, of which Ligand owns 49.9%)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pelican Expression Technology platform is a robust, validated, cost-effective and scalable platform for recombinant protein production, and is especially well suited for complex, large-scale proteins. Global manufacturers have demonstrated consistent success with the platform and the technology is currently outlicensed for multiple commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. The platform contributes significant value to biopharmaceutical development programs by shortening timelines and reducing costs associated with research and development through commercial manufacturing of therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increased structural complexities, the Pelican Expression Technology platform is well positioned to meet these growing needs as one of the most comprehensive and broadly available, commercially validated protein production platforms in the industry. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Investment Highlights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we announced the sale of our Pelican business, inclusive of the Pelican Expression Technology platform, and a merger of Pelican with Primordial Genetics to form a new company, Primrose Bio. As part of the investment, Ligand retained the existing commercial royalties related to the Pelican Expression Technology platform and owns 49.9% of Primrose Bio. We also entered into a purchase and sale agreement with Primrose, whereby we invested $15 million in exchange for a portion of the economic rights from the two existing contracts of Primordial Genetics and an economic interest in potential future revenues generated from the Pelican business. Ligand retains the pre-spin royalty rights from the Pelican Expression Technology, including economic rights to Jazz&#8217;s RYLAZE, Merck&#8217;s VAXNEUVANCE and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s Pneumosil and MenFive vaccines, among others. We had originally acquired the Pelican business through the acquisition of Pfenex in 2020. After incubating this technology for three years, we now have five commercial royalty streams from the platform, and with the spinoff and merger, we retain a significant equity stake. We consider the acquisition of Pfenex and spin-off of Pelican Technology Holdings, Inc. to be a very successful transaction and expect these assets will continue to generate significant revenues for the Company.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we announced an investment of $30 million to acquire a 13% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. Soticlestat is a Phase 3, first-in-class, novel mechanism of action molecule being studied by Takeda in two rare pediatric epilepsies: Lennox-Gastaut syndrome (LGS) and Dravet syndrome. Takeda is one of the world's leading pharmaceutical companies in neurology and rare diseases. LGS and Dravet are two very difficult treat conditions, with high unmet clinical needs despite having a few products that have been recently approved. Takeda has stated it anticipates regulatory filings for soticlestat in its fiscal year 2024. If regulatory approval is granted, commercialization and royalties to Ligand could begin a year later. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we closed a $20 million acquisition of Tolerance Therapeutics, a holding company owned by the inventors of TZIELD (teplizumab). TZIELD is the first disease-modifying therapy approved to treat patients with type-1 diabetes (T1D). It is a CD3-directed antibody indicated to delay the onset of stage-3 T1D in adults and in children aged eight years and older with stage-2 T1D. TZIELD was granted breakthrough therapy designation by the FDA in 2019 and was approved by the FDA in November 2022. TZIELD is marketed by Sanofi following its $2.9 billion acquisition of Provention Bio in 2023. Sanofi recently announced new data from the TZIELD PROTECT Phase 3 trial, which showed TZIELD&#8217;s potential to slow the progression of stage 3 T1D in newly diagnosed children and adolescents. These findings were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Sanofi has a robust history in the diabetes space. Sanofi has been featuring TZIELD as one of their key launches with significant blockbuster potential. Ligand is owed a royalty of less than 1% on worldwide net sales of TZIELD.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Novan Acquisition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the bankruptcy court approved a $12.2 million bid from Ligand to purchase certain assets of Novan, Inc., including berdazimer gel, all assets related to the NITRICIL&#8482; technology platform and the rights to one commercial stage asset. Prior to Novan's bankruptcy, we had a royalty interest in berdazimer topical gel, 10.3%. Berdazimer topical gel, 10.3% was approved by the FDA in January 2024, with a brand name of ZELSUVMI. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZELSUVMI&#8482; (berdazimer) topical gel, 10.3% is a first-in-class topical medication for the treatment of molluscum contagiosum in adults and pediatric patients one year of age or older. The FDA approved ZELSUVMI as the novel drug for the treatment of molluscum infections. ZELSUVMI is the first and only topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting to treat this highly contagious viral skin infection.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we incubate this newly acquired business, the Novan team is actively preparing for commercialization. Consistent with our business model, we are engaging with potential commercial partners to maximize the value for Ligand shareholders through a strategic transaction.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial and Clinical Stage Partnered Portfolio</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a large portfolio of assets currently generating royalties and future potential revenue-generating programs, including over 85 fully-funded by our partners. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalties on Commercial Products</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table provides an overview of our current portfolio of royalties:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"><tr><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Royalty Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Royalty Revenue (in millions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated 2023 Product Revenue<br/>&#160;(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen/Ono/Beigene</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5% - 3.0%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.6</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,503.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.5</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$397.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%-40%&#185;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.1</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.2</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$51.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.1</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$653.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.5</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$198.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filspari</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IgA Nephropathy</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.7</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$29.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nexterone</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.5</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.7</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23.6</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  We receive tiered profit sharing of 25% on quarterly profits less than $3.75 million, 35% on quarterly profits greater than $3.75 million but less than $7.5 million and 40% on quarterly profits greater than $7.5 million. If therapeutic equivalence is achieved, quarterly profit changes to 50% of quarterly profits.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Partnered Commercial Programs</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following programs represent important revenue-generating components of our current portfolio. For information about the royalties owed to us for certain of these programs, see &#8220;Royalties&#8221; later in this business section.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyprolis (Amgen, Ono, BeiGene)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Amgen for use with Kyprolis (carfilzomib) and granted Amgen an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand&#8217;s Captisol technology and is approved in the United States for the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">In combination with dexamethasone, lenalidomide plus dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj and dexamethasone, or isatuximab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. Under this agreement, we are entitled to receive revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis based on our patents and applications relating to the Captisol component of Kyprolis which are not expected to expire until 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rylaze (Jazz Pharmaceuticals)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Jazz announced the U.S. launch of RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), previously referred to as JZP458. RYLAZE, which was approved by the FDA in June 2021, is a recombinant erwinia </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients one month or older who have developed hypersensitivity to E. coli-derived asparaginase.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Jazz announced that the European Commission (EC) had granted marketing authorization for RYLAZE, to be marketed as Enrylaze&#174;. Jazz began a rolling launch in the second half of 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Jazz is utilizing our technology for the development of PF745 (JZP341), a long-acting Erwinia asparaginase for the treatment of ALL and other hematological malignancies. Jazz has worldwide rights to develop and commercialize PF745.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ligand is eligible to receive up to $152 million in milestone payments and tiered low-single digit royalties based on worldwide net sales of any products resulting from this collaboration, including Rylaze.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filspari (Travere) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2012, Ligand licensed the world-wide rights to sparsentan to Travere Therapeutics. Travere recently received F</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DA accelerated approval for FILSPARI (sparsentan) for the treatment of immunoglobulin A nephropathy (IgAN). FILSPARI is the first and only dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and is the first non-immunosuppressive treatment indicated for IgAN. Travere anticipates a review opinion by the Committee for Medicinal Products for Human Use (CHMP) on the potential approval for sparsentan for the treatment of IgAN in Europe in the first quarter of 2024. Additionally, Travere is on track to submit a supplemental New Drug Application (sNDA) for the conversion of the existing U.S. accelerated approval in IgAN to full approval.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Travere also completed regulatory engagement on focal segmental glomerulosclerosis (FSGS) in which the FDA communicated that the Phase 3 DUPLEX study results alone are not sufficient to support an sNDA submission for an FSGS indication for sparsentan. As a result, Travere plans to conduct additional analyses of FSGS data with plans to re-engage the FDA in 2024, and implemented a strategic reorganization in the fourth quarter of 2023 to focus near-term resources on the ongoing FILSPARI launch in IgAN.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our lic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ense agreement with Travere, we are entitled to receive over $50 million in potential milestone payments, as well as a 9% royalty on any future worldwide sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teriparatide Injection Product (PF708) (Alvogen/Adalvo)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the teriparatide injection product with the acquisition of Pfenex in October 2020. Teriparatide injection is a drug indicated for various uses including the treatment of osteoporosis in certain patients at high risk for fracture. Teriparatide injection was developed using our Pelican Expression Technology and was approved by the FDA in 2019 in accordance with the 505(b)(2) regulatory pathway, with FORTEO as the reference product. Our commercialization partner, Alvogen, launched the product in June 2020 in the United States. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Alvogen, has exclusively licensed the rights to commercialize and manufacture the teriparatide injection product in the United States, while Adalvo has the rights to commercialize in the EU, certain countries in the Middle East and North Africa (MENA), and the rest of world (ROW) territories (the latter defined as all countries outside of the EU, U.S. and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). In August 2020, marketing authorization throughout the EU was received under the trade name Livogiva and in December 2020 in Saudi Arabia under the name Bonteo. In December of 2022, we terminated a license agreement with Beijing Kangchen Biological Technology Co., Ltd. (Kangchen) thereby regaining the right to commercialize PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand along with a non-exclusive right to conduct development activities in such countries with respect to PF708. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our agreements with Alvogen, we are eligible to receive tiered gross profit sharing of between 25% and 40% of quarterly profits prior to an &#8220;A&#8221; therapeutic equivalence designation, which increases to a flat 50% if an &#8220;A&#8221; rating is achieved.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our EU, MENA and ROW agreements with Adalvo, we may be eligible to receive additional upfront and milestone payments of $1.5 million and may also be eligible to receive up to 60% of gross profit derived from product sales and regional license fees, if approved, depending on geography, cost of goods sold and sublicense fees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evomela (Acrotech and CASI)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the U.S., and CASI Pharmaceuticals for sales in China. Evomela received marketing approval by the NMPA in August of 2019. It is the only approved and commercially available melphalan product in China. Evomela is a Captisol-enabled melphalan IV formulation which is approved by the FDA for use in two indications:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a high-dose conditioning treatment prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT. The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, Acrotech Biopharma has marketing rights worldwide excluding China and CASI Pharmaceuticals has rights to market in China. We are eligible to receive over $50 million in potential milestone payments, royalties on global net sales of the Captisol-enabled melphalan product and revenue from Captisol material sales. Acrotech and CASI&#8217;s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event before ten years after the commercial launch. Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or earlier under certain circumstances. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. The agreement may be terminated by either party for an uncured material breach or unilaterally by Acrotech and CASI by prior written notice.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VAXNEUVANCE (Merck) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VAXNEUVANCE, a 15-valent pneumococcal conjugate vaccine, also known as V114, was approved in the U.S. in July of 2021 for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older, and subsequently in children 6 weeks through 17 years of age in June of 2022. VAXNEUVANCE was also approved in Europe in October 2022 for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years and older and in infants, children and adolescents from 6 weeks to less than 18 years of age. VAXNEUVANCE utilizes CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology&#8482; platform. We are entitled to low single digit royalties derived from net sales of Vaxneuvance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, Merck announced the FDA accepted for priority review a new BLA for V116, Merck's investigational 21-valent pneumococcal conjugate vaccine specifically designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults. The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition. The FDA has set a PDUFA date, or target action date, of June 17, 2024. If approved, Ligand is entitled to a royalty on worldwide net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pneumosil (Serum Institute of India, SII)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SII began commercialization of its 10-valent pneumococcal conjugate vaccine, Pneumosil, which is produced using CRM197 made in the Pelican Expression Technology platform, in the second quarter of 2020. Pneumosil is designed primarily to help fight against pneumococcal pneumonia among children, with an advantage of targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries. Pneumosil achieved WHO Prequalification in December 2019, allowing the product to be procured by United Nations agencies and Gavi, the Vaccine Alliance, and subsequently achieved Indian Marketing Authorization in July 2020, and SII announced commercial launch of the product in India in December 2020. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TZIELD (Sanofi)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired a royalty of less than 1% on net sales of TZIELD through our acquisition of Tolerance Therapeutics in the fourth quarter of 2023. TZIELD is the first disease-modifying therapy to be approved in type 1 diabetes (&#8220;T1D&#8221;). It is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and children aged 8 years and older with Stage 2 T1D. TZIELD was granted Breakthrough Therapy Designation in 2019 and was approved by the FDA in November 2022. TZIELD is marketed by Sanofi, following its acquisition of Provention Bio, Inc., the developer of TZIELD, in 2023 for $2.9 billion. Sanofi recently announced new data from TZIELD&#8217;s PROTECT Phase 3 trial which showed TZIELD&#8217;s potential to slow the progression of Stage 3 T1D in newly diagnosed children and adolescents. TZIELD met the study&#8217;s primary endpoint, significantly slowing the decline of C-peptide levels, compared to placebo. Under our agreement with Tolerance, we are entitled to receive royalties through December 1, 2032.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nexterone (Baxter)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with Baxter, related to Baxter's Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada. We supply Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement. Under the terms of the license agreement, we will continue to earn milestone payments, royalties, and revenue from Captisol material sales. We will earn royalties on net sales of Nexterone through early 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veklury (Gilead)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Gilead for sales of Veklury (remdesivir). Gilead received marketing approval from the FDA in October 2020. Veklury is an antiviral treatment for COVID-19. The product has regulatory approvals for the treatment of moderate or severe COVID-19 in over 70 countries. We are supplying Captisol to Gilead under a 10-year supply agreement. We are also supplying Captisol to Gilead&#8217;s voluntary licensing generic partners who are manufacturing remdesivir for 127 low- and middle-income countries. We receive our commercial compensation for this program through the sale of Captisol.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zulresso (Sage)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with Sage, related to Sage's Zulresso, a Captisol-enabled formulation of brexanolone for the treatment of postpartum depression (PPD). Under the terms of the agreement, we receive royalties and revenue from Captisol material sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noxafil-IV (Merck)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supply agreement with Merck related to Merck&#8217;s NOXAFIL-IV, a Captisol-enabled formulation of posaconazole for IV use. NOXAFIL-IV is marketed in the United States, EU, Japan and Canada. We receive our commercial compensation for this program through the sale of Captisol. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duavee or Duavive (Pfizer) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is responsible for the marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue. Pfizer has combined bazedoxifene with the active ingredient in Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women. Pfizer is marketing the combination treatment under the brand names Duavee and Duavive in various territories. Net royalties on annual net sales of Duavee/Duavive are payable to us through the life of the relevant patent or ten years from the first commercial sale, whichever is longer, on a country-by-country basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exemptia, Vivitra, Bryxta and Zybev (Zydus Cadila)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases. Zydus Cadila uses the Selexis technology platform for Exemptia. We earn royalties on sales by Zydus Cadila for ten years following approval.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following approval.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zydus Cadila&#8217;s Bryxta and Zybev (bevacizumab biosimilar) is marketed in India for various indications. Zydus Cadila uses the Selexis technology platform for Bryxta and Zybev. We earn royalties on sales by Zydus Cadila for ten years following approval.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FYCOMPA IV (Eisai)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Eisai, is developing an intravenous Fycompa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (perampanel), formulated with Captisol, as a substitute in Japan for oral tablets as an adjunctive therapy in patients with partial onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January of 2023, Eisai announced that it obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa in Japan as an alternative therapy when oral administration is temporarily not possible. We are entitled to revenue from Captisol material sales and tiered royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Partnered Pipeline Programs</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a highly diversified partnered pipeline of development stage assets that either have or are nearing regulatory approval, or given the area of research or value of the license terms, we consider particularly noteworthy. We are eligible to receive milestone payments and royalties on these programs. This list does not include all of our partnered programs. In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply. The following table represents development-stage assets with disclosed royalty rates:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.672%"><tr><td style="width:1.0%"/><td style="width:28.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.901%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333399;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development stage assets with disclosed royalties</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensee</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-single digit to low-teen royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DGAT-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0% - 7.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine (RPL554)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FBPase Inhibitor (VK0612)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5% - 9.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME-344</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI Pharma</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low single digit royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral EPO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5% - 8.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0% - 9.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARM (VK5211)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% - 9.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TR Beta (VK2809 and VK0214)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 9.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0% - 10.0%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TR-Beta - VK2809 and VK0214 (Viking) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Viking, is developing VK2809, a novel selective thyroid hormone receptor beta (TR-beta) agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia and non-alcoholic steatohepatitis (NASH). VK2809 is currently in a Phase 2b clinical trial (the VOYAGE study) in patients with biopsy-confirmed NASH. VK0214, another novel, orally available, TR-beta agonist, is in development for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales. Our TR Beta programs partnered with Viking are subject to CVR sharing and a portion of the cash received will be paid out to CVR holders.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, Viking presented new results from the ongoing Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed NASH. The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting&#174; 2023, the annual meeting of the American Association for the Study of Liver Diseases. The newly reported findings demonstrated robust and comparable liver fat reductions in patients with or without Type 2 diabetes, as well as patients with either F2 or F3 fibrosis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensifentrine &#8211; RPL554 (Verona)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensifentrine is a first-in-class, selective, dual inhibitor of phosphodiesterase 3 and 4 enzymes combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. Ligand obtained the rights to ensifentrine in 2018 in the acquisition of Vernalis. Our partner, Verona Pharma, recently completed the Phase 3 ENHANCE-21 and ENHANCE-12 trials evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and the NDA was accepted by the U.S. FDA in September 2023. The PDUFA date for ensifentrine is June 26, 2024. Under the terms of our agreement with Verona, we are entitled to development and regulatory milestones, including a &#163;5.0 million payment upon the first approval by any regulatory authority, and low single digit royalties on potential future sales.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verona recently announced that it has entered into a debt financing facility providing the company with access to up to $400 million from funds managed by Oxford Finance LLC and Hercules Capital, Inc. The debt facility provides non-dilutive capital and further financial flexibility to support Verona Pharma&#8217;s continued growth, including the planned commercial launch of ensifentrine.. The debt facility replaces the existing facility of up to $150 million with an affiliate of Oxford. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Soticlestat (Takeda)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, we entered into an agreement with Ovid Therapeutics for a 13% interest in soticlestat royalties. Ovid sold its rights in soticlestat to Takeda in 2021. Under the terms of its agreement with Takeda, Ovid is eligible to receive regulatory and commercial milestone payments of up to $660 million, as well as tiered royalties on net sales of soticlestat at percentages ranging from the low-double-digits up to 20%, if soticlestat is approved and successfully commercialized. Takeda is currently studying soticlestat in two pivotal Phase 3 trials in people with Lennox-Gastaut syndrome (LGS) and Dravet </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">syndrome (DS) and announced that it anticipates regulatory filings for soticlestat in its fiscal year 2024. Ovid has no ongoing obligations or costs associated with the development of soticlestat.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our agreement with Ovid, we are entitled to receive regulatory and sales-based milestones of up to $85.8 million as well as 13% of royalties received by Ovid.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ganaxalone IV (Marinus)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Marinus, is conducting Phase 3 clinical trials with Captisol-enabled ganaxolone IV in patients with refractory status epilepticus. Marinus has exclusive worldwide rights to Captisol-enabled ganaxolone, a GABA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptor modulator, for use in humans. We are entitled to development and regulatory milestones, revenue from Captisol material sales, and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ciforadenant &#8211; CPI-444 (Corvus)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Corvus, is conducting a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The Phase 1b/2 study is being conducted by the Kidney Cancer Research Consortium (KCRC) and is led by The University of Texas MD Anderson Cancer Center. Under the terms of our agreement with Corvus, we are entitled to development and regulatory milestones and tiered royalties on potential future sales. The aggregate potential milestone payments from Corvus are approximately $220 million for all indications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">QTORIN (Palvella)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the economic rights to QTORIN&#8482; 3.9% rapamycin anhydrous gel (QTORIN&#8482; rapamycin, formerly PTX-022) from Palvella in December 2018. QTORIN&#8482; rapamycin is a novel, topical formulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of high-strength rapamycin currently in development for the treatment of Microcystic Lymphatic Malformations (Microcystic LM). In November 2023, Palvella announced that the FDA granted Breakthrough Therapy Designation to QTORIN rapamycin for the treatment of microcystic LMs. Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 patients in the U.S. There are currently no FDA-approved treatments for microcystic LMs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lasofoxifene (Sermonix) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lasofoxifene is a selective estrogen receptor modulator for osteoporosis treatment and other diseases, discovered through the research collaboration between Pfizer and Ligand. Our partner, Sermonix has a license for the development of oral lasofoxifene, its lead investigational drug, for the United States and additional territories. Sermonix is currently conducting the Phase 3 ELAINE-3 clinical trial to assess the efficacy of lasofoxifene in combination with Eli Lilly and Company&#8217;s CDK4/6 inhibitor abemaciclib (Verzenio&#174;) compared to fulvestrant and abemaciclib in pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. Under the terms of the agreement, we are entitled to receive over $45 million in potential regulatory and commercial milestone payments as well as royalties on potential future net sales. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, Sermonix announced it entered into a strategic collaboration and exclusive license agreement with Henlius for the rights to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lasofoxifene in China. Under the terms of the agreement, Henlius will receive exclusive rights and sublicenses to lasofoxifene for at least two estrogen receptor-positive (ER+)/HER2- breast cancer indications in the territory, with Sermonix retaining all other global rights. Sermonix plans to work with Henlius to accelerate the clinical development of the Phase 3 ELAINE-3 multi-regional clinical trial in China, making lasofoxifene available to Chinese patients as soon as possible. In December 2023, Sermonix activated and began enrollment for ELAINE-3 in the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pradefovir (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chinese licensee, Xi'an Xintong Medicine Research (following its acquisition of Chiva Pharmaceuticals), is developing pradefovir, an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of HBV infection. Pradefovir was developed using Ligand&#8217;s HepDirect technology. Xi'an Xintong </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submitted the pradefovir NDA in May 2023, and it is under priority review by the Chinese FDA (NMPA). We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MB07133 (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chinese licensee Xi'an Xintong Medicine Research is also developing MB07133, a liver specific, HepDirect prodrug of cytarabine monophosphate, for the potential treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. MB07133 is currently in Phase 2 in China. We are entitled to an annual licensing maintenance fee and royalties on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milestone Payments</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our programs under license with our partners may generate milestone payments to us if our partners reach certain development, regulatory and commercial milestones. The following table represents the maximum value of our milestone payment pipeline by technology, development stage and partner (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.058%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Technology*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Partner*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pelican</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$195.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$950.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $170.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $80.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$150.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP/Hep Direct/BEPro</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $330.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regulatory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $800.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCE/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $1,200.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt; $900.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$750.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$1,900.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$1,900.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;$1,900.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">*All tables exclude any annual access fees and collaboration revenue for development work.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Full Portfolio Details</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled one of the largest portfolios of biopharmaceutical assets in the industry which provides investors the opportunity to participate in the biotech industry while mitigating the industry&#8217;s usual inherent clinical binary risks. Our portfolio consists of assets which currently generate revenue through royalties on commercial products as well as Captisol sales on commercial products. In addition to these assets, we have a substantial pipeline of development stage assets that currently generate contractual payments through milestone and license fees with future potential for royalties and Captisol material sales for those programs under our Captisol technology.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"/><td style="width:36.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.325%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen/Adalvo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women's Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alvogen/Hikma/Nanjing King-Friend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voriconazole</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen/Beigene/Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nexterone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biocad</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Teberif</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FYCOMPA</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elutia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ECM portfolio</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical device/Cardiology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis/Daiichi-Sankyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnebro</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ingenus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ML-141</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baxdela</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Menarini</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frovatriptan</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fareva</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noxafil-IV</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SB206</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"/><td style="width:36.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mekinist</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Posaconazole</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duavee</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vfend-IV</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tzield</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabolic </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sedor/Lupin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sesquient</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute of India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serum Institute of India</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meningococcal</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filspari</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vivitra</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bryxta/ZyBev</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maropitant</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exemptia</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zydus Cadila</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vortuxi</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3/Pivotal or Regulatory Submission Stage</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reproxalap</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BendaRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bendamustine</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marinus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganaxalone IV</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V116</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumococcal adult</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohara Pharmaceuticals</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPH203</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opthea</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OPT-302</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlook Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ONS-5010</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTX-022</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SQ Innovation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Furosemide</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunshine Lake</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilazodone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soticlestat</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine (RPL554)</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Respiratory Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acrivon</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACR-368</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anebulo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANEB-001</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CurX</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Topiramate</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTR-01</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genetic Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncternal</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zilovertamab</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sato</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SB206 (Japan)</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"/><td style="width:36.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-981</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-925</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensifentrine</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cystic Fibrosis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK5211</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK2809</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apotex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meloxicam</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Migraine</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACLX-001</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACLX-002</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China Resources Double Crane</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CX2101A</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID 19</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSL-324</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JZP-341</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long Acting Erwinia Asparaginase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jupiter Biomedical Research</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viright</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEI Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ME-344</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V117</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pneumococcal</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MIK-665</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NUC-1010</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revision Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rev0100</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAGE-689</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAK-243</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaxxas</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nanopatch</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VK-0214</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genetic Disease</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary of selected programs available for license</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Zelsuvmi, discussed above, we have a number of unpartnered programs focused on a wide-range of potential indications or diseases with the potential for further development or licensing:</span></div><div style="margin-bottom:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.074%"><tr><td style="width:1.0%"/><td style="width:44.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Development Stage</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Targeted Indication or Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Iohexol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luminespib/Hsp90 Inhibitor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Sertraline, Oral Concentrate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depression</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCR1 Antagonist</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Busulfan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Cetirizine Injection</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CE-Silymarin for Topical formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun damage</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FLT3 Kinase Inhibitors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GCSF Receptor Agonist</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blood disorders</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with a third-party manufacturer, Hovione, for Captisol production. Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal. Manufacturing operations for Captisol are performed primarily at Hovione's Portugal and Ireland facilities. We believe we maintain adequate inventory of Captisol to meet our current partner needs and that our Captisol capacity will be sufficient to meet future partner needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers. If the supply interruption continues beyond a designated period, we may terminate the agreement. In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event, we may also obtain Captisol from a third party and have previously identified such parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current term of the agreement with Hovione is through December 2024. The agreement will automatically renew for successive two-year renewal terms unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term. In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event. We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events. We have ongoing minimum purchase commitments under the agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes. For a discussion of the risks associated with competition, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Governance Highlights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to policies and practices focused on environmental sustainability, positively impacting our social community and maintaining and cultivating good corporate governance. By focusing on such ESG policies and practices, we believe we can affect a meaningful and positive change in our community and maintain our open, collaborative corporate culture. We will continue our proactive shareholder and employee engagement in 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See www.ligand.com for information about our ESG policies and practices. However, note that the information contained on our website is not intended to be part of this filing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety (EHS)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing a safe and healthy workplace, promoting environmental excellence in our communities, and complying with all relevant regulations and industry standards. We establish and monitor programs to reduce pollution, prevent injuries, and maintain compliance with applicable regulations. By focusing on such practices, we believe we can affect a meaningful, positive change in our community and maintain a healthy and safe environment. During 2023, we progressed our $2.5 million solar investment at Kansas University Innovation Park; made Environmental, Social and Governance (ESG) related charitable donations; and evolved numerous programs from our ESG-focused outreach committees. We expect to continue our effort and to refine our EHS policies and practices in 2024. More information on our EHS policies and initiatives is available on our website at www.ligand.com. However, note that the information contained on our website is not intended to be part of this filing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries. We and our partners, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the research and development, testing, manufacture, quality, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products. These activities are subject to additional regulations that apply at the state level. There are similar regulations in other countries as well. For both currently marketed products and products in development, failure to comply with applicable regulatory requirements at any time during the product development process, approval process or after approval, can, among other things, result in delays, the suspension of regulatory approvals, regulatory enforcement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actions, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, FDA approval is required before a drug or biological product may be marketed in the United States and they are also subject to other federal, state, and local statutes and regulations. The process required by the FDA before pharmaceutical products may be marketed in the United States generally involves the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">completion of extensive preclinical laboratory tests and preclinical animal studies, certain of which must performed in accordance with Good Laboratory Practice regulations and other applicable requirements ;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the FDA of an IND application, which must become effective before human clinical studies may begin;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approval by an independent institutional review board or ethics committee at each clinical site before each clinical study may be initiated;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (GCP) requirements to establish the safety and efficacy, or with respect to biologics, the safety, purity and potency of the product candidate for each proposed indication;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preparation of and submission to the FDA of an NDA or BLA after completion of all pivotal clinical studies that include substantial evidence of safety, purity, and potency of the drug from analytical studies and from results of nonclinical testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of an FDA advisory committee review, where appropriate and if applicable;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the proposed product is produced to assess compliance with cGMP, and potential FDA inspection of nonclinical study and clinical trial sites that generated the data in support of the NDA or BLA to ensure compliance with GCP; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug in the United States.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs, which among other things, impose certain procedural and documentation requirements upon BLA or NDA holders and any third-party manufacturers. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon manufacturers and their subcontractors. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences for non-compliance include, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fines, warning letters or holds on post-approval clinical studies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the risks associated with government regulations, see below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are issued or pending for the following key products or product families. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers. For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and pending patent applications covering Captisol and methods of making Captisol are owned by us. The patents covering the Captisol product with the latest expiration date is expected to be in 2033 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see, e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)). Other patent applications covering methods of making Captisol, if issued, potentially have terms to 2041. We also own several patents and pending patent applications covering drug products containing Captisol as a component. Globally, we own over 400 issued patents covering all of the foregoing Captisol compositions, methods and related technology. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ten Captisol patents in several families are listed in the Orange Book in connection with one or more prescription drugs currently on the market. These Captisol-enabled drugs include Nexterone (Baxter), Kyprolis (Amgen), Noxafil (Merck), Evomela (Acrotech/CASI), Baxdela (Melinta) and Zulresso (Sage). These patents are listed in the table below, and each patent family containing these patents has pending and/or granted counterparts in Europe, China and Japan.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Orange Book-listed Captisol Patents</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Country</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent No.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Title</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Expiration (nominal)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"> &#8225;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">7635773</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">8410077</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9200088</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10117951</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9750822</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9493582</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Alkylated Cyclodextrin Compositions And Processes For Preparing And Using The Same</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/27/2033</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10040872</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Alkylated Cyclodextrin Compositions And Processes For Preparing And Using The Same</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10/21/2033</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10864183</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Injectable Nitrogen Mustard Compositions Comprising A Cyclodextrin Derivative And Methods Of Making And Using The Same</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5/28/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10940128</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Injectable Melphalan Compositions Comprising A Cyclodextrin Derivative And Methods Of Making And Using The Same</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5/28/2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">11020363</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Injectable Nitrogen Mustard Compositions Comprising A Cyclodextrin Derivative And Methods Of Making And Using The Same</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5/28/2030</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8225;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expiration dates are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account disclaimers or extensions that are or may be available in these jurisdictions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments. For a discussion of the risks associated with patent and proprietary rights, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyprolis </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents protecting Kyprolis include those owned by Amgen and those owned by us. The United States patent listed in the Orange Book relating to Kyprolis owned by Amgen with the latest expiration date is not expected to expire until 2029. Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033. Amgen filed suit against several generic drug companies over their applications to make generic versions of Kyprolis. Several generics have settled with Amgen on confidential terms. However, it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; generic product will be on a date that is held as confidential in 2027 or sooner, depending on certain occurrences. One generic company, Cipla Limited/Cipla USA, Inc. chose not to settle the litigation with Amgen, and proceeded to trial. The District Court upheld the validity of patent claims from three of the patents and the judgment was upheld on appeal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ligand UK Development Limited</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our sale of Vernalis (R&amp;D) Limited to HitGen in December 2020, Ligand retained a portfolio of fully-funded shots on goal, which now include S65487, a Bcl-2 inhibitor, and S64315, an Mcl-1 inhibitor for treatment of cancers, both of which are partnered with Servier in collaboration with Novartis and VER250840 (an oral, selective Chk1 inhibitor for treatment of cancer). These programs and their IP are now owned by Ligand UK Development Limited, which has a worldwide patent portfolio of over 180 granted patents in over 50 countries. This patent portfolio is mature, with expected expiry dates between 2024 and 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pelican Expression Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the merger of Pelican and Primrose, Pfenex assigned a global patent portfolio consisting of over 200 patents and over 25 pending patent applications to Pelican, while retaining three patents and six pending patent applications directed to methods of producing Erwinia asparaginase. Additionally, as part of the merger of Pelican and Primrose, Pfenex acquired a non-exclusive, worldwide, royalty free, irrevocable, and fully sublicensable license to a portfolio of approximately 90 patents and approximately 15 pending patent applications which cover various aspects of the Pelican Expression Technology platform that are critical in helping support and retain contractual relationships including Jazz&#8217;s RYLAZE, Merck&#8217;s VAXNEUVANCE and V116 vaccines, Alvogen&#8217;s Teriparatide, and Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novan</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the acquisition of certain assets of Novan, we acquired a robust IP portfolio that consists of over 45 U.S. patents, 120 non-U.S. patents, and 25 pending patent applications worldwide along with substantial know-how and trade secrets.  This IP portfolio provides material coverage for our platform technologies, licensed products and product candidates, in addition to ZELSUVMI, which was approved by the FDA on January 5, 2024. There are 14 issued U.S. patents covering ZELSUVMI which are expected to be listed in the Orange Book and which are expected to expire during the time period beginning in 2026 and ending in 2035. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize and take care of our employees by offering a wide range of competitive pay, recognition, and benefit programs. We are proud to provide our employees the opportunity to grow and advance as we invest in their education and career development. As of December&#160;31, 2023, we have 58 employees, of whom 24 are involved directly in scientific research and development activities. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on skilled, experienced, and innovative employees to conduct the operations of our company. Our key human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. We frequently benchmark our compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are located. We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization. Our notable health, welfare and retirement benefits include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">equity awards through our 2002 Stock Incentive Plan;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized health insurance;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">401(k) Plan with matching contributions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tuition assistance program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paid time off.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our workforce. As of December 31, 2023, approximately 17% and 10% of our workforce are Asian and Hispanic, respectively. Additionally, 52% of our workforce is female and 48% is male. We believe that our business benefits from the different perspectives a diverse workforce brings.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to maintain an inclusive environment free from discrimination of any kind, including sexual or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported, including a confidential hotline. All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.ligand.com. We make available on our website, without charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. You may obtain copies of these documents by visiting the SEC&#8217;s website at www.sec.gov. In addition, we use X (@Ligand_LGND) and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.  Investors should monitor our X account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts. These website addresses and the information accessible through our X account are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following is a summary description of some of the many risks we face in our business. You should carefully review these risks in evaluating our business, including the businesses of our subsidiaries. You should also consider the other information described in this report, including the information contained in our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Additional risks not presently known to us or that we currently deem immaterial also may impair our business.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary of Risks Related to our Business:</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those described below. The principal risks and uncertainties affecting our business include, but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future revenue based on Kyprolis, Evomela, Teriparatide and Rylaze as well as royalties from our other partnered products, may be lower than expected;  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future revenue from sales of Captisol material to our license partners may be lower than expected;  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily on collaboration relationships to generate milestone and royalty payments and our collaboration partners have significant discretion when deciding whether to pursue any development program, and any failure by our partners to successfully develop a product candidate or a termination or breach of any of the related agreements, or a change in their strategy or the focus of their development and commercialization efforts with respect to our partnered programs, could reduce our milestone and license fee revenue, and potentially reduce future royalties;  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to create or sustain growth of our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Information available to us about the biopharmaceutical products underlying the royalties we buy may be limited and, therefore, our ability to analyze each product and its potential future cash flow may be similarly limited;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve;  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures; and  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Reliance on Third Parties:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue based on Kyprolis, Evomela, Teriparatide and Rylaze as well as royalties from our other partnered products, may be lower than expected.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant portion of our royalty revenue is based on sales of Kyprolis by Amgen, sales of Evomela by Acrotech Biopharma, sales of Teriparatide by Alvogen/Adalvo  and sales of Rylaze by Jazz. Royalties, including payments from the foregoing partners, are expected to be a substantial portion of our ongoing revenues for the foreseeable future. Any setback that may occur with respect to any of our partners' products, and in particular Kyprolis, could significantly impair our operating results and/or reduce our revenue and the market price of our stock. Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, including failure by any of the foregoing partners to enforce their respective intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates. These products also are or may become subject to generic competition. For example, we entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. The entry of generic competition for Evomela may materially and adversely affect the revenue we derive from Evomela sales. Also, Amgen previously settled patent litigation related to Kyprolis on confidential terms with several parties, but it was publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.&#8221; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue from sales of Captisol material to our license partners may be lower than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of Captisol material to our collaboration partners, including Amgen, represent a significant portion of our current revenues. Any setback that may occur with respect to Captisol could significantly impair our operating results and/or reduce the market price of our stock. Setbacks for Captisol could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products using Captisol. In addition, we may continue to generate no revenue from Captisol sales related to remdesivir due to a number of factors, including alternative treatments for COVID-19 that have been or will be developed by other companies and the decrease in COVID-19 infections, in which case the commercial opportunity could be continue to be limited. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If products or product candidates incorporating Captisol material were to cause any unexpected adverse events, the perception of Captisol safety could be seriously harmed. If this were to occur, we may not be able to sell Captisol unless and until we are able to demonstrate that the adverse event was unrelated to Captisol, which we may not be able to do. Further, the FDA could require us to submit additional information for regulatory review or approval, including data from extensive safety testing or clinical testing of products using Captisol. This would be expensive and it may delay the marketing of Captisol-enabled products and receipt of revenue related to those products, which could significantly impair our operating results and/or reduce the market price of our stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol from Hovione, our third party manufacturer, primarily at their facilities in Ireland and Portugal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Hovione were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source, which could potentially take a considerable length of time and impact our revenue and customer relationships. In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers, although there is no assurance that we could do so timely or at acceptable costs, if at all. In addition to manufacturing at Hovione&#8217;s facilities in Ireland and Portugal, we have  processing capacity for Captisol in both the United States and England.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain inventory of Captisol, which has a five-year shelf life, at three geographically dispersed storage locations in the United States and Europe. If we were to encounter problems maintaining our inventory, such as natural disasters, at one or more of these locations, it could lead to supply interruptions. In addition, we rely on Hovione to expand manufacturing capacity of Captisol and any failure by Hovione to timely implement such increased capacity could adversely affect our ability to supply Captisol to our partners. While we believe we maintain adequate inventory of Captisol to meet our current partner needs, and our Captisol capacity will be sufficient to meet future partner needs, our estimates and projections for Captisol demand may not be correct and any supply interruptions could materially adversely impact our operating results.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on our arrangements with our partners and licensees to sell products using our Captisol technology. These agreements generally provide that our partners may terminate the agreements at will. If our partners discontinue sales of products using Captisol, fail to obtain regulatory approval for products using Captisol, fail to satisfy their obligations under their agreements with us, choose to utilize a competing product, or if we are unable to establish new licensing and marketing relationships, our financial results and growth prospects would be materially affected. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under most of our Captisol outlicenses, the amount of royalties we receive will be reduced or will cease when the relevant patent expires. Our low-chloride patents and foreign equivalents are not expected to expire until 2033, our high purity patents and foreign equivalents, are not expected to expire until 2029 and our morphology patents and foreign equivalents are not expected to expire until 2026 in the United States, but the initially filed patents relating to Captisol expired starting in 2010 in the United States and in 2016 in most countries outside the United States. If our other intellectual property rights are not sufficient to prevent a generic form of Captisol from coming to market and if in such case our partners choose to terminate their agreements with us, our Captisol revenue may decrease significantly.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely heavily on collaboration relationships to generate milestone and royalty payments and our collaboration partners have significant discretion when deciding whether to pursue any development program, and any failure by our partners to successfully develop a product candidate or a termination or breach of any of the related agreements could reduce our milestone and license fee revenue, and potentially reduce future royalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for developing and commercializing many of our product candidates includes entering into collaboration agreements, outlicenses, and development funding and royalty purchase agreements with corporate partners and others. These agreements give our collaboration partners significant discretion when deciding whether or not to pursue any development program. Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaboration arrangements to develop and commercialize our unpartnered assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaborators may develop products, either alone or with others that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our or our partners' programs. If product candidates are approved for marketing under our collaboration programs, revenues we receive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will depend on the manufacturing, marketing and sales efforts of our collaboration partners, who generally retain commercialization rights under the collaboration agreements. Generally, our current collaboration partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaboration partners breach (for example, by not making required payments when due, or at all) or terminate their agreements with us or otherwise fail to conduct their collaboration activities successfully, including due to insolvency events, ongoing product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates. Any such dispute or litigation could delay, interrupt or terminate the collaboration research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaboration partners may change their strategy or the focus of their development and commercialization efforts with respect to our partnered programs, and the success of our partnered programs could be adversely affected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaboration partners terminate their collaborations with us or do not commit sufficient resources to the development, manufacture, marketing or distribution of our partnered programs, we could be required to devote additional resources to our partnered programs, seek new collaboration partners or abandon such partnered programs, all of which could reduce our revenues and otherwise have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, biopharmaceutical development is inherently uncertain and very few therapeutic candidates ultimately progress through clinical development and receive approval for commercialization. If our partners do not receive regulatory approval for a sufficient number of therapeutic candidates originating from our partnerships, we may not be able to sustain our business model. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we or our partners obtain the approvals necessary to sell any of our unpartnered assets or partnered programs, we must show through preclinical studies and human testing that each potential product is safe and effective. We and/or our partners have a number of partnered programs and unpartnered assets moving toward or currently awaiting regulatory action.  Failure to show any product's safety and effectiveness could delay or prevent regulatory approval of a product and could adversely affect our business. The product development and clinical trials process is complex and uncertain.  For example, the results of preclinical studies and initial clinical trials may not necessarily predict the results from later large-scale clinical trials.  In addition, clinical trials may not demonstrate a product's safety and effectiveness to the satisfaction of the regulatory authorities. A number of companies have suffered significant setbacks in advanced clinical trials or in seeking regulatory approvals, despite promising results in earlier trials. The FDA may also require additional clinical trials after regulatory approvals are received.  Such additional trials may be expensive and time-consuming, and failure to successfully conduct those trials could jeopardize continued commercialization of a product.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed at which we and our partners complete our scientific studies and clinical trials depends on many factors, including, but not limited to, the ability to obtain adequate supplies of the products to be tested and patient enrollment. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial and other potential drug candidates being studied. Delays in patient enrollment for our or our partners&#8217; trials may result in increased costs and longer development times. In addition, our partners have rights to control product development and clinical programs for products developed under our collaborations. As a result, these partners may conduct these programs more slowly or in a different manner than expected.  Moreover, even if clinical trials are completed, we or our partners still may not apply for FDA or foreign regulatory approval in a timely manner, or the FDA or foreign regulatory authority still may not grant approval.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate discovery, early-stage development, and product reformulation programs may require substantial additional capital to complete successfully.  Our partners&#8217; development programs may require substantial additional capital to complete successfully, arising from costs to: conduct research, preclinical testing and human studies; establish pilot scale and commercial scale manufacturing processes and facilities; and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support these programs. While we expect to fund our research and development activities from cash generated from operations to the extent possible, if we are unable to do so, we may need to complete additional equity or debt financings or seek other external means of financing. These financings could depress our stock price. If additional funds are required to support our operations and we are unable to obtain them on terms favorable to us, we may be required to cease or reduce further development or commercialization of our products, to sell some or all of our technology or assets or to merge with another entity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to create or sustain growth of our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our business depends on our ability to acquire royalties and we may not be able to identify and acquire a sufficient number of royalties, or royalties of sufficient scale, to invest the full amount of capital that may be available to us in the future, or at our targeted amount and rate of deployment, which could prevent us from executing our growth strategy and negatively impact our results of operations. Changes in the royalty market, including its structure, participants and growth rate, changes in preferred methods of financing and capital raising in the biopharmaceutical industry, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire royalties, fewer royalties (or fewer royalties of significant scale) being available, or increased competition for royalties. Even if we continue to acquire royalties, they may not generate a meaningful return for a period of several years, if at all, due to numerous factors including the structure of the transaction, or circumstances relating to the underlying products. As a result, we may not be able to create or sustain growth of our business as we expect or at all.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition in acquiring royalties and locating suitable royalties to acquire.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Therefore, competition to acquire such royalties is intense and may increase. We compete with other potential acquirers for these opportunities, including companies that market the products on which royalties are paid, financial institutions and others. These competitors may be able to access lower cost capital, may be larger than us, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Information available to us about the biopharmaceutical products underlying the royalties we buy may be limited and, therefore, our ability to analyze each product and its potential future cash flow may be similarly limited.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have limited information concerning the products generating the royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product, sales of our products and licenses to our technology. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations, exclusivity terms, license terms or license terminations for the products underlying our portfolio, products and technology, are accurate. These assumptions involve a significant element of subjective judgment and may be adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product or technology. The risks relating to these assumptions may be exacerbated for development-stage product candidates due to the uncertainties around their development, labeling, regulatory approval, commercialization timing, manufacturing and supply, competing products or related factors. With respect to our partnered programs, our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties or license, milestone or other service payments, may also prove, and in the past have proven, to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets, or our current or future products or technology, may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect or at all, which could adversely affect our financial condition and results of operation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The insolvency of any of our partners or third-parties who are developing or commercializing products to which we have economic rights could adversely affect our receipt of cash flows on the related milestones or royalties that we own.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our partners or third-parties who are developing or commercializing products to which we have economic rights were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due to us under any license agreement, royalty purchase agreement or other contract under which we have acquired economic rights, pending a resolution of the insolvency proceeding. Unless we obtained a secured interest, any unpaid royalty payments under our license agreements with our partners and third-parties due for the period prior to the filing of the bankruptcy proceeding could become unsecured claims against such partner or third-party, which might not be paid in full or at all. The actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under such agreements. Given the nature of our royalty purchase agreements, royalty payments </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to our partners or third-parties prior to or after a bankruptcy proceeding may not be subject to the insolvency proceeding and may be considered our property, meaning there is a reduced risk of payment delay and/or non-payment. Nevertheless, a partner or third-party or another party in interest in an insolvency proceeding may attempt to recharacterize the royalty purchase agreement and claim that the royalty payments are property of the bankruptcy estate, in which case we would rely upon contractual protections related to such recharacterizations, which may not be respected in bankruptcy. In addition, certain of agreements with our partners or third-parties permit us to take a secured interest in the intellectual property underlying the licenses and royal purchase agreements, which may improve our risk profile in an insolvency proceeding.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases and depending on the terms of the agreement, we are not the licensor and instead are dependent on the licensor to enforce its right to royalties under an agreement with a licensee. In any bankruptcy proceeding, the licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, such partner or third-party could elect to reject the license agreement. Though this would prohibit such partner or third-party from continuing to market the applicable product, it would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a partner or other payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the Distribution, together with certain related transactions, failed to qualify as a reorganization under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or the Merger failed to qualify as a reorganization under Section 368(a) of the Code, we could incur significant tax liabilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Distribution and the Merger were conditioned upon receipt of a tax opinion from outside counsel to the effect that the Distribution qualified as a reorganization under Sections 355 and 368(a)(1)(D) of the Code, that the Merger would not cause Section 355(e) of the Code to apply to the Distribution and that the Merger would be treated as a reorganization under Section 368(a) of the Code. The opinion was delivered in connection with the closing of the Merger and was based on, among other things, certain facts, assumptions, representations and undertakings from us, OmniAb and New OmniAb, including those regarding the past and future conduct of the companies&#8217; respective businesses and other matters. If any of these facts, assumptions, representations, or undertakings were incorrect or not satisfied, we may not be able to rely on the opinion, and we and our stockholders could be subject to significant U.S. federal income tax liabilities. In addition, the opinion is not binding on the IRS or the courts, and notwithstanding the opinion, the IRS could determine on audit that the Distribution or Merger does not qualify as a reorganization if it determines that any of the facts, assumptions, representations or undertakings on which the opinion is based are not correct or have been violated or that the Distribution or Merger should be taxable for other reasons, including as a result of a significant change in stock or asset ownership after the Distribution. If the Distribution, together with certain related transactions, is ultimately determined not to qualify as a reorganization, or the Merger is ultimately determined not to qualify as a reorganization, we and our stockholders that are subject to U.S. federal income tax could incur significant U.S. federal income tax liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Separation and Distribution may expose Ligand to potential liabilities arising out of state and federal fraudulent conveyance laws and legal dividend requirements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Separation and Distribution are subject to review under various state and federal fraudulent conveyance laws. Fraudulent conveyance laws generally provide that an entity engages in a constructive fraudulent conveyance when (i) the entity transfers assets and does not receive fair consideration or reasonably equivalent value in return; and (ii) the entity: (a) is insolvent at the time of the transfer or is rendered insolvent by the transfer; (b) has unreasonably small capital with which to carry on its business; or (c) intends to incur or believes it will incur debts beyond its ability to repay its debts as they mature. An unpaid creditor or an entity acting on behalf of a creditor (including without limitation a trustee or debtor-in-possession in a bankruptcy by New OmniAb or Ligand or any of their respective subsidiaries) may bring an action alleging that the Separation or Distribution or any of the related transactions constituted a constructive fraudulent conveyance. If a court accepts these allegations, it could impose a number of remedies, including without limitation, voiding New OmniAb&#8217;s claims against Ligand, requiring New OmniAb stockholders to return to Ligand some or all of the shares of New OmniAb common stock issued via the Distribution and Merger, or providing Ligand with a claim for money damages against New OmniAb in an amount equal to the difference between the consideration received by Ligand and OmniAb&#8217;s fair market value at the time of the Distribution.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure of insolvency for purposes of the fraudulent conveyance laws will vary depending on which jurisdiction&#8217;s law is applied. Generally, an entity would be considered insolvent if (i) the present fair saleable value of its assets is less than the amount of its liabilities (including contingent liabilities); (ii) the present fair saleable value of its assets is less than its probable liabilities on its debts as such debts become absolute and matured; (iii) it cannot pay its debts and other liabilities (including contingent liabilities and other commitments) as they mature; or (iv) it has unreasonably small capital for the business in which it is engaged. We cannot assure you what standard a court would apply to determine insolvency or that a court would determine that New OmniAb or Ligand or any of their subsidiaries were solvent at the time of or after giving effect to the Distribution.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Distribution of OmniAb common stock is also subject to review under state corporate distribution statutes. Under the DGCL, a corporation may only pay dividends to its stockholders either (i) out of its surplus (net assets minus capital) or (ii) if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared or the preceding fiscal year. Although Ligand intended to make the Distribution of OmniAb common stock entirely from surplus, we cannot assure you that a court will not later determine that some or all of the Distribution to Ligand stockholders was unlawful.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, use or sale of our potential products or our licensees' products or potential products may infringe the patent rights of others.  If others obtain patents with conflicting claims, we may be required to obtain licenses to those patents or to develop or obtain alternative technology. We may not be able to obtain any such licenses on acceptable terms, or at all.  Any failure to obtain such licenses could delay or prevent us from pursuing the development or commercialization of our potential products, platform and technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, our success will depend on our ability and the ability of our partners to obtain and maintain patents and other intellectual property rights for our and their potential products and technologies. Our patent position is uncertain and involves complex legal and technical questions for which legal principles are unresolved.&#160;Even if we or our partners do obtain patents, such patents may not adequately protect the technology we own or have licensed.&#160; </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We permit our partners to list our patents that cover their branded products in the Orange Book. If a third party submits a new drug application (NDA) or abbreviated new drug application (ANDA) for a generic drug product that relies in whole or in part on studies contained in our partner&#8217;s NDA for their branded product, the third party will have the option to certify to the FDA that, in the opinion of that third party, the patents listed in the Orange Book for our partner&#8217;s branded product are invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug product. A third party certification that a new product will not infringe Orange Book-listed patents, or that such patents are invalid, is called a paragraph IV patent certification. If the third party submits a paragraph IV patent certification to the FDA, a notice of the paragraph IV patent certification must be sent to the NDA owner and the owner of the patents that are subject to the paragraph IV patent certification notice once the third-party&#8217;s NDA or ANDA is accepted for filing by the FDA. A lawsuit may then be initiated to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of the receipt of notice of a paragraph IV patent certification automatically prevents the FDA from approving the generic NDA or ANDA until the earlier of the expiration of a 30-month period, the expiration of the patents, the entry of a settlement order stating that the patents are invalid or not infringed, a decision in the infringement case that is favorable to the NDA or ANDA applicant, or such shorter or longer period as the court may order. If a patent infringement lawsuit is not initiated within the required 45-day period, the third-party&#8217;s NDA or ANDA will not be subject to the 30-month stay.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several third parties have challenged, and additional third parties may challenge, the patents covering our partner&#8217;s branded products, including Kyprolis and Evomela, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. We may from time to time become party to litigation or other proceedings as a result of Paragraph IV certifications. For example, as a result of the settlement of one such matter, Teva will be permitted to market a generic version of Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential. Also, as noted above, Amgen previously settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.&#8221; </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot assure you that all of the potentially relevant prior art information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention-relating to our and our partners&#8217; patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we or our partners may be subject to a third party pre-issuance submission of prior art to the USPTO. Even if our patent applications do successfully issue and even if such patents cover our or our partner&#8217;s products or potential products, third parties may initiate litigation or opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our or our partners&#8217; products and compete directly with us and our partners, without payment to us or our partners, or limit the duration of the patent protection of our and our partners&#8217; technology and products. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our technologies infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. As discussed above, we may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our technologies could materially affect our business and our ability to gain market acceptance for our technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our partner&#8217;s products or technologies. Any adverse outcome of such litigation or other proceedings could result in one or more or our patents being held invalid or unenforceable, which could adversely affect our ability to successfully execute our business strategy and negatively impact our financial condition and results of operations. However, given the unpredictability inherent in litigation, we cannot predict or guarantee the outcome of these matters or any other litigation. Regardless of how these matters are ultimately resolved, these matters may be costly, time-consuming and distracting to our management, which could have a material adverse effect on our business. It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any conflicts with the patent rights of others could significantly reduce the coverage of our patents or limit our ability to obtain meaningful patent protection.  For example, our European patent related to Agglomerated forms of Captisol was limited during an opposition proceeding, and the rejection of our European patent application related to High Purity Captisol was upheld on appeal. In addition, any determination that our patent rights are invalid may result in early termination of our agreements with our license partners and could adversely affect our ability to enter into new license agreements. We also rely on unpatented trade secrets and know-how to protect and maintain our competitive position. We require our employees, consultants, licensees and others to sign confidentiality agreements when they begin their relationship with us. These agreements may be breached, and we may not have adequate remedies for any breach.  In addition, our competitors may independently discover our trade secrets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also need to initiate litigation, which could be time-consuming and expensive, to enforce our proprietary rights or to determine the scope and validity of others' rights.  If this occurs, a court may find our patents or those of our licensors invalid or may find that we have infringed on a competitor's rights. In addition, if any of our competitors have filed patent applications in the United States prior to March 2013 which claim technology we also have invented, the United States Patent and Trademark Office may require us to participate in expensive interference proceedings to determine who has the right to a patent for the technology.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our agreements with some of our partners, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects. The occurrence of any of the foregoing problems could be time-consuming and expensive and could adversely affect our financial position, liquidity and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our products, platform and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our platform and services may be impaired.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States and in other countries with respect to our platform, our software and our technologies, without infringing the intellectual property rights of others.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our platform and related technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents in our industry is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that issues as a patent), will exclude others from making, using, importing, offering for sale, or selling products or services that are substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties or deemed unenforceable by a court. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our products, platform and technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may identify third party intellectual property and technology we may need to acquire or license in order to engage in our business, including to develop or commercialize new technologies. However, such licenses may not be available to us on acceptable terms or at all. Furthermore, geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future license partners and the maintenance, enforcement or defense of our issued patents or those of any current or future license partners. For example, the United States and foreign government actions related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our or our license partners&#8217; patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we or our license partners would not be able to prevent third parties from practicing our or our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents directed to our platform and technology could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to our patents in this </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that any resulting protection may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products, platform and technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be aware of all third party intellectual property rights potentially relating to our products, platform and technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions included in each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the priority of these inventions, we may have to participate in interference proceedings (with respect to patent applications filed prior to March 2013), derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The validity, scope and enforceability of any patents that cover our partners&#8217; biologic product candidate can be challenged by third parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For biologics, the Biologics Price Competition and Innovation Act of 2009, BPCIA, provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell biosimilar or interchangeable versions of brand name biological products. Due to the large size and complexity of biological products, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in an Orange Book and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal pre-litigation process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, sponsors may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of non-infringement. Such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our partners&#8217; ability to prevent third parties from competing with their products or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products, platform and technology. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce and protect our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our future owned and licensed patents. Depending on future actions by the United States Congress, the United States courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our license partners&#8217; ability to obtain new patents and patents that we or our license partners&#8217; might obtain in the future. For example, on June 1, 2023, the European Union Patent Package (EU Patent Package) regulations were implemented with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (UPC) for litigation involving European patents. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Our or our license partners&#8217; European patent applications, if issued, could be challenged in the UPC. During the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. We or our license partners may decide to opt out future European patents from the UPC, but doing so may preclude us or our license partners from realizing the benefits of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPC. Moreover, if we or our license partners do not meet all of the formalities and requirements for opt-out under the UPC, our or our license partners&#8217; future European patents could remain under the jurisdiction of the UPC. The UPC will provide our and our license partners&#8217; competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunction. Such a loss of patent protection could have a material adverse impact on our or our license partners business and ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on in-licenses from third parties. If we lose these rights, our business may be materially and adversely affected, our ability to develop improvements to our technology platform may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation, as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to royalty-bearing license agreements that grant us rights to practice certain patent rights that are related to our products, platform and technology. In spite of our efforts to comply with our obligations under our in-license agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such in-license is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, absent the rights granted to us under our license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our development and commercialization activities that are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which ultimately may not be successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our rights to certain components of our technology platform, may be licensed to us on a non-exclusive basis. The owners of these non-exclusively licensed technologies are therefore free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the third party, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, partners or other third parties have an interest in our or our in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems, including our software, workflows, consumables and reagents. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially and adversely affected and our business could be harmed.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our technology platform, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States may be less willing, or unwilling, to protect trade secrets. Further, we may need to share our trade secrets and confidential know-how with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the products we may market or license to our collaboration partners and the royalties we receive will depend in large part on the extent to which coverage and reimbursement is available from government and health administration authorities, private health maintenance organizations and health insurers, and other healthcare payors. Significant uncertainty exists as to the reimbursement status of healthcare products. Healthcare payors, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products. Even if a product is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover the costs associated with the research, development, marketing and sale of the product. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any product, market acceptance and any sales could be reduced.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is implemented to reign in rising healthcare expenditures. By way of example, the Affordable Care Act (ACA) was enacted in 2010 and included a number of provisions affecting the pharmaceutical industry, including, among other things, annual, non-deductible fees on any entity that manufactures or imports some types of branded prescription drugs and increases in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, beginning April 1, 2013, Medicare payments to providers were reduced under the sequestration required by the Budget Control Act of 2011, which will remain in effect through 2032, unless additional Congressional action is taken. Additionally, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024.  Previously, the Medicaid rebate was capped at 100% of a drug&#8217;s average manufacturer price, or AMP.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which was fully implemented in 2019. At this time, it is unclear how the introduction of this Medicare quality payment program will impact overall physician reimbursement. The cost of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States. There have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive orders designed to, among other things, bring more transparency to product pricing, review </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the federal government and the individual states in the United States have become increasingly active in developing proposals, passing legislation and implementing regulations designed to control drug pricing, including price or patient reimbursement constraints, discounts, formulary flexibility, marketing cost disclosure, drug price increase reporting, and other transparency measures. These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on the pharmaceutical industry cannot yet be fully determined, but is likely to be significant.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage and payment criteria and in additional downward pressure on the prices that can be realized for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us or our partners from being able to generate revenue, attain profitability, or commercialize drugs. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for drug candidates or additional pricing pressures. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our commercialization partners market products in a manner that violates healthcare laws, we may be subject to civil or criminal penalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners are subject to federal and state healthcare laws, including fraud and abuse, government price reporting, anti-kickback, false claims, physician payment transparency and civil monetary penalties. These laws may impact, among other things, financial arrangements with physicians, sales, marketing and education programs and the manner in which any of those activities are implemented. If our operations or those of our collaboration partners are found to be in violation of any of those laws or any other applicable governmental regulations, we or our collaboration partners may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment, exclusion from government healthcare programs or the curtailment or restructuring of operations, any of which could adversely affect our ability to operate our business and our financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by our collaboration partners, governmental or regulatory agencies, and the courts. CMS, the Department of Health &amp; Human Services Office of Inspector General, and other governmental agencies have pursued manufacturers that were alleged to have failed to report these data to the government in a timely or accurate manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that any submissions by our collaboration partners to federal healthcare programs, and other governmental drug pricing programs, will not be found to be incomplete or incorrect.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners may be subject to federal, state, and foreign laws and regulations that govern data privacy and security. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and may increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure, and protection of personal information, including state data breach notification laws, federal and state health </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information privacy laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively, HIPAA) or applicable state laws.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also adopted comparable privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act of 2018 (CCPA) went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with data breach litigation. Further, the California Privacy Rights Act (CPRA) generally went into effect on January 1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation (GDPR) governs certain collection and other processing activities involving personal data about individuals in the European Economic Area (EEA). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On October 7, 2022, President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Intelligence Activities&#8217; which introduced new redress mechanisms and binding safeguards to address the concerns raised by the CJEU in relation to data transfers from the EEA to the United States and which formed the basis of the new EU-US Data Privacy Framework (DPF), as released on December 13, 2022. The European Commission adopted its Adequacy Decision in relation to the DPF on July 10, 2023, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. The DPF also introduced a new redress mechanism for EU citizens which addresses a key concern in the previous CJEU judgments and may mean transfers under standard contractual clauses are less likely to be challenged in future. With the advice of outside counsel and privacy experts, we take appropriate steps to ensure transfers of personal data outside the EEA and the UK, including to the United States, are conducted in a manner consistent with applicable law and legal requirements. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames. Since the beginning of 2021, after the end of the transition period following the United Kingdom&#8217;s departure from the European Union, we are also subject to the United Kingdom data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. . On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to U.S. entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the FTC also has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5 of the FTC Act. Failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states&#8217; attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with applicable data privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules or regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we or our partners are ultimately unable to obtain regulatory approval for product candidates, our business will be substantially harmed. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of drugs and biologics are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., neither we nor our partners are permitted to market our product candidates in the U.S. until we receive approval of a biologics license application (BLA) or an NDA from the FDA. The process of obtaining such regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and comparable regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval of a product candidate is never guaranteed. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize a drug or biological product candidate in the U.S. or abroad, we or our partners must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses, and in the case of biological products in the U.S., that such product candidates are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we or our partners believe available nonclinical or clinical data support the safety purity, potency or efficacy of our product candidates, such data may not be sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us or our partners to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of clinical development programs. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or execution of clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or ambiguous results from clinical trials or results may not meet the level of statistical significance or persuasiveness required by the FDA or comparable foreign regulatory agencies for approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected drug-related side effects may be experienced by participants in clinical trials or by individuals using drugs similar to the applicable product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we or our partners seek approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our or our partners&#8217; interpretation of data from preclinical studies or clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may not agree that the data collected from clinical trials are acceptable or sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with us or our partners regarding the formulation, labeling and/or product specifications;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than those sought by us or our partners, and/or may include significant restrictions on distribution and use;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers utilized for clinical and commercial supplies; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. Even if we or our partners eventually complete clinical trials and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials and/or the implementation of burdensome monitoring requirements to address safety concerns. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate, which could materially and adversely impact our revenues, business and prospects.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any regulatory approvals that we or our partners may receive for our respective product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will remain subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with current Good Manufacturing Practices (cGMPs) and Good Clinical Practice requirements for any clinical trials that we or they may conduct. In addition, manufacturers of drug and biological products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. In addition, regulatory approvals require the submission of periodic reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, and such approvals may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a Risk Evaluation and Mitigation Strategy as a condition of approval, which could include requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our partners or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may lead to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal by the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of approvals; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product seizures or detentions, or refusal to permit the import or export of products; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our or our partners&#8217; ability to commercialize and generate revenue from products and could require us or our partners to expend significant time and resources in response and could generate negative publicity. In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be promulgated that could prevent, limit or delay marketing authorization of any product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates we or our partners develop. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDA&#8217;s review and approval of new products is delayed, the timing of our or our partners&#8217; development process may be delayed which would result in delayed milestone revenues and materially harm our operations of business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, any resurgence of the virus or emergence of new variants may lead to further inspectional or administrative delays. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our or our partners&#8217; regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in our industry, our partners and we face an inherent risk of product liability as a result of the clinical testing of our product candidates in clinical trials and face an even greater risk for commercialized products. Although we are not currently a party to product liability litigation, if we are sued, we may be held liable if any product or product candidate we develop causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates, partnered products or products that we may develop, injury to our reputation, discontinuation of clinical trials, costs to defend litigation, substantial monetary awards to clinical trial participants or patients, loss of revenue and product recall or withdrawal from the market and the inability to commercialize any products that we develop. We have product liability insurance that covers our clinical trials up to a $15.0&#160;million annual limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. If we are sued for any injury caused by our product candidates, partnered products or any future products, our liability could exceed our total assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to handling of hazardous materials and other regulations governing environmental safety.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce. Our activities that are subject to these regulations include, among other things, our use of hazardous materials and the generation, transportation and storage of waste. Although we have secured clearance from the EPA historically, and currently are operating in material compliance with applicable EPA rules and regulations, our business could be adversely affected if we discover that we or an acquired business is not in material compliance with these rules and regulations. In the future, we may pursue the use of other surfactant substances that will require clearance from the EPA, and we may fail to obtain such clearance. Existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, that may have a negative effect on our business and results of operations. It is also impossible to eliminate completely the risk of accidental environmental contamination or injury to individuals. In such an event, we could be liable for any damages that result, which could adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may also be subject to laws and regulations not specifically targeting the healthcare industry.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain regulations not specifically targeting the healthcare industry also could have material effects on our operations. For example, the California Financing Law (the &#8220;CFL&#8221;), Division 9, Sections 22000-22780.1 of the California Financial Code, could be applied to us as a result of loans or similar arrangements we enter into with partners. If a regulator were to take the position that such loans were covered by the California Financing Law, we could be subject to regulatory action that could impair our ability to continue to operate and may have a material adverse effect on our profitability and business as we currently do not hold a CFL finance lenders license. Pursuant to an exemption under the CFL, a person may make five or fewer commercial loans with a California nexus in a 12-month period without a CFL finance lenders license if such loans are &#8220;incidental&#8221; to the business of the person making the loan. This exemption, however, creates some uncertainty as to which loans could be deemed as incidental to our business. In addition, there is another exemption that would allow a person without a CFL finance lenders license to make a single commercial loan with a California nexus in a 12-month period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Related to Our Strategic Transactions:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any difficulties from strategic acquisitions could adversely affect our stock price, operating results and results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources and could prove to be more difficult or expensive than we predict. The diversion of our management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for stockholders or the incurrence of indebtedness.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result of unidentified risks, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in-process research and development charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Risks:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to risks arising from pandemic and epidemic diseases.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future pandemics, including the residual effects of the COVID-19 pandemic, or other public health epidemics, pose the risk that we or our employees, contractors, including our CROs, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. Although we have lifted the restrictions we previously imposed on in-person access to our facilities and currently do not believe the COVID-19 pandemic is having a material impact on our business, we cannot guarantee that pandemics, such as COVID-19 or the emergence of variants thereof, or a similar event, will not impact our operations in the future.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our partners reported that their operations were impacted by the COVID-19 pandemic, with such impacts including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who had contracted the virus or to prevent the spread of the virus. In addition, certain of our partners reported negative impacts on product sales which impacted our royalty revenues. Although we believe that we and our partners have adjusted our business practices to the impacts of the COVID-19 pandemic, in the future, we may experience similar pandemics or epidemic diseases that could severely impact our business, drug manufacturing and supply chain, nonclinical activities and clinical trials and our partners&#8217; business may be impacted in similar ways, including due to delays or difficulties in enrolling patients in clinical trials, diversion of healthcare resources away from the conduct of clinical trials, interruption of, or delays in receiving, supplies of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Captisol or other product or product candidates from contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may result in cancellations of Captisol orders or refunds if we fail to deliver Captisol timely, interruption or delays to discovery and development pipelines and difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the COVID-19 pandemic impacted the trading price of shares of our common stock. The extent to which the emergence of new variants of COVID-19, or any other outbreak of a pandemic or epidemic disease, impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.  Further, to the extent any pandemic or epidemic disease adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the royalties from the sales of Kyprolis, Evomela and other products sold by our partners; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the success of our collaboration partners&#8217; preclinical and clinical programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing of Captisol purchases for use in clinical trials and commercial products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our internal development programs, which may change from time to time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">expenditures that we may incur to acquire or develop additional product candidates and platform technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">future accounting pronouncements or changes in our accounting policies. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the FASB either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our results of operations. For example, in May 2014, FASB issued an accounting standard for revenue recognition-Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606-that supersedes most current revenue recognition guidance. The guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services.  The guidance became effective in fiscal 2018. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Ligand estimates and books royalties in the same quarter that our partners report the sale of the underlying product. We rely on our partners&#8217; earning releases and other information from our partners to determine the sales of our partners&#8217; products and to estimate the related royalty revenues. If our partners report incorrect sales, or if our partners delay reporting of their earnings release, our royalty estimates may need to be revised and/or our financial reporting may be delayed. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $48.0 million and $165.1 million, respectively.  Our federal NOLs expire through 2037 and our state NOLs begin to expire in 2028, if not utilized. Under the Tax Act, any federal NOLs arising in taxable years ending after December 31, 2017 will carry forward indefinitely. As of December&#160;31, 2023, we had federal and California research and development tax credit carryforwards of approximately $8.5 million and $29.4 million, respectively. The federal research and development tax credit carryforwards expire in various years through 2040, if not utilized. The California research and development credit will carry forward indefinitely. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (Code) if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Furthermore, under the Tax Act, although the treatment of tax losses generated in tax years beginning before December 31, 2017 has generally not changed, tax losses generated in tax years beginning after December 31, 2017 may only offset 80% of our taxable income. This change may require us to pay federal income taxes in future years despite having potentially generated a loss for federal income tax purposes in prior years. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of a catastrophic disaster could disrupt our business, damage our facilities beyond insurance limits, increase our costs and expenses, or we could lose key data which could cause us to curtail or cease operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are vulnerable to damage, business disruptions and/or loss of vital data from natural or man-made disasters, such as earthquakes, tornadoes, severe weather conditions, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Our ability to obtain Captisol supply from our third-party manufactures could be disrupted if the operations of these manufacturers were affected by a natural or man-made disaster or other business interruption. In addition, we rely on our partners to generate most of our revenues through royalties, Captisol sales and development activities and any disruptions to their business as a result of such disasters could negatively impact our revenues.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on information technology system and any failure, inadequacy, interruption or security lapse of our information technology systems, including any cyber security incidents, could harm our ability to operate our business effectively.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. We operate some of these systems and networks, but we also rely on third-party providers for various products and services across our operations. Despite the implementation of security measures, our information technology systems and those of our partners and third party service providers are vulnerable to attack, damage, and interruption from cyber-attacks, computer viruses and malware (e.g. ransomware), security breaches, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the technologies used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers&#8217; employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The White House, SEC and other regulators have also increased their focus on companies&#8217; cybersecurity vulnerabilities and risks.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our service providers are from time to time, subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failures, accidents or security breaches, if such an event were to occur and cause interruptions in our or our critical third parties&#8217; operations, it could lead to the loss of trade secrets or other intellectual property, as well as the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our business, reputation, and financial condition could be harmed. Any losses, costs or liabilities may not be covered by, or may exceed the coverage limits of, any or all applicable insurance policies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our Credit Agreement may limit our flexibility in operating our business and adversely af ect our financial health and competitive position, and all of our obligations under our Credit Agreement are secured by certain of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">collateral and the collateral of certain of our subsidiaries, as Guarantors. If we default on these obligations, our lenders could foreclose on such assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we entered into a $75.0 million Revolving Credit Facility with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors, and the Lenders entered into the Credit Agreement with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer agreed to make loans and other financial accommodations to us in an aggregate amount of up to $75.0 million. Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. As a result, if we default on any of our obligations under the Credit Agreement, the Lenders could foreclose on their security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this report, we have been borrowed approximately $0.5 million under the Revolving Credit Facility. In order to service any indebtedness we may incur in the future, we would need to generate cash from our operating activities or other financings. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. Our business may not be able to generate sufficient cash flow from operations, and future borrowings or other financings may not be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This could place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary affirmative and negative covenants that limit our ability to engage in certain transactions that may be in our long-term best interest. The affirmative covenants include, among others, covenants requiring us to maintain a leverage ratio of no greater than 2.50 to 1.00 (increasing to 3.00 to 1.00 with respect to the fiscal quarter in which a material permitted acquisition is consummated and the immediately subsequent three fiscal quarters thereafter) and maintain minimum consolidated EBITDA (as defined in the Credit Agreement) for any trailing four-quarter period of not less than $45 million. The negative covenants include, among others, limitations on our ability to incur indebtedness and certain liens, make certain investments, become liable under contingent obligations in certain circumstances, make certain restricted payments, make certain dispositions within guidelines and limits, engage in certain affiliate transactions, alter our fundamental business and make certain fundamental changes.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are currently in compliance with the covenants contained in the Credit Agreement, we may breach these covenants in the future. Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, the Lenders may choose to declare an event of default and require that we immediately repay all amounts outstanding under the agreement, terminate any commitment to extend further credit and foreclose on the collateral. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use or draw down on our Credit Agreement or use other debt in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We draw down on or use debt to finance a portion of our deployed capital. The use of debt creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow and the level of our indebtedness could limit our ability to respond to changing business conditions. Our Credit Agreement imposes, and other debt we may incur in the future may impose, affirmative and negative covenants that could impact our operations and affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our Credit Agreement or other future indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price pertaining to our acquisitions in recent years have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to market and credit risks that could diminish their value and these risks could be greater during periods of extreme volatility or disruption in the financial and credit markets, which could adversely impact our business, financial condition, results of operations, liquidity and cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are subject to risks of credit defaults and changes in market values. Periods of macroeconomic weakness or recession, heightened volatility or disruption in the financial and credit markets could increase these risks, potentially resulting in other than temporary impairment of assets in our investment portfolio. Any event reducing the estimated fair value of these securities, other than on a temporary basis, could have a material and adverse effect on our business, results of operations, financial condition, liquidity and cash flows. If our investment manager, fails to react appropriately to difficult market, economic and geopolitical conditions, our investment portfolio could incur material losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a risk management framework in place to identify, assess and prioritize risks, including the market and credit risks to which our investments are subject. As part of that framework, we test our investment portfolio based on various market scenarios. Under certain stressed market scenarios, unrealized losses on our investment portfolio could lead to material reductions in its carrying value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in fair value below the amortized cost of a security requires management to assess whether an impairment has occurred. The decision on whether to record an impairment is determined in part by our assessment of the financial condition and prospects of a particular issuer, projections of future cash flows and recoverability of the particular security as well as management&#8217;s assertion of whether it is more likely than not that we will sell the particular security before recovery.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our charter documents and concentration of ownership may hinder or prevent change of control transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions contained in our certificate of incorporation and bylaws may discourage transactions involving an actual or potential change in our ownership.  In addition, our Board of Directors may issue shares of common or preferred stock without any further action by the stockholders. Our directors, officers and certain of our institutional investors collectively beneficially own a significant portion of our outstanding common stock. Such provisions and issuances may have the effect of delaying or preventing a change in our ownership. If changes in our ownership are discouraged, delayed or prevented, it would be more difficult for our current Board of Directors to be removed and replaced, even if you or our other stockholders believe that such actions are in the best interests of us and our stockholders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act provides for concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, and as such, the exclusive jurisdiction clauses set forth above would not apply to such suits. The choice of forum provisions in our amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been volatile and could experience a sudden decline in value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Continued volatility in the overall capital markets could reduce the market price of our common stock in spite of our operating performance. Further, high stock price volatility could result in higher share-based compensation expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future. Many factors may have a significant impact on the market price of our common stock, including, but not limited to, the following factors: results of or delays in our preclinical studies and clinical trials; the success of our collaboration agreements; publicity regarding actual or potential medical results relating to products under development by us or others; announcements of technological innovations or new commercial products by us or others; developments in patent or other proprietary rights by us or others; comments or opinions by securities analysts or major stockholders or changed securities analysts&#8217; reports or recommendations; future sales or shorting of our common stock by existing stockholders; regulatory developments or changes in regulatory guidance; litigation or threats of litigation; economic and other external factors or other disaster or crises; the departure of any of our officers, directors or key employees; period-to-period fluctuations in financial results; and price and volume fluctuations in the overall stock market.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to remediate the identified material weakness in our internal control over financial reporting, or if we experience additional material weakness or other deficiencies or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately and timely report our financial results, in which case our business may be harmed, investors may lose confidence in the accuracy and completeness of our financial reports, and the price of our common stock may decline.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and reporting on the effectiveness of our system of internal control. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. We are required to furnish annually a report by management of its assessment of the effectiveness of our internal control over financial reporting as of the end of our most recent fiscal year. In addition, our independent registered public accounting firm is required to provide a related attestation report on our internal control over financial reporting.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2023 year-end assessment of internal control over financial reporting, we determined that the material weakness related to the ineffective process-level control activities in the business combination processes were unremediated as of December 31, 2023. For further discussion of the material weakness identified and our remedial efforts, see Item 9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to remediate successfully our existing or any future material weakness or other deficiencies in our internal control over financial reporting: the accuracy and timing of our financial reporting may be adversely affected; our liquidity, our access to capital markets, the perceptions of our creditworthiness, and our ability to complete acquisitions may be adversely affected; we may be unable to maintain compliance with applicable securities laws, Nasdaq listing requirements, and the covenants under our debt instruments regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; and investors may lose confidence in our financial reporting. If any such event or circumstance were to occur, our stock price could decline and our business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations and economic downturn.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, military conflicts, including the wars between Russia and Ukraine and Israel and Hamas, terrorism, public health emergencies or pandemics, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future to contribute to, increased volatility and diminished expectations for the economy and the markets. Sanctions imposed by the United States and other countries in response to military conflicts, including the wars between Russia and Ukraine and Israel and Hamas, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may further decline. We cannot provide assurance that our investments are not subject to adverse changes in market value. If our investments experience adverse changes in market value, we may have less capital to fund our operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_19"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unresolved Staff Comments</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_799"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cybersecurity</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology (NIST), the International Organization for Standardization (ISO) and other applicable industry standards. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST, ISO and other standards as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity awareness training of our employees, incident response personnel, and senior management; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party risk management process for service providers, suppliers, and vendors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cybersecurity Governance</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the Committee) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior management team, including the Senior Director of Information Services, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. The Senior Director of Information Services has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.  </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Properties</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal facilities leased as of December&#160;31, 2023, including the location and size of each facility, and their designated use. We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed. </span></div><div style="margin-top:5pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:13.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate <br/>Square Feet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jupiter, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate headquarter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,850</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Boston, MA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,840</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Las Vegas, NV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lawrence, KS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Durham, NC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,300</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2032</span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">(1) Including lease executed in November 2023 with occupancy expected in approximately the second quarter of 2024.</span></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_25"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (11), Commitments and Contingencies&#8212;Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_28"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mine Safety Disclosures</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_34"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;LGND.&#8221; As of February&#160;26, 2024, there were approximately 339 holders of record of the common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business, to pay down debt and potentially for share repurchases. Any future determination to pay dividends on common stock will be at the discretion of our Board of Directors and will depend upon our financial condition, results of operations, capital requirements and such other factors as the board deems relevant. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December&#160;31, 2023, we did not repurchase any shares of our common stock under the stock repurchase program approved by our Board of Directors in April 2023, which allowed us to acquire up to $50 million of our common stock from time to time through April 2026.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the 2023 Annual Meeting Proxy Statement as defined in Item 10 below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalization. The graph compares total stockholder returns of our common stock, of all companies traded on the Nasdaq Stock market, as represented by the Nasdaq Composite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Index, and of the Nasdaq Biotechnology Stock Index, as prepared by The Nasdaq Stock Market Inc.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><img src="lgnd-20231231_g4.jpg" alt="2023 Stock Performance.jpg" style="height:323px;margin-bottom:5pt;vertical-align:text-bottom;width:652px"/></div><div style="margin-top:9pt;text-align:center;text-indent:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Value of $100 Invested Over Time</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:37.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite-Total Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">[RESERVED]</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_40"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_43"></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) will help readers understand our results of operations, financial condition, and cash flows. It is provided in addition to the accompanying consolidated financial statements and notes.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OmniAb Separation and Spin-Off</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the Merger Agreement, by and among our company, Avista Public Acquisition Corp. II (New OmniAb) and OmniAb, Inc., a Delaware corporation and then wholly-owned subsidiary of our company (OmniAb), and Orwell Merger Sub Inc. (Merger Sub), pursuant to which New OmniAb combined with OmniAb, our then-antibody discovery business (the OmniAb Business), in a Reverse Morris Trust transaction. Pursuant to the Separation Agreement, we transferred the OmniAb Business, including certain of our related subsidiaries, to OmniAb and, in connection therewith, distributed (the Distribution) to Ligand stockholders 100% of the common stock of OmniAb.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Distribution on November 1, 2022, in accordance with and subject to the terms and conditions of the Merger Agreement, Merger Sub merged with and into OmniAb (the Merger), with OmniAb continuing as the surviving company in the Merger and as a wholly-owned subsidiary of New OmniAb. After the Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after October 31, 2022. As a result, OmniAb's historical financial results through the Separation are reflected in our consolidated financial statements as discontinued operations.</span></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MD&amp;A is organized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Detailed discussion of our revenue and expenses from continuing operations for years ended December&#160;31, 2023, 2022 and 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity and Capital Resources.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discussion of key aspects of our consolidated statements of cash flows, changes in our financial position, and our financial commitments.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Critical Accounting Policies and Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion of significant changes we believe are important to understand the assumptions and judgments underlying our consolidated financial statements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Recent Accounting Pronouncements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2023 vs. FY 2022</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol - Core</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol - COVID</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88,066)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64,931)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by $64.9&#160;million, or 33%, to $131.3&#160;million in 2023 compared to $196.2&#160;million in 2022 primarily due to the $88.1&#160;million decrease in sales of COVID-related Captisol. The lower sales were due to reduced demand for remdesivir, a treatment for moderate or severe COVID-19. Core Captisol sales were $28.4&#160;million in 2023 compared to $16.4&#160;million in 2022. The higher sales were due to the timing of customer orders. Royalty revenue increased by $11.4&#160;million, or 16%, to $83.9&#160;million in 2023 compared to $72.5&#160;million in 2022. The increase in royalty revenue is primarily due to the increases in sales of Kyprolis, Rylaze and Pneumosil. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2022 vs. FY 2021</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol - Core</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol - COVID</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241,544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,299)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue from continuing operations decreased by $45.3 million, or 19%, to $196.2 million in 2022 compared to $241.5 million in 2021 primarily due to the $52.8 million decrease in sales of COVID-related Captisol. The lower sales were due to reduced demand for remdesivir, a treatment for moderate or severe COVID-19. Core Captisol sales were $16.4 million in 2022 compared to $23.4 million&#160;in 2021. The lower sales were due to the timing of customer orders. Royalty revenue increased by $23.6 million, or 48%, to $72.5 million in 2022 compared to $48.9 million in 2021. The increase in royalty revenue is driven primarily by increases in sales of drugs using the Pelican platform (Rylaze, Pneumosil and Teriparatide) along with an increase in sales of Kyprolis. Contract revenue decreased year over year in 2022 by $9.1 million primarily due to the timing of partner milestone events.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is a function of our partners' product sales and the applicable royalty rate. Kyprolis royalty rate is under a tiered royalty rate structure with the highest being 3.0%. Evomela has a contractually fixed royalty rate of 20%. Teriparatide injection has a tiered gross profit share between 25% and 40% on sales that have been adjusted for certain deductible items as defined in the respective license agreement. The Rylaze royalty rate is in the low single digits. Contract revenue includes service revenue, license fees and development, regulatory and sales based milestone payments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents royalty revenue by program:</span></div><div style="text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Royalty Revenue </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 Royalty Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyprolis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teriparatide injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.8%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.5%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,945.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,036.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) - Teriparatide injection sales have been adjusted for certain deductible items as defined in the respective license agreement, and the royalty revenue is based on a tiered gross profit share.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Costs and Expense</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2023 vs. FY 2022</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42,315)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71,715)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses for 2023 decreased by $71.7 million or 37% compared with 2022. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Captisol decreased year over year in 2023 primarily due to lower sales of Captisol during 2023 and by the capacity ramp-up right of use asset impairment of $9.8 million recorded in the fourth quarter of 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles decreased by $0.6 million in 2023 compared to 2022 with the decrease primarily due to the cessation of amortization of certain Pelican intangibles resulting from the sale of the Pelican business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any one time, we are working on multiple programs. As such, we generally do not track our R&amp;D expenses on a specific program basis. Our R&amp;D expenses decreased by $11.5 million in 2023 compared to 2022, with the decrease primarily due to lower share-based compensation and employee-related expenses, partially offset by an increase in R&amp;D expenses due to the Novan acquisition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased by $17.3 million in 2023 compared to 2022 primarily due to decreases in share-based compensation expense including a one-time charge associated with the retirement of our former CEO in the fourth quarter of 2022, and employee-related expenses, partially offset by an increase in G&amp;A expenses due to the Novan acquisition.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2022 vs. FY 2021</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,349)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses from continuing operations for 2022 increased by $55.5 million, or 40% compared with 2021. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Captisol decreased year over year in 2022 primarily due to lower sales of Captisol during 2022, partially offset by the capacity ramp-up right of use asset impairment of $9.8 million recorded in the fourth quarter of 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles remained steady in 2022 compared to 2021 as there have been no significant changes to the gross balance of intangible assets over these periods.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any one time, we are working on multiple programs. As such, we generally do not track our R&amp;D expenses on a specific program basis. Our R&amp;D expenses increased by $4.0 million in 2022 compared to 2021 due to higher employee-related expenses and increased facility related expenses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $23.3 million in 2022 compared to 2021 primarily due to increases in stock compensation expense including a one-time charge associated with the retirement of our former CEO in the fourth quarter of 2022, headcount-related expenses and legal expenses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income in 2021 was due to reducing the fair value of the CVR liability associated to the acquisition of Pfenex to zero, as the CVR payment expiration date passed on December 31, 2021 without achieving the triggering event. We did not have any other operating income in 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide forward-looking estimates of costs and time to complete our ongoing research and development projects as such estimates would involve a high degree of uncertainty. Uncertainties include our inability to predict the outcome of research and clinical studies, regulatory requirements placed upon us by regulatory authorities such as the FDA and EMA, our inability to predict the decisions of our partners, our ability to fund research and development programs, competition from other entities of which we may become aware in future periods, predictions of market potential for products that may be derived from our work, and our ability to recruit and retain personnel or third-party contractors with the necessary knowledge and skills to perform certain research. Refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional discussion of the uncertainties surrounding our research and development initiatives.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of Pelican</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on sale of Pelican in the amount of $2.1 million for 2023 represents the excess of the fair value of 1) our investment in Primrose Bio and other economic rights; 2) the carrying amount of Pelican business assets and liabilities together with allocated goodwill as of September 18, 2023, the date of sale; and 3) $15.0 million consideration paid.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2023 vs. FY 2022</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuation in the gain (loss) from short-term investments is primarily driven by the realized gain of $44.4 million from the sales of 5.0 million shares of Viking common stock in 2023, compared to no Viking shares sold in 2022. In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fluctuation is driven by the changes in the fair value of our ownership in Viking common stock (an unrealized gain of $2.6 million in 2023 as compared to an unrealized gain of $32.2 million in 2022). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term investments. The year over year increase in 2023 is primarily due to the significant interest rate increases by the federal reserve during 2023. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2023 Notes. In May 2023, the 2023 Notes matured, and we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash. The decrease in interest expense was primarily due to the zero debt outstanding balance after May 2023 compared to 2022. See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (8), Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, increased year over year in 2023 primarily due to a current expected credit loss (CECL) adjustment over the Elutia commercial license right of $3.2 million and a Selexis commercial license right impairment loss of $0.9 million compared to no CECL adjustment over similar assets in 2022. In addition, we recorded a $4.2 million gain on our debt extinguishments in 2022 compared to no loss on debt extinguishments in 2023.  See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (8), Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2022 vs. FY 2021</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,263)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,646)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuation in the gain (loss) from short-term investments is primarily driven by the changes in the fair value of our ownership in Viking common stock (an unrealized gain of $32.2 million in 2022 as compared to an unrealized loss of $9.6 million in 2021).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term investments. The year over year increase in 2022 is primarily due to the significant interest rate increases by the federal reserve during 2022.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2023 Notes. The year over year decrease was primarily due to the adoption of ASU 2020-06 which significantly reduced the debt discount balance subject to amortization. See additional information in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, we carried a lower average debt outstanding balance during 2022 as compared 2021. During 2022, we repurchased $266.4 million in principal of the 2023 Notes for $261.4 million in cash, including accrued interest of $0.5 million. See additional information in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (8), Debt.&#8221;</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, increased year over year in 2022 primarily due to a $4.2 million gain on our debt extinguishments in 2022 compared to $7.3&#160;million loss on debt extinguishments in 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See additional information in &#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (8), Debt.&#8221;</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax benefit (expense)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2023 vs. FY 2022</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:58.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense (benefit) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,219)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for 2023 and 2022 was 15% and 114%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions, which we expect to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. In 2023, the variance from the U.S. federal statutory rate of 21% was primarily attributable to the decrease in unrecognized tax benefits. In 2022, the variance from the U.S. federal statutory rate of 21% was primarily due to limitations on the deductibility of stock-based compensation for certain officers and a discrete tax expense of $24.8 million related to the valuation allowance established during the fourth quarter of 2022 against deferred tax assets for California research and development credits and net operating losses. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 requires taxpayers to capitalize and amortize R&amp;D expenditures over five years for domestic research and fifteen years for foreign research pursuant to Section 174 of the Internal Revenue Code of 1986, as amended. We recorded an increase of $4.7&#160;million to our current federal income tax expense and deferred tax assets for continuing operations during 2022 due to the capitalization of R&amp;D under Section 174. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7.2 million (11.3%) decrease from unrecognized tax benefits</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.2 million (3.4%) increase from the return to provision</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.2 million (1.9%) decrease from stock based compensaiton</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.0 million (1.6%) decrease from the foreign-derived intangible income deduction</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.8 million (1.3%) decrease from Section 162(m) limitation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$24.8 million (68.9%) increase from valuation allowance adjustments</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$5.9 million (16.3%) increase from Section 162(m) limitation</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.4 million (6.7%) decrease from the foreign-derived intangible income deduction</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.3 million (3.6%) increase due to excess tax benefits from share-based compensation which are recorded as a discrete item within the provision for income tax pursuant to ASU 2016-09</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss from Discontinued Operations</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss from discontinued operations for the years ended December 31, 2023, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $1.7 million, $28.1 million and $19.2 million, respectively. See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (4), Spin-off Of OmniAb.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_46"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we had approximately $170.3 million in cash, cash equivalents, and short-term investments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cash and cash equivalents and short-term investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased by $41.6 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from last year, due to factors described in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flow Summary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary source of liquidity, other than our holdings of cash, cash equivalents, and investments, has been cash flows from operations. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have liquidated our short-term investments and/or issued debt and equity securities to finance our business needs as a supplement to cash provided by operating activities. Our short-term investments include U.S. government debt securities, investment-grade corporate debt securities, bond funds and certificates of deposit. We have established guidelines relative to diversification and maturities of our investments in order to provide both safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. Additionally, we own certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 1.7 million shares of common stock in Viking.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we entered into an At-The-Market Equity Offering Sales Agreement (Sales Agreement) with Stifel, Nicolaus &amp; Company, Incorporated (Agent), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100.0 million in &#8220;at the market&#8221; offerings through the Agent (ATM Offering). The shelf registration statement relating to such shares included a prospectus covering the offering, issuance and sale of up to $100.0 million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the shelf registration statement. As of December 31, 2023 we have not issued any shares of common stock in the ATM Offering.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued the 2023 Notes with an aggregate principal amount of $750.0 million. A portion of the proceeds from such issuance totaling $49.7 million were used to repurchase 260,000 shares of our common stock. During 2021, we repurchased $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we repurchased $266.4 million in principal of the 2023 Notes for $261.4 million in cash, including accrued interest of $0.5 million. On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make payments to operating leases, including rental commitments on leases that have not yet commenced. For information on these obligations, see detail in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (7), Leases.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have commitments under our supply agreement with Hovione for Captisol purchases. The total purchase obligation as of December&#160;31, 2023 was $28.8 million, of which $8.6 million is expected to be paid within a year and the remaining amount is expected to be paid between 1 to 3 years.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $500.0 million of our common stock from time to time over a period of up to three years.  Our $500.0 million stock repurchase program expired in September 2022. In April 2023, our Board of Directors approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $50.0 million of our common stock from time to time through April 2026. We expect to acquire these shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchase of Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, we entered into a $75 million Revolving Credit Facility with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (each as defined in the Credit Agreement) entered into the Credit Agreement with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make loans and other financial accommodations to us in an aggregate amount of up to $75.0 million. At our option, borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term SOFR or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from 1.75% to 2.50% per annum for Term SOFR loans and 0.75% to 1.50% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from 0.30% to 0.45%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $74.5&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.5&#160;million for a letter of credit. The maturity date of the Revolving Credit Facility is October 12, 2026.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; continued advancement of research and development efforts; potential stock repurchases; and other business initiatives we plan to strategically pursue, including acquisitions and strategic investments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $3.2&#160;million in fair value of contingent consideration liabilities associated with the acquisitions to be settled in future periods.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Summary</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.664%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,577&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59,947)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(275,990)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137,761)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we generated cash from operations primarily from collections on our trade receivables. We used cash for investing activities primarily for the purchases of commercial license rights, Novan acquisition and investment in Primrose Bio, partially offset by cash from the sale and maturity of short-term investments including Viking shares. During the year, we used </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash for financing activities, including the repayment of the remaining $76.9 million principal amount upon maturity of the 2023 Notes and $0.3 million accrued interest in cash.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we generated cash from operations primarily from collections on our trade receivables. We generated cash from investing activities primarily from the sale and maturity of short-term investments. During the year, we used cash for financing activities, including the payments related to the extinguishment of certain 2023 Notes.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we generated cash from operations primarily due to the increase in net income. We generated cash from investing activities primarily from the sale and maturity of short-term investments. During the year, we used cash for financing activities, including the payments related to the extinguishment of certain 2023 Notes, partially offset by cash received from issuance of common stock under employee stock plans and bond hedge settlement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_49"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606 in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the occurrence of the development milestone or regulatory approval. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets &#8212; Impairment Assessments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Goodwill</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is evaluated annually for impairment using either a quantitative or qualitative analysis. Goodwill is tested for impairment at the reporting unit level, and is based on the net assets for each reporting unit, including goodwill and intangible assets.  Goodwill is assigned to each reporting unit, as this represents the lowest level that constitutes a business and is the level at which management regularly reviews the operating results. The Company performs a quantitative analysis using a discounted cash flow model and other valuation techniques, but may elect to perform a qualitative analysis.  In addition, goodwill is evaluated for impairment whenever an event occurs or circumstances change that would indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Events or circumstances that may result in an impairment review include changes in macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, other relevant entity-specific events, specific events affecting the reporting unit or sustained decrease in share price.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual goodwill impairment test was performed using a qualitative analysis in 2023 and 2022. A qualitative analysis is performed by assessing certain trends and factors, including projected market outlook and growth rates, forecasted and actual sales and operating profit margins, discount rates, industry data, and other relevant qualitative factors. These trends and factors are compared to, and based on, the assumptions used in the most recent quantitative analysis performed for each reporting unit. The results of the qualitative analyses did not indicate a need to perform quantitative analysis. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, during an interim period we used a quantitative assessment for goodwill and the relative fair value method to reallocate goodwill for the OmniAb business and Ligand core business due to the reorganization of the Company&#8217;s business discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (4), Spin-off of OmniAb.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Intangible Assets</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly perform reviews to determine if an event occurred that may indicate the carrying values of our intangible assets are impaired. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by comparing its carrying amounts to its undiscounted cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows and the pattern of utilization of a particular asset.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair value of identifiable intangible assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">                                                                                                                                                                                          </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the United States are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure and recognize compensation expense for all share-based payments, including restricted stock, ESPP and stock options, based on the estimated fair value. Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. A PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion and Modification of Equity Awards Outstanding at Separation Date</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the Merger Agreement to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-Distribution Ligand stock received a number of otherwise-similar awards either in post-Distribution Ligand stock or in a combination of post-Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the Merger Agreement that we entered into in connection with the Distribution. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the Separation; for OmniAb employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#8220;regular way&#8221; and &#8220;ex-distribution&#8221; markets during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five-trading day period prior to the closing of the business combination.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_52"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from interest rates and equity prices which could affect our results of operations, financial condition and cash flows. We manage our exposure to these market risks through our regular operating and financing activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Portfolio Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, our investment portfolio included investments in available-for-sale securities of $147.4 million, including the investment in Viking common stock of $32.2 million. These securities are subject to market risk and may decline in value based on market conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our licensing and business operations, we are exposed to foreign currency risk. Foreign currency exposures arise from transactions denominated in a currency other than the functional currency and from foreign denominated revenues and profit translated into U.S. dollars. Our license partners sell our products worldwide in currencies other than the U.S. dollar. Because of this, our revenues from royalty payments are subject to risk from changes in exchange rates. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase Captisol from Hovione, located in Lisbon, Portugal. Payments to Hovione are denominated and paid in U.S. dollars; however, the unit price of Captisol contains an adjustment factor which is based on the sharing of foreign currency risk between the two parties. The effect of an immediate 10% change in foreign exchange rates would not have a material impact on our financial condition, results of operations or cash flows. We do not currently hedge our exposures to foreign currency fluctuations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in interest rates related primarily to our investment portfolio. Our investment policy and strategy are focused on the preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy. We typically invest in highly rated securities, with the primary objective of minimizing the risk of principal loss. Our investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates across all maturities would not materially impact the fair market value of the portfolio in either period. </span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_55"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements and Supplementary Data</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_58"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:94.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_61">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-36">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_61">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_64">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_67">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_67">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_70">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_70">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_73">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_73">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_76">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_79">65</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Ligand Pharmaceuticals Incorporated (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes, (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;29, 2024, expressed an adverse opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:64.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment assessment of finite-lived intangibles </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, the Company&#8217;s finite-lived intangible assets totaled $299.6 million. As discussed in Note 1 to the consolidated financial statements, the Company reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable.  The Company did not identify indicators of impairment for its finite-lived intangibles at December 31, 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s assessment of impairment is challenging due to the degree of subjective auditor judgment necessary in evaluating management&#8217;s process to identify potential indicators of impairment and the related assessment of the severity of such indicators in determining whether a triggering event has occurred. A high degree of auditor judgment was required to evaluate potential triggering events which included market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results. The evaluation of triggering events could have a significant effect on the Company&#8217;s impairment assessment and the determination of whether further quantitative analysis of finite-lived intangible assets was required.</span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:64.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding of management&#8217;s process to identify indicators of impairment, including the qualitative analysis and related inputs and assumptions used in performing the analyses. We evaluated the design and tested the operating effectiveness of the controls that address the identification of indicators of impairment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company&#8217;s evaluation of indicators of impairment for finite-lived intangibles, our audit procedures included, among others, assessing the methodologies and testing the completeness and accuracy of the Company&#8217;s analysis of events or changes in circumstances. As part of our evaluation, we considered market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results, in assessing whether an indicator of impairments exists. </span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of the investment in Primrose Bio, Inc. <br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the consolidated financial statements, in September 2023, the Company acquired a non-controlling interest in Primrose Bio, Inc. The Company received common shares, preferred shares and restricted shares of Primrose Bio, Inc. in consideration for the sale of 100% of its ownership in Pelican. Determining the fair value of the investment in Primrose Bio, Inc. as consideration received required management to make significant judgments about the valuation methodologies, including the unobservable inputs and other assumptions and estimates used in the valuation of the investment in Primrose Bio, Inc. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s determination of the fair value of the consideration received involved complex judgement due to the selection of valuation methodologies and estimation used by management in determining the fair value of the Company&#8217;s investment in Primrose Bio, Inc. The Company used significant unobservable inputs which are significant to the valuation of the consideration received, such as discount rates, weight-average cost of capital, projected revenues and estimates of future cash flows. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s valuation of its investment in Primrose Bio, Inc. This included controls over management&#8217;s assessment of the significant inputs and estimates included in the determination of the fair value.   </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, evaluating the valuation methodologies used by the Company and testing significant unobservable inputs, estimates and the mathematical accuracy of the Company&#8217;s valuation calculation.  We involved our valuation specialists to assist with the application of these procedures.  We compared significant inputs and underlying data used in the Company&#8217;s valuation to agreements, information available from third-party sources and market data.  We obtained and evaluated information that corroborates or contradicts the Company&#8217;s inputs and assumptions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-37">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-38">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29, 2024</span></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_64"></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">22,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-41">147,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-42">166,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">32,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">30,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-45">23,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-46">13,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-47">6,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-48">4,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">237,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">263,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="f-55">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-56">8,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-57">299,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-58">342,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-59">103,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-60">105,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial license and other economic rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-61">67,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-62">10,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-63">15,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-64">12,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-65">6,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-66">10,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-67">3,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-68">4,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investment in Primrose Bio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-69">12,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-71">35,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-72">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">5,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-75">787,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-76">762,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">5,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">12,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">15,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="f-81">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="f-82">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue   </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-84">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-85">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-86">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-87">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-88">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 convertible senior notes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">76,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">16,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">98,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="f-94">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:LiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-95">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-96">3,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-97">31,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-98">30,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">27,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">21,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-103">86,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-104">165,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-105"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-106"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-107"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-108">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-110">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-114">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-117"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-118">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-119"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-120">60,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-121"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-122">17,556</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-124">16,951</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-125">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-126">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-127">198,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-128">147,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-129">817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-130">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-131">503,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-132">450,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">700,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-134">597,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-135">787,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">762,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_67"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:62.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:62.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-137">83,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-138">72,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-139">48,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-140">28,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-141">104,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-142">164,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-143">19,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-144">19,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-145">28,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-146">131,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-147">196,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-148">241,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="f-149">10,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="f-150">52,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="f-151">62,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-152">33,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-153">34,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-154">34,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">24,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">36,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-157">32,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-158">52,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-159">70,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-160">46,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="f-163">37,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-164">121,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-165">193,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-166">137,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Gain on sale of Pelican</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-167">2,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">11,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">3,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">103,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-173">46,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-174">28,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-175">5,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-176">7,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-177">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-178">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-179">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-180">1,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-181">19,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-182">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-185">1,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-186">4,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-187">7,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-188">51,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-189">32,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-190">31,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income tax from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-191">63,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-192">36,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-193">72,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-194">9,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-195">41,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-196">4,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-197">53,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-198">5,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-199">76,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-200">1,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-201">28,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-202">19,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss):</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">33,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-205">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net income (loss) from continuing operations per share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-206">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-207">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-208">4.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net loss from discontinued operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-209">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-210">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-211">1.16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net income (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-212">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-213">1.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-214">3.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in basic per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-215">17,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-216">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-217">16,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income (loss) from continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-218">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-219">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-220">4.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net loss from discontinued operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-221">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-222">1.67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-223">1.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-224">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-225">1.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-226">3.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in diluted per share calculation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-227">17,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-228">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-229">17,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_70"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-230">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-231">33,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-232">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gain (loss) on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-233">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-234">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-235">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-236">52,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-237">33,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-238">57,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">capital</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">income (loss)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retain earnings</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">equity</span></div></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-239">16,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-240">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">318,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-242">801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">709,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock<br/>compensation plans, net of shares withheld for payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-245">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-246">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-247">27,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-248">27,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-249">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-250">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-251">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-252">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reacquisition of equity due to 2023 debt extinguishment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-253">12,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-254">12,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Warrant and bond hedge unwind transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" scale="3" id="f-255">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" scale="3" id="f-256">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-258">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-259">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-260">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">372,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-262">917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">449,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">821,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-265">ASU 2020-06 adoption, net of tax (Note 1)</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-266">51,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-267">35,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">15,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock<br/>compensation plans, net of shares withheld for payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-269">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-270">5,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">5,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-272">60,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-273">60,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-274">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-275">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bond hedge transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" scale="3" id="f-276">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" scale="3" id="f-277">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distribution of OmniAb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-278">229,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-279">229,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">33,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">33,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-282">16,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-283">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">147,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-285">984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-286">450,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">597,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock<br/>compensation plans, net of shares withheld for payroll taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-288">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-289">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-290">17,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-291">17,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-292">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-293">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-294">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-295">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Final distribution of OmniAb </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-296">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-297">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Final tax impact of OmniAb distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" format="ixt:num-dot-decimal" scale="3" id="f-298">5,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" format="ixt:num-dot-decimal" scale="3" id="f-299">5,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-300">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-301">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-302">17,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-303">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-304">198,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-305">817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-306">503,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-307">700,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_76"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:59.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-308">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-309">33,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-310">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of Pelican</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-311">2,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="f-314">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="f-315">748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-316">36,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation of fixed assets and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-317">36,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-318">51,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-319">51,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-320">46,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-321">28,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-322">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization/accretion of premium (discount) on investments, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-323">1,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-324">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-325">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-326">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-327">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-328">16,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-329">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-333">4,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-334">7,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of commercial license and other economic rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="f-335">878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="f-336">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights" scale="3" id="f-337">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment to credit loss reserves of commercial license rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-338">3,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss of commercial license rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:ImpairmentLossOnCommercialLicenseRights" scale="3" id="f-341">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:ImpairmentLossOnCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:ImpairmentLossOnCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-344">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-345">5,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-346">4,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-347">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-348">60,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-349">38,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses from equity method investment in Primrose Bio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-350">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-353">11,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-354">20,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-355">8,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-356">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-357">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-358">1,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and dispositions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-359">2,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-360">55,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-361">28,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-362">10,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-363">12,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-364">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other economic rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-365">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-368">4,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-369">3,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-370">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable and payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-371">1,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-372">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-373">3,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-374">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-375">6,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-376">17,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-377">9,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-378">6,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-379">8,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-380">49,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-381">137,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-382">78,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of commercial license rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PurchaseforCommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-383">50,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:PurchaseforCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:PurchaseforCommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-386">3,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-387">17,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-388">8,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-389">126,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-390">51,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-391">181,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from commercial license rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="f-392">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="f-393">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:ProceedsFromCommercialLicenseRights" scale="3" id="f-394">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-395">148,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-396">209,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-397">154,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturity of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-398">45,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-399">24,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-400">67,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for equity method investment - Nucorion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="f-402">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for investment in Primrose Bio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-404">15,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for Novan acquisition, net of restricted cash received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-407">10,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-411">960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-412">1,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used) provided in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-413">11,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-414">163,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-415">30,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash transferred to OmniAb at separation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsForSeparation" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:PaymentsForSeparation" format="ixt:num-dot-decimal" scale="3" id="f-417">1,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:PaymentsForSeparation" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment at maturity/repurchase of 2023 Notes </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-419">76,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-420">260,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-421">155,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments under finance lease obligations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-422">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-423">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-424">9,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for OmniAb transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-426">6,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-428">949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from bond hedge settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="f-432">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-433">18,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-434">22,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-435">3,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-436">33,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-437">4,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-438">8,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-439">6,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:59.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-442">18,446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-444">1,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-445">1,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-446">59,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-447">275,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">137,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-449">22,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-450">25,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-451">28,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-452">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-453">19,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-454">47,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and  cash equivalents  at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-455">22,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-456">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-457">19,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid during the year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-458">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-459">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-460">3,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-461">8,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-462">11,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-463">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of tangible assets acquired, net of cash and restricted cash received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" format="ixt:num-dot-decimal" scale="3" id="f-464">17,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="3" id="f-467">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-470">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-473">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-476">19,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash paid for Novan </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-479">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued Primrose transaction costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid" scale="3" id="f-482">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty from commercial license rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" scale="3" id="f-485">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued commercial license rights purchases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" scale="3" id="f-488">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued debt issuance costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-491">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued fixed asset purchases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-495">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-496">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedInventoryPurchases" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:AccruedInventoryPurchases" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:AccruedInventoryPurchases" format="ixt:num-dot-decimal" scale="3" id="f-499">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-500">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-501">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-502">221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_79"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_82"></div><div style="margin-top:14pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this report to &#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Ligand Pharmaceuticals Incorporated and its consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-503" continuedAt="f-503-1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-503-1" continuedAt="f-503-2"><ix:nonNumeric contextRef="c-1" name="lgnd:BusinessSpinOffAndMigrationPolicyTextBlock" id="f-504" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. We operate in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-505">one</ix:nonFraction> reportable segment: development and licensing of biopharmaceutical assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-506" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:continuation id="f-507-1" continuedAt="f-507-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the spin-off of the OmniAb antibody discovery business (the&#8220;OmniAb Business&#8221;) in November 2022 met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-507-2"> (&#8220;ASC 205-20&#8221;).</ix:continuation> For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Spin-off of OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-508" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-509" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-510" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-62" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-511">33</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-512">45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-513">47</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-514">20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-515">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-516">12</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-517">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;<ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-518">10</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;<ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-519">10</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><ix:nonNumeric contextRef="c-1" name="lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" id="f-520" continuedAt="f-520-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-2" continuedAt="f-503-3"><ix:continuation id="f-520-1" continuedAt="f-520-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of other income (expense) within the consolidated statements of operations.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three&#160;months and less than twenty-five months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-520-2">Equity securities consist of mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, Equity securities in Primrose Bio, or non-current other assets, based on the nature of the securities and their availability for use in current operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses </span></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-521-1">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.</ix:continuation> During the years ended December&#160;31, 2023, 2022 and 2021, we considered the current and expected future economic and market conditions and concluded an increase of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-522">0.2</ix:nonFraction>&#160;million, a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-523">0.3</ix:nonFraction>&#160;million, and an increase of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-4" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-524">0.01</ix:nonFraction>&#160;million of allowance for credit losses, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-525" continuedAt="f-525-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-525-1">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</ix:continuation> During the years ended December&#160;31, 2023 and 2022, we recorded an obsolete inventory charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-526">0.2</ix:nonFraction>&#160;million and  $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-527">1.1</ix:nonFraction>&#160;million, respectively. There was <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="f-528">no</ix:nonFraction> adjustment to inventory recorded for the year ended December&#160;31, 2021. As of December&#160;31, 2023 and 2022, inventory included prepayments of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-529">4.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-530">5.9</ix:nonFraction>&#160;million, respectively, to our supplier for Captisol.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-531" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:f-532">one</span> to <ix:nonNumeric contextRef="c-74" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-533">nine years</ix:nonNumeric>, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-534" continuedAt="f-534-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-3" continuedAt="f-503-4"><ix:continuation id="f-534-1" continuedAt="f-534-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-534-2">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</ix:continuation> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="right" contextRef="c-75" decimals="INF" name="lgnd:NumberOfContingentValueRightsIssued" format="ixt-sec:numwordsen" scale="0" id="f-535">four</ix:nonFraction> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (6), Fair Value Measurement and Note (9), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-536" continuedAt="f-536-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2023, noting no impairment. </span></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-536-1">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</ix:continuation> We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-4" continuedAt="f-503-5"><ix:nonNumeric contextRef="c-1" name="lgnd:CommercialLicenseRightsPolicyTextBlock" id="f-537" continuedAt="f-537-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For commercial license rights, we account them in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Receivables, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and are measured at amortized cost using the prospective effective interest method described in ASC 835-30,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If management determines it can reliably estimate future cash flows of the asset, we amortize the asset using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. If cash flows are not reliably estimable, the asset is accounted for using the non-accrual method. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate commercial license rights for impairment on an individual basis. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize an allowance for current expected credit losses under ASC 326 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments &#8211; Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our commercial license rights. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for changes in projected cash flows and credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other economic rights, which are characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce the asset as the funds are expended. </span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:continuation id="f-537-1" continuedAt="f-537-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights are evaluated for impairment on an ongoing basis. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Commercial License and Other Economic Rights</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-537-2">&#8221;.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-538" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="lgnd:OtherInvestmentsPolicyPolicyTextBlock" id="f-539" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments present equity securities that primarily include common stocks, preferred stocks we invested. Equity securities without readily determinable or estimable fair values are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-540" continuedAt="f-540-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Captisol Sales</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-5" continuedAt="f-503-6"><ix:continuation id="f-540-1" continuedAt="f-540-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-540-2">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.</ix:continuation> During the year ended December&#160;31, 2023, the amount recognized as revenue that was previously deferred at December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-541">0.1</ix:nonFraction> million. During the year ended December&#160;31, 2022, the amount recognized as revenue that was previously deferred at December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-542">0.4</ix:nonFraction> million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-543" continuedAt="f-543-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-544">35,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-545">30,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-546">27,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-547">10,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-548">10,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-549">10,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teriparatide injection </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-550">11,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-551">15,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-552">5,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rylaze </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-553">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-554">8,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-555">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-556">13,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-557">7,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-558">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-559">83,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-560">72,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-561">48,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-6" continuedAt="f-503-7"><ix:continuation id="f-543-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol - Core</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-562">28,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-563">16,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-564">23,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol - COVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-566">88,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-567">140,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-568">28,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-569">104,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-570">164,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-571">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-572">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-573">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-574">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-575">2,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-576">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-577">16,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-578">9,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-579">17,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-580">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-581">6,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-582">6,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-583">19,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-584">19,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-585">28,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-586" continuedAt="f-586-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-586-1">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (CRO) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-587" continuedAt="f-587-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a <ix:nonNumeric contextRef="c-109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-588">three-year</ix:nonNumeric> period, with a range of <ix:nonFraction unitRef="number" contextRef="c-110" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-589">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-111" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-590">200</ix:nonFraction>% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be <ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="f-591">0</ix:nonFraction>% given that except for 2007, during which we declared a cash dividend on our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-592">2.50</ix:nonFraction> per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the <ix:nonNumeric contextRef="c-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-593">six month</ix:nonNumeric> anniversary of the date of grant, and 1/48 each month thereafter for <ix:nonNumeric contextRef="c-115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-594">forty-two months</ix:nonNumeric>. RSUs and PSUs granted to employees vest over <ix:nonNumeric contextRef="c-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-595">three years</ix:nonNumeric>. All option awards generally expire <ix:nonNumeric contextRef="c-117" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-596">ten years</ix:nonNumeric> from the date of grant.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-587-1">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-7" continuedAt="f-503-8"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-597" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-598" continuedAt="f-598-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. The 2023 Notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:continuation id="f-598-1" continuedAt="f-598-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-598-2">, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-599" continuedAt="f-599-1" escape="true">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</ix:nonNumeric></span><ix:continuation id="f-599-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-600">17,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-601">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-602">16,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-603">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-605">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-606">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-608">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-609">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-612">17,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-613">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-614">17,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-615">4,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-616">6,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-617">4,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><div style="margin-top:5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-618" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-619" escape="true"><ix:continuation id="f-503-8"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Updates, Recently Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, we adopted ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2021-08&#8221;). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic 606&#8221;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued updated accounting guidance related to annual and interim segment disclosures. The updated accounting guidance, among other things, requires disclosure of certain significant segment expenses. We will adopt the updated accounting guidance in our Annual Report on Form 10-K for the year ended December 31, 2024. We do not expect impact from the adoption of the new accounting guidance will have material impact to our segment disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_752"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-622" continuedAt="f-622-1" escape="true">Sale of Pelican Business and Investment in Primrose Bio</ix:nonNumeric></span></div><ix:continuation id="f-622-1" continuedAt="f-622-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#8220;Pelican&#8221;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration" format="ixt:num-dot-decimal" scale="0" id="f-623">2,146,957</ix:nonFraction> common shares, <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration" format="ixt:num-dot-decimal" scale="0" id="f-624">4,278,293</ix:nonFraction> preferred shares and <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration" format="ixt:num-dot-decimal" scale="0" id="f-625">474,746</ix:nonFraction> restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" format="ixt:num-dot-decimal" scale="6" id="f-626">15.0</ix:nonFraction> million in exchange for <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="lgnd:InterestInPotentialDevelopmentMilestone" scale="-2" id="f-627">50</ix:nonFraction>% of potential development milestones and certain commercial milestones from <ix:nonFraction unitRef="contract" contextRef="c-131" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-628">two</ix:nonFraction> contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive <ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-629">25</ix:nonFraction>% of sales revenue of PeliCRM197 above $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="lgnd:SalesRevenueMilestone" format="ixt:num-dot-decimal" scale="6" id="f-630">3.0</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-631">35</ix:nonFraction>% of all PeliCRM197 licensing revenue in perpetuity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#8217;s RYLAZE, Merck&#8217;s VAXNEUVANCE and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-632" continuedAt="f-632-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-633">8,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-634">19,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="3" id="f-635">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-636">8,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" scale="3" id="f-637">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="3" id="f-638">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" scale="3" id="f-639">495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-640">8,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="3" id="f-641">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNetAsset" format="ixt:num-dot-decimal" scale="3" id="f-642">27,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="3" id="f-643">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" format="ixt:num-dot-decimal" scale="3" id="f-644">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNetContributions" format="ixt:num-dot-decimal" scale="3" id="f-645">47,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock" id="f-646" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-647">13,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-648">32,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-649">3,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-650">49,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="f-651">4.1</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-652">2.1</ix:nonFraction>&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="f-653">1.2</ix:nonFraction>&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we will receive <ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-654">25</ix:nonFraction>% of sales revenue of PeliCRM197 above $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="lgnd:SalesRevenueMilestone" format="ixt:num-dot-decimal" scale="6" id="f-655">3.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-656">35</ix:nonFraction>% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and thus, will be recognized as the underlying contingencies are resolved.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will receive <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="lgnd:InterestInPotentialDevelopmentMilestone" scale="-2" id="f-657">50</ix:nonFraction>% of potential development milestones and certain commercial milestones from <ix:nonFraction unitRef="contract" contextRef="c-131" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-658">two</ix:nonFraction> contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of  $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-659">3.2</ix:nonFraction>&#160;million, at the disposition date, which was included under other long-term asset in our <ix:nonNumeric contextRef="c-1" name="lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-660">consolidated balance sheet</ix:nonNumeric>. They </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-622-2" continuedAt="f-622-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are recognized as derivative assets under ASC 815,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and has been marked to fair value as of December&#160;31, 2023 with an adjustment of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-661">0.3</ix:nonFraction>&#160;million. Any change in fair value is recorded to Other income (expense) in our consolidated statement of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Fair Value Measurement&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investment in Primrose Bio</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over its operating and financial results. In applying the equity method, we record the investment at fair value. Ligand's proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations for the year ended December&#160;31, 2023. Our equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Our share of the net loss of Primrose Bio since the divestiture date for year ended December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="f-662">1.8</ix:nonFraction>&#160;million, which reduced Ligand's equity method investment accordingly.  Any income of loss from our equity method investments are recorded to Other income (expense) in our consolidated statement of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the Series A preferred stock investment in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value. There have been no observable price changes or impairments identified since September 18, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, our President and Chief Operating Officer, Matt Korenberg, became a board member of Primrose Bio.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-663" continuedAt="f-663-1" escape="true">Acquisition</ix:nonNumeric></span></div><ix:continuation id="f-663-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novan</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2023, we closed the transaction to acquire certain assets of Novan, Inc. (&#8220;Novan&#8221;) pursuant to the agreement we entered into with Novan on July 17, 2023 for $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-664">15.0</ix:nonFraction> million in cash (which agreement contemplated Novan filing for bankruptcy relief) and provided up to $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-665">15.0</ix:nonFraction> million in debtor-in-possession (&#8220;DIP&#8221;) financing inclusive of a $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-666">3.0</ix:nonFraction> million bridge loan funded on the same day. Novan filed for Chapter 11 reorganization on July 17, 2023. On September 27, 2023, the bankruptcy court approved our $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-667">12.2</ix:nonFraction> million bid to purchase from Novan its lead product candidate berdazimer topical gel, <ix:nonFraction unitRef="number" contextRef="c-145" decimals="3" name="lgnd:BusinessCombinationAcquiredPercentage" scale="-2" id="f-668">10.3</ix:nonFraction>%, all other assets related to the NITRICIL technology platform and the rights to one commercial stage asset. The remaining commercial assets of Novan will be sold to other parties. The approved $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-669">12.2</ix:nonFraction> million bid was credited to the $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-670">15.0</ix:nonFraction> million DIP financing, with the balance of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="f-671">2.8</ix:nonFraction> million and accrued interest repaid to us. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as business combination. We recorded $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-672">3.1</ix:nonFraction> million of acquisition-related costs for legal, due diligence and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for the year ended December&#160;31, 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-673" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-674">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-675">13,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-676">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" scale="3" id="f-677">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="3" id="f-678">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-679">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-680">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-681">2,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-682">3,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-683">13,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for Novan, including restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-684">10,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DIP loan fees and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="lgnd:BusinessCombinationLoanFeesAndInterest" format="ixt:num-dot-decimal" scale="3" id="f-685">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-686">12,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. Acquired intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-687">10.7</ix:nonFraction>&#160;million related to core technology. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="c-142" decimals="3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="f-688">29</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="c-142" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-689">15</ix:nonNumeric> years. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired other liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-690">13.7</ix:nonFraction>&#160;million related to a royalty and milestone payments purchase agreement, entered by Novan in 2019 and assumed as part of the acquisition, which previously provided Novan $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="lgnd:ContingentMilestonePurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-691">25.0</ix:nonFraction>&#160;million of funding used primarily in the clinical development of berdazimer topical gel, <ix:nonFraction unitRef="number" contextRef="c-145" decimals="3" name="lgnd:BusinessCombinationAcquiredPercentage" scale="-2" id="f-692">10.3</ix:nonFraction>%. Pursuant to the purchase agreement, Novan will pay ongoing quarterly payments, calculated based on an applicable percentage per product of any upfront fees, milestone payments, royalty payments or equivalent payments received by Novan pursuant to any out-license agreement, net of any upfront fees, milestone payments, royalty payments or equivalent payments paid by Novan to third parties pursuant to any agreements under which Novan has in-licensed intellectual property with respect to such products.  If Novan decides to commercialize any product on its own following regulatory approval, as opposed to commercializing through an out-license agreement or other third-party arrangement, Novan will be obligated to pay a low single digits royalty on net sales of such products. This contract liability was fair valued based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the related programs mentioned above, by applying a discount rate of <ix:nonFraction unitRef="pure" contextRef="c-146" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-693">14.0</ix:nonFraction>% (revenue risk-adjusted discount rate).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired, liabilities assumed and purchased intangibles are provisional. Specifically, the provisional amounts include estimated projections on the completion of the clinical development process and projected revenue related to commercializing products based on the underlying technology as well as the assumed underlying contracts. The accounting for these amounts falls within the measurement period and, therefore, we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:continuation id="f-622-3" continuedAt="f-622-4">Spin-off of OmniAb</ix:continuation></span></div><ix:continuation id="f-622-4" continuedAt="f-622-5"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the Separation Agreement to separate our OmniAb Business and the Merger Agreement, pursuant to which APAC would combine with OmniAb, and acquire Ligand's OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#8220;Transactions&#8221;).  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the closing date of the Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the Distribution. Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the Distribution, Ligand distributed on a pro rata basis to its shareholders as of October 26, 2022 shares of the common stock of OmniAb representing <ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" scale="-2" id="f-694">100</ix:nonFraction>% of Ligand&#8217;s interest in OmniAb. Immediately following the Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#8220;OABI.&#8221; After the Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company determined its antibody discovery business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="lgnd:DeferredTaxAssetsAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-695">1.7</ix:nonFraction> million tax provision adjustment related to deferred taxes during the year ended December&#160;31, 2023 that was attributable to the discontinued operations. <ix:continuation id="f-632-1" continuedAt="f-632-2">The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):</ix:continuation></span></div><ix:continuation id="f-632-2" continuedAt="f-632-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:76.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-696">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-698">25,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-699">35,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-700">26,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-701">35,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-702">10,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-703">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-704">38,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-705">36,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-706">13,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-707">10,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-708">62,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-709">60,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-710">36,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-711">24,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-713">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:fixed-zero" scale="3" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="f-715">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" scale="3" id="f-716">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" sign="-" name="lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-717">1,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" scale="3" id="f-718">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" scale="3" id="f-719">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-720">35,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-721">24,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-722">7,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-723">5,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-724">28,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-725">19,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-632-3"><ix:continuation id="f-622-5"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" sign="-" name="lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" scale="3" id="f-726">554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-727">1,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-728">13,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-729">14,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" format="ixt:num-dot-decimal" scale="3" id="f-730">9,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" format="ixt:num-dot-decimal" scale="3" id="f-731">9,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:CapitalExpenditureDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-734">5,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:CapitalExpenditureDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-735">4,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersInvestingActivity" scale="3" id="f-736">960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersInvestingActivity" scale="3" id="f-737">720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-738">1,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-739">1,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-740">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-741">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_91"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="c-1" name="lgnd:CommercialLicenseAndOtherEconomicRightsTextBlock" id="f-742" continuedAt="f-742-1" escape="true">Commercial License and Other Economic Rights</ix:nonNumeric></span></div><ix:continuation id="f-742-1" continuedAt="f-742-2"><ix:nonNumeric contextRef="c-1" name="lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" id="f-743" continuedAt="f-743-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, commercial license and other economic rights consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elutia and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-744">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-745">11,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-746">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-747">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-748">9,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-749">8,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-750">8,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-751">7,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="lgnd:CommercialLicenseRights" scale="3" id="f-752">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-753">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-754">8,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-755">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ovid </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-756">30,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" scale="3" id="f-757">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-758">30,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:fixed-zero" scale="3" id="f-759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:fixed-zero" scale="3" id="f-760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tolerance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-762">25,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" scale="3" id="f-763">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-764">25,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:fixed-zero" scale="3" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:fixed-zero" scale="3" id="f-766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-768">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-770">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:fixed-zero" scale="3" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:fixed-zero" scale="3" id="f-772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-774">87,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-775">20,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-776">67,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:CommercialLicenseRightsGross" format="ixt:num-dot-decimal" scale="3" id="f-777">28,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:CommercialLicenseRightsCumulativeAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-778">18,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:CommercialLicenseRights" format="ixt:num-dot-decimal" scale="3" id="f-779">10,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="lgnd:CommercialLicenseRightsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-780">11.2</ix:nonFraction> million, credit loss adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="lgnd:CommercialLicenseRightsCreditLossAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-781">8.1</ix:nonFraction> million, and impairment of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="lgnd:CommercialLicenseRightsImpairments" format="ixt:num-dot-decimal" scale="6" id="f-782">0.9</ix:nonFraction> million as of December&#160;31, 2023. </span></div></ix:nonNumeric><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="f-743-1">(2) Amounts represent accumulated amortization to principal of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="lgnd:CommercialLicenseRightsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-783">11.6</ix:nonFraction> million and credit loss adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="lgnd:CommercialLicenseRightsCreditLossAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-784">6.5</ix:nonFraction> million as of December&#160;31, 2022.</ix:continuation> </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis, S.A. (Selexis) in April 2013 and April 2015, CorMatrix Cardiovascular, Inc. (CorMatrix) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. ("Elutia") in September 2023) in 2017, Dianomi Therapeutics, Inc. in January 2019, Ovid Therapeutics Inc. in October 2023, Tolerance Therapeutics, Inc. in November 2023, and Palvella Therapeutics, Inc. in December 2023. Commercial license and other economic rights acquired are accounted for as financial assets as further discussed below. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively. We recorded a $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="lgnd:ImpairmentOfCommercialLicense" format="ixt:num-dot-decimal" scale="6" id="f-785">0.9</ix:nonFraction> million impairment loss for Selexis commercial license rights during the year ended December&#160;31, 2023 as a result of recently reduced programs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Elutia Inc. pursuant to which we will receive royalties from certain marketed products that Elutia acquired from CorMatrix. Pursuant to the agreement, we received $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:ProceedsFromRoyaltiesReceived" format="ixt:num-dot-decimal" scale="6" id="f-786">10.0</ix:nonFraction> million in 2017 from Elutia to buydown the royalty rates on the products CorMatrix sold to Elutia. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Elutia (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a <ix:nonFraction unitRef="number" contextRef="c-167" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="f-787">5</ix:nonFraction>% royalty on the products Elutia acquired in the CorMatrix Asset Sale, reduced from the original <ix:nonFraction unitRef="number" contextRef="c-168" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="f-788">20</ix:nonFraction>% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-742-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;) between CorMatrix and us. In addition, Elutia has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" format="ixt:num-dot-decimal" scale="6" id="f-789">10.0</ix:nonFraction> million of additional milestones tied to cumulative net sales of the products Elutia acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Elutia in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of <ix:nonFraction unitRef="number" contextRef="c-167" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="f-790">5</ix:nonFraction>% on such pipeline products. The Amended Interest Purchase Agreement will terminate <ix:nonNumeric contextRef="c-170" name="lgnd:RoyaltyAgreementExpirationPeriod" format="ixt-sec:duryear" id="f-791">10</ix:nonNumeric> years from the date of the first commercial sale of such products. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Elutia commercial license right as a financial asset in accordance with ASC 310. During the year ended December&#160;31, 2023, we further considered the current and expected future economic and market conditions and recorded a $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="lgnd:CommercialLicenseRightsCreditLossAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-792">3.2</ix:nonFraction> million credit loss adjustment to Elutia commercial license rights based on the assessment of current company performance and nonpayment by Elutia in recent quarters. This credit loss adjustment was recorded to General and administrative expense in our consolidated statement of operations. As of December 31, 2023, management is in process of modifying the payment terms with Elutia and has placed the loan on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2023 is <ix:nonFraction unitRef="number" contextRef="c-172" decimals="3" name="lgnd:ForecastedCashFlowsEffectiveInterestRatePercent" scale="-2" id="f-793">2.5</ix:nonFraction>%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2023 and 2022 were allocated accordingly between revenue and the amortization of the commercial license rights. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had accounted for commercial license rights related to Dianomi on a non-accrual basis and had fully reserved the credit loss as of December&#160;31, 2022. Dianomi Therapeutics, Inc. was dissolved in July 2023; therefore, we removed the related commercial license rights as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we made an investment of $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" format="ixt:num-dot-decimal" scale="6" id="f-794">30</ix:nonFraction> million to acquire a <ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-795">13</ix:nonFraction>% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. We performed predominant analysis and determined that the predominant characteristics of the underlyings are the sales-based milestones and royalties since the value of the projected cash flows tied to the underlyings are highly correlated with changes in the projected cash flows from royalties and commercial milestones and not the regulatory milestones. Therefore, the Ovid contract qualifies for the royalty scope exception under ASC815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and is accounted for as a financial asset in accordance with ASC 310. As soticlestat is in Phase 3 clinical trials, management has placed the investment on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we acquired Tolerance Therapeutics, Inc. (&#8220;Tolerance Therapeutics&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-796">20</ix:nonFraction> million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of TZIELD (teplizumab), that is owed a royalty of less than <ix:nonFraction unitRef="number" contextRef="c-175" decimals="2" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="f-797">1</ix:nonFraction>% on worldwide net sales. TZIELD is marketed by Sanofi in 2023. We account for the Tolerance commercial license right as a financial asset in accordance with ASC 310</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Due to the early stages of TZIELD's commercialization, management has placed the investment on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we announced the expansion of its strategic partnership with Palvella to accelerate Phase 3 development of QTORIN rapamycin for the treatment of Microcystic Lymphatic Malformations ("Microcystic LMs").  According to the terms of the second amendment to the development funding and royalties agreement, Palvella received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" format="ixt:num-dot-decimal" scale="6" id="f-798">5.0</ix:nonFraction> million from Ligand. In return for the upfront payment, among other contractual changes, the tiered royalty payable by Palvella to Ligand was increased to between <ix:nonFraction unitRef="number" contextRef="c-177" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-799">8.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-178" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-800">9.8</ix:nonFraction>% based on annual aggregate worldwide net sales of QTORIN rapamycin. We are not obligated to provide additional funding to Palvella for development or commercialization of OTORIN. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce our asset as the funds are expended by Palvella. As of December 31, 2023, of the $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" format="ixt:num-dot-decimal" scale="6" id="f-801">5.0</ix:nonFraction> million upfront funding related to the second amendment with Palvella, none of the funding to Palvella was expended, and we will reduce our asset as the funds are expended by Palvella in the future. Our CEO and director, Todd Davis, is a director of Palvella, who beneficially owns less than <ix:nonFraction unitRef="number" contextRef="c-179" decimals="2" name="lgnd:MinimumBeneficialOwnershipInReportingEntityPercentage" scale="-2" id="f-802">2</ix:nonFraction>% of Palvella's outstanding equity. Mr. Davis recused himself from all of the board's consideration of the agreement between us and Palvella, including any financial analysis, the terms of the amendment and the vote to approve the purchase agreement and the related transactions.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-803" continuedAt="f-803-1" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="f-803-1" continuedAt="f-803-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><div style="padding-left:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-804" continuedAt="f-804-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-805">115,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-806">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-807">107,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-809">32,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-810">32,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><ix:nonNumeric contextRef="c-1" name="lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-813"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></ix:nonNumeric></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-814">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-817">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-818">150,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-819">39,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-820">107,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-821">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-822">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-825">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-826">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-828">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-830">3,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-832">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-833">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-834">103,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-835">3,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-836">99,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="f-837">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-838">63,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-839">63,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-842">166,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-843">67,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-844">99,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-845">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-846">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-849">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-850">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-852">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="lgnd:AmountsOwedToFormerLicensorFairValueDisclosure" scale="3" id="f-854">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="lgnd:AmountsOwedToFormerLicensorFairValueDisclosure" scale="3" id="f-855">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="lgnd:AmountsOwedToFormerLicensorFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="lgnd:AmountsOwedToFormerLicensorFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-858">3,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-859">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-860">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-861">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) In connection with the Purchase and Sale Agreement with Primrose Bio, we received <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="lgnd:InterestInPotentialDevelopmentMilestone" scale="-2" id="f-862">50</ix:nonFraction>% of potential development milestones and certain commercial milestones from <ix:nonFraction unitRef="contract" contextRef="c-131" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-863">two</ix:nonFraction> contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under other </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-803-2" continuedAt="f-803-3"><ix:continuation id="f-804-1" continuedAt="f-804-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">long-term asset in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The fair value of the derivative assets was determined using a discounted cash flow approach using a discount rate in line with the stages of the underlying contracts.</span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-804-2">(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="cvr" contextRef="c-213" decimals="INF" name="lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" format="ixt-sec:numwordsen" scale="0" id="f-864">four</ix:nonFraction> tradable CVRs, <ix:nonFraction unitRef="cvr" contextRef="c-213" decimals="INF" name="lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" format="ixt-sec:numwordsen" scale="0" id="f-865">one</ix:nonFraction> CVR from each of <ix:nonFraction unitRef="cvr" contextRef="c-214" decimals="INF" name="lgnd:NumberOfContingentValueRightsSeries" format="ixt-sec:numwordsen" scale="0" id="f-866">four</ix:nonFraction> respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every <ix:nonNumeric contextRef="c-213" name="lgnd:BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" format="ixt-sec:durwordsen" id="f-867">six months</ix:nonNumeric> as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="INF" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-868">375.0</ix:nonFraction> million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:ContractWithCustomerAssetGross" format="ixt:num-dot-decimal" scale="6" id="f-869">10.0</ix:nonFraction> million payment upon initiation of a Phase 3 clinical trial.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-871" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-870" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-872">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to equity security warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="f-873">135</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of derivative assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="f-874">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-875">3,531</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-876">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-877">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-878">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-879">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-880">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-881">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-882">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="f-883">274</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-884">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-885">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-886">265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-887">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets and long-lived assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-888"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="0" id="f-889">no</ix:nonFraction></ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended December&#160;31, 2023. Other than the finance lease equipment discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (7), Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="0" id="f-890"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-891">no</ix:nonFraction></ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended and December&#160;31, 2022. There was <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-892"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="0" id="f-893">no</ix:nonFraction></ix:nonFraction> impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-803-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued liabilities, deferred revenue, current operating lease liabilities, current financing lease liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license rights are measured and carried on the balance sheet at amortized cost using the effective interest method or on a non-accrual basis. Management calculates the fair value of commercial license rights using a forecasted royalty receipts.  The projected future cash flows derive from royalty payments and milestones, then discounted using appropriate individual discount rates. The fair value of commercial license and other economic rights assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair value and related carrying values of commercial license rights as of December&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="lgnd:CommercialLicenseRightsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-894">75.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="lgnd:CommercialLicenseRightsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-895">62.3</ix:nonFraction>&#160;million, respectively.  The estimated fair value and related carrying value of the commercial license rights as of December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="lgnd:CommercialLicenseRightsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-896">13.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="lgnd:CommercialLicenseRightsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-897">10.2</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_100"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-899" continuedAt="f-899-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-898" continuedAt="f-898-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-899-1" continuedAt="f-899-2"><ix:continuation id="f-898-1" continuedAt="f-898-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance lease</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="lgnd:PurchaseCommitmentConsiderationPaidToDate" format="ixt:num-dot-decimal" scale="6" id="f-900">69.1</ix:nonFraction> million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory" format="ixt:num-dot-decimal" scale="6" id="f-901">50.2</ix:nonFraction> million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-902">18.9</ix:nonFraction> million was recognized as a right of use asset. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the current COVID status, our forecast for COVID-related Captisol has been significantly reduced, which triggered an indicator of impairment of the right of use asset as of December&#160;31, 2022. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:FinanceLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-903">9.8</ix:nonFraction>&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December&#160;31, 2022. As of December&#160;31, 2022 the remaining right of use asset balance is $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-904">4.0</ix:nonFraction>&#160;million which will be amortized straight-line over the remaining <ix:nonNumeric contextRef="c-72" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-905">6</ix:nonNumeric> years lease term. In the year-ended December&#160;31, 2023, we recorded no impairment to this asset group as there have been no indicators of impairment, and as of December&#160;31, 2023, the remaining right of use asset balance is $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-906">3.4</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating lease </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to <ix:nonNumeric contextRef="c-74" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-907">nine years</ix:nonNumeric>, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="c-74" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-908">five years</ix:nonNumeric>. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-899-2"><ix:continuation id="f-898-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" format="ixt:num-dot-decimal" scale="6" id="f-909"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-910">1.1</ix:nonFraction></ix:nonFraction>&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.</span></div><ix:nonNumeric contextRef="c-1" name="lgnd:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-911" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-912">6,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-913">10,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-914">3,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-915">4,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-916">9,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-917">15,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-918">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-919">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-920">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-921">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:LeaseLiabilityCurrent" scale="3" id="f-922">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LeaseLiabilityCurrent" scale="3" id="f-923">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-924">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-925">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-926"><span style="-sec-ix-hidden:f-927">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-928">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-929">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-930">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-931">11,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-933" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-932" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-934">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-935">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-936">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-937">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-938">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-939">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-940">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-941">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-942">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-944">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-946">8,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-947">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:OperatingLeaseLiabilityTenantImprovementAllowance" scale="3" id="f-948">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:FinanceLeaseLiabilityTenantImprovementAllowance" format="ixt:fixed-zero" scale="3" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-950">2,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-951">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-952">6,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-953">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-954">7.4</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-955">7.7</ix:nonFraction>%. As of December&#160;31, 2022, our operating leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-956">9.3</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-957">7.1</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-958">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-959">1.7</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-960">1.4</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-961">0.3</ix:nonFraction> million) and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-962">0.7</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-963">0.7</ix:nonFraction> million) for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our finance leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-964">3.4</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-965">6.8</ix:nonFraction>%. As of December&#160;31, 2022, our finance leases have a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-966">1.1</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-967">4.1</ix:nonFraction>%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December&#160;31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities were both $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-4" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="6" id="f-968">0.05</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022. Finance lease expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-969">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-970">2.3</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_103"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-971" continuedAt="f-971-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-971-1" continuedAt="f-971-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-222" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-972">0.75</ix:nonFraction>% Convertible Senior Notes due 2023</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-973">750</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-222" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-974">0.75</ix:nonFraction>% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-975">733.1</ix:nonFraction> million. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-971-2" continuedAt="f-971-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-976">16.9</ix:nonFraction> million of issuance costs, which primarily consisted of underwriting, legal and other professional fees and is being amortized to interest expense using the effective interest method over the <ix:nonNumeric contextRef="c-223" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-977">five years</ix:nonNumeric> expected life of the 2023 Notes. The effective interest rate for the year ended December&#160;31, 2023 is <ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-978">0.5</ix:nonFraction>%. During the year ended December&#160;31, 2023 we recognized a total of $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="f-979">0.6</ix:nonFraction> million in interest expense which includes $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="6" id="f-980">0.4</ix:nonFraction> million in contractual interest expense and $<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-981">0.2</ix:nonFraction> million in amortized issuance costs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-982">152.0</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-983">156.0</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-984">0.3</ix:nonFraction>&#160;million. We accounted for the repurchase as a debt extinguishment, which resulted in (1) a loss of $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-985">7.3</ix:nonFraction>&#160;million reflected in other income (expense), net, in our consolidated statement of operations for the year ended December&#160;31, 2021, (2) a $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" sign="-" name="lgnd:IncreaseDecreaseInDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="f-986">13.7</ix:nonFraction>&#160;million reduction in debt discount, and (3) a $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-987">10.2</ix:nonFraction>&#160;million reduction to additional paid in capital, related to the reacquisition of the equity component in our consolidated balance sheet as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-988">266.4</ix:nonFraction> million in principal amount of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-989">261.4</ix:nonFraction> million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-990">0.5</ix:nonFraction> million We accounted for the repurchase as a debt extinguishment, which resulted in a gain of $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-991">4.2</ix:nonFraction> million reflected in other income (expense), net, in our consolidated statement of operations for the year ended December&#160;31, 2022, and a $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" sign="-" name="lgnd:IncreaseDecreaseInDebtDiscount" format="ixt:num-dot-decimal" scale="6" id="f-992">1.3</ix:nonFraction> million reduction in debt discount. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-993">76.9</ix:nonFraction> million principal amount and $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-994">0.3</ix:nonFraction> million accrued interest in cash.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="c-222" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-995">3,018,327</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-222" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-996">206.65</ix:nonFraction> per share and are exercisable when and if the 2023 Notes are converted. We paid $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="lgnd:PaymentsforConvertibleBondHedges" format="ixt:num-dot-decimal" scale="6" id="f-997">140.3</ix:nonFraction> million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants did not have any rights with respect to the convertible bond hedges.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering <ix:nonFraction unitRef="shares" contextRef="c-222" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-998">3,018,327</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-222" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-999">315.38</ix:nonFraction> per share, subject to certain adjustments. We received $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="f-1000">90.0</ix:nonFraction> million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, in connection with the repurchases of approximately $<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-1001">20.3</ix:nonFraction>&#160;million in principal of the 2023 Notes for approximately $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1002">19.1</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-1003">0.1</ix:nonFraction>&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, in connection with the repurchases of $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-1004">152.0</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1005">156.0</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-1006">0.3</ix:nonFraction>&#160;million, we entered into Warrant Early Unwind Agreements and Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. We paid $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="lgnd:PaymentsToUnwindWarrants" format="ixt:num-dot-decimal" scale="6" id="f-1007">18.4</ix:nonFraction>&#160;million as part of the Warrant Early Unwind Agreements reducing the number of shares covered by the warrants from <ix:nonFraction unitRef="shares" contextRef="c-222" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1008">3,018,327</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1009">2,559,254</ix:nonFraction>.  As of December 31, 2023, the number of warrants that remain outstanding is <ix:nonFraction unitRef="shares" contextRef="c-224" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1010">545,000</ix:nonFraction>. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, in connection with the repurchases of $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="lgnd:DebtInstrumentRepurchasedAmountDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1011">227.8</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1012">223.7</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-1013">0.4</ix:nonFraction>&#160;million made during the six months ended June 30, 2022, we entered into Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-971-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-1014" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the 2023 Notes (in thousands) as of December&#160;31, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:71.212%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.588%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-1015">76,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="f-1016">159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-1017">76,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="f-1018">74,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, we entered into a $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1019">75.0</ix:nonFraction> million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (as defined in the Credit Agreement) entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make loans and other financial accommodations to us in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1020">75.0</ix:nonFraction> million. At our option, borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term Secured Overnight Financing Rate ("Term SOFR") or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from <ix:nonFraction unitRef="number" contextRef="c-236" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1021">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-237" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1022">2.50</ix:nonFraction>% per annum for Term SOFR loans and <ix:nonFraction unitRef="number" contextRef="c-238" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1023">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-239" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1024">1.50</ix:nonFraction>% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from <ix:nonFraction unitRef="number" contextRef="c-240" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1025">0.30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-241" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1026">0.45</ix:nonFraction>%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1027">74.5</ix:nonFraction>&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1028">0.5</ix:nonFraction>&#160;million for letter of credit. The maturity date of the Revolving Credit Facility is October 12, 2026.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were no events of default or violation of any covenants under our financing obligations.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_109"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-1029" continuedAt="f-1029-1" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><ix:continuation id="f-1029-1" continuedAt="f-1029-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1029-2" continuedAt="f-1029-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-1030" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2023 and 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bond Fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1031">63,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1033">537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1034">63,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1035">17,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1036">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1037">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1038">17,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1039">14,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1040">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1041">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1042">14,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1043">11,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1044">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1045">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1046">11,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1047">6,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1048">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1049">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1050">6,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1051">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1053">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1054">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1055">5,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-1057">5,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-1058">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1059">120,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1060">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-1061">5,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1062">115,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bond fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1063">81,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1065">1050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1066">80,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1067">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1068">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1070">7,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1071">6,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1072">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1073">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1074">6,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1075">5,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1076">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1077">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1078">4,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1079">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-1081">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1082">2,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1083">5,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1084">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-1085">4,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1086">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1088">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-1089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-1090">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1091">108,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-1092">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-1093">5,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1094">103,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-1095" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-1096">55,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1097">55,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-1098">13,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1099">13,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-1100">68,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1101">68,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-1102" continuedAt="f-1102-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1029-3" continuedAt="f-1029-4"><ix:continuation id="f-1102-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1103">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1104">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1107">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1108">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1109">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1110">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1111">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1112">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1113">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1114">2,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1115">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1116">10,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1119">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1120">10,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1121">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1122">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1125">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1126">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-1128">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1129">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1130">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1131">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1132">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1133">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1134">17,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1135">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1136">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1137">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1138">20,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1139">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1140">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1143">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1144">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1145">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1146">3,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1147">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="f-1148">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1149">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1150">4,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1152">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1156">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1157">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1158">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1161">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1162">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1163">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1164">12,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1165">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="f-1166">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1167">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1168">13,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of <ix:nonFraction unitRef="position" contextRef="c-4" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-1169">31</ix:nonFraction> positions which were in an unrealized loss position with a total of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-1170">0.01</ix:nonFraction> million unrealized losses as of December&#160;31, 2023. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments: Investment in Viking:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ownership in Viking was approximately <ix:nonFraction unitRef="number" contextRef="c-257" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="f-1171">1.7</ix:nonFraction>% as of December&#160;31, 2023, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and December&#160;31, 2022, our investment in Viking is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-1172">32.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-1173">63.1</ix:nonFraction> million, respectively, and included in short-term investments on the balance sheet. During the year ended December&#160;31, 2023, we sold <ix:nonFraction unitRef="shares" contextRef="c-257" decimals="-5" name="lgnd:NumberOfSharesSoldOfEquityMethodInvestee" format="ixt:num-dot-decimal" scale="6" id="f-1174">5.0</ix:nonFraction> million shares of Viking common stock and recognized a realized gain of $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1175">44.4</ix:nonFraction> million. During the year ended December&#160;31, 2021, we sold <ix:nonFraction unitRef="shares" contextRef="c-258" decimals="-5" name="lgnd:NumberOfSharesSoldOfEquityMethodInvestee" format="ixt:num-dot-decimal" scale="6" id="f-1176">0.6</ix:nonFraction> million shares of Viking common stock and recognized a realized gain of $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1177">3.6</ix:nonFraction> million. There were no sales of Viking common stock during the year ended December&#160;31, 2022. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-1178" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1179">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1180">14,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1181">12,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1182">7,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1183">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1184">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1185">22,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1186">22,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1187">6,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1188">10,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1189">15,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1190">12,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:f-1191">one</span> to <ix:nonNumeric contextRef="c-74" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-1192">nine years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1193">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1194">3.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-1195">2.4</ix:nonFraction> million was recognized for the years ended December&#160;31, 2023, 2022, and 2021, respectively, and was included in operating expenses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><ix:continuation id="f-1029-4" continuedAt="f-1029-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-1196" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1197">103,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1198">105,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Completed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1199">42,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1200">55,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1201">20,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1202">22,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1203">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1204">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1205">1,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1206">1,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1207">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1208">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1209">19,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1210">17,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1211">360,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1212">362,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1213">93,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1214">65,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1215">402,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1216">448,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to <ix:nonNumeric contextRef="c-4" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1217">20</ix:nonNumeric> years. Amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1218">33.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1219">34.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1220">34.2</ix:nonFraction> million was recognized for the years ended December&#160;31, 2023, 2022, and 2021, respectively. Estimated amortization expense for the years ending December&#160;31, 2024 through 2028 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1221"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1222"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1223"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1224"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-1225">32.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year. For each of the years ended December&#160;31, 2023, 2022, and 2021, there was <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1226"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1227"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1228">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairment of intangible assets with finite lives.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1229" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1230">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1231">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1232">2,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-1233">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer deposit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:AccruedCustomerDepositsCurrent" scale="3" id="f-1234">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:AccruedCustomerDepositsCurrent" scale="3" id="f-1235">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:LicenseeAccrualCurrent" scale="3" id="f-1236">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LicenseeAccrualCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1237">3,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="f-1238">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="f-1239">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1240">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1241">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="f-1242">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="f-1243">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1244">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1245">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1246">12,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1247">15,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-1248" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:UnrecognizedTaxBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1249">14,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:UnrecognizedTaxBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1250">21,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novan contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1251">13,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:OtherMiscellaneousNonCurrentLiabilities" scale="3" id="f-1253">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:OtherMiscellaneousNonCurrentLiabilities" scale="3" id="f-1254">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1255">27,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1256">21,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we entered into <ix:nonFraction unitRef="agreement" contextRef="c-273" decimals="INF" name="lgnd:NumberOfContingentValueRightAgreements" format="ixt-sec:numwordsen" scale="0" id="f-1257">four</ix:nonFraction> CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div><ix:nonNumeric contextRef="c-1" name="lgnd:ScheduleofContingentLiabilitiesTableTextBlock" id="f-1258" continuedAt="f-1258-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2023 and 2022 (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1258-1"><ix:continuation id="f-1029-5"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:21.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="f-1259">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="f-1260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1261">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="f-1262">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1263">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1264">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="f-1265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="f-1266">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1267">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="f-1268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1269">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1270">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="f-1271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1272">551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="f-1273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1274">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1275">3,707</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="f-1276">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1277">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1278">3,513</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1279">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1280">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" format="ixt:fixed-zero" scale="3" id="f-1281">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1282">3,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_112"></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1283" continuedAt="f-1283-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-1283-1" continuedAt="f-1283-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-1284" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense from continuing operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1285">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1286">10,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1287">9,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1288">19,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1289">39,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1290">19,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1291">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1292">50,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1293">29,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion and Modification of Equity Awards Outstanding at Separation Date</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the Merger Agreement to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-Distribution Ligand stock received a number of otherwise-similar awards either in post-Distribution Ligand stock or in a combination of post-Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the Merger Agreement that we entered into in connection with the Distribution. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the Separation; for OmniAb employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#8220;regular way&#8221; and &#8220;ex-distribution&#8221; markets during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five-trading day period prior to the closing of the business combination.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;). The amended and restated 2002 Plan, which is referred to herein as the &#8220;Restated Plan&#8221; was amended to increase the shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="c-290" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1294">1.0</ix:nonFraction> million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, our board of directors (the &#8220;Board&#8221;) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the &#8220;2022 Inducement Plan&#8221;). The terms of the 2022 Inducement Plan are substantially similar to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved <ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1295">300,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-292" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1296">1.0</ix:nonFraction> million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1283-2" continuedAt="f-1283-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1297" continuedAt="f-1297-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1298">2,561,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1299">85.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-293" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1300">6.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1301">59,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1302">393,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1303">159.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1304">619,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1305">54.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1306">136,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1307">110.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1308">2,199,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-30" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1309">106.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1310">6.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1311">113,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1312">1,391,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-30" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1313">98.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1314">5.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1315">80,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1316">2,199,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-30" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1317">106.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1318">6.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1319">113,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1320">863,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1321">91.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-294" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1322">34,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1323">38.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-294" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1324">40,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1325">78.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1326">2,987,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-295" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1327">102.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-294" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1328">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1329">14,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at October 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1330">1,769,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-295" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1331">102.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-294" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1332">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1333">13,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of October 31, 2022, before Separation and Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1334">2,987,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-295" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1335">102.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-294" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1336">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1337">14,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation due to Separation, Before Regrant</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-296" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1338">2,987,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-1339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1340">3,584,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-298" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1341">60.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1342">50,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-298" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1343">30.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1344">542,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-298" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1345">56.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1346">2,991,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1347">61.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-298" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1348">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1349">30,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1350">1,559,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1351">60.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-298" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1352">4.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1353">17,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1354">2,991,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1355">61.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-298" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1356">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1357">30,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1358">537,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1359">72.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1360">489,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1361">45.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1362">399,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1363">66.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1364">2,640,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1365">65.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1366">5.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1367">8,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1368">1,784,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1369">64.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1370">4.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1371">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1372">2,640,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1373">65.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1374">5.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1375">8,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-1297-1">(1) Options granted primarily relate to the modifications in connection with the Separation which resulted in new stock option grants at the modification date fair value.</ix:continuation> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-299" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1376">36.65</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-300" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1377">28.90</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-301" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1378">80.08</ix:nonFraction> per share, respectively. The total intrinsic value of all options exercised during 2023, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1379">12.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1380">4.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1381">77.3</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1382">22.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1383">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1384">33.0</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1283-3" continuedAt="f-1283-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-1385" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-302" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1386">32.78</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-302" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1387">49.99</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1388">301,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-302" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1389">3.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-303" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1390">42.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1391">290,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-303" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1392">42.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1393">50.36</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1394">52.30</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1395">99,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-304" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1396">7.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-305" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1397">52.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1398">42,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-305" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1399">52.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1400">52.84</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1401">52.84</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1402">357,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-306" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1403">5.11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-307" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1404">52.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1405">221,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-307" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1406">52.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1407">54.81</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1408">58.28</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1409">270,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-308" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1410">5.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-309" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1411">55.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1412">244,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-309" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1413">55.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-310" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1414">58.49</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-310" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1415">66.54</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1416">283,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-310" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1417">5.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-311" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1418">62.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1419">160,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-311" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1420">61.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1421">66.70</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1422">68.74</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1423">450,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-312" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1424">4.81</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-313" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1425">67.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1426">380,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-313" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1427">68.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-314" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1428">69.39</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-314" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1429">75.09</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1430">484,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-314" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1431">8.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-315" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1432">72.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1433">109,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-315" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1434">72.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-316" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1435">78.56</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-316" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1436">99.80</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1437">209,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-316" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1438">4.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-317" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1439">89.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1440">192,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-317" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1441">90.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-318" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1442">103.42</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-318" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1443">103.42</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1444">170,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-318" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1445">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-319" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1446">103.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1447">128,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-319" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1448">103.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-320" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1449">114.15</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-320" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1450">114.15</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1451">12,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-320" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1452">4.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-321" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1453">114.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1454">12,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-321" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1455">114.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1456">2,640,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1457">5.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1458">65.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1459">1,784,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1460">64.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1461" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1462">3.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-323" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1463">4.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1464">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-325" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1465">4.3</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-326" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1466">0.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-327" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1467">1.2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-322" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1468">45</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-323" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1469">54</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-324" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1470">49</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-325" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1471">55</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-326" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1472">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-327" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1473">63</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-322" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1474">4.7</ix:nonNumeric> to <ix:nonNumeric contextRef="c-323" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1475">5.3</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-324" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1476">2.0</ix:nonNumeric> to <ix:nonNumeric contextRef="c-325" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1477">6.5</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-326" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1478">4.7</ix:nonNumeric> to <ix:nonNumeric contextRef="c-327" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1479">6.3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1480">26.2</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-117" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1481">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1482">1.1</ix:nonFraction> million of total unrecognized compensation cost related to non-vested OmniAb stock options received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-329" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1483">0.9</ix:nonNumeric> years. </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-1484" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-330" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1485">264,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-330" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1486">138.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1487">260,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1488">89.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1489">138,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1490">120.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1491">19,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1492">58.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at October 31, 2022, before Separation and Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1493">366,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1494">114.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited due to Separation, Before Regrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-333" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1495">366,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-1496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1497">424,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-335" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1498">75.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1499">73,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-335" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1500">75.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1501">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-335" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1502">89.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-336" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1503">348,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1504">75.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1505">203,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-337" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1506">83.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1507">181,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-337" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1508">74.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1509">20,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-337" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1510">65.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1511">350,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-338" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1512">81.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1283-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1513">15.2</ix:nonFraction>&#160;million. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-340" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1514">1.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1515">0.1</ix:nonFraction>&#160;million of total unrecognized compensation cost related to non-vested OmniAb stock awards received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-342" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1516">0.1</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-343" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-1517">30,801</ix:nonFraction> shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="f-1518">1,250</ix:nonFraction> shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to <ix:nonFraction unitRef="number" contextRef="c-344" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1519">85</ix:nonFraction>% of the fair market value of the common stock on the first of a <span style="-sec-ix-hidden:f-1520">six</span> month offering period or purchase date, whichever is lower. There were <ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1521">5,080</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1522">8,479</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1523">8,448</ix:nonFraction> shares issued under the ESPP in 2023, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, our Board of Directors has approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1524">50.0</ix:nonFraction> million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. During the years ended December&#160;31, 2023, 2022 and 2021, we did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="f-1525"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="f-1526">no</ix:nonFraction></ix:nonFraction>t repurchase any common stock, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the Market Equity Offering Program</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we filed a registration statement on Form S-3 (the &#8220;Shelf Registration Statement&#8221;), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Stifel, Nicolaus &amp; Company, Incorporated (the &#8220;Agent&#8221;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="lgnd:SaleOfStockAuthorizedOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1527">100.0</ix:nonFraction>&#160;million in &#8220;at the market&#8221; offerings through the Agent (the &#8220;ATM Offering&#8221;). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="lgnd:SaleOfStockAuthorizedOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1528">100.0</ix:nonFraction>&#160;million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. To date, we have not issued any shares of common stock in the ATM Offering.</span></div></ix:continuation><div id="iddb0f73760bc4f19bc0fe394970fd53f_115"></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1529" continuedAt="f-1529-1" escape="true">Commitment and Contingencies: Legal Proceedings</ix:nonNumeric></span></div><ix:continuation id="f-1529-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received <ix:nonFraction unitRef="complaint" contextRef="c-349" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1530">three</ix:nonFraction> civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the <ix:nonFraction unitRef="complaint" contextRef="c-349" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1531">three</ix:nonFraction> complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_118"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1532" continuedAt="f-1532-1" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1532-1" continuedAt="f-1532-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1533" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:66.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1534">1,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1535">10,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-1536">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1537">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1538">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1539">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1540">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1541">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1543">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1544">10,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1545">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1546">9,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1547">3,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1548">2,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1549">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1550">34,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1551">1,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1552">10,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1553">30,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1554">4,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1555">9,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1556">41,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1557">4,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1558" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:66.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1559">13,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1560">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1561">15,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1562">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1563">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1564">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-1565">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-1566">2,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" scale="3" id="f-1567">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-1568">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-1569">535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1570">7,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1571">7,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="f-1572">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="f-1573">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="f-1574">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="f-1575">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-1576">7,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1577">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1578">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1579">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="f-1580">405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="f-1581">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1582">1,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" format="ixt:fixed-zero" scale="3" id="f-1583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" scale="3" id="f-1584">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" format="ixt:fixed-zero" scale="3" id="f-1585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subpart F income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome" scale="3" id="f-1586">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome" scale="3" id="f-1587">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1588">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1589">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1590">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1591">12,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1592">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1593">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1594">1,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" scale="3" id="f-1595">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1596">5,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1597">3,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1598">1,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1599">24,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1600">11,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1601">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1602">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-1603">3,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1604">9,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1605">41,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1606">4,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2023, 2022 and 2021. The valuation allowance amount in connection with the deferred taxes decreased $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1607">1.2</ix:nonFraction>&#160;million in 2023, increased $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1608">24.8</ix:nonFraction> million in 2022 and increased $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-1609">11.2</ix:nonFraction> million in 2021.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1610" continuedAt="f-1610-1" escape="true">Deferred tax assets </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1532-2" continuedAt="f-1532-3"><ix:continuation id="f-1610-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(liabilities) are comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:76.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1611">45,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1612">53,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1613">26,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1614">26,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1615">4,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1616">4,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1617">11,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1618">11,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1619">15,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1620">14,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1621">103,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1622">110,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1623">57,699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1624">57,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1625">46,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1626">53,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1627">66,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1628">64,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1629">10,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1630">10,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1631">77,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1632">75,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1633">31,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1634">22,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1635">48.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1636">165.1</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2028. We also have $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1637">8.5</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2040. We have $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1638">29.4</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1639">95.5</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1640">16.5</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1641">81.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1642">168.3</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2028. We also had $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1643">8.5</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2040. We had $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1644">29.0</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1645">96.1</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-1646">15.6</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2023 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" id="f-1647" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2023, 2022 and 2021 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1648">29,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1649">29,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1650">31,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1651">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1652">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1653">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1654">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1656">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1657">6,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1658">512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1659">3,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1660">22,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1661">29,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1662">29,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1663">20.6</ix:nonFraction> million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1532-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2023 and December&#160;31, 2022, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, and United Kingdom with varying statutes of limitations. The federal statute of limitation remains open for the 2020 tax year to the present.&#160;The state income tax returns generally remain open for the 2019 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.  The Company's 2019 and 2020 California tax returns are under examination by the California Franchise Tax Board. The Company does not anticipate that the examination will result in a material adjustment to its financial statements.  No other income tax returns are currently under examination. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_124"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_127"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controls and Procedures</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for maintaining disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, and have concluded our disclosure controls and procedures were not effective at a reasonable assurance level as of December&#160;31, 2023 due to the material weakness described below.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the material weakness described below, management performed additional analyses and other procedures to ensure that our consolidated financial statements were prepared in accordance with GAAP. Accordingly, management believes that the consolidated financial statements included in this Annual Report fairly present, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented, in accordance with GAAP.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles; providing reasonable assurance that receipts and expenditures are made in accordance with our management and directors; and providing reasonable assurance that</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) as set forth in the 2013 Internal Control-Integrated Framework. Based on our evaluation under the 2013 framework in Internal Control - </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrated Framework, management concluded that our internal controls over financial reporting were not effective as of December&#160;31, 2023 as a result of the material weakness discussed in the paragraphs that follow below.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management concluded that the Company did not implement and maintain effective controls related to the valuation of the acquired intangible and contract liability, specifically controls over the review of cash flow forecasts used in the valuation of the acquired intangible asset and the discount rate used in the valuation of the contract liability. The deficiencies in our internal control over financial reporting due to the material weakness described above did not result in any misstatement in our consolidated financial statements or other disclosures. These deficiencies created, however, a reasonable possibility that a material misstatement in our consolidated financial statements would not be prevented or detected on a timely basis.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Remediation Plan</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to address the identified material weakness and enhance our internal controls related to our business combination purchase price allocation process, we continue to maintain our financial reporting process we followed to prepare consolidated financial statements in accordance with GAAP for audit committee meetings on a quarterly and annual basis. We have hired additional accounting personnel and third party consultants with appropriate knowledge, experience, and/or training commensurate with our technical accounting and financial reporting requirements to enhance the process going forward. Our ongoing remediation efforts are focused on continued employee training related to internal control over financial reporting. Management  will continue to work to improve the respective process and controls over our business combination purchase price allocation process. However, the material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, has audited the Company&#8217;s consolidated financial statements included in this Annual Report on Form 10-K and has issued an attestation report, included herein, on the effectiveness of our internal control over financial reporting as of December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stockholders and Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Ligand Pharmaceuticals Incorporated&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, because of the effect of the material weakness described below on the achievement of the objectives of the control criteria, Ligand Pharmaceuticals Incorporated (the Company) has not maintained effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management&#8217;s assessment. Management has identified a material weakness in the design and operation of controls related to the Company&#8217;s valuation of the acquired intangible asset and contract liability in a business combination, specifically controls over the review of cash flow forecasts used in the valuation of the acquired intangible asset and the discount rate used in the valuation of the contract liability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes. This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the 2023 consolidated financial statements, and this report does not affect our report dated February&#160;29, 2024 which expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29, 2024</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_130"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"/><td style="width:28.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:69.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">      </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">     Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2023, none of our officers or directors <ix:nonNumeric contextRef="c-362" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1664"><ix:nonNumeric contextRef="c-362" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1665">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-362" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1666"><ix:nonNumeric contextRef="c-362" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1667">terminated</ix:nonNumeric></ix:nonNumeric> any such trading arrangements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_139"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Board of Directors has adopted a Code of Conduct and Ethics Policy (&#8220;Code of Conduct&#8221;) that applies to all officers, directors and employees. The Company will promptly disclose (1) the nature of any amendment to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our Code of Conduct that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. The Code of Conduct can be accessed via our website (http://www.ligand.com), Corporate Overview page. You may also request a free copy by writing to: Investor Relations, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information under Item&#160;10 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2023.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_142"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Compensation</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;11 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_145"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;12 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_148"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;13 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_151"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Accountant Fees and Services</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;14 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_157"></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits and Financial Statement Schedule</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Financial statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:91.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_58">Index to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_58">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_61">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_64">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_67">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_67">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_70">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_70">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_73">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_73">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_76">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_76">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_79">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iddb0f73760bc4f19bc0fe394970fd53f_79">65</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Schedules not included herein have been omitted because they are not applicable or the required information is in the consolidated financial statements or notes thereto.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The following exhibits are filed as part of this Form 10-K and this list includes the Exhibit Index.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Filing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex21.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex21.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex21.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of March, 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated, OmniAb, Inc. and Orwell Merger Sub Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex22.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex22.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex22.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation and Distribution Agreement, dated as of March 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/0000936392-98-001000.txt">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of the Company. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-58823</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 9, 1998</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616301000008/0000886163-01-000008-0002.txt">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2000 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2001</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616304000015/ex3-6.txt">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 30, 2004 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2004</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510264942/dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November&#160;19, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000157/exhibit36.htm">3.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certification of Incorporation of the Company, dated June 19, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-233130</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616320000116/exhibit31-ligandxfourt.htm">3.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fourth Amended and Restated Bylaws of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgndexhibi41.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specimen stock certificate for shares of the common stock of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit43_ligand-descripti.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit43_ligand-descripti.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description of Registered Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000038/ligand-2022annualmeetingpr.htm#i858b093ea9a44e01b80bfe450a9cebf2_350">10.1#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Stock Incentive Plan (as amended and restated effective June 10, 2022)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 22, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appendix A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000063/lgnd-2019annualmeetingproxy.htm#sb6e62536bc644ccb9ea4178e9b4c6808">10.2#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Employee Stock Purchase Plan (as amended and restated effective June 6, 2019)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 24, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appendix B</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000031/lgnd-ex105_optionagreement.htm">10.3#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Option Grant Notice and Stock Option Agreement under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000095013706000420/a16037orexv10w289.txt">10.4#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Issuance Agreement for non-employee directors under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-131029</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;13, 2006</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.289</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">10.5#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">10.6#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan - Performance-Based RSU Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">10.7#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Executive Officer Change in Control Severance Agreement </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August&#160;22, 2007</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000027/a103-changeinctrlseverance.htm">10.8#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Change in Control Severance Agreement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit_108xligand-amended.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit_108xligand-amended.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit_108xligand-amended.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Severance Plan, effective November 1, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/dathttps://www.sec.gov/Archives/edgar/data/886163/000088616323000050/a101_ligand-directorcompen.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/dathttps://www.sec.gov/Archives/edgar/data/886163/000088616323000050/a101_ligand-directorcompen.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/dathttps://www.sec.gov/Archives/edgar/data/886163/000088616323000050/a101_ligand-directorcompen.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director Compensation and Stock Ownership Policy, as amended and restated, effective August 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_102xligand-2022ind.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_102xligand-2022ind.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_102xligand-2022ind.htm">#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012_amendmenttolig.htm">10.12#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment to 2022 Employee Inducement Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_103xligand-formofs.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_103xligand-formofs.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_103xligand-formofs.htm">#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Option Agreement under the Company&#8217;s 2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit104_ligand-formofrs.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit104_ligand-formofrs.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit104_ligand-formofrs.htm">#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Award Agreement under the Company&#8217;s 2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_105xligand-formofp.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_105xligand-formofp.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_105xligand-formofp.htm">#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Award Agreement under the Company&#8217;s 2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1014_ligand-separat.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1014_ligand-separat.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1014_ligand-separat.htm">#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation Agreement , effective December 12, 2022, by and between Ligand Pharmaceuticals Incorporated and John Higgins</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1015_ligand-severan.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1015_ligand-severan.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1015_ligand-severan.htm">#**</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance Agreement, effective December 5, 2022, by and between Ligand Pharmaceuticals Incorporated and Todd C. Davis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000129/exhibit101-taxmattersagree.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000129/exhibit101-taxmattersagree.htm">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Matters Agreement, dated as of November 1, 2022, by and among OmniAb, Inc.(f/k/a Avista Public Acquisition Corp. II) Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc. (f/k/a OmniAb, Inc.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000135/exhibit101-aremployeematte.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000135/exhibit101-aremployeematte.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000135/exhibit101-aremployeematte.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Employee Matters Agreement, dated as of August 18, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. (f/k/a OmniAb, Inc.), OmniAb, Inc. (f/k/a Avista Public Acquisition Corp. II) and Orwell Merger Sub Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement, dated January 26, 2011, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;31, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of TR Beta Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol&#174; Supply Agreement, dated December&#160;20, 2002, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1st Amendment to Captisol&#174; Supply Agreement, dated July&#160;29, 2005, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.101</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2nd&#160;Amendment to Captisol&#174; Supply Agreement, dated March&#160;1, 2007, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.102</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3rd&#160;Amendment to Captisol&#174; Supply Agreement, dated January&#160;25, 2008, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.103</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4th&#160;Amendment to Captisol&#174; Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.104</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, dated September&#160;3, 1993, between CyDex L.C. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.105</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">31</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to License Agreement, dated February 24, 1998, between CyDex, Inc. and The University of Kansas</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.106</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.107</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.111</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exclusive License Agreement, dated June&#160;4, 1996, between Pfizer,&#160;Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.108</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum to Nonexclusive License Agreement, dated December&#160;11, 2001, between CyDex, Inc. and Pfizer,&#160;Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Stream and Milestone Payments Purchase Agreement, dated April 29, 2013, between the Company and Selexis S.A. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">40</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Master License Agreement dated May 21, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">41</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to Master License Agreement dated September 6, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 31, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">42</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to Master License Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1044_palvella-first.htm">10.44</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment  No. 1 to Development Funding and Royalties Agreement, dated as of May 22, 2020, by and between the Company and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ligand-ex1045xpalvellaxame.htm">10.45</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment No. 2 to Development Funding and Royalties Agreement, dated as of November 29, 2023, by and between the Company and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd_123121xexhibit1037.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd_123121xexhibit1037.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd_123121xexhibit1037.htm">**</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated March 20, 2018.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 9, 2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-033093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">49</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-o.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-o.htm">50</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-o.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">51</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312522255529/d379227dex12.htm">10.52</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At-the-Market Equity Offering Sales Agreement, dated September 30, 2022, by and between the Registrant and Stifel, Nicolaus &amp; Company, Incorporated</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-3ASR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-267678</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000075/edgarizedcitiligandcredita.htm">10.53</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement, dated as of October 12, 2023, by and among the Registrant, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein), and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 18, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123123xexhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subsidiaries of the Company </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123123xexhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123123xexhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123123xexhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123123xexhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit97_ligand-clawbackp.htm">97</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Policy for Recovery of Erroneously Awarded Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The following financial information from our Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statement of Comprehensive Income, (iv) Consolidated Statements of Stockholders' Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements. </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, formatted in Inline XBRL and contained in Exhibit 101.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and submitted separately to the Securities and Exchange Commission.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicates management contract or compensatory plan.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*&#160;&#160;&#160;&#160;Certain schedules and annexes have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the U.S. Securities and Exchange Commission upon request.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">**&#160;&#160;&#160;&#160;Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_160"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"/><td style="width:28.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:69.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-K Summary</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="iddb0f73760bc4f19bc0fe394970fd53f_163"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.695%"><tr><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.104%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIGAND&#160;PHARMACEUTICALS&#160;INCORPORATED</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Todd C. Davis,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;29, 2024 </span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;TODD C. DAVIS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Todd C. Davis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; OCTAVIO ESPINOZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Octavio Espinoza</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN W. KOZARICH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John W. Kozarich</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JASON M. ARYEH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jason M. Aryeh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;NANCY R. GRAY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nancy R. Gray</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; JASON HAAS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jason Haas</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN L. LAMATTINA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. LaMattina</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;STEPHEN L. SABBA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stephen L. Sabba</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;MARTINE ZIMMERMANN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Martine Zimmermann</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>exhibit1012_amendmenttolig.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i426a3afcd9904a2f81dd535924ad13f7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDMENT TO LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AMENDMENT TO THE LIGAND PHARMACEUTICALS INCORPORATED 2022 EMPLOYMENT INDUCEMENT PLAN (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), effective as of January 30, 2024, is made and adopted by Ligand Pharmaceuticals Incorporated, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Plan (as defined below).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Company maintains the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, pursuant to Article Six, Section III of the Plan, the Plan may be amended by the Board  of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing, the Board hereby amends the Plan as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">Section Article One, Section V.A of the Plan is hereby amended and restated in its entirety to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;Subject to adjustment pursuant to this Section V, the number of shares of Common Stock which may be issued or transferred pursuant to Awards under the Plan is 525,000 shares.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">This Amendment shall be and is hereby incorporated in and forms a part of the Plan.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">Except as expressly provided herein, all other terms and provisions of the Plan shall remain unchanged and in full force and effect.  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>3
<FILENAME>exhibit1044_palvella-first.htm
<DESCRIPTION>EX-10.44
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if2636fc1c4f045f1b7681981dcc97c35_1"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.44</font></div></div><div style="margin-top:3.95pt;padding-left:175.12pt;padding-right:175.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO</font></div><div style="padding-left:2.07pt;padding-right:2.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT</font></div><div style="margin-top:12pt;padding-left:10pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This First Amendment to Development Funding and Royalties Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made effective as of May 22, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Palvella Therapeutics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Palvella</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, together with Ligand, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and each individually a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12.05pt;padding-left:10pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties are parties to that certain Development Funding and Royalties Agreement, entered into and effective as of December 13, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-top:12pt;padding-left:10pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in connection with a Qualified Financing Event on the date hereof, Palvella is issuing shares of Series C Preferred Stock to investors at a purchase price of $5.2879 per share&#59;</font></div><div style="margin-top:12pt;padding-left:10pt;padding-right:6.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to 12.11 of the Agreement, the Agreement may only be amended or modified by a written instrument signed by the Parties&#59; and</font></div><div style="margin-top:12pt;padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties desire to amend the Agreement as set forth herein.</font></div><div style="margin-top:12.05pt;padding-left:10pt;padding-right:6.05pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, hereby agree to amend the Agreement as follows&#58;</font></div><div style="padding-left:46pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:5.4pt;padding-right:5.75pt;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.&#160;&#160;&#160;&#160;Section 4.2 of the Agreement is hereby amended to at the following to the end of such Section 4.2&#58;</font></div><div style="margin-top:12pt;padding-left:82pt;padding-right:77.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Notwithstanding the above, upon a Qualified Financing Event, One Million Five Dollars and Thirty-Four Cents ($1,000,005.34) of the Milestone Payment payable by Palvella upon a Qualified Financing Event pursuant to this Section 4.2 may be satisfied with the issuance by Palvella to Ligand of One Hundred Eighty-Nine Thousand One Hundred Twelve (189,112) shares of Palvella&#8217;s Series C Preferred Stock at a purchase price of $5.2879 per share. For clarity, the remaining One Million Nine Hundred Ninety-Nine Thousand Nine Hundred Ninety-Four Dollars and Sixty-Six Cents ($1,999,994.66) shall be paid in cash in accordance with this Section 4.2. In connection with the issuance of such Series C Preferred Stock, Ligand shall be required to execute the Series C Preferred Stock Purchase Agreement, Second Amended and Restated Investors Rights Agreement, Second Amended and Restated Voting Agreement, and Second Amended and Restated Right of First Refusal and Co-Sale Agreement, each being entered</font></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if2636fc1c4f045f1b7681981dcc97c35_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.44</font></div></div><div style="margin-top:3.95pt;padding-left:82pt;padding-right:69.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into among Palvella and the purchasers of Series C Preferred Stock.&#8221;</font></div><div style="padding-left:46pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:5.4pt;padding-right:6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.&#160;&#160;&#160;&#160;Capitalized terms not defined in this Amendment have their respective meanings as defined in the Agreement.</font></div><div style="padding-left:5.4pt;padding-right:6.1pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.&#160;&#160;&#160;&#160;As hereby amended and supplemented, the Agreement shall remain in full force and effect. In the event of a conflict between the terms hereof and the Agreement, this Amendment shall control. From and after the Amendment Effective Date, any reference to the Agreement shall be a reference to the Agreement as amended hereby.</font></div><div style="margin-top:12.05pt;padding-left:5.4pt;padding-right:6.05pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.&#160;&#160;&#160;&#160;This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. The facsimile or electronic signature of any Party shall constitute the valid and binding execution hereof by such Party.</font></div><div style="padding-left:5.4pt;padding-right:5.6pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.&#160;&#160;&#160;&#160;If any provision of the Agreement including this Amendment is found to be invalid, illegal or unenforceable, no other provision of this contract shall be affected and all other provisions shall be enforced to the full extent of the law.</font></div><div style="margin-top:12.05pt;padding-left:5.4pt;padding-right:5.9pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.&#160;&#160;&#160;&#160;This Amendment shall be governed by, enforced, and will be construed in accordance with the laws of the State of New York, United States without regard to any Applicable Law, rule or principle that would result in the application of the laws of any other jurisdiction.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:2.4pt"><font><br></font></div><div style="padding-left:2.22pt;padding-right:2.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank - Signature Page Follows.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:175.15pt;padding-right:175.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if2636fc1c4f045f1b7681981dcc97c35_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.44</font></div></div><div style="margin-top:3.95pt;padding-left:10pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have executed this Amendment as of the Amendment Effective Date.</font></div><div><font><br></font></div><div style="margin-top:10.2pt"><font><br></font></div><div style="padding-left:199.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LIGAND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:12pt;padding-left:199.05pt;padding-right:118.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div><font><br></font></div><div style="margin-top:8.45pt"><font><br></font></div><div style="padding-left:231.45pt;padding-right:69.65pt;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Charles Berkman&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Charles Berkman</font></div><div style="padding-left:231.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel &#38; Secretary</font></div><div style="margin-top:11.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:200.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">PALVELLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:12pt;padding-left:200.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PALVELLA THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="margin-top:8.4pt"><font><br></font></div><div style="padding-left:236.85pt;padding-right:64.25pt;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Wesley H. Kaupinen&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Wesley H. Kaupinen</font></div><div style="padding-left:236.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.05pt"><font><br></font></div><div style="padding-left:2.1pt;padding-right:2.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to First Amendment to Development Funding and Royalties Agreement&#93;</font></div><div style="height:38.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>4
<FILENAME>ligand-ex1045xpalvellaxame.htm
<DESCRIPTION>EX-10.45
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i094182beceff45c9ae9332dd3660a59c_1"></div><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="margin-top:4pt;padding-left:20.45pt;padding-right:20.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE LIGAND PHARMACEUTICALS INCORPORATED HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIGAND PHARMACEUTICALS INCORPORATED IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:4pt;padding-left:20.45pt;padding-right:20.45pt;text-align:center"><font><br></font></div><div style="margin-top:4pt;padding-right:40.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Version</font></div><div style="margin-top:8.4pt;padding-left:17.57pt;padding-right:17.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 2 TO</font></div><div style="padding-left:17.5pt;padding-right:17.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT</font></div><div style="margin-top:13.8pt;padding-left:42pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIS AMENDMENT NO. 2 TO DEVELOPMENT FUNDING AND ROYALTIES</font></div><div style="padding-left:5.95pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made and entered into effective as of November 29, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware company having a place of business at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, California 92121, U.S.A., (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ligand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PALVELLA THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware company having a place of business at 125 Strafford Avenue, Suite #360, Wayne, PA 19087, and its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Palvella</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and amends that certain Development Funding and Royalties Agreement, effective as of December 13, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as amended effective as of May 22, 2020, by and between Ligand and Palvella (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Palvella and Ligand may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:12pt;padding-left:17.5pt;padding-right:17.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Ligand is engaged in the development and commercialization of pharmaceutical products&#59;</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Palvella owns or otherwise controls certain intellectual property rights and regulatory filings relating to the compound designated as PTX-022 (as defined below), which is the subject of clinical development&#59;</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to the Agreement, Ligand contributed to the funding of the development of PTX-022 in exchange for the right to receive future payments based on the development and commercialization of PTX-022&#59; and</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties wish to amend the Agreement to (a) enable the near-term initiation of the Phase 3 pivotal clinical study of PTX-022 in Microcystic Lymphatic Malformations, (b) expand the scope of the Agreement to include potential collaborations on additional product candidates generated from Palvella&#8217;s proprietary QTORIN&#8482; platform, and (c) amend certain other terms of the Agreement, subject to the terms and conditions set forth in this Amendment.</font></div><div style="margin-top:11.95pt;padding-left:5.95pt;padding-right:40.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and of the mutual covenants herein contained, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.05pt">Amendments to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;The Agreement is hereby amended as of the Amendment Effective Date as follows&#58;</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.05pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is hereby amended by adding &#8220;accounts receivable arising from, and all other rights to payment of,&#8221; after &#8220;&#8230;means, with respect to any Product&#8230;&#8221;.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.38pt">The definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is hereby deleted and replaced in its entirety with the following&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:77.95pt;padding-right:40.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to the Products, worldwide, and (b) with respect to the Option Products, the United States of America, including its territories and possessions.&#8221;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt">The text set forth on Appendix A to the Agreement is hereby deleted and replaced in its entirety with the following&#58;</font></div><div style="margin-top:12pt;padding-left:77.95pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;PTX-022 is a novel, anhydrous, rapamycin topical gel formulation at any concentration amount of rapamycin. Development activities for PTX-022 being conducted as of the Amendment Effective Date use a 3.9% concentration of rapamycin. For the avoidance of doubt, PTX-022 shall include any topical gel formulation of rapamycin at any concentration and for any indication, including, but not limited to, 3.9% concentration.&#8221;</font></div><div style="margin-top:12pt;padding-left:113.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">The following defined terms are hereby added to Article 1 of the</font></div><div id="i094182beceff45c9ae9332dd3660a59c_4"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.290%"><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement&#58;</font></div><div style="margin-top:12pt"><font><br></font></div></div><div style="display:inline-block;max-width:1.418%;min-width:0.418%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.292%"><div><font><br></font></div><div style="padding-left:6pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; means November 29, 2023. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">Amendment Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in Section 4.1.</font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Back-Up Security Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3.1(b).</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bankruptcy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#8217; rights generally.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:84.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">Effective Date Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in Section 4.1. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in Section 4.10.</font></div><div style="padding-left:5.95pt;padding-right:19pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">Option Commencement Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in Section 4.10.1. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">&#8221; has the meaning set forth in Section 4.10.2.</font></div><div style="padding-left:6pt;padding-right:40.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any novel topical product candidate owned by Palvella or any of its Affiliates that is generated by or on behalf of Palvella or any of its Affiliates from Palvella&#8217;s proprietary QTORIN&#8482; platform.</font></div><div style="margin-top:11.9pt;padding-left:5.95pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Product Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on a, Option Product-by-Option Product basis, the purchase price for the </font></div></div></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.290%"><div style="margin-top:11.9pt;padding-left:5.95pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Product Revenue Participation Right set forth on Appendix F attached hereto that is selected by Ligand and specified in the applicable Option Exercise Notice.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Product Revenue Participation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on an Option Product- by-Option Product basis, all of Palvella&#8217;s right, title and interest in, to and under the Option Product Royalties, including the right to receive the Option Product</font></div></div><div style="display:inline-block;max-width:1.418%;min-width:0.418%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.292%"></div></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_7"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalties, whether now owned or existing or hereafter arising or acquired, together with all proceeds thereof.</font></div><div style="margin-top:12pt;padding-left:77.95pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Product Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on an Option Product-by-Option Product basis during the applicable Option Product Royalty Term, an undivided percentage interest in all aggregate Net Sales of the Option Product in the Territory in the amount of the Option Product Royalty Rate.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:40.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Product Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on an Option Product-by-Option Product basis, the royalty rate set forth Appendix F attached hereto that corresponds to the applicable Option Product Purchase Price selected by Ligand.</font></div><div style="margin-top:12pt;padding-left:78pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has meaning set forth in Section 4.1.</font></div><div style="margin-top:12pt;padding-left:77.95pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenue Participation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all of Palvella&#8217;s right, title and interest in, to and under the Royalties, including the right to receive the Royalties, whether now owned or existing or hereafter arising or acquired, together with all proceeds thereof.</font></div><div style="margin-top:12pt;padding-left:77.95pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on a Product-by-Product and country-by-country basis during the applicable Royalty Term, an undivided percentage interest in all aggregate Net Sales of the Products in the Territory in the amount of the Royalty Rate.</font></div><div style="margin-top:12pt;padding-left:77.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the following royalty rates&#58;</font></div><div style="margin-top:12pt;padding-left:206.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Net Sales Tier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Rate</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_10"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.805%"><div style="margin-top:6pt;padding-left:77.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For that portion of annual aggregate Net Sales of Products in a Calendar Year that are less than or equal to &#91;***&#93;</font></div><div style="margin-top:6pt;padding-left:77.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For that portion of annual aggregate Net Sales of Products in a Calendar Year &#91;***&#93; but less than or equal to &#91;***&#93;</font></div><div style="margin-top:5.95pt;padding-left:77.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For that portion of annual aggregate Net Sales of Products in a Calendar Year that are greater than &#91;***&#93;</font></div><div style="margin-top:6pt;padding-left:63.4pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.388%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.807%"><div style="padding-left:63.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">%</font></div><div><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="padding-left:63.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">%</font></div><div><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="padding-left:63.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">%</font></div></div></div><div style="margin-top:4.2pt"><font><br></font></div><div style="padding-left:77.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 4.3.2.</font></div><div style="margin-top:12pt;padding-left:77.95pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Uniform Commercial Code as in effect from time to time in the State of New York&#59; provided, that, if, with respect to any financing statement or by reason of any provisions of Applicable Law, the perfection or the effect of perfection or non-perfection of the Back-Up Security Interest or any portion thereof granted pursuant to Section 4.3.1(b) is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of New York, then &#8220;UCC&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_13"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;padding-right:41pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financing statement relating to such perfection or effect of perfection or non- perfection.</font></div><div style="margin-top:12pt;padding-left:113.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.63pt">The last sentence of Section 2.2 is hereby deleted.</font></div><div style="margin-top:12pt;padding-left:113.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.96pt">The following language is hereby added to the end of Section 2.2&#58;</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;&#8220;The Amendment Payment is required to be spent on development of the Product in accordance with the Development Plan and the Development Budget, each of which may be amended from time to time in accordance with this Section 2.2. Palvella will report on the use of such funds in its quarterly report to Ligand to be delivered in accordance with Section 3.3.1.&#8221;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Section 4.1 of the Agreement is hereby deleted and replaced in its entirety with the following&#58;</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:40.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1 Payment of Purchase Price. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration for the rights granted under this Agreement to Ligand, including without limitation the right to receive the payments set forth in Sections 4.2 and 4.3, and to fund the Development activities described in this Agreement, Ligand shall pay Palvella (a) a one-time payment of Ten Million Dollars ($10,000,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on the Effective Date to an account designated in writing by Palvella, and (b) a one-time payment of Five Million Dollars ($5,000,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and together with the Effective Date Payment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on the Amendment Effective Date to an account designated in writing by Palvella. The Parties acknowledge and agree that the Effective Date Payment was paid in full as of the Effective Date.&#8221;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.33pt">All references to the Upfront Payment in the Agreement are hereby replaced with references to the Purchase Price.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt">Section 4.3 of the Agreement is hereby deleted and replaced in its entirety with the following&#58;</font></div><div style="margin-top:11.95pt;padding-left:78pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3  Purchase, Sale and Assignment of Revenue Participation Right.</font></div><div style="margin-top:12pt;padding-left:149.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:11.95pt">Purchase, Sale and Assignment.</font></div><div style="margin-top:12pt;padding-left:114pt;padding-right:40.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">On the Effective Date and upon the terms and subject to the conditions of this Agreement, including receipt of the Purchase Price, Palvella shall sell, transfer, assign and convey to Ligand, without recourse (except as expressly provided herein), and Ligand shall purchase, acquire and accept from Palvella, the Revenue Participation Right. Immediately upon the sale to Ligand by Palvella of the Revenue Participation Right pursuant to this Section 4.3, all of Palvella&#8217;s right, title and interest in and to the Revenue Participation Right shall terminate, and all such right, title and interest shall vest in Ligand.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:113.95pt;padding-right:40.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.4pt">It is the intention of the Parties that the sale, transfer, assignment and conveyance contemplated by this Section 4.3 be, and is, a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by Palvella to Ligand of all of Palvella&#8217;s right, title and interest in and to the Revenue Participation Right. Neither Palvella nor Ligand intends the transactions contemplated by this Section 4.3 to be, or for any purpose characterized as, a loan from Ligand to Palvella or a pledge, financing transaction or a borrowing. It is the intention of the Parties that the beneficial interest in and title to the Revenue Participation Right and any &#8220;proceeds&#8221; (as such term is defined in the UCC), including, without limitations, all cash, cash equivalents, dividends, distributions, instruments, securities or other property, at any time and from time to time received, receivable, paid or otherwise distributed in respect thereof, shall not be part of Palvella&#8217;s estate in the event of the filing of a petition by or against Palvella under any Bankruptcy Laws. Palvella hereby waives, to the maximum extent permitted by Applicable Law, any right to contest or otherwise assert that the transactions contemplated by this Section 4.3 do not constitute a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by Palvella to Ligand of all of Palvella&#8217;s right, title and interest in and to the Revenue Participation Right under Applicable Law, which waiver shall, to the maximum extent permitted by Applicable Law, be enforceable against Palvella. Accordingly, Palvella shall treat the sale, transfer, assignment and conveyance of the Revenue Participation Right as a sale of &#8220;accounts&#8221; or &#8220;payment intangibles&#8221; (as appropriate) in accordance with the UCC, and Palvella hereby authorizes Ligand to file financing statements (and continuation statements with respect to such financing statements when applicable) or amendments thereof or supplements thereto or other instruments as Ligand may from time to time deem reasonably necessary or appropriate in order to notify of such sale and assignment in accordance with the UCC, naming Palvella as the seller and Ligand as the buyer with respect to the Revenue Participation Right. Not in derogation of the foregoing statement of the intent of the Parties in this regard but subject to Sections 4.3.1(e) and (f) below, and for the purposes of providing additional assurance to Ligand in the event that, despite the intent of the Parties, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, Palvella does hereby grant to Ligand, as security for the payment of Royalties, a continuing first- priority security interest in and to all of Palvella&#8217;s right, title and interest in, to and under (i) the Revenue Participation Right and the Royalties (excluding, for the avoidance of doubt, that portion of the accounts and payment intangibles, each as defined in the UCC, that does not comprise the Revenue Participation Right), and (ii) the Palvella Patents and any Know-How that are &#91;***&#93; (the Palvella Patents and Know-How described in (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Back-Up Security</font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:114pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Palvella does hereby authorize Ligand, from and after the Amendment Effective Date, to file such financing statements (and continuation statements with respect to such financing statements when applicable) or amendments thereof or supplements thereto or other instruments as Ligand may from time to time deem reasonably necessary or appropriate in order to perfect and maintain the security interests granted hereunder in accordance with the UCC, in such manner and such jurisdictions as are necessary or appropriate to perfect such security interest&#59; provided, that the Product IP shall exclude &#91;***&#93;. Palvella shall execute and deliver to Ligand such agreements, assignments, or instruments and do all such other things as Ligand may deem reasonably necessary or appropriate to assure Ligand and the security interests hereunder are perfected, provided, however, that any such assistance by Palvella for any perfection action taken in jurisdictions other than the United States of America shall be at Ligand&#8217;s cost. Ligand may not enforce the Back-Up Security Interest other than if a court of competent jurisdiction determines the transaction contemplated hereby should be characterized as a loan, financing transaction or a borrowing, and not a true sale, including, but not limited, to in connection with any Bankruptcy Event relating to Palvella.</font></div><div style="margin-top:11.95pt;padding-left:114pt;padding-right:40.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Notwithstanding any provision in this Agreement to the contrary, Ligand is only agreeing, on the terms and conditions set forth in this Agreement, to purchase, acquire and accept the Revenue Participation Right and is not assuming any liability or obligation of Palvella of whatever nature, whether presently in existence or arising or asserted hereafter.</font></div><div style="margin-top:12pt;padding-left:114pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.35pt">On the Amendment Effective Date, upon confirmation of the receipt of the Purchase Price in full, Palvella shall deliver to Ligand a duly executed bill of sale evidencing the sale, transfer, assignment and conveyance of the Revenue Participation Right in the form attached hereto as Appendix E.</font></div><div style="margin-top:12pt;padding-left:114pt;padding-right:40.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1pt"><font><br></font></div><div id="i094182beceff45c9ae9332dd3660a59c_16"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.261%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement.</font></div><div style="margin-top:4.5pt;padding-left:42pt;padding-right:40.8pt;text-align:justify"><font><br></font></div></div><div style="display:inline-block;max-width:1.476%;min-width:0.476%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.263%"><div style="padding-left:42pt;padding-right:40.8pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:42pt;padding-right:40.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Notwithstanding Section 2.4.2 of this Agreement to the contrary, Palvella shall use reasonable good faith efforts to negotiate License terms that retain in place the Back-Up Security Interest with respect to the Product IP. If, despite the use of such reasonable good faith efforts, Palvella desires to enter into an exclusive License for one or more geographical territories that meets the requirements of Sections 2.4.1 and</font></div><div style="padding-left:42pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.2 with terms which would require a modification or a release of the Back-Up Security with respect to the Product IP in the applicable geographical territory that is being exclusively licensed under such License, Ligand shall consider in good faith any request from Palvella in relation to such potential modification or release. Palvella shall provide written notice of such request to Ligand, and the following terms shall apply&#58; (i) Ligand shall, within five (5) Business Days of receipt of Palvella&#8217;s written notice, provide a response reasonably outlining what modification and or release Ligand will agree to provide, if any, and on what terms, and will use reasonable efforts to negotiate in good faith to reach an agreement on such modification and or release, if any&#59; and (ii) upon reaching agreement with Palvella on such terms, Ligand shall execute as necessary and deliver to Palvella all documents as Palvella shall reasonably request to evidence such modification or release, if any, as applicable.</font></div><div style="margin-top:11.95pt;padding-left:10.5pt;padding-right:40.8pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6pt">Royalty Term. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalties will be remitted under this Section 4.3, on a country-by-country and Product-by-Product basis, commencing on First Commercial Sale of such Product in such country until the last to occur of&#58; (i) the expiration of the last-to-expire Valid </font></div></div></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.261%"><div style="margin-top:11.95pt;padding-left:10.5pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Claim in such country that Covers such Product&#59; (ii) the expiration of Regulatory Exclusivity in such country covering such Product&#59; and (iii) the fifteenth (15th) anniversary of the First Commercial Sale of such Product in such country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).&#8221;</font></div><div style="margin-top:12pt;padding-left:41.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.96pt">Appendix E attached hereto is hereby added as a new Appendix E to the</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:23.9pt;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.23pt">The following is hereby added as a new Section 4.10 to the Agreement&#58;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10  Option to Purchase Option Product Revenue Participation Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Palvella hereby grants Ligand an exclusive option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), on an Option Product-by-Option Product basis, to purchase, acquire and accept from Palvella, all of Palvella&#8217;s right, title and interest in, to and under the Option Product Revenue</font></div></div><div style="display:inline-block;max-width:1.476%;min-width:0.476%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.263%"></div></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_19"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1pt"><font><br></font></div><div id="i094182beceff45c9ae9332dd3660a59c_22"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.805%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.45pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:333%">Agreement. the following&#58;</font></div><div style="margin-top:4.5pt;padding-left:2.3pt;padding-right:40.9pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.388%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.807%"><div style="padding-left:2.3pt;padding-right:40.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participation Right for each Option Product on the terms and conditions set forth in this Section 4.10.</font></div><div style="margin-top:12pt;padding-left:2.3pt;padding-right:40.7pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.7pt">If at any time prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> anniversary of the Effective Date, Palvella or any of its Affiliates completes the first human clinical trial for an Option Product in the Territory (including completion of dosing of all patients, closing of all applicable clinical trial databases, and receipt of top-line results for such clinical trial), Palvella shall provide written notice thereof to Ligand, along with a copy of the top-line results for such clinical trial (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Commencement Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Additionally, Palvella shall also provide to Ligand any other information related to such top-line results that is reasonably requested by Ligand in order to enable Ligand to evaluate whether to exercise the Option.</font></div><div style="margin-top:12pt;padding-left:2.3pt;padding-right:40.75pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.7pt">Ligand shall have the right to exercise the Option by providing written notice of exercise to Palvella (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after the date Ligand receives the Option Commencement Notice. The Option Exercise Notice shall include the Option Product Purchase Price selected by Ligand and the Option Product Royalty Rate corresponding to such Option Product Purchase Price.</font></div><div style="margin-top:12pt;padding-left:2.3pt;padding-right:40.8pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.7pt">If Ligand delivers an Option Exercise Notice to Palvella within the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day period set forth in Section 4.10.2, the Parties shall enter into an amendment to this Agreement within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days of Palvella&#8217;s receipt of such Option Exercise Notice that provides for Ligand&#8217;s purchase, acquisition and acceptance from Palvella of all of Palvella&#8217;s right, title and interest in, to and under the applicable Option Product Revenue Participation Right in consideration for receipt of the applicable Option Product Purchase Price.</font></div><div style="margin-top:12pt;padding-left:2.3pt;padding-right:40.8pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.7pt">If Ligand has not delivered an Option Exercise Notice to Palvella within the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day period set forth in Section 4.10.2, then Palvella shall have no additional obligations to Ligand under this Agreement with respect to the applicable Option Product or the Option </font></div></div></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.805%"><div style="margin-top:12pt;padding-left:2.3pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Revenue Participation Right for such Option Product.</font></div><div style="margin-top:11.95pt;padding-left:2.3pt;padding-right:40.9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.7pt">The Option shall terminate immediately as of the consummation of a Change of Control or IPO of Palvella or its parent Affiliate.&#8221;</font></div><div style="margin-top:12pt;padding-left:38.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.67pt">Appendix F attached hereto is hereby added as a new Appendix F to the</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:38.3pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.01pt">Article 7 of the Agreement is hereby deleted in its entirety and replaced with</font></div><div style="margin-top:12pt"><font><br></font></div><div style="padding-left:2.3pt;padding-right:40.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1&#160;&#160;&#160;&#160;Mutual Termination.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be terminated by mutual written agreement of the Parties.</font></div><div style="margin-top:12pt;padding-left:2.3pt;padding-right:40.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.7pt">Automatic Termination.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless earlier terminated as provided in Section 7.1, following the Effective Date, this Agreement shall continue in full</font></div></div><div style="display:inline-block;max-width:0.388%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.807%"></div></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_25"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.45</font></div></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force and effect until all Royalties constituting the Revenue Participation Right have been paid to Ligand, at which point this Agreement shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Survival. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary in this Article 7, the following provisions shall survive termination of this Agreement&#58; this Section 7.3, Section 7.4, and Articles 1, 5 (for the term set forth in Section 5.1), 8, 10, 11 and</font></div><div style="padding-left:78pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12. Termination of the Agreement shall not relieve any Party of liability in respect of breaches under this Agreement by any Party on or prior to termination.&#8221;</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:40.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">UCC Terminations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Immediately upon the termination of this Agreement, and provided that Palvella fulfilled its obligations under the Agreement and after Ligand has promptly, reasonably and in good faith ensured that there are no outstanding payments or other obligations owned to Ligand by Palvella under the Agreement, pursuant to Section 7.1 or Section 7.2, (a) any security interest created pursuant to Section 4.3.1(b) shall automatically terminate, without delivery of any instrument or performance of any act by any Person, (b) Palvella shall be permitted, and is hereby authorized, to terminate any financing statements which have been filed pursuant to Section 4.3.1(b), and (c) Ligand shall execute and deliver to Palvella all documents as Palvella shall reasonably request to evidence any such termination.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.33pt">Section 12.1 of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:40.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.1 Assignment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may not be assigned or otherwise transferred by either Party without the consent of the other Party, which consent will not be unreasonably withheld, delayed or conditioned&#59; provided, however, that either Party may, without such consent, assign this Agreement together with all of its rights and obligations hereunder to its Affiliates, or to a successor in interest in connection with the transfer or sale of all or substantially all of its business to which this Agreement relates, or in the event of a Change of Control, subject to the assignee agreeing to be bound by the terms of this Agreement and, if Palvella is the assigning Party, guarantees or similar or better credit support being provided, as necessary, to ensure that Ligand has substantially identical credit recourse. If Palvella sell, assigns or otherwise transfers ownership of the Product IP to a Third Party, then Palvella shall also assign this Agreement to such Third Party and such Third Party shall assume Palvella&#8217;s obligations under this Agreement and acknowledge such assumption under the assignment agreement. Any purported assignment in violation of the preceding sentences will be void. Any permitted assignee or successor will assume and be bound by all obligations of its assignor or predecessor under this Agreement.&#8221;</font></div><div style="margin-top:12.6pt;padding-left:6pt;padding-right:40.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">o.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The following is hereby inserted immediately following Section 12.15 of the Agreement&#58;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.622%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_28"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77.95pt;padding-right:40.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.16 Intercreditor Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Ligand hereby agrees that in the event of a bona fide financing by Palvella in which the bank, financial institution or other similar lender or creditor, requires a security interest over certain assets of Palvella, including the Product IP and the receivables related thereto, (a) Ligand shall enter into, and shall not unreasonably object to or delay execution of, an intercreditor agreement with such lender or creditor on terms reasonably acceptable to Ligand and such lender or creditor, and (b) such lender or creditor, under the terms of the intercreditor agreement, shall have the right to sell, assign or otherwise transfer ownership of the Product IP to a Third Party, provided that this Agreement is also assigned to such Third Party and such Third Party assumes Palvella&#8217;s obligations under this Agreement and acknowledges such assumption in writing.&#8221;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Amendment may be executed in one or more counterparts (including without limitation by way of PDF or electronic transmission), each of which will be deemed an original, but all of which together will constitute one and the same instrument. When executed by the Parties, this Amendment will constitute an original instrument, notwithstanding any electronic transmission, storage and printing of copies of this Amendment from computers or printers. For clarity, PDF signatures will be treated as original signatures.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:40.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Except as modified by this Amendment, the Agreement remains in full force and effect. The Agreement, as modified by this Amendment, constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof, and supersedes all prior or contemporaneous proposals, oral or written, confidentiality agreements, and all other communications between the Parties with respect to such subject matter, including without limitation the Prior CDA.</font></div><div style="margin-top:12pt;padding-left:17.55pt;padding-right:17.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.2pt"><font><br></font></div><div style="padding-left:17.52pt;padding-right:17.52pt;text-align:center"><font><br></font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:17.52pt;padding-right:17.52pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:40.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each of the Parties has caused its duly authorized officer to execute and deliver this Amendment as of the Amendment Effective Date.</font></div><div style="margin-top:12pt;padding-left:222pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div style="margin-top:2.35pt"><font><br></font></div><div style="margin-bottom:0.2pt;padding-left:222pt;padding-right:40.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:91%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:91%;text-decoration:underline"> &#47;s&#47;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:91%;text-decoration:underline"> Matthew Korenberg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:91%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:91%"> Name&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:91%">Matthew Korenberg</font></div><div style="padding-left:253.95pt"><img alt="image_10.jpg" src="image_10.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:293px"></div><div style="margin-top:0.45pt;padding-left:222pt"><img alt="image_11.jpg" src="image_11.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:301px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President &#38; COO</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.2pt"><font><br></font></div><div style="padding-left:222pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PALVELLA THERAPEUTICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:222pt;padding-right:40.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Wesley H. Kaupinen&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; Wesley H. Kaupinen</font></div><div style="padding-left:222pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer and President</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.6pt"><font><br></font></div><div style="padding-left:25.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Amendment No. 2 to Development Funding and Royalties Agreement&#93;</font></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_31"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.659%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:189.95pt;padding-right:216.85pt;text-indent:19.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Appendix E </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%;text-decoration:underline">Form of Bill of Sale</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.55pt"><font><br></font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.217%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div><div id="i094182beceff45c9ae9332dd3660a59c_34"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.659%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">DocuSign Envelope ID&#58; 55A34BBE-B962-48C8-B039-1BD3A58CBF80</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:12.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.55pt;padding-right:17.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix F</font></div><div style="margin-top:13.8pt;padding-left:17.52pt;padding-right:17.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Option Product Purchase Prices and Option Product Royalty Rates</font></div><div><font><br></font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;148944419.1&#124;&#124;&#160;&#160;&#160;&#160;&#124;   038741-0064&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>lgnd_123123xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id7d4d5fa065147f789c18ac7aa58e53a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:49.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergan Ligand Retinoid Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aramed Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cita NeuroPharmaceuticals Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LHNC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Holdings UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand JVR, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals International, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Development Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Group Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Research Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurogen Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfenex Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacopeia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen Technology, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verrow Pharmaceuticals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>lgnd_123123xexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ifb49d824f72f40c193699aa8f9d83686_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1) Registration Statement (Form S-3 ASR No. 333-267678) of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) Registration Statement (Form S-8 No. 333-266737) pertaining to the 2022 Employment Inducement Plan of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3) Registration Statement (Form S-8 No. 333-265545) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Registration Statement (Form S-8 No. 333-252480) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Registration Statement (Form S-8 No. 333-233130) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated&#59; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;29, 2024, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December&#160;31, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29, 2024</font></div><div><font><br></font></div><div style="height:130.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>lgnd_123123xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibef148489b3143679a6f565c9a1c907a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, Todd C. Davis, certify that&#58;</font></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.064%"><tr><td style="width:1.0%"></td><td style="width:11.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;29, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.557%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:14pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Todd C. Davis</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:14pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd C. Davis</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:12pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:12pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>lgnd_123123xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i97b829595e8a45d3bc7cbe832d1aae5f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, Octavio Espinoza, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-bottom:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;February&#160;29, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Octavio Espinoza</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Octavio Espinoza</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>lgnd_123123xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i839fb611d65248b8afa58a88ec5a0de1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Todd C. Davis, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.944%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Todd C. Davis</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd C. Davis</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Octavio Espinoza, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.206%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Octavio Espinoza</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Octavio Espinoza</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>10
<FILENAME>exhibit97_ligand-clawbackp.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0ae8aa81128241b0ad6e4b6e345435ff_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 97</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIGAND PHARMACEUTICALS INCORPORATED POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), effective as of October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Persons Subject to Policy</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall apply to current and former &#8220;executive officers&#8221; (as defined in Exchange Act Rule 10D-1(d)) of the Company (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compensation Subject to Policy</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall apply to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is &#8220;received&#8221; shall be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is &#8220;received&#8221; in the Company&#8217;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Recovery of Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Company is required to prepare a Restatement, the Company shall recover, reasonably promptly, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee has determined that recovery would be Impracticable. Recovery shall be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by the Company.  For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any person&#8217;s right to voluntarily terminate employment for &#8220;good reason,&#8221; or due to a &#8220;constructive termination&#8221; (or any similar term of like effect) under any plan, program or policy of or agreement with the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Manner of Recovery&#59; Limitation on Duplicative Recovery</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Committee shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation, Erroneously Awarded Compensation or time-vesting equity awards, reimbursement or repayment by any person subject to this Policy of the Erroneously Awarded Compensation, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by the Company or an affiliate of the Company to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already recovered by the Company from the recipient of such Erroneously Awarded Compensation may be credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Administration </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose. The Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and in such event references herein to the &#8220;Committee&#8221; shall be deemed to be references to the Board.  Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company and its affiliates, equityholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the Company, as permitted under applicable law, including any Applicable Rules. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy will be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Indemnification&#59; No Liability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall not indemnify or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall the Company directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person&#8217;s potential obligations under this Policy.  None of the Company, an affiliate of the Company or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Application&#59; Enforceability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any other clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates, including any such policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based plan or award agreement thereunder or similar plan, program or agreement of the Company or an affiliate or required under applicable law (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Recovery Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The remedy specified in this Policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to the Company or an affiliate of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Severability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions in this Policy are intended to be applied to the fullest extent of the law&#59; provided, however, to the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendment and Termination</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">automatically when the Company does not have a class of securities listed on a national securities exchange or association.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Definitions</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Applicable Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221; means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association on which the Company&#8217;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on which the Company&#8217;s securities are listed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Human Capital Management and Compensation committee of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the amount of Incentive-Based Compensation received by a current or former Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as determined on a pre-tax basis in accordance with the Applicable Rules. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Financial Reporting Measure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any measure determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP&#47;IFRS financial measures, as well as stock or share price and total equityholder return. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means United States generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means international financial reporting standards as adopted by the International Accounting Standards Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Impracticable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) the direct costs paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation&#59; provided that the Company (i) has made reasonable attempts to recover the Erroneously Awarded Compensation, (ii) documented such attempt(s), and (iii) provided such documentation to the relevant listing exchange or association, (b) to the extent permitted by the Applicable Rules, the recovery would violate the Company&#8217;s home country laws pursuant to an opinion of home country counsel&#59; provided that the Company has (i) obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in such violation, and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person&#58; (a) after beginning service as an Officer&#59; (b) who served as an Officer at any time during the performance period for that compensation&#59; (c) while the issuer has a class of its securities listed on a national securities exchange or association&#59; and (d) during the applicable Three-Year Period. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an accounting restatement to correct the Company&#8217;s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Three-Year Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs the Company to prepare such Restatement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The &#8220;Three-Year Period&#8221; also includes any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">However, a transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>lgnd-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4cc674fd-25ef-4a1f-be1e-ae22ba8e96aa,g:9cb8df18-e655-4252-b500-06985d41d3f6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ligand.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.ligand.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBio" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio">
        <link:definition>0000010 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisition" roleURI="http://www.ligand.com/role/Acquisition">
        <link:definition>0000011 - Disclosure - Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAb" roleURI="http://www.ligand.com/role/SpinoffofOmniAb">
        <link:definition>0000012 - Disclosure - Spin-off of OmniAb</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialLicenseandOtherEconomicRights" roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights">
        <link:definition>0000013 - Disclosure - Commercial License and Other Economic Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.ligand.com/role/FairValueMeasurement">
        <link:definition>0000014 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ligand.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.ligand.com/role/Debt">
        <link:definition>0000016 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails">
        <link:definition>0000017 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ligand.com/role/StockholdersEquity">
        <link:definition>0000018 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedings" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings">
        <link:definition>0000019 - Disclosure - Commitment and Contingencies: Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ligand.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioTables" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables">
        <link:definition>9954473 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionTables" roleURI="http://www.ligand.com/role/AcquisitionTables">
        <link:definition>9954474 - Disclosure - Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbTables" roleURI="http://www.ligand.com/role/SpinoffofOmniAbTables">
        <link:definition>9954475 - Disclosure - Spin-off of OmniAb (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialLicenseandOtherEconomicRightsTables" roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsTables">
        <link:definition>9954476 - Disclosure - Commercial License and Other Economic Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.ligand.com/role/FairValueMeasurementTables">
        <link:definition>9954477 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ligand.com/role/LeasesTables">
        <link:definition>9954478 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.ligand.com/role/DebtTables">
        <link:definition>9954479 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>9954480 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.ligand.com/role/StockholdersEquityTables">
        <link:definition>9954481 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ligand.com/role/IncomeTaxesTables">
        <link:definition>9954482 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
        <link:definition>9954484 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
        <link:definition>9954485 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails">
        <link:definition>9954486 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails">
        <link:definition>9954487 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails">
        <link:definition>9954488 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails">
        <link:definition>9954489 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionNarrativeDetails" roleURI="http://www.ligand.com/role/AcquisitionNarrativeDetails">
        <link:definition>9954490 - Disclosure - Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9954491 - Disclosure - Acquisition - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbNarrativeDetails" roleURI="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails">
        <link:definition>9954492 - Disclosure - Spin-off of OmniAb - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails">
        <link:definition>9954493 - Disclosure - Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails" roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails">
        <link:definition>9954494 - Disclosure - Spin-off of OmniAb - Schedule of non-cash items and capital expenditures of the discontinued operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails">
        <link:definition>9954495 - Disclosure - Commercial License and Other Economic Rights - Schedule of Commercial License and Other Economic Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommercialLicenseandOtherEconomicRightsNarrativeDetails" roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails">
        <link:definition>9954496 - Disclosure - Commercial License and Other Economic Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954497 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
        <link:definition>9954498 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>9954499 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ligand.com/role/LeasesNarrativeDetails">
        <link:definition>9954500 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails">
        <link:definition>9954501 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>9954502 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1">
        <link:definition>9954502 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.ligand.com/role/DebtNarrativeDetails">
        <link:definition>9954503 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" roleURI="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails">
        <link:definition>9954504 - Disclosure - Debt - Equity and Liability Components of Financing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsInvestmentCategoriesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails">
        <link:definition>9954505 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>9954506 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>9954507 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsNarrativeDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails">
        <link:definition>9954508 - Disclosure - Balance Sheet Account Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsPropertyandEquipmentDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails">
        <link:definition>9954509 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>9954510 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAccruedLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails">
        <link:definition>9954511 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails">
        <link:definition>9954512 - Disclosure - Balance Sheet Account Details - Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsContingentLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails">
        <link:definition>9954513 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareBasedCompensationDetails" roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails">
        <link:definition>9954514 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954515 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionPlanActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails">
        <link:definition>9954516 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityBreakdownofOptionsOutstandingDetails" roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails">
        <link:definition>9954517 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAssumptionsDetails" roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails">
        <link:definition>9954518 - Disclosure - Stockholders' Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails">
        <link:definition>9954519 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedingsNarrativeDetails" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails">
        <link:definition>9954520 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9954521 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails">
        <link:definition>9954522 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954523 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxesDetails" roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails">
        <link:definition>9954524 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>9954525 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lgnd_ImpairmentOfCommercialLicense" abstract="false" name="ImpairmentOfCommercialLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContractRevenueMember" abstract="true" name="ContractRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSixMember" abstract="true" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_MetabasisTherapeuticsMember" abstract="true" name="MetabasisTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" abstract="false" name="BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" abstract="true" name="BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DeferredTaxAssetsAdjustments" abstract="false" name="DeferredTaxAssetsAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ImpairmentLossOnCommercialLicenseRights" abstract="false" name="ImpairmentLossOnCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" abstract="true" name="NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetContributions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" abstract="true" name="USDistrictCourtForTheNorthernDistrictOfOhioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AccruedSubcontractorExpensesCurrent" abstract="false" name="AccruedSubcontractorExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentLiabilitiesMember" abstract="true" name="ContingentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_SelexisAndDianomiMember" abstract="true" name="SelexisAndDianomiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" abstract="false" name="BusinessCombinationAcquisitionCostIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" abstract="false" name="DebtInstrumentRepurchasedAmountDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" abstract="true" name="LicenseFeesMilestonesAndOtherProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_OmniabSeparationMember" abstract="true" name="OmniabSeparationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VikingTherapeuticsInc.Member" abstract="true" name="VikingTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" abstract="true" name="NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRights" abstract="false" name="LiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NucorionMember" abstract="true" name="NucorionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationTable" abstract="true" name="BasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" abstract="false" name="AdjustmentToCreditLossReservesOfCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PartnerAMember" abstract="true" name="PartnerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" abstract="false" name="AmountsOwedToFormerLicensorFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHolders" abstract="false" name="PaymentsToContingentValueRightHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VestingPeriodTwoMember" abstract="true" name="VestingPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidToDate" abstract="false" name="PurchaseCommitmentConsiderationPaidToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_OtherInvestmentsPolicyPolicyTextBlock" abstract="false" name="OtherInvestmentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_LicenseFeesMember" abstract="true" name="LicenseFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsGross" abstract="false" name="CommercialLicenseRightsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedSupplierExpensesCurrent" abstract="false" name="AccruedSupplierExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RoyaltyEvomelaMember" abstract="true" name="RoyaltyEvomelaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PaymentsforConvertibleBondHedges" abstract="false" name="PaymentsforConvertibleBondHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsPolicyTextBlock" abstract="false" name="CommercialLicenseRightsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_NumberOfContracts" abstract="false" name="NumberOfContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_BusinessCombinationLoanFeesAndInterest" abstract="false" name="BusinessCombinationLoanFeesAndInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PalvellaMember" abstract="true" name="PalvellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AccruedCustomerDepositsCurrent" abstract="false" name="AccruedCustomerDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" abstract="false" name="ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NumberOfSharesSoldOfEquityMethodInvestee" abstract="false" name="NumberOfSharesSoldOfEquityMethodInvestee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationShareConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_EmployeeStockPurchasePlanAbstract" abstract="true" name="EmployeeStockPurchasePlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PrimroseBioMember" abstract="true" name="PrimroseBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolCOVIDMember" abstract="true" name="MaterialSalesCaptisolCOVIDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" abstract="false" name="OperatingLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentMilestonePurchaseAgreement" abstract="false" name="ContingentMilestonePurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsCreditLossAdjustment" abstract="false" name="CommercialLicenseRightsCreditLossAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" abstract="false" name="ForecastedCashFlowsEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lgnd_AtTheMarketEquityOfferingMember" abstract="true" name="AtTheMarketEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_EquityMethodInvestmentsAllocationMember" abstract="true" name="EquityMethodInvestmentsAllocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsImpairments" abstract="false" name="CommercialLicenseRightsImpairments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" abstract="false" name="AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BelowMilestoneMember" abstract="true" name="BelowMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ConsiderationClassficationAxis" abstract="true" name="ConsiderationClassficationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_MetabasisMember" abstract="true" name="MetabasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ShareBasedCompensationInitialOfferingPeriod" abstract="false" name="ShareBasedCompensationInitialOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_RoyaltyRylazeMember" abstract="true" name="RoyaltyRylazeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotesDue2023Member" abstract="true" name="ConvertibleSeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" abstract="false" name="BusinessSpinOffAndMigrationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_PelicanTechnologyHoldingsIncMember" abstract="true" name="PelicanTechnologyHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PeliCRM197Member" abstract="true" name="PeliCRM197Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PalvellaTherapeuticsIncMember" abstract="true" name="PalvellaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" abstract="false" name="BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" abstract="false" name="AccruedDebtIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CyDexMember" abstract="true" name="CyDexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTenMember" abstract="true" name="ExercisePriceRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_SalesContractInterestInSalesRevenue" abstract="false" name="SalesContractInterestInSalesRevenue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolMember" abstract="true" name="MaterialSalesCaptisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_RoyaltyKyprolisMember" abstract="true" name="RoyaltyKyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_CydexPharmaceuticalsIncMember" abstract="true" name="CydexPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" abstract="false" name="LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" abstract="false" name="MinimumBeneficialOwnershipInReportingEntityPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ConsiderationClassficationDomain" abstract="true" name="ConsiderationClassficationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_TwoThousandTwoStockIncentivePlanMember" abstract="true" name="TwoThousandTwoStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_UnrecognizedTaxBenefitsNoncurrent" abstract="false" name="UnrecognizedTaxBenefitsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersInvestingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_GainLossOnShortTermInvestments" abstract="false" name="GainLossOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VestingPeriodOneMember" abstract="true" name="VestingPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" abstract="true" name="DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationLineItems" abstract="true" name="BasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lgnd_InterestInPotentialDevelopmentMilestone" abstract="false" name="InterestInPotentialDevelopmentMilestone" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_ProceedsFromCommercialLicenseRights" abstract="false" name="ProceedsFromCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationContingentValueRights" abstract="false" name="IncomeTaxReconciliationContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeEightMember" abstract="true" name="ExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" abstract="false" name="NonCashChangeInEstimatedFairValueOfContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ElutiaAndCorMatrixMember" abstract="true" name="ElutiaAndCorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_MilestoneMember" abstract="true" name="MilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ScheduleofContingentLiabilitiesTableTextBlock" abstract="false" name="ScheduleofContingentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_OtherMiscellaneousNonCurrentLiabilities" abstract="false" name="OtherMiscellaneousNonCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" abstract="false" name="AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRights" abstract="false" name="CommercialLicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" abstract="true" name="NotesRepurchasedDuringCurrentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedInventoryPurchases" abstract="false" name="AccruedInventoryPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" abstract="true" name="CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsIssued" abstract="false" name="NumberOfContingentValueRightsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_SaleOfStockAuthorizedOfferingAmount" abstract="false" name="SaleOfStockAuthorizedOfferingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RestrictedStockUnitsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsSeries" abstract="false" name="NumberOfContingentValueRightsSeries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_Phase3ClinicalTrialMember" abstract="true" name="Phase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RoyaltyOtherMember" abstract="true" name="RoyaltyOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PartnerBMember" abstract="true" name="PartnerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_CurrentPortionOfLiabilityForContingentValueRights" abstract="false" name="CurrentPortionOfLiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DerivativeAssetsMember" abstract="true" name="DerivativeAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInDebtDiscount" abstract="false" name="IncreaseDecreaseInDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" abstract="false" name="PurchaseCommitmentConsiderationPaidAllocatedToInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentLiabilityRollForward" abstract="true" name="ContingentLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" abstract="false" name="FinanceLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PurchaseforCommercialLicenseRights" abstract="false" name="PurchaseforCommercialLicenseRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsForSeparation" abstract="false" name="PaymentsForSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_CorporateShareRepurchaseAbstract" abstract="true" name="CorporateShareRepurchaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ProductRoyaltyPercentage" abstract="false" name="ProductRoyaltyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" abstract="false" name="ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_PartnerCMember" abstract="true" name="PartnerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RoyaltyTeriparatideInjectionMember" abstract="true" name="RoyaltyTeriparatideInjectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_SelexisMember" abstract="true" name="SelexisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_LicenseeAccrualCurrent" abstract="false" name="LicenseeAccrualCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" abstract="false" name="AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CorMatrixMember" abstract="true" name="CorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" abstract="false" name="CommercialLicenseAndOtherEconomicRightsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AmendedESPPMember" abstract="true" name="AmendedESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSevenMember" abstract="true" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightAgreements" abstract="false" name="NumberOfContingentValueRightAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_AboveMilestoneMember" abstract="true" name="AboveMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" abstract="false" name="ScheduleOfFairValueOfTheConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_SalesRevenueMilestone" abstract="false" name="SalesRevenueMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolCoreMember" abstract="true" name="MaterialSalesCaptisolCoreMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_OvidTherapeuticsMember" abstract="true" name="OvidTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_SoticlestatMember" abstract="true" name="SoticlestatMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NovanIncMember" abstract="true" name="NovanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeNineMember" abstract="true" name="ExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PaymentsToUnwindWarrants" abstract="false" name="PaymentsToUnwindWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsCumulativeAdjustments" abstract="false" name="CommercialLicenseRightsCumulativeAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" abstract="false" name="FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsAccumulatedAmortization" abstract="false" name="CommercialLicenseRightsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ToleranceTherapeuticsMember" abstract="true" name="ToleranceTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EquitySecuritiesAllocationMember" abstract="true" name="EquitySecuritiesAllocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsFairValueDisclosure" abstract="false" name="CommercialLicenseRightsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_RoyaltyAgreementExpirationPeriod" abstract="false" name="RoyaltyAgreementExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_BusinessCombinationAcquiredPercentage" abstract="false" name="BusinessCombinationAcquiredPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_PrimordialGeneticsMember" abstract="true" name="PrimordialGeneticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" abstract="false" name="AmortizationOfCommercialLicenseAndOtherEconomicRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>lgnd-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4cc674fd-25ef-4a1f-be1e-ae22ba8e96aa,g:9cb8df18-e655-4252-b500-06985d41d3f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fd1fa0e6-1174-4c25-a9c1-221f884b3e71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_us-gaap_AccountsPayableCurrent_fd1fa0e6-1174-4c25-a9c1-221f884b3e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a9118c0a-e0db-4f95-a225-bc8612f5e55b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a9118c0a-e0db-4f95-a225-bc8612f5e55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_ed19f164-4caa-4e56-bfd2-196742ac202c" xlink:href="lgnd-20231231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_ed19f164-4caa-4e56-bfd2-196742ac202c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b0ff959f-c180-40eb-862b-b2d647ba971e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b0ff959f-c180-40eb-862b-b2d647ba971e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b14f02bd-bf77-4062-bf3b-1f77e45bf9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b14f02bd-bf77-4062-bf3b-1f77e45bf9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6f36c6bb-093c-4a7e-acfc-679f8e2e4eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6f36c6bb-093c-4a7e-acfc-679f8e2e4eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_23bb5f44-e98d-4d41-9dfa-44fa4630e0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc4eda4e-150d-4d65-8543-2c8ee40f28df" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_23bb5f44-e98d-4d41-9dfa-44fa4630e0c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f8abb050-d18c-4fe4-97fa-d9b405c8470e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:to="loc_us-gaap_LiabilitiesCurrent_f8abb050-d18c-4fe4-97fa-d9b405c8470e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_86282bd2-e6d2-451d-852f-0e9826d7eb06" xlink:href="lgnd-20231231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:to="loc_lgnd_LiabilityForContingentValueRights_86282bd2-e6d2-451d-852f-0e9826d7eb06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64d44259-ac2b-4d21-ae68-942c41b24187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64d44259-ac2b-4d21-ae68-942c41b24187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82d95470-8b40-4888-a330-0a9aa519275e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82d95470-8b40-4888-a330-0a9aa519275e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89c99f65-3446-4610-9dff-38798ef8a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89c99f65-3446-4610-9dff-38798ef8a3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_61b7088b-7e06-48bc-b760-6fcf4af2ac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3ac51b6b-3e0f-4030-b7c3-cc1823702229" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_61b7088b-7e06-48bc-b760-6fcf4af2ac4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be35a84e-5532-4f11-b5d5-05595b7818b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be35a84e-5532-4f11-b5d5-05595b7818b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_47650a32-2d6b-4d73-9902-c705d0e2f1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_ShortTermInvestments_47650a32-2d6b-4d73-9902-c705d0e2f1a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_de6afce0-a36b-4684-81a7-4885d376bbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_de6afce0-a36b-4684-81a7-4885d376bbfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d6d04453-ddeb-45c5-8ee5-f804016a71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_InventoryNet_d6d04453-ddeb-45c5-8ee5-f804016a71ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a61b3d75-69aa-4f75-b6ed-bf76e00fbb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a61b3d75-69aa-4f75-b6ed-bf76e00fbb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_473c8034-916e-4ee5-973c-794a1af85503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_OtherAssetsCurrent_473c8034-916e-4ee5-973c-794a1af85503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_7140bc3a-4ef3-4622-a84f-95b0830bbfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1a4dab1e-e617-4529-a723-fc9a3e5eb5f5" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_7140bc3a-4ef3-4622-a84f-95b0830bbfd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf0683ea-a64d-456c-9537-3d7b66c25eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bb6dae83-1a48-4e33-8999-a36483d8badc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf0683ea-a64d-456c-9537-3d7b66c25eb6" xlink:to="loc_us-gaap_PreferredStockValue_bb6dae83-1a48-4e33-8999-a36483d8badc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_57651fba-f8b9-491d-a318-203a08656cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf0683ea-a64d-456c-9537-3d7b66c25eb6" xlink:to="loc_us-gaap_CommonStockValue_57651fba-f8b9-491d-a318-203a08656cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_01d1f6f8-d0a4-4e31-ad55-72131adac197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf0683ea-a64d-456c-9537-3d7b66c25eb6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_01d1f6f8-d0a4-4e31-ad55-72131adac197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b7214d13-f94a-4575-b007-982a408e1ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf0683ea-a64d-456c-9537-3d7b66c25eb6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b7214d13-f94a-4575-b007-982a408e1ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_802492f3-a326-4c11-98f4-3c325b26533f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bf0683ea-a64d-456c-9537-3d7b66c25eb6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_802492f3-a326-4c11-98f4-3c325b26533f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b87e0972-7f08-4828-8bc3-7a35f89f4bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_AssetsCurrent_b87e0972-7f08-4828-8bc3-7a35f89f4bd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_81fdacf6-6dfd-43a4-8e1a-9df87e7e8941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_81fdacf6-6dfd-43a4-8e1a-9df87e7e8941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ccaf4de2-fe67-4e9b-a5dc-5c92f838a368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ccaf4de2-fe67-4e9b-a5dc-5c92f838a368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_105798c8-f836-46f6-90e5-f1fb1856b894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_Goodwill_105798c8-f836-46f6-90e5-f1fb1856b894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_aeeeaebe-a56a-4e1b-aae5-d518c0354e76" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRights"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_lgnd_CommercialLicenseRights_aeeeaebe-a56a-4e1b-aae5-d518c0354e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b994c7c5-9a3c-4492-ad08-0cbc5674f68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b994c7c5-9a3c-4492-ad08-0cbc5674f68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_33925b88-1867-4121-aa84-67435232518e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_33925b88-1867-4121-aa84-67435232518e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_121b930b-ad07-4d83-81c0-1221fef5e7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_121b930b-ad07-4d83-81c0-1221fef5e7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7791ddd8-0019-4ca9-bec9-a32e3249ca6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_EquityMethodInvestments_7791ddd8-0019-4ca9-bec9-a32e3249ca6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_9f2ccced-c29b-4731-9fda-d9601927d34b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_OtherInvestments_9f2ccced-c29b-4731-9fda-d9601927d34b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3997b7b4-4a9b-498e-9c03-4cef03f68042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7bb8b193-1129-460c-9ba7-d9753bf3145f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3997b7b4-4a9b-498e-9c03-4cef03f68042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_52927b7b-f25f-4c31-8eda-5b5b454d0620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_13c739bf-5f40-46ca-a4ee-129b9e579f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52927b7b-f25f-4c31-8eda-5b5b454d0620" xlink:to="loc_us-gaap_Liabilities_13c739bf-5f40-46ca-a4ee-129b9e579f2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8c9e07b1-f88b-4f29-bc78-cd66a9536c57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52927b7b-f25f-4c31-8eda-5b5b454d0620" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8c9e07b1-f88b-4f29-bc78-cd66a9536c57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6334048d-ea65-4e16-bd03-df2a8752dab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52927b7b-f25f-4c31-8eda-5b5b454d0620" xlink:to="loc_us-gaap_StockholdersEquity_6334048d-ea65-4e16-bd03-df2a8752dab5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_676326bf-ff2b-42a7-8e35-074407fda975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_7007de50-3428-433d-9934-8e657e916f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_676326bf-ff2b-42a7-8e35-074407fda975" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_7007de50-3428-433d-9934-8e657e916f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bacda02a-c328-4d9a-a47c-9cf71bea2fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_676326bf-ff2b-42a7-8e35-074407fda975" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bacda02a-c328-4d9a-a47c-9cf71bea2fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1cc0ea0e-8cb8-4716-85e2-e5e993620c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_09b7eb5c-271c-4c6c-bb12-39ef4038e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1cc0ea0e-8cb8-4716-85e2-e5e993620c0b" xlink:to="loc_us-gaap_GainLossOnInvestments_09b7eb5c-271c-4c6c-bb12-39ef4038e4fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7dabfc50-0117-4e81-baf6-ab905ae57c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1cc0ea0e-8cb8-4716-85e2-e5e993620c0b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7dabfc50-0117-4e81-baf6-ab905ae57c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_758ddc07-87a5-4360-8ad9-252465416316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1cc0ea0e-8cb8-4716-85e2-e5e993620c0b" xlink:to="loc_us-gaap_InterestExpense_758ddc07-87a5-4360-8ad9-252465416316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_038509dc-5175-490d-a458-ba0b1ec916f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1cc0ea0e-8cb8-4716-85e2-e5e993620c0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_038509dc-5175-490d-a458-ba0b1ec916f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_dd34f141-31fc-48b5-8239-2b689ee10adb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1cc0ea0e-8cb8-4716-85e2-e5e993620c0b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_dd34f141-31fc-48b5-8239-2b689ee10adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dac86c4f-0aeb-4143-b802-8b8b14e1d43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_40a64957-1ec7-4068-bb17-4bea17b61f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_dac86c4f-0aeb-4143-b802-8b8b14e1d43e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_40a64957-1ec7-4068-bb17-4bea17b61f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_bb802828-0c5d-4ad2-a2ce-f944cb02feba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_dac86c4f-0aeb-4143-b802-8b8b14e1d43e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_bb802828-0c5d-4ad2-a2ce-f944cb02feba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e10e00c-2f09-4e7f-8ce9-03b60993725a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_899d6211-ebce-4a4e-81ac-d0eb088e1dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e10e00c-2f09-4e7f-8ce9-03b60993725a" xlink:to="loc_us-gaap_OperatingIncomeLoss_899d6211-ebce-4a4e-81ac-d0eb088e1dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a0415e6a-cf97-4d3f-9f4c-7abb6059e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e10e00c-2f09-4e7f-8ce9-03b60993725a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a0415e6a-cf97-4d3f-9f4c-7abb6059e11c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_a790ce2a-6086-437a-a4bf-013168831326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_579df1bf-6f8e-4f42-b3ae-db32faaae13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDirectMaterial"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_a790ce2a-6086-437a-a4bf-013168831326" xlink:to="loc_us-gaap_CostDirectMaterial_579df1bf-6f8e-4f42-b3ae-db32faaae13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_cce5800c-0874-4fbe-96cd-70454cc701a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_a790ce2a-6086-437a-a4bf-013168831326" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_cce5800c-0874-4fbe-96cd-70454cc701a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7b0ecd6f-df80-4dd2-bf91-4efa3601c77e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_a790ce2a-6086-437a-a4bf-013168831326" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7b0ecd6f-df80-4dd2-bf91-4efa3601c77e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_66072f7d-dafa-4772-9208-fb15c62e1742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_a790ce2a-6086-437a-a4bf-013168831326" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_66072f7d-dafa-4772-9208-fb15c62e1742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_df1e5a34-74dc-4f6d-b7cb-aa3c8c255186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_a790ce2a-6086-437a-a4bf-013168831326" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_df1e5a34-74dc-4f6d-b7cb-aa3c8c255186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79fa1188-c5b5-4d87-b72a-362b9bcc06f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec26d627-642b-40e6-88da-82f4e6f6472c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79fa1188-c5b5-4d87-b72a-362b9bcc06f9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec26d627-642b-40e6-88da-82f4e6f6472c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_8e0ab3d3-9bfb-4d95-ad8f-da5ef3a62a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79fa1188-c5b5-4d87-b72a-362b9bcc06f9" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_8e0ab3d3-9bfb-4d95-ad8f-da5ef3a62a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_88bf1bac-1a77-4487-8740-69cfbe70e9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79fa1188-c5b5-4d87-b72a-362b9bcc06f9" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_88bf1bac-1a77-4487-8740-69cfbe70e9ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d7b72e92-afac-4cef-aa4c-7bbae100c6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5feace4f-4027-4509-bfc4-a749f308c409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d7b72e92-afac-4cef-aa4c-7bbae100c6b2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5feace4f-4027-4509-bfc4-a749f308c409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f6052bde-219a-4847-9914-6584162b47ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_d7b72e92-afac-4cef-aa4c-7bbae100c6b2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f6052bde-219a-4847-9914-6584162b47ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1fed4480-8616-4a2a-98c5-c69d4a35b345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_49aa9f8d-1cbc-4798-b745-cdcdce4b928c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1fed4480-8616-4a2a-98c5-c69d4a35b345" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_49aa9f8d-1cbc-4798-b745-cdcdce4b928c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_70d58c5c-e05f-4239-8055-c3c39dc7fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1fed4480-8616-4a2a-98c5-c69d4a35b345" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_70d58c5c-e05f-4239-8055-c3c39dc7fd76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_aeb752d1-54e7-4f15-9762-edf26afba509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f449a50-ac2f-4f1e-b79f-d363c1de6c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_aeb752d1-54e7-4f15-9762-edf26afba509" xlink:to="loc_us-gaap_NetIncomeLoss_9f449a50-ac2f-4f1e-b79f-d363c1de6c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7c883b83-ba7c-49a3-ac4d-6c8db474364a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_aeb752d1-54e7-4f15-9762-edf26afba509" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7c883b83-ba7c-49a3-ac4d-6c8db474364a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e663c112-95b0-47fc-86dd-a53998166457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77307c57-99c7-4860-adfc-16448b744033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e663c112-95b0-47fc-86dd-a53998166457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77307c57-99c7-4860-adfc-16448b744033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64ce9f1b-bc35-45e6-aaf2-afe386230cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e663c112-95b0-47fc-86dd-a53998166457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64ce9f1b-bc35-45e6-aaf2-afe386230cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a90a569-1ec6-4f55-9ad5-76a145ed3ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e663c112-95b0-47fc-86dd-a53998166457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a90a569-1ec6-4f55-9ad5-76a145ed3ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation_1ad91661-3e29-4505-b286-399a145fd3fb" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsForSeparation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_lgnd_PaymentsForSeparation_1ad91661-3e29-4505-b286-399a145fd3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7111238e-fca7-4892-93e1-f881d8a100b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7111238e-fca7-4892-93e1-f881d8a100b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0d935212-e618-45a5-835d-d71d6e753bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0d935212-e618-45a5-835d-d71d6e753bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_fa7d75e2-b4fd-4bee-97cb-153325b0ba37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_fa7d75e2-b4fd-4bee-97cb-153325b0ba37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_94957e85-17dd-4b70-92fb-b72dbe33b666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_94957e85-17dd-4b70-92fb-b72dbe33b666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_201977aa-c832-4107-92c4-cbb6618c53ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_201977aa-c832-4107-92c4-cbb6618c53ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_98fa9ac2-da32-4569-bef2-713228307a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_98fa9ac2-da32-4569-bef2-713228307a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_b842f560-2f35-4a0f-9784-a79962f0ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_b842f560-2f35-4a0f-9784-a79962f0ef90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_6e836fdb-e415-4c08-bee6-0b169e0000ef" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_6e836fdb-e415-4c08-bee6-0b169e0000ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_94f30be4-b5dc-408e-9e9a-349550e0b841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26944b80-1fa5-499d-8668-79de12b02056" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_94f30be4-b5dc-408e-9e9a-349550e0b841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ccab7268-8bc4-41d9-9fb0-57c01cef4717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ccab7268-8bc4-41d9-9fb0-57c01cef4717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_55d4625c-b8e9-42b1-b8c3-be85c5332af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_55d4625c-b8e9-42b1-b8c3-be85c5332af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_0b44cd2c-d8a1-49d0-92d9-5f874026b292" xlink:href="lgnd-20231231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_0b44cd2c-d8a1-49d0-92d9-5f874026b292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_60b8d367-3798-4598-bf95-c60aa6d78d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_60b8d367-3798-4598-bf95-c60aa6d78d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_fef3d333-6493-4572-88fe-35cbfeca7008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_fef3d333-6493-4572-88fe-35cbfeca7008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_86938294-06d8-4be2-b564-29d5cad7202a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_86938294-06d8-4be2-b564-29d5cad7202a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c58ed02-42b6-4604-ab57-3c3eaac45605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c58ed02-42b6-4604-ab57-3c3eaac45605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4ef0ef2d-e37b-4458-8a9c-08770fa326ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4ef0ef2d-e37b-4458-8a9c-08770fa326ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_d518c0ad-9684-4d20-a5d0-40ebdd099864" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_34d90d56-9326-437c-8f1a-39136d832965" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_d518c0ad-9684-4d20-a5d0-40ebdd099864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b2b21cd-5c60-4af9-980c-d3dc64cc15d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_NetIncomeLoss_0b2b21cd-5c60-4af9-980c-d3dc64cc15d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_023dac1a-be1e-45b7-bf7a-12445a0477a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_023dac1a-be1e-45b7-bf7a-12445a0477a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_925d6f57-c374-4be3-8c8a-35c66b62a5cd" xlink:href="lgnd-20231231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_925d6f57-c374-4be3-8c8a-35c66b62a5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ec0fe43e-5b67-42d6-b6b9-a5c03568d7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ec0fe43e-5b67-42d6-b6b9-a5c03568d7ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_5c87dd6e-1779-419c-be49-90438eeab153" xlink:href="lgnd-20231231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_5c87dd6e-1779-419c-be49-90438eeab153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_df5a9d52-beff-457d-accc-c1d0aeed59fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_df5a9d52-beff-457d-accc-c1d0aeed59fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_dbbb8f7b-f626-4084-9b12-33c1df1b4e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_dbbb8f7b-f626-4084-9b12-33c1df1b4e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fcec83f6-8710-4f4e-8624-7ad89a7b11a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fcec83f6-8710-4f4e-8624-7ad89a7b11a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_0b3c0af0-6c6e-4ed7-a429-782a2cf6a36c" xlink:href="lgnd-20231231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_0b3c0af0-6c6e-4ed7-a429-782a2cf6a36c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_acae01c5-6ea9-4470-9d73-866c93bb9e8c" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_acae01c5-6ea9-4470-9d73-866c93bb9e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnCommercialLicenseRights_9cbd751b-de1e-4491-9e2f-aac7ae2245a0" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentLossOnCommercialLicenseRights"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_lgnd_ImpairmentLossOnCommercialLicenseRights_9cbd751b-de1e-4491-9e2f-aac7ae2245a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_7bdc05ad-14d1-44a8-8c8f-0514044ac4de" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_7bdc05ad-14d1-44a8-8c8f-0514044ac4de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_53e0d865-ea75-45e0-aee2-38e7263ee281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_ShareBasedCompensation_53e0d865-ea75-45e0-aee2-38e7263ee281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e42d1027-525c-475c-848c-9233f533e1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e42d1027-525c-475c-848c-9233f533e1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ebf12057-a50a-45c9-bafe-e68d76529e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ebf12057-a50a-45c9-bafe-e68d76529e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c843ddac-fdf4-4d81-9bca-9716b9d980cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c843ddac-fdf4-4d81-9bca-9716b9d980cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_502c6de9-5025-410b-b073-f33df7d68def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_502c6de9-5025-410b-b073-f33df7d68def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e4f663b5-7b76-4747-aa51-0d202bd7c078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e4f663b5-7b76-4747-aa51-0d202bd7c078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_9cb7d2fe-e26f-46bc-b7aa-de6999b59c84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_9cb7d2fe-e26f-46bc-b7aa-de6999b59c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01d57dfa-ffa5-4a49-ac1d-5bbadeef0560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01d57dfa-ffa5-4a49-ac1d-5bbadeef0560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_13babbeb-0786-4235-8427-4eb9fba12d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_13babbeb-0786-4235-8427-4eb9fba12d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_75059f3f-46fd-4521-98c7-7867414d28dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_75059f3f-46fd-4521-98c7-7867414d28dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47e26b15-0a6c-4a98-a1a2-a47eead7b25e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47e26b15-0a6c-4a98-a1a2-a47eead7b25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f72d20b0-4f2c-4bfe-9bae-2164471bb5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_443f454b-4ea7-4058-a4e0-c59bf6a3c3da" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f72d20b0-4f2c-4bfe-9bae-2164471bb5a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_692baddf-9495-4386-afe2-f4b042c1bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_48db15b7-c300-4e13-85fc-3d1e349f078a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_692baddf-9495-4386-afe2-f4b042c1bd7e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_48db15b7-c300-4e13-85fc-3d1e349f078a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_315df291-8b56-4a8b-a96b-9cf79ab5bcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_692baddf-9495-4386-afe2-f4b042c1bd7e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_315df291-8b56-4a8b-a96b-9cf79ab5bcbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0f7cdd00-74d3-48fe-8166-b2b43a846908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0f7cdd00-74d3-48fe-8166-b2b43a846908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_a1ddc7df-cb1e-4a33-95a9-2159aacfe5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_a1ddc7df-cb1e-4a33-95a9-2159aacfe5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_52419ac4-bde5-47de-ad3f-264383799faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_52419ac4-bde5-47de-ad3f-264383799faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_331a797e-a6d1-4b0a-976a-7b039c5578e5" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_331a797e-a6d1-4b0a-976a-7b039c5578e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_25ea0fa5-9aea-4a1a-bf22-a4f91d1e4c73" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_25ea0fa5-9aea-4a1a-bf22-a4f91d1e4c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_78cf6b12-bd16-4262-b17e-4401a48e39b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_78cf6b12-bd16-4262-b17e-4401a48e39b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_93bc420d-b9c1-4173-a5d2-6e72c34df17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_93bc420d-b9c1-4173-a5d2-6e72c34df17a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_2451ab64-502a-4777-a122-3ea66251c185" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_2451ab64-502a-4777-a122-3ea66251c185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_206bed8f-c1c5-41e7-b819-8607be47659f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_9dcffd08-6c54-4c17-aa96-a316417c2715" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_206bed8f-c1c5-41e7-b819-8607be47659f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_6cb5e993-4ebc-45aa-a610-bf90cdccf00d" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_3c1eebfc-58ca-4210-ab46-953eb8bf57f0" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_6cb5e993-4ebc-45aa-a610-bf90cdccf00d" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_3c1eebfc-58ca-4210-ab46-953eb8bf57f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_ba74bf58-4b27-4c90-ac3e-0a4769a02445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_6cb5e993-4ebc-45aa-a610-bf90cdccf00d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_ba74bf58-4b27-4c90-ac3e-0a4769a02445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_9b99f847-0fa3-40a2-9be5-2b829aff9ab1" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_6cb5e993-4ebc-45aa-a610-bf90cdccf00d" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_9b99f847-0fa3-40a2-9be5-2b829aff9ab1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a274ea16-7ffe-4915-b5a4-31346175fc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest_8575bff1-9d7b-4ef3-8607-51d10d6e17d3" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a274ea16-7ffe-4915-b5a4-31346175fc5c" xlink:to="loc_lgnd_BusinessCombinationLoanFeesAndInterest_8575bff1-9d7b-4ef3-8607-51d10d6e17d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6131d999-f2b1-4d32-b093-479536ab95f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a274ea16-7ffe-4915-b5a4-31346175fc5c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6131d999-f2b1-4d32-b093-479536ab95f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_586e594f-42d7-459b-b85e-45b87d4361f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d3ba889c-1edc-43ec-8f96-4c951c4ccced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_586e594f-42d7-459b-b85e-45b87d4361f9" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d3ba889c-1edc-43ec-8f96-4c951c4ccced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2a90d090-57e0-4667-8cc7-ccbfb82f1ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_586e594f-42d7-459b-b85e-45b87d4361f9" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_2a90d090-57e0-4667-8cc7-ccbfb82f1ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6a28609b-a16a-4a1e-8693-b29fb87d681e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_c8914f75-807f-4d55-b32d-a20af7106b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6a28609b-a16a-4a1e-8693-b29fb87d681e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_c8914f75-807f-4d55-b32d-a20af7106b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_d89e8f35-a801-4bba-a9bc-6191374a138e" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6a28609b-a16a-4a1e-8693-b29fb87d681e" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_d89e8f35-a801-4bba-a9bc-6191374a138e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5ee72ce6-b157-46a5-975f-61d52447e2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6a28609b-a16a-4a1e-8693-b29fb87d681e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5ee72ce6-b157-46a5-975f-61d52447e2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_e99ec3d5-9f7d-4201-a57d-9c3c48430313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_293b9999-d222-4848-8d27-eef52e39d4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_e99ec3d5-9f7d-4201-a57d-9c3c48430313" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_293b9999-d222-4848-8d27-eef52e39d4f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_9146216b-492c-49d4-8c27-7098d5c6bda4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_e99ec3d5-9f7d-4201-a57d-9c3c48430313" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_9146216b-492c-49d4-8c27-7098d5c6bda4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_117ae3f8-95d5-473c-8264-488547dcbfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_35dc554a-0ae1-4d64-9b61-dcb72afff080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_117ae3f8-95d5-473c-8264-488547dcbfd9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_35dc554a-0ae1-4d64-9b61-dcb72afff080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_fac38195-b3a5-4db4-a66a-e694ab7c2e83" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_117ae3f8-95d5-473c-8264-488547dcbfd9" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_fac38195-b3a5-4db4-a66a-e694ab7c2e83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_a5b7d63d-b398-4234-bd5d-6e2418750f11" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_fc31d05f-5fc0-491f-b5df-e2c8b5b4fcdf" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_a5b7d63d-b398-4234-bd5d-6e2418750f11" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_fc31d05f-5fc0-491f-b5df-e2c8b5b4fcdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_8730eea2-6379-4b62-8441-ec3aeeeb917d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_a5b7d63d-b398-4234-bd5d-6e2418750f11" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_8730eea2-6379-4b62-8441-ec3aeeeb917d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_3d2f254e-f8d3-4e41-86ee-8d84dd0fb888" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_a5b7d63d-b398-4234-bd5d-6e2418750f11" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_3d2f254e-f8d3-4e41-86ee-8d84dd0fb888" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_a9a12f9a-943e-4dc4-b83c-633fa07e743b" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRights"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsGross_bcc50a94-b9a3-4fdb-a6fe-550456c20fb7" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_CommercialLicenseRights_a9a12f9a-943e-4dc4-b83c-633fa07e743b" xlink:to="loc_lgnd_CommercialLicenseRightsGross_bcc50a94-b9a3-4fdb-a6fe-550456c20fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments_58962a32-cda9-4a1c-9063-b9cb39f2b9d6" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCumulativeAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_CommercialLicenseRights_a9a12f9a-943e-4dc4-b83c-633fa07e743b" xlink:to="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments_58962a32-cda9-4a1c-9063-b9cb39f2b9d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d7f79a7a-563f-4f12-9324-f9d77486b04a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6746315e-12db-45f1-8e30-fc5d0c5ae437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d7f79a7a-563f-4f12-9324-f9d77486b04a" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6746315e-12db-45f1-8e30-fc5d0c5ae437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b79c0ac7-e183-4ebd-95cd-325769226850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d7f79a7a-563f-4f12-9324-f9d77486b04a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b79c0ac7-e183-4ebd-95cd-325769226850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3b6245b5-26a4-486f-806c-2130d7c86217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d7f79a7a-563f-4f12-9324-f9d77486b04a" xlink:to="loc_us-gaap_DerivativeAssets_3b6245b5-26a4-486f-806c-2130d7c86217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_613b2b11-da8c-41c6-8feb-2cebd3aa9095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_692287fa-bc12-436c-a99e-4090fa82b1ce" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_613b2b11-da8c-41c6-8feb-2cebd3aa9095" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_692287fa-bc12-436c-a99e-4090fa82b1ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_283d4bcf-c0eb-40ef-8c91-04a69472bc3c" xlink:href="lgnd-20231231.xsd#lgnd_AmountsOwedToFormerLicensorFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_613b2b11-da8c-41c6-8feb-2cebd3aa9095" xlink:to="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_283d4bcf-c0eb-40ef-8c91-04a69472bc3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_315de61d-ba55-4cbe-abaf-709312ad9858" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_f088bfff-c343-43da-938c-f71203474777" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_315de61d-ba55-4cbe-abaf-709312ad9858" xlink:to="loc_lgnd_LeaseLiabilityCurrent_f088bfff-c343-43da-938c-f71203474777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5cf12d57-5740-4caa-8256-6625d6bd6c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_315de61d-ba55-4cbe-abaf-709312ad9858" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5cf12d57-5740-4caa-8256-6625d6bd6c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e400b173-9f58-4505-8f9e-ab02cbee6784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_315de61d-ba55-4cbe-abaf-709312ad9858" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e400b173-9f58-4505-8f9e-ab02cbee6784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_2ae92477-c12a-4d72-82ca-05f43e63f466" xlink:href="lgnd-20231231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2d5f30c2-65b6-4485-bb04-d68988f24ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_2ae92477-c12a-4d72-82ca-05f43e63f466" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2d5f30c2-65b6-4485-bb04-d68988f24ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ae9fe935-fb63-44dc-af2e-074354812810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_2ae92477-c12a-4d72-82ca-05f43e63f466" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ae9fe935-fb63-44dc-af2e-074354812810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_2362be83-c8f8-489a-a237-36949ad021fb" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_49b024ec-84e2-4833-abe5-699233352ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_2362be83-c8f8-489a-a237-36949ad021fb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_49b024ec-84e2-4833-abe5-699233352ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b3c136ac-e8f8-4b85-b05f-1db291329e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_2362be83-c8f8-489a-a237-36949ad021fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b3c136ac-e8f8-4b85-b05f-1db291329e03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fa4f3556-8dcf-4cab-a45e-a7c30b38a93b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fa4f3556-8dcf-4cab-a45e-a7c30b38a93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e1c1dade-9faf-4e1d-aa2f-8e6a30277b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e1c1dade-9faf-4e1d-aa2f-8e6a30277b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0bbb65bc-6e78-4def-80f4-d82c79011efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0bbb65bc-6e78-4def-80f4-d82c79011efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a8da01d3-897e-4ce4-97ec-5c6bf839064e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a8da01d3-897e-4ce4-97ec-5c6bf839064e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5a53eb35-7a0e-414a-b5b1-988f962949b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5a53eb35-7a0e-414a-b5b1-988f962949b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_30003f96-e7d9-4bf5-9998-d39b2a173432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_71f2c171-ed93-4364-bd88-d06414f00580" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_30003f96-e7d9-4bf5-9998-d39b2a173432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0016a8e9-1f35-46f6-8b7d-c4daa580ff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0016a8e9-1f35-46f6-8b7d-c4daa580ff9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_862af15f-bb16-4ef4-b2fd-ea8c482e7138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_862af15f-bb16-4ef4-b2fd-ea8c482e7138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f672da2c-c696-4f33-89b9-89a5a908fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f672da2c-c696-4f33-89b9-89a5a908fcdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_50375702-1132-4e77-975e-bd2fee4f4db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_50375702-1132-4e77-975e-bd2fee4f4db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9d5f6b57-8807-4143-a28b-b98c8fd8f94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9d5f6b57-8807-4143-a28b-b98c8fd8f94d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_d4e43b3d-dd29-43e5-8529-3c8faa01b697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d108b81f-b2cc-4310-bd0a-5f72d121e5fb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_d4e43b3d-dd29-43e5-8529-3c8faa01b697" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f56677e-343f-4520-a15d-472ff1b9e534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_2f669857-b147-47eb-bd2a-f607258e52b6" xlink:href="lgnd-20231231.xsd#lgnd_OperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f56677e-343f-4520-a15d-472ff1b9e534" xlink:to="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_2f669857-b147-47eb-bd2a-f607258e52b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7afb72e3-e335-4d32-a6a6-cb4099e99a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f56677e-343f-4520-a15d-472ff1b9e534" xlink:to="loc_us-gaap_OperatingLeaseLiability_7afb72e3-e335-4d32-a6a6-cb4099e99a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e8280af6-6149-4efc-afaa-07d002be2a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f56677e-343f-4520-a15d-472ff1b9e534" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e8280af6-6149-4efc-afaa-07d002be2a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_01aaf63f-e560-4411-9ed6-a6144584eecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_4dffaaca-355d-4b87-94b7-ead243db5c87" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_01aaf63f-e560-4411-9ed6-a6144584eecc" xlink:to="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_4dffaaca-355d-4b87-94b7-ead243db5c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_51dc15de-09e8-4497-b967-b09be693cda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_01aaf63f-e560-4411-9ed6-a6144584eecc" xlink:to="loc_us-gaap_FinanceLeaseLiability_51dc15de-09e8-4497-b967-b09be693cda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_bba19311-0e16-483d-9e18-f583469a98b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_01aaf63f-e560-4411-9ed6-a6144584eecc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_bba19311-0e16-483d-9e18-f583469a98b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_09114613-f00f-406a-9e79-3382f22d137f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ee24c6c6-4118-4779-80fc-9d2000a04c40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_09114613-f00f-406a-9e79-3382f22d137f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ee24c6c6-4118-4779-80fc-9d2000a04c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_350867db-decf-4036-89a5-a7ccdf3875e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_09114613-f00f-406a-9e79-3382f22d137f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_350867db-decf-4036-89a5-a7ccdf3875e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e75f8079-f58a-482f-8de5-622394d980a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7d52d281-402a-43f9-b402-8e61a6752c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e75f8079-f58a-482f-8de5-622394d980a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7d52d281-402a-43f9-b402-8e61a6752c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ea64f17d-091e-49c2-a586-21944b5b5c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e75f8079-f58a-482f-8de5-622394d980a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ea64f17d-091e-49c2-a586-21944b5b5c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c2053bf6-a76f-42f7-a2df-eefa59f224bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e75f8079-f58a-482f-8de5-622394d980a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c2053bf6-a76f-42f7-a2df-eefa59f224bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ca508db6-fc36-4c1e-9b79-046b5f79dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_261118f3-dcf3-414a-a0a5-a62dd614c34e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ca508db6-fc36-4c1e-9b79-046b5f79dcb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_261118f3-dcf3-414a-a0a5-a62dd614c34e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d1447b82-48b9-4ca3-bab0-fd0261369e54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ca508db6-fc36-4c1e-9b79-046b5f79dcb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d1447b82-48b9-4ca3-bab0-fd0261369e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_d64b7985-a189-4164-a24a-5cc875376301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_70fd3630-f712-4ca4-bea8-38511fcff97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_d64b7985-a189-4164-a24a-5cc875376301" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_70fd3630-f712-4ca4-bea8-38511fcff97d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c933dcc1-1e06-44bb-acc5-e49d32fbacaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_d64b7985-a189-4164-a24a-5cc875376301" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c933dcc1-1e06-44bb-acc5-e49d32fbacaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5bfc997-e917-4dc5-b68d-6e449b2146ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_751c4e44-fc58-4b9b-ac59-3335e4b12acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5bfc997-e917-4dc5-b68d-6e449b2146ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_751c4e44-fc58-4b9b-ac59-3335e4b12acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_508f3916-f01f-42bd-82e5-9b9f9c48f345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5bfc997-e917-4dc5-b68d-6e449b2146ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_508f3916-f01f-42bd-82e5-9b9f9c48f345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_357ca4f8-ce10-44cb-a527-26eaa60af2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_d2c76ce4-0946-4070-ae54-c7abaa5d68a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_357ca4f8-ce10-44cb-a527-26eaa60af2c0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_d2c76ce4-0946-4070-ae54-c7abaa5d68a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a37919bd-7d5f-4471-89f6-596bf0f394c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_357ca4f8-ce10-44cb-a527-26eaa60af2c0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a37919bd-7d5f-4471-89f6-596bf0f394c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_42ee4da3-5814-49f5-a6d5-ad674d1385cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1ee7aab0-7639-4063-b78f-29895ae249e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_42ee4da3-5814-49f5-a6d5-ad674d1385cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1ee7aab0-7639-4063-b78f-29895ae249e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_953870b1-4b08-4768-b0f4-2d4a20daa713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_42ee4da3-5814-49f5-a6d5-ad674d1385cc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_953870b1-4b08-4768-b0f4-2d4a20daa713" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0feeb74f-ce29-442c-9db2-09c32ea4c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_386db808-6b9e-4c75-a04e-670dbff4b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0feeb74f-ce29-442c-9db2-09c32ea4c01d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_386db808-6b9e-4c75-a04e-670dbff4b7c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_106ab0e0-8f02-4491-943e-c7fcb989ebfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0feeb74f-ce29-442c-9db2-09c32ea4c01d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_106ab0e0-8f02-4491-943e-c7fcb989ebfb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_6be846df-ddeb-4564-adb7-26e777d9eb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_6be846df-ddeb-4564-adb7-26e777d9eb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0d0eb966-281b-4a44-bcc7-c747e50ffe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0d0eb966-281b-4a44-bcc7-c747e50ffe7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_1dc218e8-9e89-44d1-843a-48aa6d4e84de" xlink:href="lgnd-20231231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_1dc218e8-9e89-44d1-843a-48aa6d4e84de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_bea10c6b-7f62-4773-b1a9-1b2f2ada0f48" xlink:href="lgnd-20231231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_bea10c6b-7f62-4773-b1a9-1b2f2ada0f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_177fdbdd-8bd3-4c9a-b458-8dedeb90f160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_177fdbdd-8bd3-4c9a-b458-8dedeb90f160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_69a36fd1-8095-4fc3-9543-1d2cdff2794a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_69a36fd1-8095-4fc3-9543-1d2cdff2794a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseeAccrualCurrent_dcf76470-e3aa-4ede-81dc-471ef6f099e8" xlink:href="lgnd-20231231.xsd#lgnd_LicenseeAccrualCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_lgnd_LicenseeAccrualCurrent_dcf76470-e3aa-4ede-81dc-471ef6f099e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCustomerDepositsCurrent_36f1ebd5-65ac-4e1d-806f-95489a43a6a8" xlink:href="lgnd-20231231.xsd#lgnd_AccruedCustomerDepositsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02d185fc-c390-4648-9f15-c3f1188066a8" xlink:to="loc_lgnd_AccruedCustomerDepositsCurrent_36f1ebd5-65ac-4e1d-806f-95489a43a6a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cc1eb54e-d20d-42ee-9b33-abcf387f5170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_02f55bb4-0afd-48c0-b912-df9999542142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_cc1eb54e-d20d-42ee-9b33-abcf387f5170" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_02f55bb4-0afd-48c0-b912-df9999542142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_334cf688-7776-4cba-8e59-b3d643d19ba2" xlink:href="lgnd-20231231.xsd#lgnd_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_cc1eb54e-d20d-42ee-9b33-abcf387f5170" xlink:to="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_334cf688-7776-4cba-8e59-b3d643d19ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherMiscellaneousNonCurrentLiabilities_c0029dcf-22a5-4e23-b971-a25c8e491646" xlink:href="lgnd-20231231.xsd#lgnd_OtherMiscellaneousNonCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_cc1eb54e-d20d-42ee-9b33-abcf387f5170" xlink:to="loc_lgnd_OtherMiscellaneousNonCurrentLiabilities_c0029dcf-22a5-4e23-b971-a25c8e491646" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a5f78ce8-aa16-4886-ab9b-90a919c7e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b1c1ba79-718a-4119-ae95-d63c6add6dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a5f78ce8-aa16-4886-ab9b-90a919c7e76c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b1c1ba79-718a-4119-ae95-d63c6add6dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_29b86a9c-3e5f-4c04-a4fc-9f8cd9ffbe56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a5f78ce8-aa16-4886-ab9b-90a919c7e76c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_29b86a9c-3e5f-4c04-a4fc-9f8cd9ffbe56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cd96a033-ab52-4ec3-8c2e-214f90a1508e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a5f78ce8-aa16-4886-ab9b-90a919c7e76c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cd96a033-ab52-4ec3-8c2e-214f90a1508e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_73418409-4ac3-41eb-8825-d54217f0de3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55696858-aa32-4580-b779-9ffbd9cdd7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_73418409-4ac3-41eb-8825-d54217f0de3b" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55696858-aa32-4580-b779-9ffbd9cdd7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0ad44f98-6ad5-4145-8328-097e4d89be8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_73418409-4ac3-41eb-8825-d54217f0de3b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0ad44f98-6ad5-4145-8328-097e4d89be8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28d95f69-c5b1-4898-8e9c-4b703162b6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a1acf7ad-f177-4940-9779-ae154dcc2d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28d95f69-c5b1-4898-8e9c-4b703162b6b0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a1acf7ad-f177-4940-9779-ae154dcc2d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_de54f8eb-0dcc-4705-bcc5-210acafedf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28d95f69-c5b1-4898-8e9c-4b703162b6b0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_de54f8eb-0dcc-4705-bcc5-210acafedf7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_e14af22c-ca0a-4716-a6ca-4614fc359fa9" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_e14af22c-ca0a-4716-a6ca-4614fc359fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3b1c98fa-cc56-460c-add3-b9eba0520a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3b1c98fa-cc56-460c-add3-b9eba0520a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_650e04ab-1ee9-4e5d-800e-b680c57b6b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_650e04ab-1ee9-4e5d-800e-b680c57b6b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_85049346-d8aa-4ae8-9e60-51dbfe8945d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_85049346-d8aa-4ae8-9e60-51dbfe8945d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_169de636-d384-41e4-b218-86b186a86d02" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_169de636-d384-41e4-b218-86b186a86d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_9fe79ee5-6eb2-459b-a6a2-7f5e4da022f2" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_9fe79ee5-6eb2-459b-a6a2-7f5e4da022f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_50fb4558-2162-4fc0-9fee-ad8260d68c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_50fb4558-2162-4fc0-9fee-ad8260d68c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e10d159b-4371-46a0-8f4e-9d561b5f4bae" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e10d159b-4371-46a0-8f4e-9d561b5f4bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_d414927b-bff4-42dd-892b-38e93a5a52e1" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_d414927b-bff4-42dd-892b-38e93a5a52e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_fe7966f1-e90a-45c9-b349-47f93b6cc820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_fe7966f1-e90a-45c9-b349-47f93b6cc820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ee950e07-277f-4275-a40b-d84ad2d120df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ee950e07-277f-4275-a40b-d84ad2d120df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_16590b76-7aba-4cbb-a33c-56edbb586e68" xlink:href="lgnd-20231231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_16590b76-7aba-4cbb-a33c-56edbb586e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_dd5b3b31-b2c7-479a-ae3d-eaaa811cdfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_dd5b3b31-b2c7-479a-ae3d-eaaa811cdfc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_111b68a4-50f5-4746-a488-469b0de9de57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_111b68a4-50f5-4746-a488-469b0de9de57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_37d58aa0-b73b-42fd-9c4b-943d99a65c1e" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_826a014b-7b8f-4a86-8a75-8cd44173294e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_37d58aa0-b73b-42fd-9c4b-943d99a65c1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_737c1773-4daa-43d2-9119-f7da788d257d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c5786236-a7c3-4e29-8a89-4026d0d8abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_737c1773-4daa-43d2-9119-f7da788d257d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c5786236-a7c3-4e29-8a89-4026d0d8abcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_33e8c2ac-8136-416e-a587-78f2351d5e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_737c1773-4daa-43d2-9119-f7da788d257d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_33e8c2ac-8136-416e-a587-78f2351d5e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f6b26c37-bd73-4e70-84a5-a32ad0eff466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_03ea72c2-1c0f-4f02-8448-98111dd20558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f6b26c37-bd73-4e70-84a5-a32ad0eff466" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_03ea72c2-1c0f-4f02-8448-98111dd20558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c81e8619-c64b-40ff-a759-4166ecd54eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f6b26c37-bd73-4e70-84a5-a32ad0eff466" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c81e8619-c64b-40ff-a759-4166ecd54eaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f1ec53e2-4740-4027-af2c-0e2ea785ddeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d12d0100-b583-45c9-b5d3-6908dd1adaac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ec53e2-4740-4027-af2c-0e2ea785ddeb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d12d0100-b583-45c9-b5d3-6908dd1adaac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fdad38ac-94e2-494e-8c73-bc64e839ec5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ec53e2-4740-4027-af2c-0e2ea785ddeb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fdad38ac-94e2-494e-8c73-bc64e839ec5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2aa1511b-47ce-4d78-ab0e-06f313f567c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ec53e2-4740-4027-af2c-0e2ea785ddeb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2aa1511b-47ce-4d78-ab0e-06f313f567c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4a91c364-daeb-4631-a575-68214896ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ec53e2-4740-4027-af2c-0e2ea785ddeb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4a91c364-daeb-4631-a575-68214896ec51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_c374bae5-6f83-4d52-8f64-b33bff6ff82b" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f1ec53e2-4740-4027-af2c-0e2ea785ddeb" xlink:to="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_c374bae5-6f83-4d52-8f64-b33bff6ff82b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bfcf9f60-39ae-493d-8641-f6d1ba762ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_ab60f0e8-40b7-46e1-8047-452bc954aef7" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bfcf9f60-39ae-493d-8641-f6d1ba762ad8" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_ab60f0e8-40b7-46e1-8047-452bc954aef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_271c218c-9a01-4cee-9b6e-7985f1b9af74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bfcf9f60-39ae-493d-8641-f6d1ba762ad8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_271c218c-9a01-4cee-9b6e-7985f1b9af74" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>lgnd-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4cc674fd-25ef-4a1f-be1e-ae22ba8e96aa,g:9cb8df18-e655-4252-b500-06985d41d3f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:to="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_743b0916-5ecd-4aef-a152-e9ca5f8096e2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:to="loc_srt_ProductsAndServicesDomain_743b0916-5ecd-4aef-a152-e9ca5f8096e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:to="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_1eb80ac9-2ff3-49aa-8925-a24081f73061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:to="loc_us-gaap_RoyaltyMember_1eb80ac9-2ff3-49aa-8925-a24081f73061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_d5390d8c-655a-4fde-99ba-ec17513a24ff" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_d5390d8c-655a-4fde-99ba-ec17513a24ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_e41eb27e-d81e-4307-9099-7d6d9e247d4f" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:to="loc_lgnd_ContractRevenueMember_e41eb27e-d81e-4307-9099-7d6d9e247d4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1c8647a8-5c19-44e2-a87f-902759551845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_RevenuesAbstract_1c8647a8-5c19-44e2-a87f-902759551845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a4f913b-5178-421b-9580-fcd6dc610b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1c8647a8-5c19-44e2-a87f-902759551845" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a4f913b-5178-421b-9580-fcd6dc610b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_d5021711-a90f-4160-ab25-b885b37973c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_CostDirectMaterial_d5021711-a90f-4160-ab25-b885b37973c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_7b12ea4b-02f3-43ff-ac8a-58003f245c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_7b12ea4b-02f3-43ff-ac8a-58003f245c31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f452115b-7292-42f0-95f0-81e39629fb26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f452115b-7292-42f0-95f0-81e39629fb26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ed3c2fd2-f66a-4d1c-8f40-670f39f53cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ed3c2fd2-f66a-4d1c-8f40-670f39f53cd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1de0f7de-7840-4e06-8113-1f9c0864703c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1de0f7de-7840-4e06-8113-1f9c0864703c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_cf0d29ca-adb1-42e1-ad3d-31b762f3d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_cf0d29ca-adb1-42e1-ad3d-31b762f3d36b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_8777352a-a868-41c8-b519-0da0e9bf5772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_8777352a-a868-41c8-b519-0da0e9bf5772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eaeeda44-f0ad-4fd6-9951-1c8cafa49e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_OperatingIncomeLoss_eaeeda44-f0ad-4fd6-9951-1c8cafa49e6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_bbdfb410-dc8a-49b5-a0ac-3fe018bc1c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_GainLossOnInvestments_bbdfb410-dc8a-49b5-a0ac-3fe018bc1c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_62bd4bba-36ae-4544-9423-9211fb28fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_62bd4bba-36ae-4544-9423-9211fb28fe18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_521c6990-c78f-483b-8900-49c8c69da846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_InterestExpense_521c6990-c78f-483b-8900-49c8c69da846" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_14d699a4-191e-4deb-b692-46acb2239b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_14d699a4-191e-4deb-b692-46acb2239b1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f3d1c3ad-b16f-4f00-afa0-e02cc2e102b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f3d1c3ad-b16f-4f00-afa0-e02cc2e102b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ad3bf540-a596-4f22-9c8b-caf937f500b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ad3bf540-a596-4f22-9c8b-caf937f500b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2941aa0c-b38d-4215-8a48-9868ea6449ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2941aa0c-b38d-4215-8a48-9868ea6449ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ffdf440-5968-4950-ad61-02ffece8ed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ffdf440-5968-4950-ad61-02ffece8ed5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_259d59fe-9f93-42d6-bf1c-76c67d81c756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_259d59fe-9f93-42d6-bf1c-76c67d81c756" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e3bc3431-a7d3-4e77-9399-787010f22645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e3bc3431-a7d3-4e77-9399-787010f22645" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cb3eed6-98e1-434d-95d7-1c51c49b1bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_NetIncomeLoss_1cb3eed6-98e1-434d-95d7-1c51c49b1bfd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f1c67323-7ed4-4b44-929a-a84b9044d956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f1c67323-7ed4-4b44-929a-a84b9044d956" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0d035af6-bfc6-4804-9aac-5cccf8b3eb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0d035af6-bfc6-4804-9aac-5cccf8b3eb3d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_220746ec-64ca-4079-9c46-d928a4c4478f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_EarningsPerShareBasic_220746ec-64ca-4079-9c46-d928a4c4478f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ef32ed4-3c09-4962-978e-ec028eca80b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ef32ed4-3c09-4962-978e-ec028eca80b1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e1445926-9a4f-4bbc-ab42-4e6c518b0832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e1445926-9a4f-4bbc-ab42-4e6c518b0832" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fc265aec-abf8-4c32-a206-436e78ba1949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fc265aec-abf8-4c32-a206-436e78ba1949" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6959f523-66fc-4441-8fa6-898cfa5f67a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6959f523-66fc-4441-8fa6-898cfa5f67a6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4fa7d45-3ca5-452d-a718-bf1267061ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4fa7d45-3ca5-452d-a718-bf1267061ce0" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:to="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ceca84ad-ce22-43d8-83f8-df78df258d49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:to="loc_us-gaap_EquityComponentDomain_ceca84ad-ce22-43d8-83f8-df78df258d49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:to="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_917a64b0-4183-4153-8f59-c494a3b7e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_CommonStockMember_917a64b0-4183-4153-8f59-c494a3b7e47e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4fa7bd23-db04-4a55-93ce-8906ca82f19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4fa7bd23-db04-4a55-93ce-8906ca82f19d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_face16f9-229e-45c5-b992-a3e6388574a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_face16f9-229e-45c5-b992-a3e6388574a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7e5aaabb-9f66-47b5-af7f-933a71d569bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_RetainedEarningsMember_7e5aaabb-9f66-47b5-af7f-933a71d569bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8bd76dfa-67af-4548-b331-37fca9c8b87a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8bd76dfa-67af-4548-b331-37fca9c8b87a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c68c2385-84ae-4487-8b45-1d6e6f319421" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c68c2385-84ae-4487-8b45-1d6e6f319421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8f520761-73a2-4e88-b1cc-e7add9968f8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c68c2385-84ae-4487-8b45-1d6e6f319421" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8f520761-73a2-4e88-b1cc-e7add9968f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2cd0dab-cffe-4229-bf0b-62f9267bc1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockholdersEquity_e2cd0dab-cffe-4229-bf0b-62f9267bc1b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e7e31336-b2e8-481c-80e0-91c7c60488ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e7e31336-b2e8-481c-80e0-91c7c60488ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afaca4de-5726-4554-a6f2-a91af8bc3caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afaca4de-5726-4554-a6f2-a91af8bc3caa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2226be26-201a-43e8-8972-2e2b349c036d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2226be26-201a-43e8-8972-2e2b349c036d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6ccbf51b-0588-4780-8703-ed418d6302b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6ccbf51b-0588-4780-8703-ed418d6302b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0dd9a13a-c290-42cc-9796-a77bf00e73e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0dd9a13a-c290-42cc-9796-a77bf00e73e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_bf4130e5-32e0-4f50-8d21-b788e4805ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_bf4130e5-32e0-4f50-8d21-b788e4805ef7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_5bde88f6-9f34-41d4-9f29-9747a3aadd66" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_5bde88f6-9f34-41d4-9f29-9747a3aadd66" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_b9d32910-ca64-41ed-8c50-97855f632a96" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_b9d32910-ca64-41ed-8c50-97855f632a96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_1eaa010b-26cf-404e-84c6-d1235a57ccb1" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_1eaa010b-26cf-404e-84c6-d1235a57ccb1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_a7fa60f1-0769-40a5-bfc6-56f3c908d7f6" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_a7fa60f1-0769-40a5-bfc6-56f3c908d7f6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f0b73f9e-33b2-4568-ad00-e9e07e25f3b0" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f0b73f9e-33b2-4568-ad00-e9e07e25f3b0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a75375f0-9ea6-45c7-9bc1-d650d7249866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_NetIncomeLoss_a75375f0-9ea6-45c7-9bc1-d650d7249866" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_91d375d1-ae23-45d6-bc58-4f6eb1c29b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d750616-04ea-4e28-a628-70dfb17aa17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_74dce9ce-af68-4ca5-bf9b-3010ceea386a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_74dce9ce-af68-4ca5-bf9b-3010ceea386a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:to="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_04dc5721-13ce-4377-a0d5-ddb66f73443a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:to="loc_srt_OwnershipDomain_04dc5721-13ce-4377-a0d5-ddb66f73443a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:to="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NucorionMember_4077edc9-0858-4bb3-b222-3260043ba5db" xlink:href="lgnd-20231231.xsd#lgnd_NucorionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:to="loc_lgnd_NucorionMember_4077edc9-0858-4bb3-b222-3260043ba5db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_e1bf1a98-3bad-46ed-a5d3-3cd0b46634f8" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:to="loc_lgnd_PrimroseBioMember_e1bf1a98-3bad-46ed-a5d3-3cd0b46634f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d59649f1-a8b5-4b42-9024-f05ffed6f51c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d59649f1-a8b5-4b42-9024-f05ffed6f51c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f383e321-29fe-4059-bf86-733d8a9df69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f383e321-29fe-4059-bf86-733d8a9df69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_f033a8f1-6606-4048-8049-ea209e785cb9" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f383e321-29fe-4059-bf86-733d8a9df69b" xlink:to="loc_lgnd_NovanIncMember_f033a8f1-6606-4048-8049-ea209e785cb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_306c1ba9-3a4f-4775-9663-bf6d69f1e189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:to="loc_us-gaap_NetIncomeLoss_306c1ba9-3a4f-4775-9663-bf6d69f1e189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_fde708b1-db76-4816-9081-99d02a43dbff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_fde708b1-db76-4816-9081-99d02a43dbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_c970d87d-a118-461b-a6b9-09e293065e57" xlink:href="lgnd-20231231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_c970d87d-a118-461b-a6b9-09e293065e57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3fb480e0-a9e3-4a92-ab9f-89f69927f994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3fb480e0-a9e3-4a92-ab9f-89f69927f994" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_682a9b21-6e14-4194-a793-7ed2855f53d0" xlink:href="lgnd-20231231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_682a9b21-6e14-4194-a793-7ed2855f53d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b6c57842-788e-46a6-9d62-42e99f448713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b6c57842-788e-46a6-9d62-42e99f448713" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0e0c1555-e717-444f-bafe-fe2f00a18114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0e0c1555-e717-444f-bafe-fe2f00a18114" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_765242d6-5720-47df-b95b-7b769751d0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_765242d6-5720-47df-b95b-7b769751d0f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22310352-bb64-4f1d-aa83-57ffa13636eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22310352-bb64-4f1d-aa83-57ffa13636eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_ecf7275d-ad96-4a48-9e7a-8494e0463766" xlink:href="lgnd-20231231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_ecf7275d-ad96-4a48-9e7a-8494e0463766" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_d202c492-ca5d-41ef-8be5-44d873bee695" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_d202c492-ca5d-41ef-8be5-44d873bee695" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnCommercialLicenseRights_2ed503e1-d75c-4410-9eda-02a31817a5dc" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentLossOnCommercialLicenseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_ImpairmentLossOnCommercialLicenseRights_2ed503e1-d75c-4410-9eda-02a31817a5dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_38a33b6b-918b-44d7-b8c0-9bb78237270f" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_38a33b6b-918b-44d7-b8c0-9bb78237270f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_08d61f11-ab83-4932-b468-86d9b4ebc8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_ShareBasedCompensation_08d61f11-ab83-4932-b468-86d9b4ebc8dc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30b87fe0-fa69-436d-900e-215ac7f650ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30b87fe0-fa69-436d-900e-215ac7f650ae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_64345b9e-d45c-44f6-94eb-d941b15f1631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_64345b9e-d45c-44f6-94eb-d941b15f1631" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cad3cf-e8a8-45bd-afd1-1f6e1903258d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cad3cf-e8a8-45bd-afd1-1f6e1903258d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5e1bdc2d-4f48-41e1-91bd-f5f285394dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5e1bdc2d-4f48-41e1-91bd-f5f285394dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4598ca94-494a-48af-8322-d9f1bcce1645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4598ca94-494a-48af-8322-d9f1bcce1645" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_85f0a0c3-a0c1-4565-9a59-e60b6b2619d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_85f0a0c3-a0c1-4565-9a59-e60b6b2619d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf7156a6-2eb0-4a7e-bbbc-03ec9ad4d504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf7156a6-2eb0-4a7e-bbbc-03ec9ad4d504" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e584c60a-26f1-4fe9-94b4-7b2d4e67563a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e584c60a-26f1-4fe9-94b4-7b2d4e67563a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_da4efc18-8506-4e8d-bd8f-caf4ee243470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_da4efc18-8506-4e8d-bd8f-caf4ee243470" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1e810093-9edd-4f4c-a81e-c40c2b8b833f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1e810093-9edd-4f4c-a81e-c40c2b8b833f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7e7a113-1c96-47ef-80a6-6e805f49b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7e7a113-1c96-47ef-80a6-6e805f49b31f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_6f36ae61-c9b9-457b-a489-8603d129a111" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_6f36ae61-c9b9-457b-a489-8603d129a111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e581006-64e4-42af-a0af-7ea24ea28513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e581006-64e4-42af-a0af-7ea24ea28513" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_f16dc992-5227-45e5-972d-1dae7b5d63e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_f16dc992-5227-45e5-972d-1dae7b5d63e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_32ae3868-df93-4ebf-8a43-29234cadb8d8" xlink:href="lgnd-20231231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_32ae3868-df93-4ebf-8a43-29234cadb8d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0a2b2a5e-c392-411a-a82a-f39b1b0309bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0a2b2a5e-c392-411a-a82a-f39b1b0309bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_44ca24ed-e453-425a-9ab7-408c0b729d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_44ca24ed-e453-425a-9ab7-408c0b729d37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f7cd603d-4135-45eb-a143-781df28a8808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f7cd603d-4135-45eb-a143-781df28a8808" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1dd18ca4-5c9c-4251-aee4-3c06e063c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1dd18ca4-5c9c-4251-aee4-3c06e063c88c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_26986af2-23b2-416d-b6a0-a72712b8e01e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_26986af2-23b2-416d-b6a0-a72712b8e01e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fbb0be6-1a94-483a-84a4-01ab277a3f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fbb0be6-1a94-483a-84a4-01ab277a3f55" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation_271dbc28-1032-4cd7-992d-0f8d8dabdc06" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsForSeparation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_lgnd_PaymentsForSeparation_271dbc28-1032-4cd7-992d-0f8d8dabdc06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c5d74086-caf9-47fb-a2d1-f719c6dd09bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c5d74086-caf9-47fb-a2d1-f719c6dd09bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d8d634d0-615a-4fb2-8d64-958c1b4c8dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d8d634d0-615a-4fb2-8d64-958c1b4c8dd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_d595b0d8-67b1-49b3-8b43-52178b0147c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_d595b0d8-67b1-49b3-8b43-52178b0147c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_52bd1b7a-84dd-4bdb-b16c-5348f1f1b690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_52bd1b7a-84dd-4bdb-b16c-5348f1f1b690" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_bfb6cf4b-6965-4d7b-92cb-dcf1446ef47e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_bfb6cf4b-6965-4d7b-92cb-dcf1446ef47e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0973553c-e1e9-464d-b0f3-42dfa0229c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0973553c-e1e9-464d-b0f3-42dfa0229c9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25b60040-8070-4324-9359-33708dc9ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25b60040-8070-4324-9359-33708dc9ebed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_52a22ca9-b99a-4908-8ceb-a468e19cf977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_52a22ca9-b99a-4908-8ceb-a468e19cf977" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_b41fb3a7-445c-4800-8138-fbdd825d6eb8" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_b41fb3a7-445c-4800-8138-fbdd825d6eb8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e4b6835-1ff2-4dc0-9eb8-62c10abe2a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e4b6835-1ff2-4dc0-9eb8-62c10abe2a16" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ae15da23-2d75-4740-87d5-2d9251e41f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ae15da23-2d75-4740-87d5-2d9251e41f58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80fae0e0-6eb1-4432-a3b9-28b34cb43ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80fae0e0-6eb1-4432-a3b9-28b34cb43ca5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_563cb199-a62a-4453-8cb7-220c6199e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:href="lgnd-20231231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:to="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_43e8e226-d620-4aa6-b95b-da35c9d876e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:to="loc_us-gaap_InterestPaidNet_43e8e226-d620-4aa6-b95b-da35c9d876e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a40e4b7b-b04d-4bb9-af38-fead7d114bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:to="loc_us-gaap_IncomeTaxesPaid_a40e4b7b-b04d-4bb9-af38-fead7d114bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_99d8c0e5-1476-4ac8-9c7e-2b0c52096d78" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_99d8c0e5-1476-4ac8-9c7e-2b0c52096d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_33cd097b-789b-44e9-9167-cc8327d04a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_33cd097b-789b-44e9-9167-cc8327d04a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a86ce13-10bf-4667-b72d-e57cf7c9b678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_Goodwill_3a86ce13-10bf-4667-b72d-e57cf7c9b678" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3a031a30-91c0-49d5-bfea-15a44e6df249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3a031a30-91c0-49d5-bfea-15a44e6df249" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f0ba5a26-3366-4f38-95af-81da3d4c1996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f0ba5a26-3366-4f38-95af-81da3d4c1996" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9b5fd7d-0759-4770-99cd-cdeef0ce74ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_ebc70493-a331-4bb9-a058-91704163fb85" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_ebc70493-a331-4bb9-a058-91704163fb85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_346f452c-c1a9-4958-9c70-caa03bb086d9" xlink:href="lgnd-20231231.xsd#lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_346f452c-c1a9-4958-9c70-caa03bb086d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_5ab1c97f-0fba-4e3c-a300-55d6678f96f8" xlink:href="lgnd-20231231.xsd#lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_5ab1c97f-0fba-4e3c-a300-55d6678f96f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_308ee8d6-6981-44ec-8c6a-7d3acad2cc49" xlink:href="lgnd-20231231.xsd#lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_308ee8d6-6981-44ec-8c6a-7d3acad2cc49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f3113b0f-f622-4fda-b4c9-1dc1ac150ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f3113b0f-f622-4fda-b4c9-1dc1ac150ae5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases_4d1f7374-94b7-4872-a0ea-53aa89a89c3b" xlink:href="lgnd-20231231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedInventoryPurchases_4d1f7374-94b7-4872-a0ea-53aa89a89c3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b055c617-0f72-4d58-8a80-780f7eb545a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b055c617-0f72-4d58-8a80-780f7eb545a2" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:href="lgnd-20231231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:href="lgnd-20231231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_241cdf1f-a4fa-4316-ab1a-800b035111e7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:to="loc_srt_ProductsAndServicesDomain_241cdf1f-a4fa-4316-ab1a-800b035111e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c889207-2d74-437c-9844-4f51cef67a71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:to="loc_srt_ProductsAndServicesDomain_8c889207-2d74-437c-9844-4f51cef67a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_3ed80ef5-d59a-4dc2-9048-2de8940a70b9" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c889207-2d74-437c-9844-4f51cef67a71" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_3ed80ef5-d59a-4dc2-9048-2de8940a70b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ff71c97-62f9-406b-aa65-15a245425c7d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:to="loc_srt_RangeMember_8ff71c97-62f9-406b-aa65-15a245425c7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:to="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f632740-2ac4-4014-8312-dbe51fc04bcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:to="loc_srt_MinimumMember_6f632740-2ac4-4014-8312-dbe51fc04bcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e7b7337-34a9-4913-822c-5dc284db70e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:to="loc_srt_MaximumMember_7e7b7337-34a9-4913-822c-5dc284db70e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bc10dec-0674-47d1-9df4-0842c3cf83ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6bc10dec-0674-47d1-9df4-0842c3cf83ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54a49a42-8dbe-43b5-9831-6ff7817f5eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54a49a42-8dbe-43b5-9831-6ff7817f5eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_88e7d1bb-4e57-4d26-991f-a892946c6d4b" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54a49a42-8dbe-43b5-9831-6ff7817f5eac" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_88e7d1bb-4e57-4d26-991f-a892946c6d4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143824f2-0ae6-4eca-a487-d586deffbd14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143824f2-0ae6-4eca-a487-d586deffbd14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_65d41202-123b-4718-ae39-4c98a142f174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:to="loc_us-gaap_PerformanceSharesMember_65d41202-123b-4718-ae39-4c98a142f174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b3e94688-1b66-4488-a49b-8e83f7d4f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b3e94688-1b66-4488-a49b-8e83f7d4f9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_f3fc05c5-1320-46f3-b65f-dde0af9a9846" xlink:href="lgnd-20231231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_f3fc05c5-1320-46f3-b65f-dde0af9a9846" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ed7b1d9d-1216-4111-a8eb-e261dbd320f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ed7b1d9d-1216-4111-a8eb-e261dbd320f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8a1ae2a8-d34f-495a-837d-b4131c365cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8a1ae2a8-d34f-495a-837d-b4131c365cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_4913a8b2-80ac-41cd-891c-d5bcd916132e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8a1ae2a8-d34f-495a-837d-b4131c365cb7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_4913a8b2-80ac-41cd-891c-d5bcd916132e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fb0418f-c910-4a13-9ac7-7c4a8585c738_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:to="loc_us-gaap_PlanNameDomain_2fb0418f-c910-4a13-9ac7-7c4a8585c738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c581a5d3-59aa-4f02-8f86-e514c24f5dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:to="loc_us-gaap_PlanNameDomain_c581a5d3-59aa-4f02-8f86-e514c24f5dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_62c55a9f-0c09-45e8-baa7-5263c332e8fb" xlink:href="lgnd-20231231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c581a5d3-59aa-4f02-8f86-e514c24f5dd3" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_62c55a9f-0c09-45e8-baa7-5263c332e8fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8722e2de-0bd8-47a9-8641-8eca9dfdadb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:to="loc_us-gaap_VestingDomain_8722e2de-0bd8-47a9-8641-8eca9dfdadb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:to="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_ed8f3922-6e09-422a-8168-a258b585f62a" xlink:href="lgnd-20231231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:to="loc_lgnd_VestingPeriodOneMember_ed8f3922-6e09-422a-8168-a258b585f62a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_50f69c35-3010-4808-83da-a518f667bf89" xlink:href="lgnd-20231231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:to="loc_lgnd_VestingPeriodTwoMember_50f69c35-3010-4808-83da-a518f667bf89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d2e36c97-30fc-4d3c-9d74-fe8f58e7aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_NumberOfReportableSegments_d2e36c97-30fc-4d3c-9d74-fe8f58e7aac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_2a11fd48-ca9c-4c9b-a83f-117b28d15ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_2a11fd48-ca9c-4c9b-a83f-117b28d15ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_778c9411-8241-436d-9a60-a93d502ad89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_InventoryWriteDown_778c9411-8241-436d-9a60-a93d502ad89e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1a6321af-4e1a-4efa-b402-655b550f2ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_InventoryNet_1a6321af-4e1a-4efa-b402-655b550f2ea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e2628b3-1f8b-42fe-a980-decb38491e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e2628b3-1f8b-42fe-a980-decb38491e7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_18f9a6cc-8de5-45ab-8e3f-d61525ae548f" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_18f9a6cc-8de5-45ab-8e3f-d61525ae548f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b7c3199b-2164-417b-8bc9-099036eaf957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b7c3199b-2164-417b-8bc9-099036eaf957" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_66cc9567-336b-49be-84ec-cc215bfbab68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_66cc9567-336b-49be-84ec-cc215bfbab68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_bdbcdd12-05c1-4728-89b2-cdf9d7f058e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_bdbcdd12-05c1-4728-89b2-cdf9d7f058e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_02731e2d-484f-46c5-b167-1351c51f50c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_02731e2d-484f-46c5-b167-1351c51f50c5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8e624a46-f928-4cb5-b726-c47ffab591c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8e624a46-f928-4cb5-b726-c47ffab591c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b20a3291-2450-4da8-b2bc-61e42b55901f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b20a3291-2450-4da8-b2bc-61e42b55901f" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_929c556b-206e-48ad-ab1f-5dd49aa72c65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_929c556b-206e-48ad-ab1f-5dd49aa72c65" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_25806038-c812-4a98-9b37-c6456f61dc94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_25806038-c812-4a98-9b37-c6456f61dc94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_146dcbba-b6e1-4b62-adca-6fee20536f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_146dcbba-b6e1-4b62-adca-6fee20536f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_619e3359-bbde-477a-a0ad-7256a879a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_146dcbba-b6e1-4b62-adca-6fee20536f41" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_619e3359-bbde-477a-a0ad-7256a879a9ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_721e531a-32f1-4833-9d6e-447491d2ad76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_721e531a-32f1-4833-9d6e-447491d2ad76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de8b415d-421a-4dd6-8006-6a690abd1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de8b415d-421a-4dd6-8006-6a690abd1b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_96803596-ff4c-4ad9-8258-a610cb8e8f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de8b415d-421a-4dd6-8006-6a690abd1b5b" xlink:to="loc_us-gaap_SalesRevenueNetMember_96803596-ff4c-4ad9-8258-a610cb8e8f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e315cdc8-d2db-4dff-a840-8ce4a17f4657_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:to="loc_srt_NameOfMajorCustomerDomain_e315cdc8-d2db-4dff-a840-8ce4a17f4657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:to="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_40c269c2-05b4-4260-b6c0-3af4c7ff1866" xlink:href="lgnd-20231231.xsd#lgnd_PartnerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:to="loc_lgnd_PartnerAMember_40c269c2-05b4-4260-b6c0-3af4c7ff1866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_000fdc77-05db-48db-be9d-8a4383017bbb" xlink:href="lgnd-20231231.xsd#lgnd_PartnerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:to="loc_lgnd_PartnerBMember_000fdc77-05db-48db-be9d-8a4383017bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_a41db884-2296-4855-8d66-d659c5edd4b2" xlink:href="lgnd-20231231.xsd#lgnd_PartnerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:to="loc_lgnd_PartnerCMember_a41db884-2296-4855-8d66-d659c5edd4b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3b8052f5-4cdc-4846-a8bb-7dbbfb37a020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_929c556b-206e-48ad-ab1f-5dd49aa72c65" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3b8052f5-4cdc-4846-a8bb-7dbbfb37a020" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_90215162-d27c-4d1f-bc32-e87c2fab1bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_90215162-d27c-4d1f-bc32-e87c2fab1bf7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:to="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_430f4f0b-2b98-4e26-b282-956979e1f92b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:to="loc_srt_ProductsAndServicesDomain_430f4f0b-2b98-4e26-b282-956979e1f92b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:to="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:to="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_53c0dc7d-6fa9-4264-ad8b-4d4be5227c05" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyKyprolisMember_53c0dc7d-6fa9-4264-ad8b-4d4be5227c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_6fc91eb3-2e10-446e-9b81-c7f42373cba2" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyEvomelaMember_6fc91eb3-2e10-446e-9b81-c7f42373cba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyTeriparatideInjectionMember_67463b4d-55f3-4d13-8c46-78a1d8b3d2e9" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyTeriparatideInjectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyTeriparatideInjectionMember_67463b4d-55f3-4d13-8c46-78a1d8b3d2e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyRylazeMember_a170a0f8-d66c-4af7-88f7-7ab2a32b1a17" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyRylazeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyRylazeMember_a170a0f8-d66c-4af7-88f7-7ab2a32b1a17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_e7336987-56f9-4a84-801e-dbc0c353989b" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyOtherMember_e7336987-56f9-4a84-801e-dbc0c353989b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCoreMember_1a307582-10b1-43c9-980c-32ee3047000c" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolCoreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:to="loc_lgnd_MaterialSalesCaptisolCoreMember_1a307582-10b1-43c9-980c-32ee3047000c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCOVIDMember_5d61ab13-7f43-4505-8677-3b6e97987085" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolCOVIDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:to="loc_lgnd_MaterialSalesCaptisolCOVIDMember_5d61ab13-7f43-4505-8677-3b6e97987085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:to="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_da68370e-f813-4cb9-b208-1eccb1ffb479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_us-gaap_ServiceMember_da68370e-f813-4cb9-b208-1eccb1ffb479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_111aa51d-aa3f-47f8-a7e7-5a15de3cc9ff" xlink:href="lgnd-20231231.xsd#lgnd_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_lgnd_LicenseFeesMember_111aa51d-aa3f-47f8-a7e7-5a15de3cc9ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_58585f2b-09c5-423c-90d3-2663a5baead5" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_lgnd_MilestoneMember_58585f2b-09c5-423c-90d3-2663a5baead5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_f95d37e0-c336-42fb-9cb2-f4227ae59e25" xlink:href="lgnd-20231231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_f95d37e0-c336-42fb-9cb2-f4227ae59e25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56b2ba32-111d-4c62-9c8c-c21632a28df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_90215162-d27c-4d1f-bc32-e87c2fab1bf7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56b2ba32-111d-4c62-9c8c-c21632a28df7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6477b76-f1c1-4cb5-8936-8d211adcd277_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e6477b76-f1c1-4cb5-8936-8d211adcd277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7d85d1d9-7321-4183-853c-ef5e657dc552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:to="loc_us-gaap_RestrictedStockMember_7d85d1d9-7321-4183-853c-ef5e657dc552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_984dad39-9cb9-485b-8284-ed1f29ee7bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_984dad39-9cb9-485b-8284-ed1f29ee7bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_7d1bdc2d-0bdf-46b5-9b91-173ef0d8e267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_7d1bdc2d-0bdf-46b5-9b91-173ef0d8e267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_06cc4002-ec7a-4c4b-8b26-cce12ef73d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_06cc4002-ec7a-4c4b-8b26-cce12ef73d97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_be52102e-f68c-4b60-80c7-ba530ed3fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_be52102e-f68c-4b60-80c7-ba530ed3fcb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_471a92c9-86a3-4dd6-a15d-ed8fda3aa8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_471a92c9-86a3-4dd6-a15d-ed8fda3aa8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aef356a2-cd16-45cd-bc30-49211b4bcf10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aef356a2-cd16-45cd-bc30-49211b4bcf10" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_7d4be2b7-44c5-4e74-892d-c5d1e4247e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_7d4be2b7-44c5-4e74-892d-c5d1e4247e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_5e6b44af-8e0d-4e8b-b338-fcbd03dbca45" xlink:href="lgnd-20231231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_7d4be2b7-44c5-4e74-892d-c5d1e4247e3e" xlink:to="loc_lgnd_PrimordialGeneticsMember_5e6b44af-8e0d-4e8b-b338-fcbd03dbca45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a4281f85-6dec-492c-8b13-7f1b96767b95_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a4281f85-6dec-492c-8b13-7f1b96767b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5d788720-7cb3-45c1-895b-5c76d941d6b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5d788720-7cb3-45c1-895b-5c76d941d6b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d57cf87f-0040-4fdf-b3ca-e776096a7754" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5d788720-7cb3-45c1-895b-5c76d941d6b8" xlink:to="loc_srt_ScenarioForecastMember_d57cf87f-0040-4fdf-b3ca-e776096a7754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ca62d7b-803c-4e42-a7be-cfc64d5a83af_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ca62d7b-803c-4e42-a7be-cfc64d5a83af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93840aef-5109-4ef2-aff1-5fc0bd99564a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93840aef-5109-4ef2-aff1-5fc0bd99564a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_4b66a197-8286-4ee0-8804-8a84b1546150" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93840aef-5109-4ef2-aff1-5fc0bd99564a" xlink:to="loc_lgnd_PrimroseBioMember_4b66a197-8286-4ee0-8804-8a84b1546150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5bdffe95-9c12-4353-a210-599087ff25f1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:to="loc_srt_ProductsAndServicesDomain_5bdffe95-9c12-4353-a210-599087ff25f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7177e129-44a3-4b9e-b523-d8024453808c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:to="loc_srt_ProductsAndServicesDomain_7177e129-44a3-4b9e-b523-d8024453808c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PeliCRM197Member_f8b3ec71-f653-4fd0-9fef-5f5ee5b2cb2f" xlink:href="lgnd-20231231.xsd#lgnd_PeliCRM197Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7177e129-44a3-4b9e-b523-d8024453808c" xlink:to="loc_lgnd_PeliCRM197Member_f8b3ec71-f653-4fd0-9fef-5f5ee5b2cb2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain_188fa9ba-f8d4-4c9f-8878-5794b096335a_default" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:to="loc_lgnd_MilestoneDomain_188fa9ba-f8d4-4c9f-8878-5794b096335a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:to="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BelowMilestoneMember_2eb703a4-985d-4200-b851-bc70a269cd0c" xlink:href="lgnd-20231231.xsd#lgnd_BelowMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:to="loc_lgnd_BelowMilestoneMember_2eb703a4-985d-4200-b851-bc70a269cd0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AboveMilestoneMember_7e134bf6-f576-4e43-87bc-d4285e4ce5e3" xlink:href="lgnd-20231231.xsd#lgnd_AboveMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:to="loc_lgnd_AboveMilestoneMember_7e134bf6-f576-4e43-87bc-d4285e4ce5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e3bcd3b0-db0f-4964-bbc1-bc7aa6484703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e3bcd3b0-db0f-4964-bbc1-bc7aa6484703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_cfd6c8d6-2922-4cf0-9177-da4a8ac6ea8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e3bcd3b0-db0f-4964-bbc1-bc7aa6484703" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_cfd6c8d6-2922-4cf0-9177-da4a8ac6ea8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301ccfdf-3ffe-4f1e-9a6f-81508cfda237_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301ccfdf-3ffe-4f1e-9a6f-81508cfda237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8034bd08-6058-430c-a3fa-615265bd7eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8034bd08-6058-430c-a3fa-615265bd7eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_d1da6a77-12df-464b-bb2e-ea201ac9d925" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8034bd08-6058-430c-a3fa-615265bd7eed" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_d1da6a77-12df-464b-bb2e-ea201ac9d925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_99ba013c-56a1-4fcc-91bd-15150aae3640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:to="loc_us-gaap_ClassOfStockDomain_99ba013c-56a1-4fcc-91bd-15150aae3640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:to="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_15238fa3-67a7-42c4-8a69-e50d4b2fa580" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:to="loc_us-gaap_CommonStockMember_15238fa3-67a7-42c4-8a69-e50d4b2fa580" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1ab594d9-ce25-4228-929c-f3c71d87466f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:to="loc_us-gaap_PreferredStockMember_1ab594d9-ce25-4228-929c-f3c71d87466f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_169928be-203d-44b1-b810-8a15a1634176_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_169928be-203d-44b1-b810-8a15a1634176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_202bf304-1a3c-4a91-b434-01bdd21626f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_202bf304-1a3c-4a91-b434-01bdd21626f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c8c6bf11-6727-42c9-83a7-f98b85fb3845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_202bf304-1a3c-4a91-b434-01bdd21626f8" xlink:to="loc_us-gaap_RestrictedStockMember_c8c6bf11-6727-42c9-83a7-f98b85fb3845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_687d5498-f0b8-48a5-a68f-c6e831b25fa8" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_687d5498-f0b8-48a5-a68f-c6e831b25fa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_b32cd4db-ca98-4fcf-b78d-9ac05c05c8eb" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_b32cd4db-ca98-4fcf-b78d-9ac05c05c8eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InterestInPotentialDevelopmentMilestone_e133725c-4deb-42c2-8f3c-99c024e908a6" xlink:href="lgnd-20231231.xsd#lgnd_InterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_InterestInPotentialDevelopmentMilestone_e133725c-4deb-42c2-8f3c-99c024e908a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_9dbbeba0-67e9-45cc-be0f-1f24e8166371" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_NumberOfContracts_9dbbeba0-67e9-45cc-be0f-1f24e8166371" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_4bc55f13-778b-4b1a-90a4-803f2b095e47" xlink:href="lgnd-20231231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_4bc55f13-778b-4b1a-90a4-803f2b095e47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesRevenueMilestone_ab084bb2-2c21-48e0-9a70-66f7b1c420f9" xlink:href="lgnd-20231231.xsd#lgnd_SalesRevenueMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_SalesRevenueMilestone_ab084bb2-2c21-48e0-9a70-66f7b1c420f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_b390ec59-a45a-45c2-8627-75cf475c6146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_b390ec59-a45a-45c2-8627-75cf475c6146" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_0ab48cd8-aad8-4cc1-b2cb-3d03f6bb5e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_0ab48cd8-aad8-4cc1-b2cb-3d03f6bb5e0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_e8b4350e-37a2-4779-8351-df52537e2ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_BusinessExitCosts1_e8b4350e-37a2-4779-8351-df52537e2ba1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_1f5d3929-0b2b-4caa-b0e2-62521fa24cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_1f5d3929-0b2b-4caa-b0e2-62521fa24cd0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_b61c4bb8-c6cc-4807-a24a-c519702e6545" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_b61c4bb8-c6cc-4807-a24a-c519702e6545" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_43639409-1b2f-4466-9afb-2d2864e89097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_43639409-1b2f-4466-9afb-2d2864e89097" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_37387813-31bf-4671-9228-cf77fcbcf344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_37387813-31bf-4671-9228-cf77fcbcf344" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_97d6eeb0-837f-44df-9770-1cc97fda55c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_97d6eeb0-837f-44df-9770-1cc97fda55c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ccc86667-7942-4fe1-90f1-7e9c674952cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ccc86667-7942-4fe1-90f1-7e9c674952cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6a5df07-a68d-487a-b23f-835cbaf1a2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ccc86667-7942-4fe1-90f1-7e9c674952cf" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6a5df07-a68d-487a-b23f-835cbaf1a2f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_89c593ee-9863-4e6b-9a69-4539f352c3ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_89c593ee-9863-4e6b-9a69-4539f352c3ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c09199-d77e-4d8a-988b-8f00349a890f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c09199-d77e-4d8a-988b-8f00349a890f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_c7ba2c24-1e2d-4f25-b115-1654b69b532c" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c09199-d77e-4d8a-988b-8f00349a890f" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_c7ba2c24-1e2d-4f25-b115-1654b69b532c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b7f86cbc-31f5-431a-9dc7-1af58aa48a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b7f86cbc-31f5-431a-9dc7-1af58aa48a8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f6861405-548e-49c8-922b-bd848bd552e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f6861405-548e-49c8-922b-bd848bd552e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9f25de71-51c6-4648-b3c3-363795e7a1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9f25de71-51c6-4648-b3c3-363795e7a1f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_9bfc11a6-9993-4094-8775-5f8fb711d9e5" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_9bfc11a6-9993-4094-8775-5f8fb711d9e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_c41c4f56-032a-4650-b3c0-d38cb99dc17f" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_c41c4f56-032a-4650-b3c0-d38cb99dc17f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0d87b347-43c2-4a3f-8124-908781b956ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0d87b347-43c2-4a3f-8124-908781b956ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_ec38fe30-9107-453b-af15-003386be3c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_ec38fe30-9107-453b-af15-003386be3c64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_61c477f2-985d-4bbf-86c3-37a30a5cb25f" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_61c477f2-985d-4bbf-86c3-37a30a5cb25f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_499428fa-4615-483b-95c4-50d4bcd09aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_499428fa-4615-483b-95c4-50d4bcd09aeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_fc72fdd2-c92e-4d38-9159-46c77654fa31" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_fc72fdd2-c92e-4d38-9159-46c77654fa31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c915b09e-7db7-4170-8a01-968cf37561bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c915b09e-7db7-4170-8a01-968cf37561bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8f368942-3525-4c15-8d6c-d6915135e068" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8f368942-3525-4c15-8d6c-d6915135e068" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_f80eb635-8220-4c41-85e8-08a6dbedaf98" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_f80eb635-8220-4c41-85e8-08a6dbedaf98" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3b06f654-b492-4a47-a1c0-e40c3e137072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3b06f654-b492-4a47-a1c0-e40c3e137072" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c5034fdd-c60d-4c00-8d90-76c143709bcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c5034fdd-c60d-4c00-8d90-76c143709bcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_11392aee-c9c8-4bab-9fcb-bd2d065fc7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_11392aee-c9c8-4bab-9fcb-bd2d065fc7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0c9c528b-317b-48ac-9d1c-35652c23df12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_11392aee-c9c8-4bab-9fcb-bd2d065fc7dc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0c9c528b-317b-48ac-9d1c-35652c23df12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d7871099-55e2-468c-b28f-dda78de09bfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d7871099-55e2-468c-b28f-dda78de09bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7814b8a4-9cdd-47ca-b5f2-a0c791a4b940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7814b8a4-9cdd-47ca-b5f2-a0c791a4b940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_ad85c1ec-6845-467a-a4d0-aedf4f4741b0" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7814b8a4-9cdd-47ca-b5f2-a0c791a4b940" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_ad85c1ec-6845-467a-a4d0-aedf4f4741b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain_7f28b404-4484-4f00-a017-916e540e970e_default" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:to="loc_lgnd_ConsiderationClassficationDomain_7f28b404-4484-4f00-a017-916e540e970e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:to="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityMethodInvestmentsAllocationMember_fe95e574-8848-4be1-b97a-6a7ee113a5da" xlink:href="lgnd-20231231.xsd#lgnd_EquityMethodInvestmentsAllocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:to="loc_lgnd_EquityMethodInvestmentsAllocationMember_fe95e574-8848-4be1-b97a-6a7ee113a5da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquitySecuritiesAllocationMember_9614b15e-d74c-4b56-8cbb-aa1a98733bfe" xlink:href="lgnd-20231231.xsd#lgnd_EquitySecuritiesAllocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:to="loc_lgnd_EquitySecuritiesAllocationMember_9614b15e-d74c-4b56-8cbb-aa1a98733bfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetsMember_67b0d9c0-07f8-4469-b9fe-ccaa67dd05bd" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:to="loc_lgnd_DerivativeAssetsMember_67b0d9c0-07f8-4469-b9fe-ccaa67dd05bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_84d48d9b-48db-474c-b876-1f41cb696fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3b06f654-b492-4a47-a1c0-e40c3e137072" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_84d48d9b-48db-474c-b876-1f41cb696fca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2bb803d-276f-4c01-9069-dd0a2a3f1156_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2bb803d-276f-4c01-9069-dd0a2a3f1156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbca607-2edf-4e2e-b924-661c72faeaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbca607-2edf-4e2e-b924-661c72faeaf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_ace90c95-e369-4b84-94c0-e34983cf13c6" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbca607-2edf-4e2e-b924-661c72faeaf2" xlink:to="loc_lgnd_NovanIncMember_ace90c95-e369-4b84-94c0-e34983cf13c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94aec32a-c08e-416c-a5a7-bca748e0aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94aec32a-c08e-416c-a5a7-bca748e0aaf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_c0392455-3396-438a-96fb-97e8641687d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_94aec32a-c08e-416c-a5a7-bca748e0aaf2" xlink:to="loc_us-gaap_BridgeLoanMember_c0392455-3396-438a-96fb-97e8641687d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d13da6a8-530b-4000-a4b8-dc59a729b381_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d13da6a8-530b-4000-a4b8-dc59a729b381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d551c45-7265-491b-81d4-f5613214ace5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d551c45-7265-491b-81d4-f5613214ace5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bcedcda7-6cc1-4950-9847-36c2e7b05992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d551c45-7265-491b-81d4-f5613214ace5" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bcedcda7-6cc1-4950-9847-36c2e7b05992" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d48c9016-7750-4b68-a848-a34f45ac61fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d48c9016-7750-4b68-a848-a34f45ac61fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_de803ebf-fc33-4d76-9771-47484bda5e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d48c9016-7750-4b68-a848-a34f45ac61fd" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_de803ebf-fc33-4d76-9771-47484bda5e13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_20688609-1460-41db-ac46-400ed6e3d931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:to="loc_us-gaap_ValuationTechniqueDomain_20688609-1460-41db-ac46-400ed6e3d931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7b469c6c-c818-42b4-954d-3946df360cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7b469c6c-c818-42b4-954d-3946df360cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_676ad303-18f9-4402-bba1-899acec9cd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7b469c6c-c818-42b4-954d-3946df360cde" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_676ad303-18f9-4402-bba1-899acec9cd7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_82d41489-29c3-4c6d-a2a6-68e513dcf313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_82d41489-29c3-4c6d-a2a6-68e513dcf313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c81c928a-4b0b-42bc-9079-697d32f5175d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c81c928a-4b0b-42bc-9079-697d32f5175d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6c92c16c-ae6c-4736-b641-999a107ebbed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6c92c16c-ae6c-4736-b641-999a107ebbed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquiredPercentage_ade5b3c9-9689-400c-847c-e6c0a2c4c599" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationAcquiredPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_BusinessCombinationAcquiredPercentage_ade5b3c9-9689-400c-847c-e6c0a2c4c599" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_981bfc61-7414-425a-aa9b-980e4ef19d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_981bfc61-7414-425a-aa9b-980e4ef19d3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_17655a2e-d498-45e5-a741-0818c0f5f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_17655a2e-d498-45e5-a741-0818c0f5f54c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_b62a70ef-0492-46b1-86bd-32b7f16a886e" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_b62a70ef-0492-46b1-86bd-32b7f16a886e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d974f6f-589c-444a-8145-902bc5e676dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d974f6f-589c-444a-8145-902bc5e676dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_f31d1f1d-45b5-4d80-8d91-d4b9113858f6" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_f31d1f1d-45b5-4d80-8d91-d4b9113858f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentMilestonePurchaseAgreement_72c7ec5d-e139-4c23-9554-6ad6e621ad22" xlink:href="lgnd-20231231.xsd#lgnd_ContingentMilestonePurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_ContingentMilestonePurchaseAgreement_72c7ec5d-e139-4c23-9554-6ad6e621ad22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_afd8159e-770d-46c5-ac32-74dbd6094f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_afd8159e-770d-46c5-ac32-74dbd6094f7e" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bb9d667-93d9-4bd2-9e02-11dfc963b57e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8bb9d667-93d9-4bd2-9e02-11dfc963b57e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10bbb8f5-3618-42dd-a2c8-c74417496022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10bbb8f5-3618-42dd-a2c8-c74417496022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_a0627473-3821-4a9a-b541-d8293abdab10" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10bbb8f5-3618-42dd-a2c8-c74417496022" xlink:to="loc_lgnd_NovanIncMember_a0627473-3821-4a9a-b541-d8293abdab10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7aa77322-0490-470b-b3c8-f744277bbfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7aa77322-0490-470b-b3c8-f744277bbfd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_75e9e16c-e5f2-436c-8f5e-8d296ea93f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_75e9e16c-e5f2-436c-8f5e-8d296ea93f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0daa26ad-1fcc-4473-9cec-0d92d917f414" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0daa26ad-1fcc-4473-9cec-0d92d917f414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_28d54462-3770-44ad-a08d-34bb92cb361e" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_28d54462-3770-44ad-a08d-34bb92cb361e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fe43b9a2-bf2b-4316-8560-25f4352312f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fe43b9a2-bf2b-4316-8560-25f4352312f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d21e8e9a-9a36-45b3-879c-43351bcd8f43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d21e8e9a-9a36-45b3-879c-43351bcd8f43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b8c9d3cf-11ee-4169-a622-355d0156c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_Goodwill_b8c9d3cf-11ee-4169-a622-355d0156c59c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_31f6b85c-ca78-43a4-970c-faca69b16ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_31f6b85c-ca78-43a4-970c-faca69b16ffa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_5d73d829-8770-4bc0-b882-e3a38399c801" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_5d73d829-8770-4bc0-b882-e3a38399c801" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_eac3707e-8f69-4135-a0c5-c96e4adf69ad" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_eac3707e-8f69-4135-a0c5-c96e4adf69ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8ec3296d-f889-4683-9b3a-3acda9a76796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8ec3296d-f889-4683-9b3a-3acda9a76796" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest_117c22a9-2cac-4224-8513-ba1f1f2150a7" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationLoanFeesAndInterest_117c22a9-2cac-4224-8513-ba1f1f2150a7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_75ea5b68-9847-4db8-be23-c2aa4cd63389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_75ea5b68-9847-4db8-be23-c2aa4cd63389" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a4582254-de94-4a6c-ac45-91a1c139a120_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a4582254-de94-4a6c-ac45-91a1c139a120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e5906c03-a9cc-4714-9ee8-cdfb2e751524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e5906c03-a9cc-4714-9ee8-cdfb2e751524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_ccc9e89b-d50c-480a-b17a-fbbb42f9ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e5906c03-a9cc-4714-9ee8-cdfb2e751524" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_ccc9e89b-d50c-480a-b17a-fbbb42f9ff2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_a98e49c4-aac7-4bd9-b324-e53e99ae489c" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_a98e49c4-aac7-4bd9-b324-e53e99ae489c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsAdjustments_65ecd799-1d90-4d13-a7cf-9db8c765da8e" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxAssetsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:to="loc_lgnd_DeferredTaxAssetsAdjustments_65ecd799-1d90-4d13-a7cf-9db8c765da8e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0d7d7b79-85cb-42f9-88ea-79df44fec3cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0d7d7b79-85cb-42f9-88ea-79df44fec3cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1a9529ae-0464-47d4-a949-0e21a7803a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1a9529ae-0464-47d4-a949-0e21a7803a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_3ccad01d-c096-453f-928c-dd268d2579b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a9529ae-0464-47d4-a949-0e21a7803a1e" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_3ccad01d-c096-453f-928c-dd268d2579b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:to="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d681fdd-f07a-45a6-9f54-8a27554aa897_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:to="loc_srt_ProductsAndServicesDomain_9d681fdd-f07a-45a6-9f54-8a27554aa897_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:to="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_7ac7becb-528e-41c5-9527-23fc0829ec61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:to="loc_us-gaap_RoyaltyMember_7ac7becb-528e-41c5-9527-23fc0829ec61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_c681666e-14c3-4a80-838b-bc4905949242" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:to="loc_lgnd_ContractRevenueMember_c681666e-14c3-4a80-838b-bc4905949242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_e257df70-b7ee-4a7f-b214-042784cf1fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_e257df70-b7ee-4a7f-b214-042784cf1fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_038f6741-13c9-4e30-b644-82fe7fc83204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_e257df70-b7ee-4a7f-b214-042784cf1fa9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_038f6741-13c9-4e30-b644-82fe7fc83204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_ac34a5eb-592d-430a-b9eb-b1c8c6a0f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_ac34a5eb-592d-430a-b9eb-b1c8c6a0f72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_b05fec40-f4e7-410c-88dd-41c82dda7428" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_b05fec40-f4e7-410c-88dd-41c82dda7428" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bc96b959-ea7c-46f9-86dc-7b6d2099597e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bc96b959-ea7c-46f9-86dc-7b6d2099597e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2eb6224f-39fe-4148-91de-bfd0f2f651ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2eb6224f-39fe-4148-91de-bfd0f2f651ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_58b121e2-2562-4158-8179-70239f5c9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_58b121e2-2562-4158-8179-70239f5c9a1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:href="lgnd-20231231.xsd#lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_01d56cbd-75bd-46c4-a098-988ba72647e4" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_01d56cbd-75bd-46c4-a098-988ba72647e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_fec7a746-b393-421e-ae5c-4130ce99d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_fec7a746-b393-421e-ae5c-4130ce99d27a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_1fe636a2-0b88-4ca9-ae25-89d3d25c784a" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_1fe636a2-0b88-4ca9-ae25-89d3d25c784a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_d7a43a53-61e0-4c06-bb9c-4a884a58970d" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_d7a43a53-61e0-4c06-bb9c-4a884a58970d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_cfafc1c2-61bb-430b-aa0a-5b194c8317d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_cfafc1c2-61bb-430b-aa0a-5b194c8317d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca73373b-9c9f-4822-a7fc-c9bf0ac5010a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca73373b-9c9f-4822-a7fc-c9bf0ac5010a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_72c7c7af-be63-4dd5-830b-a510d04c9ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_72c7c7af-be63-4dd5-830b-a510d04c9ed6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2714c0d5-eea0-4b0b-9495-b237041af1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2714c0d5-eea0-4b0b-9495-b237041af1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_29c11d6d-8960-4851-b68b-b68c84379331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_29c11d6d-8960-4851-b68b-b68c84379331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_abf2aef4-271f-496b-9c26-31f4e37e976e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_29c11d6d-8960-4851-b68b-b68c84379331" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_abf2aef4-271f-496b-9c26-31f4e37e976e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:href="lgnd-20231231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_d3d31f10-6ba3-4af7-8a21-9e268f9352ba" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_d3d31f10-6ba3-4af7-8a21-9e268f9352ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_3d0058fd-3c51-4fb5-bf40-e2823a7bc301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_3d0058fd-3c51-4fb5-bf40-e2823a7bc301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_88186adf-eac1-491e-9cd0-02e90662583d" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_88186adf-eac1-491e-9cd0-02e90662583d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:href="lgnd-20231231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_23c9eeae-746d-4979-ab2c-937f7cad6aba" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_23c9eeae-746d-4979-ab2c-937f7cad6aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_b11306b4-6bd1-4d31-b927-133dbce91c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_b11306b4-6bd1-4d31-b927-133dbce91c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_c7f70468-0aee-4071-97f7-200a39ab5f8f" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersInvestingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_c7f70468-0aee-4071-97f7-200a39ab5f8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_5481bb14-e4e6-48e1-ab3d-29b1ce29cf97" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_5481bb14-e4e6-48e1-ab3d-29b1ce29cf97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_abbe9e8c-e682-48cf-8e07-58d78fffd9a8" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_5481bb14-e4e6-48e1-ab3d-29b1ce29cf97" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_abbe9e8c-e682-48cf-8e07-58d78fffd9a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a1c99255-92c7-4417-81a3-9785020cf0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a1c99255-92c7-4417-81a3-9785020cf0b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_87757ae8-9e25-44a3-a835-365f045adfd7" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a1c99255-92c7-4417-81a3-9785020cf0b7" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_87757ae8-9e25-44a3-a835-365f045adfd7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:to="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22ca7afa-06ef-46f5-99a2-4dd80ea582e7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22ca7afa-06ef-46f5-99a2-4dd80ea582e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_4e780810-0c0d-4c6f-b611-e3af6c763fe7" xlink:href="lgnd-20231231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_4e780810-0c0d-4c6f-b611-e3af6c763fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_f8a69a04-6486-40e6-84ee-67578c3ece5c" xlink:href="lgnd-20231231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_SelexisAndDianomiMember_f8a69a04-6486-40e6-84ee-67578c3ece5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_ead268d2-1723-4280-b384-41cfb6ea3a34" xlink:href="lgnd-20231231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_OvidTherapeuticsMember_ead268d2-1723-4280-b384-41cfb6ea3a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_07597f0f-f8c2-4227-870d-6946bda9a769" xlink:href="lgnd-20231231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_07597f0f-f8c2-4227-870d-6946bda9a769" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaMember_1048f6c2-2acd-45c8-bf70-12bfd73c260e" xlink:href="lgnd-20231231.xsd#lgnd_PalvellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_PalvellaMember_1048f6c2-2acd-45c8-bf70-12bfd73c260e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsGross_5e4b283d-9fb0-4a89-a744-52badfc9eb76" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsGross_5e4b283d-9fb0-4a89-a744-52badfc9eb76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments_a17e38ba-4a8a-4bc1-824a-dc7f8265e11a" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCumulativeAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments_a17e38ba-4a8a-4bc1-824a-dc7f8265e11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_94d94732-5c82-4be2-b8c0-86e542101b57" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRights_94d94732-5c82-4be2-b8c0-86e542101b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsAccumulatedAmortization_e3dec5ee-b9cc-4c8f-b149-c5aae5c1de01" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsAccumulatedAmortization_e3dec5ee-b9cc-4c8f-b149-c5aae5c1de01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_60cdb375-ce72-4623-ad59-d7d132a956fd" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_60cdb375-ce72-4623-ad59-d7d132a956fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsImpairments_3c988443-9c89-46cb-af38-4dcf4a466741" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsImpairments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsImpairments_3c988443-9c89-46cb-af38-4dcf4a466741" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb802d50-6d89-4cf3-b6e7-4fcf9848998e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb802d50-6d89-4cf3-b6e7-4fcf9848998e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_7fcd0321-dee2-4154-a13e-89f83f7d18d6" xlink:href="lgnd-20231231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_7fcd0321-dee2-4154-a13e-89f83f7d18d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_99894430-081d-4044-ac04-d44d49bf5696" xlink:href="lgnd-20231231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_SelexisAndDianomiMember_99894430-081d-4044-ac04-d44d49bf5696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_8ea8e8f0-29f0-42d1-b32d-1c09d09d236b" xlink:href="lgnd-20231231.xsd#lgnd_CorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_CorMatrixMember_8ea8e8f0-29f0-42d1-b32d-1c09d09d236b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_c3c8d8eb-98ed-4916-bfdd-80184cdc1dce" xlink:href="lgnd-20231231.xsd#lgnd_SelexisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_SelexisMember_c3c8d8eb-98ed-4916-bfdd-80184cdc1dce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_04acd242-5e21-46fc-8d79-15da22b8b3b3" xlink:href="lgnd-20231231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_OvidTherapeuticsMember_04acd242-5e21-46fc-8d79-15da22b8b3b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_1925485a-ab4e-4aed-87c5-9d4df9ccd1be" xlink:href="lgnd-20231231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_1925485a-ab4e-4aed-87c5-9d4df9ccd1be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_126f07ac-5859-4173-8cde-e55ca5ab004e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:to="loc_srt_RangeMember_126f07ac-5859-4173-8cde-e55ca5ab004e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:to="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_61fc981b-a303-4449-8d82-c9fc2680dfa3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:to="loc_srt_MaximumMember_61fc981b-a303-4449-8d82-c9fc2680dfa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a2b01e3-c369-42c6-92e0-2d9d611a4be2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:to="loc_srt_MinimumMember_6a2b01e3-c369-42c6-92e0-2d9d611a4be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a7b0238-b86f-45ee-ad97-f0478956ecbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a7b0238-b86f-45ee-ad97-f0478956ecbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e08cb1c1-f31d-4084-b62c-d118d9c54261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e08cb1c1-f31d-4084-b62c-d118d9c54261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_4aa3d869-b6ac-4eef-a863-3a2a3af654c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e08cb1c1-f31d-4084-b62c-d118d9c54261" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_4aa3d869-b6ac-4eef-a863-3a2a3af654c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cea89a41-f36b-4718-830e-46dcd1d40eb2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:to="loc_srt_ProductsAndServicesDomain_cea89a41-f36b-4718-830e-46dcd1d40eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb7aed1b-363c-412f-aae9-bfcd25b0d284" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:to="loc_srt_ProductsAndServicesDomain_fb7aed1b-363c-412f-aae9-bfcd25b0d284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SoticlestatMember_79f7fd4f-92a8-4145-bc9b-6b553d136931" xlink:href="lgnd-20231231.xsd#lgnd_SoticlestatMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb7aed1b-363c-412f-aae9-bfcd25b0d284" xlink:to="loc_lgnd_SoticlestatMember_79f7fd4f-92a8-4145-bc9b-6b553d136931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_255e1397-b8ce-4994-ae69-36ad008c750a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_255e1397-b8ce-4994-ae69-36ad008c750a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_e52ffb95-500e-418e-997e-63f38a91ce61" xlink:href="lgnd-20231231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_255e1397-b8ce-4994-ae69-36ad008c750a" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_e52ffb95-500e-418e-997e-63f38a91ce61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_03f73463-cbc4-426a-8ce2-3f6c6cc0e502" xlink:href="lgnd-20231231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ProductRoyaltyPercentage_03f73463-cbc4-426a-8ce2-3f6c6cc0e502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentOfCommercialLicense_d964ad4e-5839-471c-90f7-0356b111775b" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentOfCommercialLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ImpairmentOfCommercialLicense_d964ad4e-5839-471c-90f7-0356b111775b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_99a7e0dd-84ee-4cc6-8e62-4813902cf46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_99a7e0dd-84ee-4cc6-8e62-4813902cf46f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_da0e9fdb-a238-4da0-8cc7-7039ef834a0c" xlink:href="lgnd-20231231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_da0e9fdb-a238-4da0-8cc7-7039ef834a0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_3a3c7754-6951-4675-80b5-33a6d4444f2f" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_3a3c7754-6951-4675-80b5-33a6d4444f2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_e78d4b43-1b8d-4a6d-85e5-161e28725bd2" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_e78d4b43-1b8d-4a6d-85e5-161e28725bd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_1f20866e-ee60-4e6a-b0e3-a52c484a6e51" xlink:href="lgnd-20231231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_1f20866e-ee60-4e6a-b0e3-a52c484a6e51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_35143943-20ef-4259-9de3-f579fb359490" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_35143943-20ef-4259-9de3-f579fb359490" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_27d3d428-7fbf-4607-b670-d09ea5759471" xlink:href="lgnd-20231231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_27d3d428-7fbf-4607-b670-d09ea5759471" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_360448bd-ce0a-4bb2-a4d8-7fc1380a9061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_360448bd-ce0a-4bb2-a4d8-7fc1380a9061" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_64f88f84-00c9-407a-a236-c3f20b0f9b11" xlink:href="lgnd-20231231.xsd#lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_64f88f84-00c9-407a-a236-c3f20b0f9b11" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7904835a-8175-43ed-bfef-d411f74d703a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7904835a-8175-43ed-bfef-d411f74d703a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0605a94-6007-4e54-9e54-1d8ca549bb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0605a94-6007-4e54-9e54-1d8ca549bb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_97255f39-51d3-4a9f-9f33-cc7f6a919cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0605a94-6007-4e54-9e54-1d8ca549bb00" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_97255f39-51d3-4a9f-9f33-cc7f6a919cc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15dc8f2-6eff-4ba8-a70d-a63921fde848_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f15dc8f2-6eff-4ba8-a70d-a63921fde848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ad28a955-d024-4a65-9f45-b99be47fba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ad28a955-d024-4a65-9f45-b99be47fba7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f60a21be-8b97-44d8-945e-8c41c46ac944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f60a21be-8b97-44d8-945e-8c41c46ac944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2583cf8e-e502-4775-b613-91f5089aaa10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2583cf8e-e502-4775-b613-91f5089aaa10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0455a2c8-8395-4848-bd13-fcd6d225ff6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0455a2c8-8395-4848-bd13-fcd6d225ff6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_a73a52e3-8664-4aa7-8f0d-7d8b57de718f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_a73a52e3-8664-4aa7-8f0d-7d8b57de718f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilitiesMember_ddc3a4d0-4540-4c62-a3e9-33e4f025e8f6" xlink:href="lgnd-20231231.xsd#lgnd_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:to="loc_lgnd_ContingentLiabilitiesMember_ddc3a4d0-4540-4c62-a3e9-33e4f025e8f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c755f17-7205-409f-bfac-e889c11ee235_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c755f17-7205-409f-bfac-e889c11ee235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CyDexMember_9b2ae7db-0bd1-4d65-9ac6-4aa91d88992a" xlink:href="lgnd-20231231.xsd#lgnd_CyDexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:to="loc_lgnd_CyDexMember_9b2ae7db-0bd1-4d65-9ac6-4aa91d88992a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisMember_24b5983a-60dd-4dea-94b3-1a93eb171790" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:to="loc_lgnd_MetabasisMember_24b5983a-60dd-4dea-94b3-1a93eb171790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d63b61d2-e3a7-47d9-9b90-e27eb6965d37_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:to="loc_srt_RangeMember_d63b61d2-e3a7-47d9-9b90-e27eb6965d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6af0f639-90ca-493b-a8d9-423eef33f6c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:to="loc_srt_RangeMember_6af0f639-90ca-493b-a8d9-423eef33f6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e4a2b66-7a74-4e52-bd8c-27bfa5562849" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6af0f639-90ca-493b-a8d9-423eef33f6c8" xlink:to="loc_srt_MaximumMember_1e4a2b66-7a74-4e52-bd8c-27bfa5562849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a9c21a27-c9af-46fb-9eb0-134deef8a17c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_a9c21a27-c9af-46fb-9eb0-134deef8a17c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_29935446-6293-460d-818d-9566eb14cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_29935446-6293-460d-818d-9566eb14cf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_f7862f13-b5be-42cd-b7a8-f94d75286537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_29935446-6293-460d-818d-9566eb14cf32" xlink:to="loc_us-gaap_TransferredOverTimeMember_f7862f13-b5be-42cd-b7a8-f94d75286537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78fbb349-91d7-46ed-b3eb-9d15fef05a88_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:to="loc_srt_ProductsAndServicesDomain_78fbb349-91d7-46ed-b3eb-9d15fef05a88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:to="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_928c2fb4-a3c5-4143-a466-bdfebd8492b8" xlink:href="lgnd-20231231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_928c2fb4-a3c5-4143-a466-bdfebd8492b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_902a645b-ec2b-45cd-b32c-e080c17911b2" xlink:href="lgnd-20231231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_902a645b-ec2b-45cd-b32c-e080c17911b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_804eb7b7-cbb0-446a-a11b-8562afabe2ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_804eb7b7-cbb0-446a-a11b-8562afabe2ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_89e65f9d-fa30-4836-ab5a-708bfdf62dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_89e65f9d-fa30-4836-ab5a-708bfdf62dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_23ade580-7455-4d74-a66a-986c74272e41" xlink:href="lgnd-20231231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_89e65f9d-fa30-4836-ab5a-708bfdf62dd2" xlink:to="loc_lgnd_PrimordialGeneticsMember_23ade580-7455-4d74-a66a-986c74272e41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35422aad-88ef-4899-b08b-03e24337cc83_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_35422aad-88ef-4899-b08b-03e24337cc83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b6fabd-00c9-4a73-8f56-b6e0cf12de50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b6fabd-00c9-4a73-8f56-b6e0cf12de50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_6866fb65-24e7-4664-b210-7d3856c02918" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b6fabd-00c9-4a73-8f56-b6e0cf12de50" xlink:to="loc_lgnd_PrimroseBioMember_6866fb65-24e7-4664-b210-7d3856c02918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6cc3b106-a2e0-4cc3-8b33-5107bef4bc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6cc3b106-a2e0-4cc3-8b33-5107bef4bc89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9d6c2f30-5657-4795-a398-2c25731defc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9d6c2f30-5657-4795-a398-2c25731defc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_241635dc-df71-4e4c-a94d-9b049c6a6ab0" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_241635dc-df71-4e4c-a94d-9b049c6a6ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_164c4eb8-93e4-42f2-88e1-ec1b9e877563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_DerivativeAssets_164c4eb8-93e4-42f2-88e1-ec1b9e877563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_028800fb-c107-4d2b-a276-9059c2865f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_028800fb-c107-4d2b-a276-9059c2865f92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_f439ad72-8553-4491-91c2-af1bc99db1b1" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_f439ad72-8553-4491-91c2-af1bc99db1b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_f243272e-ec39-4263-8f0b-b24e04ef3296" xlink:href="lgnd-20231231.xsd#lgnd_AmountsOwedToFormerLicensorFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_f243272e-ec39-4263-8f0b-b24e04ef3296" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_438a26cf-e33a-4b3f-8cb9-1bdb50735bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_438a26cf-e33a-4b3f-8cb9-1bdb50735bfb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InterestInPotentialDevelopmentMilestone_bfe00922-e7ca-4a0e-9f33-a8262cb50c5a" xlink:href="lgnd-20231231.xsd#lgnd_InterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_InterestInPotentialDevelopmentMilestone_bfe00922-e7ca-4a0e-9f33-a8262cb50c5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_3d75dada-29e3-4598-94c4-8405d6abd8bb" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_NumberOfContracts_3d75dada-29e3-4598-94c4-8405d6abd8bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_bebb401e-de41-46be-8a0a-3752da5c7d9a" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_bebb401e-de41-46be-8a0a-3752da5c7d9a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_1588bfdf-5733-490d-9dca-f80dfef4b16e" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_1588bfdf-5733-490d-9dca-f80dfef4b16e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsSeries_90eebd7e-4df5-4a8a-a935-bf9ec863793d" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightsSeries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_NumberOfContingentValueRightsSeries_90eebd7e-4df5-4a8a-a935-bf9ec863793d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5e981f6c-d33d-4eef-b3a9-a7887942e1dc" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5e981f6c-d33d-4eef-b3a9-a7887942e1dc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_38a2307e-a7f2-49e2-8a09-68447ac43041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_Investments_38a2307e-a7f2-49e2-8a09-68447ac43041" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_cbfb8cd7-ea06-4e87-ab3b-883abf3ff639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_cbfb8cd7-ea06-4e87-ab3b-883abf3ff639" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9387aa78-3b27-413b-9f40-b2b20b99b0c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9387aa78-3b27-413b-9f40-b2b20b99b0c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dabe6a41-e715-4937-b60a-71bfb7a9149b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dabe6a41-e715-4937-b60a-71bfb7a9149b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_09dc1375-709a-4a9e-aea3-ae861501b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dabe6a41-e715-4937-b60a-71bfb7a9149b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_09dc1375-709a-4a9e-aea3-ae861501b3a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3e16a254-c063-481d-95f9-2adfec0f6047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3e16a254-c063-481d-95f9-2adfec0f6047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_603325aa-a476-4409-85c2-84af98e0ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_603325aa-a476-4409-85c2-84af98e0ec18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_b00e6a27-4492-48df-801b-db0fe9f02d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_b00e6a27-4492-48df-801b-db0fe9f02d47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a84015ec-8f8b-459b-bc8c-d3ddc491a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_6aef9e75-503e-496a-9b4d-29f65aefe9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_6aef9e75-503e-496a-9b4d-29f65aefe9c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31c3fe52-f37c-4e8d-a4b0-ac79052a667c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31c3fe52-f37c-4e8d-a4b0-ac79052a667c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_7dd0769d-8c9b-4efb-b87f-d482b90a5d65" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_7dd0769d-8c9b-4efb-b87f-d482b90a5d65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_047ebefc-a8b1-45b2-9768-3001e0ee454a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_047ebefc-a8b1-45b2-9768-3001e0ee454a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a410b45-c74c-43ee-b3ec-9ba8b0392933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_7f59a1a2-dae0-4d03-9d3f-5f50061afc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_7f59a1a2-dae0-4d03-9d3f-5f50061afc04" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9786a3c-3716-4139-baaf-9762dcb4d2ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9786a3c-3716-4139-baaf-9762dcb4d2ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_45833653-7fb5-4783-a3f4-578c133cf817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_45833653-7fb5-4783-a3f4-578c133cf817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_45833653-7fb5-4783-a3f4-578c133cf817" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_55dcc76d-a766-4092-8930-b8381e3da8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_55dcc76d-a766-4092-8930-b8381e3da8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6e81b05e-f2fd-4ed3-8652-f13b9f1749c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6e81b05e-f2fd-4ed3-8652-f13b9f1749c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_218ad08d-02e9-4de3-8d80-003eaeb04b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_218ad08d-02e9-4de3-8d80-003eaeb04b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e123e7dd-525a-43ea-9d92-23ee6330b00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e123e7dd-525a-43ea-9d92-23ee6330b00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsFairValueDisclosure_e073fd0a-31db-4d2d-9460-d44efc251e3e" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_lgnd_CommercialLicenseRightsFairValueDisclosure_e073fd0a-31db-4d2d-9460-d44efc251e3e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:to="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:to="loc_srt_ProductsAndServicesDomain_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_425e96c6-d974-4bb7-a75f-53e50d87ace7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:to="loc_srt_ProductsAndServicesDomain_425e96c6-d974-4bb7-a75f-53e50d87ace7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_63464a74-ae4c-4c10-9a2d-93886e03678e" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_425e96c6-d974-4bb7-a75f-53e50d87ace7" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_63464a74-ae4c-4c10-9a2d-93886e03678e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:to="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed606163-955e-473a-8fcc-4a74ec76e98c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:to="loc_srt_RangeMember_ed606163-955e-473a-8fcc-4a74ec76e98c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57889a85-3033-4da1-b040-0b5159e689e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:to="loc_srt_RangeMember_57889a85-3033-4da1-b040-0b5159e689e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a61a3dfe-7564-40e4-963a-3527cc49a7b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_57889a85-3033-4da1-b040-0b5159e689e7" xlink:to="loc_srt_MaximumMember_a61a3dfe-7564-40e4-963a-3527cc49a7b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_2d8fc1a4-82b8-4902-81f1-80706e7feec9" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_2d8fc1a4-82b8-4902-81f1-80706e7feec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_b0d5d5da-6bc7-4cae-b19b-2f89c197fb30" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_b0d5d5da-6bc7-4cae-b19b-2f89c197fb30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_7ecc6c8d-c3bf-466b-a9bc-7bb2b23cb5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_7ecc6c8d-c3bf-466b-a9bc-7bb2b23cb5cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseImpairmentLoss_116f0e9e-fb02-4385-9c9a-64e8228dd84a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseImpairmentLoss_116f0e9e-fb02-4385-9c9a-64e8228dd84a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3743ef87-2136-4429-84bf-90d4e9a3659d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3743ef87-2136-4429-84bf-90d4e9a3659d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_16e86a7a-61e7-4c1d-8e10-dca3d34e0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_16e86a7a-61e7-4c1d-8e10-dca3d34e0a53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_45bfc5f1-c048-4a6b-876d-986227209916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_45bfc5f1-c048-4a6b-876d-986227209916" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1ad8ba01-a753-4d7b-a51c-b585b1c7ae23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1ad8ba01-a753-4d7b-a51c-b585b1c7ae23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_f51d2326-2c1d-4164-9300-3f8b00af2191" xlink:href="lgnd-20231231.xsd#lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_f51d2326-2c1d-4164-9300-3f8b00af2191" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0a2b947f-0513-4977-a5a9-3825f3681029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0a2b947f-0513-4977-a5a9-3825f3681029" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9f8858cd-515b-4f08-a494-9c1a3dcf0a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9f8858cd-515b-4f08-a494-9c1a3dcf0a8e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e080246-827c-4af3-b488-16a345bc69e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e080246-827c-4af3-b488-16a345bc69e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4e5eb466-3d46-44d4-9a65-07912a0f9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeasePayments_4e5eb466-3d46-44d4-9a65-07912a0f9fe0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_43da6cbe-4f84-406e-999b-5ddc79e5fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeaseExpense_43da6cbe-4f84-406e-999b-5ddc79e5fb23" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_548a30a2-147f-4b0f-8db0-94c6b6d4feda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_SubleaseIncome_548a30a2-147f-4b0f-8db0-94c6b6d4feda" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9933961f-b846-4113-bc24-8a3cd880eb63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9933961f-b846-4113-bc24-8a3cd880eb63" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f0d11637-a69c-4041-a5ed-2e7450774934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f0d11637-a69c-4041-a5ed-2e7450774934" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e283281e-8b7a-4084-bb94-1bbd7e68d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e283281e-8b7a-4084-bb94-1bbd7e68d9c8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_15541b9c-5487-42be-be03-fbc7323ac8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_15541b9c-5487-42be-be03-fbc7323ac8c8" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f05b2432-da9e-4f73-a235-3072c71261c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f05b2432-da9e-4f73-a235-3072c71261c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f9b9003c-4be4-4467-b5a2-999414aa252e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f9b9003c-4be4-4467-b5a2-999414aa252e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_2a01ba5b-26be-439b-848b-2e8484b79e5b" xlink:href="lgnd-20231231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f9b9003c-4be4-4467-b5a2-999414aa252e" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_2a01ba5b-26be-439b-848b-2e8484b79e5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f0ea6914-db32-4a0f-bb37-6a5c1be90951_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f0ea6914-db32-4a0f-bb37-6a5c1be90951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_0502aa9a-679f-4dbb-9978-08f8a63bab76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_0502aa9a-679f-4dbb-9978-08f8a63bab76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c16a26d4-785d-4151-b714-405463fc040e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:to="loc_us-gaap_LineOfCreditMember_c16a26d4-785d-4151-b714-405463fc040e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_d22472bc-79fa-409f-ba85-257198be5612_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_d22472bc-79fa-409f-ba85-257198be5612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_2f086962-2676-4912-bffb-f8ef08dd3abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_2f086962-2676-4912-bffb-f8ef08dd3abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_4c115cdb-d495-451c-a9ef-5c8fabd1f8a4" xlink:href="lgnd-20231231.xsd#lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_2f086962-2676-4912-bffb-f8ef08dd3abd" xlink:to="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_4c115cdb-d495-451c-a9ef-5c8fabd1f8a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:to="loc_us-gaap_CreditFacilityDomain_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cc4c02c4-a6ea-4719-ad89-ce3521e27a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:to="loc_us-gaap_CreditFacilityDomain_cc4c02c4-a6ea-4719-ad89-ce3521e27a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4975eea3-31a6-4ecd-8bcf-92d945e661b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cc4c02c4-a6ea-4719-ad89-ce3521e27a20" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4975eea3-31a6-4ecd-8bcf-92d945e661b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ee8604ea-84fe-4223-9845-f34d3593d5f8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:to="loc_srt_RangeMember_ee8604ea-84fe-4223-9845-f34d3593d5f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:to="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_25e32a5b-55a1-4a06-87c7-eaebeb90c819" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:to="loc_srt_MinimumMember_25e32a5b-55a1-4a06-87c7-eaebeb90c819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_105b7fdb-0b2c-445e-9401-8a31f5b254b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:to="loc_srt_MaximumMember_105b7fdb-0b2c-445e-9401-8a31f5b254b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dbbf986f-fec3-4a81-b9bf-8ae62db51d89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:to="loc_us-gaap_VariableRateDomain_dbbf986f-fec3-4a81-b9bf-8ae62db51d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:to="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SecuredOvernightFinancingRateSOFRMember_bca2e942-4c91-402b-990f-56bb40e3ab6a" xlink:href="lgnd-20231231.xsd#lgnd_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:to="loc_lgnd_SecuredOvernightFinancingRateSOFRMember_bca2e942-4c91-402b-990f-56bb40e3ab6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_4b64598f-f85b-4d1d-afb2-a94b993d8b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:to="loc_us-gaap_BaseRateMember_4b64598f-f85b-4d1d-afb2-a94b993d8b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7a003a02-f0d2-4652-a898-b7c6f28520b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7a003a02-f0d2-4652-a898-b7c6f28520b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_70fd99b3-c455-4220-b9e9-65248ccceed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_70fd99b3-c455-4220-b9e9-65248ccceed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8e2f4e7c-8a8b-4baf-aea0-c3ee7d1828f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8e2f4e7c-8a8b-4baf-aea0-c3ee7d1828f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_a6798144-bd41-4fa6-a840-b029dfadca85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_a6798144-bd41-4fa6-a840-b029dfadca85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cdeb5e8c-80d2-4ad9-9bee-7643c214211b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentTerm_cdeb5e8c-80d2-4ad9-9bee-7643c214211b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_19832196-475d-4deb-96af-bcc4ef52b582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_19832196-475d-4deb-96af-bcc4ef52b582" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_daede635-f6e6-454b-bb6c-a6b0c3db3052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_InterestExpenseDebt_daede635-f6e6-454b-bb6c-a6b0c3db3052" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1d27e3a9-6068-4495-8f22-6194c05c0cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1d27e3a9-6068-4495-8f22-6194c05c0cc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_cfed580c-88da-47d8-8bb8-2d251390737d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_cfed580c-88da-47d8-8bb8-2d251390737d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_e5d4a6f1-dd1d-4f24-868c-6b5a7ab8e58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_e5d4a6f1-dd1d-4f24-868c-6b5a7ab8e58b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9f0839fc-68d2-4e0f-b54e-3a3a3fc6637a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9f0839fc-68d2-4e0f-b54e-3a3a3fc6637a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_dfdc7d3f-e791-4b10-9c14-01eedaaf1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_InterestPaid_dfdc7d3f-e791-4b10-9c14-01eedaaf1cf1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed12e3b0-3443-4c6e-9dcf-6ad795af08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed12e3b0-3443-4c6e-9dcf-6ad795af08ed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_de458bfb-e876-409f-88ff-8b82c369e882" xlink:href="lgnd-20231231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_de458bfb-e876-409f-88ff-8b82c369e882" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c8c671b0-d81e-40ee-b01c-02ba8f01f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c8c671b0-d81e-40ee-b01c-02ba8f01f72c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9a85eb64-23d5-4af0-885f-24caab56bfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9a85eb64-23d5-4af0-885f-24caab56bfbc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0cf9f6fd-b7f5-4df8-abd4-60002a3540a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0cf9f6fd-b7f5-4df8-abd4-60002a3540a8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f178807f-1826-41a2-83f5-b7afb74ce873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f178807f-1826-41a2-83f5-b7afb74ce873" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_5420ed0d-6856-40bd-90b7-0ef9f27db90e" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_5420ed0d-6856-40bd-90b7-0ef9f27db90e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ede03940-b606-4490-91f8-b13a68ecc6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ede03940-b606-4490-91f8-b13a68ecc6c2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6c5918fc-901f-4de5-973d-55f95c6e2ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6c5918fc-901f-4de5-973d-55f95c6e2ae6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToUnwindWarrants_5fec9ddb-6e68-42af-82fd-b2402298ed31" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToUnwindWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_PaymentsToUnwindWarrants_5fec9ddb-6e68-42af-82fd-b2402298ed31" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d91cd7a3-a82f-4d06-9e55-14853ad1640e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d91cd7a3-a82f-4d06-9e55-14853ad1640e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_e250c8f6-6222-4efd-b608-33d9ff73d0bf" xlink:href="lgnd-20231231.xsd#lgnd_DebtInstrumentRepurchasedAmountDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_e250c8f6-6222-4efd-b608-33d9ff73d0bf" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_36b4a61e-8ca1-4968-a020-78baa399c165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_36b4a61e-8ca1-4968-a020-78baa399c165" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7895fca7-cbdc-47b5-989f-c891b2da8752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7895fca7-cbdc-47b5-989f-c891b2da8752" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_98ef3e63-ee48-46b4-99ad-7941947dedca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_98ef3e63-ee48-46b4-99ad-7941947dedca" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7dc2ba4e-9f92-42dd-8177-7467ca044ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7dc2ba4e-9f92-42dd-8177-7467ca044ca6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b9a72832-02a9-41f6-9622-444acff43442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b9a72832-02a9-41f6-9622-444acff43442" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:to="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_51c62c9c-6c79-4fa4-a5ad-150134581fc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_51c62c9c-6c79-4fa4-a5ad-150134581fc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53fe62f7-9dd6-4e16-9f9e-64c6ff6d890c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53fe62f7-9dd6-4e16-9f9e-64c6ff6d890c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_94f73f9b-c1b2-416c-b594-0095e542aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53fe62f7-9dd6-4e16-9f9e-64c6ff6d890c" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_94f73f9b-c1b2-416c-b594-0095e542aa17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b393a256-7479-465c-962f-64fd8454cff3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b393a256-7479-465c-962f-64fd8454cff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1386e780-e1b8-48b7-b3a3-ff03974b0347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1386e780-e1b8-48b7-b3a3-ff03974b0347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_1bb7ca28-b082-49bd-ad14-7bf5e2ba2919" xlink:href="lgnd-20231231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1386e780-e1b8-48b7-b3a3-ff03974b0347" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_1bb7ca28-b082-49bd-ad14-7bf5e2ba2919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_97326ff0-9eac-4077-b7a7-f1ca715ea9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_97326ff0-9eac-4077-b7a7-f1ca715ea9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e9120b87-299c-47d3-9c5a-1e38ad1b685d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e9120b87-299c-47d3-9c5a-1e38ad1b685d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_c1899dbd-fdd9-4ece-af07-ff17cb4d3223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:to="loc_us-gaap_LongTermNotesPayable_c1899dbd-fdd9-4ece-af07-ff17cb4d3223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_558f9bca-296c-485f-8a36-80f51c12d576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_558f9bca-296c-485f-8a36-80f51c12d576" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38b313ef-7d8b-4caf-8057-677de9bc6128_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38b313ef-7d8b-4caf-8057-677de9bc6128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_97cae66e-bd03-487f-a10c-ed48fbab3204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_MutualFundMember_97cae66e-bd03-487f-a10c-ed48fbab3204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_e99844a8-28c0-44c7-ac3b-cd788f0a5c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_DemandDepositsMember_e99844a8-28c0-44c7-ac3b-cd788f0a5c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cc13692d-87db-4071-802e-3375bff07b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cc13692d-87db-4071-802e-3375bff07b31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3d4e7974-aae5-4db9-be95-a4acb32c264a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_CommercialPaperMember_3d4e7974-aae5-4db9-be95-a4acb32c264a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_0078943a-3f77-4038-8ae4-f941b08fea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_0078943a-3f77-4038-8ae4-f941b08fea2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_7333167f-6f42-43ca-b636-7af0e8e8f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_MunicipalBondsMember_7333167f-6f42-43ca-b636-7af0e8e8f8fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_154ad6fe-3585-4c8c-a997-be9c18741eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_EquitySecuritiesMember_154ad6fe-3585-4c8c-a997-be9c18741eb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1078e9ce-2615-4c11-99c2-6746072b7dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_WarrantMember_1078e9ce-2615-4c11-99c2-6746072b7dd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_060512b3-b8f5-4afc-b49d-d15cdd94682b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_060512b3-b8f5-4afc-b49d-d15cdd94682b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d844844b-13b7-4aa5-8762-d8a9ab2edec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d844844b-13b7-4aa5-8762-d8a9ab2edec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02af7b95-c528-4186-8062-6b0c3befb553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02af7b95-c528-4186-8062-6b0c3befb553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37afd0d2-ab1a-4f5d-93a3-42541e763dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37afd0d2-ab1a-4f5d-93a3-42541e763dc1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_c68c85c1-97e7-45fa-9631-1f207b5b6fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_DemandDepositsMember_c68c85c1-97e7-45fa-9631-1f207b5b6fa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_705cee5f-e98d-42cb-922c-0ad20f86ebbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_705cee5f-e98d-42cb-922c-0ad20f86ebbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f8ead92e-7cba-4df9-a61f-19886d670f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_CommercialPaperMember_f8ead92e-7cba-4df9-a61f-19886d670f35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_1837c193-f2ad-4461-a42a-4c041006d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_MunicipalBondsMember_1837c193-f2ad-4461-a42a-4c041006d76a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_fc6103de-c60c-47b2-ba8d-ea5b8e556811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_fc6103de-c60c-47b2-ba8d-ea5b8e556811" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b61752ac-e0b9-4581-b1f5-67e1f1d4e731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b61752ac-e0b9-4581-b1f5-67e1f1d4e731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6097d493-a5b7-4c82-9f50-71c8bc57c361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6097d493-a5b7-4c82-9f50-71c8bc57c361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5a92a3a7-5850-428c-a0af-2e3a10444e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5a92a3a7-5850-428c-a0af-2e3a10444e5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1b2550a9-8ac2-494d-8d36-1e084d0409c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1b2550a9-8ac2-494d-8d36-1e084d0409c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b5ff09b0-870e-42aa-b01e-5ce285446722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b5ff09b0-870e-42aa-b01e-5ce285446722" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b9ee1182-1f87-4dcb-931c-6a5284fb7042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b9ee1182-1f87-4dcb-931c-6a5284fb7042" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:to="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3244ff89-e316-4aae-bee0-cac865ca8eff_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:to="loc_srt_RangeMember_3244ff89-e316-4aae-bee0-cac865ca8eff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:to="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_71a006d3-d39e-46a3-ac26-9fa482f5c8d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:to="loc_srt_MinimumMember_71a006d3-d39e-46a3-ac26-9fa482f5c8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbe4c39f-7038-459c-b979-b1e6bb7d4dc3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:to="loc_srt_MaximumMember_cbe4c39f-7038-459c-b979-b1e6bb7d4dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:to="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f9a42971-9f3f-4270-a23c-cd5c0f867993_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:to="loc_srt_OwnershipDomain_f9a42971-9f3f-4270-a23c-cd5c0f867993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_34169eb4-22c3-44b5-b9fa-7ebf041ffc9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:to="loc_srt_OwnershipDomain_34169eb4-22c3-44b5-b9fa-7ebf041ffc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_ac733542-c3fb-4720-b9f5-b0370d503c34" xlink:href="lgnd-20231231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_34169eb4-22c3-44b5-b9fa-7ebf041ffc9d" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_ac733542-c3fb-4720-b9f5-b0370d503c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bd1e3748-d78d-46ca-a1f7-247b68a9b577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bd1e3748-d78d-46ca-a1f7-247b68a9b577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_dec3179e-0229-4e38-b5ff-bcc913cd5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_dec3179e-0229-4e38-b5ff-bcc913cd5e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_d42edd48-a509-482a-8b19-157b0e219fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_d42edd48-a509-482a-8b19-157b0e219fea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c0c48b62-7108-4946-8642-3587dd227296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c0c48b62-7108-4946-8642-3587dd227296" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_247190e0-a805-45a7-b28c-4cd199cba827" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_247190e0-a805-45a7-b28c-4cd199cba827" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_272782c6-b809-4dcd-8cfe-6d951af9a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_GainLossOnInvestments_272782c6-b809-4dcd-8cfe-6d951af9a06a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_38e82b92-bf36-4938-9739-2850e563002f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_38e82b92-bf36-4938-9739-2850e563002f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8d3ef0e9-5382-4858-8463-2456cee436ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_Depreciation_8d3ef0e9-5382-4858-8463-2456cee436ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_44a44119-4e71-41f6-ac35-c4612b104ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_44a44119-4e71-41f6-ac35-c4612b104ad9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8505895c-8086-4716-8e3c-ecfbef27fd32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8505895c-8086-4716-8e3c-ecfbef27fd32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_82ef0ea7-61a8-419a-a130-f6aaec4b4fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_82ef0ea7-61a8-419a-a130-f6aaec4b4fe6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02580a78-51df-464c-bf92-7e58ab98ad55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02580a78-51df-464c-bf92-7e58ab98ad55" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0cb7844-896f-4bc4-92f1-36ee9879ab87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0cb7844-896f-4bc4-92f1-36ee9879ab87" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e3578f76-bbff-4b24-b0c1-cfe4089651ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e3578f76-bbff-4b24-b0c1-cfe4089651ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1c109aef-6d50-4d89-90fc-78e720cc1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1c109aef-6d50-4d89-90fc-78e720cc1d48" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1aa4a61-86ad-419d-8eec-7c33137c840f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1aa4a61-86ad-419d-8eec-7c33137c840f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements_dcb503ed-de0e-414d-850d-7a1180c03d28" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_lgnd_NumberOfContingentValueRightAgreements_dcb503ed-de0e-414d-850d-7a1180c03d28" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_643c7aef-d210-45f6-bbae-49abb85769f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_643c7aef-d210-45f6-bbae-49abb85769f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_873d1cd3-f095-495e-ab62-1b4e444ed98f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:to="loc_us-gaap_OfficeEquipmentMember_873d1cd3-f095-495e-ab62-1b4e444ed98f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_47b08347-cc47-4814-87f6-81516db7d117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_47b08347-cc47-4814-87f6-81516db7d117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_ff443fef-b49c-4ce2-b5ad-fcbc7af34cb0" xlink:href="lgnd-20231231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_ff443fef-b49c-4ce2-b5ad-fcbc7af34cb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_72348c6d-a592-42f9-b5a0-28115edf7c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_72348c6d-a592-42f9-b5a0-28115edf7c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3bf14d7c-a789-47cd-98fe-64c0d4597ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3bf14d7c-a789-47cd-98fe-64c0d4597ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9ff71441-15fd-4f11-a3e3-6329fbd102ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9ff71441-15fd-4f11-a3e3-6329fbd102ac" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_33b7efd4-3385-411b-8469-684c5b681195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_33b7efd4-3385-411b-8469-684c5b681195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_a54c562a-aa59-4327-b062-3c13e2860f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_PatentedTechnologyMember_a54c562a-aa59-4327-b062-3c13e2860f1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_32d36d65-8cbf-49e7-93b7-0afcdfa5a611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_TradeNamesMember_32d36d65-8cbf-49e7-93b7-0afcdfa5a611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9f7fde01-52fc-45ff-a9e8-b70801f7794e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9f7fde01-52fc-45ff-a9e8-b70801f7794e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_22ac5a54-bb1b-495d-b3e7-5c0c022dc528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_ContractualRightsMember_22ac5a54-bb1b-495d-b3e7-5c0c022dc528" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8ce8d1f7-fabd-43a6-8b14-52d78f6996d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_Goodwill_8ce8d1f7-fabd-43a6-8b14-52d78f6996d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7edb9c0b-08e5-4e5d-942f-2b5647e8a530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7edb9c0b-08e5-4e5d-942f-2b5647e8a530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_142c441e-5029-409e-b1d4-4ee55601c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_142c441e-5029-409e-b1d4-4ee55601c5a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c220c35e-b151-4182-92f3-adb12ec0388c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c220c35e-b151-4182-92f3-adb12ec0388c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_02f740c6-78fa-4794-aa0a-584ae3184a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_02f740c6-78fa-4794-aa0a-584ae3184a56" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a1376c5-9a67-46ba-9189-62968201d30b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a1376c5-9a67-46ba-9189-62968201d30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_f3cade22-fa40-4e64-8f8b-de44dd7b1048" xlink:href="lgnd-20231231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_f3cade22-fa40-4e64-8f8b-de44dd7b1048" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_1f5d3682-1876-4b18-a3d8-228862cde897" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_1f5d3682-1876-4b18-a3d8-228862cde897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:href="lgnd-20231231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_02f740c6-78fa-4794-aa0a-584ae3184a56" xlink:to="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_9d12a448-1e29-401f-b7ef-b02fb839b23c" xlink:href="lgnd-20231231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_9d12a448-1e29-401f-b7ef-b02fb839b23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_12143bf7-c29a-41f7-b5b5-f688f0e27c60" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_12143bf7-c29a-41f7-b5b5-f688f0e27c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_35343038-450a-45b3-b295-df75ac33f6fe" xlink:href="lgnd-20231231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_35343038-450a-45b3-b295-df75ac33f6fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_57ee0669-23a5-44d7-af88-56b80acdbf71" xlink:href="lgnd-20231231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_57ee0669-23a5-44d7-af88-56b80acdbf71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_6f5170d7-ec58-407a-8b0d-f9980683172a" xlink:href="lgnd-20231231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_102dc1ad-02b8-4798-b964-bf509e50a375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_102dc1ad-02b8-4798-b964-bf509e50a375" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6aa2005-4b35-4660-abe9-5604643eed53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6aa2005-4b35-4660-abe9-5604643eed53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a7f3693-836f-4713-b3af-78976bed3d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a7f3693-836f-4713-b3af-78976bed3d37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f40a554a-c5e4-4367-9cb8-cb66f2b71249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f40a554a-c5e4-4367-9cb8-cb66f2b71249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_78e1a368-c7f7-4ea3-ba79-f23d91319d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_102dc1ad-02b8-4798-b964-bf509e50a375" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_78e1a368-c7f7-4ea3-ba79-f23d91319d8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b000632d-a4ab-414e-8c63-44569e3a0c77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:to="loc_us-gaap_PlanNameDomain_b000632d-a4ab-414e-8c63-44569e3a0c77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:to="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_ef76270e-684b-4acf-9c5f-ad691fdb7af6" xlink:href="lgnd-20231231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_ef76270e-684b-4acf-9c5f-ad691fdb7af6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OmniabSeparationMember_57e4c26a-d411-49bb-bfe6-183b8e963073" xlink:href="lgnd-20231231.xsd#lgnd_OmniabSeparationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:to="loc_lgnd_OmniabSeparationMember_57e4c26a-d411-49bb-bfe6-183b8e963073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_ff562d41-8a20-47f7-8bd3-6bc422a453eb" xlink:href="lgnd-20231231.xsd#lgnd_AmendedESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:to="loc_lgnd_AmendedESPPMember_ff562d41-8a20-47f7-8bd3-6bc422a453eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43f2da3c-e059-4353-a896-44b99b32bf78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43f2da3c-e059-4353-a896-44b99b32bf78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4474eb7e-9e75-48b2-b626-8c1f2a27407c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4474eb7e-9e75-48b2-b626-8c1f2a27407c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c856db3f-4a9a-4fd4-81ab-c9fec7895ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:to="loc_us-gaap_RestrictedStockMember_c856db3f-4a9a-4fd4-81ab-c9fec7895ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ab530a93-93f4-4da2-b643-640f4d0633f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ab530a93-93f4-4da2-b643-640f4d0633f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97f6d040-0933-45e6-8c34-994d5c8306e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97f6d040-0933-45e6-8c34-994d5c8306e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AtTheMarketEquityOfferingMember_9bbd67f8-4435-4c50-ad96-a94ad8138525" xlink:href="lgnd-20231231.xsd#lgnd_AtTheMarketEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97f6d040-0933-45e6-8c34-994d5c8306e8" xlink:to="loc_lgnd_AtTheMarketEquityOfferingMember_9bbd67f8-4435-4c50-ad96-a94ad8138525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2b91c3ca-4b2d-45d5-90e8-0f1a225ab003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2b91c3ca-4b2d-45d5-90e8-0f1a225ab003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fd7f264c-ca20-425f-805d-e47a25231806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fd7f264c-ca20-425f-805d-e47a25231806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a64ac4df-0d8f-4788-ba94-0e98683a5cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a64ac4df-0d8f-4788-ba94-0e98683a5cb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d129ff48-d19a-45f2-b839-034d26acee3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d129ff48-d19a-45f2-b839-034d26acee3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2277c20d-59ee-4796-b232-e050dab2b61f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2277c20d-59ee-4796-b232-e050dab2b61f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b402effa-e966-4c25-82d4-d9365d89ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b402effa-e966-4c25-82d4-d9365d89ccba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63fdcf1f-dad5-4937-8f2b-1de3dd6b6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63fdcf1f-dad5-4937-8f2b-1de3dd6b6b04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a1815d5-f23d-4023-a3c0-848d7606c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a1815d5-f23d-4023-a3c0-848d7606c66a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e6bd97e1-686d-4ea0-8048-67ec7eff5d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e6bd97e1-686d-4ea0-8048-67ec7eff5d7e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:href="lgnd-20231231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_07eaebaa-d1b6-4403-bb48-26c7751b6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_07eaebaa-d1b6-4403-bb48-26c7751b6a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d4a96cf-754d-4d14-9547-300800a6db59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d4a96cf-754d-4d14-9547-300800a6db59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_6126f859-ac20-4b93-9350-1bb4eb42840a" xlink:href="lgnd-20231231.xsd#lgnd_ShareBasedCompensationInitialOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_6126f859-ac20-4b93-9350-1bb4eb42840a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d22c44f1-a6df-46ad-8a88-51e52c8bb780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d22c44f1-a6df-46ad-8a88-51e52c8bb780" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:href="lgnd-20231231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65d963ed-7534-4a59-b9db-fca33b9efcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65d963ed-7534-4a59-b9db-fca33b9efcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6af9957b-b2ce-4d20-acc4-24660b78626c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6af9957b-b2ce-4d20-acc4-24660b78626c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_b5bb795e-ad58-42eb-abb8-ac5a3620a10d" xlink:href="lgnd-20231231.xsd#lgnd_SaleOfStockAuthorizedOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:to="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_b5bb795e-ad58-42eb-abb8-ac5a3620a10d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_d48288d2-a2fe-421b-9394-f11f66c1a7a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_d48288d2-a2fe-421b-9394-f11f66c1a7a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_fd82674f-9bfc-466b-8f8e-df5c872fa9e7" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_fd82674f-9bfc-466b-8f8e-df5c872fa9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_d7624b07-10f5-47b7-bfc5-f5317d861612" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_d7624b07-10f5-47b7-bfc5-f5317d861612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_8c21f45a-9f81-422f-bf20-6fdb712932bc" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_8c21f45a-9f81-422f-bf20-6fdb712932bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_06b9bf1a-9bf9-4667-bfd0-5e7fc6a3dea2" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_06b9bf1a-9bf9-4667-bfd0-5e7fc6a3dea2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_907fbf9a-9304-400a-8393-66e3898716bb" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_907fbf9a-9304-400a-8393-66e3898716bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_aa4996f2-350c-41cb-b000-1d7849243b95" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_aa4996f2-350c-41cb-b000-1d7849243b95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_3b53e9a8-26e3-4eed-bb1b-e220c0f2f8f9" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_3b53e9a8-26e3-4eed-bb1b-e220c0f2f8f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_e0babe31-a696-433d-830c-5048f67c8fec" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_e0babe31-a696-433d-830c-5048f67c8fec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_611427b2-c334-42cb-901e-1cb1853a932e" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_611427b2-c334-42cb-901e-1cb1853a932e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_074e20a6-c7bf-4742-81f5-49425e5a6f0c" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_074e20a6-c7bf-4742-81f5-49425e5a6f0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bfc71417-1c7e-46d6-9184-710b698ea59d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bfc71417-1c7e-46d6-9184-710b698ea59d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_76c6e56b-6f5b-4b75-9e3f-4786b5b34c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_76c6e56b-6f5b-4b75-9e3f-4786b5b34c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_03e1e2b3-46be-4222-80f8-5fe65e8903ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_03e1e2b3-46be-4222-80f8-5fe65e8903ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2efbb165-98ea-4a0a-a6c6-102661c13e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2efbb165-98ea-4a0a-a6c6-102661c13e87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1cdb74d9-dcbf-43a7-8d78-e784f84dbf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1cdb74d9-dcbf-43a7-8d78-e784f84dbf6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_b040225a-e293-40e6-b8e1-bd9bb16d1b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_b040225a-e293-40e6-b8e1-bd9bb16d1b2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fbfd36e8-e6e1-410a-9c43-63963591ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fbfd36e8-e6e1-410a-9c43-63963591ed60" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:to="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35544e10-984a-4e3e-a7f6-d32f8949f115_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:to="loc_srt_RangeMember_35544e10-984a-4e3e-a7f6-d32f8949f115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:to="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_821724f3-0201-47da-a965-b873cb411b02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:to="loc_srt_MinimumMember_821724f3-0201-47da-a965-b873cb411b02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1fc74b22-f79a-4a79-a0d4-d46eada835d5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:to="loc_srt_MaximumMember_1fc74b22-f79a-4a79-a0d4-d46eada835d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35ec17ba-5c54-4b74-8b49-e9bbbd7d8234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35ec17ba-5c54-4b74-8b49-e9bbbd7d8234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf95cdb5-2c49-4044-8543-82f2ddfef81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf95cdb5-2c49-4044-8543-82f2ddfef81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a23cc446-ec42-4d81-9a68-5fc0040b36b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a23cc446-ec42-4d81-9a68-5fc0040b36b5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:to="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d7fd843-65c6-4373-a441-3a97e9f98ac1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d7fd843-65c6-4373-a441-3a97e9f98ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e817ab03-c562-4ae3-a900-afbd0c2cb89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e817ab03-c562-4ae3-a900-afbd0c2cb89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b681e81d-af90-4502-92c5-1123649f275f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e817ab03-c562-4ae3-a900-afbd0c2cb89f" xlink:to="loc_us-gaap_RestrictedStockMember_b681e81d-af90-4502-92c5-1123649f275f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d87ea31e-4bbe-43de-a038-38e69e4224e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d87ea31e-4bbe-43de-a038-38e69e4224e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73798c93-0dda-48c6-bcdd-42a7c268a8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73798c93-0dda-48c6-bcdd-42a7c268a8ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e6351da-93e2-4f9b-9341-c59fe1a9cc19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e6351da-93e2-4f9b-9341-c59fe1a9cc19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_661b7b26-bb39-447a-b24f-7110fea86a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_661b7b26-bb39-447a-b24f-7110fea86a5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_569cce5c-2e08-4fe7-a7df-50da17b62328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04b01364-eb40-4932-98d2-c8d177a4d415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04b01364-eb40-4932-98d2-c8d177a4d415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5de5f914-eb7e-49c6-98bc-048358c3e557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5de5f914-eb7e-49c6-98bc-048358c3e557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81d3fbbb-c5e3-48f2-89a4-3d313680cd79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81d3fbbb-c5e3-48f2-89a4-3d313680cd79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e5305d19-aeb1-47a0-bed1-d271b885388b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e5305d19-aeb1-47a0-bed1-d271b885388b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb52273-0866-4f05-af41-2ed744a3fd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d6eb3fc3-3c7f-4db8-8813-adcf2cba5114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d6eb3fc3-3c7f-4db8-8813-adcf2cba5114" xlink:to="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:to="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:to="loc_srt_LitigationCaseTypeDomain_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a7349d54-6b2e-44b6-a22e-3c68a4447935" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:to="loc_srt_LitigationCaseTypeDomain_a7349d54-6b2e-44b6-a22e-3c68a4447935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_5d8adfe5-6d9f-4b6a-9ca5-e2e75a99d7ad" xlink:href="lgnd-20231231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a7349d54-6b2e-44b6-a22e-3c68a4447935" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_5d8adfe5-6d9f-4b6a-9ca5-e2e75a99d7ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_94154dec-1164-4e22-a3aa-d2d1da0da955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d6eb3fc3-3c7f-4db8-8813-adcf2cba5114" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_94154dec-1164-4e22-a3aa-d2d1da0da955" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e2d3f41b-905d-4b01-9b56-f79f62e1421f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e2d3f41b-905d-4b01-9b56-f79f62e1421f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_a08470db-495a-4373-b0ef-aba0e5c530bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_a08470db-495a-4373-b0ef-aba0e5c530bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7bc04234-daa9-4fd5-aa14-f6ad78d45b86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7bc04234-daa9-4fd5-aa14-f6ad78d45b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_6fa7593c-0440-48b4-854f-14c91e3876d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:to="loc_us-gaap_ForeignCountryMember_6fa7593c-0440-48b4-854f-14c91e3876d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_881b15da-37f4-4f49-b3da-08f7d5e74045_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_881b15da-37f4-4f49-b3da-08f7d5e74045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_5793edf0-f05d-4216-97af-1aa11eb3dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:to="loc_us-gaap_ResearchMember_5793edf0-f05d-4216-97af-1aa11eb3dcf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_4a48c603-100a-408a-b9b3-866bab19358f" xlink:href="lgnd-20231231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_4a48c603-100a-408a-b9b3-866bab19358f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_2e541b75-8a3b-4c0d-acf7-adbb02f61a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_2e541b75-8a3b-4c0d-acf7-adbb02f61a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c1d56fac-3ad5-420b-a1cb-04786f51d7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c1d56fac-3ad5-420b-a1cb-04786f51d7ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_bcbc208c-df67-420d-bdc3-b6fad1c269e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_OperatingLossCarryforwards_bcbc208c-df67-420d-bdc3-b6fad1c269e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1823acf1-990c-496a-b327-7387cf6bc920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1823acf1-990c-496a-b327-7387cf6bc920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_538a8dec-964e-428c-8ccf-d0d73d935d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_538a8dec-964e-428c-8ccf-d0d73d935d7c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_aa73bfe1-0475-402f-8e5d-af8627268b3b" xlink:href="lgnd-20231231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_aa73bfe1-0475-402f-8e5d-af8627268b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GainLossOnInvestments" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_ebc03e42-488e-42f5-ad64-286e2c964c8a" xlink:href="lgnd-20231231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_ebc03e42-488e-42f5-ad64-286e2c964c8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="6"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>lgnd-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4cc674fd-25ef-4a1f-be1e-ae22ba8e96aa,g:9cb8df18-e655-4252-b500-06985d41d3f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lgnd_ContingentLiabilitiesMember_e15c4688-5d70-4879-b1c8-12baff53ffda_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_ContingentLiabilitiesMember_label_en-US" xlink:label="lab_lgnd_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liabilities [Member]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilitiesMember_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilitiesMember" xlink:href="lgnd-20231231.xsd#lgnd_ContingentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilitiesMember" xlink:to="lab_lgnd_ContingentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_980065e4-658c-4a26-bfe1-cc605fd473ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity by Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_849ab09f-a8be-4170-9f38-57c25694437d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ed61fedc-5e89-4c28-a1d2-81c6a2a5f07c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_130a8d0d-9891-4f57-bb40-506b8f13669e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_87265762-2187-41a1-a6eb-8d345aac67fc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss from discontinued operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_7eccef73-a5ed-484d-bcd8-afe2533dfa7e_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$114.15-$114.15</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTenMember" xlink:to="lab_lgnd_ExercisePriceRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ec06bb41-efc4-4dbe-8e17-a90dc0477d0b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ad480e13-467a-41fa-be3c-3e0a65cf6908_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8abe6348-6f04-4f7a-8922-105c4589f5c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions and dispositions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_6d613ed7-8d8b-4057-87e7-0c3b068f8233_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc9c1ab9-4e7b-4250-8de0-b8f60760494c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7030c1ed-e92b-432e-a72a-fd3eb377e47a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_b4cce68f-8b32-4bc2-b3fa-75d5a0ad6f91_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_d3c70bb4-c262-464d-b7bb-675fc0702439_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c8103bc3-16eb-4632-881e-a157b009c769_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_a86cd3af-b3c5-41ee-aae6-f1d8b8e9838d_periodStartLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights, beginning of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_c94a9666-343f-4a18-a54d-083d829371bf_periodEndLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial rights, end of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:href="lgnd-20231231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_83aab138-4827-4565-8aea-a5a993be76bb_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b759a5ce-5766-4f86-981c-2b940f98e024_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_75eebf2d-506d-43ae-b076-34809d9ce2ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_f7cc95ea-7fc5-44c0-a750-1e4f1c1c9739_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c19dbeb5-8705-466c-b574-061bbccc761a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsSeries_942d067b-2591-47d1-ae99-69550bdf8864_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of CVR Series</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsSeries_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Series</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsSeries_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Series</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsSeries" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightsSeries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsSeries" xlink:to="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_45ec334a-4afa-43da-813e-4b19feb5a7b6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_bdb5351a-1936-4344-a686-5ea7bce8aea2_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_62abff16-58cd-4faa-88e5-df465ad25c92_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_93fe77aa-84c6-4077-9456-1029c4d2e78a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_fa949ebc-d645-4407-8f3c-6dc3f3a96d90_verboseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_88a754c2-24fd-402e-ae8e-20eb5702c29e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_72ba9ba0-3f7e-420e-990d-77daef4ef58d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_61e6c159-6ae2-4ac6-b52b-9b9e96ff512b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_c2e6f5f8-4670-4d78-b262-a6946ed9f818_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs related to obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_b7805f1b-e216-4bd7-b9fb-8988636a6cfe_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_eed2848c-3a18-4258-8912-aca6d115971a_terseLabel_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional royalties receivable under sales-based milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_label_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_documentation_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:href="lgnd-20231231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:to="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_dc6dfbfa-de3b-4fc0-894e-65d1e6007bcd_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b7610e49-0ad6-403c-978b-3077b3b56b78_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_09aba9dd-1a3a-4fee-9460-950abcd9b2e9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dc9d054c-5610-4aed-b098-4b7831d469cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_458247f4-12b7-4d40-85f4-a7f6609bddd4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_a97bac0d-40a5-4dea-a42e-2693ed7a4308_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate change for changes in federal, foreign or state law</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PalvellaMember_6299d914-ee01-43bd-b56b-f9204b8bcde5_terseLabel_en-US" xlink:label="lab_lgnd_PalvellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella</link:label>
    <link:label id="lab_lgnd_PalvellaMember_label_en-US" xlink:label="lab_lgnd_PalvellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella [Member]</link:label>
    <link:label id="lab_lgnd_PalvellaMember_documentation_en-US" xlink:label="lab_lgnd_PalvellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaMember" xlink:href="lgnd-20231231.xsd#lgnd_PalvellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PalvellaMember" xlink:to="lab_lgnd_PalvellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock_8e0b5ce3-403a-4bbc-b1ec-208f7fb2b3a0_terseLabel_en-US" xlink:label="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:label id="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments Policy [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_OtherInvestmentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:to="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BelowMilestoneMember_f01cf9a2-38d3-4a87-b146-ab91feec4ec9_terseLabel_en-US" xlink:label="lab_lgnd_BelowMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below 3 million</link:label>
    <link:label id="lab_lgnd_BelowMilestoneMember_label_en-US" xlink:label="lab_lgnd_BelowMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Milestone [Member]</link:label>
    <link:label id="lab_lgnd_BelowMilestoneMember_documentation_en-US" xlink:label="lab_lgnd_BelowMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BelowMilestoneMember" xlink:href="lgnd-20231231.xsd#lgnd_BelowMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BelowMilestoneMember" xlink:to="lab_lgnd_BelowMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ac2de0f1-90a0-47f3-8df0-ee388c0f1475_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_cd95acc6-1651-4e78-b46f-da61995d14e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_dfede6c5-19f8-4254-8d20-09f756ce7c64_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cb404050-b642-41b2-82b0-64ca03aad727_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_d2a94e2d-6b74-4e67-951a-a5d4acdbb367_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_d89291d6-777f-47d5-a617-d169fe74f961_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a904dc69-2df9-4850-b8ee-7b2aa6b91471_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_2692698e-58ff-47cf-9be9-48e9187d2204_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_101195b9-2ffc-40a4-a299-034bd89fd6c1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_f50fadd5-3da7-4b23-917a-b857f595cc32_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_4ca5bc18-efe8-480d-8763-c65185fa7ca7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_11aec946-a5a9-43cb-86b1-4322a205bf7c_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:to="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7cb79db1-7ef0-4d1e-8565-a981e1cd6898_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_b50a0f84-7731-4337-9df5-22ccb85d4d99_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired from acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_b18ae567-7a7a-467f-9e63-f562c7dcd64b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable and payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_b23df19c-3415-4a8e-b688-26530e14781a_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$78.56-$99.80</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeEightMember" xlink:to="lab_lgnd_ExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b0070628-5baa-4328-969d-f3a4126f43ad_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_a13433bf-cb18-4cce-a439-f1662e433e28_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$50.36-$52.30</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTwoMember" xlink:to="lab_lgnd_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dfac0e3a-c887-4417-a89e-70cfc92541e3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d5ce391a-6bf4-4a0c-963b-a6dd0b406953_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments, Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_70fb8b62-6738-45bb-9dac-75e9c2387362_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerBMember_5dc3bb9c-12b6-4170-8b55-8c4a3c47a140_terseLabel_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B</link:label>
    <link:label id="lab_lgnd_PartnerBMember_label_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:label id="lab_lgnd_PartnerBMember_documentation_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember" xlink:href="lgnd-20231231.xsd#lgnd_PartnerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerBMember" xlink:to="lab_lgnd_PartnerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ef35ec48-9ff5-4088-8868-71dd6f023c88_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4f955400-1a54-4332-9a64-bc4469a19f91_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_35f7c276-c73d-427e-a1c2-2f67e70fb7d9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d0e91321-d353-4102-9d9a-e2fad551b0af_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_4b830d1f-a9ed-4f07-8d96-fb07b45eab1b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_77a02f3f-062f-415d-9793-a818f72d81d4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8b4b73b2-edb1-48bf-bf61-6bc098e7ce49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_87156e9a-fc00-4d1b-a18c-77a85a21892f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_527485c4-630d-4031-a7f9-7e685f039aa4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties owed to third parties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76131aab-9f52-4ea3-9de4-8fe15b47095c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0087c79e-9519-4e3a-a86b-23b8498603c4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e033259b-5c72-406f-a5aa-a89c746d7602_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future option grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_0d4e064f-3f53-4012-bbdc-fd32d1b5a91f_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f7d47176-5e40-4f04-9a96-0f32860080bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_fc9804e2-8894-424b-9a3f-2562d26befac_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of tangible assets acquired, net of cash and restricted cash received</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d92ac340-2151-4806-83e1-ffcc44b64c5c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e0c8652a-35aa-4876-a5e5-e64b4081c547_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_eb900c79-db65-43cb-b1f4-8bc00fc7ccdd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_6169c753-93f3-4745-9a4a-945e1c33e801_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_68cce27a-f8b1-48e5-9b45-e75a659088a8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other economic rights</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_267b9965-d75e-4e1c-b6de-53b8cab9a1af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_bd6f3f25-7d43-4023-bc0c-6039ddf0e095_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_aa24f70d-48b4-4e24-bae4-74d84353b3f5_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8d50a629-c6fe-4e1b-bad9-93aff9ee4488_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_70477f50-73f4-40f8-904d-7160585d026a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Categories</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_b1eefe87-34e3-46fc-b592-6846ce130d39_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to credit loss reserves of commercial license rights</link:label>
    <link:label id="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Credit Loss Reserves Of Commercial License Rights</link:label>
    <link:label id="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Credit Loss Reserves Of Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" xlink:to="lab_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_978be987-878b-4a3d-8e8b-54448e75fb0b_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsFairValueDisclosure_f7354063-2385-450d-a69b-4cfcb877214e_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license rights, fair value disclosure</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsFairValueDisclosure" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsFairValueDisclosure" xlink:to="lab_lgnd_CommercialLicenseRightsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SalesRevenueMilestone_dde30a43-1cc4-4eed-b230-8844cd456033_terseLabel_en-US" xlink:label="lab_lgnd_SalesRevenueMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue milestone</link:label>
    <link:label id="lab_lgnd_SalesRevenueMilestone_label_en-US" xlink:label="lab_lgnd_SalesRevenueMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Milestone</link:label>
    <link:label id="lab_lgnd_SalesRevenueMilestone_documentation_en-US" xlink:label="lab_lgnd_SalesRevenueMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesRevenueMilestone" xlink:href="lgnd-20231231.xsd#lgnd_SalesRevenueMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SalesRevenueMilestone" xlink:to="lab_lgnd_SalesRevenueMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_b2ae3341-656a-4c5e-9b2d-fed2d7530de9_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and other identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodOneMember_4d9014b1-1842-4217-bf4c-3635d6281bd9_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/8 on the six month anniversary of the date of grant</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember" xlink:href="lgnd-20231231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodOneMember" xlink:to="lab_lgnd_VestingPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_9898fbe3-efb1-4d2e-be14-f884222e171d_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsGross_094cbcef-6651-4bda-88fd-7bbc0735861a_verboseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsGross_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Gross</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsGross_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsGross" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsGross" xlink:to="lab_lgnd_CommercialLicenseRightsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_9f7a8dac-3acc-421a-a72c-b4717ca42152_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_f582697a-4831-40b2-80c1-173bafaf8de1_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less tenant improvement allowance</link:label>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_7bb595ef-4f4c-43e0-bfe8-ff72e356b998_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$66.70-$68.74</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSixMember" xlink:to="lab_lgnd_ExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f919f1d0-9420-46f3-9883-92b3a7e5e4c5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_91156b9a-14eb-4bb9-ab6f-d4142350a14a_terseLabel_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi</link:label>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_label_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi [Member]</link:label>
    <link:label id="lab_lgnd_SelexisAndDianomiMember_documentation_en-US" xlink:label="lab_lgnd_SelexisAndDianomiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis and Dianomi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember" xlink:href="lgnd-20231231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisAndDianomiMember" xlink:to="lab_lgnd_SelexisAndDianomiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1e0c5dbc-e4c1-4a53-a7f3-07811233a0ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_90f73554-2943-4065-a286-e0fedb5dd6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_800ee2ee-ce76-43f0-8697-4ea1d51b98af_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bfe08a32-a658-4fe4-b261-6b7b231670b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ee379778-be60-4ce3-b680-677c4b1db6e4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3062dbbc-0a5c-4449-b3ac-efca17e2a4d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9fa460fc-8acd-450f-a1ea-ef5606c6c0c1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e1aa2feb-2e57-49ce-8497-80545efc998f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0863490c-fff2-4b6b-83bf-85c5244f34e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_770ffa5d-3023-4093-997c-0fedbd5a08c6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ee1a1ed6-0954-4d1d-a33b-02927267c9c8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c9c416d4-b07a-4e6d-b114-c76c6d9bfcd2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment , gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_bf709e1c-49a9-4aaf-873d-90d683c3d3d5_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_7fc10ccb-2dab-4e1d-95ef-9df31122156c_verboseLabel_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:href="lgnd-20231231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b065216-1fb5-48ae-8f2a-4955a161b188_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_d122223f-74fc-4f32-b403-999e9cfffa91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_da2c96cb-88e3-401c-a852-9e38b4fb48e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_df8e4d69-e843-4f40-a315-d8e2a711fcbd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquisition of equity due to 2023 debt extinguishment, net of tax</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c7428f92-543d-4956-8545-22635753a06f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_b6c2727a-85a5-4582-b4b6-768798738d81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ed2c4786-ff1d-4efd-9476-5a6d0bc43eef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_534c9007-7f9c-44b8-909c-97d288932f8b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_52f6dc4e-b773-4891-98f6-c25befd40105_terseLabel_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from commercial license rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ProceedsFromCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:href="lgnd-20231231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProceedsFromCommercialLicenseRights" xlink:to="lab_lgnd_ProceedsFromCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_6c9672d9-421d-4c18-b2bc-db0b0070f09d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55aca0f9-d28c-4a4c-888d-c54ece27a9d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_4e14e6e4-cd58-45fd-9b50-c192e5f9d726_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Activities [Abstract]</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_191b2d4e-caac-475f-b219-367d149cae98_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15c444c1-27aa-46cb-8f75-f0e1ad4b9003_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Updates, Recently Adopted and Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfDerivatives_35318e28-a92b-4923-b027-4ef4294fa680_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfDerivatives_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfDerivatives" xlink:to="lab_us-gaap_GainLossOnSaleOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_314924b5-43c7-4da5-bf4b-25fcb180bd7d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_da622226-38fa-4e8c-b664-e0ef771a6b69_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_658ecaf6-9edd-49b8-b7e1-0c66e46d3e93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4c4c03a4-3f8d-4d7a-a834-be420f21dd7a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_339396f1-d401-41f0-9ff1-b4cb88086e2b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_69872e77-8d2b-4cd5-bb46-21dc3b4c8cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2df68dd8-5326-45e6-a3aa-28e7be3c41c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5bc14bbd-0ff5-4ba6-98b2-487ce2b90b1b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bb726d43-64b5-4be2-8790-7fd3644d6637_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0d5d55a5-8265-4daf-8a31-43d4cdbe7cfe_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1b65d0ab-3a2c-48cf-b0ee-2f41460bda9a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8d3b0720-4552-4b20-b91e-0298bad12109_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_92ae3b25-23ee-4121-a55f-bd62ea2a5ea9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting right (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0b025497-7f66-4394-be50-3386a547799a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fbde9ec1-cd07-498e-a53d-09d82df90a21_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_5d1405cc-bc29-40ca-a421-36b3ef6ee502_terseLabel_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_label_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:label id="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_documentation_en-US" xlink:label="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Commercial License and Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:href="lgnd-20231231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:to="lab_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e40dbc67-0817-436e-abcf-31ca9310d3a8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f6b8dd8f-d1ae-4c6f-a3bd-b5f51d8a474c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss from discontinued operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_f5fc663a-7e46-4278-8a60-0678ffbe697f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_b34c083a-99f2-4ede-b617-8eb26c8dc935_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6934b14d-7988-4d02-a997-c5944b878e5d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6e584243-9790-43a9-abb9-d46547cce741_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9a2b324b-0e7d-4f85-9b1d-9ec078b2e50d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_56eadcf5-6010-4c6f-94c7-e3ca830778a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:to="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_99ba83fd-46fc-4624-acb2-9765a4bfba93_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SalesContractInterestInSalesRevenue_cf028fb1-87b5-45bb-a1ea-a3cc80386b88_terseLabel_en-US" xlink:label="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in sales revenue (as a percent)</link:label>
    <link:label id="lab_lgnd_SalesContractInterestInSalesRevenue_label_en-US" xlink:label="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Contract, Interest In Sales Revenue</link:label>
    <link:label id="lab_lgnd_SalesContractInterestInSalesRevenue_documentation_en-US" xlink:label="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Contract, Interest In Sales Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue" xlink:href="lgnd-20231231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SalesContractInterestInSalesRevenue" xlink:to="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_2a376617-28b5-41ed-ac2c-9494aa822f39_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_af98a21d-c9c7-4c61-af81-52e3940f1472_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_197d23e3-2d96-4f0b-9215-bc208f0dd09c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_950becfb-c53c-427a-a62c-0614bf854ead_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c509a624-5e2a-4909-b572-7dc64d349ae8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11c605e4-fc4d-4ac6-8689-e166117d9fc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_052a18a4-ea13-4d33-8223-a6fe4300419b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cf2404f9-3a83-4abb-bc0a-919fc0fc46df_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_dc1fb7b1-4161-4f33-89a8-52054bbaec0e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_61c75885-d83e-456a-bb3a-19bea8e36041_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_3b68a88f-54c4-4072-8bcf-452c1bf199a7_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_79d8f812-0222-4866-927e-bf6e71ef0c9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_25c7cb73-4c33-4de7-b5d3-25f235e37e45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_4e9b9ee7-367e-4f2e-b5b7-2063133e03c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_515533d1-b046-495b-a959-a97ae6f3bd04_totalLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Contributions</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59205a23-509c-4959-9216-b90dfff5257d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_942c7e0c-db92-4643-bb53-f79faf481775_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneAxis_a843ba96-9c74-4dd9-bbe0-89c85d5e3f6a_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_lgnd_MilestoneAxis_label_en-US" xlink:label="lab_lgnd_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_lgnd_MilestoneAxis_documentation_en-US" xlink:label="lab_lgnd_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneAxis" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneAxis" xlink:to="lab_lgnd_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConsiderationClassficationDomain_c6315430-4ea7-4cda-8b57-b3f9f4ca1db9_terseLabel_en-US" xlink:label="lab_lgnd_ConsiderationClassficationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Classfication [Domain]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationDomain_label_en-US" xlink:label="lab_lgnd_ConsiderationClassficationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Classfication [Domain]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationDomain_documentation_en-US" xlink:label="lab_lgnd_ConsiderationClassficationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Classfication [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConsiderationClassficationDomain" xlink:to="lab_lgnd_ConsiderationClassficationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fcbda76d-6c00-4337-9e2f-f18f0173f068_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_dadb7849-8ebb-41f1-af90-8036b3bebef1_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a1865f13-495d-4eb1-8188-139374cb492d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_d253f5a4-2242-438c-a068-7955cfb7d67b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_67437f15-a85e-4c5f-bc8c-972844befad4_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8ea5adce-29f0-4e01-98f2-8d8f3bb56aac_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_42778813-f613-4d6d-b932-92c504f3b633_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_e6a60c95-fe09-4ba3-b1ab-c20766df5d0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock_6e2dcd8e-d603-4ca3-83e4-5a847a2c4060_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commercial License and Other Economic Rights</link:label>
    <link:label id="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Commercial License And Other Economic Rights [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Commercial License And Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" xlink:to="lab_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_fd3cd402-428e-46aa-b492-4b87b09f358a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-Known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxAssetsAdjustments_bdabb5f1-4f71-40c0-b915-b0de1ce93e8e_terseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset adjustment</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsAdjustments_label_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Adjustments</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsAdjustments_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsAdjustments" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxAssetsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxAssetsAdjustments" xlink:to="lab_lgnd_DeferredTaxAssetsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cbbf4b8-beeb-49cd-bae0-d44e1086c123_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_d99d9da0-3af8-48d8-95b0-fca9a7c57096_terseLabel_en-US" xlink:label="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commercial license rights purchases</link:label>
    <link:label id="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commercial License Rights Purchases Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commercial License Rights Purchases Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:href="lgnd-20231231.xsd#lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:to="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_81e29ff7-1ae5-41cb-aa2f-4693fdbfab08_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_88e44bcd-0251-4294-b304-b23356fd2017_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_90014028-13c2-4a04-8b09-137c111092bb_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period of royalty agreement</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_label_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:label id="lab_lgnd_RoyaltyAgreementExpirationPeriod_documentation_en-US" xlink:label="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyAgreementExpirationPeriod" xlink:to="lab_lgnd_RoyaltyAgreementExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_b655665e-8f44-46b3-bbd3-e403427b5497_terseLabel_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_label_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Shares [Member]</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="lgnd-20231231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:to="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0c0e6fd8-5a86-4710-b13b-163153313df8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_820120f6-bf70-43df-b5a2-9adcb7657fb9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AuditInformationAbstract_label_en-US" xlink:label="lab_lgnd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_lgnd_AuditInformationAbstract_documentation_en-US" xlink:label="lab_lgnd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AuditInformationAbstract" xlink:href="lgnd-20231231.xsd#lgnd_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AuditInformationAbstract" xlink:to="lab_lgnd_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_f903395c-4ca8-4e1b-abda-a491fdbf0cc4_terseLabel_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2002 Stock Incentive Plan</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_label_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand Two Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_documentation_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand two Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:href="lgnd-20231231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:to="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4df847ab-1221-4f42-b679-b7bb4fe0979a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_31c47d51-37cf-4ec1-86b2-668f0bb51423_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EquitySecuritiesAllocationMember_783d00d6-f2d4-4afd-a600-970ca1e3a91b_terseLabel_en-US" xlink:label="lab_lgnd_EquitySecuritiesAllocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_lgnd_EquitySecuritiesAllocationMember_label_en-US" xlink:label="lab_lgnd_EquitySecuritiesAllocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Allocation [Member]</link:label>
    <link:label id="lab_lgnd_EquitySecuritiesAllocationMember_documentation_en-US" xlink:label="lab_lgnd_EquitySecuritiesAllocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquitySecuritiesAllocationMember" xlink:href="lgnd-20231231.xsd#lgnd_EquitySecuritiesAllocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EquitySecuritiesAllocationMember" xlink:to="lab_lgnd_EquitySecuritiesAllocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b866ddf1-7d1b-475e-8a3c-46b83fbeed09_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_f3c35c40-3833-42a0-945a-ccb227ba5df2_negatedTerseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in debt discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:href="lgnd-20231231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:to="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b442c84b-ee3b-4f11-a9a7-a858aea83be3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_95baba66-d5bd-4ce3-8cd7-51da99655021_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c20d5b1a-c44a-4af7-aa7d-b4e28e32e1e5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_12b88012-9bff-420c-811a-25dfc5c29ed5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_5cb5535d-4976-42fc-910b-77259ac12fb2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_8508831e-ac97-43a9-8d83-ac4a274b27fc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_56e69b7d-44c4-41cf-a059-e4616631f386_terseLabel_en-US" xlink:label="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease assets</link:label>
    <link:label id="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_label_en-US" xlink:label="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification</link:label>
    <link:label id="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_documentation_en-US" xlink:label="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:href="lgnd-20231231.xsd#lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:to="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_b5510634-6ffb-46ad-a012-a492b09dadae_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_62357568-ef1c-4007-850c-07e62d00d2dd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_1ad960c6-ffc0-4ec6-ba66-d53771e1d908_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f1ffbdb9-3093-4bd8-a12d-39a1a21f06b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_377e0979-ebb9-4e01-91f0-e0172f8c7785_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bb4ac3c1-84c4-4875-8f79-74e11646d914_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e53428d1-b7c6-4b2b-a34d-8b06cf539f32_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_31a89741-6121-4d5a-b6a5-c722601c9d82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_804185fd-370d-4072-a016-b38438f417f0_negatedTerseLabel_en-US" xlink:label="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less tenant improvement allowance</link:label>
    <link:label id="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:href="lgnd-20231231.xsd#lgnd_OperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a14e12db-75f0-4e44-8025-225836269db9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used) provided in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_36163bb0-161a-405e-ba97-5795a72cbb84_terseLabel_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contingent liabilities</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Portion of Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:href="lgnd-20231231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:to="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_050ff375-c42d-4cb8-ba24-aaf796c5337c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_73bba47a-7d69-4849-a3dd-d1b56bad0208_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6062bd72-b102-4ab2-81e1-6230900f98ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_1c00301a-9751-4277-b279-0a742fa9da2c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContracts_ab475300-4038-4547-b8bf-62cef6c471b0_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contracts</link:label>
    <link:label id="lab_lgnd_NumberOfContracts_label_en-US" xlink:label="lab_lgnd_NumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contracts</link:label>
    <link:label id="lab_lgnd_NumberOfContracts_documentation_en-US" xlink:label="lab_lgnd_NumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContracts" xlink:to="lab_lgnd_NumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NovanIncMember_48396e17-2d4d-4b43-a7fa-891790cc6017_terseLabel_en-US" xlink:label="lab_lgnd_NovanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan, Inc.</link:label>
    <link:label id="lab_lgnd_NovanIncMember_label_en-US" xlink:label="lab_lgnd_NovanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_NovanIncMember_documentation_en-US" xlink:label="lab_lgnd_NovanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NovanIncMember" xlink:to="lab_lgnd_NovanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_78e3fc6f-e176-4e57-b7b4-30cd73e63dd5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6d46e53f-8fc4-486c-9b99-1a997d7f9e35_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1fa563ba-c5ed-46a5-be10-fca00f7a0d6d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_00b55055-26d7-436e-87df-454b4f04d1c8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5e1fe0e6-1217-4775-923c-dbfea5df3bbd_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_715ef228-72e7-4a6c-8e9f-98e9f5ba5bb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_5edbb34e-75f1-4520-ac62-f4b20ae5e0e9_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e8e47ef0-2da3-4a5e-b17e-617fa79ac678_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_b8274e0b-1d0f-4538-a53f-3f6d9eb008da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_dff58c2f-e547-44c4-99c3-29df383f76d1_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision to return adjustments</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_ebb1871d-5dd5-461c-819b-a41627d08e68_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_38205871-41a4-4ef5-b76a-715cbd2dbd57_terseLabel_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating and Finance Lease Assets and Liabilities</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_90b809a1-561a-4ef5-88da-3a000d885791_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_eccd526d-f0a4-489a-9aaf-7ba7177a61a4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_d7031a1d-96cf-41a5-a1d1-a2381ef776c6_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$54.81-$58.28</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFourMember" xlink:to="lab_lgnd_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_c64233f5-00d9-4bfd-b49a-776c45c8f635_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_40504852-e338-4998-ae55-2552b5dc649d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_5503eed4-5b9a-4036-a7ef-06b2db32a6bd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7d62df99-0e93-4336-99ce-b3d37d893bd6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_de7c73ca-3733-4b36-9456-33771b364f20_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_c8743894-96f6-4353-8934-08239e149be5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_a6291ce8-b5ec-4fdf-84ad-f5029cb34557_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2023 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:href="lgnd-20231231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:to="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0ac1a2a7-168e-420c-b026-ce90dfa4db07_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4afc4d91-7ce0-435e-b696-90ee0b4a1c04_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_2bb8f5e0-c9db-46cc-9129-4d1dcd9ccd49_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_023b4608-3c1e-4f6d-9b95-e9f17cff9fc8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_59aa1ee7-d74e-4048-9c9f-825d318a9d17_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Significant Partners</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_12fdc37b-9d8e-472e-9c10-63f44ecbbb0e_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_2f2e983d-607a-4553-843f-70c7b9727a36_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of commercial license rights</link:label>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for Commercial License Rights</link:label>
    <link:label id="lab_lgnd_PurchaseforCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase for Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseforCommercialLicenseRights" xlink:to="lab_lgnd_PurchaseforCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_33089c15-77ea-4bc2-afe1-3569957324eb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_1401ad4b-9d58-4e26-ab39-dd536bb36eef_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_71c6b87e-554e-4937-adc1-6e7a86d3ce93_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dd616913-5eb8-411c-9d45-7582040e1a71_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f544f733-9c4e-4d9c-a811-b983dbc27fd3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current expense (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f158f0e2-3ab0-41db-943f-f41a5081709e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_19ce3287-e736-45dd-8e57-4b0361499075_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final tax impact of OmniAb distribution</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Tax Return To Provision</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Tax Return To Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_85f2f554-03bf-408e-868e-29eb993ccd50_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cacb9486-5f29-4a9c-8cf8-23c73e9345b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2339de75-bbaf-4e95-a808-2b891174c6bd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_ceca9acd-5af9-47f1-b3eb-c89e8024705e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ImpairmentOfCommercialLicense_7039dd9f-e3a0-4a03-aea5-3252eb0fc333_terseLabel_en-US" xlink:label="lab_lgnd_ImpairmentOfCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of commercial license rights</link:label>
    <link:label id="lab_lgnd_ImpairmentOfCommercialLicense_label_en-US" xlink:label="lab_lgnd_ImpairmentOfCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Commercial License</link:label>
    <link:label id="lab_lgnd_ImpairmentOfCommercialLicense_documentation_en-US" xlink:label="lab_lgnd_ImpairmentOfCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Commercial License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentOfCommercialLicense" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentOfCommercialLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ImpairmentOfCommercialLicense" xlink:to="lab_lgnd_ImpairmentOfCommercialLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_d08cf45b-8aa0-4376-ad93-ab42e0199819_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received as consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share Consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1749c347-d985-4ec7-8b1f-787885c6cf23_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9770b3b0-b4da-42ca-b371-095acc2d43fe_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3bdee720-6495-4a53-81c6-b1206288a216_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_82ea98b2-19c8-4cbb-8e4b-2ed8c4a4a879_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_774090a8-a9ae-4e72-9375-c348ca288cf7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_7ce6d0f0-232a-4fa4-9547-8d8c87d24b50_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition, net of cash acquired</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d25f918d-3a02-4de5-b2b9-8dbdb3582759_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of fixed assets and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_169af57d-c018-4e19-8617-5167590976e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent_f911a130-550d-49fb-b04a-e793bff5961e_terseLabel_en-US" xlink:label="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent_label_en-US" xlink:label="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits - Noncurrent</link:label>
    <link:label id="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent_documentation_en-US" xlink:label="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits - Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:href="lgnd-20231231.xsd#lgnd_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:to="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_acd5e142-cf94-408d-8a50-13702aa6fa1a_terseLabel_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year:</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year [Abstract]</link:label>
    <link:label id="lab_lgnd_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:href="lgnd-20231231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract" xlink:to="lab_lgnd_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_6b108d24-9599-4c17-b72f-6dc9812d23cd_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_aadfea96-4314-4c24-98f7-86c50270996c_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_8941ec33-d247-45ff-a264-5e709fcce364_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8f900e86-a67c-4294-940c-6a229c86135c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_33d1d89d-bfdc-418b-b003-3c129797c563_terseLabel_en-US" xlink:label="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Spin-Off And Migration [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Spin-Off And Migration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_BusinessSpinOffAndMigrationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:to="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerCMember_3ee6ab7e-1724-4dbf-85b0-01d3ca954868_terseLabel_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C</link:label>
    <link:label id="lab_lgnd_PartnerCMember_label_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:label id="lab_lgnd_PartnerCMember_documentation_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember" xlink:href="lgnd-20231231.xsd#lgnd_PartnerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerCMember" xlink:to="lab_lgnd_PartnerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5f6f0a79-afb6-49f7-83c2-f54fedc87577_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9abc9fd8-86f6-40b1-8053-5e0e8d962cf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ba29015c-79ff-41db-9a66-98977d1c47bb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e10ed0d9-d0eb-4a75-88e2-db0d698bc2cd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_10134209-e352-4a33-ac50-cf7ee4469fe2_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$103.42-$103.42</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeNineMember" xlink:to="lab_lgnd_ExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_46dc4e96-1d76-4aa8-9f35-9e2ef47dbdcb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_0ce77e02-7f3d-4090-b28f-451a7dab9556_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest 1/48 each month for forty-two months</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember" xlink:href="lgnd-20231231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodTwoMember" xlink:to="lab_lgnd_VestingPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_63d05517-8c0c-4b7b-89d6-59406d032d99_negatedLabel_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of contingent liabilities</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_label_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:href="lgnd-20231231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:to="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9d0fbee2-a842-4b6a-abae-29fa42c53859_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_cb91b8c2-01b1-46bf-9cf2-7c9ee8acfc8f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_8e05fe38-b279-4676-9119-b0e553502448_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_27968429-0f08-4dd7-b056-30770848d2fa_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant and bond hedge unwind transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aeeaa21f-2024-42b2-bd1f-c32963f31750_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_d3983d12-4fab-45b9-a91d-0c82690c435b_terseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:href="lgnd-20231231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:to="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_bc60220e-5066-4e2f-994c-869f4489071f_terseLabel_en-US" xlink:label="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued debt issuance costs</link:label>
    <link:label id="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Debt Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Debt Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:href="lgnd-20231231.xsd#lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_226d977d-a10f-4a42-81a0-4a9b614c7f8a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_70c6fc80-ab71-4f0d-94ef-7f033bf25a83_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1efaab22-543d-4dff-91b1-0ba021fedb2f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_6fed1097-b448-4fff-b119-03974eec4816_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Captisol</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5bfbb50b-5623-4dab-9656-7a4b64bd3f4b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f43c04c9-2cf8-49f8-92d4-26d1bf0e1e27_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8c397ef2-3ddf-4d84-a721-f4c22a34d588_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseImpairmentLoss_ffae46b8-18e3-4556-b87e-3efe44e0c00b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, impairment charges</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseImpairmentLoss" xlink:to="lab_us-gaap_FinanceLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_79176938-7a6e-477f-88dc-2aa51619fdf8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bc2f27c6-de48-4755-b375-a46b14f66551_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_1324a4d3-1f29-4fa5-9b9d-ee8efe566221_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod_487ce0db-42ce-4af3-b79e-8101fec43c12_terseLabel_en-US" xlink:label="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Offering Period</link:label>
    <link:label id="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod_label_en-US" xlink:label="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Initial Offering Period</link:label>
    <link:label id="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod_documentation_en-US" xlink:label="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Initial Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:href="lgnd-20231231.xsd#lgnd_ShareBasedCompensationInitialOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:to="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_f71e1e24-5f39-4dbf-9d88-bba8bc70822c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_b611b837-e86e-4044-873e-5108908b8f8a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets with fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_57f21f21-ddb7-4372-a938-cc2d9ba691ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4a2e37d2-3344-4ef7-8372-f5eb27caf5b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments, Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_90da5be9-c82a-4eca-a4a7-df507ded960e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_65e4536f-093e-4bc7-830a-2592f2adea44_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of the Consideration</link:label>
    <link:label id="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Fair Value Of The Consideration [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Fair Value Of The Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:to="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1b2b4905-9b2c-45f8-874a-f88d16ba62e8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4de964f4-fc9c-4dea-a17d-d4f90f413983_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e30de331-34c4-4f4c-ac31-56f2f2af9b56_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_f3d67460-7ff9-4c90-9384-829c2e50557c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OvidTherapeuticsMember_1716e1b4-689d-4d18-9631-68af658686f5_terseLabel_en-US" xlink:label="lab_lgnd_OvidTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ovid</link:label>
    <link:label id="lab_lgnd_OvidTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_OvidTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ovid Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_OvidTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_OvidTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ovid Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember" xlink:href="lgnd-20231231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OvidTherapeuticsMember" xlink:to="lab_lgnd_OvidTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ca9c4eb1-5b83-447a-9381-14e34a5c0acb_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_6b7388fe-e8c5-4a0a-a708-b53cac369ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AtTheMarketEquityOfferingMember_4650df58-3658-4630-aae4-8de923f3d8b9_terseLabel_en-US" xlink:label="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The Market Equity Offering</link:label>
    <link:label id="lab_lgnd_AtTheMarketEquityOfferingMember_label_en-US" xlink:label="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The Market Equity Offering [Member]</link:label>
    <link:label id="lab_lgnd_AtTheMarketEquityOfferingMember_documentation_en-US" xlink:label="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The Market Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AtTheMarketEquityOfferingMember" xlink:href="lgnd-20231231.xsd#lgnd_AtTheMarketEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AtTheMarketEquityOfferingMember" xlink:to="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f862203a-7e87-43f0-9a62-c665fab98662_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0ad5b0fe-c280-40dc-8db9-4ce517572fb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_9b581c92-10b0-42f6-b746-08f22ff9ef62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1908e581-a10e-4167-8a5e-dceac5970984_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a60aa8d6-40f3-4e58-9309-402cdacc37ce_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_25621edc-a920-4df4-b58c-5b1521c057ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6571d646-af19-4356-b956-f6e84c34bdb8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_167fad85-5bfb-4ebd-9918-266b97d63d0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies: Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4648de31-8239-4b3f-bce3-39e763fa0eba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income (loss) from continuing operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c77a8ce7-e0ee-4bc5-ba3f-07e458878983_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fd05e83f-1f47-4d46-97ff-16f41c8305ae_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retain earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9a7afd95-b2f1-42c9-8a12-f9103dcc9a6d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_c6eb39b3-cdb0-446c-abf8-1e3e72099e6c_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:to="lab_lgnd_CommercialLicenseRightsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ab7ecb79-e9b7-4f1b-86d4-c0252c5b3251_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_a037cf45-23f0-4781-a55a-5dc95627b79b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_082ac137-c5ce-4f2e-8f39-25c4878bcfe5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_210a20c0-1c48-484d-ab42-e0919f93b7cf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_362fef31-c904-441d-9d9d-27105db39769_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of CVRs issued from each CVR series</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_label_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:to="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_599ccfd3-72cd-4bfc-9802-f933bf32a692_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7c20d66b-ef94-4b30-8c59-d7e1e3dcfe01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued in public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_558cd50d-4bf8-4b10-bb24-503d7065f278_terseLabel_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of forecasted cash flows (as a percent)</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_label_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted Cash Flows, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:href="lgnd-20231231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:to="lab_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_066411d4-cf4e-4fe9-8ee6-94ef10c613cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_8d500ff4-54f5-44d9-aedf-c85bbfb120ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_3a64f043-57fe-47bf-abaa-682372ce5e65_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyprolis</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_label_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyKyprolisMember" xlink:to="lab_lgnd_RoyaltyKyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2f64dd31-f3fe-4eac-bacf-4385008c9784_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f567cb5-8961-4399-8b59-ecd5c118b076_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_a2113b89-ddbe-4134-8b52-e7e70bae640d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible senior notes outstanding (Level 2)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_0db6537a-e597-4f90-baff-60e03ba23566_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerAMember_ead2df9e-0433-402e-acb2-4a6d594dc1c0_terseLabel_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A</link:label>
    <link:label id="lab_lgnd_PartnerAMember_label_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:label id="lab_lgnd_PartnerAMember_documentation_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember" xlink:href="lgnd-20231231.xsd#lgnd_PartnerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerAMember" xlink:to="lab_lgnd_PartnerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AboveMilestoneMember_8b0a7893-ccc6-4da2-9c0a-1cb567c216e1_terseLabel_en-US" xlink:label="lab_lgnd_AboveMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Above 3 million</link:label>
    <link:label id="lab_lgnd_AboveMilestoneMember_label_en-US" xlink:label="lab_lgnd_AboveMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Above Milestone [Member]</link:label>
    <link:label id="lab_lgnd_AboveMilestoneMember_documentation_en-US" xlink:label="lab_lgnd_AboveMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Above Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AboveMilestoneMember" xlink:href="lgnd-20231231.xsd#lgnd_AboveMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AboveMilestoneMember" xlink:to="lab_lgnd_AboveMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_aee0ff16-b38f-48a7-bccf-f3bfa2bc7677_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_be7811a8-99e2-48ce-9681-84afa735c2e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_571c5258-6a12-4530-928f-e524c27f81a1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) of valuation allowance, change in amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_d8215946-e43d-48d9-b0aa-01c490504af4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_099fb9dd-6d97-4456-9c48-b8307ef00c98_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_c877bf7f-df2c-4e69-8cc8-69f75e00dbeb_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt repurchases</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:to="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_a515892d-6691-48a2-a552-14aacd47e3e8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0566a95c-3856-488a-beb8-35446ffd687f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9975d640-30cd-4072-acfc-561bf8cb56a8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_44eaddc3-b8b4-477b-bee0-ce5f5bd3221a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_fa503a7b-fcb9-4b98-9409-10b4ca6652fe_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_312ce23e-dc58-4ed5-9a40-be830f8cd2ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_64bfef39-9061-4a42-9827-9c28a3f754b5_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_66dc1df0-1c08-4fde-baef-38743a104889_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_23663b07-503a-47dd-9899-f9617e4bac57_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_212955d0-affd-449b-b67c-d974b54d6254_terseLabel_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_label_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio [Member]</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_documentation_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:href="lgnd-20231231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:to="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7763aece-e3e7-4756-9e9c-24c94163aaba_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_734afa76-235e-438f-94f5-ed555171fa9b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ImpairmentLossOnCommercialLicenseRights_d9c3ecb4-a1b4-4991-8deb-3cc939ce59eb_terseLabel_en-US" xlink:label="lab_lgnd_ImpairmentLossOnCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss of commercial license rights</link:label>
    <link:label id="lab_lgnd_ImpairmentLossOnCommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_ImpairmentLossOnCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Loss On Commercial License Rights</link:label>
    <link:label id="lab_lgnd_ImpairmentLossOnCommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_ImpairmentLossOnCommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Loss On Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnCommercialLicenseRights" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentLossOnCommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ImpairmentLossOnCommercialLicenseRights" xlink:to="lab_lgnd_ImpairmentLossOnCommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_9b946f24-e3a2-462a-b3f3-79cbde16322a_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests disposed (as a percent)</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_57ff5fb1-c8a5-4585-b62d-9ac57b347be5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upper range of exercise prices (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationLoanFeesAndInterest_1a177021-1448-45aa-8438-f3a38ea3c187_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DIP loan fees and interest</link:label>
    <link:label id="lab_lgnd_BusinessCombinationLoanFeesAndInterest_label_en-US" xlink:label="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Loan Fees And Interest</link:label>
    <link:label id="lab_lgnd_BusinessCombinationLoanFeesAndInterest_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Loan Fees And Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:to="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_802b0646-dfe4-4f3e-bf27-fb60908aea58_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3c762945-cb47-4047-aefe-db721e6c76fc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_003775f5-dd2f-4a04-a1da-974961e4d861_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_db62e7a5-3d1c-493f-9aca-ab044f1c8b1a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_60f3acea-3152-4e63-bc46-d06159c67690_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate of finance leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ff1ca84f-f5aa-462e-80f6-af20e43e8c02_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5abb2afb-51a4-46eb-8b0b-7390de676e04_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisMember_fad5ed03-9c80-46f8-8adb-9bb29d3971f4_terseLabel_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis</link:label>
    <link:label id="lab_lgnd_SelexisMember_label_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis [Member]</link:label>
    <link:label id="lab_lgnd_SelexisMember_documentation_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selexis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember" xlink:href="lgnd-20231231.xsd#lgnd_SelexisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisMember" xlink:to="lab_lgnd_SelexisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_f2d4d283-f8d2-4d5b-bfd3-545a0ad654ce_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_d297caac-da7f-4687-aba8-cd136d4cb5d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_79ea1006-2d59-4f43-9fc9-92856888b2cb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_fc5b9bcb-1492-488c-bca6-97a3f0c1adc8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_ce5b5a17-31b3-4e0e-94cc-7425a05cb963_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4dfd0d13-f8e5-46c8-ba37-3a3a9d647531_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyTeriparatideInjectionMember_977008a0-5566-43e8-a08c-a2bb03a4d197_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teriparatide injection</link:label>
    <link:label id="lab_lgnd_RoyaltyTeriparatideInjectionMember_label_en-US" xlink:label="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Teriparatide Injection [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyTeriparatideInjectionMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Teriparatide Injection</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyTeriparatideInjectionMember" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyTeriparatideInjectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyTeriparatideInjectionMember" xlink:to="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_9c2e1d88-143b-4f33-b8c3-7bdd0996b337_terseLabel_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_label_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_documentation_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:href="lgnd-20231231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:to="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_41441c3a-a130-4999-be1d-2d93c2385307_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ade71e6c-5a7f-41e6-b33b-42007187a43c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationTable_cc374b76-aa83-4a24-82e7-0cb7eb9c15c2_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable" xlink:href="lgnd-20231231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationTable" xlink:to="lab_lgnd_BasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e45c3655-6dd6-4360-9fa4-10cd0c7f31c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_af6c0604-c927-4070-b190-e03fde304ef0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_91744c06-ea62-41a7-8aa6-da79e8ba1daf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CyDexMember_a5abc0f0-9432-4d55-971e-7d986eaad2ad_terseLabel_en-US" xlink:label="lab_lgnd_CyDexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CyDex</link:label>
    <link:label id="lab_lgnd_CyDexMember_label_en-US" xlink:label="lab_lgnd_CyDexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CyDex [Member]</link:label>
    <link:label id="lab_lgnd_CyDexMember_documentation_en-US" xlink:label="lab_lgnd_CyDexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CyDex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CyDexMember" xlink:href="lgnd-20231231.xsd#lgnd_CyDexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CyDexMember" xlink:to="lab_lgnd_CyDexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ecf684c9-ac0f-4c7c-9965-4e3a866857c9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRights_670ad678-ac53-4d66-b073-7e851caba97d_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial license and other economic rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_8a386025-04de-4ca0-98bd-80e8e33af929_totalLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRights_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRights" xlink:to="lab_lgnd_CommercialLicenseRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_73eb5855-8a60-4fae-83ce-5c4833dc7cd1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_1282e17a-1fd9-4f04-9a26-b7044df23741_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc1ef669-1dd6-45e0-99db-cff93fb3925c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DemandDepositsMember_e479b7c4-29ae-4c2c-82b6-b3d03d18dc1e_terseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank deposits</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_label_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Demand Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_eb242671-9d1c-4929-abd3-2bda5de58c71_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_87b30965-e8b8-4f3d-a1f2-16212a608931_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for Novan acquisition, net of restricted cash received</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4b26a6a5-151d-41fb-aed9-478f1f79db9d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for Novan</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2c30b24a-8cb4-4f1c-bfb2-e9fa43c17847_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for Novan, including restricted cash received</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_a84b2d6d-ac25-4926-9bd9-d6f4b4b25b12_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subpart F income</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Income</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_770a7dcf-7c4a-4669-b8f2-7c8e1d8bc724_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_5300bcc3-878a-4fc9-826d-3a669ec3341b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares allowed to purchase in employee stock purchase plan per employee (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsImpairments_297f94f5-3c69-4f49-b7ba-16ec30b9f143_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsImpairments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible asset accumulated impairment</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsImpairments_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Impairments</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsImpairments_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsImpairments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Impairments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsImpairments" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsImpairments" xlink:to="lab_lgnd_CommercialLicenseRightsImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1d935c80-2487-4886-a406-7e3261e9834d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_9e244e3d-4534-487e-99cd-5ece1aa89e71_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR holders and other contingency payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_be8bbdb9-e8ca-4bf9-b784-f435fdc7ff14_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to contingent value right holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:to="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7de665a6-bf64-49dd-9791-eb4f8d23622a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_fa01054b-98c1-44e6-88fb-1885321bdbb3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization_e8f56250-6bef-4074-bb38-d8c861c2ad64_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Accumulated Amortization</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsAccumulatedAmortization" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsAccumulatedAmortization" xlink:to="lab_lgnd_CommercialLicenseRightsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_eda070b4-0862-45b9-8f2a-a2b0417ca14b_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_label_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward" xlink:href="lgnd-20231231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilityRollForward" xlink:to="lab_lgnd_ContingentLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsForSeparation_444dbf6b-c1ba-4fc7-9ed5-c9e8a55ef8e7_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsForSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash transferred to OmniAb at separation</link:label>
    <link:label id="lab_lgnd_PaymentsForSeparation_label_en-US" xlink:label="lab_lgnd_PaymentsForSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Separation</link:label>
    <link:label id="lab_lgnd_PaymentsForSeparation_documentation_en-US" xlink:label="lab_lgnd_PaymentsForSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsForSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsForSeparation" xlink:to="lab_lgnd_PaymentsForSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_813ab675-a7d5-4d31-91d3-58e427a10ebf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a63eddd3-462d-4225-b3c2-e37f8059b7d8_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_babc69fc-a05c-4aee-ab2e-09a25e17c869_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset recognized</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_f4d5aa98-0c32-43da-bb72-96f563997d7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_e94b790c-1a33-4c3d-971f-81472a89f1e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e8818523-7081-40f7-9144-4a95f03d083c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_97b20101-cae7-4a0d-b76c-5f481278dda5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_453f4b7d-a255-4041-b423-bf918df3a7c3_negatedTerseLabel_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) short-term investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_label_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_documentation_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments" xlink:href="lgnd-20231231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_GainLossOnShortTermInvestments" xlink:to="lab_lgnd_GainLossOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_192a9272-c128-4f05-9cc9-d364d0e5cb92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses from equity method investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_26767ef4-4864-4c07-bbc3-ff0996e084df_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_2cf8de7d-68a3-4c3c-8d04-3e4dce5abc2b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_d41f6f57-ab59-4e6c-a357-841e7c77e41f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_05f800cc-b09d-497f-ace4-c309bc33e9d8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_25efdacd-cc36-4bfd-9585-63d1f687acd5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_05e7fb3d-2818-4f85-80de-f9a781cc0355_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a8d89c03-d730-4909-886c-b3dae193432a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_d5b6a640-ef86-4895-a1f8-1bd58a67abd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SecuredOvernightFinancingRateSOFRMember_7bb7f2fd-dc14-4264-a8f8-8c100da886e0_terseLabel_en-US" xlink:label="lab_lgnd_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_lgnd_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_lgnd_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_lgnd_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_lgnd_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SecuredOvernightFinancingRateSOFRMember" xlink:href="lgnd-20231231.xsd#lgnd_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_lgnd_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_8961be26-d589-4138-be67-351cb0d4f073_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative assets</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisMember_b58d68e4-bc49-4fcd-acb9-338e18953ab5_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisMember_label_en-US" xlink:label="lab_lgnd_MetabasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisMember" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisMember" xlink:to="lab_lgnd_MetabasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_76c047ce-54ad-4acf-a1de-3c98b2feb6b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_40fde366-5c7a-40f5-bf74-afe83baec9be_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_320ee882-c430-41c6-a321-4d2a739fa585_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7436b249-190b-47b9-8666-b86339de7705_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_a926d91a-0cd0-4644-bead-06dbc544ea73_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_6b8c7f46-46de-45e6-bb4f-08bc762d6be3_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_1264b048-50c5-4989-a986-87e72fc94106_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e4305595-4d3a-440f-ad6b-f427308a5a8d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5e4977f3-3bc6-43aa-b343-e6cefa681d2c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6487aff0-df26-4383-9b69-5c7a844661bc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_5fd623a0-03a2-4085-86d9-f07cf5a72f36_verboseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_56d449f2-baaa-4eea-bf70-5ca04b3f631e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for OmniAb transaction costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d6d8e07b-8a20-4aa8-bae9-c162ea406349_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiability_3cb48bcc-1208-43d1-8e77-2de74a123522_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiability_label_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_lgnd_LeaseLiability_documentation_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiability" xlink:to="lab_lgnd_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_bea73c19-be97-45b3-8fe3-89fd98fc4399_negatedTerseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final distribution of OmniAb</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid in Capital, Increase Due To Separation</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid in Capital, Increase Due To Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4f848e68-a698-4a5f-ae2d-b1f0318a5428_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0eeb8f45-6117-4869-874c-ae6fb46dc820_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_cc2cef72-5cd4-454b-b6d7-581effff71bb_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) of allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b373b2c5-207d-4c1c-be38-37b3d2fae8be_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_7da498f8-5f6d-4595-8fd3-fee08df7824d_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ToleranceTherapeuticsMember_b579126d-8155-4ee4-9e3b-7de38cd2eecf_terseLabel_en-US" xlink:label="lab_lgnd_ToleranceTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tolerance</link:label>
    <link:label id="lab_lgnd_ToleranceTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_ToleranceTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tolerance Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_ToleranceTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_ToleranceTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tolerance Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember" xlink:href="lgnd-20231231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ToleranceTherapeuticsMember" xlink:to="lab_lgnd_ToleranceTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities_eaa92dbf-c29b-4f0c-9748-e6d1ed57ebe1_terseLabel_en-US" xlink:label="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities_label_en-US" xlink:label="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Non-current Liabilities</link:label>
    <link:label id="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities_documentation_en-US" xlink:label="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Non-current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherMiscellaneousNonCurrentLiabilities" xlink:href="lgnd-20231231.xsd#lgnd_OtherMiscellaneousNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherMiscellaneousNonCurrentLiabilities" xlink:to="lab_lgnd_OtherMiscellaneousNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_254142bc-8025-46dd-b47f-2c579544a872_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_87894de8-7c47-4a35-8716-78993569c062_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to contingent liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_a5ca2ac6-139c-4cc4-a889-4145cb3177ed_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_fb56cb07-a316-45ba-a92b-645f253e7ce7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f4120264-40fa-4f4f-8662-c2cd2b4679b0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_b79ba074-6ef1-408d-ab3d-e5a8eb400cad_terseLabel_en-US" xlink:label="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership interest (as a percent)</link:label>
    <link:label id="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_label_en-US" xlink:label="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Beneficial Ownership In Reporting Entity, Percentage</link:label>
    <link:label id="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_documentation_en-US" xlink:label="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Beneficial Ownership In Reporting Entity, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" xlink:href="lgnd-20231231.xsd#lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" xlink:to="lab_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_36b82e31-bda0-4f33-8c00-89c29c85b831_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fd55578-569a-4c60-83e0-13e8e2dd3d21_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d5d4ae8-a967-4294-b2da-50e3e68a6d26_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_83a89087-b395-4629-95f2-1ff1a7dc1666_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_01d4ca40-c541-4fa5-a0f0-7c20c5f8156c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6ef8de53-7fac-40db-8498-52c8a6b6e944_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3a2c48b9-7a50-46e4-b21b-976076f77b95_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_62824ec0-9789-4c52-a162-8ed5408ff226_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditure, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_0b257813-f8bf-487b-a6f9-94e15c8e640f_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Primrose transaction costs</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Cost Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Cost Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:to="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_0f3c33ec-b7de-4fd1-b35c-3a8a6c4c19ca_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss of commercial license rights</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f0392211-6654-4963-ac04-f5a349aed156_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3c171eee-0ce9-4dd3-9ce3-1a9555577a24_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d366e726-664f-4e73-9709-f7d2e9d982f0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_604b98c1-0a2d-4cf3-bc90-0f4bea4817be_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c08eb2f4-d10a-4b57-89e3-018eaba05652_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c9e3a6cf-2557-47d6-a61d-2b29146b8820_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_547e4938-1a50-482d-ac4f-46e875181291_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d035372e-54bc-462a-9107-36c09c9c3993_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_1328fde0-7835-424f-b8e9-d6fbe0b3f0f7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition:</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_c16c6987-703d-447d-a91e-1da5d1b889f8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1d65114d-a87a-4b72-adee-57ec25cc3fed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e9ea7a4a-a693-40d7-880d-3ef043dc2c94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2fd25f7e-1c4a-47f4-b8a0-578d90abd041_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3fa2b25d-ca19-45ad-a868-4fd7cbb329e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_99c92aff-0a24-4495-bd7b-21c90e97be1d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_17acd29f-5cf2-4bbb-af64-e2e37ea46132_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_795e6e7a-36eb-44bd-94ac-bd5baeebe7b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_850733d9-3e3a-4d7e-a02c-0c1560c597a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyRylazeMember_9924e201-52e3-4728-aaa5-f305fe44f6a1_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyRylazeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rylaze</link:label>
    <link:label id="lab_lgnd_RoyaltyRylazeMember_label_en-US" xlink:label="lab_lgnd_RoyaltyRylazeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Rylaze [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyRylazeMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyRylazeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Rylaze</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyRylazeMember" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyRylazeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyRylazeMember" xlink:to="lab_lgnd_RoyaltyRylazeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f699ff27-d5e9-40c6-89b0-8461b9c63425_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ad97c3c8-5895-4be9-9ac7-94ff635bca15_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e5f89a23-8537-4757-953b-7f5825061f1a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_83a36889-b66a-4003-a277-7605ff07cf3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_7654cab9-c2cc-41d1-a41e-62022aeb21e5_totalLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets sold</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Asset</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_5482782b-0f65-4239-920e-7d6938649e61_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 convertible senior notes, net</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf41a0d2-60f5-447f-9b53-ab59a329fe80_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bca1811c-1db9-4d89-bac9-265bce84eb77_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_61b4bf2d-8322-4ab8-ade0-8b1d9323d7a0_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8e21e628-5e03-4480-802d-f5827c95402b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c7e4f139-9753-445e-9203-0cfe35958341_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value per share of stock options (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e17ee497-8773-46cb-a1da-9f8ad2b9b4bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2631cc9a-30f2-4ff6-9ef2-7feb1431d420_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_ccad0413-aa1c-4385-a6cb-a26ea47bdc5e_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent value rights</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:to="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e8820044-7081-4b34-ad7b-a4edc53f73da_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_48d683cd-3352-4143-beda-c47990896686_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_2fe17a33-e7e4-48f8-acf1-040215a231b0_totalLabel_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset" xlink:href="lgnd-20231231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseRightOfUseAsset" xlink:to="lab_lgnd_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_44f3fa76-0313-42f3-ada1-e149aa5f1a49_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8d23421d-f1fd-45ce-bef2-b5c387b59b92_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_924489ba-af2d-45c9-8ee8-7e603609f74f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_90ac99f7-ba40-4f04-a0f9-8bc5934d5c9e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_dfaa27bc-4843-4d24-b4d0-ccb91ea5ed4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased in period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NucorionMember_5156426a-770c-4740-92c5-d3595071366b_terseLabel_en-US" xlink:label="lab_lgnd_NucorionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nucorion</link:label>
    <link:label id="lab_lgnd_NucorionMember_label_en-US" xlink:label="lab_lgnd_NucorionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nucorion [Member]</link:label>
    <link:label id="lab_lgnd_NucorionMember_documentation_en-US" xlink:label="lab_lgnd_NucorionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nucorion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NucorionMember" xlink:href="lgnd-20231231.xsd#lgnd_NucorionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NucorionMember" xlink:to="lab_lgnd_NucorionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2aaab024-df31-4400-8575-c55eb2b278d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_16a75192-2152-475c-8896-41787474fdc5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4f4b605a-0ac1-4013-b889-5b957fdb5803_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConsiderationClassficationAxis_a174fec8-c73c-47e4-be8b-b116112d5c13_terseLabel_en-US" xlink:label="lab_lgnd_ConsiderationClassficationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Classfication [Axis]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationAxis_label_en-US" xlink:label="lab_lgnd_ConsiderationClassficationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Classfication [Axis]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationAxis_documentation_en-US" xlink:label="lab_lgnd_ConsiderationClassficationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Classfication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationAxis" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConsiderationClassficationAxis" xlink:to="lab_lgnd_ConsiderationClassficationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_14cfc60b-ebff-4c0b-b238-c2852c48546c_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f3aa0116-5e49-44ef-b3aa-7b6be2559e71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14a1371c-8c4b-4272-89a0-0ba9e101e06c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8a8e28f4-fe52-4072-9ee3-c69b99f2354f_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average estimated useful life of finite-lived intangible assets acquired (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_cc9270c5-683e-49b5-a789-f30e10a9b287_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9234aa95-fe46-456a-b07a-3dd3e307f05a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_5cb995a1-2e8b-43f7-8724-4ebfd4f6288e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ElutiaAndCorMatrixMember_c46d4df5-514b-404d-b9b4-35e844176df6_terseLabel_en-US" xlink:label="lab_lgnd_ElutiaAndCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elutia and CorMatrix</link:label>
    <link:label id="lab_lgnd_ElutiaAndCorMatrixMember_label_en-US" xlink:label="lab_lgnd_ElutiaAndCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elutia and CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_ElutiaAndCorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_ElutiaAndCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elutia and CorMatrix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember" xlink:href="lgnd-20231231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ElutiaAndCorMatrixMember" xlink:to="lab_lgnd_ElutiaAndCorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneDomain_4d85d1ce-91c1-4521-a933-a710bcc9a1cb_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_lgnd_MilestoneDomain_label_en-US" xlink:label="lab_lgnd_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_lgnd_MilestoneDomain_documentation_en-US" xlink:label="lab_lgnd_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneDomain" xlink:to="lab_lgnd_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_10f4fac0-2680-4359-b6a1-95a2b6ed4ef0_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate used to value intangible assets acquired (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_ce3d2680-3eac-4bd2-9b2a-8ef98c18c351_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8a64672a-70cb-4bf7-80f3-19e460155658_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5dadc741-621c-416f-b108-e22e333f65cb_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0073454f-cb95-4ac2-a199-85a4e06a37c3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_4dff459b-57e5-49b2-a7b3-a2e5073e1466_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:href="lgnd-20231231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:to="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_8f57a379-a1ea-4edb-bf06-ce7656b47759_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems" xlink:href="lgnd-20231231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationLineItems" xlink:to="lab_lgnd_BasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_21e394c3-f2b1-4b3d-b7fd-555c2d762d6f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_cbf5a995-e0c6-4366-8027-83ee1307ea2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_d31ff862-3d40-4b6a-b49b-2f5b8e669f86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9cb716ad-ad92-4112-b666-725889c17604_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_7f31f555-0b05-4938-a11c-3ff75746d47b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_a9338d60-e5bc-4271-9606-e5e27351a27f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_702ffffc-383b-4cba-b740-eb5c9bd67291_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b797acfc-8105-4f16-bfc8-6c5f1f6348ec_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_dcb5fddd-4cae-4eb4-b89e-0ce11b2452d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_f9e1dd59-41e8-4d6e-8cbd-a28999f9ed97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of debt instrument (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a5d6cb5b-bff8-4742-a0b1-183542ef0121_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_253f2912-ea87-4057-bebd-7bd0d63ff8d0_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_58c86c94-512a-4dfa-bd5f-a192ad4fe244_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0da33b92-df5e-4b14-8c04-1ae918c15cad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorMatrixMember_dc0e25e5-dc07-441c-9b78-a8cf5117a7d1_terseLabel_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_label_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_CorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_CorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CorMatrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember" xlink:href="lgnd-20231231.xsd#lgnd_CorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorMatrixMember" xlink:to="lab_lgnd_CorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_be36365c-416b-4c22-9b7f-fc5982c4326d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_cf2d7960-a239-4789-b416-bd2e924554b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_46401fef-223f-47c8-ba4e-0d55a6e136f8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_1759d5ce-72ac-4119-bafe-eac3719d7d45_terseLabel_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc.</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_label_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member" xlink:href="lgnd-20231231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VikingTherapeuticsInc.Member" xlink:to="lab_lgnd_VikingTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_42f2845a-0bbb-4cd3-82be-39690e6620f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PrimroseBioMember_eff93a20-03cc-48d4-b101-5fa5b0d93a0e_terseLabel_en-US" xlink:label="lab_lgnd_PrimroseBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primrose Bio</link:label>
    <link:label id="lab_lgnd_PrimroseBioMember_label_en-US" xlink:label="lab_lgnd_PrimroseBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primrose Bio [Member]</link:label>
    <link:label id="lab_lgnd_PrimroseBioMember_documentation_en-US" xlink:label="lab_lgnd_PrimroseBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primrose Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PrimroseBioMember" xlink:to="lab_lgnd_PrimroseBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_29793872-2c28-4cbe-a647-a37232cfa02a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_28320191-628b-4d18-a9e0-de796b450815_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_782bc18e-7f36-40e3-9ae0-1af057a4b8d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a0a58684-c329-44dc-9c0f-1f244c69bd4f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3ce5ff8-e43d-4ac4-baa6-d13373f19116_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e6951c9f-5350-4397-9a5d-4b9da40de814_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_8da617fd-3898-4fd1-b727-e8ff5b00253f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b0db6d65-7375-406a-b46a-357ac9385e4d_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c64e074c-89a3-44e1-94b7-aed7ad6cb733_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ba6b9dcf-4479-4f07-9bd9-38ba0c88f963_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued fixed asset purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f45eaf51-dd25-48be-9bca-b27467ef23eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f396e64b-38c5-4e28-a04d-803b6b2bf731_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss(gain) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e4ba886f-65bb-4f1c-a473-2730c26ac8cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_00e521cf-58fa-4f8c-95be-0809ef6fa311_terseLabel_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_label_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:label id="lab_lgnd_AccruedInventoryPurchases_documentation_en-US" xlink:label="lab_lgnd_AccruedInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases" xlink:href="lgnd-20231231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedInventoryPurchases" xlink:to="lab_lgnd_AccruedInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_1c9b2e3d-83fb-43f7-9c77-9f8c69951eb5_terseLabel_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_label_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Investing Actives [Abstract]</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_documentation_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Investing Actives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:href="lgnd-20231231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:to="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2a2d06f7-b3a5-4b6f-99cb-d1ee50cd9599_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_37cfb92b-1a94-4811-98a9-acd427e82c38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4ac2a211-0bb5-405d-8f30-8f5c8d06a277_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0dc00254-6f55-43ea-87cc-d41c887d8824_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_8bf9da7d-877a-495e-b656-ee44ca7968e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_d449137e-9b2a-408e-a485-aacc215914fa_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_2266f82b-464d-4475-b87b-7a4d61dc86cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ab1c0da4-8c1c-4cfd-a806-161e8dd89b74_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_44d6f319-9bb5-4514-a697-ae1109a7abd8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3dfb1748-d84a-47ad-9260-b04b0276193d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount (including unamortized debt issuance cost)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a9a285b0-9e26-43f7-a893-84b952bc9279_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_5c0f2f86-36a3-40a4-8c81-0e984f82b713_terseLabel_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_label_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palvella Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:href="lgnd-20231231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:to="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_15205f1c-a66d-4402-beb2-fac701b54390_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_08dc38aa-6d8d-4cf0-a457-2fe047bf76e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2e5bb30b-3221-4cf5-ac1e-a0fd6c66761f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2817deb3-b0ac-4ea7-8004-b75b6a19dd28_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6fc24427-81b2-4923-9230-fde09d9f5165_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_72d4b39f-6c7b-4c89-80d2-3a9b434ad630_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_78abca16-c706-4264-b0ca-1dcd186b571f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9b82ac3-db5f-4101-a67b-3ca25e6fa8ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_928eab23-6c34-4c18-a72a-34a5fc3ae5f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SoticlestatMember_6d3a5f63-9502-4410-b5a5-4cccc2215366_terseLabel_en-US" xlink:label="lab_lgnd_SoticlestatMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soticlestat</link:label>
    <link:label id="lab_lgnd_SoticlestatMember_label_en-US" xlink:label="lab_lgnd_SoticlestatMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soticlestat [Member]</link:label>
    <link:label id="lab_lgnd_SoticlestatMember_documentation_en-US" xlink:label="lab_lgnd_SoticlestatMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soticlestat</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SoticlestatMember" xlink:href="lgnd-20231231.xsd#lgnd_SoticlestatMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SoticlestatMember" xlink:to="lab_lgnd_SoticlestatMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_4be804d4-8e3d-43f9-be83-e7755849489d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f8e54ec5-e3a7-41e7-8c90-459880445d9b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_bd18653e-fd02-46c4-a73f-e0fd6ca27df9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_605d6ede-e616-4026-aedf-ada2225e61d5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_cf17964c-770d-4494-a321-69952f27dd1c_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$58.49-$66.54</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFiveMember" xlink:to="lab_lgnd_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_52772d1e-c302-4149-8397-6607741c3a82_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_6c3aeb89-d919-4ae9-bced-6c3426e52299_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_742eb8db-8d8d-463b-9451-44bac0738ca1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractRevenueMember_27589467-61fe-4bae-8aeb-0a4d63fb4c57_terseLabel_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_label_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Revenue [Member]</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_documentation_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractRevenueMember" xlink:to="lab_lgnd_ContractRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OmniabSeparationMember_f800bf94-c163-4dd1-887c-2fa95b918d98_terseLabel_en-US" xlink:label="lab_lgnd_OmniabSeparationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniab Separation</link:label>
    <link:label id="lab_lgnd_OmniabSeparationMember_label_en-US" xlink:label="lab_lgnd_OmniabSeparationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniab Separation [Member]</link:label>
    <link:label id="lab_lgnd_OmniabSeparationMember_documentation_en-US" xlink:label="lab_lgnd_OmniabSeparationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omniab Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OmniabSeparationMember" xlink:href="lgnd-20231231.xsd#lgnd_OmniabSeparationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OmniabSeparationMember" xlink:to="lab_lgnd_OmniabSeparationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf7383a7-b3ab-42fe-a56a-9f65f4c543ea_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period in which cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_32e2369a-f80f-46de-a20a-0868a6ae6d7e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_803c2c71-a57f-4c0f-81b4-5c1f536f9d3e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest portion of repurchased amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_473c0acc-5366-4d8b-b03d-49c0ee3365ae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmendedESPPMember_428980e5-5d82-4e0b-a5b5-f254786af25f_terseLabel_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_label_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_documentation_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember" xlink:href="lgnd-20231231.xsd#lgnd_AmendedESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmendedESPPMember" xlink:to="lab_lgnd_AmendedESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_877c871c-c7df-40b8-8c99-31619687868e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_bfc45b4b-ac39-4353-8510-f6fd4f8c5c44_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease right-of-use assets</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_17b9baa9-0751-44a1-9342-677ef2cd6723_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_70f1da51-a444-40c6-ad27-ebaffe304ffe_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_884db571-1dbf-4f74-a37e-f47666f86548_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAcquiredPercentage_cbb1b259-502f-4ea9-b882-1e2a9fefe0fa_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquiredPercentage_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Percentage</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquiredPercentage_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquired Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquiredPercentage" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationAcquiredPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAcquiredPercentage" xlink:to="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5249b467-69c8-47f9-bb1f-9b1a18a390e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_69c21c19-1eef-49c0-b8a1-a35a232058e6_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Investing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Investing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersInvestingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d9f2653a-8f22-41f1-967e-7174d26e1379_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statement of Operations:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_c4e8e8fb-2728-409d-9aff-8762293e2fc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_8db98db9-1100-44c6-adb5-0a9e1ca9d0f0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e6a83a6f-ca79-466d-a297-239b18c6b263_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PelicanTechnologyHoldingsIncMember_c962d010-5b7f-4870-9912-7538aafa69af_terseLabel_en-US" xlink:label="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelican Technology Holdings, Inc.</link:label>
    <link:label id="lab_lgnd_PelicanTechnologyHoldingsIncMember_label_en-US" xlink:label="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelican Technology Holdings, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PelicanTechnologyHoldingsIncMember_documentation_en-US" xlink:label="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelican Technology Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PelicanTechnologyHoldingsIncMember" xlink:to="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_040697a1-03b0-486b-afd9-18e4f17e42cf_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from short-term investments</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_a4f954f3-f028-45eb-804f-9e849bd13ad1_terseLabel_en-US" xlink:label="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for amounts owed to a former licensor</link:label>
    <link:label id="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Owed To Former Licensor, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Owed To Former Licensor, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" xlink:href="lgnd-20231231.xsd#lgnd_AmountsOwedToFormerLicensorFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" xlink:to="lab_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_387e23a8-add1-4372-9287-e9df1d442ace_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_95c79a5f-3e89-49f0-a108-cf7cc30db7ca_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_9edaf799-b15b-446c-8242-e92de3509384_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frequency of cash payments to CVR holders</link:label>
    <link:label id="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_label_en-US" xlink:label="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders</link:label>
    <link:label id="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:to="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c6bfc4b4-840d-4768-874c-68373098a8c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_0f15801d-3df2-4e21-b410-5ae8ed365059_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_cf9c985d-0c10-49d6-b429-70a95859d5f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_aa53d204-9b2e-438a-a73b-91684fcbaab6_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_03a26420-350e-4feb-b32f-6a312b9a48e6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_cf38a533-16d2-446c-bbb7-493c5d6598ba_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bb85c6de-70d5-4434-9691-678eebb290ad_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b23be515-8b96-4441-8c9d-1f0ac2b59c21_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Pelican Business and Investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_870228ae-8514-4519-ab33-9458eaa4504e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-off of OmniAb</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_0d7b1221-24bd-42bb-9419-99375eef2277_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b55ae4e2-64c4-451d-ac20-d664d56145b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0d2f10dd-df85-47a4-8aa8-f8c114cef92f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c5f80778-34ac-410d-b5e6-cdcce763f2a4_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c11e454-9a56-4d93-b710-d1316f89c3a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_d58227b3-16fc-4e12-8995-d019782fe108_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2a981fb7-f49e-4b59-b59b-7e4f1bd54e34_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_88249b69-359b-4cab-a0a5-32391fae014a_terseLabel_en-US" xlink:label="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty from commercial license rights</link:label>
    <link:label id="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:href="lgnd-20231231.xsd#lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:to="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_92939b3a-edcf-42ca-b9d2-7a1b31476866_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_00937500-634a-4280-b94e-996238381c03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_5e31f975-e525-4f1b-a4d4-1fe48f9a7724_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of 2023 Notes outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_76dc8996-b20b-43a7-aca6-71d96f453d2c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_417c216a-b2d0-4e50-926b-8cca46503a7b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_687b8a15-4060-48d8-b5d5-0e96a9c12648_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_de657ea9-c3ed-40e0-af5d-bb552d133e35_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_351363e2-9be8-4566-8e5a-30833f7614f2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_974d55e8-de3c-46b1-b6c7-508de2f66c9b_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:href="lgnd-20231231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:to="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9688f5a0-4341-45a3-b213-1fb2dadf64dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income (loss) from continuing operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_d4f9a5a2-a7c2-44c4-af86-a440305ef457_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f83ef3-891a-4195-9e97-573038c77bc1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EquityMethodInvestmentsAllocationMember_83a3b1d0-f82f-4e88-9daf-f2c1b22c9e24_terseLabel_en-US" xlink:label="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_lgnd_EquityMethodInvestmentsAllocationMember_label_en-US" xlink:label="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments Allocation [Member]</link:label>
    <link:label id="lab_lgnd_EquityMethodInvestmentsAllocationMember_documentation_en-US" xlink:label="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityMethodInvestmentsAllocationMember" xlink:href="lgnd-20231231.xsd#lgnd_EquityMethodInvestmentsAllocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EquityMethodInvestmentsAllocationMember" xlink:to="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentMilestonePurchaseAgreement_9a8a3c2e-ead6-4f69-add6-cf7be1035c9b_terseLabel_en-US" xlink:label="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_lgnd_ContingentMilestonePurchaseAgreement_label_en-US" xlink:label="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Purchase Agreement</link:label>
    <link:label id="lab_lgnd_ContingentMilestonePurchaseAgreement_documentation_en-US" xlink:label="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentMilestonePurchaseAgreement" xlink:href="lgnd-20231231.xsd#lgnd_ContingentMilestonePurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentMilestonePurchaseAgreement" xlink:to="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyOtherMember_e9a92fdb-6749-4a88-ac87-a4f50bb7758c_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_label_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyOtherMember" xlink:to="lab_lgnd_RoyaltyOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_7f3a1936-ad8d-4778-bad2-d805b19b5eaa_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$52.84-$52.84</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeThreeMember" xlink:to="lab_lgnd_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3767493b-8129-459c-8f9e-414292ebe459_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_97512065-d27d-476a-8d32-ca1509644b9f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2d316e45-23de-415c-8942-4fb15afbf816_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_8c2ca51d-d973-4512-bd00-9d744f5b80e9_terseLabel_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, regulatory, &amp; commercial milestones and tiered royalties</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_label_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_documentation_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:href="lgnd-20231231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:to="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f2f0d464-271d-4575-8e2f-e5e558aa660d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_ea1f1d91-f526-427b-897a-0a5ed55ab495_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bfa7c216-d8e3-4407-a7da-d345e69cd8da_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration paid</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_bcf5ca58-6959-48dc-b90f-f519e4b86e92_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32cc4874-49e2-467c-9553-b9edae5c200a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_32828e4b-7a93-4f6e-9d73-ac05f364775b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novan contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_e8ae9d30-563f-43f7-8e42-9b37e0dadc8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_74b7310e-88fc-4d2e-87a7-695e4a37dd60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_e4246356-aa38-4c86-a435-21f00b42936f_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sold of equity method investee (in shares)</link:label>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_label_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Sold Of Equity Method Investee</link:label>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_documentation_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Sold Of Equity Method Investee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:to="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7a656269-300f-4c2a-8618-40599a35a8b9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_6680e790-db9c-49bd-af12-09b88933e52a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_a51586b8-1f32-499c-8d4d-15341b96ceca_terseLabel_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid for an interest in potential development milestone</link:label>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_4c749cc3-cc59-4da7-912d-1010093fdfcc_verboseLabel_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration paid</link:label>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_label_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Paid For An Interest In Potential Development Milestone</link:label>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_documentation_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Paid For An Interest In Potential Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:to="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_dcbd1b2d-c1f9-4959-b36d-89ce91209ed6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 60,000 shares authorized; 17,556 and 16,951 shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_70f6c9f6-20c7-4ef6-ad2b-e4b3856a0c6f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71c41f8f-4b46-4ebd-b39c-dc0b080d119f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_feb3a291-217c-4933-a39e-a46ea1321d20_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_a0562e32-b334-4abf-8ae7-d3671fe77f04_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_ee123e21-023f-4f95-a807-6b639e82ec0c_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased amount</link:label>
    <link:label id="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_label_en-US" xlink:label="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Amount During Period</link:label>
    <link:label id="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Amount During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:href="lgnd-20231231.xsd#lgnd_DebtInstrumentRepurchasedAmountDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:to="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_17c29603-e47c-4b57-b4f1-9f9b938bd71b_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest (as a percent)</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6b0d412b-4024-4999-8ff4-c63f4e5d352d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_33d8a07c-e20d-436d-9413-f9712864d28d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_7ae3e2d9-5870-4089-8c47-34ea508d36a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_2086eff1-da11-4c52-85bc-f5793cc20e50_terseLabel_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product royalty (as a percent)</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_label_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_documentation_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage" xlink:href="lgnd-20231231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProductRoyaltyPercentage" xlink:to="lab_lgnd_ProductRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_01dccad1-4e80-4843-8b8f-92c89076c2eb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock_86fab5ae-f507-4717-bda8-a0787620d21d_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License and Other Economic Rights</link:label>
    <link:label id="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock_label_en-US" xlink:label="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License And Other Economic Rights [Text Block]</link:label>
    <link:label id="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License And Other Economic Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" xlink:to="lab_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_666bc463-89ac-445a-b970-22ed9ccabba2_terseLabel_en-US" xlink:label="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_label_en-US" xlink:label="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]</link:label>
    <link:label id="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_documentation_en-US" xlink:label="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:href="lgnd-20231231.xsd#lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:to="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_7fbaff8c-616a-4bb7-8690-2e3de55b2dec_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3104c469-dc98-4b67-ad74-0645ab31c9a2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7527c8c6-f966-4300-9517-2c68d8b91673_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_be1d27ff-229c-4f3b-beef-f43f9bdf355d_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$32.78-$49.99</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeOneMember" xlink:to="lab_lgnd_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3fa2faf1-22d0-44f6-ba10-3ad59f9a5486_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e092e29b-53e8-41ee-a942-ee741319dcb8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_43ab5e55-4edd-4314-9a08-bd7ca88245e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ee4a0d6c-ec99-4d26-b843-13a0148c8ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3e37f0ae-94c8-4c51-b113-eff747aa9079_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c3f05184-6621-4feb-8bda-9caf0300835e_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_d82c2cf6-2fd0-4904-adce-140d3b8d6318_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bond hedge transaction</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Bond Hedge Transaction</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid In Capital, Bond Hedge Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_074b819e-ccf1-4172-a20f-b11c50de993a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_20fbfc77-30a0-437d-8e0c-cedd053ac7c9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fe0bf0de-6035-4e58-8f6d-c47485f05be4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_0e4ee0c9-efb2-422d-844a-c556bbf68a03_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_07f0cd99-1595-4e79-ae0b-fc43f9f04e65_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ed17037f-51ad-48a9-8b37-eb1505211367_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_14b9e166-ea4c-482d-b855-7b5da067c132_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual relationships</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c7bd8fc9-52b1-462f-b1c2-436324d048c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ba21abdf-47e8-4aad-b5be-bc0d1714dd43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PrimordialGeneticsMember_653e5f49-35eb-4bba-8faf-489688abe58a_terseLabel_en-US" xlink:label="lab_lgnd_PrimordialGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primordial Genetics</link:label>
    <link:label id="lab_lgnd_PrimordialGeneticsMember_label_en-US" xlink:label="lab_lgnd_PrimordialGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primordial Genetics [Member]</link:label>
    <link:label id="lab_lgnd_PrimordialGeneticsMember_documentation_en-US" xlink:label="lab_lgnd_PrimordialGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primordial Genetics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember" xlink:href="lgnd-20231231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PrimordialGeneticsMember" xlink:to="lab_lgnd_PrimordialGeneticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_844bca30-4a02-4ee1-8d13-4b44e9c23731_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab8ce1a7-a180-454e-bcfc-d17cc5c0b359_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on debt instrument (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_1dda1318-3900-4a60-bb48-8ebbbb93dfe7_terseLabel_en-US" xlink:label="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease amortization expense</link:label>
    <link:label id="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease And Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease And Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_dbacb2fe-7ae0-47a8-a2a4-e0f6adfd6267_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet:</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_006715d4-aa80-4c36-b68f-82c656b4ca17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of Pelican</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_db72a030-dc1c-46e3-b22a-3d3d9927c60c_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_373e7465-ceef-4f4a-86cd-e4bf10b4a41d_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_12ba3f4f-6946-4637-b2a3-eaed81a73a0d_negatedLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_91cc26a1-9894-4edd-9f97-1304d3214624_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_0a485bcc-fab5-4b11-b9c0-defe0f952db4_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:href="lgnd-20231231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_015b2306-5233-43c6-85a1-0f19f863ee9c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6cef8044-19eb-4675-ad29-02baf9a4608f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8b1b495f-166d-4c52-a708-46dc838b9ff5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f3fb837c-af4b-43de-9e1a-feccfec44002_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4408272d-bc33-4b78-a96b-81b2ae444b88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_ade97150-215f-403a-bdd4-a4ec5adba765_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_2b16004f-9297-4716-a288-8bb058d5d9b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_344477d0-4cee-42c1-b5f5-99dedb4c797e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c8c04ba8-54cf-4a12-a44e-802b78750f85_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6aad3dd6-72a7-4e06-955c-4d8ac5f515e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_958118e2-7229-4fc9-a460-bb175de0f396_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5cf6f137-dcb3-4e8e-a1ee-bc2913577441_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_e92ffb93-c319-4852-9e34-1111119d33df_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bond Fund</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_4c8599b1-6ad1-48ca-b904-853d919791ad_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_381555ef-d5b9-4113-897d-1180f70df095_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of civil complaints filed against entity</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7a4447bd-f9fc-41e1-b9f8-eee61f5f3d6a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_39a6ae7b-68dc-4d8a-a13a-b00cedd3ce81_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_97464c10-5996-4fa1-b71c-288812e63c27_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of consideration allocated to inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCOVIDMember_66570af8-3853-47fb-86c3-f982475afd96_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captisol - COVID</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCOVIDMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol, COVID [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCOVIDMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol, COVID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolCOVIDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:to="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_726687e8-dd6e-48b1-8bad-36588ec469dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_1a56d95e-8bfd-4d79-84ba-9ad0aeacec92_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond hedge settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f853317e-f761-4570-8c64-7e0bd00bfc48_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_89beec16-6a2c-438e-967c-0ec3aab8ebd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1a5c8a9-0a67-4e96-9cb6-8ef8e1296ed8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_cd82e9e8-0641-4620-82fb-00e0dad3dea5_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contingent liabilities</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights" xlink:href="lgnd-20231231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRights" xlink:to="lab_lgnd_LiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_092949be-86be-4406-8a16-5e892d51021f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b104b15f-9186-4fd4-82e0-96304df1fbe7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_55d6828c-39cf-490a-ad5e-901da80ce175_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available borrowing</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_eaf27960-138e-4e00-ae37-64336f8f83e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db647453-3ae8-4bc1-bb69-ee34e245cfe0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_533c61dd-9e0b-42bc-817e-bf25bb5f9093_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_cc948cbe-b023-4ee9-aa0e-80013a80f671_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1dc0acb9-c184-405a-b9cd-ac04c62dcd40_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_17258da1-5e60-4c6f-8fa8-71ce528890e5_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementsMember" xlink:to="lab_us-gaap_RoyaltyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_bcd51ad8-0345-4736-9bc7-b103e75028e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_6583fde3-4e60-4183-ad3a-ef9d989a8a32_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiabilityCurrent" xlink:to="lab_lgnd_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_f354e579-c227-4bd2-92fb-62105c2457d9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_718121cd-00ee-423f-881f-96bdecd51656_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_578139c3-3ede-47f2-96b8-59e9df52ba9f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e110ed24-c223-4cd2-8c72-0a8049a6f90a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_e5949bb5-2325-4b67-9a28-9d59b6daf557_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lower range of exercise prices (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_cad91421-c0aa-4ca8-b572-6f368790ac5d_terseLabel_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_label_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember" xlink:href="lgnd-20231231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_Phase3ClinicalTrialMember" xlink:to="lab_lgnd_Phase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f084bcf-ee66-4efa-99e8-fec3a11e51c4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_295c12ac-509c-4df8-90e6-653cf8d6f8eb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCoreMember_28221b29-4aaf-4404-9b0d-b7e4c545d559_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captisol - Core</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCoreMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol, Core [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCoreMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol, Core</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCoreMember" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolCoreMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolCoreMember" xlink:to="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_74930ebf-1d6c-4044-9a92-2ed86bbef981_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_dc07a915-85a0-43ab-97f7-9b7ea71611c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_b64a7ebb-5ff0-42db-bf5c-c3f9580a3a38_terseLabel_en-US" xlink:label="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Repurchased During Current Period, Two</link:label>
    <link:label id="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Repurchased During Current Period, Two [Member]</link:label>
    <link:label id="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Repurchased During Current Period, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:href="lgnd-20231231.xsd#lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:to="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5d80b78a-0b30-4734-97be-86c60822d308_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of premium (discount) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_99dd0cd6-cea1-4d94-b36c-6ec462c4c236_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b1d8eb08-ddc7-4985-893a-1e1a0159dd75_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ea043641-0c2e-4420-9da0-8f04cba1f927_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_67bdbb4c-379f-4c03-bef0-25a8284a8a18_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ceca9229-b94e-4c38-8e73-3551e5edd388_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_22aecb46-9ab8-4430-a919-f6d3a1eeb60a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_89729b5a-13fe-46e6-8564-54708174270e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0b674ba6-8629-4548-8022-a740d5ae255c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_eb068845-53e7-4c36-8298-52794f8a688c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_49d8bdc1-0416-4f81-b60f-6470436c71a6_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees, Milestones, and Other Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:href="lgnd-20231231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:to="lab_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_4b69e27f-36af-4ae4-a2cc-79864e24fcd0_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captisol</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolMember" xlink:to="lab_lgnd_MaterialSalesCaptisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4314651d-1ee7-431a-931d-c6d671213a0e_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_38ddb111-27ea-47a9-8fcb-0b1e8df50a6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_984b932d-2564-4d93-aeec-2979159ca266_verboseLabel_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cydex Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:href="lgnd-20231231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:to="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_05ed4be2-6a82-4d66-b4f1-0218193bec6f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedCustomerDepositsCurrent_a9d83495-9552-46dc-8257-6c2f9115a6c5_terseLabel_en-US" xlink:label="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer deposit</link:label>
    <link:label id="lab_lgnd_AccruedCustomerDepositsCurrent_label_en-US" xlink:label="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Customer Deposits, Current</link:label>
    <link:label id="lab_lgnd_AccruedCustomerDepositsCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Customer Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCustomerDepositsCurrent" xlink:href="lgnd-20231231.xsd#lgnd_AccruedCustomerDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedCustomerDepositsCurrent" xlink:to="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_357ae0c6-4a9a-4011-a4a5-071601eee7f0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_2885c495-60aa-4d56-9fcd-7b06d35170d5_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_d1db4938-da04-4ed1-8f34-3fa1ea6e7277_verboseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisTherapeuticsMember" xlink:to="lab_lgnd_MetabasisTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PeliCRM197Member_26baceea-c00b-4b23-8863-91fbdc406c2b_terseLabel_en-US" xlink:label="lab_lgnd_PeliCRM197Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeliCRM197</link:label>
    <link:label id="lab_lgnd_PeliCRM197Member_label_en-US" xlink:label="lab_lgnd_PeliCRM197Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeliCRM197 [Member]</link:label>
    <link:label id="lab_lgnd_PeliCRM197Member_documentation_en-US" xlink:label="lab_lgnd_PeliCRM197Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeliCRM197</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PeliCRM197Member" xlink:href="lgnd-20231231.xsd#lgnd_PeliCRM197Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PeliCRM197Member" xlink:to="lab_lgnd_PeliCRM197Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_48711cc3-bfe3-4b2c-beeb-4d8cc738dcfe_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69b8bd2b-8966-4fdd-8774-1d2d2ef26780_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment_3598163e-4d58-44ef-bc33-28aafa746368_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit loss adjustment</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Credit Loss Adjustment</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Credit Loss Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:to="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_f93c3238-a492-43f4-a074-1f45f798b181_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_label_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patented Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentedTechnologyMember" xlink:to="lab_us-gaap_PatentedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_857752ca-549d-4780-983b-35e7efd6459c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_c5b42ba3-5656-4e1d-b454-0e0bd7f6d048_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_684fe4a0-18d8-40d4-8890-69e8f50def32_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_37be495b-1009-4eb1-8b62-6f8126fc2611_terseLabel_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_label_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_documentation_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:href="lgnd-20231231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:to="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4cb76b3c-65a6-4b70-b999-db9e16437225_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_51dd432d-8dd0-4b4f-973e-6656554ab71d_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_2d60cec7-49eb-4969-bb7a-515cdf2f91fe_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0cbc1ad9-3dce-419c-bd3f-11131ceccf49_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_d57f84e2-7062-4ff2-b367-e7779ed3c2b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a14557ed-b5af-4735-8aee-c2fd2ee40abf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_530772df-06b5-4d63-bed9-185f56935263_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_2b74acf6-c1b5-4845-b411-6dbca2a3d161_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of CVRs issued per acquiree share</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_label_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued per Acquiree Share</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:to="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_10c860db-c5d7-4644-abe6-6c17c04ef634_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_e4fd79e6-a141-48f5-a19c-64937c5c5d82_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_c7e79b3b-2e0b-4d38-b6ba-b87ba8d2684a_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3ebcd557-b88d-40bb-8dc8-13fb52651b3c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_6067272d-412f-4f44-8522-39e6359f1c5d_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_53642954-b3da-4de4-9bcd-56f0746ca822_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">69.39</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSevenMember" xlink:to="lab_lgnd_ExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cf63956a-6119-4797-8210-00a6294f0eff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (In thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_cb944e04-2a74-4f0f-81bf-250c15b6eeaa_totalLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_14b93a5d-3f07-4caf-b730-585c90f0704c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_d9f8145e-9907-46ec-80cb-b9afdb56a457_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f537a9f7-03c3-4fea-bb80-fae7b49e5219_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b15e49cb-1b95-4e6b-985e-c028cff8a5af_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeAssetsMember_71e7b923-4a74-4692-b69a-03cb68dac9db_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_lgnd_DerivativeAssetsMember_label_en-US" xlink:label="lab_lgnd_DerivativeAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets [Member]</link:label>
    <link:label id="lab_lgnd_DerivativeAssetsMember_documentation_en-US" xlink:label="lab_lgnd_DerivativeAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetsMember" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeAssetsMember" xlink:to="lab_lgnd_DerivativeAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_3c38c4b9-86f8-448e-998b-68186349fcb5_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_f8cf8914-2b56-4f74-b80e-5d9d590b2c21_terseLabel_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Operating Activities [Abstract]</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_documentation_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:href="lgnd-20231231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:to="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_48f739b5-5c67-4fff-be0c-b8ec87cd2653_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3c1fb0e-ca91-4555-9c03-8670e8fbb157_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMember_f2ad4e87-7277-4d5f-827e-413135a882ea_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember" xlink:href="lgnd-20231231.xsd#lgnd_LicenseFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMember" xlink:to="lab_lgnd_LicenseFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_34edf939-d155-4777-9239-2e7d21c6838e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3d747193-d0f7-40d0-9408-1397ab4e9d8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7f0f1131-6edc-4558-9be7-ee9d29da9de2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment at maturity/repurchase of 2023 Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ef4bf1db-a5fb-489a-afd7-fbb12594c287_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eefe2b65-3da0-4934-b398-5c537c440418_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2a5b27df-959a-42f9-b431-8dffa9469ea7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_0b87d126-526c-4d1c-81c5-18891726d1d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to equity security warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_1e6328b7-6714-4f2d-bd0e-f5fda325a733_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_bdb19186-78c8-4eba-b363-395e40e324ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_89992b88-b059-45ee-834c-fe2f0d963e0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_67c7cfec-63e0-4e02-94d9-08cd95127104_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_09a91bb6-8d16-49f1-bfa3-ce437c4f80d6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_46feb223-c867-4c02-aea3-4b679667e958_terseLabel_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:href="lgnd-20231231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:to="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_e28377e6-9e7d-4c21-9cce-60c4943f198a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SaleOfStockAuthorizedOfferingAmount_09b267e1-679a-433d-8441-f8740bf0497f_terseLabel_en-US" xlink:label="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, authorized offering amount</link:label>
    <link:label id="lab_lgnd_SaleOfStockAuthorizedOfferingAmount_label_en-US" xlink:label="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Offering Amount</link:label>
    <link:label id="lab_lgnd_SaleOfStockAuthorizedOfferingAmount_documentation_en-US" xlink:label="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Offering Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:href="lgnd-20231231.xsd#lgnd_SaleOfStockAuthorizedOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:to="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_1856fa93-3ed2-4b15-9bd9-b1f2be3130f2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent</link:label>
    <link:label id="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_label_en-US" xlink:label="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current and Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:to="lab_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9d3c3513-30ac-49ec-b82f-a588a5430ac4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_4ea74b5b-2fc0-4468-a84d-e9fb52be74fb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8115f992-7995-4ff0-b5b1-82fe078b4713_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax differential on income/loss of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb343352-3074-4d4a-a6e9-7a4b0f687d36_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_38ad0f52-e260-4a79-9c25-1732b1571d6f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_44825b9b-74d7-40c5-9d91-17694c18f278_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_e30ab8e8-1ff2-413a-ae8b-daa34c9673a7_terseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5e715adf-efdd-4350-8990-41dc76865a5a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate of operating leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_170560f0-be73-4b5c-aa76-405b9b0c2420_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_01003b7f-b715-4780-a2a5-212c0fa026ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under amended ESSP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6045793a-938c-4723-a22d-616a1ea793ff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneMember_468b2d3f-01c6-46c9-a996-5030968fb6fe_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:label id="lab_lgnd_MilestoneMember_label_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Member]</link:label>
    <link:label id="lab_lgnd_MilestoneMember_documentation_en-US" xlink:label="lab_lgnd_MilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneMember" xlink:to="lab_lgnd_MilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_bbf0187d-9c9b-473f-97dc-2efe5237cb0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5f19e6fa-83c7-4082-90f8-e1bb24059fcd_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_214e6919-86ca-4fd5-9473-e354650d14eb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4bf3a207-ba96-4113-b903-46fc02485534_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_dac29865-8546-4112-827a-b1b06023c51a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59706675-1488-44a9-9e93-0a1bd3e7f252_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_df9af4c8-3b24-4eb7-8faf-c9554d5c9390_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_d9ee241d-45f7-4a9a-b747-34055b7403e0_verboseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:href="lgnd-20231231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_3d7b61e8-20c0-4001-830e-43e9370d2d2a_negatedTerseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution of OmniAb</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease Due To Separation</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease Due To Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToUnwindWarrants_d949f3aa-8a1b-4cc7-9842-11d11e4ef22a_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsToUnwindWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to unwind warrants</link:label>
    <link:label id="lab_lgnd_PaymentsToUnwindWarrants_label_en-US" xlink:label="lab_lgnd_PaymentsToUnwindWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Unwind Warrants</link:label>
    <link:label id="lab_lgnd_PaymentsToUnwindWarrants_documentation_en-US" xlink:label="lab_lgnd_PaymentsToUnwindWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Unwind Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToUnwindWarrants" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToUnwindWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToUnwindWarrants" xlink:to="lab_lgnd_PaymentsToUnwindWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_69217979-a264-4e04-8761-c8767e09fb17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_a4028aaa-99aa-496e-9b13-1b79360e3491_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_a541ea78-aaff-443b-8dcc-c2c400266d08_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_bf8e0756-8233-45d5-b008-fecc119a23a2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill written off</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7e701d36-713d-48b5-9b75-88b894107ada_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase the number of shares under the 2002 Stock Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_a31f43c4-9df6-4343-a3cc-cbb992d3deac_verboseLabel_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents &amp; Short-term Investments</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:href="lgnd-20231231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:to="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79269383-7a2b-4936-bf9a-486dd964f09c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightAgreements_ff23b7c8-0bf3-40d9-a761-65848453b5c4_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of CVR agreements</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightAgreements_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Contingent Value Right Agreements</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightAgreements_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Contingent Value Right Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightAgreements" xlink:to="lab_lgnd_NumberOfContingentValueRightAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_f1001fd7-7c60-45c0-b2e8-a53f01e0c732_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseeAccrualCurrent_f3031683-4cca-4f4d-b90c-6db444c03007_terseLabel_en-US" xlink:label="lab_lgnd_LicenseeAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts owed to former licensees</link:label>
    <link:label id="lab_lgnd_LicenseeAccrualCurrent_label_en-US" xlink:label="lab_lgnd_LicenseeAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensee Accrual, Current</link:label>
    <link:label id="lab_lgnd_LicenseeAccrualCurrent_documentation_en-US" xlink:label="lab_lgnd_LicenseeAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensee Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseeAccrualCurrent" xlink:href="lgnd-20231231.xsd#lgnd_LicenseeAccrualCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseeAccrualCurrent" xlink:to="lab_lgnd_LicenseeAccrualCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_08ddee1a-c40f-409d-933b-fe4e56149220_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evomela</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyEvomelaMember" xlink:to="lab_lgnd_RoyaltyEvomelaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4b8d31f0-75f5-4ae7-b526-87a43b432a41_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_d68b3267-76b3-4536-a1a2-4b2f5e257396_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_197b281a-8e12-4d35-90eb-a6a97d95c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_f21d3749-449e-48c4-a26e-58039c89b341_verboseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Costs and Expenses [Abstract]</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_1887201e-cf09-466d-9dfd-804d2023e6d2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5ae8125a-2775-4393-9058-d0f4fb68ea5e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77ca2a8e-5d07-4702-8b38-bcfdb71519ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_cf9a31df-fdef-4674-8e6c-ee056c395447_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for convertible bond hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:to="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7850685e-b7e8-49d8-9417-abd980e98ad0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_InterestInPotentialDevelopmentMilestone_1c8c8630-bfd1-4d61-975d-e9f829fd9980_terseLabel_en-US" xlink:label="lab_lgnd_InterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in potential development milestone (as a percent)</link:label>
    <link:label id="lab_lgnd_InterestInPotentialDevelopmentMilestone_label_en-US" xlink:label="lab_lgnd_InterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in Potential Development Milestone</link:label>
    <link:label id="lab_lgnd_InterestInPotentialDevelopmentMilestone_documentation_en-US" xlink:label="lab_lgnd_InterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in Potential Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InterestInPotentialDevelopmentMilestone" xlink:href="lgnd-20231231.xsd#lgnd_InterestInPotentialDevelopmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_InterestInPotentialDevelopmentMilestone" xlink:to="lab_lgnd_InterestInPotentialDevelopmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_ec3afcf2-b19e-4e75-8d0e-4157d9a3652c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_1f3d1c50-40c9-4741-a651-70bb8e897a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7cbed567-5869-4bf6-b09b-ae5027fcebee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e1a33586-4dc8-4b47-b886-a016816c77b4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_0c63157a-0488-4d5e-936e-bb09d6fabefa_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1018f8bf-9fed-4a0b-abfd-d97f08152ebb_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ea33796-9ef4-4587-98a7-ad456b8d4867_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_c55bf7b4-7c34-476a-bc3a-a09e91460994_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_716f9d1a-ce7f-4773-b024-1e60efd58b04_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8a50bc03-a3e9-4833-a421-6636f78cb536_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_98a1c7c5-b8f6-4b11-858e-221120f7ff17_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer compensation</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officer Compensation, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officer Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments_dd38ed7a-354f-42d4-a298-b0b3be700d49_negatedLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Cumulative Adjustments</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial License Rights, Cumulative Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCumulativeAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments" xlink:to="lab_lgnd_CommercialLicenseRightsCumulativeAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_79218727-736f-4d70-a68a-61a686d7d34b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9d5c1bc2-6323-40ef-af53-c57eeb8b9e9a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a66d718e-2a99-4bab-96f7-3b330a91594e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_89a86bad-d6f0-4e62-8d48-9a8a8c971f11_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDII</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_115c1c93-59c3-43df-aa19-c1feb8547f65_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_edd35885-5ce0-4f0c-a1f7-51aff3a45b56_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid to date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_aa418e02-a8a6-4761-a5cb-9422e56fbaa4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity and Liability Components of the Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_336394ea-ba1a-4bbb-b152-cc082e439093_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_1cd35079-12e2-4453-ba44-e7acf695d831_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_51b9daa9-f5ab-4062-ab98-6a6d4afe9aac_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_41f5a1d9-0414-43a3-8990-dbc178206f9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a4f321ae-6972-4014-a1c4-fdc1353c1873_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d34ba4a3-521f-4e3e-b155-1b9eb9bf6948_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>lgnd-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4cc674fd-25ef-4a1f-be1e-ae22ba8e96aa,g:9cb8df18-e655-4252-b500-06985d41d3f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/Cover" xlink:type="simple" xlink:href="lgnd-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0fc0fa57-e1c1-4b3b-8bb9-a1c7f35d2967" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentType_0fc0fa57-e1c1-4b3b-8bb9-a1c7f35d2967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_2b1b42a4-d34f-4925-b4f2-ef065fe49db7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentAnnualReport_2b1b42a4-d34f-4925-b4f2-ef065fe49db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f4ebb811-2193-4be8-a66f-fcdd9d4a4e52" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentPeriodEndDate_f4ebb811-2193-4be8-a66f-fcdd9d4a4e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_62bb55bb-0e31-4a19-8e98-e5de927e7a00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_CurrentFiscalYearEndDate_62bb55bb-0e31-4a19-8e98-e5de927e7a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_06d2669f-2a8d-4c28-9682-8f6e4d9d9e13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentTransitionReport_06d2669f-2a8d-4c28-9682-8f6e4d9d9e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b05f7e22-cb1f-45fc-b0df-bbb2324372c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityFileNumber_b05f7e22-cb1f-45fc-b0df-bbb2324372c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b9956b56-24d5-45af-8d9d-77fd3d835fb4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityRegistrantName_b9956b56-24d5-45af-8d9d-77fd3d835fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_20e80b18-3249-43c3-99b9-118a232bbc9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityIncorporationStateCountryCode_20e80b18-3249-43c3-99b9-118a232bbc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4ba441ab-bd25-4e1f-886a-7744d1d8ecf2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityTaxIdentificationNumber_4ba441ab-bd25-4e1f-886a-7744d1d8ecf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0582665b-b2ec-43cb-8a3c-50e036880cd3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityAddressAddressLine1_0582665b-b2ec-43cb-8a3c-50e036880cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_28dc075b-763a-4a6e-992c-4e30644c7748" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityAddressCityOrTown_28dc075b-763a-4a6e-992c-4e30644c7748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3145075a-929f-41b7-895b-1840fb641716" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityAddressStateOrProvince_3145075a-929f-41b7-895b-1840fb641716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_af25ebef-94c6-4def-8dc2-6cba064bb35f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityAddressPostalZipCode_af25ebef-94c6-4def-8dc2-6cba064bb35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f243bf86-de14-4b31-b0a8-eb13405c70fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_CityAreaCode_f243bf86-de14-4b31-b0a8-eb13405c70fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3b988129-df92-4685-be48-09f50da8adad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_LocalPhoneNumber_3b988129-df92-4685-be48-09f50da8adad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ea524ba1-6202-4928-bf0c-d0fc8f99315d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_Security12bTitle_ea524ba1-6202-4928-bf0c-d0fc8f99315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_933bfbeb-f95e-4b54-82b4-3bb0e78e3bba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_TradingSymbol_933bfbeb-f95e-4b54-82b4-3bb0e78e3bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_327f9960-a852-4fdb-9b3e-e2d035e1dc97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_SecurityExchangeName_327f9960-a852-4fdb-9b3e-e2d035e1dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f7006a27-3bf5-4654-820a-b4ee35f8d7ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f7006a27-3bf5-4654-820a-b4ee35f8d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7b77f8f2-2b84-4cae-80ff-be628dc0d3d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityVoluntaryFilers_7b77f8f2-2b84-4cae-80ff-be628dc0d3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8ed134ae-2ae9-43d2-8e2a-9dd11731c0f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityCurrentReportingStatus_8ed134ae-2ae9-43d2-8e2a-9dd11731c0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_27de616e-d3f6-4d71-a93f-baf49bac4b7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityInteractiveDataCurrent_27de616e-d3f6-4d71-a93f-baf49bac4b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d13a192c-cd34-4bd5-8818-82feed931c62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityFilerCategory_d13a192c-cd34-4bd5-8818-82feed931c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_75753842-a7d1-44dc-8c9d-396317ea7cbd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntitySmallBusiness_75753842-a7d1-44dc-8c9d-396317ea7cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_56c8cc8f-4590-4d9c-a70e-8e27d385c3bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityEmergingGrowthCompany_56c8cc8f-4590-4d9c-a70e-8e27d385c3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4a097f01-1a4a-40ec-a7ad-657175873801" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4a097f01-1a4a-40ec-a7ad-657175873801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_86f4d92d-267d-416d-bbc4-05c61bf3228e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_86f4d92d-267d-416d-bbc4-05c61bf3228e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_36670a3a-11f5-40c2-91cd-5cc9fc0658a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityShellCompany_36670a3a-11f5-40c2-91cd-5cc9fc0658a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e0adc2fa-b329-4acc-8b43-cbe06c7e32cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityPublicFloat_e0adc2fa-b329-4acc-8b43-cbe06c7e32cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5671cfc9-7eaa-4b2d-b767-1581b9190d87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5671cfc9-7eaa-4b2d-b767-1581b9190d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b404e5dc-3292-4b1a-ac7c-2dbf462d4f25" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b404e5dc-3292-4b1a-ac7c-2dbf462d4f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_324be55d-65c0-4a69-aa56-0001a3dc44ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_AmendmentFlag_324be55d-65c0-4a69-aa56-0001a3dc44ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b3206be1-a487-4c56-ac84-c4eb172da458" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentFiscalYearFocus_b3206be1-a487-4c56-ac84-c4eb172da458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_25630705-f81f-4077-b8a8-7254a97dbfa0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_DocumentFiscalPeriodFocus_25630705-f81f-4077-b8a8-7254a97dbfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_825b3f88-adbc-4c1a-a669-f105aa054fff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c395b1ef-d6e2-44d8-b6fe-49457b8dffda" xlink:to="loc_dei_EntityCentralIndexKey_825b3f88-adbc-4c1a-a669-f105aa054fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AuditInformation" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AuditInformationAbstract_243d48c0-1f4b-403f-85dc-aad877206cb7" xlink:href="lgnd-20231231.xsd#lgnd_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_db04f20f-f6fa-4866-8049-de0137ecf89d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_243d48c0-1f4b-403f-85dc-aad877206cb7" xlink:to="loc_dei_AuditorName_db04f20f-f6fa-4866-8049-de0137ecf89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_123a5ab3-d2e6-4e1c-ad6a-a7cefffe935f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_243d48c0-1f4b-403f-85dc-aad877206cb7" xlink:to="loc_dei_AuditorLocation_123a5ab3-d2e6-4e1c-ad6a-a7cefffe935f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a74b6804-3973-4cd4-9423-2911ff05e27d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_243d48c0-1f4b-403f-85dc-aad877206cb7" xlink:to="loc_dei_AuditorFirmId_a74b6804-3973-4cd4-9423-2911ff05e27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_92326d54-5d61-4a51-bd5c-f9803704ec93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92326d54-5d61-4a51-bd5c-f9803704ec93" xlink:to="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d22c43d-7e21-44a6-a035-ae0abed7fe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d22c43d-7e21-44a6-a035-ae0abed7fe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b689431c-3f1c-42ec-8dfb-de0bf40ce995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_ShortTermInvestments_b689431c-3f1c-42ec-8dfb-de0bf40ce995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0085d0ff-2e75-4ec2-b80e-70a17a1aa558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0085d0ff-2e75-4ec2-b80e-70a17a1aa558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c0621cdf-cc3b-46bf-9368-e161d7a98d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_InventoryNet_c0621cdf-cc3b-46bf-9368-e161d7a98d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_0a7ba36f-8e85-46ec-ac54-b813891a68ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_IncomeTaxesReceivable_0a7ba36f-8e85-46ec-ac54-b813891a68ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b5ae0b02-c235-4c6c-9957-55a697c6adac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b5ae0b02-c235-4c6c-9957-55a697c6adac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_95a09b67-7482-4f52-bb8b-60ae57a74130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_OtherAssetsCurrent_95a09b67-7482-4f52-bb8b-60ae57a74130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ed02d25-7421-418d-8bf0-f32190cd71ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a56c272f-ea0e-443f-b209-044027ade454" xlink:to="loc_us-gaap_AssetsCurrent_6ed02d25-7421-418d-8bf0-f32190cd71ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_61d869c4-8a6e-44b3-af34-b83647bc6c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_61d869c4-8a6e-44b3-af34-b83647bc6c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6926de0f-58c5-4fc3-8542-50550699ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6926de0f-58c5-4fc3-8542-50550699ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_626ea511-5c67-409d-b59e-5526a8e25352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_Goodwill_626ea511-5c67-409d-b59e-5526a8e25352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_1af6166b-0884-4d8b-92d4-44f83b3cda2f" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_lgnd_CommercialLicenseRights_1af6166b-0884-4d8b-92d4-44f83b3cda2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a3dd72c1-30e8-47d0-9394-46fc7797810d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a3dd72c1-30e8-47d0-9394-46fc7797810d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b0dda1b6-fdce-4594-a684-41b157550c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b0dda1b6-fdce-4594-a684-41b157550c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_951b798b-670d-4814-8683-c6193cf90ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_951b798b-670d-4814-8683-c6193cf90ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c2c4c057-2276-4d87-be8f-30ebc93eb3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_EquityMethodInvestments_c2c4c057-2276-4d87-be8f-30ebc93eb3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_fabb09a7-95dd-40a3-beb7-f61cbb0832df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_OtherInvestments_fabb09a7-95dd-40a3-beb7-f61cbb0832df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_017cd369-73f9-443c-a4a8-9b72c4aef0da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_017cd369-73f9-443c-a4a8-9b72c4aef0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d5e1d4df-3273-425e-a0a7-d3b4433f0b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdfeff7c-d4c4-42bd-8af8-e1535806c290" xlink:to="loc_us-gaap_Assets_d5e1d4df-3273-425e-a0a7-d3b4433f0b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92326d54-5d61-4a51-bd5c-f9803704ec93" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4d35e2b0-aa51-4c66-99f1-aca8a09adc27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_AccountsPayableCurrent_4d35e2b0-aa51-4c66-99f1-aca8a09adc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c9e0ab24-c753-4161-a9a0-b3b73e12784a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c9e0ab24-c753-4161-a9a0-b3b73e12784a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_3443bb8f-4f92-4855-9e51-8f498968544f" xlink:href="lgnd-20231231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_3443bb8f-4f92-4855-9e51-8f498968544f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c3852697-27a3-4c26-b9c8-e71363b85c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c3852697-27a3-4c26-b9c8-e71363b85c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a947302b-310c-4b2e-afab-e4a052daa215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a947302b-310c-4b2e-afab-e4a052daa215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5e94c374-0e1e-424c-8f49-8ab4f0214d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5e94c374-0e1e-424c-8f49-8ab4f0214d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_cc7379dc-9801-4099-8c35-a85bb9bea47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_cc7379dc-9801-4099-8c35-a85bb9bea47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6af4729d-92c7-4457-82e9-ebc703832c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ec89d85-780f-43d7-bb44-ddcd232d9d71" xlink:to="loc_us-gaap_LiabilitiesCurrent_6af4729d-92c7-4457-82e9-ebc703832c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_a5ad2a37-3882-4519-9756-1432ad0ccef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_a5ad2a37-3882-4519-9756-1432ad0ccef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_9e7dba40-69e6-4494-9c15-0b8505a446fd" xlink:href="lgnd-20231231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_lgnd_LiabilityForContingentValueRights_9e7dba40-69e6-4494-9c15-0b8505a446fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0c47b98b-f36c-4331-a44a-f4ac63fcf0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0c47b98b-f36c-4331-a44a-f4ac63fcf0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac7b3777-1354-40af-ab5b-cf3f5765f177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac7b3777-1354-40af-ab5b-cf3f5765f177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ed13a287-fb97-460a-a967-415330bc9b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ed13a287-fb97-460a-a967-415330bc9b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_799dc381-259b-44a9-a9f9-2d42693eb8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_Liabilities_799dc381-259b-44a9-a9f9-2d42693eb8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_004d55ca-ee9d-4e5d-8615-ad901fee4e15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_004d55ca-ee9d-4e5d-8615-ad901fee4e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_15924f33-0eff-484b-bba4-576a57f140b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:to="loc_us-gaap_PreferredStockValue_15924f33-0eff-484b-bba4-576a57f140b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_61d4aaf5-18c4-4649-bbbe-4f7c9c59493c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:to="loc_us-gaap_CommonStockValue_61d4aaf5-18c4-4649-bbbe-4f7c9c59493c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5bbab6b1-9175-4ba4-8914-8741c062ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5bbab6b1-9175-4ba4-8914-8741c062ad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10017c28-c61c-4bbb-97b8-b37465a3e66a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_10017c28-c61c-4bbb-97b8-b37465a3e66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6def396-ce22-4c89-b777-d18e964c9620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6def396-ce22-4c89-b777-d18e964c9620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1ccb7492-f08b-449b-9f82-afecf657e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5f2929ee-8ae3-4177-a11c-bcd729f838c4" xlink:to="loc_us-gaap_StockholdersEquity_1ccb7492-f08b-449b-9f82-afecf657e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9716d694-a11d-4f01-8ee5-c423dffc28f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfcc8c75-3e64-44d5-9ff6-ccdc60c50ac2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9716d694-a11d-4f01-8ee5-c423dffc28f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_191840ed-985d-497c-a213-43f2961f6fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_191840ed-985d-497c-a213-43f2961f6fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0bb30e8d-6f15-4b9f-ab5f-ab2ed04d7e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0bb30e8d-6f15-4b9f-ab5f-ab2ed04d7e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_60e772c7-514a-40ea-96a1-3c78a601746e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_PreferredStockSharesIssued_60e772c7-514a-40ea-96a1-3c78a601746e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fa791568-ff21-4554-8872-bfbebf07492c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fa791568-ff21-4554-8872-bfbebf07492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_378f898d-c059-47dd-9b9f-16c88b800b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_378f898d-c059-47dd-9b9f-16c88b800b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_75c28f0c-a248-451b-955f-9477598279b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_75c28f0c-a248-451b-955f-9477598279b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_771467c2-e315-4b35-8f54-5d1b29f229bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_CommonStockSharesIssued_771467c2-e315-4b35-8f54-5d1b29f229bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f947417-6973-45c6-bc3f-b7ab1377fb22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a93ce4f3-1fdd-4aaa-b003-fe1da24e9432" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f947417-6973-45c6-bc3f-b7ab1377fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5cf145ec-e266-4c03-b330-1e2237994319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5cf145ec-e266-4c03-b330-1e2237994319" xlink:to="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:to="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_743b0916-5ecd-4aef-a152-e9ca5f8096e2" xlink:to="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_1eb80ac9-2ff3-49aa-8925-a24081f73061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:to="loc_us-gaap_RoyaltyMember_1eb80ac9-2ff3-49aa-8925-a24081f73061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_d5390d8c-655a-4fde-99ba-ec17513a24ff" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_d5390d8c-655a-4fde-99ba-ec17513a24ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_e41eb27e-d81e-4307-9099-7d6d9e247d4f" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d907163-5070-497f-b132-4d0033dafe1d" xlink:to="loc_lgnd_ContractRevenueMember_e41eb27e-d81e-4307-9099-7d6d9e247d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2949d56-ab2a-4c5c-ad0e-e468f5a1bc4c" xlink:to="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1c8647a8-5c19-44e2-a87f-902759551845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_RevenuesAbstract_1c8647a8-5c19-44e2-a87f-902759551845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a4f913b-5178-421b-9580-fcd6dc610b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1c8647a8-5c19-44e2-a87f-902759551845" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a4f913b-5178-421b-9580-fcd6dc610b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_d5021711-a90f-4160-ab25-b885b37973c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_CostDirectMaterial_d5021711-a90f-4160-ab25-b885b37973c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_7b12ea4b-02f3-43ff-ac8a-58003f245c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_7b12ea4b-02f3-43ff-ac8a-58003f245c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f452115b-7292-42f0-95f0-81e39629fb26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f452115b-7292-42f0-95f0-81e39629fb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ed3c2fd2-f66a-4d1c-8f40-670f39f53cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ed3c2fd2-f66a-4d1c-8f40-670f39f53cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1de0f7de-7840-4e06-8113-1f9c0864703c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1de0f7de-7840-4e06-8113-1f9c0864703c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_cf0d29ca-adb1-42e1-ad3d-31b762f3d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_6a11c0b4-7250-4f07-ab90-b39149c4da52" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_cf0d29ca-adb1-42e1-ad3d-31b762f3d36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_8777352a-a868-41c8-b519-0da0e9bf5772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_8777352a-a868-41c8-b519-0da0e9bf5772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eaeeda44-f0ad-4fd6-9951-1c8cafa49e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_OperatingIncomeLoss_eaeeda44-f0ad-4fd6-9951-1c8cafa49e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_bbdfb410-dc8a-49b5-a0ac-3fe018bc1c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_GainLossOnInvestments_bbdfb410-dc8a-49b5-a0ac-3fe018bc1c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_62bd4bba-36ae-4544-9423-9211fb28fe18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_62bd4bba-36ae-4544-9423-9211fb28fe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_521c6990-c78f-483b-8900-49c8c69da846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_InterestExpense_521c6990-c78f-483b-8900-49c8c69da846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_14d699a4-191e-4deb-b692-46acb2239b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_14d699a4-191e-4deb-b692-46acb2239b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f3d1c3ad-b16f-4f00-afa0-e02cc2e102b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f3d1c3ad-b16f-4f00-afa0-e02cc2e102b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ad3bf540-a596-4f22-9c8b-caf937f500b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_a7b75d34-ba34-4d75-bd79-7668a623b12f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ad3bf540-a596-4f22-9c8b-caf937f500b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2941aa0c-b38d-4215-8a48-9868ea6449ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2941aa0c-b38d-4215-8a48-9868ea6449ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ffdf440-5968-4950-ad61-02ffece8ed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ffdf440-5968-4950-ad61-02ffece8ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_259d59fe-9f93-42d6-bf1c-76c67d81c756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_259d59fe-9f93-42d6-bf1c-76c67d81c756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e3bc3431-a7d3-4e77-9399-787010f22645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e3bc3431-a7d3-4e77-9399-787010f22645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cb3eed6-98e1-434d-95d7-1c51c49b1bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_NetIncomeLoss_1cb3eed6-98e1-434d-95d7-1c51c49b1bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f1c67323-7ed4-4b44-929a-a84b9044d956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f1c67323-7ed4-4b44-929a-a84b9044d956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0d035af6-bfc6-4804-9aac-5cccf8b3eb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0d035af6-bfc6-4804-9aac-5cccf8b3eb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_220746ec-64ca-4079-9c46-d928a4c4478f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_EarningsPerShareBasic_220746ec-64ca-4079-9c46-d928a4c4478f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ef32ed4-3c09-4962-978e-ec028eca80b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ef32ed4-3c09-4962-978e-ec028eca80b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e1445926-9a4f-4bbc-ab42-4e6c518b0832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e1445926-9a4f-4bbc-ab42-4e6c518b0832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fc265aec-abf8-4c32-a206-436e78ba1949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fc265aec-abf8-4c32-a206-436e78ba1949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6959f523-66fc-4441-8fa6-898cfa5f67a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6959f523-66fc-4441-8fa6-898cfa5f67a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4fa7d45-3ca5-452d-a718-bf1267061ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41d57d58-c611-4b78-9c20-7c9058e1fd65" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c4fa7d45-3ca5-452d-a718-bf1267061ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ed97df5f-52f5-4d53-b715-cb0c843852c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e72c151f-72a5-4452-b155-e24817ea673a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ed97df5f-52f5-4d53-b715-cb0c843852c6" xlink:to="loc_us-gaap_NetIncomeLoss_e72c151f-72a5-4452-b155-e24817ea673a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_08f36845-0657-4350-8223-b0062f06f379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ed97df5f-52f5-4d53-b715-cb0c843852c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_08f36845-0657-4350-8223-b0062f06f379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e2ef1a9a-def3-4e03-ac86-2feb9f80c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ed97df5f-52f5-4d53-b715-cb0c843852c6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e2ef1a9a-def3-4e03-ac86-2feb9f80c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7e89338e-b95b-4574-b448-b3cce6c3752d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7e89338e-b95b-4574-b448-b3cce6c3752d" xlink:to="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ceca84ad-ce22-43d8-83f8-df78df258d49" xlink:to="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_917a64b0-4183-4153-8f59-c494a3b7e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_CommonStockMember_917a64b0-4183-4153-8f59-c494a3b7e47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4fa7bd23-db04-4a55-93ce-8906ca82f19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4fa7bd23-db04-4a55-93ce-8906ca82f19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_face16f9-229e-45c5-b992-a3e6388574a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_face16f9-229e-45c5-b992-a3e6388574a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7e5aaabb-9f66-47b5-af7f-933a71d569bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fe26153c-1036-43b5-87de-bf0a4444e67e" xlink:to="loc_us-gaap_RetainedEarningsMember_7e5aaabb-9f66-47b5-af7f-933a71d569bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c68c2385-84ae-4487-8b45-1d6e6f319421" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8bd76dfa-67af-4548-b331-37fca9c8b87a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c68c2385-84ae-4487-8b45-1d6e6f319421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8f520761-73a2-4e88-b1cc-e7add9968f8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c68c2385-84ae-4487-8b45-1d6e6f319421" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8f520761-73a2-4e88-b1cc-e7add9968f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a51c3383-ac05-4312-9b0a-4650e757b103" xlink:to="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2cd0dab-cffe-4229-bf0b-62f9267bc1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockholdersEquity_e2cd0dab-cffe-4229-bf0b-62f9267bc1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e7e31336-b2e8-481c-80e0-91c7c60488ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e7e31336-b2e8-481c-80e0-91c7c60488ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afaca4de-5726-4554-a6f2-a91af8bc3caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afaca4de-5726-4554-a6f2-a91af8bc3caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2226be26-201a-43e8-8972-2e2b349c036d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2226be26-201a-43e8-8972-2e2b349c036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6ccbf51b-0588-4780-8703-ed418d6302b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6ccbf51b-0588-4780-8703-ed418d6302b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0dd9a13a-c290-42cc-9796-a77bf00e73e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0dd9a13a-c290-42cc-9796-a77bf00e73e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_bf4130e5-32e0-4f50-8d21-b788e4805ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_bf4130e5-32e0-4f50-8d21-b788e4805ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_5bde88f6-9f34-41d4-9f29-9747a3aadd66" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions_5bde88f6-9f34-41d4-9f29-9747a3aadd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_b9d32910-ca64-41ed-8c50-97855f632a96" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_b9d32910-ca64-41ed-8c50-97855f632a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_1eaa010b-26cf-404e-84c6-d1235a57ccb1" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_1eaa010b-26cf-404e-84c6-d1235a57ccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_a7fa60f1-0769-40a5-bfc6-56f3c908d7f6" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_a7fa60f1-0769-40a5-bfc6-56f3c908d7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f0b73f9e-33b2-4568-ad00-e9e07e25f3b0" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f0b73f9e-33b2-4568-ad00-e9e07e25f3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a75375f0-9ea6-45c7-9bc1-d650d7249866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_NetIncomeLoss_a75375f0-9ea6-45c7-9bc1-d650d7249866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_91d375d1-ae23-45d6-bc58-4f6eb1c29b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_StockholdersEquity_91d375d1-ae23-45d6-bc58-4f6eb1c29b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d750616-04ea-4e28-a628-70dfb17aa17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_49a81829-18d2-4f66-8f7d-f16f1c2bb420" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3d750616-04ea-4e28-a628-70dfb17aa17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_74dce9ce-af68-4ca5-bf9b-3010ceea386a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0f7208dd-e778-4195-8232-9584c797d500" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_74dce9ce-af68-4ca5-bf9b-3010ceea386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8fdc702b-d7bf-4690-afb0-7d0caff3ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8fdc702b-d7bf-4690-afb0-7d0caff3ab64" xlink:to="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:to="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_04dc5721-13ce-4377-a0d5-ddb66f73443a" xlink:to="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NucorionMember_4077edc9-0858-4bb3-b222-3260043ba5db" xlink:href="lgnd-20231231.xsd#lgnd_NucorionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:to="loc_lgnd_NucorionMember_4077edc9-0858-4bb3-b222-3260043ba5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_e1bf1a98-3bad-46ed-a5d3-3cd0b46634f8" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_0597a1d2-e72c-43a6-a3fc-308139f2c4e1" xlink:to="loc_lgnd_PrimroseBioMember_e1bf1a98-3bad-46ed-a5d3-3cd0b46634f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f383e321-29fe-4059-bf86-733d8a9df69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d59649f1-a8b5-4b42-9024-f05ffed6f51c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f383e321-29fe-4059-bf86-733d8a9df69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_f033a8f1-6606-4048-8049-ea209e785cb9" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f383e321-29fe-4059-bf86-733d8a9df69b" xlink:to="loc_lgnd_NovanIncMember_f033a8f1-6606-4048-8049-ea209e785cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36b555f2-25af-4f06-b9de-3297a62e744f" xlink:to="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_306c1ba9-3a4f-4775-9663-bf6d69f1e189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:to="loc_us-gaap_NetIncomeLoss_306c1ba9-3a4f-4775-9663-bf6d69f1e189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_fde708b1-db76-4816-9081-99d02a43dbff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_fde708b1-db76-4816-9081-99d02a43dbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_c970d87d-a118-461b-a6b9-09e293065e57" xlink:href="lgnd-20231231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_c970d87d-a118-461b-a6b9-09e293065e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3fb480e0-a9e3-4a92-ab9f-89f69927f994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3fb480e0-a9e3-4a92-ab9f-89f69927f994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_682a9b21-6e14-4194-a793-7ed2855f53d0" xlink:href="lgnd-20231231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_682a9b21-6e14-4194-a793-7ed2855f53d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b6c57842-788e-46a6-9d62-42e99f448713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b6c57842-788e-46a6-9d62-42e99f448713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0e0c1555-e717-444f-bafe-fe2f00a18114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0e0c1555-e717-444f-bafe-fe2f00a18114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_765242d6-5720-47df-b95b-7b769751d0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_765242d6-5720-47df-b95b-7b769751d0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22310352-bb64-4f1d-aa83-57ffa13636eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22310352-bb64-4f1d-aa83-57ffa13636eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_ecf7275d-ad96-4a48-9e7a-8494e0463766" xlink:href="lgnd-20231231.xsd#lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights_ecf7275d-ad96-4a48-9e7a-8494e0463766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_d202c492-ca5d-41ef-8be5-44d873bee695" xlink:href="lgnd-20231231.xsd#lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights_d202c492-ca5d-41ef-8be5-44d873bee695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnCommercialLicenseRights_2ed503e1-d75c-4410-9eda-02a31817a5dc" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentLossOnCommercialLicenseRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_ImpairmentLossOnCommercialLicenseRights_2ed503e1-d75c-4410-9eda-02a31817a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_38a33b6b-918b-44d7-b8c0-9bb78237270f" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_38a33b6b-918b-44d7-b8c0-9bb78237270f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_08d61f11-ab83-4932-b468-86d9b4ebc8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_ShareBasedCompensation_08d61f11-ab83-4932-b468-86d9b4ebc8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30b87fe0-fa69-436d-900e-215ac7f650ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_30b87fe0-fa69-436d-900e-215ac7f650ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_64345b9e-d45c-44f6-94eb-d941b15f1631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_64345b9e-d45c-44f6-94eb-d941b15f1631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cad3cf-e8a8-45bd-afd1-1f6e1903258d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b0cad3cf-e8a8-45bd-afd1-1f6e1903258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_01b62a84-2d20-46cd-901e-b624e0f51070" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5e1bdc2d-4f48-41e1-91bd-f5f285394dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5e1bdc2d-4f48-41e1-91bd-f5f285394dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4598ca94-494a-48af-8322-d9f1bcce1645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4598ca94-494a-48af-8322-d9f1bcce1645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_85f0a0c3-a0c1-4565-9a59-e60b6b2619d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_85f0a0c3-a0c1-4565-9a59-e60b6b2619d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf7156a6-2eb0-4a7e-bbbc-03ec9ad4d504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf7156a6-2eb0-4a7e-bbbc-03ec9ad4d504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e584c60a-26f1-4fe9-94b4-7b2d4e67563a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e584c60a-26f1-4fe9-94b4-7b2d4e67563a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_da4efc18-8506-4e8d-bd8f-caf4ee243470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_da4efc18-8506-4e8d-bd8f-caf4ee243470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1e810093-9edd-4f4c-a81e-c40c2b8b833f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd825cae-e4bf-4e7c-9024-a5cc22590814" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1e810093-9edd-4f4c-a81e-c40c2b8b833f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7e7a113-1c96-47ef-80a6-6e805f49b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_388c6230-1df2-49e6-abdc-3284f1f902c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7e7a113-1c96-47ef-80a6-6e805f49b31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseforCommercialLicenseRights_6f36ae61-c9b9-457b-a489-8603d129a111" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseforCommercialLicenseRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_lgnd_PurchaseforCommercialLicenseRights_6f36ae61-c9b9-457b-a489-8603d129a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e581006-64e4-42af-a0af-7ea24ea28513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e581006-64e4-42af-a0af-7ea24ea28513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_f16dc992-5227-45e5-972d-1dae7b5d63e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_f16dc992-5227-45e5-972d-1dae7b5d63e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromCommercialLicenseRights_32ae3868-df93-4ebf-8a43-29234cadb8d8" xlink:href="lgnd-20231231.xsd#lgnd_ProceedsFromCommercialLicenseRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_lgnd_ProceedsFromCommercialLicenseRights_32ae3868-df93-4ebf-8a43-29234cadb8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0a2b2a5e-c392-411a-a82a-f39b1b0309bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0a2b2a5e-c392-411a-a82a-f39b1b0309bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_44ca24ed-e453-425a-9ab7-408c0b729d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_44ca24ed-e453-425a-9ab7-408c0b729d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f7cd603d-4135-45eb-a143-781df28a8808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f7cd603d-4135-45eb-a143-781df28a8808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1dd18ca4-5c9c-4251-aee4-3c06e063c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1dd18ca4-5c9c-4251-aee4-3c06e063c88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_26986af2-23b2-416d-b6a0-a72712b8e01e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_26986af2-23b2-416d-b6a0-a72712b8e01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fbb0be6-1a94-483a-84a4-01ab277a3f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f9506be-b4df-423b-aaa7-14c5e1d0c82a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1fbb0be6-1a94-483a-84a4-01ab277a3f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation_271dbc28-1032-4cd7-992d-0f8d8dabdc06" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsForSeparation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_lgnd_PaymentsForSeparation_271dbc28-1032-4cd7-992d-0f8d8dabdc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c5d74086-caf9-47fb-a2d1-f719c6dd09bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c5d74086-caf9-47fb-a2d1-f719c6dd09bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d8d634d0-615a-4fb2-8d64-958c1b4c8dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d8d634d0-615a-4fb2-8d64-958c1b4c8dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_d595b0d8-67b1-49b3-8b43-52178b0147c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_d595b0d8-67b1-49b3-8b43-52178b0147c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_52bd1b7a-84dd-4bdb-b16c-5348f1f1b690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_52bd1b7a-84dd-4bdb-b16c-5348f1f1b690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_bfb6cf4b-6965-4d7b-92cb-dcf1446ef47e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_bfb6cf4b-6965-4d7b-92cb-dcf1446ef47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0973553c-e1e9-464d-b0f3-42dfa0229c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0973553c-e1e9-464d-b0f3-42dfa0229c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25b60040-8070-4324-9359-33708dc9ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_25b60040-8070-4324-9359-33708dc9ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_52a22ca9-b99a-4908-8ceb-a468e19cf977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_52a22ca9-b99a-4908-8ceb-a468e19cf977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_b41fb3a7-445c-4800-8138-fbdd825d6eb8" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_b41fb3a7-445c-4800-8138-fbdd825d6eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e4b6835-1ff2-4dc0-9eb8-62c10abe2a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3a84ece5-028c-4262-83fc-3104875e8eeb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e4b6835-1ff2-4dc0-9eb8-62c10abe2a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ae15da23-2d75-4740-87d5-2d9251e41f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ae15da23-2d75-4740-87d5-2d9251e41f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80fae0e0-6eb1-4432-a3b9-28b34cb43ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80fae0e0-6eb1-4432-a3b9-28b34cb43ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_563cb199-a62a-4453-8cb7-220c6199e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_563cb199-a62a-4453-8cb7-220c6199e2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:href="lgnd-20231231.xsd#lgnd_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:to="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_43e8e226-d620-4aa6-b95b-da35c9d876e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:to="loc_us-gaap_InterestPaidNet_43e8e226-d620-4aa6-b95b-da35c9d876e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a40e4b7b-b04d-4bb9-af38-fead7d114bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CashPaidDuringTheYearAbstract_ba0db040-29d8-444f-873a-6cb5689a4726" xlink:to="loc_us-gaap_IncomeTaxesPaid_a40e4b7b-b04d-4bb9-af38-fead7d114bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_83de9ef9-79db-4249-8609-5adedabd7a6a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_99d8c0e5-1476-4ac8-9c7e-2b0c52096d78" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_99d8c0e5-1476-4ac8-9c7e-2b0c52096d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_33cd097b-789b-44e9-9167-cc8327d04a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_33cd097b-789b-44e9-9167-cc8327d04a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a86ce13-10bf-4667-b72d-e57cf7c9b678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_Goodwill_3a86ce13-10bf-4667-b72d-e57cf7c9b678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3a031a30-91c0-49d5-bfea-15a44e6df249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3a031a30-91c0-49d5-bfea-15a44e6df249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f0ba5a26-3366-4f38-95af-81da3d4c1996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f0ba5a26-3366-4f38-95af-81da3d4c1996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9b5fd7d-0759-4770-99cd-cdeef0ce74ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_d9bf8242-9873-4a05-a1c6-7819895fc460" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c9b5fd7d-0759-4770-99cd-cdeef0ce74ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e4bf850-2725-401a-9b5d-7975b2adc643" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_ebc70493-a331-4bb9-a058-91704163fb85" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_ebc70493-a331-4bb9-a058-91704163fb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_346f452c-c1a9-4958-9c70-caa03bb086d9" xlink:href="lgnd-20231231.xsd#lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_346f452c-c1a9-4958-9c70-caa03bb086d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_5ab1c97f-0fba-4e3c-a300-55d6678f96f8" xlink:href="lgnd-20231231.xsd#lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_5ab1c97f-0fba-4e3c-a300-55d6678f96f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_308ee8d6-6981-44ec-8c6a-7d3acad2cc49" xlink:href="lgnd-20231231.xsd#lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_308ee8d6-6981-44ec-8c6a-7d3acad2cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f3113b0f-f622-4fda-b4c9-1dc1ac150ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f3113b0f-f622-4fda-b4c9-1dc1ac150ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedInventoryPurchases_4d1f7374-94b7-4872-a0ea-53aa89a89c3b" xlink:href="lgnd-20231231.xsd#lgnd_AccruedInventoryPurchases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_lgnd_AccruedInventoryPurchases_4d1f7374-94b7-4872-a0ea-53aa89a89c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b055c617-0f72-4d58-8a80-780f7eb545a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1b70cc2e-5b93-41a3-bbe1-8d8956d3cd84" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b055c617-0f72-4d58-8a80-780f7eb545a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1268cd24-5243-4500-a816-9e6e1454d829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_be005206-22be-4766-ab41-6a2a3597564b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1268cd24-5243-4500-a816-9e6e1454d829" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_be005206-22be-4766-ab41-6a2a3597564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBio"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5c8d4115-b376-4e22-859b-e09fabd37b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8cefd91f-f7c9-4a2e-b469-8bfe12d85ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5c8d4115-b376-4e22-859b-e09fabd37b6d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8cefd91f-f7c9-4a2e-b469-8bfe12d85ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Acquisition" xlink:type="simple" xlink:href="lgnd-20231231.xsd#Acquisition"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Acquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_618a43b5-ced3-419c-bd24-545c875f2222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4cf66ae4-83cb-49fe-90fe-55b241d63a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_618a43b5-ced3-419c-bd24-545c875f2222" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4cf66ae4-83cb-49fe-90fe-55b241d63a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAb" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAb"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAb" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_221d7ee0-253d-4513-9e49-3efbf0d824b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_645422f0-be29-4f87-bfcf-0f82236ee478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_221d7ee0-253d-4513-9e49-3efbf0d824b7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_645422f0-be29-4f87-bfcf-0f82236ee478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRights"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1b597ff3-152e-45b1-9ef8-1c59479a87df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock_bc968076-913c-46a8-ba0a-16e13594d256" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1b597ff3-152e-45b1-9ef8-1c59479a87df" xlink:to="loc_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock_bc968076-913c-46a8-ba0a-16e13594d256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_60e9ec59-98e7-4087-922f-5f9b701ec3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f7553011-fe08-4eff-a952-075b74f9b419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60e9ec59-98e7-4087-922f-5f9b701ec3c7" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f7553011-fe08-4eff-a952-075b74f9b419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f346d8b7-2996-4a8b-be18-bf526f044c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8f2150ad-10dc-48bc-8583-14406eceed8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f346d8b7-2996-4a8b-be18-bf526f044c66" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8f2150ad-10dc-48bc-8583-14406eceed8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_91d0a2ab-8033-435d-a249-61ca0d631605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f346d8b7-2996-4a8b-be18-bf526f044c66" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_91d0a2ab-8033-435d-a249-61ca0d631605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Debt" xlink:type="simple" xlink:href="lgnd-20231231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e3b8476e-1112-4332-a66d-39fd7154766a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_27a5e3a9-9bf1-401f-a2da-265dc64832f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3b8476e-1112-4332-a66d-39fd7154766a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_27a5e3a9-9bf1-401f-a2da-265dc64832f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_4c4232d6-20c0-408e-ad14-af3160a2a1e7" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_059dddec-bc52-4eed-bd1f-8df4b6584955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4c4232d6-20c0-408e-ad14-af3160a2a1e7" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_059dddec-bc52-4eed-bd1f-8df4b6584955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_02f59a41-8f80-4280-8288-06ebf70c1e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_002db9fd-c107-4cd7-a54b-27d211577043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02f59a41-8f80-4280-8288-06ebf70c1e3f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_002db9fd-c107-4cd7-a54b-27d211577043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommitmentandContingenciesLegalProceedings"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_814ca3de-d1bd-4ad6-ba6e-b7f5853574e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_905176b0-e129-42f2-92b2-bd616566610d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_814ca3de-d1bd-4ad6-ba6e-b7f5853574e4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_905176b0-e129-42f2-92b2-bd616566610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7d9b30e0-3d3e-45e8-a7f2-5f2c9fdfa212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4f3d5b21-65d7-4117-a1aa-1b83b3a81ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d9b30e0-3d3e-45e8-a7f2-5f2c9fdfa212" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4f3d5b21-65d7-4117-a1aa-1b83b3a81ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_e5305f3c-1c16-499a-b464-010985ad756c" xlink:href="lgnd-20231231.xsd#lgnd_BusinessSpinOffAndMigrationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_e5305f3c-1c16-499a-b464-010985ad756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_42e999db-9033-4bdf-85b7-81503a55900d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_42e999db-9033-4bdf-85b7-81503a55900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_b0b3233f-e905-401d-af90-be3599c00fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_b0b3233f-e905-401d-af90-be3599c00fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a5e05b3e-c8e8-4321-9f70-e8e6fea97ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_UseOfEstimates_a5e05b3e-c8e8-4321-9f70-e8e6fea97ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7081933f-609a-4d58-9a94-9011fff66f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7081933f-609a-4d58-9a94-9011fff66f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_f00e2dff-8968-4da9-ba93-f82b14b17070" xlink:href="lgnd-20231231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_f00e2dff-8968-4da9-ba93-f82b14b17070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_747c0314-811f-4367-8b23-20691ad43066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_747c0314-811f-4367-8b23-20691ad43066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_d83b6309-b89a-4233-ad73-a1a7e29f3032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_d83b6309-b89a-4233-ad73-a1a7e29f3032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1b05e40d-6024-4f25-a92e-0f141a9421f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1b05e40d-6024-4f25-a92e-0f141a9421f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_32b37291-9a7b-4ea1-a31c-345564ca5f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_32b37291-9a7b-4ea1-a31c-345564ca5f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_acb35d19-dffa-4774-afc7-a0c85e5ca0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_acb35d19-dffa-4774-afc7-a0c85e5ca0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_0f994c71-b37f-4d1a-b9d3-f83ec7dfbcd9" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_lgnd_CommercialLicenseRightsPolicyTextBlock_0f994c71-b37f-4d1a-b9d3-f83ec7dfbcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_69cb81bc-f891-4bc8-9489-851b2fab3f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_69cb81bc-f891-4bc8-9489-851b2fab3f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock_f5603c25-b274-4ac2-b712-a831b20a6759" xlink:href="lgnd-20231231.xsd#lgnd_OtherInvestmentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock_f5603c25-b274-4ac2-b712-a831b20a6759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_19112204-9ff6-4f0a-a129-9a192cf4bcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_19112204-9ff6-4f0a-a129-9a192cf4bcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bcfd606c-f6ab-4a2a-8ac2-e4fe61dc7660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bcfd606c-f6ab-4a2a-8ac2-e4fe61dc7660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9e1ec249-b038-4e63-892f-acdfca9ffb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9e1ec249-b038-4e63-892f-acdfca9ffb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5827dd05-64d6-4634-a745-4483a13be3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5827dd05-64d6-4634-a745-4483a13be3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_217322ba-7ecd-4659-b957-8598e6d18ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_217322ba-7ecd-4659-b957-8598e6d18ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b90ecec5-62d3-44d8-b03c-95bb537edb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b90ecec5-62d3-44d8-b03c-95bb537edb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fbab481f-f356-42ed-80b3-7c57c72dbe86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4daa4b3c-7d9c-407d-8cdb-0eedf0806c89" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fbab481f-f356-42ed-80b3-7c57c72dbe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6fdf4669-d1c8-4f32-83a4-137235bf1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3dacc217-5781-42a8-930b-a84fac8598b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6fdf4669-d1c8-4f32-83a4-137235bf1f2d" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3dacc217-5781-42a8-930b-a84fac8598b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e7047d93-6a48-4101-bbf8-ade339e6f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6fdf4669-d1c8-4f32-83a4-137235bf1f2d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e7047d93-6a48-4101-bbf8-ade339e6f0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fe82be6c-d247-4b23-8574-465d3be9319a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6fdf4669-d1c8-4f32-83a4-137235bf1f2d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fe82be6c-d247-4b23-8574-465d3be9319a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b935f3a1-f9ab-44ae-b723-4ed4925a5388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_92120e57-d6b8-4a49-8c82-2099eaff9eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b935f3a1-f9ab-44ae-b723-4ed4925a5388" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_92120e57-d6b8-4a49-8c82-2099eaff9eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_3ee2adbf-f62d-46d9-bc01-2bcce57818c3" xlink:href="lgnd-20231231.xsd#lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b935f3a1-f9ab-44ae-b723-4ed4925a5388" xlink:to="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_3ee2adbf-f62d-46d9-bc01-2bcce57818c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c6804f63-aa0b-48ec-938f-8ebfcf00d113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_049e38d9-26a1-4ebd-a532-e3a433b51215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c6804f63-aa0b-48ec-938f-8ebfcf00d113" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_049e38d9-26a1-4ebd-a532-e3a433b51215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dd1b66ee-2c3a-4ecc-97c4-bd512ae8f887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_95a4ae78-64c7-45e4-876b-2d7ba0f2e667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dd1b66ee-2c3a-4ecc-97c4-bd512ae8f887" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_95a4ae78-64c7-45e4-876b-2d7ba0f2e667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRightsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9fb083b-6000-4f2f-8863-d7d67152bb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock_f32efd0d-d07b-4824-81c1-8f4f94715c71" xlink:href="lgnd-20231231.xsd#lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9fb083b-6000-4f2f-8863-d7d67152bb9a" xlink:to="loc_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock_f32efd0d-d07b-4824-81c1-8f4f94715c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7ce0e554-f0d4-4b09-b078-78cd69ccba84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9715349a-96f9-412e-94cf-7a9f21869c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7ce0e554-f0d4-4b09-b078-78cd69ccba84" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9715349a-96f9-412e-94cf-7a9f21869c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9c18e395-4138-4189-a6a7-869643b11547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7ce0e554-f0d4-4b09-b078-78cd69ccba84" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9c18e395-4138-4189-a6a7-869643b11547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cd5dd375-85c5-4e52-9414-eaf0c3aabbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7ce0e554-f0d4-4b09-b078-78cd69ccba84" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cd5dd375-85c5-4e52-9414-eaf0c3aabbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b99d1606-abe9-4401-8521-e1010d0691a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_37f40775-7acf-49be-ad68-bc7032b117ac" xlink:href="lgnd-20231231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b99d1606-abe9-4401-8521-e1010d0691a7" xlink:to="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_37f40775-7acf-49be-ad68-bc7032b117ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_32df0fb0-bb18-4b93-a29d-db89348b5d65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b99d1606-abe9-4401-8521-e1010d0691a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_32df0fb0-bb18-4b93-a29d-db89348b5d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_09befe7c-8882-41e1-b922-c2543d804039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b99d1606-abe9-4401-8521-e1010d0691a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_09befe7c-8882-41e1-b922-c2543d804039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_90323ef8-77b0-4b19-955d-4f12459ba33c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_d05e9c69-34f9-4dd0-ae19-d08739239e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_90323ef8-77b0-4b19-955d-4f12459ba33c" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_d05e9c69-34f9-4dd0-ae19-d08739239e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_d21eb070-72f1-41df-8efc-5ab2927b98dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_d21eb070-72f1-41df-8efc-5ab2927b98dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e4ae4860-22dd-4ac2-836e-748e8d8265af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e4ae4860-22dd-4ac2-836e-748e8d8265af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_e17d27fb-3477-4d6b-a089-e7bea8ceadf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_e17d27fb-3477-4d6b-a089-e7bea8ceadf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_037ccb48-5a82-42b1-9baf-3510d3d61dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_037ccb48-5a82-42b1-9baf-3510d3d61dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ad9e2c7e-8cee-4fb1-8a34-64e54f7a8910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ad9e2c7e-8cee-4fb1-8a34-64e54f7a8910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6676c252-2525-40e2-a780-19d0a73ebd66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6676c252-2525-40e2-a780-19d0a73ebd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2ebf8d1d-dfe8-4974-b279-06f9df585121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_2ebf8d1d-dfe8-4974-b279-06f9df585121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_3689580f-37ef-4de6-ba20-1aaf3e286f2c" xlink:href="lgnd-20231231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_a84e00a5-9fa3-493a-bb72-8ea99fda2949" xlink:to="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_3689580f-37ef-4de6-ba20-1aaf3e286f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_82786036-4af9-442c-902a-739858fafee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ccccafcf-fbee-44b3-94be-1c5e7894a028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82786036-4af9-442c-902a-739858fafee3" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_ccccafcf-fbee-44b3-94be-1c5e7894a028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9fe3b191-b654-43d5-a557-609f4bb6dc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82786036-4af9-442c-902a-739858fafee3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9fe3b191-b654-43d5-a557-609f4bb6dc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_7f2b31a6-feeb-4aa7-a8b8-00d4fa5feacc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82786036-4af9-442c-902a-739858fafee3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_7f2b31a6-feeb-4aa7-a8b8-00d4fa5feacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1337a863-177a-48b8-830b-5be01591a167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82786036-4af9-442c-902a-739858fafee3" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1337a863-177a-48b8-830b-5be01591a167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3890058f-b87d-45ba-be39-4857e283cc28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82786036-4af9-442c-902a-739858fafee3" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_3890058f-b87d-45ba-be39-4857e283cc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b52a58ad-e764-4d00-bad6-f89302bf00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bc8f8f57-a31c-41e4-8a81-9d61b6065e19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b52a58ad-e764-4d00-bad6-f89302bf00d1" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bc8f8f57-a31c-41e4-8a81-9d61b6065e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b28e9d8d-8bad-43e8-90f1-026b6a46ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b52a58ad-e764-4d00-bad6-f89302bf00d1" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b28e9d8d-8bad-43e8-90f1-026b6a46ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_45161ef8-a8bb-4d2d-bd84-386e51df82b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b52a58ad-e764-4d00-bad6-f89302bf00d1" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_45161ef8-a8bb-4d2d-bd84-386e51df82b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_740bfde8-ca8b-49c5-9a7c-2be76511c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b52a58ad-e764-4d00-bad6-f89302bf00d1" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock_740bfde8-ca8b-49c5-9a7c-2be76511c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f844231e-1d0d-4887-95da-ea99792af085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:href="lgnd-20231231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f844231e-1d0d-4887-95da-ea99792af085" xlink:to="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c889207-2d74-437c-9844-4f51cef67a71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_241cdf1f-a4fa-4316-ab1a-800b035111e7" xlink:to="loc_srt_ProductsAndServicesDomain_8c889207-2d74-437c-9844-4f51cef67a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_3ed80ef5-d59a-4dc2-9048-2de8940a70b9" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c889207-2d74-437c-9844-4f51cef67a71" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_3ed80ef5-d59a-4dc2-9048-2de8940a70b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8ff71c97-62f9-406b-aa65-15a245425c7d" xlink:to="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f632740-2ac4-4014-8312-dbe51fc04bcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:to="loc_srt_MinimumMember_6f632740-2ac4-4014-8312-dbe51fc04bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e7b7337-34a9-4913-822c-5dc284db70e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09a161c9-8fe3-45e6-b8e2-acd0ec4a1f66" xlink:to="loc_srt_MaximumMember_7e7b7337-34a9-4913-822c-5dc284db70e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54a49a42-8dbe-43b5-9831-6ff7817f5eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6bc10dec-0674-47d1-9df4-0842c3cf83ea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54a49a42-8dbe-43b5-9831-6ff7817f5eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_88e7d1bb-4e57-4d26-991f-a892946c6d4b" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54a49a42-8dbe-43b5-9831-6ff7817f5eac" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_88e7d1bb-4e57-4d26-991f-a892946c6d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_143824f2-0ae6-4eca-a487-d586deffbd14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_65d41202-123b-4718-ae39-4c98a142f174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:to="loc_us-gaap_PerformanceSharesMember_65d41202-123b-4718-ae39-4c98a142f174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b3e94688-1b66-4488-a49b-8e83f7d4f9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b3e94688-1b66-4488-a49b-8e83f7d4f9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_f3fc05c5-1320-46f3-b65f-dde0af9a9846" xlink:href="lgnd-20231231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e336bf5a-0efa-45ee-87e3-8e0a6a2873e0" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_f3fc05c5-1320-46f3-b65f-dde0af9a9846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8a1ae2a8-d34f-495a-837d-b4131c365cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ed7b1d9d-1216-4111-a8eb-e261dbd320f1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8a1ae2a8-d34f-495a-837d-b4131c365cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_4913a8b2-80ac-41cd-891c-d5bcd916132e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8a1ae2a8-d34f-495a-837d-b4131c365cb7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_4913a8b2-80ac-41cd-891c-d5bcd916132e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c581a5d3-59aa-4f02-8f86-e514c24f5dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2fb0418f-c910-4a13-9ac7-7c4a8585c738" xlink:to="loc_us-gaap_PlanNameDomain_c581a5d3-59aa-4f02-8f86-e514c24f5dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_62c55a9f-0c09-45e8-baa7-5263c332e8fb" xlink:href="lgnd-20231231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c581a5d3-59aa-4f02-8f86-e514c24f5dd3" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_62c55a9f-0c09-45e8-baa7-5263c332e8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_8722e2de-0bd8-47a9-8641-8eca9dfdadb6" xlink:to="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_ed8f3922-6e09-422a-8168-a258b585f62a" xlink:href="lgnd-20231231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:to="loc_lgnd_VestingPeriodOneMember_ed8f3922-6e09-422a-8168-a258b585f62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_50f69c35-3010-4808-83da-a518f667bf89" xlink:href="lgnd-20231231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1f83bbdf-2bc0-4533-804f-5db056b34c1f" xlink:to="loc_lgnd_VestingPeriodTwoMember_50f69c35-3010-4808-83da-a518f667bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:href="lgnd-20231231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_485c8471-e7d9-46e9-b344-29e8beb8f1e0" xlink:to="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d2e36c97-30fc-4d3c-9d74-fe8f58e7aac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_NumberOfReportableSegments_d2e36c97-30fc-4d3c-9d74-fe8f58e7aac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_2a11fd48-ca9c-4c9b-a83f-117b28d15ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_2a11fd48-ca9c-4c9b-a83f-117b28d15ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_778c9411-8241-436d-9a60-a93d502ad89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_InventoryWriteDown_778c9411-8241-436d-9a60-a93d502ad89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1a6321af-4e1a-4efa-b402-655b550f2ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_InventoryNet_1a6321af-4e1a-4efa-b402-655b550f2ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e2628b3-1f8b-42fe-a980-decb38491e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2e2628b3-1f8b-42fe-a980-decb38491e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_18f9a6cc-8de5-45ab-8e3f-d61525ae548f" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_18f9a6cc-8de5-45ab-8e3f-d61525ae548f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b7c3199b-2164-417b-8bc9-099036eaf957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b7c3199b-2164-417b-8bc9-099036eaf957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_66cc9567-336b-49be-84ec-cc215bfbab68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_66cc9567-336b-49be-84ec-cc215bfbab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_bdbcdd12-05c1-4728-89b2-cdf9d7f058e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_bdbcdd12-05c1-4728-89b2-cdf9d7f058e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_02731e2d-484f-46c5-b167-1351c51f50c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_02731e2d-484f-46c5-b167-1351c51f50c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8e624a46-f928-4cb5-b726-c47ffab591c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8e624a46-f928-4cb5-b726-c47ffab591c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b20a3291-2450-4da8-b2bc-61e42b55901f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_c64b6e10-5ee5-415b-aa4d-a03c33b46867" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b20a3291-2450-4da8-b2bc-61e42b55901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff1b525e-7d12-40bd-98f3-263d497a1156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff1b525e-7d12-40bd-98f3-263d497a1156" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_146dcbba-b6e1-4b62-adca-6fee20536f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25806038-c812-4a98-9b37-c6456f61dc94" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_146dcbba-b6e1-4b62-adca-6fee20536f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_619e3359-bbde-477a-a0ad-7256a879a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_146dcbba-b6e1-4b62-adca-6fee20536f41" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_619e3359-bbde-477a-a0ad-7256a879a9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de8b415d-421a-4dd6-8006-6a690abd1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_721e531a-32f1-4833-9d6e-447491d2ad76" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de8b415d-421a-4dd6-8006-6a690abd1b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_96803596-ff4c-4ad9-8258-a610cb8e8f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de8b415d-421a-4dd6-8006-6a690abd1b5b" xlink:to="loc_us-gaap_SalesRevenueNetMember_96803596-ff4c-4ad9-8258-a610cb8e8f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e315cdc8-d2db-4dff-a840-8ce4a17f4657" xlink:to="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_40c269c2-05b4-4260-b6c0-3af4c7ff1866" xlink:href="lgnd-20231231.xsd#lgnd_PartnerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:to="loc_lgnd_PartnerAMember_40c269c2-05b4-4260-b6c0-3af4c7ff1866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_000fdc77-05db-48db-be9d-8a4383017bbb" xlink:href="lgnd-20231231.xsd#lgnd_PartnerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:to="loc_lgnd_PartnerBMember_000fdc77-05db-48db-be9d-8a4383017bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_a41db884-2296-4855-8d66-d659c5edd4b2" xlink:href="lgnd-20231231.xsd#lgnd_PartnerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ca591dea-9481-4120-8e2b-d6ef8f3ae1fa" xlink:to="loc_lgnd_PartnerCMember_a41db884-2296-4855-8d66-d659c5edd4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_929c556b-206e-48ad-ab1f-5dd49aa72c65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_30dadd98-2af6-4090-af17-1d794ea2da59" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_929c556b-206e-48ad-ab1f-5dd49aa72c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3b8052f5-4cdc-4846-a8bb-7dbbfb37a020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_929c556b-206e-48ad-ab1f-5dd49aa72c65" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3b8052f5-4cdc-4846-a8bb-7dbbfb37a020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a00d963-6ee6-4c35-a4f3-78a4145eb2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3a00d963-6ee6-4c35-a4f3-78a4145eb2fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:to="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_430f4f0b-2b98-4e26-b282-956979e1f92b" xlink:to="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:to="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_53c0dc7d-6fa9-4264-ad8b-4d4be5227c05" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyKyprolisMember_53c0dc7d-6fa9-4264-ad8b-4d4be5227c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_6fc91eb3-2e10-446e-9b81-c7f42373cba2" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyEvomelaMember_6fc91eb3-2e10-446e-9b81-c7f42373cba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyTeriparatideInjectionMember_67463b4d-55f3-4d13-8c46-78a1d8b3d2e9" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyTeriparatideInjectionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyTeriparatideInjectionMember_67463b4d-55f3-4d13-8c46-78a1d8b3d2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyRylazeMember_a170a0f8-d66c-4af7-88f7-7ab2a32b1a17" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyRylazeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyRylazeMember_a170a0f8-d66c-4af7-88f7-7ab2a32b1a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_e7336987-56f9-4a84-801e-dbc0c353989b" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e84336f1-4221-4c78-832c-1da395e2f305" xlink:to="loc_lgnd_RoyaltyOtherMember_e7336987-56f9-4a84-801e-dbc0c353989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCoreMember_1a307582-10b1-43c9-980c-32ee3047000c" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolCoreMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:to="loc_lgnd_MaterialSalesCaptisolCoreMember_1a307582-10b1-43c9-980c-32ee3047000c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCOVIDMember_5d61ab13-7f43-4505-8677-3b6e97987085" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolCOVIDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_daaef78b-6f94-4582-ab7c-22a4ac519ba0" xlink:to="loc_lgnd_MaterialSalesCaptisolCOVIDMember_5d61ab13-7f43-4505-8677-3b6e97987085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0876ef1e-c1e5-4f56-b538-cc014fd79bb1" xlink:to="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_da68370e-f813-4cb9-b208-1eccb1ffb479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_us-gaap_ServiceMember_da68370e-f813-4cb9-b208-1eccb1ffb479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_111aa51d-aa3f-47f8-a7e7-5a15de3cc9ff" xlink:href="lgnd-20231231.xsd#lgnd_LicenseFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_lgnd_LicenseFeesMember_111aa51d-aa3f-47f8-a7e7-5a15de3cc9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneMember_58585f2b-09c5-423c-90d3-2663a5baead5" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_lgnd_MilestoneMember_58585f2b-09c5-423c-90d3-2663a5baead5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_f95d37e0-c336-42fb-9cb2-f4227ae59e25" xlink:href="lgnd-20231231.xsd#lgnd_LicenseFeesMilestonesAndOtherProductOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_d7b65ce9-bb32-4b85-bfce-4a15b03c724d" xlink:to="loc_lgnd_LicenseFeesMilestonesAndOtherProductOtherMember_f95d37e0-c336-42fb-9cb2-f4227ae59e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_90215162-d27c-4d1f-bc32-e87c2fab1bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_976e06e3-a358-46dd-be40-2c9f66e94f3f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_90215162-d27c-4d1f-bc32-e87c2fab1bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56b2ba32-111d-4c62-9c8c-c21632a28df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_90215162-d27c-4d1f-bc32-e87c2fab1bf7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56b2ba32-111d-4c62-9c8c-c21632a28df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90c290d7-51c5-47d9-b48d-a37328a05de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90c290d7-51c5-47d9-b48d-a37328a05de0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6477b76-f1c1-4cb5-8936-8d211adcd277" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7d85d1d9-7321-4183-853c-ef5e657dc552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:to="loc_us-gaap_RestrictedStockMember_7d85d1d9-7321-4183-853c-ef5e657dc552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_984dad39-9cb9-485b-8284-ed1f29ee7bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_984dad39-9cb9-485b-8284-ed1f29ee7bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_7d1bdc2d-0bdf-46b5-9b91-173ef0d8e267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a342cd9-7f4d-4f84-9816-90c8709ec6f2" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_7d1bdc2d-0bdf-46b5-9b91-173ef0d8e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5d7c69f-085b-4063-8f2e-fb6e4243d90e" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_06cc4002-ec7a-4c4b-8b26-cce12ef73d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_06cc4002-ec7a-4c4b-8b26-cce12ef73d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_be52102e-f68c-4b60-80c7-ba530ed3fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_be52102e-f68c-4b60-80c7-ba530ed3fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_471a92c9-86a3-4dd6-a15d-ed8fda3aa8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_471a92c9-86a3-4dd6-a15d-ed8fda3aa8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aef356a2-cd16-45cd-bc30-49211b4bcf10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_02a2502c-0660-48a7-8c21-f8c6ce326420" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aef356a2-cd16-45cd-bc30-49211b4bcf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9b76de74-6afb-4743-ab6b-d1f2290f3a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9b76de74-6afb-4743-ab6b-d1f2290f3a1a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_7d4be2b7-44c5-4e74-892d-c5d1e4247e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_cd463a33-a22d-4bcd-b1c2-17cbdf4b3b05" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_7d4be2b7-44c5-4e74-892d-c5d1e4247e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_5e6b44af-8e0d-4e8b-b338-fcbd03dbca45" xlink:href="lgnd-20231231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_7d4be2b7-44c5-4e74-892d-c5d1e4247e3e" xlink:to="loc_lgnd_PrimordialGeneticsMember_5e6b44af-8e0d-4e8b-b338-fcbd03dbca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5d788720-7cb3-45c1-895b-5c76d941d6b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a4281f85-6dec-492c-8b13-7f1b96767b95" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5d788720-7cb3-45c1-895b-5c76d941d6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d57cf87f-0040-4fdf-b3ca-e776096a7754" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5d788720-7cb3-45c1-895b-5c76d941d6b8" xlink:to="loc_srt_ScenarioForecastMember_d57cf87f-0040-4fdf-b3ca-e776096a7754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93840aef-5109-4ef2-aff1-5fc0bd99564a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7ca62d7b-803c-4e42-a7be-cfc64d5a83af" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93840aef-5109-4ef2-aff1-5fc0bd99564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_4b66a197-8286-4ee0-8804-8a84b1546150" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93840aef-5109-4ef2-aff1-5fc0bd99564a" xlink:to="loc_lgnd_PrimroseBioMember_4b66a197-8286-4ee0-8804-8a84b1546150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7177e129-44a3-4b9e-b523-d8024453808c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5bdffe95-9c12-4353-a210-599087ff25f1" xlink:to="loc_srt_ProductsAndServicesDomain_7177e129-44a3-4b9e-b523-d8024453808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PeliCRM197Member_f8b3ec71-f653-4fd0-9fef-5f5ee5b2cb2f" xlink:href="lgnd-20231231.xsd#lgnd_PeliCRM197Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7177e129-44a3-4b9e-b523-d8024453808c" xlink:to="loc_lgnd_PeliCRM197Member_f8b3ec71-f653-4fd0-9fef-5f5ee5b2cb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:href="lgnd-20231231.xsd#lgnd_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MilestoneAxis_188fa9ba-f8d4-4c9f-8878-5794b096335a" xlink:to="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BelowMilestoneMember_2eb703a4-985d-4200-b851-bc70a269cd0c" xlink:href="lgnd-20231231.xsd#lgnd_BelowMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:to="loc_lgnd_BelowMilestoneMember_2eb703a4-985d-4200-b851-bc70a269cd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AboveMilestoneMember_7e134bf6-f576-4e43-87bc-d4285e4ce5e3" xlink:href="lgnd-20231231.xsd#lgnd_AboveMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MilestoneDomain_01693c81-def6-4175-832d-1ee15a2cd3bb" xlink:to="loc_lgnd_AboveMilestoneMember_7e134bf6-f576-4e43-87bc-d4285e4ce5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e3bcd3b0-db0f-4964-bbc1-bc7aa6484703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66bf1176-9ba6-433a-a7a0-5cf374b4b2b0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e3bcd3b0-db0f-4964-bbc1-bc7aa6484703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_cfd6c8d6-2922-4cf0-9177-da4a8ac6ea8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e3bcd3b0-db0f-4964-bbc1-bc7aa6484703" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_cfd6c8d6-2922-4cf0-9177-da4a8ac6ea8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8034bd08-6058-430c-a3fa-615265bd7eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_301ccfdf-3ffe-4f1e-9a6f-81508cfda237" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8034bd08-6058-430c-a3fa-615265bd7eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_d1da6a77-12df-464b-bb2e-ea201ac9d925" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8034bd08-6058-430c-a3fa-615265bd7eed" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_d1da6a77-12df-464b-bb2e-ea201ac9d925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_99ba013c-56a1-4fcc-91bd-15150aae3640" xlink:to="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_15238fa3-67a7-42c4-8a69-e50d4b2fa580" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:to="loc_us-gaap_CommonStockMember_15238fa3-67a7-42c4-8a69-e50d4b2fa580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1ab594d9-ce25-4228-929c-f3c71d87466f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0b96b838-2abe-4cab-aa24-754217ee625f" xlink:to="loc_us-gaap_PreferredStockMember_1ab594d9-ce25-4228-929c-f3c71d87466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_202bf304-1a3c-4a91-b434-01bdd21626f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_169928be-203d-44b1-b810-8a15a1634176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_202bf304-1a3c-4a91-b434-01bdd21626f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c8c6bf11-6727-42c9-83a7-f98b85fb3845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_202bf304-1a3c-4a91-b434-01bdd21626f8" xlink:to="loc_us-gaap_RestrictedStockMember_c8c6bf11-6727-42c9-83a7-f98b85fb3845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4c8a24b4-7d3f-4880-82f1-89a76c6406ae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_687d5498-f0b8-48a5-a68f-c6e831b25fa8" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_687d5498-f0b8-48a5-a68f-c6e831b25fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_b32cd4db-ca98-4fcf-b78d-9ac05c05c8eb" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_b32cd4db-ca98-4fcf-b78d-9ac05c05c8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InterestInPotentialDevelopmentMilestone_e133725c-4deb-42c2-8f3c-99c024e908a6" xlink:href="lgnd-20231231.xsd#lgnd_InterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_InterestInPotentialDevelopmentMilestone_e133725c-4deb-42c2-8f3c-99c024e908a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_9dbbeba0-67e9-45cc-be0f-1f24e8166371" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContracts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_NumberOfContracts_9dbbeba0-67e9-45cc-be0f-1f24e8166371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_4bc55f13-778b-4b1a-90a4-803f2b095e47" xlink:href="lgnd-20231231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_4bc55f13-778b-4b1a-90a4-803f2b095e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesRevenueMilestone_ab084bb2-2c21-48e0-9a70-66f7b1c420f9" xlink:href="lgnd-20231231.xsd#lgnd_SalesRevenueMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_SalesRevenueMilestone_ab084bb2-2c21-48e0-9a70-66f7b1c420f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_b390ec59-a45a-45c2-8627-75cf475c6146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_b390ec59-a45a-45c2-8627-75cf475c6146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_0ab48cd8-aad8-4cc1-b2cb-3d03f6bb5e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_0ab48cd8-aad8-4cc1-b2cb-3d03f6bb5e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_e8b4350e-37a2-4779-8351-df52537e2ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_BusinessExitCosts1_e8b4350e-37a2-4779-8351-df52537e2ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_1f5d3929-0b2b-4caa-b0e2-62521fa24cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_1f5d3929-0b2b-4caa-b0e2-62521fa24cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_b61c4bb8-c6cc-4807-a24a-c519702e6545" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_b61c4bb8-c6cc-4807-a24a-c519702e6545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_43639409-1b2f-4466-9afb-2d2864e89097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_43639409-1b2f-4466-9afb-2d2864e89097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_37387813-31bf-4671-9228-cf77fcbcf344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfDerivatives"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ac8d277-b36d-43b7-ab07-9a67506d5273" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_37387813-31bf-4671-9228-cf77fcbcf344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4912d64f-01bd-45de-b5b9-86d39cd74ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4912d64f-01bd-45de-b5b9-86d39cd74ec3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ccc86667-7942-4fe1-90f1-7e9c674952cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_97d6eeb0-837f-44df-9770-1cc97fda55c9" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ccc86667-7942-4fe1-90f1-7e9c674952cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6a5df07-a68d-487a-b23f-835cbaf1a2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ccc86667-7942-4fe1-90f1-7e9c674952cf" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6a5df07-a68d-487a-b23f-835cbaf1a2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c09199-d77e-4d8a-988b-8f00349a890f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_89c593ee-9863-4e6b-9a69-4539f352c3ac" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c09199-d77e-4d8a-988b-8f00349a890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_c7ba2c24-1e2d-4f25-b115-1654b69b532c" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c09199-d77e-4d8a-988b-8f00349a890f" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_c7ba2c24-1e2d-4f25-b115-1654b69b532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_addec1f3-b37d-4aa5-936c-33a5316b708d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b7f86cbc-31f5-431a-9dc7-1af58aa48a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_b7f86cbc-31f5-431a-9dc7-1af58aa48a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f6861405-548e-49c8-922b-bd848bd552e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f6861405-548e-49c8-922b-bd848bd552e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9f25de71-51c6-4648-b3c3-363795e7a1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_9f25de71-51c6-4648-b3c3-363795e7a1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_9bfc11a6-9993-4094-8775-5f8fb711d9e5" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_9bfc11a6-9993-4094-8775-5f8fb711d9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_c41c4f56-032a-4650-b3c0-d38cb99dc17f" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_c41c4f56-032a-4650-b3c0-d38cb99dc17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0d87b347-43c2-4a3f-8124-908781b956ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_0d87b347-43c2-4a3f-8124-908781b956ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_ec38fe30-9107-453b-af15-003386be3c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_ec38fe30-9107-453b-af15-003386be3c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_61c477f2-985d-4bbf-86c3-37a30a5cb25f" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_61c477f2-985d-4bbf-86c3-37a30a5cb25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_499428fa-4615-483b-95c4-50d4bcd09aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_499428fa-4615-483b-95c4-50d4bcd09aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_fc72fdd2-c92e-4d38-9159-46c77654fa31" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_fc72fdd2-c92e-4d38-9159-46c77654fa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c915b09e-7db7-4170-8a01-968cf37561bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c915b09e-7db7-4170-8a01-968cf37561bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8f368942-3525-4c15-8d6c-d6915135e068" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8f368942-3525-4c15-8d6c-d6915135e068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_f80eb635-8220-4c41-85e8-08a6dbedaf98" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2cc7032a-d222-4700-9eae-c40ae2271a75" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_f80eb635-8220-4c41-85e8-08a6dbedaf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e24e5de0-b90e-4b89-b4c5-f1cfe410c1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e24e5de0-b90e-4b89-b4c5-f1cfe410c1bb" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_11392aee-c9c8-4bab-9fcb-bd2d065fc7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c5034fdd-c60d-4c00-8d90-76c143709bcb" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_11392aee-c9c8-4bab-9fcb-bd2d065fc7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0c9c528b-317b-48ac-9d1c-35652c23df12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_11392aee-c9c8-4bab-9fcb-bd2d065fc7dc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0c9c528b-317b-48ac-9d1c-35652c23df12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7814b8a4-9cdd-47ca-b5f2-a0c791a4b940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d7871099-55e2-468c-b28f-dda78de09bfc" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7814b8a4-9cdd-47ca-b5f2-a0c791a4b940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_ad85c1ec-6845-467a-a4d0-aedf4f4741b0" xlink:href="lgnd-20231231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7814b8a4-9cdd-47ca-b5f2-a0c791a4b940" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_ad85c1ec-6845-467a-a4d0-aedf4f4741b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationAxis_7f28b404-4484-4f00-a017-916e540e970e" xlink:to="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityMethodInvestmentsAllocationMember_fe95e574-8848-4be1-b97a-6a7ee113a5da" xlink:href="lgnd-20231231.xsd#lgnd_EquityMethodInvestmentsAllocationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:to="loc_lgnd_EquityMethodInvestmentsAllocationMember_fe95e574-8848-4be1-b97a-6a7ee113a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquitySecuritiesAllocationMember_9614b15e-d74c-4b56-8cbb-aa1a98733bfe" xlink:href="lgnd-20231231.xsd#lgnd_EquitySecuritiesAllocationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:to="loc_lgnd_EquitySecuritiesAllocationMember_9614b15e-d74c-4b56-8cbb-aa1a98733bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetsMember_67b0d9c0-07f8-4469-b9fe-ccaa67dd05bd" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationDomain_165b8a2e-6c9d-4be9-b337-86b45180ae12" xlink:to="loc_lgnd_DerivativeAssetsMember_67b0d9c0-07f8-4469-b9fe-ccaa67dd05bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3b06f654-b492-4a47-a1c0-e40c3e137072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_a98480cd-110c-488c-8b16-7271fd462474" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3b06f654-b492-4a47-a1c0-e40c3e137072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_84d48d9b-48db-474c-b876-1f41cb696fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3b06f654-b492-4a47-a1c0-e40c3e137072" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_84d48d9b-48db-474c-b876-1f41cb696fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aba2c16c-07ff-41ef-8d87-26add4f47aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aba2c16c-07ff-41ef-8d87-26add4f47aa7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbca607-2edf-4e2e-b924-661c72faeaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a2bb803d-276f-4c01-9069-dd0a2a3f1156" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbca607-2edf-4e2e-b924-661c72faeaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_ace90c95-e369-4b84-94c0-e34983cf13c6" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0fbca607-2edf-4e2e-b924-661c72faeaf2" xlink:to="loc_lgnd_NovanIncMember_ace90c95-e369-4b84-94c0-e34983cf13c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94aec32a-c08e-416c-a5a7-bca748e0aaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7a808ed7-b6a8-4230-9c34-c2dfc175fc3a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94aec32a-c08e-416c-a5a7-bca748e0aaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_c0392455-3396-438a-96fb-97e8641687d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_94aec32a-c08e-416c-a5a7-bca748e0aaf2" xlink:to="loc_us-gaap_BridgeLoanMember_c0392455-3396-438a-96fb-97e8641687d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d551c45-7265-491b-81d4-f5613214ace5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d13da6a8-530b-4000-a4b8-dc59a729b381" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d551c45-7265-491b-81d4-f5613214ace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bcedcda7-6cc1-4950-9847-36c2e7b05992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d551c45-7265-491b-81d4-f5613214ace5" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_bcedcda7-6cc1-4950-9847-36c2e7b05992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d48c9016-7750-4b68-a848-a34f45ac61fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ef474aeb-b2a7-47c3-ad9e-d0c57e0a1ee0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d48c9016-7750-4b68-a848-a34f45ac61fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_de803ebf-fc33-4d76-9771-47484bda5e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d48c9016-7750-4b68-a848-a34f45ac61fd" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_de803ebf-fc33-4d76-9771-47484bda5e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7b469c6c-c818-42b4-954d-3946df360cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_20688609-1460-41db-ac46-400ed6e3d931" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7b469c6c-c818-42b4-954d-3946df360cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_676ad303-18f9-4402-bba1-899acec9cd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_7b469c6c-c818-42b4-954d-3946df360cde" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_676ad303-18f9-4402-bba1-899acec9cd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86eeda08-a2a3-4a5f-bdb8-e74bcf82c99d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_82d41489-29c3-4c6d-a2a6-68e513dcf313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_82d41489-29c3-4c6d-a2a6-68e513dcf313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c81c928a-4b0b-42bc-9079-697d32f5175d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_c81c928a-4b0b-42bc-9079-697d32f5175d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6c92c16c-ae6c-4736-b641-999a107ebbed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6c92c16c-ae6c-4736-b641-999a107ebbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquiredPercentage_ade5b3c9-9689-400c-847c-e6c0a2c4c599" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationAcquiredPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_BusinessCombinationAcquiredPercentage_ade5b3c9-9689-400c-847c-e6c0a2c4c599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_981bfc61-7414-425a-aa9b-980e4ef19d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_981bfc61-7414-425a-aa9b-980e4ef19d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_17655a2e-d498-45e5-a741-0818c0f5f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_17655a2e-d498-45e5-a741-0818c0f5f54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_b62a70ef-0492-46b1-86bd-32b7f16a886e" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_b62a70ef-0492-46b1-86bd-32b7f16a886e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d974f6f-589c-444a-8145-902bc5e676dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d974f6f-589c-444a-8145-902bc5e676dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_f31d1f1d-45b5-4d80-8d91-d4b9113858f6" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_f31d1f1d-45b5-4d80-8d91-d4b9113858f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentMilestonePurchaseAgreement_72c7ec5d-e139-4c23-9554-6ad6e621ad22" xlink:href="lgnd-20231231.xsd#lgnd_ContingentMilestonePurchaseAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_lgnd_ContingentMilestonePurchaseAgreement_72c7ec5d-e139-4c23-9554-6ad6e621ad22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_afd8159e-770d-46c5-ac32-74dbd6094f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_c104d162-9181-442a-ae48-0ec66e6fe179" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_afd8159e-770d-46c5-ac32-74dbd6094f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_39908610-0f1f-40ec-a3f8-0f8f0a6c44fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_39908610-0f1f-40ec-a3f8-0f8f0a6c44fa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10bbb8f5-3618-42dd-a2c8-c74417496022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8bb9d667-93d9-4bd2-9e02-11dfc963b57e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10bbb8f5-3618-42dd-a2c8-c74417496022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_a0627473-3821-4a9a-b541-d8293abdab10" xlink:href="lgnd-20231231.xsd#lgnd_NovanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10bbb8f5-3618-42dd-a2c8-c74417496022" xlink:to="loc_lgnd_NovanIncMember_a0627473-3821-4a9a-b541-d8293abdab10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee29db78-a8cc-4419-86ea-0fa14b6ca60e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7aa77322-0490-470b-b3c8-f744277bbfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_7aa77322-0490-470b-b3c8-f744277bbfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_75e9e16c-e5f2-436c-8f5e-8d296ea93f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_75e9e16c-e5f2-436c-8f5e-8d296ea93f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0daa26ad-1fcc-4473-9cec-0d92d917f414" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets_0daa26ad-1fcc-4473-9cec-0d92d917f414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_28d54462-3770-44ad-a08d-34bb92cb361e" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_28d54462-3770-44ad-a08d-34bb92cb361e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fe43b9a2-bf2b-4316-8560-25f4352312f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_fe43b9a2-bf2b-4316-8560-25f4352312f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d21e8e9a-9a36-45b3-879c-43351bcd8f43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d21e8e9a-9a36-45b3-879c-43351bcd8f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b8c9d3cf-11ee-4169-a622-355d0156c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_Goodwill_b8c9d3cf-11ee-4169-a622-355d0156c59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_31f6b85c-ca78-43a4-970c-faca69b16ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_31f6b85c-ca78-43a4-970c-faca69b16ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_5d73d829-8770-4bc0-b882-e3a38399c801" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities_5d73d829-8770-4bc0-b882-e3a38399c801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_eac3707e-8f69-4135-a0c5-c96e4adf69ad" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_eac3707e-8f69-4135-a0c5-c96e4adf69ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8ec3296d-f889-4683-9b3a-3acda9a76796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8ec3296d-f889-4683-9b3a-3acda9a76796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest_117c22a9-2cac-4224-8513-ba1f1f2150a7" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_lgnd_BusinessCombinationLoanFeesAndInterest_117c22a9-2cac-4224-8513-ba1f1f2150a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_75ea5b68-9847-4db8-be23-c2aa4cd63389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_13ef56c8-d1e8-43ac-a853-9f5a9008ec89" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_75ea5b68-9847-4db8-be23-c2aa4cd63389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b082f763-8dfd-4e67-83c4-77a64e382b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b082f763-8dfd-4e67-83c4-77a64e382b09" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e5906c03-a9cc-4714-9ee8-cdfb2e751524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a4582254-de94-4a6c-ac45-91a1c139a120" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e5906c03-a9cc-4714-9ee8-cdfb2e751524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_ccc9e89b-d50c-480a-b17a-fbbb42f9ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e5906c03-a9cc-4714-9ee8-cdfb2e751524" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_ccc9e89b-d50c-480a-b17a-fbbb42f9ff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_56aca709-51de-4f97-8456-2e3137b0e24b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_a98e49c4-aac7-4bd9-b324-e53e99ae489c" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_a98e49c4-aac7-4bd9-b324-e53e99ae489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsAdjustments_65ecd799-1d90-4d13-a7cf-9db8c765da8e" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxAssetsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_953adf27-76a5-4085-8b59-c34483130a7b" xlink:to="loc_lgnd_DeferredTaxAssetsAdjustments_65ecd799-1d90-4d13-a7cf-9db8c765da8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1f725bee-d923-4783-ad65-1a7c8a9b060b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1f725bee-d923-4783-ad65-1a7c8a9b060b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1a9529ae-0464-47d4-a949-0e21a7803a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0d7d7b79-85cb-42f9-88ea-79df44fec3cd" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1a9529ae-0464-47d4-a949-0e21a7803a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_3ccad01d-c096-453f-928c-dd268d2579b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a9529ae-0464-47d4-a949-0e21a7803a1e" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_3ccad01d-c096-453f-928c-dd268d2579b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:to="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9d681fdd-f07a-45a6-9f54-8a27554aa897" xlink:to="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_7ac7becb-528e-41c5-9527-23fc0829ec61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:to="loc_us-gaap_RoyaltyMember_7ac7becb-528e-41c5-9527-23fc0829ec61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_c681666e-14c3-4a80-838b-bc4905949242" xlink:href="lgnd-20231231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_012aaf5c-8c33-42d9-a439-88967403257f" xlink:to="loc_lgnd_ContractRevenueMember_c681666e-14c3-4a80-838b-bc4905949242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_baee8edd-729e-4e0b-b94d-b1761f167960" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_e257df70-b7ee-4a7f-b214-042784cf1fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_e257df70-b7ee-4a7f-b214-042784cf1fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_038f6741-13c9-4e30-b644-82fe7fc83204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_e257df70-b7ee-4a7f-b214-042784cf1fa9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_038f6741-13c9-4e30-b644-82fe7fc83204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_ac34a5eb-592d-430a-b9eb-b1c8c6a0f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_ac34a5eb-592d-430a-b9eb-b1c8c6a0f72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_b05fec40-f4e7-410c-88dd-41c82dda7428" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_b05fec40-f4e7-410c-88dd-41c82dda7428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bc96b959-ea7c-46f9-86dc-7b6d2099597e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bc96b959-ea7c-46f9-86dc-7b6d2099597e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2eb6224f-39fe-4148-91de-bfd0f2f651ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_3135e4bf-62c4-40cb-86b6-ffb380758c49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_2eb6224f-39fe-4148-91de-bfd0f2f651ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_58b121e2-2562-4158-8179-70239f5c9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_58b121e2-2562-4158-8179-70239f5c9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:href="lgnd-20231231.xsd#lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_01d56cbd-75bd-46c4-a098-988ba72647e4" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_01d56cbd-75bd-46c4-a098-988ba72647e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_fec7a746-b393-421e-ae5c-4130ce99d27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_fec7a746-b393-421e-ae5c-4130ce99d27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_1fe636a2-0b88-4ca9-ae25-89d3d25c784a" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_3d7ce17b-dc63-4ded-93f1-a681c034238b" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_1fe636a2-0b88-4ca9-ae25-89d3d25c784a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_d7a43a53-61e0-4c06-bb9c-4a884a58970d" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_d7a43a53-61e0-4c06-bb9c-4a884a58970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_cfafc1c2-61bb-430b-aa0a-5b194c8317d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_cfafc1c2-61bb-430b-aa0a-5b194c8317d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca73373b-9c9f-4822-a7fc-c9bf0ac5010a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca73373b-9c9f-4822-a7fc-c9bf0ac5010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_72c7c7af-be63-4dd5-830b-a510d04c9ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ae64499e-0799-4c93-a5e7-8396309fc0bc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_72c7c7af-be63-4dd5-830b-a510d04c9ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4b8c800e-7909-4425-8b17-0e3af4073c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4b8c800e-7909-4425-8b17-0e3af4073c4c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_29c11d6d-8960-4851-b68b-b68c84379331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2714c0d5-eea0-4b0b-9495-b237041af1d2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_29c11d6d-8960-4851-b68b-b68c84379331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_abf2aef4-271f-496b-9c26-31f4e37e976e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_29c11d6d-8960-4851-b68b-b68c84379331" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_abf2aef4-271f-496b-9c26-31f4e37e976e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ba7c2150-4e66-437a-9e15-e21d34249d90" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:href="lgnd-20231231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_d3d31f10-6ba3-4af7-8a21-9e268f9352ba" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_d3d31f10-6ba3-4af7-8a21-9e268f9352ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_3d0058fd-3c51-4fb5-bf40-e2823a7bc301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_3d0058fd-3c51-4fb5-bf40-e2823a7bc301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_88186adf-eac1-491e-9cd0-02e90662583d" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_6fcfe2dd-9da3-4a0d-a761-9fa90c5146f5" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_88186adf-eac1-491e-9cd0-02e90662583d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:href="lgnd-20231231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_23c9eeae-746d-4979-ab2c-937f7cad6aba" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_23c9eeae-746d-4979-ab2c-937f7cad6aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_b11306b4-6bd1-4d31-b927-133dbce91c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_b11306b4-6bd1-4d31-b927-133dbce91c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_c7f70468-0aee-4071-97f7-200a39ab5f8f" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersInvestingActivity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_9b2b92e4-d8bc-42e8-aa73-fdf396d92849" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_c7f70468-0aee-4071-97f7-200a39ab5f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_5481bb14-e4e6-48e1-ab3d-29b1ce29cf97" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_5481bb14-e4e6-48e1-ab3d-29b1ce29cf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_abbe9e8c-e682-48cf-8e07-58d78fffd9a8" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_5481bb14-e4e6-48e1-ab3d-29b1ce29cf97" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_abbe9e8c-e682-48cf-8e07-58d78fffd9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a1c99255-92c7-4417-81a3-9785020cf0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ff67124e-7344-473d-8ec0-c1562923d44e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a1c99255-92c7-4417-81a3-9785020cf0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_87757ae8-9e25-44a3-a835-365f045adfd7" xlink:href="lgnd-20231231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a1c99255-92c7-4417-81a3-9785020cf0b7" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_87757ae8-9e25-44a3-a835-365f045adfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4ffe427-8263-4b1d-ad47-3b49a403fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4ffe427-8263-4b1d-ad47-3b49a403fa4e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:to="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_22ca7afa-06ef-46f5-99a2-4dd80ea582e7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_4e780810-0c0d-4c6f-b611-e3af6c763fe7" xlink:href="lgnd-20231231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_4e780810-0c0d-4c6f-b611-e3af6c763fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_f8a69a04-6486-40e6-84ee-67578c3ece5c" xlink:href="lgnd-20231231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_SelexisAndDianomiMember_f8a69a04-6486-40e6-84ee-67578c3ece5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_ead268d2-1723-4280-b384-41cfb6ea3a34" xlink:href="lgnd-20231231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_OvidTherapeuticsMember_ead268d2-1723-4280-b384-41cfb6ea3a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_07597f0f-f8c2-4227-870d-6946bda9a769" xlink:href="lgnd-20231231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_07597f0f-f8c2-4227-870d-6946bda9a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaMember_1048f6c2-2acd-45c8-bf70-12bfd73c260e" xlink:href="lgnd-20231231.xsd#lgnd_PalvellaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1809a00c-6e21-411b-84f1-a2c66d21cfe0" xlink:to="loc_lgnd_PalvellaMember_1048f6c2-2acd-45c8-bf70-12bfd73c260e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a554f22-d283-4875-b877-46796e7f5db8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsGross_5e4b283d-9fb0-4a89-a744-52badfc9eb76" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsGross_5e4b283d-9fb0-4a89-a744-52badfc9eb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments_a17e38ba-4a8a-4bc1-824a-dc7f8265e11a" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCumulativeAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsCumulativeAdjustments_a17e38ba-4a8a-4bc1-824a-dc7f8265e11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRights_94d94732-5c82-4be2-b8c0-86e542101b57" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRights_94d94732-5c82-4be2-b8c0-86e542101b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsAccumulatedAmortization_e3dec5ee-b9cc-4c8f-b149-c5aae5c1de01" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsAccumulatedAmortization_e3dec5ee-b9cc-4c8f-b149-c5aae5c1de01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_60cdb375-ce72-4623-ad59-d7d132a956fd" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_60cdb375-ce72-4623-ad59-d7d132a956fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsImpairments_3c988443-9c89-46cb-af38-4dcf4a466741" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsImpairments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6282bf55-d716-4395-848d-d804b0e25104" xlink:to="loc_lgnd_CommercialLicenseRightsImpairments_3c988443-9c89-46cb-af38-4dcf4a466741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommercialLicenseandOtherEconomicRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d68759dc-5111-4d7b-ae9c-6780db3948dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d68759dc-5111-4d7b-ae9c-6780db3948dc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_eb802d50-6d89-4cf3-b6e7-4fcf9848998e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_7fcd0321-dee2-4154-a13e-89f83f7d18d6" xlink:href="lgnd-20231231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_7fcd0321-dee2-4154-a13e-89f83f7d18d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisAndDianomiMember_99894430-081d-4044-ac04-d44d49bf5696" xlink:href="lgnd-20231231.xsd#lgnd_SelexisAndDianomiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_SelexisAndDianomiMember_99894430-081d-4044-ac04-d44d49bf5696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorMatrixMember_8ea8e8f0-29f0-42d1-b32d-1c09d09d236b" xlink:href="lgnd-20231231.xsd#lgnd_CorMatrixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_CorMatrixMember_8ea8e8f0-29f0-42d1-b32d-1c09d09d236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_c3c8d8eb-98ed-4916-bfdd-80184cdc1dce" xlink:href="lgnd-20231231.xsd#lgnd_SelexisMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_SelexisMember_c3c8d8eb-98ed-4916-bfdd-80184cdc1dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_04acd242-5e21-46fc-8d79-15da22b8b3b3" xlink:href="lgnd-20231231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_OvidTherapeuticsMember_04acd242-5e21-46fc-8d79-15da22b8b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_1925485a-ab4e-4aed-87c5-9d4df9ccd1be" xlink:href="lgnd-20231231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a6b19726-88fa-4873-b59f-8527c894b2e7" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_1925485a-ab4e-4aed-87c5-9d4df9ccd1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_126f07ac-5859-4173-8cde-e55ca5ab004e" xlink:to="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_61fc981b-a303-4449-8d82-c9fc2680dfa3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:to="loc_srt_MaximumMember_61fc981b-a303-4449-8d82-c9fc2680dfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a2b01e3-c369-42c6-92e0-2d9d611a4be2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c8e0419-3b93-4ffa-bfac-06118d451189" xlink:to="loc_srt_MinimumMember_6a2b01e3-c369-42c6-92e0-2d9d611a4be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e08cb1c1-f31d-4084-b62c-d118d9c54261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a7b0238-b86f-45ee-ad97-f0478956ecbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e08cb1c1-f31d-4084-b62c-d118d9c54261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_4aa3d869-b6ac-4eef-a863-3a2a3af654c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e08cb1c1-f31d-4084-b62c-d118d9c54261" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_4aa3d869-b6ac-4eef-a863-3a2a3af654c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb7aed1b-363c-412f-aae9-bfcd25b0d284" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cea89a41-f36b-4718-830e-46dcd1d40eb2" xlink:to="loc_srt_ProductsAndServicesDomain_fb7aed1b-363c-412f-aae9-bfcd25b0d284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SoticlestatMember_79f7fd4f-92a8-4145-bc9b-6b553d136931" xlink:href="lgnd-20231231.xsd#lgnd_SoticlestatMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb7aed1b-363c-412f-aae9-bfcd25b0d284" xlink:to="loc_lgnd_SoticlestatMember_79f7fd4f-92a8-4145-bc9b-6b553d136931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_255e1397-b8ce-4994-ae69-36ad008c750a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a3d3a1bc-3e00-4faf-afe6-bda9dd0f0cc7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_255e1397-b8ce-4994-ae69-36ad008c750a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_e52ffb95-500e-418e-997e-63f38a91ce61" xlink:href="lgnd-20231231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_255e1397-b8ce-4994-ae69-36ad008c750a" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_e52ffb95-500e-418e-997e-63f38a91ce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_83b4f168-d09d-428d-9982-a7a22f68a8fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_03f73463-cbc4-426a-8ce2-3f6c6cc0e502" xlink:href="lgnd-20231231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ProductRoyaltyPercentage_03f73463-cbc4-426a-8ce2-3f6c6cc0e502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentOfCommercialLicense_d964ad4e-5839-471c-90f7-0356b111775b" xlink:href="lgnd-20231231.xsd#lgnd_ImpairmentOfCommercialLicense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ImpairmentOfCommercialLicense_d964ad4e-5839-471c-90f7-0356b111775b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_99a7e0dd-84ee-4cc6-8e62-4813902cf46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_99a7e0dd-84ee-4cc6-8e62-4813902cf46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_da0e9fdb-a238-4da0-8cc7-7039ef834a0c" xlink:href="lgnd-20231231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_da0e9fdb-a238-4da0-8cc7-7039ef834a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyAgreementExpirationPeriod_3a3c7754-6951-4675-80b5-33a6d4444f2f" xlink:href="lgnd-20231231.xsd#lgnd_RoyaltyAgreementExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_RoyaltyAgreementExpirationPeriod_3a3c7754-6951-4675-80b5-33a6d4444f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_e78d4b43-1b8d-4a6d-85e5-161e28725bd2" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_e78d4b43-1b8d-4a6d-85e5-161e28725bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_1f20866e-ee60-4e6a-b0e3-a52c484a6e51" xlink:href="lgnd-20231231.xsd#lgnd_ForecastedCashFlowsEffectiveInterestRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent_1f20866e-ee60-4e6a-b0e3-a52c484a6e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_35143943-20ef-4259-9de3-f579fb359490" xlink:href="lgnd-20231231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_35143943-20ef-4259-9de3-f579fb359490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_27d3d428-7fbf-4607-b670-d09ea5759471" xlink:href="lgnd-20231231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_27d3d428-7fbf-4607-b670-d09ea5759471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_360448bd-ce0a-4bb2-a4d8-7fc1380a9061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_360448bd-ce0a-4bb2-a4d8-7fc1380a9061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_64f88f84-00c9-407a-a236-c3f20b0f9b11" xlink:href="lgnd-20231231.xsd#lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8980bac3-c8a2-448c-84ac-2c8889c544da" xlink:to="loc_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage_64f88f84-00c9-407a-a236-c3f20b0f9b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc2be11e-ce3f-425f-af99-13b06adb65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc2be11e-ce3f-425f-af99-13b06adb65d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0605a94-6007-4e54-9e54-1d8ca549bb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7904835a-8175-43ed-bfef-d411f74d703a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0605a94-6007-4e54-9e54-1d8ca549bb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_97255f39-51d3-4a9f-9f33-cc7f6a919cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e0605a94-6007-4e54-9e54-1d8ca549bb00" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_97255f39-51d3-4a9f-9f33-cc7f6a919cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f15dc8f2-6eff-4ba8-a70d-a63921fde848" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ad28a955-d024-4a65-9f45-b99be47fba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ad28a955-d024-4a65-9f45-b99be47fba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f60a21be-8b97-44d8-945e-8c41c46ac944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f60a21be-8b97-44d8-945e-8c41c46ac944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2583cf8e-e502-4775-b613-91f5089aaa10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_252ba30b-306a-4cb2-acba-264378c68e92" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2583cf8e-e502-4775-b613-91f5089aaa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0455a2c8-8395-4848-bd13-fcd6d225ff6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_a73a52e3-8664-4aa7-8f0d-7d8b57de718f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_a73a52e3-8664-4aa7-8f0d-7d8b57de718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilitiesMember_ddc3a4d0-4540-4c62-a3e9-33e4f025e8f6" xlink:href="lgnd-20231231.xsd#lgnd_ContingentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cefcaeb-82a7-47b9-919f-33be32f47a36" xlink:to="loc_lgnd_ContingentLiabilitiesMember_ddc3a4d0-4540-4c62-a3e9-33e4f025e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7c755f17-7205-409f-bfac-e889c11ee235" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CyDexMember_9b2ae7db-0bd1-4d65-9ac6-4aa91d88992a" xlink:href="lgnd-20231231.xsd#lgnd_CyDexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:to="loc_lgnd_CyDexMember_9b2ae7db-0bd1-4d65-9ac6-4aa91d88992a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisMember_24b5983a-60dd-4dea-94b3-1a93eb171790" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_955f8b0d-c8db-4c6b-9ce9-bd2799aebec5" xlink:to="loc_lgnd_MetabasisMember_24b5983a-60dd-4dea-94b3-1a93eb171790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6af0f639-90ca-493b-a8d9-423eef33f6c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d63b61d2-e3a7-47d9-9b90-e27eb6965d37" xlink:to="loc_srt_RangeMember_6af0f639-90ca-493b-a8d9-423eef33f6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e4a2b66-7a74-4e52-bd8c-27bfa5562849" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6af0f639-90ca-493b-a8d9-423eef33f6c8" xlink:to="loc_srt_MaximumMember_1e4a2b66-7a74-4e52-bd8c-27bfa5562849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_29935446-6293-460d-818d-9566eb14cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a9c21a27-c9af-46fb-9eb0-134deef8a17c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_29935446-6293-460d-818d-9566eb14cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_f7862f13-b5be-42cd-b7a8-f94d75286537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_29935446-6293-460d-818d-9566eb14cf32" xlink:to="loc_us-gaap_TransferredOverTimeMember_f7862f13-b5be-42cd-b7a8-f94d75286537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_78fbb349-91d7-46ed-b3eb-9d15fef05a88" xlink:to="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_928c2fb4-a3c5-4143-a466-bdfebd8492b8" xlink:href="lgnd-20231231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_928c2fb4-a3c5-4143-a466-bdfebd8492b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_902a645b-ec2b-45cd-b32c-e080c17911b2" xlink:href="lgnd-20231231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0505a650-365c-4458-bdbe-d93eb3a582fa" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_902a645b-ec2b-45cd-b32c-e080c17911b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_89e65f9d-fa30-4836-ab5a-708bfdf62dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_804eb7b7-cbb0-446a-a11b-8562afabe2ca" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_89e65f9d-fa30-4836-ab5a-708bfdf62dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_23ade580-7455-4d74-a66a-986c74272e41" xlink:href="lgnd-20231231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_89e65f9d-fa30-4836-ab5a-708bfdf62dd2" xlink:to="loc_lgnd_PrimordialGeneticsMember_23ade580-7455-4d74-a66a-986c74272e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b6fabd-00c9-4a73-8f56-b6e0cf12de50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_35422aad-88ef-4899-b08b-03e24337cc83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b6fabd-00c9-4a73-8f56-b6e0cf12de50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_6866fb65-24e7-4664-b210-7d3856c02918" xlink:href="lgnd-20231231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b6fabd-00c9-4a73-8f56-b6e0cf12de50" xlink:to="loc_lgnd_PrimroseBioMember_6866fb65-24e7-4664-b210-7d3856c02918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97d8f2-0e71-4327-983d-9e2baf7ccd08" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6cc3b106-a2e0-4cc3-8b33-5107bef4bc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6cc3b106-a2e0-4cc3-8b33-5107bef4bc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9d6c2f30-5657-4795-a398-2c25731defc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9d6c2f30-5657-4795-a398-2c25731defc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_241635dc-df71-4e4c-a94d-9b049c6a6ab0" xlink:href="lgnd-20231231.xsd#lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_241635dc-df71-4e4c-a94d-9b049c6a6ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_164c4eb8-93e4-42f2-88e1-ec1b9e877563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_DerivativeAssets_164c4eb8-93e4-42f2-88e1-ec1b9e877563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_028800fb-c107-4d2b-a276-9059c2865f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_028800fb-c107-4d2b-a276-9059c2865f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_f439ad72-8553-4491-91c2-af1bc99db1b1" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_f439ad72-8553-4491-91c2-af1bc99db1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_f243272e-ec39-4263-8f0b-b24e04ef3296" xlink:href="lgnd-20231231.xsd#lgnd_AmountsOwedToFormerLicensorFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure_f243272e-ec39-4263-8f0b-b24e04ef3296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_438a26cf-e33a-4b3f-8cb9-1bdb50735bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_438a26cf-e33a-4b3f-8cb9-1bdb50735bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InterestInPotentialDevelopmentMilestone_bfe00922-e7ca-4a0e-9f33-a8262cb50c5a" xlink:href="lgnd-20231231.xsd#lgnd_InterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_InterestInPotentialDevelopmentMilestone_bfe00922-e7ca-4a0e-9f33-a8262cb50c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_3d75dada-29e3-4598-94c4-8405d6abd8bb" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContracts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_NumberOfContracts_3d75dada-29e3-4598-94c4-8405d6abd8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_bebb401e-de41-46be-8a0a-3752da5c7d9a" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_bebb401e-de41-46be-8a0a-3752da5c7d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_1588bfdf-5733-490d-9dca-f80dfef4b16e" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_1588bfdf-5733-490d-9dca-f80dfef4b16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsSeries_90eebd7e-4df5-4a8a-a935-bf9ec863793d" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightsSeries"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_NumberOfContingentValueRightsSeries_90eebd7e-4df5-4a8a-a935-bf9ec863793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5e981f6c-d33d-4eef-b3a9-a7887942e1dc" xlink:href="lgnd-20231231.xsd#lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5e981f6c-d33d-4eef-b3a9-a7887942e1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_38a2307e-a7f2-49e2-8a09-68447ac43041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_Investments_38a2307e-a7f2-49e2-8a09-68447ac43041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_cbfb8cd7-ea06-4e87-ab3b-883abf3ff639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_916ca96a-8673-43b2-8fbf-624f8ec98c48" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_cbfb8cd7-ea06-4e87-ab3b-883abf3ff639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_67c69dd9-7e07-47a7-b816-1b9f0b333ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_67c69dd9-7e07-47a7-b816-1b9f0b333ae6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dabe6a41-e715-4937-b60a-71bfb7a9149b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9387aa78-3b27-413b-9f40-b2b20b99b0c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dabe6a41-e715-4937-b60a-71bfb7a9149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_09dc1375-709a-4a9e-aea3-ae861501b3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dabe6a41-e715-4937-b60a-71bfb7a9149b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_09dc1375-709a-4a9e-aea3-ae861501b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dfe9ac01-71cd-41dd-864b-d672fe10fcc5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3e16a254-c063-481d-95f9-2adfec0f6047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3e16a254-c063-481d-95f9-2adfec0f6047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_603325aa-a476-4409-85c2-84af98e0ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_603325aa-a476-4409-85c2-84af98e0ec18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_b00e6a27-4492-48df-801b-db0fe9f02d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_b00e6a27-4492-48df-801b-db0fe9f02d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a84015ec-8f8b-459b-bc8c-d3ddc491a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dfedbbd-f7e8-48ab-bede-8ffb78ca0608" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_a84015ec-8f8b-459b-bc8c-d3ddc491a2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_6aef9e75-503e-496a-9b4d-29f65aefe9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_6aef9e75-503e-496a-9b4d-29f65aefe9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31c3fe52-f37c-4e8d-a4b0-ac79052a667c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31c3fe52-f37c-4e8d-a4b0-ac79052a667c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_7dd0769d-8c9b-4efb-b87f-d482b90a5d65" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_7dd0769d-8c9b-4efb-b87f-d482b90a5d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_047ebefc-a8b1-45b2-9768-3001e0ee454a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_047ebefc-a8b1-45b2-9768-3001e0ee454a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a410b45-c74c-43ee-b3ec-9ba8b0392933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09dfc88a-7f2a-4237-babe-c9efbd9b332c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5a410b45-c74c-43ee-b3ec-9ba8b0392933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_7f59a1a2-dae0-4d03-9d3f-5f50061afc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7e42f751-3a76-4fa9-b16f-e5d11cebfd1e" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_7f59a1a2-dae0-4d03-9d3f-5f50061afc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a1f11cff-f6d0-4dec-919e-bf06f4b915fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a1f11cff-f6d0-4dec-919e-bf06f4b915fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_45833653-7fb5-4783-a3f4-578c133cf817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d9786a3c-3716-4139-baaf-9762dcb4d2ca" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_45833653-7fb5-4783-a3f4-578c133cf817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_45833653-7fb5-4783-a3f4-578c133cf817" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_55dcc76d-a766-4092-8930-b8381e3da8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_55dcc76d-a766-4092-8930-b8381e3da8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6e81b05e-f2fd-4ed3-8652-f13b9f1749c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_af3d44a6-cabf-4456-8745-a0986e556ba4" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6e81b05e-f2fd-4ed3-8652-f13b9f1749c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0a354cba-37bc-4d99-97e4-d9ddaf5c8d39" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_218ad08d-02e9-4de3-8d80-003eaeb04b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_218ad08d-02e9-4de3-8d80-003eaeb04b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e123e7dd-525a-43ea-9d92-23ee6330b00e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e123e7dd-525a-43ea-9d92-23ee6330b00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsFairValueDisclosure_e073fd0a-31db-4d2d-9460-d44efc251e3e" xlink:href="lgnd-20231231.xsd#lgnd_CommercialLicenseRightsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_90cf812a-8793-4149-ac0f-8a3c510bfee2" xlink:to="loc_lgnd_CommercialLicenseRightsFairValueDisclosure_e073fd0a-31db-4d2d-9460-d44efc251e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c7873cfc-c476-4b4b-9c35-b2d47c4e801e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7873cfc-c476-4b4b-9c35-b2d47c4e801e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:to="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_425e96c6-d974-4bb7-a75f-53e50d87ace7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6b6431cc-96fe-43a3-b0b5-fb4e1791c45e" xlink:to="loc_srt_ProductsAndServicesDomain_425e96c6-d974-4bb7-a75f-53e50d87ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_63464a74-ae4c-4c10-9a2d-93886e03678e" xlink:href="lgnd-20231231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_425e96c6-d974-4bb7-a75f-53e50d87ace7" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_63464a74-ae4c-4c10-9a2d-93886e03678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:to="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57889a85-3033-4da1-b040-0b5159e689e7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed606163-955e-473a-8fcc-4a74ec76e98c" xlink:to="loc_srt_RangeMember_57889a85-3033-4da1-b040-0b5159e689e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a61a3dfe-7564-40e4-963a-3527cc49a7b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_57889a85-3033-4da1-b040-0b5159e689e7" xlink:to="loc_srt_MaximumMember_a61a3dfe-7564-40e4-963a-3527cc49a7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_27d93893-8df4-4706-895f-4f2b4f0b0e70" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_2d8fc1a4-82b8-4902-81f1-80706e7feec9" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_2d8fc1a4-82b8-4902-81f1-80706e7feec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_b0d5d5da-6bc7-4cae-b19b-2f89c197fb30" xlink:href="lgnd-20231231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_b0d5d5da-6bc7-4cae-b19b-2f89c197fb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_7ecc6c8d-c3bf-466b-a9bc-7bb2b23cb5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_7ecc6c8d-c3bf-466b-a9bc-7bb2b23cb5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseImpairmentLoss_116f0e9e-fb02-4385-9c9a-64e8228dd84a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseImpairmentLoss_116f0e9e-fb02-4385-9c9a-64e8228dd84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3743ef87-2136-4429-84bf-90d4e9a3659d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3743ef87-2136-4429-84bf-90d4e9a3659d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_16e86a7a-61e7-4c1d-8e10-dca3d34e0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_16e86a7a-61e7-4c1d-8e10-dca3d34e0a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_45bfc5f1-c048-4a6b-876d-986227209916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_45bfc5f1-c048-4a6b-876d-986227209916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1ad8ba01-a753-4d7b-a51c-b585b1c7ae23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1ad8ba01-a753-4d7b-a51c-b585b1c7ae23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_f51d2326-2c1d-4164-9300-3f8b00af2191" xlink:href="lgnd-20231231.xsd#lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_f51d2326-2c1d-4164-9300-3f8b00af2191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0a2b947f-0513-4977-a5a9-3825f3681029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0a2b947f-0513-4977-a5a9-3825f3681029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9f8858cd-515b-4f08-a494-9c1a3dcf0a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9f8858cd-515b-4f08-a494-9c1a3dcf0a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e080246-827c-4af3-b488-16a345bc69e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e080246-827c-4af3-b488-16a345bc69e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4e5eb466-3d46-44d4-9a65-07912a0f9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeasePayments_4e5eb466-3d46-44d4-9a65-07912a0f9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_43da6cbe-4f84-406e-999b-5ddc79e5fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_OperatingLeaseExpense_43da6cbe-4f84-406e-999b-5ddc79e5fb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_548a30a2-147f-4b0f-8db0-94c6b6d4feda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_SubleaseIncome_548a30a2-147f-4b0f-8db0-94c6b6d4feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9933961f-b846-4113-bc24-8a3cd880eb63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9933961f-b846-4113-bc24-8a3cd880eb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f0d11637-a69c-4041-a5ed-2e7450774934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f0d11637-a69c-4041-a5ed-2e7450774934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e283281e-8b7a-4084-bb94-1bbd7e68d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e283281e-8b7a-4084-bb94-1bbd7e68d9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_15541b9c-5487-42be-be03-fbc7323ac8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_935b68fc-babc-406c-9c0e-dd198203c843" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_15541b9c-5487-42be-be03-fbc7323ac8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0129609c-486a-45b6-beee-25d957cac666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_311a48e5-4549-455b-b9c4-9f5e8147f729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0129609c-486a-45b6-beee-25d957cac666" xlink:to="loc_us-gaap_AssetsAbstract_311a48e5-4549-455b-b9c4-9f5e8147f729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec7cca1b-f79a-464c-ad19-87d2fc256a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_311a48e5-4549-455b-b9c4-9f5e8147f729" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ec7cca1b-f79a-464c-ad19-87d2fc256a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_b87e988b-fc8d-4817-9561-4d616991f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_311a48e5-4549-455b-b9c4-9f5e8147f729" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_b87e988b-fc8d-4817-9561-4d616991f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_bac91f8d-4218-405d-b6f7-3adf15c0113c" xlink:href="lgnd-20231231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_311a48e5-4549-455b-b9c4-9f5e8147f729" xlink:to="loc_lgnd_LeaseRightOfUseAsset_bac91f8d-4218-405d-b6f7-3adf15c0113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_cb629b46-174e-4b98-815b-44bf1deb9dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0129609c-486a-45b6-beee-25d957cac666" xlink:to="loc_us-gaap_LiabilitiesAbstract_cb629b46-174e-4b98-815b-44bf1deb9dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ad53f61f-e2e6-47f7-9454-5b87d6decb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cb629b46-174e-4b98-815b-44bf1deb9dcb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ad53f61f-e2e6-47f7-9454-5b87d6decb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_34f25e6e-3f75-4c4f-8049-8d94b90fee10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad53f61f-e2e6-47f7-9454-5b87d6decb00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_34f25e6e-3f75-4c4f-8049-8d94b90fee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_80b60ab2-55c7-457d-a1d4-21fc195866b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad53f61f-e2e6-47f7-9454-5b87d6decb00" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_80b60ab2-55c7-457d-a1d4-21fc195866b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_117c3669-7384-4aa1-8248-fe0ab2bd2083" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad53f61f-e2e6-47f7-9454-5b87d6decb00" xlink:to="loc_lgnd_LeaseLiabilityCurrent_117c3669-7384-4aa1-8248-fe0ab2bd2083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5e45732-e0d4-4ac1-8616-27e32e2b7bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cb629b46-174e-4b98-815b-44bf1deb9dcb" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5e45732-e0d4-4ac1-8616-27e32e2b7bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_047d5b6e-94f2-4390-a43a-04e10f33f036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5e45732-e0d4-4ac1-8616-27e32e2b7bc4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_047d5b6e-94f2-4390-a43a-04e10f33f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_33974ed0-c341-472e-8692-8d85ed4caea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f5e45732-e0d4-4ac1-8616-27e32e2b7bc4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_33974ed0-c341-472e-8692-8d85ed4caea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_e1674056-d7e2-4665-9dda-d5a7df590605" xlink:href="lgnd-20231231.xsd#lgnd_LeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_cb629b46-174e-4b98-815b-44bf1deb9dcb" xlink:to="loc_lgnd_LeaseLiability_e1674056-d7e2-4665-9dda-d5a7df590605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ada187bb-e141-4064-a74d-f5f3b6bae413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0129609c-486a-45b6-beee-25d957cac666" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ada187bb-e141-4064-a74d-f5f3b6bae413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_31e605ed-08b5-4818-87d9-573b4e4cf9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31e605ed-08b5-4818-87d9-573b4e4cf9ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eea1c81b-13a1-48b2-a394-aad9e544bb44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eea1c81b-13a1-48b2-a394-aad9e544bb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c8c4982-997c-4035-80f2-5d1b6c99dd04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c8c4982-997c-4035-80f2-5d1b6c99dd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5e1ceb1f-8981-433c-9446-530b41a781cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5e1ceb1f-8981-433c-9446-530b41a781cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8fc11754-1569-4cd0-b6ec-56a549516cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8fc11754-1569-4cd0-b6ec-56a549516cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_557e5d5b-c36f-4cc2-bbe8-c836389ead0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_557e5d5b-c36f-4cc2-bbe8-c836389ead0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_94975ad8-883b-416b-a366-9c5116b9b10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_94975ad8-883b-416b-a366-9c5116b9b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b274b817-5b72-4485-8f7d-22aea58e5214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b274b817-5b72-4485-8f7d-22aea58e5214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_ef099d60-9470-4f38-ae58-b84ecc8cc453" xlink:href="lgnd-20231231.xsd#lgnd_OperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_ef099d60-9470-4f38-ae58-b84ecc8cc453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a0bed48e-5574-404c-ad4b-8daa9cbd5757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a0bed48e-5574-404c-ad4b-8daa9cbd5757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_77bfc131-7d89-4f3e-9711-66dc3b02eefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cb6c56fd-a284-4c12-bca1-f5492ffc05e9" xlink:to="loc_us-gaap_OperatingLeaseLiability_77bfc131-7d89-4f3e-9711-66dc3b02eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31e605ed-08b5-4818-87d9-573b4e4cf9ed" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_b6f0de20-efde-4808-974b-263fa7e03238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_b6f0de20-efde-4808-974b-263fa7e03238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f684d592-79a4-4ff8-a6a4-0efa7cbcfb09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f684d592-79a4-4ff8-a6a4-0efa7cbcfb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c114847f-fc3b-4822-8dbd-98e4d2ff2535" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c114847f-fc3b-4822-8dbd-98e4d2ff2535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e4ff3864-d652-4966-825e-fa0a02d00e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e4ff3864-d652-4966-825e-fa0a02d00e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c0cf6460-991d-43a3-ad41-333015e240fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c0cf6460-991d-43a3-ad41-333015e240fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_af8da242-8c1a-4b29-b5c3-456ce7fdf781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_af8da242-8c1a-4b29-b5c3-456ce7fdf781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cd30ea3e-11d5-448f-a513-7a6323f384a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cd30ea3e-11d5-448f-a513-7a6323f384a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_c361b015-2acc-4f7b-9054-2b7fcf2fc527" xlink:href="lgnd-20231231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_c361b015-2acc-4f7b-9054-2b7fcf2fc527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8e698ad3-9c1e-479d-83b7-158940a4f1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_8e698ad3-9c1e-479d-83b7-158940a4f1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_ed3aae08-251d-490d-93fe-0fcb428b8f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_85b5c870-b678-43ee-bae0-2ccc7baf5342" xlink:to="loc_us-gaap_FinanceLeaseLiability_ed3aae08-251d-490d-93fe-0fcb428b8f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20231231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8e0b3752-417a-4f28-9487-643a70eef530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8e0b3752-417a-4f28-9487-643a70eef530" xlink:to="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f9b9003c-4be4-4467-b5a2-999414aa252e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f05b2432-da9e-4f73-a235-3072c71261c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f9b9003c-4be4-4467-b5a2-999414aa252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_2a01ba5b-26be-439b-848b-2e8484b79e5b" xlink:href="lgnd-20231231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f9b9003c-4be4-4467-b5a2-999414aa252e" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_2a01ba5b-26be-439b-848b-2e8484b79e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f0ea6914-db32-4a0f-bb37-6a5c1be90951" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_0502aa9a-679f-4dbb-9978-08f8a63bab76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_0502aa9a-679f-4dbb-9978-08f8a63bab76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c16a26d4-785d-4151-b714-405463fc040e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d4245313-e78c-4b0c-8dab-3b515a998ebf" xlink:to="loc_us-gaap_LineOfCreditMember_c16a26d4-785d-4151-b714-405463fc040e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_2f086962-2676-4912-bffb-f8ef08dd3abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_d22472bc-79fa-409f-ba85-257198be5612" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_2f086962-2676-4912-bffb-f8ef08dd3abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_4c115cdb-d495-451c-a9ef-5c8fabd1f8a4" xlink:href="lgnd-20231231.xsd#lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_2f086962-2676-4912-bffb-f8ef08dd3abd" xlink:to="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_4c115cdb-d495-451c-a9ef-5c8fabd1f8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cc4c02c4-a6ea-4719-ad89-ce3521e27a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f07c4d8c-8f59-4c28-a08c-0fd92d5cd130" xlink:to="loc_us-gaap_CreditFacilityDomain_cc4c02c4-a6ea-4719-ad89-ce3521e27a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4975eea3-31a6-4ecd-8bcf-92d945e661b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cc4c02c4-a6ea-4719-ad89-ce3521e27a20" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4975eea3-31a6-4ecd-8bcf-92d945e661b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ee8604ea-84fe-4223-9845-f34d3593d5f8" xlink:to="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_25e32a5b-55a1-4a06-87c7-eaebeb90c819" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:to="loc_srt_MinimumMember_25e32a5b-55a1-4a06-87c7-eaebeb90c819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_105b7fdb-0b2c-445e-9401-8a31f5b254b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8f01cbf-9e47-4d6b-b351-8d8f4161084c" xlink:to="loc_srt_MaximumMember_105b7fdb-0b2c-445e-9401-8a31f5b254b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_dbbf986f-fec3-4a81-b9bf-8ae62db51d89" xlink:to="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SecuredOvernightFinancingRateSOFRMember_bca2e942-4c91-402b-990f-56bb40e3ab6a" xlink:href="lgnd-20231231.xsd#lgnd_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:to="loc_lgnd_SecuredOvernightFinancingRateSOFRMember_bca2e942-4c91-402b-990f-56bb40e3ab6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_4b64598f-f85b-4d1d-afb2-a94b993d8b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_640449ed-2e22-4d3e-b54d-f53160c5829b" xlink:to="loc_us-gaap_BaseRateMember_4b64598f-f85b-4d1d-afb2-a94b993d8b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a04a9e6a-7bb9-4b8c-92a4-d2abcd905fe6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7a003a02-f0d2-4652-a898-b7c6f28520b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7a003a02-f0d2-4652-a898-b7c6f28520b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_70fd99b3-c455-4220-b9e9-65248ccceed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_70fd99b3-c455-4220-b9e9-65248ccceed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8e2f4e7c-8a8b-4baf-aea0-c3ee7d1828f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_8e2f4e7c-8a8b-4baf-aea0-c3ee7d1828f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_a6798144-bd41-4fa6-a840-b029dfadca85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_a6798144-bd41-4fa6-a840-b029dfadca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cdeb5e8c-80d2-4ad9-9bee-7643c214211b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentTerm_cdeb5e8c-80d2-4ad9-9bee-7643c214211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_19832196-475d-4deb-96af-bcc4ef52b582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_19832196-475d-4deb-96af-bcc4ef52b582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_daede635-f6e6-454b-bb6c-a6b0c3db3052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_InterestExpenseDebt_daede635-f6e6-454b-bb6c-a6b0c3db3052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1d27e3a9-6068-4495-8f22-6194c05c0cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_1d27e3a9-6068-4495-8f22-6194c05c0cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_cfed580c-88da-47d8-8bb8-2d251390737d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_cfed580c-88da-47d8-8bb8-2d251390737d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_e5d4a6f1-dd1d-4f24-868c-6b5a7ab8e58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_e5d4a6f1-dd1d-4f24-868c-6b5a7ab8e58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9f0839fc-68d2-4e0f-b54e-3a3a3fc6637a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9f0839fc-68d2-4e0f-b54e-3a3a3fc6637a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_dfdc7d3f-e791-4b10-9c14-01eedaaf1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_InterestPaid_dfdc7d3f-e791-4b10-9c14-01eedaaf1cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed12e3b0-3443-4c6e-9dcf-6ad795af08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed12e3b0-3443-4c6e-9dcf-6ad795af08ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_de458bfb-e876-409f-88ff-8b82c369e882" xlink:href="lgnd-20231231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_de458bfb-e876-409f-88ff-8b82c369e882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c8c671b0-d81e-40ee-b01c-02ba8f01f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_c8c671b0-d81e-40ee-b01c-02ba8f01f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9a85eb64-23d5-4af0-885f-24caab56bfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9a85eb64-23d5-4af0-885f-24caab56bfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0cf9f6fd-b7f5-4df8-abd4-60002a3540a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0cf9f6fd-b7f5-4df8-abd4-60002a3540a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f178807f-1826-41a2-83f5-b7afb74ce873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f178807f-1826-41a2-83f5-b7afb74ce873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_5420ed0d-6856-40bd-90b7-0ef9f27db90e" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_5420ed0d-6856-40bd-90b7-0ef9f27db90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ede03940-b606-4490-91f8-b13a68ecc6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ede03940-b606-4490-91f8-b13a68ecc6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6c5918fc-901f-4de5-973d-55f95c6e2ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_6c5918fc-901f-4de5-973d-55f95c6e2ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToUnwindWarrants_5fec9ddb-6e68-42af-82fd-b2402298ed31" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToUnwindWarrants"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_PaymentsToUnwindWarrants_5fec9ddb-6e68-42af-82fd-b2402298ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d91cd7a3-a82f-4d06-9e55-14853ad1640e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d91cd7a3-a82f-4d06-9e55-14853ad1640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_e250c8f6-6222-4efd-b608-33d9ff73d0bf" xlink:href="lgnd-20231231.xsd#lgnd_DebtInstrumentRepurchasedAmountDuringPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_e250c8f6-6222-4efd-b608-33d9ff73d0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_36b4a61e-8ca1-4968-a020-78baa399c165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_36b4a61e-8ca1-4968-a020-78baa399c165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7895fca7-cbdc-47b5-989f-c891b2da8752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7895fca7-cbdc-47b5-989f-c891b2da8752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_98ef3e63-ee48-46b4-99ad-7941947dedca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_98ef3e63-ee48-46b4-99ad-7941947dedca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7dc2ba4e-9f92-42dd-8177-7467ca044ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7dc2ba4e-9f92-42dd-8177-7467ca044ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b9a72832-02a9-41f6-9622-444acff43442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6e0aea59-cc22-461c-82a1-43b7c8238eff" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b9a72832-02a9-41f6-9622-444acff43442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8fe99cf6-41ed-487a-ba9c-c2c905f59a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8fe99cf6-41ed-487a-ba9c-c2c905f59a48" xlink:to="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53fe62f7-9dd6-4e16-9f9e-64c6ff6d890c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_51c62c9c-6c79-4fa4-a5ad-150134581fc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53fe62f7-9dd6-4e16-9f9e-64c6ff6d890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_94f73f9b-c1b2-416c-b594-0095e542aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53fe62f7-9dd6-4e16-9f9e-64c6ff6d890c" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_94f73f9b-c1b2-416c-b594-0095e542aa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1386e780-e1b8-48b7-b3a3-ff03974b0347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b393a256-7479-465c-962f-64fd8454cff3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1386e780-e1b8-48b7-b3a3-ff03974b0347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_1bb7ca28-b082-49bd-ad14-7bf5e2ba2919" xlink:href="lgnd-20231231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1386e780-e1b8-48b7-b3a3-ff03974b0347" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_1bb7ca28-b082-49bd-ad14-7bf5e2ba2919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1251bd79-2e64-4d7c-a1ac-7d28d267d4c2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:to="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_97326ff0-9eac-4077-b7a7-f1ca715ea9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_97326ff0-9eac-4077-b7a7-f1ca715ea9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e9120b87-299c-47d3-9c5a-1e38ad1b685d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_e9120b87-299c-47d3-9c5a-1e38ad1b685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_c1899dbd-fdd9-4ece-af07-ff17cb4d3223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract_8f2cf46d-bc4a-471b-9e4e-660345c15cd1" xlink:to="loc_us-gaap_LongTermNotesPayable_c1899dbd-fdd9-4ece-af07-ff17cb4d3223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_558f9bca-296c-485f-8a36-80f51c12d576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c05651ea-b33e-455c-b9ae-c5b3cd0650c2" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_558f9bca-296c-485f-8a36-80f51c12d576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_ff8761c1-e0d5-4282-8c81-ffef81657fdb" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_ff8761c1-e0d5-4282-8c81-ffef81657fdb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38b313ef-7d8b-4caf-8057-677de9bc6128" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_97cae66e-bd03-487f-a10c-ed48fbab3204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_MutualFundMember_97cae66e-bd03-487f-a10c-ed48fbab3204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_e99844a8-28c0-44c7-ac3b-cd788f0a5c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_DemandDepositsMember_e99844a8-28c0-44c7-ac3b-cd788f0a5c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cc13692d-87db-4071-802e-3375bff07b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cc13692d-87db-4071-802e-3375bff07b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3d4e7974-aae5-4db9-be95-a4acb32c264a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_CommercialPaperMember_3d4e7974-aae5-4db9-be95-a4acb32c264a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_0078943a-3f77-4038-8ae4-f941b08fea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_0078943a-3f77-4038-8ae4-f941b08fea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_7333167f-6f42-43ca-b636-7af0e8e8f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_MunicipalBondsMember_7333167f-6f42-43ca-b636-7af0e8e8f8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_154ad6fe-3585-4c8c-a997-be9c18741eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_EquitySecuritiesMember_154ad6fe-3585-4c8c-a997-be9c18741eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1078e9ce-2615-4c11-99c2-6746072b7dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9cdb4a2-32f2-4b8a-8a61-0b9d4b23b3dd" xlink:to="loc_us-gaap_WarrantMember_1078e9ce-2615-4c11-99c2-6746072b7dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_70e98741-3903-4821-b45d-288ac0974774" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_060512b3-b8f5-4afc-b49d-d15cdd94682b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_060512b3-b8f5-4afc-b49d-d15cdd94682b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d844844b-13b7-4aa5-8762-d8a9ab2edec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d844844b-13b7-4aa5-8762-d8a9ab2edec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02af7b95-c528-4186-8062-6b0c3befb553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02af7b95-c528-4186-8062-6b0c3befb553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37afd0d2-ab1a-4f5d-93a3-42541e763dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_815573fb-79d7-4fa1-9628-dc9e3a525065" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37afd0d2-ab1a-4f5d-93a3-42541e763dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_3e876b3b-c017-40ca-9a0c-23dde8ea5337" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_31ef1972-f48f-420b-ab8c-fe02a2bb4c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_3e876b3b-c017-40ca-9a0c-23dde8ea5337" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_31ef1972-f48f-420b-ab8c-fe02a2bb4c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_fa283c5f-d20e-4791-8235-29d670221b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_31ef1972-f48f-420b-ab8c-fe02a2bb4c06" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_fa283c5f-d20e-4791-8235-29d670221b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_316038d7-92b4-4603-be3e-f602fa5eb688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_31ef1972-f48f-420b-ab8c-fe02a2bb4c06" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_316038d7-92b4-4603-be3e-f602fa5eb688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_8835e319-f9a7-468c-bb8c-c137c1815cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_31ef1972-f48f-420b-ab8c-fe02a2bb4c06" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_8835e319-f9a7-468c-bb8c-c137c1815cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e074dfd1-cf0b-4954-ba6c-c9d1bc47023f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_3e876b3b-c017-40ca-9a0c-23dde8ea5337" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e074dfd1-cf0b-4954-ba6c-c9d1bc47023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_912da75f-1dc6-43ac-9b69-3153e1cbf3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e074dfd1-cf0b-4954-ba6c-c9d1bc47023f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_912da75f-1dc6-43ac-9b69-3153e1cbf3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_96c3a45a-5283-4ec9-a44a-dd2615d3f851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e074dfd1-cf0b-4954-ba6c-c9d1bc47023f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_96c3a45a-5283-4ec9-a44a-dd2615d3f851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_454df965-f7b7-4112-94a1-de7a1a353fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e074dfd1-cf0b-4954-ba6c-c9d1bc47023f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_454df965-f7b7-4112-94a1-de7a1a353fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_4f559b70-24cb-426c-ab22-16d2d958770b" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4f559b70-24cb-426c-ab22-16d2d958770b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6380dd3-dfa3-42d1-b8e4-7960dd0c54a1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_c68c85c1-97e7-45fa-9631-1f207b5b6fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_DemandDepositsMember_c68c85c1-97e7-45fa-9631-1f207b5b6fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_705cee5f-e98d-42cb-922c-0ad20f86ebbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_705cee5f-e98d-42cb-922c-0ad20f86ebbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f8ead92e-7cba-4df9-a61f-19886d670f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_CommercialPaperMember_f8ead92e-7cba-4df9-a61f-19886d670f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_1837c193-f2ad-4461-a42a-4c041006d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_MunicipalBondsMember_1837c193-f2ad-4461-a42a-4c041006d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_fc6103de-c60c-47b2-ba8d-ea5b8e556811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89ab636c-b034-4b8e-af19-ee71f5151b0a" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_fc6103de-c60c-47b2-ba8d-ea5b8e556811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_85793ddf-75f4-4a15-be7e-2f4056dfbf40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b61752ac-e0b9-4581-b1f5-67e1f1d4e731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b61752ac-e0b9-4581-b1f5-67e1f1d4e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6097d493-a5b7-4c82-9f50-71c8bc57c361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6097d493-a5b7-4c82-9f50-71c8bc57c361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5a92a3a7-5850-428c-a0af-2e3a10444e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_458312ac-cdc4-496f-b892-c68148b7d7cf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_5a92a3a7-5850-428c-a0af-2e3a10444e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_5bece921-b7d2-48b0-9bbb-0acedce5b138" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1b2550a9-8ac2-494d-8d36-1e084d0409c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1b2550a9-8ac2-494d-8d36-1e084d0409c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b5ff09b0-870e-42aa-b01e-5ce285446722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b5ff09b0-870e-42aa-b01e-5ce285446722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b9ee1182-1f87-4dcb-931c-6a5284fb7042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_ac8fac51-d3cd-4e32-8e76-6efb3f88cbc7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b9ee1182-1f87-4dcb-931c-6a5284fb7042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_1b9c3896-b78e-427a-a6a6-33e1dbcaea58" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_1b9c3896-b78e-427a-a6a6-33e1dbcaea58" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:to="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3244ff89-e316-4aae-bee0-cac865ca8eff" xlink:to="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_71a006d3-d39e-46a3-ac26-9fa482f5c8d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:to="loc_srt_MinimumMember_71a006d3-d39e-46a3-ac26-9fa482f5c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbe4c39f-7038-459c-b979-b1e6bb7d4dc3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7b06e4c-4c5d-4723-8744-e700dae3e57b" xlink:to="loc_srt_MaximumMember_cbe4c39f-7038-459c-b979-b1e6bb7d4dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:to="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_34169eb4-22c3-44b5-b9fa-7ebf041ffc9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f9a42971-9f3f-4270-a23c-cd5c0f867993" xlink:to="loc_srt_OwnershipDomain_34169eb4-22c3-44b5-b9fa-7ebf041ffc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_ac733542-c3fb-4720-b9f5-b0370d503c34" xlink:href="lgnd-20231231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_34169eb4-22c3-44b5-b9fa-7ebf041ffc9d" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_ac733542-c3fb-4720-b9f5-b0370d503c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_121019b8-26d7-48b2-b7cc-18a2153d9b06" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bd1e3748-d78d-46ca-a1f7-247b68a9b577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_bd1e3748-d78d-46ca-a1f7-247b68a9b577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_dec3179e-0229-4e38-b5ff-bcc913cd5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_dec3179e-0229-4e38-b5ff-bcc913cd5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_d42edd48-a509-482a-8b19-157b0e219fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_d42edd48-a509-482a-8b19-157b0e219fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c0c48b62-7108-4946-8642-3587dd227296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c0c48b62-7108-4946-8642-3587dd227296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_247190e0-a805-45a7-b28c-4cd199cba827" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_247190e0-a805-45a7-b28c-4cd199cba827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_272782c6-b809-4dcd-8cfe-6d951af9a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_GainLossOnInvestments_272782c6-b809-4dcd-8cfe-6d951af9a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_38e82b92-bf36-4938-9739-2850e563002f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_38e82b92-bf36-4938-9739-2850e563002f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8d3ef0e9-5382-4858-8463-2456cee436ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_Depreciation_8d3ef0e9-5382-4858-8463-2456cee436ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_44a44119-4e71-41f6-ac35-c4612b104ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_44a44119-4e71-41f6-ac35-c4612b104ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8505895c-8086-4716-8e3c-ecfbef27fd32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_8505895c-8086-4716-8e3c-ecfbef27fd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_82ef0ea7-61a8-419a-a130-f6aaec4b4fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_82ef0ea7-61a8-419a-a130-f6aaec4b4fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02580a78-51df-464c-bf92-7e58ab98ad55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02580a78-51df-464c-bf92-7e58ab98ad55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0cb7844-896f-4bc4-92f1-36ee9879ab87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0cb7844-896f-4bc4-92f1-36ee9879ab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e3578f76-bbff-4b24-b0c1-cfe4089651ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e3578f76-bbff-4b24-b0c1-cfe4089651ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1c109aef-6d50-4d89-90fc-78e720cc1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1c109aef-6d50-4d89-90fc-78e720cc1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1aa4a61-86ad-419d-8eec-7c33137c840f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1aa4a61-86ad-419d-8eec-7c33137c840f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightAgreements_dcb503ed-de0e-414d-850d-7a1180c03d28" xlink:href="lgnd-20231231.xsd#lgnd_NumberOfContingentValueRightAgreements"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_773b7bd8-c412-4449-a419-b6f72375bf04" xlink:to="loc_lgnd_NumberOfContingentValueRightAgreements_dcb503ed-de0e-414d-850d-7a1180c03d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_1111cf48-abde-479b-ba6b-feb2ea53197e" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_1111cf48-abde-479b-ba6b-feb2ea53197e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_643c7aef-d210-45f6-bbae-49abb85769f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_873d1cd3-f095-495e-ab62-1b4e444ed98f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:to="loc_us-gaap_OfficeEquipmentMember_873d1cd3-f095-495e-ab62-1b4e444ed98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_47b08347-cc47-4814-87f6-81516db7d117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_47b08347-cc47-4814-87f6-81516db7d117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_ff443fef-b49c-4ce2-b5ad-fcbc7af34cb0" xlink:href="lgnd-20231231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_512abcf1-18e0-405d-aaac-da46c860498d" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_ff443fef-b49c-4ce2-b5ad-fcbc7af34cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_56d10489-fe42-4712-913a-f8d9da9f95c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_72348c6d-a592-42f9-b5a0-28115edf7c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_72348c6d-a592-42f9-b5a0-28115edf7c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3bf14d7c-a789-47cd-98fe-64c0d4597ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3bf14d7c-a789-47cd-98fe-64c0d4597ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9ff71441-15fd-4f11-a3e3-6329fbd102ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ba665af8-3c40-4cae-9eba-6a8472d9a7a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9ff71441-15fd-4f11-a3e3-6329fbd102ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_1aa90fc6-46e2-4ae4-9d1f-d8af3dffe13b" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_1aa90fc6-46e2-4ae4-9d1f-d8af3dffe13b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_33b7efd4-3385-411b-8469-684c5b681195" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_a54c562a-aa59-4327-b062-3c13e2860f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_PatentedTechnologyMember_a54c562a-aa59-4327-b062-3c13e2860f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_32d36d65-8cbf-49e7-93b7-0afcdfa5a611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_TradeNamesMember_32d36d65-8cbf-49e7-93b7-0afcdfa5a611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9f7fde01-52fc-45ff-a9e8-b70801f7794e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9f7fde01-52fc-45ff-a9e8-b70801f7794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_22ac5a54-bb1b-495d-b3e7-5c0c022dc528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ec6540a-e8a3-4c0e-a96e-f8edae9d2962" xlink:to="loc_us-gaap_ContractualRightsMember_22ac5a54-bb1b-495d-b3e7-5c0c022dc528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_56de89d2-f031-439a-a2bc-73bc6cf67369" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8ce8d1f7-fabd-43a6-8b14-52d78f6996d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_Goodwill_8ce8d1f7-fabd-43a6-8b14-52d78f6996d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7edb9c0b-08e5-4e5d-942f-2b5647e8a530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7edb9c0b-08e5-4e5d-942f-2b5647e8a530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_142c441e-5029-409e-b1d4-4ee55601c5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_142c441e-5029-409e-b1d4-4ee55601c5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c220c35e-b151-4182-92f3-adb12ec0388c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df4a8402-565c-43a1-b88c-96577393885d" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_c220c35e-b151-4182-92f3-adb12ec0388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e96245ff-c61d-4d29-b52e-9b919ec5be29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e96245ff-c61d-4d29-b52e-9b919ec5be29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a61fa5bd-d6c2-4f58-9bbd-9fa355dcf6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a61fa5bd-d6c2-4f58-9bbd-9fa355dcf6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCustomerDepositsCurrent_18e57110-99f5-4115-a0e8-1c2c618294cf" xlink:href="lgnd-20231231.xsd#lgnd_AccruedCustomerDepositsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_lgnd_AccruedCustomerDepositsCurrent_18e57110-99f5-4115-a0e8-1c2c618294cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseeAccrualCurrent_73b13f2d-11d8-4d91-bf33-bf8a9bd2b7e1" xlink:href="lgnd-20231231.xsd#lgnd_LicenseeAccrualCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_lgnd_LicenseeAccrualCurrent_73b13f2d-11d8-4d91-bf33-bf8a9bd2b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_ecefdd37-8f9c-4b92-a651-2cb1e1731444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_ecefdd37-8f9c-4b92-a651-2cb1e1731444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_bf0510af-2c1a-4b22-96aa-b8f523153b39" xlink:href="lgnd-20231231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_bf0510af-2c1a-4b22-96aa-b8f523153b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_eb8a1702-ae40-486f-b91a-760cb513f900" xlink:href="lgnd-20231231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_eb8a1702-ae40-486f-b91a-760cb513f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_280e8bcf-aec0-41dc-b9c8-6a6538e3280c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_280e8bcf-aec0-41dc-b9c8-6a6538e3280c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_70cd044d-c90c-41c7-9d24-163a2b8ee074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb5ecda3-1d2c-49b8-9680-9f9654d68abb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_70cd044d-c90c-41c7-9d24-163a2b8ee074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb631d32-5598-4a66-a32a-efdc3e0e3264" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_8dc6d9f1-7603-40e1-b02d-a9355439cdf8" xlink:href="lgnd-20231231.xsd#lgnd_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb631d32-5598-4a66-a32a-efdc3e0e3264" xlink:to="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_8dc6d9f1-7603-40e1-b02d-a9355439cdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_072dc513-efd5-411c-bec7-376318b67f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb631d32-5598-4a66-a32a-efdc3e0e3264" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_072dc513-efd5-411c-bec7-376318b67f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherMiscellaneousNonCurrentLiabilities_11268f50-8eff-4b46-a860-bd676adafb25" xlink:href="lgnd-20231231.xsd#lgnd_OtherMiscellaneousNonCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb631d32-5598-4a66-a32a-efdc3e0e3264" xlink:to="loc_lgnd_OtherMiscellaneousNonCurrentLiabilities_11268f50-8eff-4b46-a860-bd676adafb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_14354f22-e9b4-44e5-8634-83084b77c48a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_cb631d32-5598-4a66-a32a-efdc3e0e3264" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_14354f22-e9b4-44e5-8634-83084b77c48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_9bb8cbeb-8415-41ab-bf87-5b124cce3575" xlink:href="lgnd-20231231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_9bb8cbeb-8415-41ab-bf87-5b124cce3575" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a1376c5-9a67-46ba-9189-62968201d30b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_f3cade22-fa40-4e64-8f8b-de44dd7b1048" xlink:href="lgnd-20231231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_f3cade22-fa40-4e64-8f8b-de44dd7b1048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_1f5d3682-1876-4b18-a3d8-228862cde897" xlink:href="lgnd-20231231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_725795c1-9d44-47a2-8bdd-e75c3b0e355f" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_1f5d3682-1876-4b18-a3d8-228862cde897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_02f740c6-78fa-4794-aa0a-584ae3184a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b281e083-fdc9-4947-876f-504cbe6973b5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_02f740c6-78fa-4794-aa0a-584ae3184a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:href="lgnd-20231231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_02f740c6-78fa-4794-aa0a-584ae3184a56" xlink:to="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_9d12a448-1e29-401f-b7ef-b02fb839b23c" xlink:href="lgnd-20231231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_9d12a448-1e29-401f-b7ef-b02fb839b23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_12143bf7-c29a-41f7-b5b5-f688f0e27c60" xlink:href="lgnd-20231231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_12143bf7-c29a-41f7-b5b5-f688f0e27c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_35343038-450a-45b3-b295-df75ac33f6fe" xlink:href="lgnd-20231231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_35343038-450a-45b3-b295-df75ac33f6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_57ee0669-23a5-44d7-af88-56b80acdbf71" xlink:href="lgnd-20231231.xsd#lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities_57ee0669-23a5-44d7-af88-56b80acdbf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_6f5170d7-ec58-407a-8b0d-f9980683172a" xlink:href="lgnd-20231231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_3b2dfe11-4740-4891-94ab-78028419bce5" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_6f5170d7-ec58-407a-8b0d-f9980683172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae0ea314-5068-44ab-8972-54829e14abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae0ea314-5068-44ab-8972-54829e14abd0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b6aa2005-4b35-4660-abe9-5604643eed53" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a7f3693-836f-4713-b3af-78976bed3d37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9a7f3693-836f-4713-b3af-78976bed3d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f40a554a-c5e4-4367-9cb8-cb66f2b71249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9f3927e9-cacd-444c-85b1-65ee898d12a2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f40a554a-c5e4-4367-9cb8-cb66f2b71249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_102dc1ad-02b8-4798-b964-bf509e50a375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b04cb7c9-d4d4-401e-8a81-3dafa355a343" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_102dc1ad-02b8-4798-b964-bf509e50a375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_78e1a368-c7f7-4ea3-ba79-f23d91319d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_102dc1ad-02b8-4798-b964-bf509e50a375" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_78e1a368-c7f7-4ea3-ba79-f23d91319d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5c96424c-fdd5-4063-965b-1d2abdc936c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5c96424c-fdd5-4063-965b-1d2abdc936c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b000632d-a4ab-414e-8c63-44569e3a0c77" xlink:to="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_ef76270e-684b-4acf-9c5f-ad691fdb7af6" xlink:href="lgnd-20231231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_ef76270e-684b-4acf-9c5f-ad691fdb7af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OmniabSeparationMember_57e4c26a-d411-49bb-bfe6-183b8e963073" xlink:href="lgnd-20231231.xsd#lgnd_OmniabSeparationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:to="loc_lgnd_OmniabSeparationMember_57e4c26a-d411-49bb-bfe6-183b8e963073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_ff562d41-8a20-47f7-8bd3-6bc422a453eb" xlink:href="lgnd-20231231.xsd#lgnd_AmendedESPPMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_680d5633-a235-4752-bb5e-c00c86960dae" xlink:to="loc_lgnd_AmendedESPPMember_ff562d41-8a20-47f7-8bd3-6bc422a453eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43f2da3c-e059-4353-a896-44b99b32bf78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4474eb7e-9e75-48b2-b626-8c1f2a27407c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4474eb7e-9e75-48b2-b626-8c1f2a27407c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c856db3f-4a9a-4fd4-81ab-c9fec7895ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdcba183-2434-43c5-9271-1957da89ddc9" xlink:to="loc_us-gaap_RestrictedStockMember_c856db3f-4a9a-4fd4-81ab-c9fec7895ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97f6d040-0933-45e6-8c34-994d5c8306e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ab530a93-93f4-4da2-b643-640f4d0633f8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97f6d040-0933-45e6-8c34-994d5c8306e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AtTheMarketEquityOfferingMember_9bbd67f8-4435-4c50-ad96-a94ad8138525" xlink:href="lgnd-20231231.xsd#lgnd_AtTheMarketEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97f6d040-0933-45e6-8c34-994d5c8306e8" xlink:to="loc_lgnd_AtTheMarketEquityOfferingMember_9bbd67f8-4435-4c50-ad96-a94ad8138525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f85b253-5f5c-485d-bff2-4fc8dd2939ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2b91c3ca-4b2d-45d5-90e8-0f1a225ab003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2b91c3ca-4b2d-45d5-90e8-0f1a225ab003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fd7f264c-ca20-425f-805d-e47a25231806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fd7f264c-ca20-425f-805d-e47a25231806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a64ac4df-0d8f-4788-ba94-0e98683a5cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a64ac4df-0d8f-4788-ba94-0e98683a5cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d129ff48-d19a-45f2-b839-034d26acee3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d129ff48-d19a-45f2-b839-034d26acee3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2277c20d-59ee-4796-b232-e050dab2b61f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2277c20d-59ee-4796-b232-e050dab2b61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b402effa-e966-4c25-82d4-d9365d89ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b402effa-e966-4c25-82d4-d9365d89ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63fdcf1f-dad5-4937-8f2b-1de3dd6b6b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63fdcf1f-dad5-4937-8f2b-1de3dd6b6b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a1815d5-f23d-4023-a3c0-848d7606c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a1815d5-f23d-4023-a3c0-848d7606c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e6bd97e1-686d-4ea0-8048-67ec7eff5d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e6bd97e1-686d-4ea0-8048-67ec7eff5d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:href="lgnd-20231231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_07eaebaa-d1b6-4403-bb48-26c7751b6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_07eaebaa-d1b6-4403-bb48-26c7751b6a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d4a96cf-754d-4d14-9547-300800a6db59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8d4a96cf-754d-4d14-9547-300800a6db59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_6126f859-ac20-4b93-9350-1bb4eb42840a" xlink:href="lgnd-20231231.xsd#lgnd_ShareBasedCompensationInitialOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_6126f859-ac20-4b93-9350-1bb4eb42840a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d22c44f1-a6df-46ad-8a88-51e52c8bb780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_14138981-71b1-4adf-8788-3633b239a6a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d22c44f1-a6df-46ad-8a88-51e52c8bb780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:href="lgnd-20231231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a4cfb0-da0f-440f-a588-29c30c07415d" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65d963ed-7534-4a59-b9db-fca33b9efcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65d963ed-7534-4a59-b9db-fca33b9efcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6af9957b-b2ce-4d20-acc4-24660b78626c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6af9957b-b2ce-4d20-acc4-24660b78626c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_b5bb795e-ad58-42eb-abb8-ac5a3620a10d" xlink:href="lgnd-20231231.xsd#lgnd_SaleOfStockAuthorizedOfferingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_abb39d4e-2481-4534-95b3-fcf38ee984ab" xlink:to="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_b5bb795e-ad58-42eb-abb8-ac5a3620a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e01ba6fa-3363-4fd3-970f-2e67bdf13493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e01ba6fa-3363-4fd3-970f-2e67bdf13493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e18ebfa8-150f-4cd6-a146-6a38d18cc2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e18ebfa8-150f-4cd6-a146-6a38d18cc2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6299ffa4-f69a-4f00-92b2-8ababeef84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6299ffa4-f69a-4f00-92b2-8ababeef84b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b62ca607-5aba-4641-942b-a35ebc8dc02f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b62ca607-5aba-4641-942b-a35ebc8dc02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41cf3d69-9d5e-490d-806c-3aba9dc4e43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4f0f587b-de2b-482d-8178-32cec5664a6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41cf3d69-9d5e-490d-806c-3aba9dc4e43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5b4c2882-ec8e-43bb-8976-30d882e0a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5b4c2882-ec8e-43bb-8976-30d882e0a1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_33f95b0a-0577-469c-8b4b-864495a626b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_33f95b0a-0577-469c-8b4b-864495a626b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5616dff3-e0a4-4d2d-ace5-19a7f021ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5616dff3-e0a4-4d2d-ace5-19a7f021ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_02cb6f11-b779-4a68-a98f-024c5ae2dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_02cb6f11-b779-4a68-a98f-024c5ae2dc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9822325f-10e3-4649-831e-247418d2ff6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9822325f-10e3-4649-831e-247418d2ff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_05f962d2-5628-40be-9137-c68169337993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_05f962d2-5628-40be-9137-c68169337993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_324fd465-3089-4181-af98-d25fe573841f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a13f1ae-ee04-4e6d-9100-2a688003e0fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_324fd465-3089-4181-af98-d25fe573841f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e141fa64-75fe-44d8-bfb4-0a313e7b4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e141fa64-75fe-44d8-bfb4-0a313e7b4f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f5a99579-fc32-465b-ae7a-2390c443ed92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f5a99579-fc32-465b-ae7a-2390c443ed92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15068979-790b-4884-96e2-d79b679bf004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15068979-790b-4884-96e2-d79b679bf004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c9b30fcb-128e-40f8-a6fd-f8a56d3d2f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c9b30fcb-128e-40f8-a6fd-f8a56d3d2f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4a101aca-565c-4cb5-b910-6e8249fb7e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4a101aca-565c-4cb5-b910-6e8249fb7e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_caa0f040-668f-4ebe-bd2c-166e427a2405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_caa0f040-668f-4ebe-bd2c-166e427a2405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd0d8c9a-5e37-43d7-8d29-97ea8daa6cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd0d8c9a-5e37-43d7-8d29-97ea8daa6cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6a64914e-e3a1-47a9-8b0b-598879378dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30a8a140-10a3-4342-bb3c-7e3b544c0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6a64914e-e3a1-47a9-8b0b-598879378dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e7354fe6-bd32-4174-b538-8d114af6f992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e7354fe6-bd32-4174-b538-8d114af6f992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d48288d2-a2fe-421b-9394-f11f66c1a7a7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_fd82674f-9bfc-466b-8f8e-df5c872fa9e7" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_fd82674f-9bfc-466b-8f8e-df5c872fa9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_d7624b07-10f5-47b7-bfc5-f5317d861612" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_d7624b07-10f5-47b7-bfc5-f5317d861612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_8c21f45a-9f81-422f-bf20-6fdb712932bc" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_8c21f45a-9f81-422f-bf20-6fdb712932bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_06b9bf1a-9bf9-4667-bfd0-5e7fc6a3dea2" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_06b9bf1a-9bf9-4667-bfd0-5e7fc6a3dea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_907fbf9a-9304-400a-8393-66e3898716bb" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_907fbf9a-9304-400a-8393-66e3898716bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_aa4996f2-350c-41cb-b000-1d7849243b95" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_aa4996f2-350c-41cb-b000-1d7849243b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_3b53e9a8-26e3-4eed-bb1b-e220c0f2f8f9" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_3b53e9a8-26e3-4eed-bb1b-e220c0f2f8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_e0babe31-a696-433d-830c-5048f67c8fec" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_e0babe31-a696-433d-830c-5048f67c8fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_611427b2-c334-42cb-901e-1cb1853a932e" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_611427b2-c334-42cb-901e-1cb1853a932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_074e20a6-c7bf-4742-81f5-49425e5a6f0c" xlink:href="lgnd-20231231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5ffbd604-f81e-41df-a05b-79393f1dab7e" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_074e20a6-c7bf-4742-81f5-49425e5a6f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6a523fd-ad9c-4216-9dd6-b399826f6899" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bfc71417-1c7e-46d6-9184-710b698ea59d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bfc71417-1c7e-46d6-9184-710b698ea59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_76c6e56b-6f5b-4b75-9e3f-4786b5b34c21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_76c6e56b-6f5b-4b75-9e3f-4786b5b34c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_03e1e2b3-46be-4222-80f8-5fe65e8903ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_03e1e2b3-46be-4222-80f8-5fe65e8903ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2efbb165-98ea-4a0a-a6c6-102661c13e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2efbb165-98ea-4a0a-a6c6-102661c13e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1cdb74d9-dcbf-43a7-8d78-e784f84dbf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1cdb74d9-dcbf-43a7-8d78-e784f84dbf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_b040225a-e293-40e6-b8e1-bd9bb16d1b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_b040225a-e293-40e6-b8e1-bd9bb16d1b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fbfd36e8-e6e1-410a-9c43-63963591ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_01c73a76-55b4-40f8-b6a6-3d10e855451c" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_fbfd36e8-e6e1-410a-9c43-63963591ed60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fa291fb0-5ca2-4271-861a-34da129d24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fa291fb0-5ca2-4271-861a-34da129d24fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:to="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_35544e10-984a-4e3e-a7f6-d32f8949f115" xlink:to="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_821724f3-0201-47da-a965-b873cb411b02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:to="loc_srt_MinimumMember_821724f3-0201-47da-a965-b873cb411b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1fc74b22-f79a-4a79-a0d4-d46eada835d5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f8c09b6-1c8a-4ac0-a428-71b8883d06e6" xlink:to="loc_srt_MaximumMember_1fc74b22-f79a-4a79-a0d4-d46eada835d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1c295165-4f88-4453-a977-a124b536c120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35ec17ba-5c54-4b74-8b49-e9bbbd7d8234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35ec17ba-5c54-4b74-8b49-e9bbbd7d8234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf95cdb5-2c49-4044-8543-82f2ddfef81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf95cdb5-2c49-4044-8543-82f2ddfef81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a23cc446-ec42-4d81-9a68-5fc0040b36b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4cc38e5f-9b63-44f3-a55a-e972dd44cbac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a23cc446-ec42-4d81-9a68-5fc0040b36b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ae055bb-ebb2-427c-832b-18a6279e668b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ae055bb-ebb2-427c-832b-18a6279e668b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:to="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e817ab03-c562-4ae3-a900-afbd0c2cb89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2d7fd843-65c6-4373-a441-3a97e9f98ac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e817ab03-c562-4ae3-a900-afbd0c2cb89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b681e81d-af90-4502-92c5-1123649f275f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e817ab03-c562-4ae3-a900-afbd0c2cb89f" xlink:to="loc_us-gaap_RestrictedStockMember_b681e81d-af90-4502-92c5-1123649f275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_485f778d-593d-4887-b815-3b7fdc63ea21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d87ea31e-4bbe-43de-a038-38e69e4224e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d87ea31e-4bbe-43de-a038-38e69e4224e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73798c93-0dda-48c6-bcdd-42a7c268a8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73798c93-0dda-48c6-bcdd-42a7c268a8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e6351da-93e2-4f9b-9341-c59fe1a9cc19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2e6351da-93e2-4f9b-9341-c59fe1a9cc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_661b7b26-bb39-447a-b24f-7110fea86a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_661b7b26-bb39-447a-b24f-7110fea86a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_569cce5c-2e08-4fe7-a7df-50da17b62328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d4753f7-f340-4074-8595-4ace6518c18d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_569cce5c-2e08-4fe7-a7df-50da17b62328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77a7e683-4567-4ac7-939d-59c9dbe24e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04b01364-eb40-4932-98d2-c8d177a4d415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04b01364-eb40-4932-98d2-c8d177a4d415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5de5f914-eb7e-49c6-98bc-048358c3e557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5de5f914-eb7e-49c6-98bc-048358c3e557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81d3fbbb-c5e3-48f2-89a4-3d313680cd79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_81d3fbbb-c5e3-48f2-89a4-3d313680cd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e5305d19-aeb1-47a0-bed1-d271b885388b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e5305d19-aeb1-47a0-bed1-d271b885388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb52273-0866-4f05-af41-2ed744a3fd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c45eb13-6d97-49cb-90e3-439dedf6cdc6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5eb52273-0866-4f05-af41-2ed744a3fd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c032c66e-db80-4571-a366-3d500189e467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c032c66e-db80-4571-a366-3d500189e467" xlink:to="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:to="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a7349d54-6b2e-44b6-a22e-3c68a4447935" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c45d6f7f-6225-4f96-9bee-7b9ed5a99ff3" xlink:to="loc_srt_LitigationCaseTypeDomain_a7349d54-6b2e-44b6-a22e-3c68a4447935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_5d8adfe5-6d9f-4b6a-9ca5-e2e75a99d7ad" xlink:href="lgnd-20231231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a7349d54-6b2e-44b6-a22e-3c68a4447935" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_5d8adfe5-6d9f-4b6a-9ca5-e2e75a99d7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d6eb3fc3-3c7f-4db8-8813-adcf2cba5114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d173451c-b097-46af-945b-ae53d00e7d6d" xlink:to="loc_us-gaap_LossContingenciesLineItems_d6eb3fc3-3c7f-4db8-8813-adcf2cba5114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_94154dec-1164-4e22-a3aa-d2d1da0da955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d6eb3fc3-3c7f-4db8-8813-adcf2cba5114" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_94154dec-1164-4e22-a3aa-d2d1da0da955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cfd50aa5-3017-4352-b84b-a4738850e115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6461ae85-21dc-4260-872b-0bb86031b9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cfd50aa5-3017-4352-b84b-a4738850e115" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6461ae85-21dc-4260-872b-0bb86031b9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_caba4773-58c0-44e4-a8fa-fe971a95b177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6461ae85-21dc-4260-872b-0bb86031b9b8" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_caba4773-58c0-44e4-a8fa-fe971a95b177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_576bfbc7-c95f-436c-a2a2-29293d5de14f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6461ae85-21dc-4260-872b-0bb86031b9b8" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_576bfbc7-c95f-436c-a2a2-29293d5de14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ef93ba89-0898-4a5b-8656-f4cc3b42a755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6461ae85-21dc-4260-872b-0bb86031b9b8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ef93ba89-0898-4a5b-8656-f4cc3b42a755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dc26229c-0752-4cc5-90d6-eb5e258474c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6461ae85-21dc-4260-872b-0bb86031b9b8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dc26229c-0752-4cc5-90d6-eb5e258474c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2086ff47-9b02-468b-bcd3-03d7fbdefa97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cfd50aa5-3017-4352-b84b-a4738850e115" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2086ff47-9b02-468b-bcd3-03d7fbdefa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8619553a-ded6-495e-89ab-268edf8f2fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2086ff47-9b02-468b-bcd3-03d7fbdefa97" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_8619553a-ded6-495e-89ab-268edf8f2fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7d24b368-0d58-410f-a033-661bdd7b0fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2086ff47-9b02-468b-bcd3-03d7fbdefa97" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7d24b368-0d58-410f-a033-661bdd7b0fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4177a9d-2b01-47db-9395-20749fff151a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2086ff47-9b02-468b-bcd3-03d7fbdefa97" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b4177a9d-2b01-47db-9395-20749fff151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2c9de0b3-c454-409e-9b67-4d2691bca084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cfd50aa5-3017-4352-b84b-a4738850e115" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2c9de0b3-c454-409e-9b67-4d2691bca084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6d263632-d3d9-4cc4-b148-1f768e229fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6d263632-d3d9-4cc4-b148-1f768e229fa4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b3d0e36d-eb8d-42ba-98ae-92062cbcad07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b3d0e36d-eb8d-42ba-98ae-92062cbcad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1d4afb07-196f-4c12-850b-2cbc2dfb3f97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1d4afb07-196f-4c12-850b-2cbc2dfb3f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_bb089ae4-b173-4910-b176-e658db3c945a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_bb089ae4-b173-4910-b176-e658db3c945a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_78e5099c-4e17-404b-abed-c127d7893165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_78e5099c-4e17-404b-abed-c127d7893165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_ae5723d7-f5cb-4f45-ba28-3e6da3062143" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_ae5723d7-f5cb-4f45-ba28-3e6da3062143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_ec649f6d-4ed9-4e0e-b090-e7e9154b0d31" xlink:href="lgnd-20231231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_ec649f6d-4ed9-4e0e-b090-e7e9154b0d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_63bea9e9-f540-4303-8fce-7d881b7973c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_63bea9e9-f540-4303-8fce-7d881b7973c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_323efe8a-2312-4cb8-ac61-e849a7319339" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_323efe8a-2312-4cb8-ac61-e849a7319339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_d0699575-7e62-4990-8aad-573d667a25ce" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_d0699575-7e62-4990-8aad-573d667a25ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_7ed82710-8abd-4074-bd97-0d566d5bc771" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_7ed82710-8abd-4074-bd97-0d566d5bc771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0425aca8-5594-4aa5-bd7f-f53229211f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0425aca8-5594-4aa5-bd7f-f53229211f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_355b6aa5-00e4-42ae-b9f1-45efa8c8adf5" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_355b6aa5-00e4-42ae-b9f1-45efa8c8adf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_a8adc55d-49bc-4bbe-9ecc-944d0661bb85" xlink:href="lgnd-20231231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_a8adc55d-49bc-4bbe-9ecc-944d0661bb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_65f65dd0-9d27-453d-8342-b1a318a42774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_65f65dd0-9d27-453d-8342-b1a318a42774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1fb72eec-e441-4ea3-92d7-6ce16f2a886d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1fb72eec-e441-4ea3-92d7-6ce16f2a886d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_096b926a-78f3-489e-98b7-955c9ac21191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_c46cc4fb-b8e7-4291-9894-efa6aee8718f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_096b926a-78f3-489e-98b7-955c9ac21191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2f949dac-602d-4907-9bfd-9ffbc56d1989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2f949dac-602d-4907-9bfd-9ffbc56d1989" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e2d3f41b-905d-4b01-9b56-f79f62e1421f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_a08470db-495a-4373-b0ef-aba0e5c530bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_a08470db-495a-4373-b0ef-aba0e5c530bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_7bc04234-daa9-4fd5-aa14-f6ad78d45b86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_7bc04234-daa9-4fd5-aa14-f6ad78d45b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_6fa7593c-0440-48b4-854f-14c91e3876d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7ecf34c-3697-477d-ae2d-41827b90040f" xlink:to="loc_us-gaap_ForeignCountryMember_6fa7593c-0440-48b4-854f-14c91e3876d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_881b15da-37f4-4f49-b3da-08f7d5e74045" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_5793edf0-f05d-4216-97af-1aa11eb3dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:to="loc_us-gaap_ResearchMember_5793edf0-f05d-4216-97af-1aa11eb3dcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_4a48c603-100a-408a-b9b3-866bab19358f" xlink:href="lgnd-20231231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_4a48c603-100a-408a-b9b3-866bab19358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_2e541b75-8a3b-4c0d-acf7-adbb02f61a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_56a73939-51b1-4798-b218-012e10828b5a" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_2e541b75-8a3b-4c0d-acf7-adbb02f61a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b9a7a17a-8d5c-4ea3-bdf7-f49434d32492" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c1d56fac-3ad5-420b-a1cb-04786f51d7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c1d56fac-3ad5-420b-a1cb-04786f51d7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_bcbc208c-df67-420d-bdc3-b6fad1c269e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_OperatingLossCarryforwards_bcbc208c-df67-420d-bdc3-b6fad1c269e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1823acf1-990c-496a-b327-7387cf6bc920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1823acf1-990c-496a-b327-7387cf6bc920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_538a8dec-964e-428c-8ccf-d0d73d935d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3ad7b43e-8453-45a3-b42d-80dd7114ef60" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_538a8dec-964e-428c-8ccf-d0d73d935d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e61eb05e-7481-4425-8d21-d1fd33667a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e61eb05e-7481-4425-8d21-d1fd33667a69" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_af155cdc-b3b7-4449-9431-b74294dded52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_af155cdc-b3b7-4449-9431-b74294dded52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ccac10c7-e29b-4193-a091-f2a4dd626ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ccac10c7-e29b-4193-a091-f2a4dd626ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_efcd441d-4f1f-4c39-bef2-84d17af08656" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_efcd441d-4f1f-4c39-bef2-84d17af08656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c42323ec-3c56-40a9-aba3-109983db7174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c42323ec-3c56-40a9-aba3-109983db7174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3b3e3ce0-c9bb-4970-b29f-8e4c87b82e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3b3e3ce0-c9bb-4970-b29f-8e4c87b82e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ef0c59f9-349c-4194-9569-964f72967dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ef0c59f9-349c-4194-9569-964f72967dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8196b237-09ac-4892-a397-439e90cc080f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8196b237-09ac-4892-a397-439e90cc080f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9089ee7e-ed7e-4199-a2e9-792bc16e9445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_340caae9-3c04-418d-a167-312d7889aa48" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9089ee7e-ed7e-4199-a2e9-792bc16e9445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7438160-9558-4a68-aeb0-b31c78e9523f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e61eb05e-7481-4425-8d21-d1fd33667a69" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7438160-9558-4a68-aeb0-b31c78e9523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_b5ef1011-9ec0-4440-972b-31849ce9d30b" xlink:href="lgnd-20231231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7438160-9558-4a68-aeb0-b31c78e9523f" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_b5ef1011-9ec0-4440-972b-31849ce9d30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_45102044-3cb1-44c0-bed2-0b8603054ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7438160-9558-4a68-aeb0-b31c78e9523f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_45102044-3cb1-44c0-bed2-0b8603054ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7b37ae4d-fdac-45e8-bbcd-92f5db1e5590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7438160-9558-4a68-aeb0-b31c78e9523f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7b37ae4d-fdac-45e8-bbcd-92f5db1e5590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3c5f10e7-4145-4a82-8a2c-5f9aed85ecdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e61eb05e-7481-4425-8d21-d1fd33667a69" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3c5f10e7-4145-4a82-8a2c-5f9aed85ecdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20231231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8959e993-630e-4351-8c4e-3a3c2a7fd39b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8959e993-630e-4351-8c4e-3a3c2a7fd39b" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_312d713f-3a1b-4e3a-b037-2e6ebcf68ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_312d713f-3a1b-4e3a-b037-2e6ebcf68ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_aa7b0591-fa68-4b6f-9d2d-f40656afd125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_aa7b0591-fa68-4b6f-9d2d-f40656afd125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_18a39cc8-f087-49d5-92b6-040b38a28545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_18a39cc8-f087-49d5-92b6-040b38a28545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b211f321-3975-4268-9beb-03de7f2ff7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b211f321-3975-4268-9beb-03de7f2ff7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4fad337b-2913-4eb7-b16f-5103db9559ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3fd715b8-0621-473e-be5b-0dc363cff0c4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4fad337b-2913-4eb7-b16f-5103db9559ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="lgnd-20231231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_10.jpg
<TEXT>
begin 644 image_10.jpg
MB5!.1PT*&@H    -24A$4@  !?D    %" 8   #V2.:P    "7!(67,  $SE
M  !,Y0%USO"5    3DE$051XG.W8L0D , P#0>V_M(.S0:H@N(?K52M)!@
M    Z++E]P@      ."=DQ\      $HY^0$     H-0]^4>2)$F2)$F2)%5V
5 !5SINX!%H(,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
MB5!.1PT*&@H    -24A$4@  !B(    %" 8   #(6_0/    "7!(67,  $SE
M  !,Y0%USO"5    2TE$051XG.W.P0D , P#,>^_= O>(02"#O2_)'D
M   #VO8$      !P4]N>        ;FK;$P      P$V2)$F2)$F2)$ES?7CJ
2;.744>;8     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_5.jpg
<TEXT>
begin 644 image_5.jpg
MB5!.1PT*&@H    -24A$4@   S    0@" 8    Y>;D.   61TE$051X7NW7
M,0T , S L/(GW?Y#L$CV&0:9!0  B)@W    _,K     &08&  #(,#   $"&
M@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!
M   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0
M,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,
M#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P
M )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "0
M86   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@
M  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8
M@ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( ,
M P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#
M  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P
M9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08
M&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@
M "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @
MP\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/
M    &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P
M !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9
M!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&
M  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@
MR# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P
M,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#
M $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  !
MAH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:!
M 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$
M #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R
M# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,
M  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#
MD&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A
M8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086
M ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  "
M# ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P#
M P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,
M &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D
M&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8
M   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&
M(,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##
MP    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\
M   9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/
M&08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&
M!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8
M ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(
M,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P
M  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,
M0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&
M@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!
M   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0
M,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,
M#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P
M )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "0
M86   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@
M  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8
M@ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( ,
M P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#
M  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P
M9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08
M&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@
M "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @
MP\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/
M    &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P
M !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9
M!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&
M  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@
MR# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P
M,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#
M $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  !
MAH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:!
M 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$
M #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R
M# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,
M  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#
MD&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A
M8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086
M ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  "
M# ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P#
M P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,
M &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D
M&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8
M   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&
M(,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##
MP    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\
M   9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/
M&08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&
M!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8
M ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(
M,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P
M  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,
M0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&
M@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!
M   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0
M,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,
M#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P
M )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "0
M86   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@
M  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8
M@ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( ,
M P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#
M  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P
M9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08
M&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@
M "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @
MP\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/
M    &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P
M !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9
M!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&
M  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@
MR# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P
M,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#
M $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  !
MAH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:!
M 0  ,@P,  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$
M #(,#   D&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R
M# P  )!A8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,
M  "086   ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#
MD&%@  " # ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A
M8   @ P# P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086
M ( , P,  &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  "
M# ,#  !D&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P#
M P  9!@8   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,
M &08&   (,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D
M&!@  "##P    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8
M   @P\     9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&
M(,/     &08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##
MP    !D&!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\
M   9!@8  ,@P,   0(:! 0  ,@P,  "086   ( , P,  &08&   (,/
M&08&  #(,#   $"&@0$  #(,#   D&%@  " # ,#  !D&!@  "##P    !D&
M!@  R# P  ! AH$!   R# P  )!A8   @ P# P  9!@8   @P\     9!@8
M ,@P,   0(:! 0  ,@P,  "086   (", W::>?NX<3S_     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>lgnd-20231231_g1.jpg
<TEXT>
begin 644 lgnd-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI+"!*96YN
M>0  !9 #  (    4   0HI $  (    4   0MI*1  (    #.#   )*2  (
M   #.#   .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                 #(P,C,Z,3(Z,#@@,3,Z-#DZ,S0 ,C R,SHQ,CHP." Q
M,SHT.3HS-    $P :0 L "  2@!E &X ;@!Y    _^$+'&AT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7
M-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z
M>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A
M+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM
M<#I#<F5A=&5$871E/C(P,C,M,3(M,#A4,3,Z-#DZ,S0N.# R/"]X;7 Z0W)E
M871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q
M.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI
M/DQI+"!*96YN>3PO<F1F.FQI/CPO<F1F.E-E<3X-"@D)"3PO9&,Z8W)E871O
M<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D9CI21$8^/"]X.GAM<&UE=&$^#0H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(#P_>'!A8VME="!E;F0])W<G/S[_VP!#
M  <%!08%! <&!08(!P<("A$+"@D)"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8
M(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_
MP  1" &M!,4# 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%
M!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q
M%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ
M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\
MT /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$
M_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_
MHH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0
M _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_
M - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B
M@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #
M_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\
MT /_ "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z*
M/H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_
M "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0
M _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^
M@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0 _\
M)-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #
M_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z
M_P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P D
MV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_
M "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_
M (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;
M_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\
M)-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\
MA+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\
M:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P D
MV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$
ML^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH
M_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;
M_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2S
MX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_
M (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\
M:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@
M3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\
MA+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QK
MY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/
M_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$
ML^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG
M^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_]
M #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2S
MX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z
M* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T
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M%_S?@'UGR,RBM/ ]*,#TH^HO^;\ ^L^1F45IX'I1@>E'U%_S?@'UGR,RBM/
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MWH *TQT%9E:8Z"O1P.\OD<>*Z"T445Z1QA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-;[C?2G
M4UON-]*3V&MS-HHHKYT]<^P/@9_R1?0O^WC_ -*)**/@9_R1?0O^WC_THDHH
M X?Q'_R:/8?]<;?_ -'"OG>OHCQ'_P FCV'_ %QM_P#T<*^=Z "M,=!696F.
M@KT<#O+Y''BN@M%%%>D<84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !36^XWTIU-;[C?2D]AK<S
M:***^=/7/L#X&?\ )%]"_P"WC_THDHH^!G_)%]"_[>/_ $HDHH X?Q'_ ,FC
MV'_7&W_]'"OG>OHCQ'_R:/8?]<;?_P!'"OG>@ K3'05F5ICH*]' [R^1QXKH
M+1117I'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4UON-]*=36^XWTI/8:W,VBBBOG3US[ ^!
MG_)%]"_[>/\ THDHH^!G_)%]"_[>/_2B2B@#A_$?_)H]A_UQM_\ T<*^=Z^B
M/$?_ ":/8?\ 7&W_ /1PKYWH *TQT%9E:8Z"O1P.\OD<>*Z"T445Z1QA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %-;[C?2G4UON-]*3V&MS-HHHKYT]<^P/@9_P D7T+_ +>/
M_2B2BCX&?\D7T+_MX_\ 2B2B@#A_$?\ R:/8?]<;?_T<*^=Z^B/$?_)H]A_U
MQM__ $<*^=Z "M,=!696F.@KT<#O+Y''BN@M%%%>D<84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !36^XWTIU-;[C?2D]AK<S:***^=/7/L#X&?\D7T+_MX_P#2B2BCX&?\D7T+
M_MX_]*)** .'\1_\FCV'_7&W_P#1PKYWKZ(\1_\ )H]A_P!<;?\ ]'"OG>@
MK3'05F5ICH*]' [R^1QXKH+1117I'&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UON-]*=36^
MXWTI/8:W,VBBBOG3US[ ^!G_ "1?0O\ MX_]*)**/@9_R1?0O^WC_P!*)**
M.'\1_P#)H]A_UQM__1PKYWKZ(\1_\FCV'_7&W_\ 1PKYWH *TQT%9E:8Z"O1
MP.\OD<>*Z"T445Z1QA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1)11\#/^2+Z%_P!O'_I1)10!P_B/_DT>P_ZXV_\ Z.%?.]?1'B/_ )-'L/\
MKC;_ /HX5\[T %:8Z"LRM,=!7HX'>7R./%=!:***](XPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "NL^%O_)4M _Z^A_(UR==9\+?^2I:!_P!?
M0_D:BI\#]"H?$C[ KA/C5_R1_6_^V'_I1'7=UPGQJ_Y(_K?_ &P_]*(Z\.E_
M$CZH].I\#/DZBBBO?/*"BBB@ HHHH **** "BBB@ HHHH **** "OL?X=?\
M)-?#W_8/B_\ 017QQ7V/\.O^2:^'O^P?%_Z"*X,;\".K#?$SI:^*?%?_ ".>
MM?\ 80G_ /1C5]K5\4^*_P#D<]:_["$__HQJSP/Q,O$[(R:***],X@HHHH *
M*** "BBND\#>"K_QSXB33K']U"@WW-R1E84]?<GH!W/MDA2DHJ[&DV[(3P9X
M'U?QQJWV32HML49!N+J0?NX5/KZGC@=_S-?3W@KX=:'X'LP-.A\Z]9<37LH!
MD?U _NK[#\<]:V/#WAW3?"^BPZ7H]NL,$0Y./FD;'+L>['U_I6G7CU\1*H[+
M8]"G14-7N%(2%4EB  ,DGM7G_C_XNZ/X+WV5N!J.K8_X]HVPL1]9&[?[HY^G
M6OGOQ3\1/$OB^5_[6U%UMF.19P'9"H]-H^]]6R:*6&G4UV03K1AIU/IK5_B?
MX-T1BE]K]JTB]8[<F9@?0[ <?C7,7'[0G@Z!L10:I<#/WHK= /\ QYQ7S+17
M9'!TUN<[Q$^A]+Q?M#^$)&P]IJ\0]7@C_I(:V].^,W@;46"#61;.?X;F%XQ_
MWUC;^M?)M%-X.F]KB6(F?<=AJ5CJEN+C3+RWO(3TDMY5D7\P:LU\.:?J=]I-
MVMUI=Y/9SKTD@D*-^8KUSP;^T!J%BT=IXP@^WV_3[9"H69/=EZ-^A^M<U3!R
MCK'4WCB(OXM#Z&=%D1D=0RL,,I&01Z5X]\0O@79:HDNI>#ECLKW!9K+[L,W^
M[_</_COTZUZGHVMZ;X@TR/4-&O([NUDZ/&>A]".H/L>:@\3>)-/\)Z#/JVK2
M[(8AA5&-TK'HBCN3_B>@KFIRG"7N[FTXQE'4^,+VRNM-OI;._@DM[F%MLD4B
M[64^A%05M>+O%-]XQ\27&KZEM5Y/ECC7[L2#[JCUQZ]SFL6O=C>VIY;M?0**
M**8@HHHH **** "BBB@ HHHH 5$:1U1%+,QPJ@9)/I7V-\/O"Z^$/!%AI94"
MX">;<L/XI6Y;\N%^BBOG_P""/A3_ (2+QY'>W$>ZSTD"YDR.&DS^[7\_F_X"
M:^I:\S&U+M01VX:&G,%%<3XZ^(EKX,UK0;*;8?M]S_I))_U4'W=__?1!^BM7
M;=>E<+BTDWU.I23;1\N?''PI_P (_P".WO[>/;9ZL#<+@<"7/[P?F0W_  .O
M-J^M/BYX4_X2KP!=) FZ]L?]*ML#DE1\R_BN>/7%?)=>QA:G/3UW1YU:'+/U
M"BBBNDQ"BBB@ HHHH **** "BBB@">Q_Y"-M_P!=5_F*^Y:^&K'_ )"-M_UU
M7^8K[EKS<=O'YG9ANH5RWQ!\#VGCKPT]C/MBNXLR6EP1S$^.A_V3T(^AZ@5U
M-%<$9.+NCK:35F?#NIZ;=Z/JEQI^I0M!=6SE)(VZ@C^G?/>JM?37QE^&W_"4
MZ6=:T:'.L6:?-&@YN8Q_#CNP[>O3TQ\R].M>W1JJK&YYE2FX2L%%%%;&8444
M4 %%%% !7TW^SY_R363_ +"$O_H*5\R5]-_L^?\ )-9/^PA+_P"@I7)C/X1T
M8?XSU&OD;XO?\E9UW_KJG_HM:^N:^1OB]_R5G7?^NJ?^BUKEP7\1^AOB?A1Q
ME%%%>J< 4444 %%%% 'TW^SY_P DUD_["$O_ *"E>HUY=^SY_P DUD_["$O_
M *"E>HUX5?\ BR/4I? C/N]?T>PN&M[[5K&VF4 F.:Y1&&>G!.:A_P"$K\._
M]![2_P#P,C_QKYK^.7_)6=1_ZY0_^BUKSVNN&#4HJ5]S"6(<9-6/M;_A*_#O
M_0>TO_P,C_QH_P"$K\._]![2_P#P,C_QKXIHJOJ,>Y/UE]C[9B\2Z%,Q$.M:
M=(0,D)=H?ZUHQRQS)OA=9%_O*<BOA6IK6]NK&82V5S-;R#H\,A0_F*3P*Z2&
ML3W1]S45\EZ'\8O&FALH&JM?PCK%?CS0?^!'YOR:O6O"7Q]T35Y([7Q' =(N
M&P/.W;X&/N>J_B"!W-<\\+4AKN:QKPEY'HNO^&=&\46)M-=T^&\CP=I=?F3W
M5ARI^AKP+Q[\"]0T*.74/"[2:G8+EGMR,SQ#\/OCZ8/L>M?1\,T5S DUO(DL
M4BADD1@RL#T((ZBGUG3K3I/0N=.,UJ?"?3K17TA\5/@]!K\4^M^&(5AU8#?-
M;+@)=>I'H_OT/?GFOG&2-X96CE1DD1BK*PP5(Z@CL:]BE5C5C='GU*;@[,;1
M116IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-;[C?2
MG4UON-]*3V&MS-HHHKYT]<^P/@9_R1?0O^WC_P!*)**/@9_R1?0O^WC_ -*)
M** .'\1_\FCV'_7&W_\ 1PKYWKZ(\1_\FCV'_7&W_P#1PKYWH *TQT%9E:8Z
M"O1P.\OD<>*Z"T445Z1QA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %=9\+?^2I:!_U]#^1KDZZSX6_\E2T#_KZ'\C45/@?H5#XD?8%<)\:O^2/
MZW_VP_\ 2B.N[KA/C5_R1_6_^V'_ *41UX=+^)'U1Z=3X&?)U%%%>^>4%%%%
M !1110 4444 %%%% !1110 4444 %?8_PZ_Y)KX>_P"P?%_Z"*^.*^Q_AU_R
M37P]_P!@^+_T$5P8WX$=6&^)G2U\4^*_^1SUK_L(3_\ HQJ^UJ^*?%?_ ".>
MM?\ 80G_ /1C5G@?B9>)V1DT445Z9Q!1110 4444 36=I/J%]!9V<32W%Q(L
M<4:CEF)P!^=?7WP_\&6W@?PK#IT05[I\27<X'^LD(Y_ =!_B37D/[/GA$7VK
MW/B:\CS%8Y@M<CK*1\S?\!4X_P"!>U?0U>7C*MWR+H=V'A9<S"O'_C!\6&\/
M[_#_ (:F U-A_I-RO/V8'^%?]LCOV'OTZ[XG^-U\$>$9+F$@ZC=$PV:'G#8Y
M<CT4<_7 [U\D3SRW-Q)/<2-++*Q=W<Y9F)R23W)-+"T%/WY;!7J\ONH:[M)(
MSR,7=B2S,<DGU)I***]4X0HHHH **** "BBB@#>\)>,M8\%ZL+[1K@J&($UN
M_,<R^C#^O4=JT/B#\0K_ ,?:M'/<(;6R@7%O:!]P0G[S$X&2?7'3 KD:*GDC
MS<UM2N:5N7H%%%%42%%%% !1110 4444 %%%% !1178?"WPI_P )=X]LK2:/
M?9VY^TW61D&-3]T_[QPOXFE*2C%R8XIR=D?0/P?\*?\ "+> +43Q[+V__P!*
MN,CD;A\JGZ+CCU)KNF8*I9B H&22>E+7G?QK\5?\(YX!FMK=]MYJI-K%@\A"
M/WC?]\\>Q85X7O5:GFSU-*</0^?OB)XI/B_QQ?ZFC%K;=Y-J#VB7A>.V>6^K
M&OHKX/\ BO\ X2GP!:F>3?>V'^BW&3R=H^5C]5QSZ@U\G5Z1\#_%7_"/^/([
M&XDVV>K 6[Y/ D_Y9G\R5_X%7J8BBG2LNAPTJC4[OJ?4E?(OQ5\*?\(EX^O+
M:&/9971^TVN!P$8\J/\ =;(^@'K7UU7F'QV\*_VYX(_M2W3-WI#&;@<M">''
MX8#?\!-<&%J<E2SV9U5X<T/0^8J***]D\X**** "BBB@ HHHH **** )['_D
M(VW_ %U7^8K[EKX:L?\ D(VW_75?YBON6O-QV\?F=F&ZF7XGU"?2?".L:C:;
M1/:6,T\6X9&Y(RPR.XR*I>"/&-CXV\-PZG8G9)]RY@)R89 .5]QW![C\14GC
MG_DG?B/_ +!5U_Z*:OEKX>^.;OP+XD2]AW2V<N$O+<'B1/4?[0Z@_AT)K"E1
M]K3;6Z-:E3DFK['V%7SW\;_AK_9UQ)XJT.#%I,V;Z%!_JG)_U@'HQZ^A/OQ[
MUIFI6FL:7;ZAITRSVMP@>.1>A!_KVQVJ:XMX;NVEM[F-9894*21N,JRD8((]
M,5G2J2I3N7."G&Q\+T5W/Q2^'LW@;Q 3;*TFD7C%K67KL]8V/J.WJ.?7'#5[
M<9*<>9'F2BXNS"BBBJ$%%%% !7TW^SY_R363_L(2_P#H*5\R5]-_L^?\DUD_
M["$O_H*5R8S^$=&'^,]1KY&^+W_)6==_ZZI_Z+6OKFOD;XO?\E9UW_KJG_HM
M:Y<%_$?H;XGX4<91117JG %%%% !1110!]-_L^?\DUD_["$O_H*5ZC7EW[/G
M_)-9/^PA+_Z"E>HUX5?^+(]2E\"/E7XY?\E9U'_KE#_Z+6O/:]"^.7_)6=1_
MZY0_^BUKSVO8H_PX^AYU3XV%%%%:D!1110 4444 =KX!^)VL>!KM(T=KS2F;
M][92-P/4H?X6_0]Z^HO#?B33?%>B0ZIHTXE@D&"#PT;=U8=B/_K]#7Q177?#
MGQY=^!?$2W*EI-/G(2\MQ_&O]X?[0ZC\1WKDQ&'4US1W.BE6<79['U]7AWQS
M^&ZRP2>+=$@"R)SJ$2#[P_YZX]1_%[<]C7M=G>6^H64-Y92K-;SH)(I$.0ZD
M9!%22Q1SPO%,BR1R*5=&&0P/!!'I7F4ZDJ<KH[9Q4XV9\*T5U7Q'\(MX+\:W
M6G(#]DD_?VC'O$Q.!]005_"N5KW8R4E='EM-.S"BBBF(**** "BBB@ HHHH
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M -*(Z\.E_$CZH].I\#/DZBBBO?/*"BBB@ HHHH **** "BBB@ HHHH ****
M"OL?X=?\DU\/?]@^+_T$5\<5]C_#K_DFOA[_ +!\7_H(K@QOP(ZL-\3.EKXI
M\5_\CGK7_80G_P#1C5]K5\4^*_\ D<]:_P"PA/\ ^C&K/ _$R\3LC)HHHKTS
MB"BBB@ HHKH? .E#6OB!HE@P#))>(T@/=%.YA^2FE)V5QI7=CZI\ ^'AX7\"
MZ7I939-'"'GXY\UOF?\ (DCZ 5T5%9'BS6/[ \(:KJH(#VMJ\D>>[X^4?]]8
MKY_6<O-GK:11\T?&3Q4WB;X@7,43[K+32;6  \$@_.WXMGGT K@:5F9W+.2S
M,<DDY)-)7OPBH144>5*3D[L****HD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *^F_@/X4_L3P4=6N8]MWJS"09'*PCA!^/+>X(]*\!\%
M>&Y?%OC"PT>/<$FDS,X_@B'+G\@<>^*^S((8[:WC@@01Q1*$1%'"J!@ 5P8R
MI9*".O#PN^8?7RC\9?%7_"3>/[B.!]UGIN;6'!X8@_.WXMD?117T'\2_%(\(
M^!+[4(WVW4B_9[7U\U@0#^ RW_ :^/B2223DGJ:C!4]7-E8F?V0I8Y'BD62-
MBCH0RLIP01WI**](XC[*\!>)E\7>"M/U;(\]X]EPH_AE7AOS/(]B*WY8HYX7
MAF19(Y%*NC#(8$8(-?/'[/?BK[!X@NO#MR^(=07S;?)X$RCD?BH_\=%?15>'
M7I^SJ-'J4I<\+GQEXX\-2>$O&6H:0^XQPR;H&/\ %$W*'ZX.#[@U@5]#_M"^
M%/MNAVOB6V3,UB1!<D=XF/RG\&./^!U\\5ZU"I[2FF>?5AR2L%%%%;&84444
M %%%% !1110!/8_\A&V_ZZK_ #%?<M?#5C_R$;;_ *ZK_,5]RUYN.WC\SLPW
M4PO'/_)._$?_ &"KK_T4U?&%?9_CG_DG?B/_ +!5U_Z*:OC"KP/PL6)W1ZE\
M&OB5_P (MJ8T769\:/>/\CN>+60_Q>RGOZ=?7/TUUZ5\)U]"?!#XE?VC;Q^%
M=<GS=PKBQF<_ZU /]63ZJ.GJ![<K%4+_ +R/S"A5^RSU+Q-X<L/%?A^YTC5$
MW0S+PP^]&PZ.ON/_ *U?(/BKPQ?^$/$5QI.J)B2(YCD ^69#]UU]C^AR.U?:
ME<5\3OA_!X[\.E(@L>JVH+V<QXR>\;?[)_0X/J#SX:O[.5GLS:M3YU=;GR11
M4MW:SV-Y-:WD30SPN4DC<8*L#@@U%7L'G!1110 5]-_L^?\ )-9/^PA+_P"@
MI7S)7TW^SY_R363_ +"$O_H*5R8S^$=&'^,]1KY&^+W_ "5G7?\ KJG_ *+6
MOKFOD;XO?\E9UW_KJG_HM:Y<%_$?H;XGX4<91117JG %%%% !1110!]-_L^?
M\DUD_P"PA+_Z"E>HUY=^SY_R363_ +"$O_H*5ZC7A5_XLCU*7P(^5?CE_P E
M9U'_ *Y0_P#HM:\]KT+XY?\ )6=1_P"N4/\ Z+6O/:]BC_#CZ'G5/C84445J
M0%%%% !1110 4444 ?0/[/?B]KO3[KPO>R;GM!]HM,GGRR?G7\&((_WCZ5[7
M7QM\/]=/ASQ]I&H[RL27"QS<_P#+-_E;]"3]0*^R:\C%T^6I==3T,/+FC;L>
M3?M!>'1J/@R#6HDS/I<P#D#K%(0I_)MGZU\V5]M>(]*77/#.I:6P!^UVLD(S
MV)4@'\#@U\2D%6(8$$'!![5U8.=X./8PQ$;2OW"BBBNTY@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FM]QOI3J:WW&^E)[#6YFT445\Z>N?8'
MP,_Y(OH7_;Q_Z4244? S_DB^A?\ ;Q_Z4244 </XC_Y-'L/^N-O_ .CA7SO7
MT1XC_P"31[#_ *XV_P#Z.%?.] !6F.@K,K3'05Z.!WE\CCQ706BBBO2.,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK/A;_R5+0/^OH?R-<G7
M6?"W_DJ6@?\ 7T/Y&HJ? _0J'Q(^P*X3XU?\D?UO_MA_Z41UW=<)\:O^2/ZW
M_P!L/_2B.O#I?Q(^J/3J? SY.HHHKWSR@HHHH **** "BBB@ HHHH **** "
MBBB@ K['^'7_ "37P]_V#XO_ $$5\<5]C_#K_DFOA[_L'Q?^@BN#&_ CJPWQ
M,Z6OBGQ7_P CGK7_ &$)_P#T8U?:U?%/BO\ Y'/6O^PA/_Z,:L\#\3+Q.R,F
MBBBO3.(**** "O2/@-:"X^*=O*>MM;32C\5V?^SUYO7J_P"SJH/Q$O20"5TN
M0C(Z?O8JQKNU*1I2^-'TK7G/QVO3:?"N[B4D?:KB&$X]-V__ -DKT:O*/VB2
MP^'5GMS@ZI&&QZ>5+_7%>105ZL3T*OP,^:J***]T\L**** "BBB@"?[#=_\
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M?Q $HWXC(S[+7-@ZG+/E?4VQ$+QYNQX=1117K' %%%% !1110 4444 3V/\
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MX=?\DU\/?]@^+_T$5P8WX$=6&^)G2U\4^*_^1SUK_L(3_P#HQJ^UJ^*?%?\
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MWQ>_Y*SKO_75/_1:U]<U\C?%[_DK.N_]=4_]%K7+@OXC]#?$_"CC****]4X
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MCH*S*TQT%>C@=Y?(X\5T%HHHKTCC"BBB@ HHHH **** "BBB@ HHHH ****
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MNN$^-7_)'];_ .V'_I1'7ATOXD?5'IU/@9\G4445[YY04444 %%%% !1110
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M;_KJO\Q7W+7PU8_\A&V_ZZK_ #%?<M>;CMX_,[,-U,+QS_R3OQ'_ -@JZ_\
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M%:D!1110 45OZ)X%\3^(F7^R-$NYD;I*T>R/_OML+^M>L^%/V=U1TN/&-^)
M.?L=F2 ?9I",_@!^-93K4X;LTC3E+9'D_@_P3K/C;5!::/;DQJ1Y]RXQ'"/5
MCZ^@')KZI\$^"=,\#:&MAIJ^9*^&N+IEP\[>I] .P[?7).QI>E6&BZ?'8Z3:
M0VEM&/EBB7:/K[GW/)JW7E5L1*KILCNITE#7J%>-_'+XC)INGR>%M'F!O;I<
M7LB'_4QG^#_>8=?0?45L?%/XL6_A"UDTO19(Y]<D7!_B6U!'WF]6YX7\3QP?
MF.YN9[VZEN;N5YIYF+R22-EG8\DD]S6V%P[;YY;&=:K9<L2.BBBO4.$****
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M?_"K?!/_ $+=E_WR?\:Z7[=:?\_4/_?P4?;K3_GZA_[^"L^>:V;*Y8]CFO\
MA5O@G_H6[+_OD_XT?\*M\$_]"W9?]\G_ !KI?MUI_P _4/\ W\%'VZT_Y^H?
M^_@I\]3NQ<L>QSD?PQ\%1N&7PW8$_P"U'N'Y&M:P\+Z#I;!M-T33[1AT:&U1
M#^8&:N-J%FBEFNX%4#))E''ZUG7?C#PW8 _;-?TR'V>[C!_+.:+SEW':*-FB
MO/M4^-_@C35;RM1EOY%_Y9VD#'/_  )L+^M>>^(/VB]0N%:+PUI45F#P)[IO
M-?ZA1@ _7=5QP]670B5:$>I[SJ6J6.CV$E[JEW#:6T8^:69PH'M]?:O#/'WQ
M[>Y273O!(>&,Y5]1D7#,/^F:G[O^\>?8=:\CUOQ'K'B2[^TZYJ,][)_#YK?*
MG^ZHX7\ *S*[Z6$C'66K.6>(<M(Z#I)'FE:25V>1V+,S')8GJ2>YIM%%=IS!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UON-]*
M=36^XWTI/8:W,VBBBOG3US[ ^!G_ "1?0O\ MX_]*)**/@9_R1?0O^WC_P!*
M)** .'\1_P#)H]A_UQM__1PKYWKZ(\1_\FCV'_7&W_\ 1PKYWH *TQT%9E:8
MZ"O1P.\OD<>*Z"T445Z1QA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1TZ444 ;FG^-?$^E #3]?U&%%&!&+E
MB@_X"3C]*VX?C)X]@7:GB!R/]NVA<_F4-<114.G![I%*<ELSNC\:?'Y!']O_
M )6<'_Q%9UY\3?&E\I$_B2_4'_GC+Y7_ *!BN6HH5."VBA\\GU)KJ\N;Z8RW
MMQ-<2'J\SEV/XFH:**L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *:WW&^E.IK?<;Z4GL-;F;1117SIZY]@? S_DB^A?]O'_
M *4244? S_DB^A?]O'_I1)10!P_B/_DT>P_ZXV__ *.%?.]?1'B/_DT>P_ZX
MV_\ Z.%?.] !6F.@K,K3'05Z.!WE\CCQ706BBBO2.,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IK?<;Z4ZFM]QOI2>PUN9M%%%?.GKGV!\#/^2+Z%_P!O'_I1)11\#/\ DB^A
M?]O'_I1)10!P_B/_ )-'L/\ KC;_ /HX5\[U]$>(_P#DT>P_ZXV__HX5\[T
M%:8Z"LRM,=!7HX'>7R./%=!:***](XPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:O\ PTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\
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M]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P#
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M_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\
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M!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_PTYK'_0O6/\
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M(AXE_P"A>U7_ , I/_B:]8_X:<UC_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\
MA$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_
MPTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\ P"D_
M^)KUC_AIS6/^A>L?^_ST?\-.:Q_T+UC_ -_GH \G_P"$0\2_]"]JO_@%)_\
M$T?\(AXE_P"A>U7_ , I/_B:]8_X:<UC_H7K'_O\]'_#3FL?]"]8_P#?YZ /
M)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[
M_/1_PTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\
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M]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P#
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M_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>lgnd-20231231_g2.jpg
<TEXT>
begin 644 lgnd-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+Z17AI9@  34T *@    @ ! $[  (
M   0   !2H=I  0    !   !6IR=  $    @   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2&5R;6%N+"!-96QA;FEE   %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,U,@  DI(  @    ,U,@  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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MR?4T44YAL4+W/)_PH$-HSCI0#M8$4YU .5^Z>10 W)]33T?^%S\IZ^WO3**
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MV(>/XL=S3,GU-%% !DGJ:*5%W-CH.I/I0QRQ(X':@!*,GU-.3!RI[]#Z&FT
M&3ZFGM\Z;OXAPWO[TRE1MK<].A% "4J+N;'0=SZ4AP"<'(]:=N CP.IZT #R
M%CQPHZ#/2FY/J:** #.>M%.484OZ=/K3: "C)]33OO1^Z_J*;0 JNRG()I7
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M$CH&57W*I8<@TS9_MK2.V]B>GH/2DH&*1CN#]*2@#/2B@0#D^E.V?[:TW%%
M$B1!G +KR:8[;F)Z>@]*2GO\PWCOU]C2ZC&4J-M;/4=QZTE/3Y07/;[ON:8A
M7B".1O7\Z;L_VUIM% P(P?6BBB@0H&>X'UI=G^VM-((.#UHH E1 %9\JVT<
M5$3D\TJ-M8'\QZT.NUN.0>0:.HQ*DB&_*'@$9!/:HZ>?DCQ_$W7V%#!";/\
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MI<D0-A2.QI*#UXHH$*S;FR:2@8/4X_"G83^^?RH ;3G^7"#MU^M/C"C+*V7
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M1M02\L-9O4E5LD-,S*_LRDX(^M>R>+UM?BE\%D\5);K#JNFJS2;1TVG]XO\
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M3*I)U9N21S[GHO9>*^@/V=G,?A+777JMR",^T=?/M?0'[/7_ ")OB#_KN/\
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MIZ@S _\ ?IZZOQO\./$'CCXMZT^DPQQ6L9B5[JX8K&#Y2<# ))^@KEO@P/\
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MM$@LCYRVZOE 1R&D8X&!Z#KZ]JXKXO>/8_&OB"---8G2[#*0DC'F,?O/CT.
M![#WISFJTXQAK9W;"G%TU*<NUOO/0?B&/M?[.FB36:DP1QVC2 'HNS;^C$5X
M"DD8<$Q_CFO:_A!XTTK5/#,W@3Q6Z"*4,EJTK861&ZQY[,"<C_ZU9>O?L]^(
M+;47_L"YM;VR8YC,LGER*/1AC!^H//H*4)*E4E&>EW= TZE.+CT5CR4HQFV
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MA%[=3ZFFTACBR?\ //\ \>IM%.9-@&>IYQZ4Q#:<K*!\R9/KFD4;F SC-)0
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M_'C2%E(X3!]<TVCKTH$%%*Z[&P3D]_:A5WYQU SCUH 4,@'*9/UI=Z?\\_\
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M;_TS3\J!AG9#@?>?K]*94DIWXD P#Q@=C4="!CXF"MAONMP::Z%'*GM0JEF
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MQ9LFDH&+O8_Q'\Z2@ D@#J:5\ X7G'?UH$)2AF'0D?C0I /S=#UH9=K$'_\
M70 ;V_O'\Z=GS(^3EE_E3*56*L"*!B44K8S\O3^5"D#YCVZ"@0\L8U"*<$\M
MC^5,WO\ WF_.D)R<GK1188I8GJ2?QI*55W,!^9]*0XSQTH$%+O8?Q'\Z5,'Y
M3QGH?2FT +O;^\?SIS_.H?OT;_&F4JMMSW!&"*!B4JJ68 =32' )P<CUIP.U
M3CJ>/H*!"O(?NH2%7@4W>W]X_G2446 "2>IS]:*51P6[+_.DH .G2EWM_>/Y
MTHPR>A7]:;0 Y9'5@0QX]Z'4 Y7[K<BFTX'Y2K=.H/H:!C:<B@G+?=7DTVG,
M0%VKTZD^IH$#2NS9+'\#2;V_O'\Z2B@ ))Z\T4[&U,G^+I3:  $CH<?2EWM_
M>/YTK<X8<9ZCWIM #TD/*NQ*MP::RE6(/44E.)W+S]X<?44#&T]#Y:;_ .(\
M+_C3!@GDX%*S;CZ < 4"#>W]YOSHWM_>/YTE% !12MQ\N.G7ZT@.#R,T *&(
MZ$C\:-[?WC^=###<<CM24 2 F1"K'+#E<_RJ.@$@@CJ.E*Q!.1QGJ/2@8E2$
MF)-JG#'EO\*8I .3SCH/6D)).3UH 7>W]X_G06)ZDG\:2E4;FQ0(2B@G)Z8I
MR<Y7')Z?6@!-[?WC^=&]O[Q_.DHH >Y\Q _5APW]#3*56VGU!&"*0X!.#D>M
M P4%F '4T]Y",*A(5>F._O2 A5X^\>/I3: %WM_>/YTA8GJ2?K13EP,L><=!
M[T"&T=.E%.^\G Y7^5 ";V_O'\Z5975@0QR/>FT4 .D !W+]UN1[4VG*WRE6
MZ=0?0TV@!T8!.6^ZO)]_:AI'9B2Q_.AB-H5>G4GU--H&+O;^\?SI,YZT4[@)
MTY;]*!#: 2.AQ13F'1AC#>G:@!-[?WC^=.1R3M<DJW!SV]Z910 ,"K$'J**<
M3N49ZCCZTT8)Y.!0 ]#Y:[^YX7_&F[V_O-^=#-N/H!P!24#%WM_>/YTE'6E;
M ^5><=_6@0E*&(Z$C\:0'!YZ4K+M8@T &]O[Q_.G@F1"A))'*_X5'0"001P1
M0 44K$$Y'&>H]*%P#ENW0>M #R3&@4'#-RW^%,WM_>/YTA)))/4T4 *6)ZDG
MZFDI47<W/ ')-(QR>!@4 %+O8=&/YTJ#<=O<]/K3: %WM_>/YT]SYB;SRPX;
M_&HZ56VGU!X(]:!B4#GI0<!C@Y%.4A?F_B[>WO0(5V*816.%ZX/>F[V_O'\Z
M2B@ ))ZDGZT4Y%!RS=!^OM32<G- !2[V_O'\Z4 ,GHR_K3: %\QQ_$WYTZ3Y
ML./XNOL:93E;&5/W6Z^WO0,;2HNYL=!W/I24[("87J>I_I0(&D8M]XX[#/2D
MWM_>/YTE% !UZT4X#:FX]3T']:;0  D=#BEWM_>/YTK#*[QQS@CTIM #UE96
MR22.XSU%-==K<<CJ#ZBDIV[*8/;I_A0,;3T)7+CMP/K3*<S<!5^Z/UH$)O?^
M\WYT;V_O'\Z2B@ HIS#8-O?O[>U-!P<D9]J  $CH2/I2[V_O'\Z'7:1CH1D4
ME $B.6S&[<-TSV-1D8.#12LV[!/7O[T#$I^6CC !P6Y./2FKC/S=/YT,Q9LF
M@0;V_O'\Z"S'J2?QI*55W, * $HI6()^4<"E3!^5N,]_2@! S#H2/QHWM_>/
MYTA!!(/6B@!Y/F1\\LOZBF4JMM8$4AQGCI0,.M/>0C"*2%7T/6D0A?F_B[?X
MTV@!=[?WC^=(23U.?K13E7.2>@_6@0VB@G))Z4Y1O7 ^\!GZT )O;^\?SHWO
M_>;\Z2B@!\GS8D'?K]:92JV,@]#UI* %0 L,].II6E=FSN(]@>E&0$P.K=:;
M0,7>W]X_G2$D]>:*<!M3<>IZ#^M AM ..G%%.897>/H1Z4 )O;^\?SIRRLK9
MR2.XSU%,HH <Z[6XY!Y!]J;2[LI@]NE)0 ]#L4O_ !=%IN]O[S?G0Q!P%Z#I
M[TE Q=[?WC^=)13G&P;>_<_TH$-H!(Z$CZ4*<-DC/M2NNT\<@\@T )3A&QZ"
MOJ__ (4K\/\ _H ?^3EQ_P#%T?\ "E?A_P#] #_R<N/_ (NN+Z[3[/\ KYG3
M]6F?*2P2,P '7WIKL"WR_=' KZO'P6\  Y&@<_\ 7[<?_'*/^%*^ .^@Y/K]
MLG_^+I?7:?9_U\Q_5YGR=2HVULGD="/45]8?\*5^'_\ T /_ "<N/_BZ#\%?
M &.-!Q[_ &R?C_Q^G]=I]F+ZM/N?*)A<'&/UI#&XZBOJ\_!;P 3DZ!S_ -?E
MQ_\ %T?\*5^'_P#T /\ R<N/_BZ7UVGV?]?,?U:1\G45]8_\*5^'_P#T /\
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MIGRC'\WR'^+I]>U'DR#^']:^KA\%O ((*Z$01Z7D_P#\71_PI7X?_P#0 _\
M)RX_^+I?7:?9_P!?,?U>9\H&-AU%-KZQ_P"%*_#_ /Z '_DY<?\ Q='_  I7
MX?\ _0 _\G+C_P"+I_7:?9_U\Q?5IGR=0 3TKZQ_X4K\/_\ H ?^3EQ_\71_
MPI7X?_\ 0 _\G+C_ .+H^NT^S#ZM,^4!$Y_AIZQM&ID8=.!]:^K/^%*_#_\
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M"NA$'VO)_P#XNG]=I]F+ZO,^43#(#]W]:0QL.HKZO_X4K\/_ /H ?^3EQ_\
M%T?\*5^'_P#T /\ R<N/_BZ/KM/L_P"OF'U:1\G45]8_\*5^'_\ T /_ "<N
M/_BZ/^%*_#__ * '_DY<?_%T?7:?9A]6F?)P!/2G")S_  U]7_\ "E?A_P#]
M #_R<N/_ (NC_A2OP_\ ^@!_Y.7'_P 71]=I]G_7S#ZM,^4UC,:EW' X'UJ*
MOK'_ (4MX!P0-"(!ZXO)^?\ Q^C_ (4K\/\ _H ?^3EQ_P#%T?7:?9_U\P^K
M3/DZI%4RI@?>7]17U;_PI7X?_P#0 _\ )RX_^+H'P6\ C(&A'!ZC[9/_ /%T
M?7:?9A]7F?*/DO\ W?UII4CJ*^L/^%*_#_\ Z '_ ).7'_Q='_"E?A__ - #
M_P G+C_XNCZ[3[/^OF'U:1\G45]8_P#"E?A__P! #_R<N/\ XNC_ (4K\/\
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M^+H_X4K\/_\ H ?^3EQ_\73^NT^S_KYB^K3/DZE"D]!7UA_PI7X?_P#0 _\
M)RX_^+H_X4K\/_\ H ?^3EQ_\71]=I]G_7S#ZM,^4/*?^[3B#%'@\,W\J^K?
M^%*_#_\ Z '_ ).7'_Q='_"E? /'_$B.!V^V3_\ Q=+Z[3[/^OF/ZO,^3J*^
ML?\ A2OP_P#^@!_Y.7'_ ,71_P *5^'_ /T /_)RX_\ BZ?UVGV8OJTSY3V&
M9-R\LO#?XTTQ./X:^KO^%+> <$?V$2N<X^V3\?\ C]'_  I7X?\ _0 _\G+C
M_P"+I?7:?9_U\Q_5Y'R>5(ZBDKZQ_P"%*_#_ /Z '_DY<?\ Q='_  I7X?\
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MX_\ BZ7UV'9_U\Q_5Y'R<01UHKZQ_P"%*_#_ /Z '_DY<?\ Q='_  I7X?\
M_0 _\G+C_P"+I_7:?9B^K3/D[K3A&QZ"OJ__ (4K\/\ _H ?^3EQ_P#%T?\
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M_P @.^_Z]Y/_ $$US?PX_P"0+=?]?'_LHKHA%.E)^AA.352"7F=7=/)'9S/
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MTA$26<'YF;'KVXY)JGAFI<B>I,<0G'G:T.WHK@+SP_XAT:T;4+?5Y)WB&^1
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M45R/A;Q-<WFFWL5Z/-NK*,N#WD !X/OD?K6)I$-_XIDGGFU]K:X5ODA#'GW
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M+_6.X*>Y ! _2NNL_#&CV$CO:6GEM)&8V/FN<J>HY-3V6DVNCVLR:3;B,O\
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MK+4=/@2TG622.%=Z=UXQS6A<VT-Y;M!=1++$XPR,,@U3TS0=.T>21]/@\II
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MGIG!Y]:F_L33_P"U_P"T_L_^F?\ /7>WICIG'3VK1XB+?79HA8>5GMNF<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **^4?C1_P E>UK_ +8?^B(ZX6NZ.$YH
MIW.:5>S:L?=%%?"]%/ZG_>_ 7UCR/NBBOA>BCZG_ 'OP#ZQY'W117PO11]3_
M +WX!]8\C[HHKX7HH^I_WOP#ZQY'W117PO11]3_O?@'UCR/NBBOA>BCZG_>_
M /K'D?=%%?"]%'U/^]^ ?6/(^Z**^%Z*/J?][\ ^L>1]T45\+T4?4_[WX!]8
M\C[HHKX7HH^I_P![\ ^L>1]T45\+T4?4_P"]^ ?6/(^Z**^%Z*/J?][\ ^L>
M1]T45\+T4?4_[WX!]8\C[HHKX7HH^I_WOP#ZQY'W117PO11]3_O?@'UCR/NB
MBOA>BCZG_>_ /K'D?=%%?"]%'U/^]^ ?6/(^Z**^%Z*/J?\ >_ /K'D?=%%?
M"]%'U/\ O?@'UCR/NBBOA>BCZG_>_ /K'D?=%%<+\%_^20Z+_P!M_P#T?)7=
M5Q2CRR:.F+NDPHK@_B]_R*-K_P!?R?\ HN2O&JZ:6&]I'FN85*W)*UCZAHKY
M>HK;ZE_>_ CZSY'U#17R]11]2_O?@'UGR/J&BOEZBCZE_>_ /K/D?4-%?+U%
M'U+^]^ ?6?(^H:*^7J*/J7][\ ^L^1]0T5\O44?4O[WX!]9\CZAHKY>HH^I?
MWOP#ZSY'U#17R]11]2_O?@'UGR/J&BOEZBCZE_>_ /K/D?4-%?+U%'U+^]^
M?6?(^H:*^7J*/J7][\ ^L^1]0T5\O44?4O[WX!]9\CZAHKY>HH^I?WOP#ZSY
M'U#17R]11]2_O?@'UGR/J&BOEZBCZE_>_ /K/D?4-%?+U%'U+^]^ ?6?(^H:
M*^7J*/J7][\ ^L^1]0T5\O44?4O[WX!]9\CZAHKY>HH^I?WOP#ZSY'U#17R]
M11]2_O?@'UGR/J&BO&OA#_R-UU_UXO\ ^C(Z]EKCJT_9RY;F].?/&X445X16
ME"A[:^MK&5>O[*VE[GN]%>$45T_4?[WX?\$Y_KW]W\?^ >[T5X111]1_O?A_
MP0^O?W?Q_P" >[T5X111]1_O?A_P0^O?W?Q_X![O17A%%'U'^]^'_!#Z]_=_
M'_@'N]%>$44?4?[WX?\ !#Z]_=_'_@'N]%>$44?4?[WX?\$/KW]W\?\ @'N]
M%>$44?4?[WX?\$/KW]W\?^ >[T5X111]1_O?A_P0^O?W?Q_X![O17A%%'U'^
M]^'_  0^O?W?Q_X![O17A%%'U'^]^'_!#Z]_=_'_ (![O17A%%'U'^]^'_!#
MZ]_=_'_@'N]%>$44?4?[WX?\$/KW]W\?^ >[T5X111]1_O?A_P $/KW]W\?^
M >[T5X111]1_O?A_P0^O?W?Q_P" >[T5X111]1_O?A_P0^O?W?Q_X![O17A%
M%'U'^]^'_!#Z]_=_'_@'N]%>$44?4?[WX?\ !#Z]_=_'_@'N]%>$44?4?[WX
M?\$/KW]W\?\ @'N]%>$44?4?[WX?\$/KW]W\?^ >[T5X111]1_O?A_P0^O?W
M?Q_X![O17A%>[US5Z'L;:WN=%"O[6^EK!117F'B__D:KS_@'_H"UA%79T-V/
M3Z*\6HJ_9D\Q[317BU%'LPYCVFBO%J*/9AS'M-%>+44>S#F/::*\6HH]F',>
MTT5XM11[,.8]IHKQ:BCV8<Q[317BU%'LPYCVFBO%J*/9AS'M-%>+44>S#F/:
M:*\6HH]F',>TT5XM11[,.8]IHKQ:BCV8<Q[317BU%'LPYCVFBO%J*/9AS'M-
M%>+44>S#F/::*\6HH]F',>TT5XM11[,.8]IHKQ:BCV8<Q[317BU%'LPYCVFB
MO%J]/\(?\BK9_P# _P#T-JF4;(:=S:HHHJ"@HHHH **** /E'XT?\E>UK_MA
M_P"B(ZX6NZ^-'_)7M:_[8?\ HB.N%KVZ7\./H>;/XF%%%%:$!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!]7?!?_ ))#HO\ VW_]'R5W5<+\%_\
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MY<=]GY_H%%%%>F><3V5H]_?0VL)57F<(I8\ GUKIO^%<ZO\ \_%E_P!]O_\
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MU]:XME*L588(."#VJH5%.Z6Z)G3<$GNA****U,PHHHH **** "BBB@ HHHH
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M::22X ($><+QGM61KVFV-C)#)IEXL\,R[@A8%D^M/F5["MI<R****8@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT_PA_P BK9_\#_\
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MK>W$2VA$\K6[E)))'8_Q#D#@Y(YKO_ &J>")_' T[P?X4N4GM_,,FI3DDQ@
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M=ZR?V<V#:KK^.,PQ$+_P)JYCQ7\:?$7B?3)--2.WTZTF7;*MN"7D'<%B>GL
M*Y7PKXKU3P=K(U+19567:4=)%W)(I_A8?@/>B-%N,TU:_G<<JB]VSO8Z/X<V
MMQ9_&C3(KJ&2&1;N0%9%*D':WK71^./!U_XV^/%]IU@"D82%KBX(RL*>6N2?
M?T'<USFL?%W6M8\4Z1KTEE81W.E!_)15<HY88.X;L_D14UC\:?$5AXAU/68;
M+2VN-3$0F5XI-B^6I5=HWY'!YR35<M2ZE;5)K\1N<&Y*^]CN?B'K3>#?#,7@
MCP)8W(_=XNKJ&)F*@]1N Y=NY[#CZ8'PZ\":0/!.I^*_%KWIM(1)&]E;NT99
M$QNWX()YXQD#CGVA_P"&B/%G_0/T;_OQ+_\ '*Q_#OQAU_P_?:C((+2ZMM0N
M'N9;656V([G+;#G(!]#FHC3JJ$EU?4;G3;79=#V+X4ZIX<U6+49/"7AF32+2
M((C7,O)G;GY<Y.<=>IZUYU\!2!\3M3][*7'_ ']2JO\ PO[Q/%=,UI8:5#;;
M=J6WDOM7GKD,#G]/:N"T/Q)J7ASQ!'K&DS"&Z1B>F58'JI'<&JA2E>3?56WN
M*52/*DN]SI1:W%K\=HA<P21%O$ 8;U(R#/D'\17K.J7%M;_M,:5]J*@R:44A
M+?WSYF/TR/QKRGQ'\7-:\2WFCW5W96$4NDW N8O+5]KN"#\P+=..@_.L3Q7X
MVU3Q?XAAUF^6"UNX8UCC-F&0+M)((RQ.<GKFFJ<VHJ72Z_"PI3C>376S_&YT
M'Q@T?65^)U_+<VMQ*EVZFT=4+!UV@!5]Q@C%=WXYCFTG]G/3-/\ $!VZBWDI
M''(?F4AMV/J$X-<QI?[0/B:RL%@O;2QOY$7"SR*R,?=MIP?P KA_%GC/6?&F
MHK=ZW<!O+&(H8QMCB'?:/ZG)J53J.,:;V36OH/GAS.?5IZ>IZK\:'8?"WPD@
M)VL(R1ZD0C'\Z/";L_[,>N!B2%,X4'L/E/\ ,FO-O$_Q"U7Q9H6G:3J-O9Q0
M:< (F@1PS87;\Q+$=/0"C3OB%JNF>!;OPI;V]FUC=ER\CHYE&[&<$-CMZ4W2
MDZ<H]W<F,TI0?9'*T445UF!]7?!?_DD.B_\ ;?\ ]'R5W5<+\%_^20Z+_P!M
M_P#T?)7=5XE7^)+U/2A\*.#^+W_(HVO_ %_)_P"BY*\:KV7XO?\ (HVO_7\G
M_HN2O&J]/"?PCBK_ !A111748'J&F?\ )"[SZO\ ^C!63X?^)%QH_A6?3ID:
M:YB7;9R'D*#V;Z=1^58<'B^_M_"<GA](;8VDF<N5;S.3GKNQ^E8-<RHIN2GL
MW<V]I91Y=T>I_"Z:2XTGQ!-.[222$,[L<EB5;)JI\)]-M7&HZK)")[FU 6%"
M,E<@G(]SC&?K7*^'_%]_X;M+NWL8;:1+O&\S*Q(P".,,/6JV@>(]0\-WQN=-
MD4%QMDC<91Q[BE*E)N?+I>UOD.,TE&^MF[_,](T/6(_B-87NC>(+-HIHF,B2
MPH0(^>.3T89QSU%<]\2Y[>QNK70M/L4M;>VC5S((@#*<8'S=2!_//I4>H?%;
M6[NT:&UAMK)G&&EB!+?AD\5D:YXSO_$.FPVFJ6UG(\.-ER$82^_.['/?BHA2
MFIIVLNU_Q+E4BXM7N^_Z'H7@FSM-#^'C7.IW0LAJ!+-.2 4!&U<9[XY'UJ?P
M;:^%]&OI;;1-=-Y+>  PR2*<E<G(P!VS7FNN>,M0U[2;;3;B&U@MK8@HMNC+
MG P,Y8]!61IU_-I>I6]]:D":WD#KNZ$CL?:FZ$I\SD[7_I$^U45%);?F7_%>
ME?V+XHOK(#$:R%H_]QN1^AQ6/6OXC\277B>_CO+Z"WBE2/R\P*PW#.1G)/K6
M1733YE!*6YE4:<FXA1115D!1110 4444 %%%% !1110 4444 %%%% !1110
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M'2O]QOY+0_/PO3_?_P#:E<U?:M>ZE'$E[-YJPC"#8HQ^0]J#JUZ=+&G&;_1
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MG_ /_0%KT^O,/%__ "-5Y_P#_P! 6N"&YWRV,6BBBMC,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O3_"'_ "*MG_P/_P!#:O,*]/\ "'_(JV?_
M  /_ -#:HGL5'<VJ***Q- HHHH **** /E'XT?\ )7M:_P"V'_HB.N%K[)U/
MPQH&HZC+=:AH>FW5Q)C?-/:1N[8  R2,G@ ?A53_ (0KPM_T+6C_ /@!%_\
M$UWPQ48Q2L<LJ#;;N?(-%?7W_"%>%O\ H6M'_P# "+_XFC_A"O"W_0M:/_X
M1?\ Q-5]<CV)^KON?(-%?7W_  A7A;_H6M'_ / "+_XFC_A"O"W_ $+6C_\
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MT?7(]@^KON?(-%?7W_"%>%O^A:T?_P  (O\ XFC_ (0KPM_T+6C_ /@!%_\
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M&T__ ,!4_P */^$<T/\ Z VG_P#@*G^%'UV/8/JS[GS_ $5] ?\ ".:'_P!
M;3__  %3_"C_ (1S0_\ H#:?_P" J?X4?78]@^K/N?/]%?0'_".:'_T!M/\
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MK_A1_9.G?\^%K_WY7_"CVB#E/,**]/\ [)T[_GPM?^_*_P"%']DZ=_SX6O\
MWY7_  H]H@Y3S"BO3_[)T[_GPM?^_*_X4?V3IW_/A:_]^5_PH]H@Y3S"BO3_
M .R=._Y\+7_ORO\ A1_9.G?\^%K_ -^5_P */:(.4\PHKT_^R=._Y\+7_ORO
M^%']DZ=_SX6O_?E?\*/:(.4\PHKT_P#LG3O^?"U_[\K_ (4?V3IW_/A:_P#?
ME?\ "CVB#E/,**]/_LG3O^?"U_[\K_A1_9.G?\^%K_WY7_"CVB#E/,**]/\
M[)T[_GPM?^_*_P"%']DZ=_SX6O\ WY7_  H]H@Y3S"O3_"'_ "*MG_P/_P!#
M:C^R=._Y\+7_ +\K_A6I9Q1P6J1P1K&BYPJ* !SZ"IE*Z&E8FHHHJ"@HHHH
M**** *D_^N:HZDG_ -<U1T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!;@_P!2M25'!_J5J2@"*Y_U8^M5:M7/^K'UJK0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% $UM_K#]*LU6MO]8?I5F@ JA5^J
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7ZH5?H *J3
M_P"N:K=5)_\ 7-0!'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %6X/]2M5*MP?ZE: )**** "BBB@ HHHH J3_ZYJCJ2?\ US5'0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %N#_ %*U)4<'^I6I* (K
MG_5CZU5JU<_ZL?6JM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 36W^L/TJS5:V_UA^E6: "J%7ZH4 %%%% !14-W=P6%G+=7DJPP0J7DD
M<X"J.I-8'_"Q?!__ $,5A_W]II-[";2W.EHJ"ROK;4K**[L)DGMYANCE0Y##
MU%3TMA[A1110 4456M-1M+Z:ZAM)A)):2^5.H!&Q\ X_(B@"S159=1M&U5]-
M68&\2(3-%@Y"$D YZ=0:LT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)]3\0WMCINF75R^IRQ2S7=X\<JJAPB8$;84+@CGO3Y%^%_OM_F)R:OZV_/\
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MZR\+-X?(DN+%UD5Q,P+,'8L>0!W8U GA"'_A%KO0;K4]1N[6Y0QAYY$:2),
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M%%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $=%%% !7EUU_P D_P#B%_V$;K_T%*]1KEI?!?F^'_$.F?;\?VU<2S^;Y/\
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M110 5;@_U*U4JW!_J5H DHHHH **** "BBB@"I/_ *YJCJ2?_7-4= !1110
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MQ%9I#?"1'A?S(+B!RDL#_P!Y&'0UGZ?X+@M]3AO]4U34-9N+;FV^W2*5A/\
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M=0!@8' HI2=W<<59!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:W4@"7 ,8#Q;A_%QD$9Z5D>,;SQ7JEOI!UC2[;1;5=5M@+878N);E]XQ@J
MH&3CK7HNN:!I_B*P%IJD)=%<21NC%'B<=&5AR#65I/@+3M,U./4+F^U/5[J#
M/D2:G=F?R,_W!P!]>M:1J+FYI=[_ *D.'N\L>UOT,C5/#UQH_BJ_U>W\.6_B
M&RU,J\L)6/SK>15QE=_#*>.,YS6OX4L[X75W>WF@Z?H<$@"6]M"B&? ZF1TX
MYX^4=*Z>BLN=VL7RZW"BBBH*"BBB@ HHHH **** "K]4*OT %5)_]<U6ZJ3_
M .N:@".BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-V> .>_M2WNL6>GZE86-R["?4'9( %)!*KN.3VXI\KO85TU<O4444AA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6X/]2M2
M5'!_J5J2@"*Y_P!6/K56K5S_ *L?6JM !1110!R_CRTNY])L+FQM9+MM/U&"
M[D@A&9'1&^;:.YP>E4O%>F_\)9HVE:O::6UY]AN#.=.OH/+:>/!5UVOT;'(S
MZ"NUHJU)I:=[B:N_E;^OO/-O(\.7TD-MH?P[66[=U$@O=*%M% N?F+.RXSCH
M%SFM?6[:]\/^,HO$MC837]C+9BSO+>U7=+$%;<CJO\0Y(('-=E13]IJ3RHYS
M2_$UWK>L1QZ?HMY#IJHQGN[^)K<[OX5C0C+>YX'O3/"EI<6VM>)WN()8DGU/
M?$SH5$B^4@RI/49!&1Z5TU%+F2V72WXW'9]3S^]TV^>'XA!+.X8WD:BVQ$Q\
M_P#T?'R<?-SQQWKHKBWG;X=R6PAD,YTLQB(*=V[RL;<=<YXQ6]12<KQMZ?@K
M%+22EZ_B<!/HNJ1>&_".KZ?9O-J&B0)YMB_R/(C1!9%&>C#T/I3];\07?BS1
M9]#T'1=4AN;Y##-/?VC016J-PQ8MU.,X"YKO**MU.9W:(4>5))G(2Z1+9>-/
M"L=M!-):6-C<0-,$)5/E0+N/0$XJG87%WX$U+4[2^TR^O-*O+M[NUN[* S&,
MORT;JOS#!Z'H<UW=%+G?7^M;CY4EI_6ECC=(M[WQ%XT'B2[L9]/L+2U:ULX;
MI-DTI<@M(R]5&   >:J:/-JW@.WET:;0;_5M/29WL;K3E1SL=BVR168%2"3S
MTKO:YB]\,ZQ'J=S>>'?$<EB+MM\UO=6XN8PV,93+ KP.F<>U-26W3^O^")QZ
M]?Z1D>%)]3NOB=K=SK%LMI)+I]NT=L'#M#'O< ,1QNX)./6LK7],O%\<3>%K
M5,Z9XCFCOIRIQY2Q_P"O'_ ]J<^]=GI7AB32;2_ECU*2YUF_&9M1N(P?F PN
M$& %7LH_.C0O#,^GZI<:OK.I'5-4GC$/G>2(DBB!SL1 3C)Y)SS5*:4KKHOZ
M_$33:?G^']*YOJH10J@!0, #M2T45@:!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!-;?ZP_2K-5K;_6'Z59H *H5?JA0 4444 %%
M%% !6'K^O7VFW5O9:/HL^J7MP"P&[RH8U'4M(00.O09-;E>>>+=6'_";+IFO
M:[=:!HHLQ+#+;2>3]JEW?,IEQQ@?PC!.:J"O*PF[*YO:/XO-T-3@US3WTJ^T
MN,37,!D$JF,@D.KC&00#VXJA8^.-5N(K/4;CPO/'HUZRB&ZAN!-*JL<*SQ*,
M@'/8G%<YX+FT]?%GBF;1K>^U"S&GPF-;EV>2['SY*F3DAN0.QJI%JNEZ2EG-
MX!UV^%Y+<)'_ ,(W.QD49;#IL8;H\#)SG'%;JFG*UNW]?UL9.34=^YV^H>+M
M2;7KW2_#>A?VK)IRH;MWNU@"EAE57(.XX^@JQ-XSM+?PM#K%Q9WD4D[B"*Q>
M+;,\Q.T1@'J<@\],<US'B.;PV?%5X^I:EJ'A/5XU79>13>6M[&!PW0JX&<8/
M-4-5BU?Q-\/M#U?4_MLGV"_,LTMFIAGEM\LHF51R&VX; [9J5!.*;\OZ[?Y?
M>4Y--V\SJH_&.JV-Y:KXJ\.MI5I>2+%%=1W:SK&[?=60 #;GIGD9K%N?%/B^
M+XJM80>'VFM19MLM?[0C57C\W'VG)'![;.M9$EIX.U:6SLK'Q'XC\02W,R$6
M<5^TFT @[W# !0O7G!KI=;U"U\/_ !8LM3U>46MC<:2]K'.X.SS1*&VD]CBK
M48J2T[]^W]?\.2VW%Z]OS_K_ (8TM4\5Z@OB"XT?PYHHU6YLXDENC)=+ L8;
M.U02#DD#Z5L:%J_]M:4EVUG<64FYDDM[E-K1NIP1[C/<<&N*\4S>&W\63?VM
M?W_AC4XXE\C4H9C$MW'UQGE6P>-IYKH/ .J:AJ_A<7.J2-.1/(EO=-%Y9N80
M<)(5[9%9<JY+V_K^OF7?WK'34445D6%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %7ZH5?H *J3_ZYJMU4G_US4 1T
M444 %%%9-MI5Q#K#W;W&Z-B3C)RV>Q_SVJHI.]V3)M;(UJYOX@>(KCPKX*O=
M5LHUDN(]J1[AE5+,%W'Z9KI*P?&NJ:5I/A6YG\06DMWI[XBFBCCW\,<9/(P/
M>DMT4<5;Z7\1(-'MM?TKQ7'K<TJ)*VG/ BQR*<957SCO_LUW^H>(+'0M%CU#
MQ%/'IRE1O5VW8<C)48^\>O2O)]<T'3O"'AU_$_P_\736L2E72S-R)(ILD#:!
MW/L0>G:K'B"^35/'W@>^\6Q)#I=S8B4QS?ZI9V4DAL\==G7VKJ<%4>FU^UGM
M>Q@GRJ[[=]_,]$\/>.O#GBF9X=$U..>9!DQ,K1OCU 8 D?2J^L?$CPGH.I&P
MU/5XX[E3AT2-Y-A]&*@@'VJ&<>"4\<:>3]C&NB)C;"#.[;CG.WC.,XW=LXKA
MK/4KS7M-U_4O#6E>'='T4RRK=SWRL\TI"Y)P.!D'IZGO62C%ZV=K?KW_ . :
M7>W4Z?XC>))[?1?#][X>U$K#>ZE$AEMWR)8R#D9]*Z'Q#XX\.^%IDAUS4DMY
MI!E8E1I'QZD*"0/<UXM;.S?"'PJ&)(7Q" OL,L?ZUVUUJ5YK'Q&UBW\(:-HD
M-[8HL=[J6IABSC_95?3&,^PSVK65)+W>S?Z&4:C?O>2_-FWXP\607?PKU+6_
M"NIABBIY=Q"<,AWJ""#R#@]".]1:3\5/"L&FZ9::IKL9OVMHO.8H[*'*C.YP
M-H.>O/%>9:;(Y^'WQ$0RPRJ+J$[K88B8F4Y*#L#CCVQ7=Z(G@H_!N,SC3_L_
MV+_22P7S/.V_-[[]W3OTQ1*$80=U?5?BKE1E*37S7W-&E\3=<O-.TO0;C1KY
MH5NM3BC:2%AB2-@3C/<&N@\0^-/#_A7RQKNI1VTD@RD05G<CUVJ"<>]>-DW9
M^$'@[[9O_P"0VOD[^OEY;'X=<5JHNMGXU>(/LMUI-O?;5^SG549LPX&/+Q[8
MS^/O0Z27N]F_PL2JC:YO)?FSUG0_$.E>)+#[9HE['=P@[6*Y!4^A4X(/U%:5
M>:?#[1;FS\=:YJ$NLZ-<M,@2[L],+ 1R9&&*GI_%^)->EUA4BHO0UBV[W"BB
MBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *MP
M?ZE:J5;@_P!2M $E%%% !1110 4444 5)_\ 7-4=23_ZYJCH **** ,VTUI+
MO4&MA"RXSM8GKCU':M*F+#$DC2)&BNWWF"@$_4T^JDXMZ(F*DMV<5\6_^2=7
M?_7>#_T:M=?<?\>,O_7,_P JR_%^@?\ "3^%;S2EE$,DRAHI".%=2&4GVR!7
M/S:YXWN=,;3$\)^3J+H8C>M>1FV7(QY@_B([[<9IVYJ?*M[O\4O\@^&:D]O^
M#_P3G]+U76]/^'/@>V\.W$4$]_<FW<S1AUVG>>0>>,9X(Z5T4%UXC\,>*]*L
M=:UE=;L=69X@[6J0R02JNX8V\%2 >O2B3PC=:=9^#+"P0W,6D78>YER%P/+8
M%L$_WCT&>M:GB72[R_\ $?AFYM(?,ALKQY+AMP&Q3&P!Y//)[5M*47-M=6S*
M,9*"3Z)?><Q!XKUJWTBUUJYO-]E!KD]G?)Y* >09"B-D+D;3CD=<\YKH]:UF
M];QMH^B:5<>2FQ[W4'"*W[A>%7D'&YCU&#Q530?"T\O@G6-%UJ#R?MUW=L 6
M#?*[DJW!/L:9\/?#^L6<-]J/BQ%_M2Y$=M@,&Q#$NU>A/WCEC]:GW;7[?C=?
MH]2]?O\ \_U1A0>,Y?$?GWZ>.M-\.0"1DM;)EA>0JIP'EWG/.,[1C@U-=>/=
M4OOAO/J&E3VJZM:ZC'8O+" \,K>8HW+G/RL&'TR:6QT"Z\)QRZ6?!5MX@M5D
M=K.\B$(<JQ)"2;^01G&[D8J]J?A[6;OP'':G3+""^DU"&X:UT]5C2-!*IP22
M S!1R>^.*OW+KM==N_W[;DRYK/OK^3_X'F-\07_B+PMHMHNH^(8W?4+Y8I]3
M-DJQV$97LHX/(P"WKS6IH<VMQ07DDNMV>O:9]G,EM?QA%D5\?=(3Y6'?/'XU
MH>)VUF.W@ET:QM]2A5R+RPE(5IXR/X6;Y00><'K7->'M O!XAU/4[/0?^$=T
M^>P,'V'>F;B8G(DV(2JX''OFLKW@_G_7_#?YFEK27R_/^MSGO$1U[7_AQX8U
M9]=\GSIK82Q"T0[YFDPLN1C&W^[C!Q787-WK6BZQX3TR]U8:A)=W$Z7=Q]E2
M+S@(V9?E&=N..AYQ5!O"^KM\(M)TR.V4:KIY@G^S/( ':-]Q3<,CD=^E:%Y;
M:MKFN>%-4DTF6R%I<3O=122HS0@QE5)P><GTSUK5M7:TM=]NVG]?\ RBG9-[
M\J^_4PYO&3Z[JU^(_&=AX9L[.=[>&)A"\T[+P9&\P\+G. !S5JQ\>WTW@OQ!
M- UKJFJ:+\HGM/FBN%(RLH /IG(!_A-,'A^X\,:E?HOA&W\16%W</<P3(L7G
M0%SDQL'ZC.<$&MC3;'Q#!X9OIK/3=(TG4YI/,M[2*(;508^21EX9B,\@8&>]
M0^7E^[]/GW_JQ?O<_P _P_+M_5RIX8N]:O+JSN['Q98^([&7_C]B,<<36^1G
M<FSGKQM:NYKS>'1]0U;Q9I.H6WA(>&[BUF\V^O1+'^^7&#$ A^?<3U(&,5Z1
M4U+:/^OP"%PHHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** +<'^I6I*C@_U*U)0!%<_P"K'UJK5JY_U8^M5: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH FMO]8?I5FJUM_K#]*LT %4*OU0H **
M** "BBB@ ILD4<R[98UD .<,N>:=10 @4 Y  /TIHAB$IE$:"0C!<*,G\:?1
M0 R2&*8 2QI( <C<H.*?110 Q(8HF9HXT0L<L54#/UIS(KC#J&&<X(S2T4 ,
MDACF4+-&L@!R R@T\<=*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J_5"K] !52?_7-5NJD_^N:@".BB
MB@ HHHH *CN+>&ZMY(+F))H9%*O&ZAE8'L0:DK+\2:[#X:T*;5+F)YHX612D
M9&3N8+W^M-*[L@VU,.W^%/@NVU(7L6B1^8K;@K2NR _[A./PQBN@UG0=,\0:
M<;'6;..ZMR<A'&-I]01R#[BM '(S5#2=3?4UNR]E<6GV>Y> "=-OFA?XU]5/
M8U3E*6[V)22U74S?#W@3PYX6G>?1--2"=Q@S,[2/CT!8G ^E4Y?A?X.GU=M2
MET6)IW8NPWOY98]]F=OZ5UM%'/*][ARQM:QSJ> ?#2:1:Z6NFXL[2Y^U01>?
M)\DO][.[)^A.*BUKX<^%O$&J_P!HZKI2RW1QO=9'3?CIN"D UJ6NMI+'J<MW
M:SV,.GS.C2W"X6154,9%]5YZ^U7K6ZAO;.&ZM)!+!,@DC=>C*1D'\J.::=[_
M -,.6.UC!B\ >&(-/U"Q@TI(K74BINHDED57VG(QAOEP>RXJE+\*?!<UZET^
MB1[T &U97"''3*AL'\>O?-=A11[2:=[ARQM:QEZIX:TC6;6TMM1LUDALI5EM
MXU=HQ&RC"D;2.GITJMXB\%^'_%?EG7-.2XDC&$E#,C@>FY2#CV/%3ZSKRZ/J
M&DVK0-*=2NOLRL&QY9VEL^_2M:E>2U'IL9>@^&M'\,6;6NAV,=I&QR^TEF<^
MI8Y)_$UJ444FVW=@DDK(****0PHHHH ***K'4K,:J--,Z_;3#YXA_B\O.-WT
MSQ0!9HJA9ZF]WJVH6365Q"MF4"SR)A)]RY^0]\=#5^GL 4444@"BBB@ HHHH
M **** "BBB@ HHHH **** "K<'^I6JE6X/\ 4K0!)1110 4444 %%%% %2?_
M %S5'4D_^N:HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M MP?ZE:DJ.#_ %*U)0!%<_ZL?6JM6KG_ %8^M5: "BBB@#)U_P 0P:!#;AH)
MKN[NY/*M;2W +S/C/&<  #DD\"LVV\8S0ZA;VGB70[K1#=OY=O-)+'-$[GHA
M="=K'L#U]:D\5Z%?W]UI>K:(\/\ :.E2M)'%<$B.9'7:Z$CH2.AJM'XMB>[M
MM/\ %^@SZ3+/*JPO<!)K9Y?X0LB\!L],@5K%)K:_]="9.QOIJ+-KTFF_8YPJ
M6ZS?:BO[MB6(V _WAC./>KU<W#?W)^)MW8M.YM$TJ.98L_*',C M]< 5C:-!
MJOCN"76KC7;_ $NPDE=+&UTYUC(16*[W8J2Q)&<=!4\MU<&[-K^MKG>T5POA
MRXUZU\;:WI.M:DU[%:6,3VTFT*74EOF8#C=Q@D=<51\+:1X@\2>#+35KWQ7J
M5O>R1L;=;=D$:@$X+@J=Y.,G)]J?)97OII^-_P#(.;6W]=/\SN]5U%M,M8YD
MLY[LR3QQ%(%W%0S ;C[#.3[54U_Q"FA_9(8[2:^OKZ0QVMI"5#2$#).6(  '
M))KEI/$^IWWPWT753+]GO9M0MX)VAX#?O_+?\#@\>]1>+O#\]S\1/#[)KNJ0
M?;)+C8(I$ MML7_+/*G&>^<U2IZVEW?X),3EI==O\SLAJ]REQI<%UI5Q'+?!
M_-V$2):E5SAV''/0&M2N5U&>\TSQ3X2TV.^GEBE\])VD8%I]D606P.3GFJ,+
M:GXUU_5%CU>[TK2-,N3:(EBP26XE4 NS.0<*,X '6IY;ZK^M;#O;<[BBL70=
M-UC2Y+FWU#5/[3L_E-I+.H\]?57( ##I@]>M<7JU_#9K=R:C\0Y5UN,NT=M8
M,K0QD9*H80K$\8SN.:7+=VN.^AZ=17GNL>(M8U'X?^&M2TRX%E?ZE=VJ.RC*
M@OD'([KGG%3:M::MX/GT[4X/$&H:E#->Q6UY;7S(RNLC;=R84;""1P.*KV;O
M9OK;YD\ZM==K_+^D=K)?6L-]#9RSHMS<*S11$_,X7&XCZ9%3UYMXC\-2W/Q4
MTB1->U6W>\M[DJ8I5'V<*%^5,J< YYSFNZU74$T+P]=7\^Z5;*W:1LGYGVKG
M\SBH:2BGW_S92NY-%^N?'BK?;Z])%IT\[Z/,83%#\[SG8K?*,=?FQBL?2_#^
MNZYI<.KZIXHU*ROKJ,31V]D46"W##*KL*G?@$9R>:Y_3KW5]/\&^/;JZG$>J
MV]X^9X!M!98D <#MD '\:M4TFTWM_FB>:]FNK_1GJT;^9$KE2NY0=IZCVIU<
M3XSU:[LK?0A+?7&G:3</C4=0MUR\0V90;L':&;JV/RK0\-^9$UQ<VGB)=;T1
MH]T3R2+++$XSN&]>JX]><U+C9.0U*]D=-17!:'::OXXT\:]>Z]J.EV]RS&RL
M].=8Q'&"0&<E268XSZ5H:CJNL>$? ]W=:O/#J=]"_E6LB)L\[<P6/>. #D\X
MXH<&G;KV!23UZ'6T5QJ^$=?:R^U2>,-275RN_P"79]E#_P!WRMOW>W7-9EUX
MNU#4?"&@WZ.;.\?6H;*]2$_*2)"KK_NG&?QIJG=V3[+[Q<VEV>BT5S'C[4+O
M3?#]O-83O!(U_;1ED."5:0 C\0:H:[_:^H_$BVT:QU>XTZQ?2VGN#!MWG$F/
ME)!"L<@9P>,THQ<OQ_!7&W;\/Q=CMJ@@OK6YNKBWMYTDFM6"S(IYC)&0#^'-
M<EIHU/1?&I\.SZM=:C87MB]Q!-=,&G@=6"L-P R/F!&>F*RO!GAJ6S\<^(2-
M>U646EW$76252+DM$#^\^7G&>,8X IJ"=W?I?\;"<FNG7]+GI-%>=ZIJGG>-
M]1L/$?B*\\/P(L8TQ8I1!'."OS.7((8[N-I./:NST*/4(M(B35KR&^G4G%S"
MNT2IGY6(Z9QC..,]*3C:-Q\VMB2PU%KZZOH6LY[<6D_E!Y5P)AM!W+ZCG'U!
MJ[7!RZQJ"Z-X\E%W('L)9!:MG_4@0*PQ^))J"32?$4?@Q?$/_"47_P#:L5F+
MKR/D^RG";MA3;SQQNSG/-/E5KMVV_%!=WLO/\&>AT52T6_.JZ%8:@R>6;JWC
MF* _=+*#C]:NU#3B[,::DKH****0PHHHH FMO]8?I5FJUM_K#]*LT %4*OU0
MH **** "BH;RY6SM'G92P0=!WJ'3=0&HV[2",QE6P03G]:KE=N;H3S).Q<K&
M\1>*-.\-01F]:1[BXR+>V@B,DDI R<*.<#N>E;-<7XNTW5;3Q):>)M'LAJ0@
MLY+2XM!($<(QSO0GC([CN*2LWJ46O!7CJQ\6Z?%DBWU+RA+-:,K*0,_>7/WE
M]Q5K2?&>EZQK1TJWCO8;L1-*$N;5XLJ" 2-P&>37+?#+4_#^J:3H=M+$T>MZ
M=9L(?/C9&9#PQ0]'7\ZV+G_DM%C_ -@67_T:M;SA%5'&W?\ "YE"3=._I^G^
M9HZYXTTK0;Y+"5;J\OF3S/LEC;M-(%_O$#H/K5O0?$FF^)+62;2YF8POLFAE
M0I)$WHRGD5@?#F-;B/7=6FP]W>:K.DCGJ$C;:B?0 =/>B\0:?\9-,DMAM.J:
M=-'<J/XO+(*L??G&:CEC?EZVO^%QN3LWTO;\;':455O-5T_3F5=0OK:U+C*B
M>94W?3)YIMIK&F:A*8K#4;2ZD W%(9U<@>N :SLS0N5EVOB/3+SQ%=:):W'F
M7UG&))T4<(">F>F>1Q5+Q5KEQ81P:9HRK+K.HDI:H>1$/XI6_P!E1S[G K \
M,Z%;^'OB7+96Q:1O[%22:=^7GD,S%G8]R35QBFKOS)DVEIY?G8Z+7O&.E^'[
MJ*SN/M%U?2KO2SLH&FE*_P![:.@^M3Z!XGTSQ)%,=-E<2V[;9[>>,QRPGT93
MR/Y5@^ 4%WJ_BG5I\/=R:M):[CR5CB "K[#G-&LJ-/\ BYX=N;8!7U*VN+:Y
M _C5%#J3]#345?EZVO\ A<3;U:Z?YV.BTCQ%INN7%]!IUQYDUA.8+B,@AD8>
MQ[<'GV-)KWB/3/#5I%<:O<>4DTJPQ@*69V/8 5Y=I=I=Z+>:WXQTA))9+/6K
MJ+4+53_Q\6VX$D#^\I)8?C4'BU+CQ7HDGC&^62*S6Z@@TBW?(Q$95#3$>K=O
M;\*N-).4==':_P [?U]_8F<W&,O*]OE?^O\ ASVRBN>\>:I>:+X%U34-,E\F
MZ@B#1R;0VT[@.A!!ZUB0Z;\0+S34U7_A([:VNWC$J:6+%3".,A&<G=GU(K%1
MNKMV-&[:'>45Y[??$C?X/T>\MC;:??:M,UN7O'Q%:,A(D9LXR!C@=\BJ4?C&
M30=2L&?QKI_B:UNKA+>X@584EA+' D3RSR <9!SQ5JE)NQ+FDKGI]%<%87'B
MG7?&VN6T&N1V.EZ9>1JL:VB/)("@8IN/1??D\UTGBB;5(=*!T>\LK!FD FO+
MP_+;Q]V"GAC[$@5#C:WG^I2=[^1LT5YYX;\4SIXVM]#_ .$GMO$]M=P22":*
M.-7MW0 X)3Y2",^]5K37=>UW4M2%IXHM-,U.UNI(H-#N($PZJ?EW$_.=WJO3
M-7[-W_']">=?I^IZ917!^*O$.IVVN:3I5UJT/AJ"ZM6FGORBR*900/)5G&T=
M<Y(YJW)K^J>%O!>I:GXAN+75%M<?9+JW(3[4K8"[@.%.XX)'%3R.U_ZWL/FU
ML=C3))HH2@ED1#(VU S ;CZ#U->5S^++^PTUM7'Q!T6^NXU\V32%$(B<8R8T
M8'?GT.3D]J?XV75-?NO".K:3KK6=I?W4!M8#:(_V>1D9O-))^8XXVGBK5%W2
M;)=16;7:YZI15?3X;FVTZ"&_N_MMRB!9;CRQ'YK=VVC@9]!5BLGN:(****0!
M1110 4444 %%%% !5^J%7Z "JD_^N:K=5)_]<U $=%%% !1110 5Q_Q5_P"2
M<W__ %T@_P#1J5V%<_XYT.\\1>#[O3--:%;F5HV0SL0GRNK<D GM50=IQ;[K
M\Q/5-&^OW1]*\GU#5M8;P/K\EKJEU%=IXE-O!-YK$QIYJ *.?N\_=Z5UEI+\
M0?M<(O;3PZ+;>HE,4TQ<)GG&1C.*SIO ^IOX=U.Q$MKYMUKO]HQDNVT1>8K8
M/R_>PIXZ>]:P2C+WO+\T9RNX66__  '^I0\3:/K7A*.QO=&\4:G-/?7<=E<B
M^D$T?[W(\Q$QA2#R .*NW%A>^"?$6AR6NN:GJ-MJEV+.Z@U&?S02RDATX^4@
MCH.*Z'Q=H=UKUEI\5FT2M;:C!=/YK$ HC9(& >:/$VAW6L7NA2VK1*NGZBEU
M+YC$$H%8$# .3S[41G=*_?\ #3_@A*.CMV_'7_@''7MM<>(/#?CB*\U748DL
M=0N'B$-P5RJP@B(YS^[)/*C%%G=2^ _@Y#J]MJ%[>7%Y;6WE+?2F6.V9U PB
M@<*,YV\]!74:7X6GAM_$]O?R1^5K-W+)&8B251XPO.0.>#5*Q\*:K?>")/#/
MB-[6..WCCBL[NR=BY\O[KE6 P1A> 3WIJ2Y;=/=_+4IJ\K_XOST.*NO$NF:;
M8G4-$\8:_>:U$/,\N[AF:"Y/=#&4"J#T&,8]:ZR\U#4/&?B2VT6ROKK2+!-.
MCOKR2V;9.YD^[&&_A ZD_A5LP?$&ZA73Y9](M%R%DU2 NTA7U6(C 8^YP*L:
M[X=U9-=M_$/ABXM_[2C@^S7$-YD1W46<\E1\K \@@4W*-U_73T_X8BTK:?UJ
M<SJ_AZ^T#QIX31=9O=1TR3425COY/-DBD"-T?&2I&>#TQ74^-]7O[&WT[3=&
MD6"^U>[6UCN&7=Y"X)9\'J0!P*R)O#GB[6_%&BZQK<^G6\&G7)<6-LSMA2I!
M8N1\S9P,8 Q71^*_#I\1:;"MM<FSO[.=;FSN0N?+D7ID=P<D$5+:]WFU[E).
M[Y>W^9R^M^'M3\':--X@T?Q)JUY<6*^=<6^HW/FPW*#EAMQ\IQG!%-UR;5_$
M'C[1K+1]8NM,LKW26N+CR7Y"%@<J#P'Y W8R 35R]T?QIXGM!I/B!M*L--?
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M_8:=.LK:?JB7]U/.2&F/S%VX!Y);@?K6MXFT.ZUF]T*6U:)5T_44NI?,8@E
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M *XO2BHNSMU:_!?YCDVKKR_S.FL[E;RRAN4CEB69 X29"CKD9P5/(/M6)?\
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M,TY4XIMOJWMY$QFW%6[)EK7/B)X6\.ZA]BU;5HXKD?>C2-Y"G^]M!Q]#6/\
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M"&VOH+I$BE0<*7#<J0,9ZYJ&Z\%ZI;^ S9J%O=5N]4BU"\,9"KN,JL^W<1P
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MZW2&U%])MSK20)?;<3"W8LA/J,^O7':KM87@O2K[1?!]C8:K+YEU$AW /NV
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M*** "BBB@ HHHH **** "BBB@ HHHH FMO\ 6'Z59JM;?ZP_2K- !5"K]4*
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M;QMQM8'&,\ ]*GL=!L+'PW%H:0B6QC@\@I)SO7&#N]2>_P!:IU(ZOS_"]_\
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MA.W].*R_&/A.?Q!\2/#UQ/IHO-(AAF2[+D;5R#C(SGKCI7?[@6(!&1U&:4G
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M44 %%%% !1110 4444 %%%% !1110 5?JA5^@ JI/_KFJW52?_7-0!'1110
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MC"H JCT IU-B#K"BRN'D"@,P&-Q[G':G5SO<U6P4444AA1110 4444 %%%%
M!1110 4444 %%%% !1110 5;@_U*U4JW!_J5H DHHHH **** "BBB@"I/_KF
MJ.I)_P#7-4= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6
MX/\ 4K4E1P?ZE:DH BN?]6/K56K5S_JQ]:JT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!-;?ZP_2K-5K;_6'Z59H *H5?JA0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5^J%7Z "JD_\ KFJW52?_
M %S4 1T444 %%%% !116'XO\0/X<T!KJV@%Q=S2I;VL+' >5SA0?;O\ A32;
M=D!N45P5[9>.]$TV763XCM]3DMT,T^F-9+'$ZCEE1Q\P(&<$]>]0:QXIU[4]
M<\,P>$9XH8=:LI)W-Q$'$0PIWGOE02,9P2>:M4VW9/\ JU_T(<[*[_KI^IZ)
M2.BR(4D4,K#!5AD$5P=W=>)O!-S9W>LZVNNZ5<W"6]QOM4@DMRYPKJ5X*YQD
M&H7O_%VM^/\ 7=$TK58M.T^R\EOM+6RR/%N0'8@. <G));.,<4>SOL]/^&_S
M'S6W.VL=&TS3'D?3=-M+-I#EVMX%C+?7 YJ[7%Z7JNM:!XL@\/\ B:^CU.&^
MADELK\0B)]R<M&ZCCIR"/_U5--G\5>.()-7TO7DT'3&D=+**.S29Y54[=[E^
MF2#P*.1O6^G<7,COZ;)(D,;22NJ(HRS,< #U)KSN]\8ZW:^"_$T-V\,&OZ%M
M5IX4!217P4D"L"!D9R*B\4Z/XLD^'>J76I>*E+/:F::VAL$"! A+1*V=V#D?
M-UX]Z/9VU;'S>1Z4K*Z!D8,K#((.012UYPMQX@\-?#W29Y=<^VRW-U9)&WV.
M./RH7V@QXYW<?Q=:Z;QAJEYI5MI3V$OE-<:K;6\IVAMT;OAAR.,COUING:5D
M^MOR_P R8SO&[[7_ #_R.AJCK.L6>@Z5)J&HNR6\14,54L?F8*.![D5QK7'B
MO7O'6OZ3IVO)I>GZ>8"KBT260%H\[1GL3DDG)Z 52OO%NOV/@_Q!;W=S$VKZ
M+=P0?;(X5VS([(0Q0@@$J3D41IMM>=ON=O\ ,;E8]*,\2RI$TJ"20$HA8!F
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M:NJ6N;9+FU681R@^5\KINX..<CW%>GU1L]&L['5;_4;=&%QJ!0SL6)!V+M7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7ZH5?H *J3_ZYJMU
M4G_US4 1T444 %%%% !117/>.?$[^$/"L^KQVJW31.B^4S[ =S8ZX/K32N[
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M5.G)2<;;$J2:YCIJ***@H**** )K;_6'Z59JM;?ZP_2K- !5"K]4* "BBB@
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M,Q4>W'':MJ;2[.XU2VU&:'==VJND,FXC:'QN&,X.<#K4J48[?UHU^I33>_\
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M%!;7#EI4)FRS_(WR_= 7&!CJ:Z/1M0NY_B-XDLIIW>VMH;5H8B?E0LK%L?7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *OU0J_0 54G_P!<U6ZJ3_ZYJ (Z*** "BBB@ HHK/U[6[3PYH=UJNHL
M5@MDW$#JQZ!1[DX% &A17F-GJ_Q0\26BZMI%II&FV,HWV]M=%C)(G8DX[_\
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MI6N?$7QC=:O:K=FTU B%)"2J$LQ+8Z9^4<TG@'0M+\9ZYXEU/Q7;I?ZC'?-
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M]2M $E%%% !1110 4444 5)_]<U1U)/_ *YJCH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"W!_J5J2HX/]2M24 17/^K'UJK5JY_U8^M5
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FMO]8?I5FJU
MM_K#]*LT %4*OU0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW]:DHH C\B/^[^M'D1_W?UJ2B@"/R(_[OZT>1'_=_6I** (_(C_N_K1Y$?\
M=_6I** $50JX7@4M%% ",H<889%,\B/^[^M244 1^1'_ '?UH\B/^[^M244
M1^1'_=_6CR(_[OZU)10!'Y$?]W]:/(C_ +OZU)10!'Y$?]W]:/(C_N_K4E%
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MZT>1'_=_6I** (_(C_N_K1Y$?]W]:DHH C\B/^[^M'D1_P!W]:DHH C\B/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>lgnd-20231231_g3.jpg
<TEXT>
begin 644 lgnd-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+Z17AI9@  34T *@    @ ! $[  (
M   0   !2H=I  0    !   !6IR=  $    @   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2&5R;6%N+"!-96QA;FEE   %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,R-0  DI(  @    ,R-0  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M-#+M;'7T/K0 E.!RA7TY%-H!(.10 4Y?E4M^ IM!)('M0 444#GI0 JKG.>
M!S24]_E&P<X/)]33* %9=N.X(R*2GI\XV'U^4^],Z4 %.8[E![C@TV@$@$=C
MUH *<3M0+Z\FFT$EB2>IH ***5%W-CIZGTH -OR;CZX'O2  L,\#UI7;<>.
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MZ4]_D78.N?F/O0 RE9=N.X(R*2GI\PV'N>#[T ,HH(P<&B@!S?,H8?0_6FT
MD9]Z* ',=J!!]6IM!.>M% !2[?EW>^![T*I=L#\_2E=MQ '0# H ;]:5EVMC
M_)I*?G>F#]Y>GN* &4 D$$=1110 YP,[EZ-^E- R<#K1DXQVH!(.10 YST5>
MB_J:;110 4I7"@GOVI47=DG[HY-(S;FST]O2@ 5=S8Z>E)13G^8;QUZ-]: &
MTY&VMST/!IM% "LNUB*$7<W/ ')I"2<9[=*,D CL>M "NV]L_D/2DHHH *5E
MVMCOWIR#8OF'_@(]_6F4 *%RI([=J2E5MK T,,-QT/(H 2GH=RE#WY'UIE%
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MDH D2;8X.U?RICKM;U'4'UI*<#O7:>HY'^% QM*B[VQT]3Z4E.)V+M'4]?\
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M=O0G.,&N\OD;_AD^W7'/R\?]O->%>4_]W]:RH4HJ<G?:3+G4DX1TW1]!>!?
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M*<XVX7N.OUIXC,2[W'.?E^M1=:-QBJ0&^89'>AEVMBDJ15:5< 9*_P J (Z
M2K CJ*?Y+^GZBD,;*,D<470M1'QNRO0\X]*5"%RQZCH/>FT4 '6BG")R,@<?
M6E\E_3]11= -5=S "AL;CMZ=J>ZF%=I^\PY]A4= QR?-E.YZ?6FT5*8FD42+
MSGKVYHV#<BIR-M;G[IX-+Y+_ -W]::R,GWABC0!",$CK3@=L9Q]YOT%-HH$%
M%/\ )?\ N_K2B"0GA?U%%T.S&H,Y8]%IM/D^4^6.BGGW-,H$.QNCR.J]:;2J
MVUL]NA^E/:W=3TR.W-&PR.G @H5/;D4ODO\ W?UIA!4X/6C< ISD8"KT'ZFF
MTJJ6.%ZT"$HI_DO_ '?UIRP-U<84<G!HNAV8S&V/)ZMT^E-I6;<V3^ ]*2@0
MYP.&7HW;T--I\8WG9Z]/K08)!U7]12N,93F.Y0?XAP?>E\I_[OZTRF(50"P!
M.!W-#MN;/;L/2DI51F^Z,_C0 E%/\E_[OZTX1F)=[COA1GO1=#L1N-N%[CK0
MIPW/([TA.3DT4"%==K$=?0^M)4B(94.W[R_J*3R7]/U%*X[# 2I!'44KX+97
MH><>E*8W49(X^M-IB'(0#N/;H/>FDY.313A&Y&0./K0 VE52S "G>3)Z?J*5
MU,*@'[S#GV%%QV&,06..G:E7!!4]>H--H!P<B@045*8BZAXQP>V>AIODO_=_
M6BZ'9@3LCVCJW+?T%,H)).3R:*!!12HI=@H[TLC G"_='3_&@#W_ %__ )-5
ML_\ KWM__1HKY^KW#P[\8/!UGX T[P[X@T>_OQ;P+'-&;:*2)R#D'#.,\^HJ
M1_B3\)$;!\#M]1I=MS_X_7%!SIRG[K=VV=+49PCK:R/"Z]V^%W_) /%?UNO_
M $0M9?B#X@_#"_\ #NH6FD^#VMKZ:W=+>8Z=;IY;D8#9#DC![BL?P9\1M)\.
M?#'6_#E[;WKWFH&8Q20QH8UWQ!!N)8'J.P-55<ZM*2Y;/_@A2Y:=6,KF=\'_
M !+!X9^(EK->N([6\1K661C@)N(*D^VX#\*Z/XV_#^_L?$D_B/3;=[C3[XAY
MFC7/D28P=WHIQG/3.?:O)&(+948'I7J/@SXX:SX9T^'3]:M/[6L54+$SOLE1
M.F V"& ]"/QJZL)<RJ0W6GJB*<DDX2V9YFL4EQ.EO:QO*[':B1J6+M[ =:^G
M?@SX%N?!_AN>YU9/+U'4BKO$>L2+G:I]^23]<=JY27X_>'[2-YM(\*,MV>C.
M8XQ^+*":U_@]XNUKQKX@U_5]:<"&.**.&- 1'",L2%]^Y/7I7/7E5E2=XV74
MTA&$9IWNSB?@UI5KJ7Q?U":\19#9+-/"K<_/Y@4''L&/Z50^+'CKQ%=^.-2T
MP7]S965E,88K:&0QA@/XFQ][/7GL:YO0O%-WX6\<RZYI;*_ES2;D;[LR,Q^4
M_7].M>I7WCSX3^-0E]XLTF>WOU4!R4<,V.V^(_,/3./PJI1:E&;5TE8=U[\;
MV;9Y5X%\/WOBGQM86=LKR?OUEN).NR-6!9B?\\D5Z5^TE_R%=!_ZX3?^A+3+
MOXO>'/#]G_97PXT3[#'(P\V\>,*Q'L"26.. 6/'I7,_%SQ_I?CR^TR72+>\@
M%G'(D@NT522Q!&-K-Z4WSU*L)<MDK_D2E&$)J]V[?F=DO_)I7Y_^E5>%M\RA
MQ]#7HX^(NDCX'?\ "&_9[W^T?^>NQ/)_UWF==V>GMUKS=6QUZ'J*VIQ:G4;Z
MMD3DG3BCVS]FW_D)Z_\ ]<(?_0FKA/!^MQ^'OBY;ZE<OLMXKV19F/14<LA)^
MF[-:7PD^(&E> KS4Y=7@O)UNXT2/[*BL05))SN9?6N$O[A+F^N)H@P265I/F
MZ\DD4N5^WDVM&K!=>RMUN>O?M >$KE-8A\4V<9EL[B)8KAT&1&XX4GV(P,^H
M]Z\8KUGP'\;)-$TM-$\5V;:GIJIY:2+AI$3^Z5;AU^I&/>NC;Q?\%8C]LCT2
M)YA\PA73SU],'Y*R@ZE!<CC==&BY<M5\U[,J?L^>#[M+^X\47D316_DF"UW#
M'FDD;F'L,8SWR?2O/_BW_P E7UW_ *[K_P"BUKT%?C["_BFTF>PN+3P_;*ZB
MW@"M+*VW )!(4 9^Z#^?;RSQSKMMXF\;:EK%@DT=O=R!D68 . % Y )';UIT
MU4E7YY*RM^J"7)&DXIZW_0H:!_R,NF?]?<7_ *&*]A_:4_X^_#_^Y/\ S2O'
M-+N4MM2M+N4,1:SI*X4<LJL"<>_%=Q\7/B%I/CZ?2WT>WO(19K()/M2(N=Q7
M&-K-_=-:5(N56FUTO^1%-I1FGU2_,[#X6''P"\5GK\UU_P"B%KPMU"M\OW3R
M*]'\&?$72?#OPPUOPY>V][)>:@9O*>%$,:[X@@W$L#U'8&O-PWRE6^H]J<(M
M59RZ.WY!*2=*,>NIZ=^S]_R4QO\ KQE_FM<W\2,#XG>(';HMX_XFIOA?XOL/
M!/B\ZKJL-S- ;9XMMLJLV21CAF QQZUD>,-9@\0>+]3U2R21+>ZN&EC64 ,
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MS'4 AB-LB,%P&!SN8?WO>O,R<DT1B_;SET:7Y"NO91CUNST?X$M_Q=*T4_\
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M?AR]M[V2\U S>4\*(8UWQ!!N)8'J.P-:XB+E2:7]:F="2C5BWL>?0;5O8).
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M$+_Q9PO^-,H **>!OC/JG/X4R@ !*L"."*?( <.O1OT-,I5;&0W0_I0 E.C
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ME1]C9ZCH1ZBAUVL1^5(8E2QKYL14D IR"?Y5%3Y#M41KT'WO<T,$'E?[:?\
M?5(8\#.Y3]#3:*>H!1000 3WZ4 $@D=J!#@F1G<H^II?*_VT_P"^J910,E=?
M*B"@Y+\DCI]*BIZ'<I0\YY7V-,I(&%3M'YJ+)N52>NXXR?6HHU#/AC@=2?:A
MWWMGH.@'H*.H"^5_MI_WU367;W!^AI**8@HH((.#UHP< ]C0 _R_]M/^^J!%
MG^-!_P "IE%&H]"28;6"#HHQ]?>HZ><O%GNO!^G:F4(&*C;'##M^M2R0;6X9
M0#R 3R*9'@ NW\/0>IIA)))/)-+J'0?Y7^VG_?5,8;3C(/T-% !)XIB"@#)Q
MP/K1001UH ?Y7^VG_?5.C@W. 64CN >345 )!!'!%+4>@K'<Q)[FDI\B]'7H
MW/T/<4RF(D@Y?RSR'X^GO08<'&]#_P "H_U<6?XW_05'2&/\K_;3_OJF448)
M!/84Q!2JNX]0/J:2@C!P>M #_*_VT_[ZIR1[0S[E)49 !R:BI4;:P)Y'<>HI
M:CT$HITB;'XY!Y!]13:8B6$>8K1GC^($]J:8L?QI_P!]4K_NTV#J>6_PJ.D,
M<8\?Q+_WU3:*,'&>U,04JIN[J/J:0 GI10 _RO\ ;3_OJE8>7%@%3O/)!STJ
M.GQ$'*-T;H?0TAC**"""0>"*55+L%'4TQ$H3S80Q*J4XR3C(IGE?[:?]]42,
M"=J?<7I_C3*2N,<R;1G<I^AIM%!!'6F(*<(\C.Y?Q--P<9[44 /\K_;3_OJE
ME^7;&.BCMW-1U(/WD1'\2<CW%(9'0"001U%%/B4%B6^ZHR??VIB'R1;\2 JN
MX9P3BF>5_MI_WU368NV324M1Z"LNWN#]#24 9.!13$ &3BG^5_MI_P!]4P@C
M&>_2B@"5(<N,LI'H#R:C=R[ECWI 2""."*DD 91(HP#PP]#2ZCZ$=/B;;( >
M0W!'K3*D3]W'O_B/"^WO38(5X-K$;T//]ZF^5_MI_P!]4RBC4- (P<4444"%
M5=W<#ZFG>5_MI_WU3""#@]:*!DR)Y8:3*L5' !S@^M0TY'V-GJ.A'J*)$V-Q
MRIY!]J74.@VI81YBM&?3()[&HJD?]W&$'WCRW^%#!">5_MI_WU08\?Q)_P!]
M4RBGJ 448XS0 3TH$.5-PSN4?4TOE?[:?]]4RB@9*P\J'@@E^I'IZ5%3XB#^
M[;[K=/8^M,(*L0>HI(&%3!?-A!)"E.,GH142J78*.IITK G:GW5Z>_O0P0>5
M_MI_WU2,FT9W*?H:;13 **",=:,'&>U A_E_[:?]]4>5_MI_WU3**-1CG4 Y
M7[K<BFU)'CRV\S.WMCKFD/E=M_Z4@&4K-N"Y'(&,^M!V8XW9]Q24Q#D;9DCK
MC /I3:*4;<?-G/M0 E.0#EF^ZO7W]J!Y??=^E*^W8NS..^?6@8PDDDGJ:<C
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M;HOZF@!I&#BE R"1VI*53M8&@!**5UVMCJ.Q]:2@!ZG<I0_5?K3**"2QR>M
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MRB@ IR 9W-]U?U]J:26.3UHR< =A0 ,2S$GJ:*** !1N.!13CE8Q_M<_A3:
M C !]:*>GS90]^GUIG2@ I[?.@;^)>#]*90"0<B@ IZ_(A;N>!_C3*"23S0
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M@_\ BZ)/@QX]*JJ>'RO7(^V0?GG?7U=11]<J=E_7S']7@?)W_"E?B!_T /\
MR<M__BZ/^%*_$#_H ?\ DY;_ /Q=?6-%'UVIV0OJT#Y1'P9\>F( ^'MQ!/6\
M@&/;[]!^"_CS_H7<?]OT'_Q=?5U%'URIV7]?,?U>!\GGX*^/^WA_'_;[!_\
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M!@8^V0<?^/U]844?7*G9?U\P^KP/D[_A2OQ _P"@!_Y.6_\ \71_PI7X@?\
M0 _\G+?_ .+KZQHH^NU.R#ZM ^4O^%,^/&1?^*>W$#DF]@'_ +/33\%_'IZ>
M'<?]OT'_ ,77U?11]<J=E_7S']7@?)Q^"OC_ +>'\?\ ;[!_\71_PI7X@?\
M0 _\G+?_ .+KZQHH^NU.R%]6@?)W_"E?'_\ T /_ "=M_P#XNG#X+>/>_AW/
M_;]!_P#%U]7T4?7:G9?U\P^K0/E)?@QX\5@?^$=QCO\ ;8#C_P ?J/\ X4MX
M_//]@?\ DY!_\77UC11]<J=D'U>!\G?\*5^('_0 _P#)RW_^+H'P7\?HP)T$
MC!ZB[@./_'Z^L:*/KM3L@^K0/E)O@QX[+$CPYQ_U_0?_ !=-/P6\>]O#N/\
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MKZPHH^N5.R_'_,/J\#Y._P"%*_$#_H ?^3EO_P#%T?\ "E?B!_T /_)RW_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV7RKB%([.2<E9E)&')5L@Y_E6UJ7C.^T3PKX=A\.^')K^\U*VC%O!'N$$ V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$_CB+Q1J&G3Z986%L]O86]TNV:5GQOD9?X1@8 /-=Q6<^E]^O]>EBH[NVW_
M_P [A1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '"^+U&H_$?P?I-U\UGON+QHR,J\D:?)GZ$D
MUW5<SXS\/7FK16.HZ(\<>L:3/Y]IYOW),C#QL>P8<9JBOQ%,47E:AX5\0P7X
M&#;16)E#-_LR+\I'OD5I\4$ET_J_Z?(EZ2N_Z_K?YFYJLNF^%]-U;Q!]CB20
M1&:Y>- 'FV+\H)[^@^M<UIF@^*?$&F1:MJWBJ]TNZND$L-G81QB&W4C*JVY2
M7/KDBK<&EZ]XK\,:W;^*1'8QZHK):6:@,UHFW +L/O,3SCM^@IZ7XSU#0=*A
MTKQ)X<UB34K2,1![&T,\5UM& R..!G&2#C%-)I-+?03=[/IK_7YB67BG5_\
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M6\66&D>(-*TB=E:XU*1T4!U'E!5W;F'IVJKXAUN[L/$WABULID%MJ-S+'/\
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MOS3B1ESN5^JXXP!QQ6/=>)=2O/A?X1M[B2]G?5Y_L]Y)9@M/+$F[<J\YW,%
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MJ>A%3S72N]4_\O\ @CY4GIV_S_X!Q&C#P;<^)=-6TTJZ\):W Q*6YM/LIN5
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MJXMXM4L$>+RKL'RKB)\91BO(.1D$5*E;E3??\>;_ #'RWYFEV_"W^14\6?\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKND4;22,J(H+,S'
M '4DT -N+B&TMI+BZE2&&)2\DCMA54<DD]A7SE\3?C'<^(FETCPS+):Z5RLL
MX^62Y_JJ>W4]_2JWQ8^*<WBN\DTC193'HL+<LN0;MA_$?]D'H/Q/;'F->C0P
M]O>F<=6K?2(4](V?IT]:?%#NY;IZ>M6 ,<"N^QS$:0JO7D^IJ6BBF(*6BEH
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M$UM=6LFR6!QW4X(Z<8((JN9*WJ*S=_0P_B-"]A:Z=XIM5)GT*Y$LH4<O;O\
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M^\>P_$UY!>WDM_>RW5PVZ25MQ]O;Z545<Y<15Y(\JW9!6EI>F_:6\Z8?N5/
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%0W=RMG9S7$GW8D+'WQVH
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MX7C_ 'AR/TS7=5SS5F:Q=T%%%%04%%%% !1110 4444 %%%% !1110 4444
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M;_:-QX?\'W5HDT<<QL]SLF]@H."H'4C\Z<*[6F_S%*DGJ?/M+7;?%VQM=/\
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M "BBB@ HHHH **** "BBB@ KY*^+D_VCXKZX_7$J)US]V-5_I7UK7Q_\2_\
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MK6C+EJ)D5(\T6CY3K0C;=&K>HK/JU:/E2GIR*]H\TLT44M, HHHI >@_!?\
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MV7V_7+:(C**V]_H.?_K?C7IU3,UPD='(****@[@HHHH **** "BBB@ HHHH
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M=&)&YFZ/QVJ>H(64W,X$QD((RA'W.*GH **** "BBB@ HHHH **** "BBB@
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M:DA6'JD1ZO[GV_G6EH?A**S*W&H[99QRL?54_P 372U#EV.NCA_M3     8
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M'ZU]=T$!E*L 01@@]ZWCBIK?4RE0B]CXFHKZA\2_"3POXB5Y$M!IMVV3Y]F
MF3ZE/NG\@?>O&/%WPE\0^%@]Q''_ &G8*,FXME.4'JZ=1]1D>]=E/$0GILSG
ME2E$X6BBBN@Q"BBB@ KH/#WCKQ%X7(&D:G+'"#DV\GSQ'_@)X'U&#7/T4G%2
M5F--K5'MNB?M!C:$\1:.<CK-8MU_X Q_]FKN],^*_@S5.(]:BMWQRMTK18_%
MAC\C7RO17-+"TWMH;*O-;GV?::G8:@BO87MM<JPR&AE5P?R-6J^)JNQ:UJD"
M[8-2O(QZ).P_D:Q>#[,T6([H^S*;)(D2%I75%'4L<"OCR+6M=N9!#%J>H2,_
M&T7+G/ZUN66BG>MQJDK74X& '8L%]N>M"P;[@\0NQ]#:UXZT31XR/M*WD_.(
M;9@YS[GH/Y^U>=ZS\1-:U3<EM(+" _PP'YC]7Z_EBN4HKIIX:$/-F$ZTI>0Y
MW>1R\C,[,<EF.2:;2XI<5U6,1M&*>!118!F#Z45)2T 145+@'M2>6#TXH MZ
M9KFIZ/)OTV]E@YR5#94_53P:[[0_BFCE8=?M_+/3[1 "1^*]?RS]*\S*D4E8
MU*,*FZ-(U)1V/HBSU2PU"-9+&\@G5NGER _IV/M5JOFVIX[Z[A&(;J:,8QA9
M".*Y'@NTCH6)[H^BZ1G5%W.P4>I.*^>/[4U#_G^N?^_S?XU7>624@R.SD="Q
MS2^I/K(/K*['OMUXDT6RS]IU2U0CJHE!;\AS7/:A\4-%M@191SWK=BJ[%_-N
M?TKR&BM8X."W=R'B)/8[#5?B5K5^&2S\NPB/_/(9?'^\?Z 5R4TTMQ,TMQ(\
MLC'+.[%B?J33**Z8PC#X482E*6["BBBK)"BBB@ HJUI^F7NJW0M].MI+B4]D
M'3W)Z >YKT+0_A8BA9M?N-QZ_9X#@?BW^'YUE4JPI_$S2-.4]CS>"":YF6*V
MB>61NB1J6)_ 5T^F_#C7K\!IHH[*,]YVYQ_NC)_/%>N:?I5AI4/E:=:16Z=]
MB\M]3U/XU;KAGC)/X4=,<.OM,\_LOA/9( =0U">8]Q"H0?3G-;MMX!\-VW33
MA*WK+(S?IG'Z5T=%<\JU26[-E3@MD9T7AW18/]5I-DI]1;KG\\58&FV*IL6R
MMPO]T1+C^56:*RYF^I=D4)-"TB5<2Z79./1K=#_2JUQX8TV6'9;PBV('RF+@
M#\.E;%%/FEW"R.'O?#M]9Y9$\^/^]'R?Q'6LH@@X(P17IM5[G3[2\'^DVZ2'
M^\1@_GUK15>Y#AV/.J569?NL1]#773^$K1\F"62(^A^8?Y_&J$OA"Z7_ %-Q
M$_\ O K_ (U?/%D\K,074XZ3/_WT:7[7<?\ /9_SK2;POJ2]$C;Z/_C4:^&]
M39F'D ;3CEQS3YHBLS.:XF;[TKGZL:96TGA34&^\84^KG^@JW#X/;_EO=@>R
M)G]31SQ0^5G-5+;VL]U)LMXGD;T49Q796WAK3H,%HVF8=Y&S^@XK4CBCAC"1
M(J*.BJ, 5#JKH4H=SE[#PF[8?4)-@_YYH<G\36]%H^GPJ%6SA..[+N/YFKE%
M9.39:BD0BSME.5MX@?9!0UE:M]ZVA/UC%344KL93?1].D^]9PC_=7;_*J<WA
M?3I/N+)%_N/G^>:V**?,T*R.5N/"$J\VMRK_ .S(,?J*R+O2;VRR9[=PH_C'
M*_F*]!HJE4:W)<$>945W=[H-C>Y+1>5(?XX^#^(Z&N;U#PY>6>7B'VB(?Q(.
M1]16L9ID.+1D4445H2%%%% !5BTU"ZL6S:S,@[KG(/X=*KT4@.DM?%SC O+<
M-ZM&<?H?\:UH/$6FSX_?^6?212/UZ5PM%0Z<65S,](BNK>;_ %,\<G^ZX-2U
MYE3UGE3[DKK]&(J/9>97.>E4$@#).![UYPD]U(X1)968G  8\ULV6C 8DOCY
MC]D)R!]?6DZ=MV-2N=0UW"JY#A_]TYJK)>2/]WY![57 P,#@4CNL:[G8*/4F
MIL.XXDDY/)I*HRZFB\1*7/J>!522_N)/X]H]%XI7"QLDXZTPS1+UD0?5A6"S
MLYRS%C[FDHN.QO?:(?\ GM'_ -]"G+(C?==3]#7/T47"QT5%8"321_<D9?H:
MLQZG,OWP''Y&BX6-A)&0Y1B/I5J*^/249]Q65#?PR\$[&]&JS3T8C661'&58
M'\:=6/2AB.A(I6'<UZ*R=[?WC^=(23UHL%S4::-?O.H_&HGO8E^[EOH*SZ*+
M!<LO>R-]W"BJY8L<L23ZFDHIB"BBB@ HHHH **55+-A1D^U6XK$GF4X]A0!4
M STYJ9+25_X=H]ZOI$D8^10*=2N.Q46P'\;D_05*MI"/X<_4U-12NQC!#&.D
M:_E3MB#HJ_E2T4@&^5'_ '%_*LS4O#MAJ:DR1^5+VDCX/X^M:M%%R914E9GG
MFH^$M0LLM OVJ(=XQ\P^J_X9K#961BK@JP."",$5Z_5:[TZSOEQ=VT<ONR\C
M\>M6I=SDGA4_A9Y13E9D.58J?8UW5SX)T^4DV\LT!],[@/SY_6LR;P+=+_Q[
MW<+_ .^I7^6:KF1SO#U%T.=6]NEZ7$O_ 'V:7[?=_P#/Q)_WU6N_@W5E^ZL+
M_P"[)_C40\)ZN79?LZC;W+C!IW1/LZO9F6UW</\ >GD/U<U$3GK70)X+U1OO
M&!/]YS_05<@\"2''VF]5?41H3^IQ2YD-4:CZ')5+;VT]U(([:)Y7/9%S7?6O
M@_2[?!D22X;_ *:-Q^0Q6S#;PVT>RWB2)/[J* *7,;1PLG\3.,TWP5<38?4I
M! G_ #S0Y8_CT'ZUUUCIUKIL/EV<*QCN>I;ZGO5FBH;;.N%*$-@HHHI&H444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5#:LK+)MF:7$C EA]T^E35'!YFU
M_-*$[SC9Z>_O0!)1110 4444 %%%% !1110 4444 %%%% !1110!Y[XU^$&C
M>)Q)=Z:%TO4FY\R-?W<I_P!M1W]QSZYKY^\1>&-5\*ZD;+6K5H9.2CCE)1ZJ
MW<?Y-?8=9NO^'M,\3:6^GZQ;+/"W()X9#_>4]C752Q$H:/5&-2DI:K<^.**[
M'Q_\.]0\$7^YB;G3)F(M[H#_ ,=?T;]#U'<#CJ].,E)71Q-.+LPHHHJB0HHH
MH *GM+26]N%A@7+'J>P'J:9!!)<SI#"NYW. *[?3-.CTVU$:?,[<N_\ >/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7Z***
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M(8N"Y'4U?+6&EZ3=16]X+B6X7;\OY=OJ: .>HHHH **** "BBB@":S.+R/\
MWJW*PK7_ (^XO]X5NU2$S8TC_CU?_?/\A5^L_2/^/=_]_P#I6A2>XPHHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%'YGVB7>L83C85/S'
MCG-2U6@51?7)6W=&.W=(3Q)QV^E %FBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKG=2
M\?\ A71]1EL-3UNVMKJ$@21.3E<C([>A%,LOB+X2U&]BM++7;6:XF8)'&I.6
M/ITJN635["<DMSI:*SM&U_2O$-M)<:+>QWD43^6[QYPK8SC]16C2::T8PHHH
MI %%%% !1110 4444 07EY%8VK3SD[5XP.I/I69I.MP7,[6Y:;>[%D,I!_X"
M,5B>+/&WA.&-]/N_$%G%=Q/DQAB^UAQAMH.#SWI?"D$6JO%J5G=6]Q:(W#PR
MJ^3Z<'C\:?*[7L*ZO8[2BBBD,***S!XCTEO$9T$7JG5%C\PVVULA<9SG&.GO
M32;V TZ**SM:U_2_#MFMUK=['9P.XC623."V"<?H:0&C17)_\+1\$_\ 0QV?
MYG_"M*/QAH$VIV.GQ:E&]UJ$(GM8PK?O4()# XQT4_E5<DNPN9=S:HHHJ1A1
M110 4444 %%%% !1110 4444 >#?$>(Q>/M0ST?RV'OF-?ZYKF!]X5WOQ=M#
M%XFM;D#Y9[8#/^TK'/Z%:X&O<HN].+/,J*TV2TM%%;&84M%%( I:** )[*TD
MO[^"T@&99Y%C7ZDXKI/B!=QMKT6F6I_T;2X$MT'N ,G^0_"G_#^WCCU2[UFY
M&8-*MVF/NY!"C\MWX@5I:G:^&=*ALO\ A)K6]GU6ZC^UW#VSCDNQ.U@6 '<<
M<\5S2FO:=[?U_7J;QC[AP%='X%U%-.\5VZSX\B[!MI0>A#\#]<5IGXB-%<BW
MMM)LUT=1L^Q,@)9?4GU_#\^M6M*M?"'B"XN;/2+.]MM0FA=[=IWPL;@9 7#<
M^O/843FW%J4= C%7]UF<=>U'PEJE]HEPJ:A81R&/[+=C<NWJI'IQ@XZ>U5]2
M\;ZA=6\=KI:)H]K&<B*Q)CR?4D8JYXY3^T+;2O$")M-Y!Y4XQ]V5."#^H_X#
M7'4X1C)*36HI2E%V3T.OB^($[)"^HZ387]Y ,174T?SC'0GW^F*T].\17NL^
M%=5O=0D\VYTR[@NX6V@;,MC:/; 8?C7&B/\ LK:UU;V]T+NU+1@R;O+W<!OE
M/##'0UVN@:-);^%;?3Y4Q=:]=(Q3NMNA#%C^ /\ WT*SJ1IQ5TOZZEPE)O4P
M?B#;);>-[[R^!)LDQZ$J,_KDUS5;OC74$U+QA?SQ-NC5Q$I'<* O\P36%6].
MZ@K]C*?Q.P444M:$!1112&1SG$7U-5:L7)X4?C5>FA,]W^&L)B\!6)(P9#(_
M3_;;^@KJJRO#%H;#PKIELPPR6R;AZ,1D_J36K7A5'>;9ZD5:*04445!04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $5S<1VEN\\YVH@R361IVO6
M\]\\3&8><_R>81A>V!CI6CJ=F;_3I;=6VLV"I/3(.:Y[3_#MZM_&]RJQQQN&
M)W [L>F* .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Q-4&+X^Z@UGW(W6LH_V36KK"8EC?U7'Y?_KK.(R"#T-6MB3G:*5E*.5/
M4'%)4%!1110 4444 * 68!022< #O70:A']F\,0V]\P^TALQ+GD#/^!K#M9_
MLUW%,%W>6X;![X-;^I::VLO'?:=()!( K*QQLQ_GI0!0TK58X(6LK]/,M)/S
M2M&&PF4$Z)JJF)N1&[=/Y_RJ*33M%MMMI=7#"YQ\TH)P#Z>@K.U32CIRQ.LR
MS12YVLH_SZT :S7<UC,+76Y8[J&X'S%>2GZ"I>-/46EZ?M&F3\12GG9Z G^M
M8^F:0+Z"2XFN%@AC.&)%:6C.KS76GLXN;!$+!G&,=.GZ_EF@!LNB:BD,EG:2
MHUF[;P6."?8_D*S;O0KZSC,CQAT'5HSG']:LV%FUW9R375]+#8QMM +'G\.G
MI5G]YHR17=E=&ZL7;:Z$]* .<HK4U^S2UU - ,13*)% ' ]?\^]9= !1110
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M^.*Q[CPOX<>3$/B"73W'WK?4+8K(O\JP]3\3:MJ][%=7MXYD@;=#L^41GKD
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ME0 WQ).CWZ01'(@C"$^_^<5CTI)9B6)))R2>])0 4444 %%%.1#(ZJO5C@4
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MNIV6L:=#?Z9<QW5K,-T<L9R&_P ^E7*G.*NT2I1;LF6J***@H**** "BBB@
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M%% !1110 4444 %%%% !6%XW_P"1!U[_ +!\_P#Z :W:PO&__(@Z]_V#Y_\
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MNPJ[0$ )!Q]58?A7)S>.O$FH_"+5O$^I1V4D;7R1V4$UJKH$WX)(/WN3C/\
MLUD?%72]3\/^/+N#0@1;^+84B= /O2;UW >Y./P<UV'Q0T:'P]\!QI-M]RT^
MSQYQ]X[QEOQ.3^-3:%E.WQ-+TUU+]Y-P[7?X:?UY')?%YO$-YX,T"^FEM4T.
M2"W98(D"L+AHR2< <*!G S^%=3K>M?$7PI\/_P"V-0N-.EFM[E-Z01;E-NP
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MR;GYD;K[>U5L(FMK=;:$(O)ZL?4U+114%!1110 4444 %%%% !1110 4444
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M'^"K3PO:^8VVXU"0?O)\?=']U?0?S_0=/117E2DY.[.^,5%604445(PHHHH
M**** "BBB@ HHHH *\JT:^\26GCSQDOAW1K748VOXS(T]YY)0^6, #:<UZK7
M*^%-&O\ 3?%'BF[O8/*@U"]26V?>I\Q1& 3@'(Y]<5<&DW?M^J(GJEZ_HR[H
M5]XDNWG7Q!I%KIB*@\IX;OS]Q[Y&!C%>?W:>$R+G[=XLU?6->!<_:M-DG<PM
MS@*D644#T/O7INOZ?-JWAW4-/MI_L\UU;/$DO]PLI -<;I+^*[+PI!X<L/"J
M6%S#;BW-\]U']F7 P9%"G>Q/7! YZFG%Z-K1C?1,S7UW5)OAUX6\:RW$K2V$
MJG4%0D+/"S&-V91P2.&]N:W_ !G>3:IK?A_PYIES)&;Z?[7=2P.5(MH^2,CD
M!C@5/X.\-3VWPMM?#WB"W\N1K:2"XB+*V S-W!(Z'UK.^''A;6]*N[R_\5!3
M=Q0QZ=9L&#9MH^C<$XW$@X//'2M9.//)KHVU^GW/4S7-R+NU;^OE?\!&M[CQ
MYXRU>RO+ZZMM#T5TM_LUI,8C=3%=S%V7G:,@  U%>V<OP[\1:--I5]=RZ-JE
MVMC<6-U.TPB=\[)(V8DCD<C/-7K[2M<\->++[7?#=BNK6>J!#>Z?YPBD211@
M21EOE.1U!Q35TW7?&'B#3KWQ!I@T;2M+F^TPVCSK+-<3 85FV\*JY)QDG-3%
M[=NOZ_\  *DM^_3]/^"9VFZ$WB;X@>*UU35-2^PV=U"L-G!=O$@8Q ECM(/X
M=.35WQFN@_V['_PEGB>>&T\D"#2+:5XV=LG+L(CO?V'08-:WAK2+[3_%7BB\
MNX/+@O[J*2V?>I\Q1$%)P#D<COBLB.SUOPOXTUS4H- ?7(M6=)(KBWGC22':
MN/*8.1A>X(I)W:5]DOOLOQ_R#HWYO[KLH^"]51M9\1:/IUSJ$^D0V:7%JNHI
M()(BP8,H,@#%. 1FJ7PX\#KKO@/3;SQ)J%]/&T1%I:P73PQP1@D X0C<QZDG
MV':MSP_HOB4^,=?U?7K2&%=0L8XX$AF#K&1N_=YX)(R"3@#)XK.\&KXX\%>%
M[32[_P .?VO$JDQ_9KN-9+<DY\MPQP1GHRD\5=]'9ZZ?K^/]=2;:KMK^AJ>&
M[B]T'QEJ'A&\OIM0M/L8OK":Y;=*B;MK1LW\6#T)[5RVG>))O#OP2T);2Y%G
M/J%Z]H+HIO\ LZM,Y9P.Y"@X]Z[/PSH6K2:]J'B?Q-%#;ZA>0+;06<,F\6L(
MYVENC,3R2..*RM,\$:G)\+M,TR?;8:UIMR;RV+L'5)5E9EW%2000<''K2O'[
M7]V_X_IN59_9\[?=_F85]<>#['2Y;OPYXHU6+7(4+Q74LUS)Y[@9VR(P*D-T
M(P.M>@V^KRZQ\./[69&MY[C36F91D%'\LYQWX-9DNO>-KJV-E:^$ULK]AM-[
M/>1O;1?[8 .]AW P/>NDO[:ZG\-W-JS+/=R6C1DJ-@=RA' )XR?>LZK]QK]2
MJ=N='GWAKP2-;^'VGZKJ.MZL^KS68EAO%O9%\CC*@*#@XXSD$GFE\'^'6\=^
M#[?7O$VK:E+J-R&$4EO=/ MN$8H"B*0,_+DD@Y)KLO">FW>F> M+TZ^B\J[@
MLDBDCW [6"X(R#@_G57X<:/?:#X T[3=6@^SW</F>9'O5L9D8CE21T([UK.>
ML[/KI^.WX&<8^[&_S_#<S?#>J:EJWPON'U#6DL+VV>>U?5'1<+Y;E?,() S@
M=?7FN,US4O#>A:,VJ>#M<UF\U>T9'-UYEQ/#<?, PE8CR\$9Z8YQ6])X)UN?
MX=OIYMH_M<.M27_V*65=EW%YQ<(6!(&X$'G\:?XR3QAXQ\(7.DZ9X9;2T8*9
M!<W46^7# ^6@5L <?>8C@<#FG%KGO?JK].WX;Z#MI;U_/^M2WXNMKK6/B'X9
MTU-3O+&UN;2YDN5M)C&9% 4[<CIUZ]<9Q5/7IM*\$^.O#3W-Q)%8VEA>X::5
MI78DJ0H+$EB2< 5T=]HU_-\0O#^IQP9L[.SN(IY-Z_(S!=HQG)S@]!3-<\.S
M:I\1_#VIR627%C807&^1RI$<AV[#M)R3P>0.*B,DN5=/>_\ ;OZ0FFTV_P"[
M_P"V_P!,J^"YKGQ=-_PEFH7;+"Q>*RTV*0A+90<$R#^*0X[_ '>U<M%XB\/>
M*=4U*[\8ZU=Q00W4EO9:=;O/'&D:'&]C$!N9B">3Q791Z'J'A_QP;_0K?S])
MU9LZC;*ZK]GF[3J"1D'HP'/?!JI;VFO>"M0OX])T@ZWHU[</=1I!.D<UK(_+
MKAR RD\C!R*$XWNNVGE_7?J59VMY_P!?\,9OA'5+:]\1:GX6L-4OM2T2:R\^
MWN)6D$ML<[7B$C ,>H(/4>M1?#GPEI]EXD\0RV\U\O\ 9^JM'%']K?8P\M>7
M7.'/S'DUV?AZ?Q'>W-U=Z_:P:=:N%6UL%<22ICJSN.,GT&<>M9.C6.M^'_&F
MK1KI?VS2]7O/M8OHYT7[.2@#*Z'D_=&,9ZT^9W:\N_FOT$UI\_T?Z_U8[.BB
MBN<U"BBB@ HHHH **** "BBB@ H(R,'D444 9%[IQCS) ,IW7TK/KIZHW>FI
M-EXL(_IV-4F*Q@SVT=POSCGLPZBLN>PEAY WKZBMV6&2%]LJE3_.HZ=KB.=H
MK<EM(9N709]1P:J2:5_SRD_!A4V'<SJ*LMI]PO\ !N^AJ,VTXZPO^"TAD5%2
M>1,>D3_]\FG"TG;I$WXC% $-%6TTV=OO;4^IJS'I<:\R,7]AP*=F!F*K.V$!
M8^@%7[?3"<-<' _NBM".)(EQ&H4>PIU.PKB(BQJ%0!0.PIZ(TCA$4LQZ 5/;
M6,MS@@;4_O&MBWM8[9<1CD]6/4T7$165BML-[_-(>_I5NBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBD==\;*21N!&5."/H: .#M-&\4^"9+J+PU;6>
MM:-+.\\=E+-Y$\!8Y958@JRYR1G%:-MXM@U[0=;B2WN=-U.PMW%S9W VR0DH
M2K C@@XX(-4[&?Q=X4B;3I]*F\36B,?LU]#=(L^TG(659",D9QN!.:ET+P]J
M=_K&LZ[XCMX[";5+9;..RBE\PPQ 'EV'!8D]N!ZUK)7B[]M^I,7:2?F:7@2>
M6Y^'NAS7$KRRR6,;/([%F8[>I)ZFO/I]2U0_ ..ZMKV?[>=0V),TK;O^/LJ
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MEX=UR]^QZ1K%I>7&TOY44F6P.IK;IJQHIRJ*#Z@4ZL';H:J_4****0PHHHH
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M'@]U(_&G^$?#M]I$VJZCK$UN^H:M<">:.U!\J+"[0JYY/'4G&:GFO#5_U?\
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M<@8 VCUJHP<I6)<DE<]1HKGPSQ^(-:9=:$^VTC*Z>/O6IPWS]?XOIVJO\/\
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M#OL(I9+Z7:8G%NTD2+N 8LPX'!XYZD5T&D^(K#5])DU&%I8;>$D2/=0M!MP
M2<.!Q@]>E'*^7FZ!S+FMU(] \*:5X;,[Z;#(9[D@S7%Q,TLLF.@+L2<#TZ5L
MUR ^)WA[B4_V@M@6VC46L)1;'G&?,VXQ[]*V]9\1Z7H.EQZCJ=TL5I+(D:S
M;ERWW3D=O?I3DIW]X2Y>AJ45REI\2/#]UJ-O:%KRV%V^RVN+JSDBAG8] KL
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MX[8X"X YXI1E%*_D_P!0DF]%Y?H4?AO_ ,S1_P!C!=?^RUVM9>B:!:Z#]O\
ML<DS_;[R2\E\U@<.^,@8 XX[Y^M:E9R:;7HOR+6[]7^84445(PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K,E\-:+/K:ZQ/I=I)J*XVW3Q N,< Y]1ZUIT4TVM@W"BBB
MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% $-K96MC&Z65M#;H[F1EBC"!F
M)R6..I/<U-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>lgnd-20231231_g4.jpg
<TEXT>
begin 644 lgnd-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :Y#9(# 2(  A$! Q$!_\0
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MZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\
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MG_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\
MDFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZ
MJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\
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M^J?_ "31_P .N/V8O^B9_P#E?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\
MR31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9
MB_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]
M4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\
MY)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^
M5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7
M_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\
M*_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_
M ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/
MV8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5
M_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_
M .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ*
M/E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S
M%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__
M "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI
M_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#K
MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
ME?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4
M_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DFOJJB
M@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_X=<?
MLQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))KZJHH ^5?^'7'[,7_ $3/
M_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^
MJ?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_P
MZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_
M )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_
M5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJ
MHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7
M'[,7_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$
MS_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*
M_JG_ ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?
M\.N/V8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G
M_P"5_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E
M?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^
MJJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_A
MUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\
M1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\
MROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-
M'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B
M9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\
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M31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\
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M,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\
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M1_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\
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MJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH
M^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^
MS%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_J
MG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P D
MT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_ ,DT?\.N
M/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/V8O^B9_^
M5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))K
MZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2:^JJ*
M /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_ (=<
M?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_RO
MZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\
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MG_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\
MDFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZ
MJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\
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M2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _E7HHHH _?[_@EQ_R8G\,O^XG_P"G2[KZJKY5_P""
M7'_)B?PR_P"XG_Z=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HKF?B)\3/"GPE\-3>(/&7B"P\-Z-$0IN]0F$:LQ!(
M10>68X.%4$G' KY(\0?\%@OV?M&U!K:UE\3:Y$'*?:]/TD+$1D_,/.DC;'']
MW/(XH ^W:*\(^ _[;WP=_:,O#IWA#Q9#_;>3C1]3C-I=N!WC1\>8,<_(6QWQ
M7N] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>(_%7]L+X=?
M!OXQ>%_AEXDN=0B\4^)%M6L([>S,D+"XN'MXMS@X7]Y&V?0<U[=0 4444 %%
M%% !1110 4444 %%%% !1110 4453UG6+'P[I%]JNIW<-AIMC ]S=7=PX2.&
M)%+.[,> H ))/84 7**^(-:_X+"? #2=<EL+<^*-6MXV91J5EI2BW?&.0))4
MDP<G'R=C[9^VK:<75O%,%9!(@<*XPPR,X(]: ):**^9-?_X*5?LW^%]=U+1M
M2^(ZP:CIUS):7,2Z+J,@26-BCJ'2W*L P/*D@]B10!]-T5\J_P##T;]F+_HI
MG_E U3_Y&KZ/\$^,]&^(GA'1_$_AZ\_M#0]6M8[RRNO*>+S87&5;8X#+D'HP
M!]J -NBBOG3QI^WM\*/AS\:%^%_BB[U70?$K74-JLE[I[):'S<>7)YV=OEMN
M'S]!SG&#@ ^BZ*** "BOG>3]O#X52?';_A4.FW6JZYXT^W?V<T.EV#30+,!F
M0&7( $8W;VZ+L;/0U]$4 %%%% !1110 4444 %%%% !112,P522< <DF@!:*
M^5_BM_P4T^ /PGU673+CQ;)XEU&%BLL'ANW-XL9!Q@RY$1/7@.2,'.*P/A__
M ,%8OV??'6JVVGW&LZMX3EN&V)+X@L/*A!XQNDC:14!SU8@#')% 'V/1572]
M5LM<TZVU#3KRWU"PN8Q+!=6LJRQ2H1D,K*2&!'<5:H **** "BBB@ HHHH *
M*** "BBB@ HKR_\ :&_:.\&_LP^"[+Q3XXFO(-)O-033(FL;8SOYSQR2 %0>
M!MA?GZ>M=KX'\7Z=\0O!>@>*=(:1])US3[?4[-IDV.89HUDC++V.UAD=J -N
MBBB@ HHK'U#QAH>E>(M*T&\U:SMM;U42&QTZ291<7 C4N[(F=Q554DG&!^(H
M V**XKXS?%[P]\!OAKK'CKQ7)<0Z!I7D_:7M83+(/-F2%,*.OSR+^&:C^"OQ
MD\-_'[X<:9XX\)2W$V@ZBTRP/=PF&0F.5HGRIZ?,C4 =S1110 4444 %%%%
M!117R1X]_P""HGP,^&_C?7O"FM7^N)J^B7TVGW:PZ6SH)HG*.%;/(RIYH ^M
MZ*^*O^'O/[//_01\0?\ @G?_ !H_X>\_L\_]!'Q!_P""=_\ &@#[5HKRS]GC
M]I3P7^U!X1U#Q)X&GO)],L;YM/F:^MC XF$:2$!2>1MD7GZUZG0 4444 %%8
M^H>,-#TKQ%I6@WFK6=MK>JB0V.G23*+BX$:EW9$SN*JJDDXP/Q%;% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '\J]%%% '[_ '_!+C_DQ/X9?]Q/_P!.EW7U57RK
M_P $N/\ DQ/X9?\ <3_].EW7U50 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDU*Y6(S,!DJBDY<X[*":\Y\%_MS_  %^(&O1:-HGQ0T.;4IF"10W3O:>:Q.
MJ-,J*S$] "2:_/#]C7]GV\_X*-?%+QC\8?C5?7NK^';&\%G;Z7#<M%%-,1YG
MV92IW1P11O'\J%2QD!W9W9^J_P!H#_@E7\'?'WP]U&'P+X<3P7XPM[=FTV\L
MKF4Q2RJIV13I([*48X!< ,.N3R" ?;-<?#\8? ]Q\1I_ ,7BO27\;0)YDN@+
M=(;Q%,:RY,>=P&QE;Z$&OB+_ ()%_M(>(/B!X1\3_"WQA=S7FK^#_+?3YKMR
MT_V-F:-H&)Y/E.H )Z"0+T45\Q?M3^&/$OC[_@JSXI\&^%M:N- OO$\NFZ/<
M7]J</'9RZ5:_:<$<X\H/D C(R,X)H _2[Q!^WI^S]X7\13:'J'Q3T--1AD\J
M18&DGB1\X(,L:-&,'@_-QWQ7K7_"Q/"O_"$_\)C_ ,))I/\ PB?V?[5_;GVV
M/[%Y/_/3SMVS;GC.:^7=4_X)2_L_W'PXN?#EEX9N+76&M6BA\227\[WB3X^6
M9AO$;<\E=@4CC K\\_\ @GW\%-9_:E\47GPH\6^(]3A^%'A6>3Q!?Z#:3F-;
MF\8I"J;@,@':2>> 'V[6<M0!^JWAO]O#X >+O$$.B:9\4M#DU&:7R8DG:2!)
M')P%621%0Y/3!YR,=17O.<\CD5^:?_!0#_@G?\(/ 7[-OB#QOX \.MX5U[PV
ML$_^CWD\T=W"94C=)%ED;! D+AQ\V4 )(-?1O_!-/X@:E\1?V-? =YJ]U)>Z
MA8K<:6]Q*<LT<$[I"">^(A&N>^V@#U?1?VE/A3XC\,ZSXBTSXB>&[S0=%V?V
MCJ46I1&"U+YV"1\X4M@X'4XXKCO"O[>'P \::Y%I&E?%+0WOYG\N-+II+57;
ML \JJI)[8//'K7Y&?\$Z?V8W_:L^(6I>'O$&HWT'PWT,1:OK%C:3F,7EQ\T=
MO$<="09OF'(4.%*ELU^D/Q^_X)>_!SQ]\+]1T[P5X3M?!_BRUM6;2=0L)74/
M,JDI'/N8AT9L!F/S#J#Q@@'V6K!E!!R#R"*QO&'C;P_\/M"GUKQ/KFG^'M(A
MP)+[5+I+>%2>@+N0,GL.IKX4_P""0O[06N?$#X<^)OAKXINYKO5O!<L0LI;I
MR\OV.3>ODDG)(B>,@<\+(BCA157]I#]C;XJ_M9_ME:5<>-XGL_@1I($=J;/4
MXM_EK$&DQ#NW+)--\I?;D(%Y^44 ?0#_ /!1;]G&.\-L?BII1D#[-RV]R4SG
M'WQ%MQ[YQ[U[EX+\=>'?B-H$&N>%M<T_Q%H\Q(COM,N4GB)'5=RDC(SR.H[U
M\_:I_P $V?V;KKPW)I9^'%G90K$RB]AO;E;B/C[_ )ID))'7YLCU!KXO_P""
M9=S<?!O]N3XI_"72-9;5_")BOHXY-P99VM+A1!/\IV[O+=P<<'=["@#]/O'W
MQA\#_"RZTBV\8>*])\-W&KN\>GQZE=)"UTR% PC#'YB#(F<?WAZUQ/CK]LGX
M*?#/QJ_A+Q-\1M&TGQ!&RI-9R.S>0S=%E=5*1G&#AR, @G@U\,_\%OM0GTK4
M/@3>VK^7<VTNLS1/@':ZG3RIP>#R!7<?!O\ X)/_  Y\;?"/2=?^)6HZ_J_C
M_P 10+K&I:I;:AY?E2SCS2BJ4(8C>-S.&+,&(P#@ 'N7QF\$_LU>//CS\/?%
M?CGQ%I/_  L1+?3YO#*_VZT)NH1=/):/%$CA95:9GVG!#=.17TY>7EOIUI-=
M7<\=K:PH9)9IG"(B@9+,QX  [FOR=_;^TZVT?_@I1^SI864"6UG:V?AR""&,
M86.-=9N%50/0  ?A7J__  6D\>>(O#?P3\'Z!I<UQ:Z)KVJ2IJLL+%5E$48:
M*!SW5F9GQW,(]* /HS6O^"@O[.^@:E)877Q5T5[B-BC&T$US'D$@XDB1D/([
M&O8/ /Q*\*?%304UKP?XBTWQ+I3-L^U:9<I.BMW5MI^5O]DX-?)'[.O[(/[(
M/Q(^%^E_\(GHNB>.EDLHS=WUQJ$DFH;RH#-,HD#0/GJH" $\ <5A_LX_L#>/
M/V7?VNM5\3^"?$&GQ_!F^1XI])O;Z9KV:%X2R)L$11FAGQM=G!*9YRS4 ?>^
M<<G@5X/XN_;M^ /@75IM-U?XI:$E["[1RQ6;O=^6P."K&%7 (/&":^3_ /@K
M+\>/%DOB+P3\ ? MU-;:EXL6.741:R^7)=+/.8+:UW#[JNZN7'<; >"0?9/A
M'_P2O^!7@/P/:Z9XD\,KXVU^2$"_U?4+J=3)(0"PB1'58U!SMP-V.K&@#Z9^
M''Q8\&_%_0_[8\%>)M,\3Z<#M>;3;E9?*8_PNH.4;_98 UH^,_&V@?#OPU>>
M(?$^KV>@Z'9[/M&H7\PBABWNJ)N8\#+LJCW85^1?[2WPNU'_ ()>_M'>#?B)
M\+;V^'@C77<3:/<7!=2L;J9[*1CR\91U:-GRRD$Y)3<?M?\ X*5:U:>)/^"?
M'CS5K"3SK&_M](NK>0?QQOJ-FRG\010![;XH_:5^%G@SP+IWC+6?'NA6/AG4
ME9[#4&O%9;T*<-Y"KEI2.X0$UB_#+]L;X+?&+7DT3PC\1='U36).(K%W>WFF
M/I&DJJ9#[+DU^??_  3G_8E\.?M+?#FW^(GQ=DO?%.EV#MHOA[06O)(;:"WA
M.69O+*MCS';"A@,ARP8MQ4_X*:_L-^ OV>_ .A?$WX7VESX5FAU>*RO-/@NI
MI8\NCO'<1N[LT;*\0& <'>",%>0#]=**\Q_9C\?ZA\4_V>?AWXLU8AM5U;1+
M6XNW48#S&,!V [98$X]Z].H AO+R#3[6:ZNIX[:VA0R2S3.$2-0,EF8\  <Y
M-> ZM_P4"_9WT74C87'Q7T-YPVW=:F6YBSG'^LC1D_'-?%W_  4&^('B[]IK
M]KCPO^S%X2U233M$6:V751"^$FG>/[1))* 1O2"WPX3^\&[[<?4WAC_@EW^S
MKX?\'Q:'=>!SKD_EA9]6O[^X^US.!]_<DBA#[1A5]J /I3P;XW\/?$/0+?7/
M"^MZ?XAT>X_U5]IMRD\3$=1N4D9'<=1WKY)_X*>_'+P?H?[,/Q(\#Q^+M*@\
M<W-O8I'H)NE%X\3WEN7Q'G<08M[?0$U\DZ?9:S_P3 _;JT3PWIFLWE]\*_%[
M6WF0WD@(>UFD,1>0#"^;;R!B& !*#' <BOIG_@J?^SY\/;K]G7XA_%27PU _
MQ M8]-BAUOSI?,13?6T)&S?L_P!6[+]WOZT >>?\$U=-_9MN/@#X4T;Q/'X"
MU?XF>(+RZ%UINMPVUSJ#M]IDC@B"2@L 8TC8*.#NSWK],:_/_P#X)F_LL?"O
M6OV<?A?\4;WP?;7'CU)[VY76FGG$@DBU"YCC;:'V?*B*/N]J_0"@#"\=>*8/
M W@?Q#XDN<?9M'TZXU"7<<#;%$TAS^"FOR=_X)A_L=_#[]IKP3X^\:_%/PZ_
MBAFUE+.RD>_NK79((_-N&_<2)N+&>+[V<;>,9.?T!_;TFU]?V1?B3:^&='U+
M7M:U#3AI\5CI5K)<SNDTJ13$(@)VK$\C$XX -?GM^R-^RG^U)\1/@W%H>F^.
M+[X(> H+Z>5(?+GL]2OIV(621ECV2E!M"?.ZK\HPIY- 'V[_ ,.N/V8O^B9_
M^5_5/_DFOH_P3X,T;X=>$='\,>'K/^S]#TFUCL[*U\UY?*A085=[DLV .K$G
MWK\G_B->?M8?\$W=5TCQ-JOCN7XG> +F=;61=2O)[RUW$$^2ZS'S+=B%8J\9
MVY').2I_4'X'?%_1OCU\)_#?CW0-R:;K5J)A#(07@D!*2Q,1QN2174D<';F@
M#NJ^)_\ @I]^Q[_PT+\*_P#A,/#=EYOC[PI \L*1+F34+(9:6WXY9EY=!SSN
M4??S7VQ10!\/_P#!+G]K[_A?GPK_ .$(\27OF^._"<"QM),^9-0L 0L<_/)9
M,K&YYYV,3E^.W_X*'?M;Q?LM_!B9=(N4'CSQ$'LM%BX+0<8ENR/2,,,9ZNR<
M$;L?&?[9WPHUK]@G]J7P[^T!\.K,KX2U;4&>]T^+*PQ7#Y-Q:M@86.=-[)_=
M8-@#8M:?[._@75/^"DW[6FL_&OQK830_"[PQ<);Z5I-T,I,8_F@M2.00,^=-
MU!9POW6X /;/^"6O['LOPC\$O\5/&5L[^//%4/F6R70)EL+%R'&[/(EF.'8G
MD+L'!W@_<?B3Q-I'@_1+O6=>U2ST72+1/,N+[4)U@@A7U9V( 'U-:73@<"OR
M2_:(U/7?^"@7[?4?P1M];N=*^'/A2YEBO([5NK6X_P!+G*\J92Y,"%@0H(..
M7! /N2/_ (*'?LYS:D+!?BKHXG,GE[FCG6+.<9\TQ[,?[6['O7ONC:UI_B/2
MK74])O[75--NHQ+;WEG,LT,R'HR.I(8'U!KYEN/^"8O[.5QX/.@#P L1\K8-
M4CO[@7P?;CS/-+\MGG:04S_#CBOEG]B?7]>_8[_;@\3_ +-&JZI<:UX2U9WE
MTF69L+!*+<W44H7.%,D68W"CF0)V% 'ZDW%Q%9V\L\\J001*7DDD8*J*!DDD
M\  =Z\!\1?M__L\^%]3DL+[XK:')<1\,;$R7D?T\R%'4_G7F7_!2CX._&WX_
M>$?#/@KX7V<<GAN>X:?Q [:C%:M+@H(48.REXUR\C+SDJG&5%=%X _X)B_L^
M^#/"5II-_P""(/$U^L"I=ZMJEQ,T]Q)@;G #A8\GL@&/UH ]N^%/Q^^'7QPM
M9I_ GC+2?$WDJ'FALK@&>%3P"\1PZ GNRBND\9^-M ^'?AJ\\0^)]7L]!T.S
MV?:-0OYA%#%O=43<QX&795'NPK\>_C9\-=!_8?\ ^"AWPQE^%E_):Z5J-S93
M3Z9]I,YM5FN6M[BU)+%BC1\@.21OZ\ U]Z_\%1_^3$_B;_W#/_3I:4 >F^-O
MVN/@Y\._#.A^(-?^(>BV>D:XK2:9<1S&?[6BDAGC6,,S(",%L8!XSFNV^'?Q
M-\*?%SPS#XA\&^(+#Q)HLK&,7FGS"15< $HPZHX!&58 C(R.:_*O_@GW^PGX
M>_:J^&,GCWXK:CJFJZ=:DZ#H&EVET8%M[>')9R0,_?D;:H(&0Y;<6X_3?X!_
M GPQ^SA\-;'P/X12Y_LBUFFG$MXZR3RO+(SDNP50Q (4<?=11VH ]$K\S_\
M@JM^TOXHN/%/A[]GGX=RW"ZQKX@;5GL92LT_GN8X+$$8(#\,_JK(.A8'],*_
M('P?&GC?_@M=>-JL?FK:ZS>-''-D\VNF2"$CZ&)&'^Z* /L7]FS_ ()H_"+X
M*>$;)/$?AG2_'_BZ2(&_U37;5;J#S#R5A@D!1$!X!V[CC)/8=+\=O^"?/P7^
M-WA2^L%\&:/X1UQXV-IKGA^QCLYH)L?*[K&%69<XRKYXS@J<$?2E% 'YH?\
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MROJ_@']GO2(='UA;<V6DP)>^2+*.:8M/(DLK9#[7E*G=D,P(Z4 ;?Q,_:_\
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M89AD*&=SCU8U]IW'[$/P"NH7B?X1>$@K#!,>F1HWX,H!'X&OR:_8I_X*0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?RKT444 ?O]_P $N/\ DQ/X9?\
M<3_].EW7U57RK_P2X_Y,3^&7_<3_ /3I=U]54 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5P/Q\^'1^+GP3\<^#$8)/K>CW5E YZ+
M,T;"-C[!]I_"N^HH _+?_@BW\5(=%7XA_"+6&.G:U'>_VU:65PI21V"K!=)@
M]&3RH/EZ\M_=-?J17YW?MG_\$[/%GB#XJ+\:/@)J:Z)X[-Q]LOM-%T+0RW
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M\ ]-;QYX!U0_O]#5#<3"$,S)!-"")'*9.R6(D^N-Q4Z/Q(^/'[9'[5GA2Z\
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M[-0MI'P">R(S?0&@#D_^"52JO[#O@,A0"T^I$D#J?M\XR?P _*N6_P""PO\
MR9^__8P6/\I:],_X)U_#SQ)\*_V1_!OAKQ;I%QH6O6<M^T]A=@"2,/>S.F<$
M]593^-<Y_P %//A;XL^,'[,;>'_!FA77B+6?[:M+C['9J"_EJ)-S<D<#(_.@
M#T']A7_DS_X2?]B_;_RKW6O(/V0?"FK^!?V8_AKX?U^PFTO6=.T6"WN[.< /
M#(!RK>XKU^@#\E]#N(_!O_!;6\_MHK$+Z\E2VFG8 !I](_<@'U8LL8'JV*_6
MBOAS_@H1^PGKOQ\UG1/B=\,KR/3OB9H*1H('E$ ODB?S(624X"31L3M9N""
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M23^GWP[\ Z-\+? NA>$?#UM]DT71;..RM8NIV(N-S'NQ.6)[DD]Z .BHHHH
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MY?7EH+V0E,JCQ;_- 9&R..0<BL>W_;F_;";0VT,_LSZB_BE%\G^V6T:_6T+
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M99"3D\^4I[T >@_\%3-+N]4_8B\>?9$:3[/)87$JKU,:WL.X_09W?AFOB?\
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M]MSP9K?Q"_95^(OAWPYILVKZYJ&GK%:V-N 9)6\Z,X&?8$_A0!Y+_P $D_\
MDRWP_P#]A/4/_1YK[*KY;_X)K_#7Q1\)?V5=%\.^,-%NO#^N0ZA>RR6-X )%
M5YB5)P3U'-?4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '\J]%%% '[_?\ !+C_ ),3^&7_ '$__3I=U]55\J_\$N/^3$_A
ME_W$_P#TZ7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y5_\$0](OM+U3XPF
M]LKBT#PZ3M\^)DW8:[SC(YZBOU4HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*9-,EO$\LKK'$BEF=S@*!R23V%0:7JMEK=C%>Z=>6]_9RY,=Q:RK)&^"0<,I
M(/((_"@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!_*O1110!^_W_!+C_DQ/X9?]Q/_ -.EW7U57RK_ ,$N/^3$
M_AE_W$__ $Z7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >7?M
M/?&:#]G[X"^,_'<IC-QI=BQLHY>5ENW(CMT([@RNF<=LGM7Q#^P;_P %#OB/
M\6/CU:^ /BS]@@BU[2S<Z)+;V(MF:8*)4Y!PRR1"0C_:50.35+_@KW\1-1\>
M>+OAA\ ?##?:-6UB]BU"ZMT)^:65S;V<9([9:9B#_L'TKF?^"F'P3G_9KNO@
M1\5? R_9W\(PV?AUKA5VCS+0"2S=P.N\).K9ZA5'.: /UBHKEOA9\1-,^+7P
MW\->,]';=INN6$-]"I.2F]02C?[2G*GW4UR'[3'[27A7]EGX8W/C'Q2TLZ>:
MMK8Z=:X\^]N&!*QIG@<*S%CP IZG (!ZQ17YMZ?^WU^U3X\TQ?$G@[]FIIO"
MLZ^?:R7$-W-)/">59&!C\P%<89$(/;TKV?\ 8Y_X*'Z'^TYXGO\ P1KOARX\
M"?$*Q21VTFXE,D=R(SB4(S*K+(G5HV7(&2"V&P ?7M%?/W[8/[97A7]D'PC8
M7^KVDVNZ_JKO'I>A6L@CDN-@&]W<@[(UW*"V"<L  ><?+TG[=G[6Z:6?$1_9
ME=/#BIY[1M:7GVGR@,DXSNZ<Y\OISB@#](J*^:?V,OVY?"O[86CZE'9:=-X;
M\6:2JR7^AW$HFQ&QP)8I %WIN^4Y4%3C(Y4G _:%_;BOO@A^UC\-/@Y!X1M]
M6MO%_P#9F_5I+YHGMOM=_):G$80AMHCW?>&<XXZT ?6M%%?)7B+]N*^T/]NC
M3/V?E\(V\UG>>5G73?,)%WV9N/\ 4[,'!&W[WO0!]:T5\[_MQ_M57?[(/PGT
MGQC9^'8?$TM]K<.D&TGNS;A \%Q+OW!&R1Y &,?Q=>*\ \9_\%-/%WC.]M='
M^ 7PIO/B7J=M96]SK.HQ0SW%E9S.@9X$$0!?:25\QF4$J<*PYH _0>BOSS^
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MKXEK/_!3/XW?$#[7KGP>_9ZU76O UNSK'J^H:?>7;7(4_>'D!44CNBM)CN:
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M:?\ \%*/V@_BU;W6M?"C]G6XU3PK$[K'?7,-U>>:%.,!XQ&A?U1-Q'ZUZO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _E7HHHH _?[_@EQ_P F)_#+
M_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#ITNZ^JJ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J&\O(-/M)[JYE2"V@1I999#A451DL3V  J:OD;_ (*A?'#_
M (4W^RIKMG9W'DZYXM<:#:;6^81R*3<OCK@0JZY[&1: /S_^"?[37PW\8?\
M!0CQ-\;_ (K^)/["T"T>XGT&.6QN;HNP M[1"D,;[=D&7)('S@'J:^K_ -KC
M]MK]F#]H3]GCQIX(C^)"2:E>69FTTOH6I+MO(B)(/F-M\H+J%)_NLU-_X)__
M + _PTU7]F+PSXB^(O@?3O$7B/Q$7U99M05BT-K)@6Z+@CY3&JR?64U]&?\
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MJIX5C\=?M\?"7PU-DPZSHND:<^&VG;-JMW&>>W#5<_X(Y_\ )R7Q<_[!C?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#^5>BBB@#]_O\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)
M<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY>_
M:^_85TO]L+Q#X9OM?\9ZKHNG:#!)%!IMC!&Z,\C@RR%FY#,J1K[;/>OJ&B@"
MII.EVNAZ79Z;80):V-G"EO!!&,+'&BA54>P  _"K=%% 'S?^V+^Q#X8_;%M?
M#7]M:Q>>'[_0GF\F^L(4D>2.4+NC8-VRBD>G/J:Z_6OV8?"_CW]GW2?A-X]D
MF\8Z5I]G!:+J5P!#=%H5VQ3JR_=E"@ L.N6SD,0?8:* /SC_ .'0-_X;DN;;
MP-^T%XJ\*:).[%K#[&TA93CAFBN858X')V<\<<5[O^RK_P $\_AW^RWK4GB:
MVN+[Q;XVD1T_M[5MH, <8?R8UX0MSEB6;!(W8)!^I:* /)/VD/V7O G[4_@V
M'P_XVL9G^RR--8ZE8R"*[LY",%HW((P1C*L"IPN1D CXZC_X)!ZWIMJ=(T;]
MHOQ/IGAAOE?2%L'*,N2=ORW:IW_N=<G'-?I!10!\_P#[*O[$WP\_9)T^[;PO
M#=:GX@OXQ%>Z]J;*]S+&#N\M0H"QQYP=JC)PNXL0"-C]J/\ 9-\$?M:>#;30
M_%Z75M<Z?(\VFZKI[A+BSD8 -C<"K(VU=RD8.T=" 1[110!^:^A?\$9887CT
MW7/C?X@U/P>DF_\ L.ST[[+\N[( 9KB1 ??RNO.!7NWAK_@G+X \"_'KP1\2
M/"M]=:!;^$[-;2TT"")7AEPDJM))*QWL[&9F+'DFOK*B@#P_]KO]EG2OVNOA
MMIO@_5]<O- MK'5H]66YLHDD=G2&:((0W&")R?\ @(KT;X4^ ;?X4_#/PKX,
MM+N2^M?#^EV^F174RA7E6&-8P[ < D+GBNJHH ^:OVA?V(=#_:$^-W@7XDZA
MXEU#2;[PG]F\FQM8$>.?R;DW W,W(R3CCM7TK110!\U?#O\ 8AT/X=_M4>)_
MCA;^)=0N]5UW[5YFE2P(((O.*DX8?,<;>_K7I7Q^_9W\#_M+>!W\+>.=+-[9
MJ_G6UU;OY=S9RXQYD,F#M.#@@@J1P017I=% 'YM0_P#!'?4=%-WIWAS]H+Q)
MHGA>Y8^9I*:<QWJ>H=DND1CTY\OMTKZ3_91_8+^''[)K3:EH:76N^++F'R)]
M?U0J91&3DI"B@+$I(&<98XY8BOI*B@#A?C3\$_"/[0'@&]\'>-=,&IZ-<LL@
MVL4E@E7[LL3CE'&3R.H)!R"0?AW_ (= W_AN2YMO W[07BKPIHD[L6L/L;2%
ME..&:*YA5C@<G9SQQQ7Z.44 ?+7[*O\ P3S^'?[+>M2>)K:XOO%OC:1'3^WM
M6V@P!QA_)C7A"W.6)9L$C=@D'ZEHHH *^7/V4?V#-!_93^('BCQ5I7BG4==N
M->MS;R6]Y!'&D0,HDRI7D\C'-?4=% 'S+\=_V&=#^._[1'@?XMW_ (GU#2]1
M\*I8I#IUO!&\,_V:[DN5W,>1N:0J<=A7TU110!\U>*?V(=#\4_M<:1\>I?$N
MH0:OIOD[-(2!# _EPF(9?[W(.:Z7]KO]EG2OVNOAMIO@_5]<O- MK'5H]66Y
MLHDD=G2&:((0W&")R?\ @(KW"B@#E?A3X!M_A3\,_"O@RTNY+ZU\/Z7;Z9%=
M3*%>588UC#L!P"0N>*^%_B9_P1B\!>,?'FHZYX?\:ZGX2TN]G-P=&CL4N4@9
MCEEB<NI5,YP"&QZFOT2HH ^8_P!KO]AG1_VOK'P/!K_BS4M'E\+QW2+/9V\<
MANFG$ 9GW=#_ *.#Q_>->R_%3X-^%OC5\-[[P-XOT\:IH5Y$B.N=DB,F"DB,
M.4=2 01].02*[>B@#\Z=*_X)$ZAX-U*>/P7^T)XN\*^'9IC*^FVENR2MQA=T
MD5Q&I8# W>7SCH*] L?^"4'PCLOA5XD\,R7.IZGXFUY8_M'C+4BD]]"R3)+F
M%2 L88I@_P 3!B"QK[6HH \S_9Q^"B_L\?"'1? $&O7?B.RTDRK;7E[$L<HC
M>1I A"\$*68#VP.U>;?L:_L0Z'^QK_PE_P#8WB74/$7_  DGV/S?MT"1^3]G
M\_;MV]<^><Y_NBOI6B@ HHHH ^7/V4?V#-!_93^('BCQ5I7BG4==N->MS;R6
M]Y!'&D0,HDRI7D\C'-6?CO\ L,Z'\=_VB/ _Q;O_ !/J&EZCX52Q2'3K>"-X
M9_LUW)<KN8\C<TA4X["OIJB@ KYJ\4_L0Z'XI_:XTCX]2^)=0@U?3?)V:0D"
M&!_+A,0R_P![D'-?2M% !7R5^U=_P3G\&?M7?$G2O&6K:]J.@7UK9QV-S%I\
M4;+=QH[,I8MR& =ER.V/2OK6B@"OI^GVVDZ?;6-G"EM9VT2PPPQC"QHH 50.
MP  %<U\5/A3X6^-7@?4O"'C+28M9T*_4"6WD)5E8'*NC#E'4\A@0176T4 ?G
M#<?\$=V\.ZQ>2?#[X[>)O!FC71(DL?L9EE93QM:6*XA##!QRE>S_ ++O_!-C
MX<?LV>)H_%LMY?>-O&L19H=6U8*J6S,,,\4(R Y!/SLS'DX(R:^MZ* ,#Q[X
M#T'XG>#M6\*^)]-AU?0=4@:WN[.<?*ZGN".58$ AA@@@$$$"O@O4?^"/\'AW
M6KVZ^&7QN\5?#^SN7W?95@,[*,'Y3)%/ 6 S@;@2!U)SFOT3HH ^-OV;_P#@
MF+X!^!OC:W\<>(-;U+XC^-+:03VVH:NHC@@F'298MS%I!V9W;! ( (!KZ?\
MBE\,] ^,GP]USP7XHM6O-"UBW-O<Q(^QQR&5U;LRLJL#V*BNJHH ^$/V>O\
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ML22<L[L22[L<DL2237B-Q^PSH=Q^V4/VACXGU :R'5_[%\B/[/\ +8"R^_\
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M#DC/I7FO[(G[+.E?LB_#;4O!^D:Y>:_;7VK2:LUS>Q)&ZN\,,10!>, 0 _\
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MX6-SSU\K\*_2JB@#QC]F/]DWP'^RAX3N-'\'6LTMY>E7U'6+]@]U>,HP-S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E7HHHH _?[_ ()<
M?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_ "8G\,O^XG_Z=+NOJJ@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$VEEC']LTB\CNHMPZJ60D!AGD=17R%\(_\ @DG\#O"7@:SLO&>B7'C7Q+)
MIOM2FU*YMT64@%U@2%XPJ!NA8%L=3SBOD[XT^"+[_@EA^U7X*\2^ =:OI/AY
MXF+-<Z1>SE@\,;JMS;R$ !PBRH\;D;E)&<X)8 _8VO.?B5^T9\+_ (.W:VGC
M3Q[H/AR_9!(+&]OD6Y*$X#>2"7VGUQC@UA_M;?%+Q'\(OV>?%OB?P;I-YKGB
M>.W6'3(+&S>[9)975!,40'Y8PQ?)X^4 ]<5\1_L-?\$Z/"GQ;^'2?%3XXVVJ
M>*_$OB2YFN8]-U"\N(/)1963S)RC+(\KLC-\S;=K*,9S0!^AOPX^,G@7XOV,
MEYX)\7:/XH@BQYO]EWB3-%GH'4'<A]F KL:_'O\ ;E_9TM/^"?/CSP'\7/@C
MJ5[X;AN;U[632IKIYTBD51($!<EY(9$#*Z.6Z#GY@!^LW@+Q7#X\\#>'?$UO
M$T$&LZ;;:C'$QR46:)9 I..P;% &]1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?RKT444 ?O]_P2X_Y,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9
M?]Q/_P!.EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDC-((C'#YX1"W(BEM_WBJ3A"FT?>-;7_  PS^UE_T=3J'_@3>?\ Q5-^$_\
MP3:^*_A7]I3PI\6_&/Q;L_%^IZ3=QRW4UQ%.]S<0K&8S'O8_W"5&>U '&_\
M!;;5)=#U?X"ZC J-/9SZQ<1K("5+(VGL,X/3(KL/AO\ \$S;/]HKPY;_ !-^
M/GC'Q)K7CWQ3;QZA)!IUQ%;Q:?%(NZ. !HWY564;1A5^Z%.,GA/^"YW_ #1/
M_N-_^V%?J/HD:PZ+81H-J);QJH] %% 'X=Z5IWQ>_8__ &J_&/[/OPM\62B3
MQ1<6^D6MU.2JHERL4D5XH!Q'.D3E3(!Q\^!D*1]>:U_P1>\ :AX'NU7QSXFN
M_'TL32G6[R6(VLUV5)W/#Y9?RRQR1YA?_:->??$*-9?^"V?AL.H89M6P1W&D
ML0?S K]5J /S:_X(T_%WQ'KGAOX@_#;Q#?S7D'A>:VGTQ+B0N]NDAE2:%23Q
M&K1(54< NWK7S5^V%:^-M2_X*H>)M,^'5[-IOC'5)M/TNQO+=MKP"YT>W@E?
M<!E (I)"7'*@%@00#7LW_!('_DOWQY_[9_\ I5-3U:T7_@N?<?:P,E5$)8X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '\J]%%% '[_?\$N/^3$_AE_W$_\ TZ7=?55?*O\ P2X_Y,3^&7_<
M3_\ 3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z*** /W^_X)<?\
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M&SZ&@#IO^"X/BRXL_ OPK\,HV+74=2OM1D7/5K>**-/TNGK]$_AOX1M_A_\
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M$<BM!Y4Q"KEFC;>.1Y>.C&O%?^&=_P!IW_H[G_S&NE__ !R@#ZJHK^<KX"_
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M -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\
MT-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0
MT_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3
M\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P
M_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_
M /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\
M_P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_
M  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\
M!C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &
M-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8W
MW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??
M_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\
MAT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'
M0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(=
M'[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?
MM317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U
M-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T
M5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317
MXK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?B
MM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W
M_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\
M.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY
M4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3
MXW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C
M?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-_
M_0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]
M#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-
M/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_
M#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/
M_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__
M /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\
M\&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P
M8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C
M??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]
M_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_
M ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\
MR'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(
M='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT
M?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_
MPY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#
ME3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5
M/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^
M-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW
M_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_
M -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\
MT-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0
MT_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3
M\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P
M_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_
M /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\
M_P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_
M  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\
M!C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &
M-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8W
MW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??
M_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\
MAT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'
M0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(=
M'[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?
MM317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U
M-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T
M5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317
MXK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?B
MM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W
M_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\
M.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY
M4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3
MXW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C
M?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-_
M_0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]
M#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-
M/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_
M#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/
M_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__
M /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\
M\&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P
M8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C
M??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]
M_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_
M ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\
MR'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(
M='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT
M?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_
MPY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#
ME3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5
M/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^
M-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW
M_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_
M -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\
MT-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0
MT_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3
M\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P
M_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_
M /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\
M_P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_
M  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\
M!C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &
M-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8W
MW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??
M_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\
MAT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'
M0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(=
M'[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?
MM317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U
M-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T
M5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317
MXK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?B
MM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W
M_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\
M.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY
M4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3
MXW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C
M?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-_
M_0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]
M#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-
M/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_
M#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/
M_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__
M /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\
M\&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P
M8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C
M??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]
M_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_
M ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\
MR'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(
M='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT
M?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_
MPY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#
ME3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5
M/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^
M-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW
M_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_
M -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\
MT-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0
MT_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3
M\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P
M_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_
M /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\
M_P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_
M  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\
M!C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &
M-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8W
MW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??
M_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\
MAT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'
M0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(=
M'[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?
MM317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U
M-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T
M5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317
MXK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?B
MM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W
M_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\
M.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY
M4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3
MXW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C
M?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-_
M_0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]
M#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-
M/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_
M#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/
M_P#P8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__
M /!C??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\
M\&-]_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P
M8WW_ ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C
M??\ R'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]
M_P#(='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_
M ,AT?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\
MR'1_PY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(
M='_#E3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT
M?\.5/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_
MPY4^-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#
ME3XW_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5
M/C?_ -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^
M-_\ T-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW
M_P#0T_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_
M -#3\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\
MT-/P_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0
MT_#_ /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3
M\/\ _P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P
M_P#_  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_
M /\ !C??_(= '[4T5^*W_#E3XW_]#3\/_P#P8WW_ ,AT?\.5/C?_ -#3\/\
M_P &-]_\AT ?M317XK?\.5/C?_T-/P__ /!C??\ R'1_PY4^-_\ T-/P_P#_
M  8WW_R'0!^U-%?BM_PY4^-__0T_#_\ \&-]_P#(='_#E3XW_P#0T_#_ /\
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M6_X(J?\ )TWBG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_*O_@N=_S1/_N-_P#MA7ZJ5^5?_!<[_FB?_<;_ /;"@#[_ /V3
MO^36?@W_ -B9HW_I##7JM>5?LG?\FL_!O_L3-&_](8:]5H **** "BBB@#^5
M>BBB@#]_O^"7'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /Q6_P""*G_)TWBG_L3+K_TNL:_:FOQ6_P""*G_)TWBG_L3+K_TNL:_:
MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*O_@N=_P T3_[C
M?_MA7ZJ5^5?_  7._P":)_\ <;_]L* /O_\ 9._Y-9^#?_8F:-_Z0PUZK7E7
M[)W_ ":S\&_^Q,T;_P!(8:]5H **** "BBB@#^5>BBB@#]_O^"7'_)B?PR_[
MB?\ Z=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%;_@BI_R=-XI_P"Q
M,NO_ $NL:_:FOQ6_X(J?\G3>*?\ L3+K_P!+K&OVIH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "ORK_P""YW_-$_\ N-_^V%?JI7Y5_P#!<[_F
MB?\ W&__ &PH ^__ -D[_DUGX-_]B9HW_I##7JM>5?LG?\FL_!O_ +$S1O\
MTAAKU6@ HHHH **** /Y5Z*** /W^_X)<?\ )B?PR_[B?_ITNZ^JJ^5?^"7'
M_)B?PR_[B?\ Z=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#\5O^"*G_)TWBG_L3+K_ -+K&OVIK\5O^"*G
M_)TWBG_L3+K_ -+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "ORK_ ."YW_-$_P#N-_\ MA7ZJ5^5?_!<[_FB?_<;_P#;"@#[_P#V3O\
MDUGX-_\ 8F:-_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H **** "BBB@#^
M5>BBB@#]_O\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^J
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /Q6_X(J?\ )TWBG_L3+K_TNL:_:FOQ6_X(J?\ )TWBG_L3+K_TNL:_
M:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK_TNL:_:FOQ6_P""*G_)TWBG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_*O_@N=_P T3_[C?_MA7ZJ5^5?_  7._P":)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_ ."YW_-$_P#N-_\
MMA7ZJ5^5?_!<[_FB?_<;_P#;"@#[_P#V3O\ DUGX-_\ 8F:-_P"D,->JUY5^
MR=_R:S\&_P#L3-&_](8:]5H **** "BBB@#^5>BBB@#]_O\ @EQ_R8G\,O\
MN)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_X(J?\ )TWBG_L3
M+K_TNL:_:FOQ6_X(J?\ )TWBG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBI_R=-XI_P"Q,NO_ $NL:_:FOQ6_X(J?\G3>*?\ L3+K_P!+K&OVIH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !7Y5_\%SO^:)_]QO_ -L*_52ORK_X+G?\T3_[C?\ [84 ??\
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MK:Q(H4^HW70./50>PK[P^"7P]M/A/\(/!O@^Q@6W@T;2K>T*A0"9%C'F.?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5^5?_!<[_FB?_<;_ /;"OU4K\J_^"YW_ #1/_N-_^V% 'W_^R=_R:S\&
M_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM !1110 4444 ?RKT444 ?
MO]_P2X_Y,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M*W_!%3_DZ;Q3_P!B9=?^EUC7[4U^*W_!%3_DZ;Q3_P!B9=?^EUC7[4T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%4M8UK3_#]A)?:I?VNFV4?+W-Y,L4:_5F( H*C%R:C%7;/BC_@IM_S
M3;_N)?\ MK7PW7UA^WO\8O"'Q2U#P?:>%=9CUE])^V_:Y8$?RE,GD; KD /_
M *MN5R.G-?)]>%B&G5;1_8_!&'K87A_#4J\'&2YM&K/6<FM'W6H4445SGW1]
M5_\ !.'_ )+AKG_8NS_^E-K7Z.U^<7_!.'_DN&N?]B[/_P"E-K7Z.U[.%_AG
M\F^)'_(_E_AC^04445V'Y<%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5^5?_!<[_FB?_<;_P#;"OU4K\J_^"YW
M_-$_^XW_ .V% 'W_ /LG?\FL_!O_ +$S1O\ TAAKU6O*OV3O^36?@W_V)FC?
M^D,->JT %%%% !1110!_*O1110!^_P!_P2X_Y,3^&7_<3_\ 3I=U]55\J_\
M!+C_ ),3^&7_ '$__3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?BM_P $5/\ DZ;Q3_V)EU_Z76-?M37X
MK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%>2?&C]I[P1\$H9(=4OO[0US;F/1K AY^1
MP7YQ&.G+'..@-3*2BKR9VX/!8G,*RP^%IN<WT2O_ $O/8]:9@JEF(  R2>U?
M,_QO_;H\(?#?[1IGAGR_%VOKE2;>3_0X&_VY1]\C^ZF?0LIKX]^-W[6WC?XT
M-/927/\ 8/AQB0-)T]R%=?29^#)]#A?]D5XD 6( &37FU,7TIG[WP_X:0A:O
MG,KO^2+T_P"WI=?1?>SNOBG\;/&/QDU3[9XGU>6[B5BT-C'^[M8/]R,< XXW
M'+'N37(Z-HNH>(M3M].TNRN-1O[AMD-K:Q-))(WH% R:^AO@A^P[XQ^)OV?4
MO$ ?PCX>?#B2ZCS=SK_TSB.-H(_B?'4$!J^^/A3\#?!OP8TW[+X9TE+>=U"S
MZA/B2ZG_ -^0C..^T84=@*RIX>=5\TCZ3..-<HX=I?4\OBISCHHPLHQ]6M/D
MKOO8_,CQ3^R]\4?"<UA#<>#-7OY;JU6Z(TNSEO%@RS+Y<CQJ5$GR[BH)P&7/
M7%8O_"B?B7_T3SQ7_P""2Y_^(K]CZ*Z?J<>Y\!3\4\?&*4\/!OU:/QP_X43\
M2_\ HGGBO_P27/\ \11_PHGXE_\ 1//%?_@DN?\ XBOV/HH^IQ[FG_$5,;_T
M#1^]GQO_ ,$\/ GB7P3_ ,)__P )%X=U;0?M7]G^1_:=E+;>;M^T[MN]1NQN
M7..FX>M?9%%%=E.'LXJ*/RK.\UGG>85,PJ147.VBVTBH_H%%%%:'AA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5^5?_  7._P":)_\ <;_]L*_52ORK_P""YW_-$_\ N-_^V% 'W_\ LG?\
MFL_!O_L3-&_](8:]5KRK]D[_ )-9^#?_ &)FC?\ I##7JM !1110 4444 ?R
MKT444 ?O]_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_AE_W$_\ TZ7=?55
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'XK?\$5/^3IO%/\ V)EU_P"EUC7[4U^*W_!%3_DZ;Q3_ -B9=?\ I=8U
M^U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_2ZQK]J:_%;_@BI_P G3>*?^Q,NO_2ZQK]J: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M84444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8?$K[/J?B02>$?#[88?:(_\ 3)U_V(C]T'^\^.H(5A7FRG5Q#LC]\P>4</\
M!.'^LUI)2_GEK)^45^D5ZW/G?1-#U'Q+JEOINDV-QJ6H7#;(K6UB,DCGT"@9
M-?8_P0_X)ZW=]]GU;XDW1LH.'&A6,@,K>TLHX7_=3)Y^\IKZX^%?P1\'?!G2
M_L?AC28[65UVSWTO[RZG_P!^0\XSSM&%'8"N[KLIX51UGJ?EO$'B1BL9>AE2
M]E#^9_&_3I'\7YHQ_"?@_1/ NBPZ1X?TNVTC3H1\MO:QA5SZGNS'NQR3W-;%
M%%=^VQ^,U*DZLG.H[M[MZMA11100%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?E7_P %SO\ FB?_ '&__;"OU4K\J_\ @N=_S1/_ +C?_MA0!]__ +)W
M_)K/P;_[$S1O_2&&O5:\J_9._P"36?@W_P!B9HW_ *0PUZK0 4444 %%%% '
M\J]%%% '[_?\$N/^3$_AE_W$_P#TZ7=?55?*O_!+C_DQ/X9?]Q/_ -.EW7U5
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^*W_!%3_DZ;Q3_ -B9=?\ I=8U^U-?BM_P14_Y.F\4_P#8F77_ *76
M-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BM_P $5/\
MDZ;Q3_V)EU_Z76-?M37XK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1YA'NJD5R.M6JNT?P/TFAPIPQP[!5L6HMK[55I_<M(_A<\HU[Q%JOBC4'O\
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M59.4GU;N_O84444S(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"@#[_P#V3O\ DUGX-_\ 8F:-_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK_TNL:_:FOQ6_P""*G_)TWBG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK#1$R?IYT@_DGXU]S45UPPL([ZGY;F?B1G&,O'"VHQ\M9?>_T2/-/A[^S?\
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M[T*#Y%TOR7%N3WCD'([<<@X&0:X:N%C+6&C/V'AWQ%Q>7\N'S.]6G_-]M?\
MR7SU\^A^4'PN^,?BSX.ZT-1\,:K)9EB//M7^>WN .TD9X/UX(SP17Z!_ ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTG0M-MM)TZ$?);6L81!ZGCJ3W)Y/>M6BBN\_&YSE4DYS=V]VPHHHH("BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\J_^"YW_-$_^XW_ .V%?JI7Y5_\%SO^:)_]QO\ ]L* /O\ _9._
MY-9^#?\ V)FC?^D,->JUY5^R=_R:S\&_^Q,T;_TAAKU6@ HHHH **** /Y5Z
M*** /W^_X)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\ N)_^G2[KZJH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M![<-P?EQS7M]>I&2FKQ9_/6.R_%9;6>'QE-PFNC_ $Z->:T"BBBJ//"BBB@
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MX HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_1J/B#_PJ;#_  H ^JJ*^5?^&I/CM_T:CX@_\*FP_P */^&I/CM_T:CX@_\
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M_1J/B#_PJ;#_  H_X:D^.W_1J/B#_P *FP_PH ^JJ*^5?^&I/CM_T:CX@_\
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M@_\ "IL/\* /JJBOE7_AJ3X[?]&H^(/_  J;#_"C_AJ3X[?]&H^(/_"IL/\
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M  J;#_"@#ZJHKY5_X:D^.W_1J/B#_P *FP_PH_X:D^.W_1J/B#_PJ;#_  H
M^JJ*^5?^&I/CM_T:CX@_\*FP_P */^&I/CM_T:CX@_\ "IL/\* /JJBOE7_A
MJ3X[?]&H^(/_  J;#_"C_AJ3X[?]&H^(/_"IL/\ "@#ZJKS_ .-GQLT/X#^%
M;77]?M=0O+.YO4L4CTV.-Y!(T<C@D.Z#;B-N^<D<5XK_ ,-2?';_ *-1\0?^
M%38?X5XG^UI\9OB5\1/ASIVF^,?@EJGPVTR+58[B/5;[6K:\2680S*( D0W
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M$'_A4V'^% 'U517RK_PU)\=O^C4?$'_A4V'^%'_#4GQV_P"C4?$'_A4V'^%
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MLC^,O@H\]\83K_AE22NK649_=K_TVCY,9]^5_P!K/%?5W_#4GQV_Z-1\0?\
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M_1J/B#_PJ;#_  H_X:D^.W_1J/B#_P *FP_PH ^JJ*^5?^&I/CM_T:CX@_\
M"IL/\*/^&I/CM_T:CX@_\*FP_P * /JJBOE7_AJ3X[?]&H^(/_"IL/\ "C_A
MJ3X[?]&H^(/_  J;#_"@#ZJHKY5_X:D^.W_1J/B#_P *FP_PH_X:D^.W_1J/
MB#_PJ;#_  H ^JJ*^5?^&I/CM_T:CX@_\*FP_P */^&I/CM_T:CX@_\ "IL/
M\* /JJBOE7_AJ3X[?]&H^(/_  J;#_"C_AJ3X[?]&H^(/_"IL/\ "@#ZJHKY
M5_X:D^.W_1J/B#_PJ;#_  H_X:D^.W_1J/B#_P *FP_PH ^JJ*^5?^&I/CM_
MT:CX@_\ "IL/\*/^&I/CM_T:CX@_\*FP_P * /JJBOE7_AJ3X[?]&H^(/_"I
ML/\ "C_AJ3X[?]&H^(/_  J;#_"@#ZJHKY5_X:D^.W_1J/B#_P *FP_PH_X:
MD^.W_1J/B#_PJ;#_  H ^JJ*^5?^&I/CM_T:CX@_\*FP_P */^&I/CM_T:CX
M@_\ "IL/\* /JJBOE7_AJ3X[?]&H^(/_  J;#_"C_AJ3X[?]&H^(/_"IL/\
M"@#ZJHKY5_X:D^.W_1J/B#_PJ;#_  H_X:D^.W_1J/B#_P *FP_PH ^JJ*^5
M?^&I/CM_T:CX@_\ "IL/\*/^&I/CM_T:CX@_\*FP_P * /JJBOE7_AJ3X[?]
M&H^(/_"IL/\ "C_AJ3X[?]&H^(/_  J;#_"@#ZJHKY5_X:D^.W_1J/B#_P *
MFP_PKB-<_P""C7BGPCKSZ1XD^!\^@WL8_>1W'BNUF:,_W66&-RI]F J9245>
M3._!8#%9E66'PE-SF^B_7LO-Z'V]--';PO+*ZQ11J6=W("J ,DDGH*^6?CA^
MWIX8\"_:-+\&)'XKUM<J;H,18PM_O#F4^R<?[7:OC[XT_M1^./C9+);ZC??V
M9H6[*:/IY*0X[>8>LAZ?>XST KR..-YI%CC5G=B%55&22>@ KS:F+;TIG[[D
M'AK2HVQ&<RYG_(GHO\3Z^BLO-HZWXE?%OQ9\6]8.H^*-8GU&123% 3M@@![1
MQCY5_ 9..2:PO#OAO5?%VKP:7HNG7.JZC.<1VUI$9';WP.P[GH*[>U_9P^+6
M^PNT^$_B76M.EQ)(EM/;64I3TS.^4)]2A^E?47PR^(GQ)^$.C_V?X7_8YUJP
M5@!-<GQ38/<3D=Y)"-S?3H,\ 5G3P\ZCYI:'NYSQSE.04_J>7152<=$HZ0CZ
MM:?)?-HK? __ ()ZLWV?5OB7=;1PZZ#82\_2:8?^@I_WUVK[3\-^&=)\'Z/!
MI6B:=;:5IT Q';6L81!ZG ZD]R>3WKYH_P"&I/CM_P!&H^(/_"IL/\*/^&I/
MCM_T:CX@_P#"IL/\*].G2C37NH_GG.>(<QSVISXVI==(K2*]%^KN_,^JJ*^5
M?^&I/CM_T:CX@_\ "IL/\*/^&I/CM_T:CX@_\*FP_P *U/G#ZJHKY5_X:D^.
MW_1J/B#_ ,*FP_PH_P"&I/CM_P!&H^(/_"IL/\* /JJBOE7_ (:D^.W_ $:C
MX@_\*FP_PH_X:D^.W_1J/B#_ ,*FP_PH ^JJ*^5?^&I/CM_T:CX@_P#"IL/\
M*/\ AJ3X[?\ 1J/B#_PJ;#_"@#ZJHKY5_P"&I/CM_P!&H^(/_"IL/\*/^&I/
MCM_T:CX@_P#"IL/\* /JJBOE7_AJ3X[?]&H^(/\ PJ;#_"C_ (:D^.W_ $:C
MX@_\*FP_PH ^JJ*^5?\ AJ3X[?\ 1J/B#_PJ;#_"C_AJ3X[?]&H^(/\ PJ;#
M_"@#ZJHKY5_X:D^.W_1J/B#_ ,*FP_PH_P"&I/CM_P!&H^(/_"IL/\* /JJB
MOE7_ (:D^.W_ $:CX@_\*FP_PH_X:D^.W_1J/B#_ ,*FP_PH ^JJ*^5?^&I/
MCM_T:CX@_P#"IL/\*/\ AJ3X[?\ 1J/B#_PJ;#_"@#ZJHKY5_P"&I/CM_P!&
MH^(/_"IL/\*/^&I/CM_T:CX@_P#"IL/\* /JJBOE7_AJ3X[?]&H^(/\ PJ;#
M_"C_ (:D^.W_ $:CX@_\*FP_PH ^JJ*^5?\ AJ3X[?\ 1J/B#_PJ;#_"C_AJ
M3X[?]&H^(/\ PJ;#_"@#ZJHKY5_X:D^.W_1J/B#_ ,*FP_PH_P"&I/CM_P!&
MH^(/_"IL/\* /JJBOE7_ (:D^.W_ $:CX@_\*FP_PH_X:D^.W_1J/B#_ ,*F
MP_PH ^JJ*^5?^&I/CM_T:CX@_P#"IL/\*/\ AJ3X[?\ 1J/B#_PJ;#_"@#ZJ
MHKY5_P"&I/CM_P!&H^(/_"IL/\*/^&I/CM_T:CX@_P#"IL/\* /JJBOE7_AJ
M3X[?]&H^(/\ PJ;#_"C_ (:D^.W_ $:CX@_\*FP_PH ^JJ*^5?\ AJ3X[?\
M1J/B#_PJ;#_"C_AJ3X[?]&H^(/\ PJ;#_"@#ZJHKY5_X:D^.W_1J/B#_ ,*F
MP_PH_P"&I/CM_P!&H^(/_"IL/\* /JJBOE7_ (:D^.W_ $:CX@_\*FP_PH_X
M:D^.W_1J/B#_ ,*FP_PH ^JJ*^5?^&I/CM_T:CX@_P#"IL/\*/\ AJ3X[?\
M1J/B#_PJ;#_"@#ZJHKY5_P"&I/CM_P!&H^(/_"IL/\*/^&I/CM_T:CX@_P#"
MIL/\* /JJBOE7_AJ3X[?]&H^(/\ PJ;#_"C_ (:D^.W_ $:CX@_\*FP_PH ^
MJJ*^5?\ AJ3X[?\ 1J/B#_PJ;#_"C_AJ3X[?]&H^(/\ PJ;#_"@#ZJHKY5_X
M:D^.W_1J/B#_ ,*FP_PH_P"&I/CM_P!&H^(/_"IL/\* /JJBOE7_ (:D^.W_
M $:CX@_\*FP_PH_X:D^.W_1J/B#_ ,*FP_PH ^JJ*^5?^&I/CM_T:CX@_P#"
MIL/\*/\ AJ3X[?\ 1J/B#_PJ;#_"@#ZJHKY5_P"&I/CM_P!&H^(/_"IL/\*/
M^&I/CM_T:CX@_P#"IL/\* /JJBOE7_AJ3X[?]&H^(/\ PJ;#_"C_ (:D^.W_
M $:CX@_\*FP_PH ^JJ_*O_@N=_S1/_N-_P#MA7U5_P -2?';_HU'Q!_X5-A_
MA7P!_P %6OBEX[^)7_"KO^$U^%&H?##[%_:GV3[=JL%[]NW_ &/?M\H?)LV)
MG/7S!CH: /U4_9._Y-9^#?\ V)FC?^D,->JUY5^R=_R:S\&_^Q,T;_TAAKU6
M@ HHHH **** /Y5Z*** /W^_X)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\
M,O\ N)_^G2[KZJH **** /SS_P""@W[;GB;2?&-M\ O@J)[OXAZL\=K?ZEIY
M_?6;2@;;: _PS,I#-)D>6IX(;)3TO]AO_@GSX?\ V7].B\3^(S!XE^*%W&3/
MJ;#?%I^X?-%;9YR<D-*?F;D#:"0?GOQM_P $=?%WC3XA:_XOF^,=K#J>KZA<
M:A)*ND2[U:5V8C=Y^?XB/I5#_AS-XX_Z+K_Y39__ )(H _52ORD_;4<?LX_\
M%-OAC\6]10VWAK6?LDEW?[3M0(IL[K/J4@:-\#LPKUS]EO\ X)F^*OV?/CMX
M9\?ZE\5_^$ELM(^U>9I?V&6/SO-M98!\S3,!M,H;H?N_C7U/^TM^S3X/_:F^
M',OA/Q=#*BI)]HL=2M"%N;&< @21D@@@@D,I!# ^H! !ZC8WUMJEC;WEE<17
M=G<1K+#<0.'CD1AE65AP00001US7Y2Z[J%I^UG_P5V\/R^'98]7\.>!_L\DN
MH6[AHMMCF9G##@K]KE$8(X)(/0YKJ++_ ()C_M ^&])E\&:#^T?<V?P^8%!:
M1S7L!$9)W(+=9"BJ03E1)@D\^M?7'[(?[&'@W]D'PM>6>AS3:UXAU+:=2U^\
MC5)9]OW8T49\N(')"9)R<EFP, 'SE_P6D^&=WXF^!7A/QC:6YG'AG5FBNF4$
MF*WND"ES[>9%"OU<5]=?LN_%W2OCA\!?!?BO3+V&\>YTV".^2-PS6]XD:K/$
MXZAE<'KU!!Z$5WGB_P (Z/X^\+ZKX<\06$.J:)JEN]K>6<XRDL;C# XY'L1R
M#@@@BOSLNO\ @EC\3?A/XFU&X^!/QTU#PCH.I/\ O;"[FN+>5$P1AG@)69E!
M^5BB$9ZY&2 9?_!8[X@1>-M0^&/P7\.R)JOBF[U47\^GV[@O%(Z^1:(W/#2&
M:0@'G !Z,,_HOX"\-V?PN^&/AW0&GBM]/\.Z/;6)GD<+&D5O J;BQZ !,Y/:
MOE?]E'_@FYI/P.\?/\2/'?BJZ^)7Q%9FDBOKU&\FVD88:4>8S/++C($CD8R<
M*#@U]1_%[P/)\3OA/XU\'17:Z?+XAT2]TA;MX_,$!G@>(.5R-P7?G&1G'6@#
M9T/Q1HWB>.631M7L=62$A9&L;E)@A/0$J3C\:_+C]M1Q^SC_ ,%-OAC\6]10
MVWAK6?LDEW?[3M0(IL[K/J4@:-\#LPKZW_81_8QO?V-_#OBS3+SQ3!XH;7+J
M"Y62"R:V$/EHRX(+MG.[VZ5Z9^TM^S3X/_:F^',OA/Q=#*BI)]HL=2M"%N;&
M< @21D@@@@D,I!# ^H! !ZC8WUMJEC;WEE<17=G<1K+#<0.'CD1AE65AP000
M01US7Y2Z[J%I^UG_ ,%=O#\OAV6/5_#G@?[/)+J%NX:+;8YF9PPX*_:Y1&".
M"2#T.:ZBR_X)C_M ^&])E\&:#^T?<V?P^8%!:1S7L!$9)W(+=9"BJ03E1)@D
M\^M?7'[(?[&'@W]D'PM>6>AS3:UXAU+:=2U^\C5)9]OW8T49\N(')"9)R<EF
MP, 'SE_P6D^&=WXF^!7A/QC:6YG'AG5FBNF4$F*WND"ES[>9%"OU<5]=?LN_
M%W2OCA\!?!?BO3+V&\>YTV".^2-PS6]XD:K/$XZAE<'KU!!Z$5WGB_PCH_C[
MPOJOASQ!80ZIHFJ6[VMY9SC*2QN,,#CD>Q'(."""*_.RZ_X)8_$WX3^)M1N/
M@3\=-0\(Z#J3_O;"[FN+>5$P1AG@)69E!^5BB$9ZY&2 9?\ P6.^($7C;4/A
MC\%_#LB:KXIN]5%_/I]NX+Q2.OD6B-SPTAFD(!YP >C#/Z.?#?PA%\/?AWX6
M\+0$&#0]*M=,C*]-L,*QC]%KY2_91_X)N:3\#O'S_$CQWXJNOB5\169I(KZ]
M1O)MI&&&E'F,SRRXR!(Y&,G"@X-?:% !1110 4444 ?BM_P14_Y.F\4_]B9=
M?^EUC7[4U^*W_!%3_DZ;Q3_V)EU_Z76-?M30 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117CGQ<_:N^'WP?\
MZVO]4_M;6H^/[)TO$TP;T<YVQ_1B#Z U,I**O)G=@\#BLPJJAA*;G)]$K_\
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M]3M;GQ9?)R9-4DQ#N]H4P"/9]U>_Z1HNG^'[&.QTNPMM-LH_N6]G"L4:_15
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**Z3\^"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\J_^"YW
M_-$_^XW_ .V%?JI7Y5_\%SO^:)_]QO\ ]L* /O\ _9._Y-9^#?\ V)FC?^D,
M->JUY5^R=_R:S\&_^Q,T;_TAAKU6@ HHHH **** /Y5Z*** /W^_X)<?\F)_
M#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\ N)_^G2[KZJH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%;_ ((J?\G3
M>*?^Q,NO_2ZQK]J:_%;_ ((J?\G3>*?^Q,NO_2ZQK]J: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0&BJCA81:DF]#CQGB/FV.PM7"5*5-1J1<792O:2L[>^]=>P4445V'Y4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWI7A+2+?2]%TZVTO3K<;8[:UB$:+^ [GN>IK2HHKO/QV4Y5).<W=OJ%%%%!
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5_\%SO^
M:)_]QO\ ]L*_52ORK_X+G?\ -$_^XW_[84 ??_[)W_)K/P;_ .Q,T;_TAAKU
M6O*OV3O^36?@W_V)FC?^D,->JT %%%% !1110!_*O1110!^_W_!+C_DQ/X9?
M]Q/_ -.EW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK?\$5/^3IO%/_
M &)EU_Z76-?M37XK?\$5/^3IO%/_ &)EU_Z76-?M30 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME-_9CHOGU?S=O)!11170?$!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>:_&+]GWP;\;M.\KQ!IP34
M(TVV^K6F([J'T ;'S+_LL"/;/->E44I14E9G5A<57P56-?#3<)K9IV9^5/QU
M_9%\9?!5I[\1'Q!X94DC5K*,_NE_Z;1\F/Z\KT^;/%>'1R-&ZNC%'4Y#*<$'
MU%?N*ZK(K*RAE88*L,@CTKY9^/'["/AOQ]]HU?P8T/A;7FR[6H4BQN&]U _=
M'W08_P!GO7F5<(UK3/W_ (=\285.7#9TK/\ G2T_[>73U6GDCP?X#_MW^)/
M/V;2/&:S>*=!7"+=%@;ZW7V8\2CV<Y_VNU??/P^^)GAKXI:$FK^&-6@U2S.
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M^D,->JT %%%% !1110!_*O1110!^_P!_P2X_Y,3^&7_<3_\ 3I=U]55\J_\
M!+C_ ),3^&7_ '$__3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?BM_P $5/\ DZ;Q3_V)EU_Z76-?M37X
MK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/90!67HNAZCXDU*'3M)L+G4[^8[8[6TB:61S[*H)-?7_ ,(?^"=NJZGY-_\
M$+5!I%N?F_LG3662X/L\O*)]%W?45]F_#OX3^$OA3IOV+PMH=KI2%0LDT:[I
MIL?WY#EF_$\=J4,-.>L]#7-O$#*<HA]6RV*JRCHE'2"^?7_MU->:/B#X1?\
M!//Q'XB\F_\ '=^/#5@V&.GVI66\<>A;E(__ !X^JBOM/X8_!'P7\'['R/"^
MAV]E,R[9;UQYES-_O2M\V,\[1@#L!7=45Z-.C"GLC\)SGBK-<\;6*JVA_+'2
M/W=?FV%%%%;GR(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW9^!Y_QIF>>WI.7LZ7\L>O\ B>\OP7D%%%%=)\ %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML+?3=/MUVQ6MK$(XT'LHXJ_117<?C\I2G)RD[MA11102%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?E7_P %SO\ FB?_ '&__;"OU4K\J_\ @N=_S1/_ +C?_MA0
M!]__ +)W_)K/P;_[$S1O_2&&O5:\J_9._P"36?@W_P!B9HW_ *0PUZK0 444
M4 %%%% '\J]%%% '[_?\$N/^3$_AE_W$_P#TZ7=?55?*O_!+C_DQ/X9?]Q/_
M -.EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^*W_!%3_DZ;Q3_ -B9=?\ I=8U^U-?BM_P14_Y.F\4_P#8
MF77_ *76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>D5Z+=_@?(OPA_X)WZ'HGD7_ (_U(Z]>+AO[,L&:*T4^C/P\GX;/QKZS\/\
MAO2O">E0Z9HNG6NE:?",1VUG$L<:^^ .OOWK2HKT84XTU[J/PG-<]S'.I\^.
MJN79;17HEI\]PHHHK0\$**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?8GP0_8;\'_#/[/J?B()XN\0)APUS'BT@;_8B/WB/[SYZ @+7THJA5  P!P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTC_G]QX%\(?V+/A]\+?(O+JT/BK6X\-]MU1 T:,.\</W5YY&[<P[&O?%4*H
M& . !2T5Z$8Q@K11^(8_,L9FE7VV-JN<O-[>BV2\D%%%%6>:%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'K_B>\OR\@HHHKI/@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44451Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !117S_ /%G]JC3?AI\</"'@ES%):7Q8:I-
MGFW+_+!SV^;K[5SUJ]/#Q4ZCLKI?><V(Q-+"P4ZSLFTOO/H"BFHPD564[E89
M!'>G5T'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H **** "BBB@#^5>BBB@#]_O\
M@EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_X(
MJ?\ )TWBG_L3+K_TNL:_:FOQ6_X(J?\ )TWBG_L3+K_TNL:_:F@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_X#7'_QNOR(HH_UDQ7\D?Q_S#_6[&?\^X_C_F?KO_PV9\&/^AZM/_ :X_\
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M_#9GP8_Z'JT_\!KC_P"-T?\ #9GP8_Z'JT_\!KC_ .-U^1%%'^LF*_DC^/\
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M?\P_UNQG_/N/X_YGZ[_\-F?!C_H>K3_P&N/_ (W1_P -F?!C_H>K3_P&N/\
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M.ZD@ZLL,T,A_$2%?_':[H<0X.7Q77R_R9Z5/BK+Y_$I1]5_DV?I317PEHO\
MP5 C.U=7^'S+_>ELM4!_)&B'_H5=YHO_  4D^&=_M6_TKQ%I;]V:VBEC'XK+
MG_QVNZ&<8&IM47SNOS/2IY]EM3:LOG=?FCZQHKPK1?VW/@QK6U5\8I9RG_EG
M>V5Q%C_@1CV_K7>:+\=/AUXBVC3O'7AVZ=ND:ZG")/\ ODMG]*[H8K#U/@J)
M_-'I4\=A:O\ #JQ?HT=S14-K>07T(FMIX[B)NDD3AE/XBIJZCM"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?R+[D'U/#?\ /N/W(\T_X9G^%'_1/?#O_@OC_P */^&9_A1_T3WP[_X+X_\
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M4?5J'\B^Y!]3PW_/N/W(\T_X9G^%'_1/?#O_ (+X_P#"C_AF?X4?]$]\._\
M@OC_ ,*]+HH^K4/Y%]R#ZGAO^?<?N1YI_P ,S_"C_HGOAW_P7Q_X4?\ #,_P
MH_Z)[X=_\%\?^%>ET4?5J'\B^Y!]3PW_ #[C]R/-/^&9_A1_T3WP[_X+X_\
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MD^"QF%C/$8?EGL_BCKWMIN?FAK7_  39^)=AN:PU;P[JB=E6YEBD/X-%M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P /#O#'_1*/C!_X1LO_ ,75%/\ @I9\/&N+BVD\'>/=/NX.&AU31X[-@V.
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MCXP?^$;+_P#%T?\ #P[PQ_T2CXP?^$;+_P#%T ?55%?*O_#P[PQ_T2CXP?\
MA&R__%T?\/#O#'_1*/C!_P"$;+_\70!]545\J_\ #P[PQ_T2CXP?^$;+_P#%
MT?\ #P[PQ_T2CXP?^$;+_P#%T ?55%?*O_#P[PQ_T2CXP?\ A&R__%T?\/#O
M#'_1*/C!_P"$;+_\70!]545\J_\ #P[PQ_T2CXP?^$;+_P#%T?\ #P[PQ_T2
MCXP?^$;+_P#%T ?55%?*O_#P[PQ_T2CXP?\ A&R__%T?\/#O#'_1*/C!_P"$
M;+_\70!]545\J_\ #P[PQ_T2CXP?^$;+_P#%T?\ #P[PQ_T2CXP?^$;+_P#%
MT ?55%?*O_#P[PQ_T2CXP?\ A&R__%T?\/#O#'_1*/C!_P"$;+_\70!]545\
MJ_\ #P[PQ_T2CXP?^$;+_P#%T?\ #P[PQ_T2CXP?^$;+_P#%T ?55%?*O_#P
M[PQ_T2CXP?\ A&R__%T?\/#O#'_1*/C!_P"$;+_\70!]545\J_\ #P[PQ_T2
MCXP?^$;+_P#%T?\ #P[PQ_T2CXP?^$;+_P#%T ?55%?*O_#P[PQ_T2CXP?\
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M9W&H74=M:P27-Q(=J0PH7=CZ #DU[!X*_8]^+?CKRY+7P?=Z=;-S]HU<K9J
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MR_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T
M?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517
MRK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.
M\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H
M^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&
MR_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q=
M'_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.
M\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CX
MP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&
MR_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T
M?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517
MRK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.
M\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H
M^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&
MR_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q=
M'_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.
M\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CX
MP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&
MR_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T
M?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517
MRK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.
M\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H
M^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&
MR_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q=
M'_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.
M\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CX
MP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&
MR_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T
M?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517
MRK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.
M\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H
M^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&
MR_\ Q='_  \.\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q=
M'_#P[PQ_T2CXP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.
M\,?]$H^,'_A&R_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CX
MP?\ A&R__%T ?55%?*O_  \.\,?]$H^,'_A&R_\ Q='_  \.\,?]$H^,'_A&
MR_\ Q= 'U517RK_P\.\,?]$H^,'_ (1LO_Q='_#P[PQ_T2CXP?\ A&R__%T
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M:^4GCT$1_G4EOX3\47+;5\&>+%/_ $T\.7R#\S"*.;.*'\_XO_,.;/\ #?\
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M+_\ %T ?55%?*O\ P\.\,?\ 1*/C!_X1LO\ \71_P\.\,?\ 1*/C!_X1LO\
M\70!]545\J_\/#O#'_1*/C!_X1LO_P 71_P\.\,?]$H^,'_A&R__ != 'U51
M7RK_ ,/#O#'_ $2CXP?^$;+_ /%T?\/#O#'_ $2CXP?^$;+_ /%T ?55%?*O
M_#P[PQ_T2CXP?^$;+_\ %T?\/#O#'_1*/C!_X1LO_P 70!]545\J_P##P[PQ
M_P!$H^,'_A&R_P#Q='_#P[PQ_P!$H^,'_A&R_P#Q= 'U517RK_P\.\,?]$H^
M,'_A&R__ !='_#P[PQ_T2CXP?^$;+_\ %T ?55%?*O\ P\.\,?\ 1*/C!_X1
MLO\ \71_P\.\,?\ 1*/C!_X1LO\ \70!]545\J_\/#O#'_1*/C!_X1LO_P 7
M1_P\.\,?]$H^,'_A&R__ != 'U517RK_ ,/#O#'_ $2CXP?^$;+_ /%T?\/#
MO#'_ $2CXP?^$;+_ /%T ?55%?*O_#P[PQ_T2CXP?^$;+_\ %T?\/#O#'_1*
M/C!_X1LO_P 70!]545\J_P##P[PQ_P!$H^,'_A&R_P#Q='_#P[PQ_P!$H^,'
M_A&R_P#Q= 'U517RK_P\.\,?]$H^,'_A&R__ !='_#P[PQ_T2CXP?^$;+_\
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M&R__ !='_#P[PQ_T2CXP?^$;+_\ %T ?55%?*O\ P\.\,?\ 1*/C!_X1LO\
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M+_\ %T ?55%?*O\ P\.\,?\ 1*/C!_X1LO\ \71_P\.\,?\ 1*/C!_X1LO\
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M)_L(VW[*5KJWB/Q%JT?BCXDZXGEWNIQ[S%;1%@[0Q,_S/N<!FD8 L0ORC!W
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ME#_WV*]]\%?\$V? .B[)/$6LZMXEG7&Z.,K9P-Z_*NY__'ZB.6YEC7S5$_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JGJ6C:?K,0BU"QMKZ,?P7,*R#\F!]!
M^57**32>C$TFK,\ZUG]G7X7Z_DWG@#P\SGK)#IT4+GIU9 ">@[UP>L_L(_!G
M5LF/PS-ILAZO9ZC<#T_A9V4=.P[U] T5RSP>&J?'33^2.&I@,)5^.E%_)'R%
MK/\ P31^'UUEM-\1>(M/8_PS20SH.G0>6I]>_>N"UG_@E_>1Y;2?B!!-Z1WF
MF-'C_@2RMGOVK[ZHK@GD^!GO3^YM?J>;4X?RVIO2MZ-K\F?F3K/_  3?^*.G
MY:SOO#VJKV6&[DC?\0\8'ZUP>L_L5_&;1,F3P5/<H.CV=W;SY_!9"WYBOURH
MKAGP[A)?"Y+Y_P# /-J<*8"7PN2^:_5'XHZS\%_B!X=R=3\$>(;)1_RTFTN9
M4_!MN#U]:Y":"2VE:.:-HI%ZHZD$?@:_=VJ6IZ+I^M1>7J%A:W\?]RZA60?D
MP-<,^&H_8J_>O^">;4X/C_R[K?>O^"C\+**_9G6OV<?A;K^XWG@#P\6;J\&G
MQPN?JR ']:X/6OV#O@SJVXQ>&[C3';JUEJ,X_1W91^ KAGPYB5\$T_O7Z'FU
M.$<7'X*D7]Z_1GY7:;K.H:-*9=/OKFQD/\=M,T9_,$>I_.NXT;]HKXH:#@6?
MC_Q$J#I'-J,LR#KT5R0.I[5]NZU_P3/\ 76YM,\2>(=/8_PSO#.@^@\M3^M<
M'K7_  2_OH]S:3\0+>?TCO=,:/'_  )9&S^5<W]D9E1_AK[G_P %''_8.;X?
M^$ONDO\ -'C6C?MW?&;2<"3Q-#J48Z)>:=;GU_B5%8]>Y[5WNC?\%+_B!:X7
M4_#GA[4%'\4*30.?J?,8?I67K7_!.#XI:=N:SO?#VJKV$%Y)&_XAXU'ZUP6M
M?L7?&;0]QE\$W%R@Z-97,%QG\$D)_2CFSBA_/^+_ ,PY\_PO_/S\9?YGT;HW
M_!4"SDPNK?#^>'UDL]363/\ P%HEQV[UWFC?\%(/A=J&%O+'Q#I3=VFM(Y$_
M I(3^E?GUK7P;\?>'=QU/P5X@L%7^.?3)E3\&*X-<E-#);R-'*C1R*<,K@@C
MZBFLZS"CI-_>O^&&N(LUH.U1W]8V_*Q^MVC?MJ?!G6\"/QK!;.>J7EI<08_%
MHPOY&N\T;XT?#_Q%@:9XW\/7S'_EG#JD+/\ BN[(Z>E?BE177#B2NOC@G]Z_
MS.ZGQ=B5_$IQ?I=?YG[N0SQW,2R0R++&W1T8$'\14E?A7IFM:CHLOF:??W5A
M)_?M9FC/YJ17=:+^T;\4?#^/L7C_ ,0A5Z1S:A),@^BN2/TKNAQ+3?QTFO1W
M_P CTJ?&%)_Q*+7H[_HC]FJ*_*'1?V\?C-I.T2^)+?4T7HM[IT!_5$5C^)KO
M-%_X*8>/[7:NI^&_#VH*/XH$F@<_4^8P_2NZ'$&#EO=?+_*YZ5/BK+Y_%S1]
M5_DV?I%17PSHO_!4"RDVKJW@"X@]9++4UES_ ,!:-<?G7>:+_P %'_A;J.U;
MRR\0Z4W=I[..1/P*2,?TKNAF^!J;55\[K\STJ>>Y;4VK+YW7YH^JJ*\1T7]M
M+X,ZYM$7C6WMG/5;VUG@Q^+QA?R-=YHOQF\ >(MHTSQMX>OF/\$&IPL_XKNR
M/RKNABJ%3X*B?S1Z5/&8:K_#JQ?HT=E13(9H[B-9(G62-AE60Y!^AI]=)V!1
M110 4444 %%%% !116!H_CK1-?\ $VMZ!8WR3ZKHWE?;;<=8O,4LGUX%2Y*+
M2;W)<HQ:3>^QOT445104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%5[K4+6QV_:;F&WW?=\V0+GZ9K&N_B)X4T]7:Z\3:/;!#M8
MS7\2[3G&#EN.:ERC'=D2G&/Q.QT-%</=?'/X;V+[+CX@>%H'QG;)K-LIQZX+
MUBW7[47PELU#2?$'0F!./W5V)#^2YK%XBC'>:^]&$L5AX_%42^:/4J*\6O/V
MS/@Q8^9YGCJS;9U\FVN)?RVQG/X5CW7[>'P5MV41^*IKD$<F+2[L ?\ ?48K
M%X["QWJQ^]&$LRP4=Z\?_ E_F?0-%?,MU_P4.^$=NI,<^M71!QMBT_!/O\S"
MLBZ_X*4?#"!F6+1_%-S@9#)9VX4GTYG!_2LGF>"CO57WG/+.<OCO6C]Y]8T5
M\:W7_!3;P:@7[-X0UR4_Q>;)"F/IAFS6/>?\%0--02?9?A]=3$'Y/.U58\_7
M$38_6L7G& CO4_!_Y&$L_P LCO67W/\ R/N*BO@:Z_X*A7C2 V_PZ@B3'(EU
MAG.?J(!6)=?\%./%S1@6W@[18GSR99IG&/3 (K%YY@%M._R?^1A+B3+%M4O\
MG_D?HI17YJW?_!2SXERM(+?0?"T",,+NMKAW7CKGSP#S[5C77_!1+XMW&WRV
MT.VQU\JP)S]=SG]*R?$&"6UW\CGEQ3ERV<G\C]0Z*_*.[_;V^-%RKB/Q+;6I
M8Y!ATNV.WGH-R']<UD77[:GQIO'W2>.;A3C'[JRM8Q^2Q"L7Q'A.D9?<O\S"
M7%N!6T)/Y+_,_7.BOQRNOVIOBW>*%D^(&MJ <_NKDQG\UQ61=_'WXFWWF>?\
M0_%+K)]Y/[9N A]MH?'Z5B^)*'2F_P #"7%^'^S2E^!^TE%?B'=?$SQA?,K7
M/BO7+AE& 9=1F8C\VK&NM7OKY2MS>W%PI.XK+*S GUY-9/B:/2E^/_ ,)<80
M^S0?_@7_  #]R;K6+"Q9EN;ZVMV4;F$LJJ0/4Y-8UU\3?!]B%-SXKT.W#?=\
MW485S],M7XB45B^)I=*7X_\  .>7&$_LT%_X%_P#]H[OX_?#*Q$GG?$/PLC1
MG#(-8MRX/IM#Y_2LBZ_:H^$EI($?X@:(Q(S^ZN/,'YJ"*_'.BL7Q)7Z4U^)A
M+B_$_9I1_$_7&Z_;6^"MF@>3QS PSC]U8W4A_)8C^=9-W^WM\%[=I!'XDNKH
M*,@PZ9<C?QG W(/ISBORDHK)\1XM[1C]S_S,)<6XY[0BOD_\S]0KK_@HG\);
M?;Y;:Y<YZ^58 8^NYQ^E8UW_ ,%+?AK$KBWT'Q3.ZG"[K:W16YZY\\G]*_-:
MGPPR7$BQQ1M+(W 1 23]!6+X@QKVM]Q@^*,QEMRKY'Z'W7_!3CPDKXMO!VM2
MICK+-"AS] 36+=?\%0K15'V?X<S2MGD2ZP$&/P@-?#UKX.U^^4M;Z'J5PJG!
M:*TD8 _@*VK7X,?$&^?9;>!?$MP^-VV+2+ACCUX2E_;&93^%_P#DJ_R)_M_-
MZGPR^Z*_R/K"[_X*@:F_F?9?A]:0Y^YYVJ-)CZXB7/Z5CW7_  4V\9,R_9O"
M.A1+CD2O,Y/Y,*^?K3]FSXJWJH8_AYXD4.<#SM-EC[XYW 8^IK9M?V0?C'>;
MO+\!ZBNWKYKQ1_EN<9_"CZ]FT]G+_P !_P" ']I9[4V<OE'_ "1Z?=?\%*/B
MA.I6+2/"UMSD,EG<%@/3YIR/TK(NO^"AWQ=N&8QW&C6H(P%BT\$#W&YC6!:?
ML+_&RZ://@Y8$<9WS:G9C'&>0)21^5:UK_P3[^,5Q&6DTO3;8YQMEU*,GZ_+
MD4<^<3_G^YH/:9_4_P"?GW-?H9]U^WA\:[@+Y?BN&VQU\K2[0Y^NZ(UCW?[9
M7QFO1()/'5XOF')\FWMX_P ML8Q^%>AVO_!-WXIW$A5]1\,VP SNEO9B#[?+
M"36O9_\ !,SQXXC^U>*/#L))^?R6N),?3,:Y_2CV&<3_ )_O?^8?5L_J;^T_
M\"?^9X==?M1?%J[<,_Q!UU2!C]U=M&/R7%8MU\<OB/?1[+CX@>*9TSNVR:S<
ML,^N"]?4=K_P3"UU@WVGQWI\1_A\JPD?/URZXK9M?^"7<:LIN?B0SKCYDBT0
M*<^Q-P?Y4?V;FL]T_P#P)?YA_9&=U-U+YR7_ ,D?%EW\0O%6H-(;KQ+K%R9!
MM<S7\K;AC&#EN>.*QKK4+J^V_:;F:XV_=\URV,^F:_0.U_X)A^'44?:?'&J2
MMGDQ6<<8QZ8+-6S:_P#!,[X>*S?:?$GB>5<<"*:W0C\X31_8F83^)?B@_P!7
M,TJ?%'[Y(_-RBOT[L_\ @G'\*+;R_,N/$5WMZ^=?1C?]=L0_3%:]K_P3_P#@
MY;J0^CZA<DG.Z74I01[?*15KA[&/>R^?_ -(\*Y@]W%?/_@'Y6T5]S?MB_!_
MX._ GP#%'H'A.*#Q1JA\JUDDU"ZF\E!C=)M>4KGTR.QKX9KQL9A)8.K[*;3?
ME_2/G\?@9Y?6]A4DG+ROI]Z05]K?\$Y?C1_9&O:G\/M3N,6NH#[9II<_=F48
MD3_@2[3_ , /K7Q36KX5\27G@_Q)IFMZ>YCO+"X2XC(.,E3G'T(X_&G@L5+!
MUXUETW].H\NQDL!BH5X]-_3J?N717'_"3XAV7Q4^'NC>);%PR7D"F1<\I(!A
MU/X_S%=A7Z_"<:D5..S/WJG4C5@IP=T]0HHHJS0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_P""YW_-
M$_\ N-_^V%?JI7Y5_P#!<[_FB?\ W&__ &PH ^__ -D[_DUGX-_]B9HW_I##
M7JM>5?LG?\FL_!O_ +$S1O\ TAAKU6@ HHHH **** /Y5Z*** /W^_X)<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JCJFA:;KD?EZCIUKJ$>,;;J!91^3 U>HI-)Z,32DK,\WUK
M]F_X6^(-QO/ 'A\LW5X+".!S]6C"FN#UK]@WX,ZMN,7ARXTMVZM9:C./T=V
M_*OH2BN2>#PU3XZ:?R1PU,OPE7XZ47\D?'^M?\$S_ =UN.E^)?$&GL>@N&AG
M4?0"-3C\:X/6O^"8&H1[FTCQ_;7']U+W36BQ[%ED;/Y5]^45PSR; SWIV]&U
M^IYM3A_+:F]*WHVOU/S'UK_@G%\4]-W&SN_#^K+_  BWO)$8_421J ?QK@]:
M_8O^,NA[C-X)N;E!T:RN8+C/T".3^E?KI17#/AW"2^%R7S_X!YM3A3 R^%R7
MS7ZH_$_6O@[X]\.;CJG@KQ!8*O5[C3)D7ZABN"*Y&2)X9&CD1HY%.&5A@@^A
M%?N]6?JWA_2]>C\O4]-L]13&-MW DHQZ88'U/YUPSX:C]BK]Z_X)YM3@^/\
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M%% !1110 4444 %%%% !7Y5_\%SO^:)_]QO_ -L*_52ORK_X+G?\T3_[C?\
M[84 ??\ ^R=_R:S\&_\ L3-&_P#2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4
M444 %%%% '\J]%%% '[_ '_!+C_DQ/X9?]Q/_P!.EW7U57RK_P $N/\ DQ/X
M9?\ <3_].EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!^*W_  14_P"3IO%/_8F77_I=8U^U-?BM_P $5/\
MDZ;Q3_V)EU_Z76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$)NG7_9@R"/^!E?QK[:^$?[*_P /_@Z(;G3=*&IZU'S_ &MJF)IPWJG&V/\
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M8CBS%U-*$%'\7_E^!]:^-O\ @I-X]UKS(_#FBZ3X:@;[LD@:\G7_ ($VU/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^D,->JT %%%% !1110!_*O1110!^_P!_P2X_Y,3^&7_<3_\ 3I=U]55\J_\
M!+C_ ),3^&7_ '$__3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?BM_P $5/\ DZ;Q3_V)EU_Z76-?M37X
MK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQX2_\$=K_P#&Z[RBL_84OY%]R,OJU#_GVON1P?\ PH/X8_\ 1./"7_@CM?\
MXW6SX9^&_A+P3=2W/AWPMHN@W$R>7)-IFGPVSNN0=I**"1D X/I71T4XT:<7
M=12?H5&A1B^:,$GZ(****V-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5O\ @BI_R=-XI_[$RZ_]+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH
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M=_>]0HHHKO/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MACM[>,;4BB0*JCT ' J:NJ.#@OB=S\ZS#Q0S*O>."I1I+N_>?Z+\&?+/@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5^5?_!<[_FB?_<;_ /;"OU4K
M\J_^"YW_ #1/_N-_^V% 'W_^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]
MB9HW_I##7JM !1110 4444 ?RKT444 ?O]_P2X_Y,3^&7_<3_P#3I=U]55\J
M_P#!+C_DQ/X9?]Q/_P!.EW7U50 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!^*W_!%3_DZ;Q3_P!B9=?^EUC7[4U^
M*W_!%3_DZ;Q3_P!B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_P7._YHG_W&
M_P#VPK]5*_*O_@N=_P T3_[C?_MA0!]__LG?\FL_!O\ [$S1O_2&&O5:\J_9
M._Y-9^#?_8F:-_Z0PUZK0 4444 %%%% '\J]%%% '[_?\$N/^3$_AE_W$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _%;_@BI_P G3>*?^Q,NO_2ZQK]J:_%;_@BI_P G3>*?^Q,NO_2ZQK]J
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHKSOQQ^T-\.?AT9$UWQ=IMO<Q\-
M:02?:)P?0QQAF'X@4G)1U;.K#X7$8N?L\/3<Y=HIM_<CT2BOCCQO_P %(O#F
MG^9#X4\,7VKR#@7.HR+:Q?4*N]F'L=IKY[\<?MP_%;QEYD<&L0^&[1^/)T:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\J_^"YW_ #1/_N-_^V%?
MJI7Y5_\ !<[_ )HG_P!QO_VPH ^__P!D[_DUGX-_]B9HW_I##7JM>5?LG?\
M)K/P;_[$S1O_ $AAKU6@ HHHH **** /Y5Z*** /W^_X)<?\F)_#+_N)_P#I
MTNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\5O^"*G_)TWBG_ +$RZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"D,->JUY5^R=_R:S\&_P#L3-&_](8:]5H **** "BBB@#^5>BBB@#]_O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E7_P %SO\
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M+YR_5GP;78> ?@_XW^*5P(?"?A;5-=^;:TMI;,84/^W(?D7_ ($17ZU_#?\
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M+B_-6%HHHK(P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_P""YW_-$_\ N-_^V%?J
MI7Y5_P#!<[_FB?\ W&__ &PH ^__ -D[_DUGX-_]B9HW_I##7JM>5?LG?\FL
M_!O_ +$S1O\ TAAKU6@ HHHH **** /Y5Z*** /W^_X)<?\ )B?PR_[B?_IT
MNZ^JJ^5?^"7'_)B?PR_[B?\ Z=+NOJJ@ HHHH ^9?VVOVV=._9!T/0X4\.7G
MB?Q5XC$Z:191,$M]T?EAFE?ENLJ855);D97K7X^_MB>'_C;JUYX9^*'QLCEL
MM2\9?:DTO3;D&*6TMK;R3M%O_P L(_\ 2!M4_.2'9AD[F_H$U#P=H6K^(=,U
MZ^T>QO-:TM)(['4+BW5YK59-OF")R,INV+G&,[17YA_\%SO^:)_]QO\ ]L*
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MCN558_82DCD"E_8A_8.^&WPX^!/AN_\ %7@O1O%'C'7K"+4-3NM=L(KLP&9
MPMXUD4A%16"MC[S!B21@#YU_X+E7SF7X,V0XCQJ\K>A/^A@?ES^=?JC:VL5C
M:PV\*".&%%C11T"@8 _*@#\D/V[/@W9?L%_'GX<_&OX30-H.FWU^ZWNBVK%+
M9)8]K/$@'2*>)I%*=!M;& 0!^LN@:Y:>)M!TW6+"3S;#4+:.[MY,8W1R*'4_
MB"*^$/\ @M-81W'[+GAFY('FV_BZVVMCG:UI=@C\3M/X5]/_ +'M[+J'[*7P
M@FF+M(?"FFJ6DZG;;(N?TH ]?HHHH **X?XO?&SP1\!O#=MK_CW7X?#NCW-V
MMC%=3Q22!IV1W5,1JQR5C<],?+7D7_#R']FW_HJ6G_\ @%=__&: /SK_ ."*
MG_)TWBG_ +$RZ_\ 2ZQK]J:_!C_@EW\=_ O[/?Q^U_Q'\0==7P]HUUX8N-/A
MNFM9[C=.UW:2*FV%'896*0Y(Q\O7D5^H7_#SW]F7_HIT?_@EU'_Y'H ^I:*^
M:O\ AY#^S;_T5+3_ /P"N_\ XS1_P\A_9M_Z*EI__@%=_P#QF@#Z5HKYJ_X>
M0_LV_P#14M/_ / *[_\ C-'_  \A_9M_Z*EI_P#X!7?_ ,9H ^E:*^:O^'D/
M[-O_ $5+3_\ P"N__C-'_#R']FW_ **EI_\ X!7?_P 9H ^E:*^:O^'D/[-O
M_14M/_\  *[_ /C-'_#R']FW_HJ6G_\ @%=__&: /I6BOFK_ (>0_LV_]%2T
M_P#\ KO_ .,T?\/(?V;?^BI:?_X!7?\ \9H ^E:*^:O^'D/[-O\ T5+3_P#P
M"N__ (S1_P /(?V;?^BI:?\ ^ 5W_P#&: /I6BOFK_AY#^S;_P!%2T__ , K
MO_XS1_P\A_9M_P"BI:?_ . 5W_\ &: /I6BOFK_AY#^S;_T5+3__  "N_P#X
MS1_P\A_9M_Z*EI__ (!7?_QF@#Z5HKYJ_P"'D/[-O_14M/\ _ *[_P#C-'_#
MR']FW_HJ6G_^ 5W_ /&: /I6BOFK_AY#^S;_ -%2T_\ \ KO_P",T?\ #R']
MFW_HJ6G_ /@%=_\ QF@#Z5HKYJ_X>0_LV_\ 14M/_P# *[_^,T?\/(?V;?\
MHJ6G_P#@%=__ !F@#Z5HKYJ_X>0_LV_]%2T__P  KO\ ^,T?\/(?V;?^BI:?
M_P" 5W_\9H ^E:*^:O\ AY#^S;_T5+3_ /P"N_\ XS1_P\A_9M_Z*EI__@%=
M_P#QF@#Z5HKYJ_X>0_LV_P#14M/_ / *[_\ C-'_  \A_9M_Z*EI_P#X!7?_
M ,9H ^E:\-_;;_Y-A\9_]N7_ *6P5SG_  \A_9M_Z*EI_P#X!7?_ ,9KS#]I
M;]MCX,_%SX*^(/"G@SQI!XAUS4&MA';6]I<)M"7$<K,S/&H VQMWZU%2+E"2
M79_D?1<.1<LZP2BO^7L/PDCX;K/O)M\F >%JW<2>5$3WZ"LROSK-L1RI48]=
M6?3^._%CP]"EPYA9>].TZENR?NQ^;7-\EW-.WD\V,'OWKI_AKXFL_!?Q&\*Z
M_?B1[+2M6M+Z=(0#(T<4R.P4$@$X4XR1SWKA@Q48!(%)6,<XE"$5RW:ZW/E*
M7CSB*>4T\#/!>TJJ'+*;G9/2U^51OJM_>6I]T>.O^"F5W)YD/A#PI!;+T6ZU
M>9I6/OY4>T _\#-?/'CK]K+XG_$ 2QZCXKOX;23(-KI["TBV_P!TB, L/]XF
MO'JJWVJ6>FQ[[R[@M4_O32*@_4U,\XQV(?+%_<C\ICXAYO%\N64*5%]XT^>7
MWU74:^5OD:<FH32,S$_,QR6/)-0M/(W5S6=I/BCPKJ-UY5SXPT32D_Y[7<[L
MG_D)'/Z5ZIX7T;X$W&UO$?[1/A^Q[M'I>CW]SGVW/%'CZX-1'"YGBOLR^>GY
MV.'%9QQEGFF*Q-:2?1R<8_\ @-U'\#SFBOJ3PO<?L.Z+Y;ZI\6KKQ!(/OK<+
M=0Q'Z"*W5A_WT:]>\+_M(?L.^#?+.EZQX5CDCY2:XTBZN95]P\L+-G\:[:?#
MN*EK4DH_C_7WGET>$\;4UJRC'\7_ %\SX5\.^#/$'BZ;RM"T+4M:ESC9I]I)
M.<^F$!KUOPO^Q-\8O%&UE\)/I<!_Y;:I<16^/JA;?_X[7VK#_P %&OV:;:%(
MH?B=IL42#"HEA=A0/0 0T_\ X>0_LV_]%2T__P  KO\ ^,UZU+ANC'^+4;]-
M/\SW*/".'C_&JM^EE_F>"^%_^"8_B:\\MO$7C'2]+!Y:/3K>2[8>V6\L9_/\
M:]>\+_\ !-WX;:2$?6-2US7I@?F5ITMX3_P%%W#_ +[K<_X>0_LV_P#14M/_
M / *[_\ C-'_  \A_9M_Z*EI_P#X!7?_ ,9KUJ>38&EM3OZZ_P# /=H\/Y;1
MVI7?G=_\#\#T/PO^R[\*/!^TZ=X$T<NOW9+V'[6X]PTQ<@^]>EV=E;Z?;I;V
ML$5M @PL4*!%4>P' KYQ_P"'D/[-O_14M/\ _ *[_P#C-'_#R']FW_HJ6G_^
M 5W_ /&:]6G2ITE:G%+T5CVJ5"E15J4%'T5CZ5HKYJ_X>0_LV_\ 14M/_P#
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M-'_#R']FW_HJ6G_^ 5W_ /&: /I6BOFK_AY#^S;_ -%2T_\ \ KO_P",T?\
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M_P 9H ^E:*^:O^'D/[-O_14M/_\  *[_ /C-'_#R']FW_HJ6G_\ @%=__&:
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M_P# *[_^,T?\/(?V;?\ HJ6G_P#@%=__ !F@#Z5HKYJ_X>0_LV_]%2T__P
MKO\ ^,T?\/(?V;?^BI:?_P" 5W_\9H ^E:*^:O\ AY#^S;_T5+3_ /P"N_\
MXS1_P\A_9M_Z*EI__@%=_P#QF@#Z5HKYJ_X>0_LV_P#14M/_ / *[_\ C-'_
M  \A_9M_Z*EI_P#X!7?_ ,9H ^E:*^:O^'D/[-O_ $5+3_\ P"N__C-'_#R'
M]FW_ **EI_\ X!7?_P 9H ^E:*^:O^'D/[-O_14M/_\  *[_ /C-'_#R']FW
M_HJ6G_\ @%=__&: /I6BOFK_ (>0_LV_]%2T_P#\ KO_ .,T?\/(?V;?^BI:
M?_X!7?\ \9H ^E:*^:O^'D/[-O\ T5+3_P#P"N__ (S1_P /(?V;?^BI:?\
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M3_\ P"N__C-'_#R']FW_ **EI_\ X!7?_P 9H ^E:*^:O^'D/[-O_14M/_\
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M_LV_]%2T_P#\ KO_ .,T?\/(?V;?^BI:?_X!7?\ \9H ^E:*^:O^'D/[-O\
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M_P#X!7?_ ,9H ^E:*^:O^'D/[-O_ $5+3_\ P"N__C-'_#R']FW_ **EI_\
MX!7?_P 9H ^E:*^:O^'D/[-O_14M/_\  *[_ /C-'_#R']FW_HJ6G_\ @%=_
M_&: /I6BOFK_ (>0_LV_]%2T_P#\ KO_ .,T?\/(?V;?^BI:?_X!7?\ \9H
M^E:*^:O^'D/[-O\ T5+3_P#P"N__ (S1_P /(?V;?^BI:?\ ^ 5W_P#&: /I
M6BOFK_AY#^S;_P!%2T__ , KO_XS1_P\A_9M_P"BI:?_ . 5W_\ &: /I6BO
MFK_AY#^S;_T5+3__  "N_P#XS1_P\A_9M_Z*EI__ (!7?_QF@#Z5HKYJ_P"'
MD/[-O_14M/\ _ *[_P#C-'_#R']FW_HJ6G_^ 5W_ /&: /I6BOFK_AY#^S;_
M -%2T_\ \ KO_P",T?\ #R']FW_HJ6G_ /@%=_\ QF@#Z5HKYJ_X>0_LV_\
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M2T__ , KO_XS0!]*T5\U?\/(?V;?^BI:?_X!7?\ \9H_X>0_LV_]%2T__P
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ME1Y[9A8-&![*J_6G?\/(?V;?^BI:?_X!7?\ \9H_X>0_LV_]%2T__P  KO\
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M3_\ P"N__C-'_#R']FW_ **EI_\ X!7?_P 9H ^E:*^:O^'D/[-O_14M/_\
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M_LV_]%2T_P#\ KO_ .,T?\/(?V;?^BI:?_X!7?\ \9H ^E:*^:O^'D/[-O\
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M_P#X!7?_ ,9H ^E:*^:O^'D/[-O_ $5+3_\ P"N__C-'_#R']FW_ **EI_\
MX!7?_P 9H ^E:*^:O^'D/[-O_14M/_\  *[_ /C-'_#R']FW_HJ6G_\ @%=_
M_&: /I6BOFK_ (>0_LV_]%2T_P#\ KO_ .,T?\/(?V;?^BI:?_X!7?\ \9H
M^E:*^:O^'D/[-O\ T5+3_P#P"N__ (S1_P /(?V;?^BI:?\ ^ 5W_P#&: /I
M6BOFK_AY#^S;_P!%2T__ , KO_XS1_P\A_9M_P"BI:?_ . 5W_\ &: /I6BO
MFK_AY#^S;_T5+3__  "N_P#XS1_P\A_9M_Z*EI__ (!7?_QF@#Z5HKYJ_P"'
MD/[-O_14M/\ _ *[_P#C-'_#R']FW_HJ6G_^ 5W_ /&: /I6BOFK_AY#^S;_
M -%2T_\ \ KO_P",T?\ #R']FW_HJ6G_ /@%=_\ QF@#Z5HKYJ_X>0_LV_\
M14M/_P# *[_^,T?\/(?V;?\ HJ6G_P#@%=__ !F@#Z5HKYJ_X>0_LV_]%2T_
M_P  KO\ ^,T?\/(?V;?^BI:?_P" 5W_\9H ^E:*^:O\ AY#^S;_T5+3_ /P"
MN_\ XS1_P\A_9M_Z*EI__@%=_P#QF@#Z5HKYJ_X>0_LV_P#14M/_ / *[_\
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MKYJ_X>0_LV_]%2T__P  KO\ ^,T?\/(?V;?^BI:?_P" 5W_\9H ^E:*^:O\
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M_P#@%=__ !F@#Z5HKYJ_X>0_LV_]%2T__P  KO\ ^,T?\/(?V;?^BI:?_P"
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M;]N7PGX93P7>? Z?6O$MK#]EC\33Z9/,&P-OF2/')Y$DG(.X,%.,D-S7K?[
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M_P#@+'_A6M10!D_\(GH?_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U%
M&3_PB>A_] ;3_P#P%C_PH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\
MP%C_ ,*/^$3T/_H#:?\ ^ L?^%:U% &3_P (GH?_ $!M/_\  6/_  H_X1/0
M_P#H#:?_ . L?^%:U% &3_PB>A_] ;3_ /P%C_PH_P"$3T/_ * VG_\ @+'_
M (5K44 9/_")Z'_T!M/_ / 6/_"C_A$]#_Z VG_^ L?^%:U% &3_ ,(GH?\
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M  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\
M_ 6/_"C_ (1/0_\ H#:?_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/
M_H#:?_X"Q_X5K44 9/\ PB>A_P#0&T__ ,!8_P#"C_A$]#_Z VG_ /@+'_A6
MM10!D_\ ")Z'_P! ;3__  %C_P */^$3T/\ Z VG_P#@+'_A6M10!D_\(GH?
M_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U% &3_PB>A_] ;3_P#P%C_P
MH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\ P%C_ ,*/^$3T/_H#:?\
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M_P#@+'_A6M10!D_\(GH?_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U%
M&3_PB>A_] ;3_P#P%C_PH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\
MP%C_ ,*/^$3T/_H#:?\ ^ L?^%:U% &3_P (GH?_ $!M/_\  6/_  H_X1/0
M_P#H#:?_ . L?^%:U% &3_PB>A_] ;3_ /P%C_PH_P"$3T/_ * VG_\ @+'_
M (5K44 9/_")Z'_T!M/_ / 6/_"C_A$]#_Z VG_^ L?^%:U% &3_ ,(GH?\
MT!M/_P# 6/\ PH_X1/0_^@-I_P#X"Q_X5K44 9/_  B>A_\ 0&T__P !8_\
M"C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\ _ 6/_"C_ (1/0_\ H#:?
M_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/_H#:?_X"Q_X5K44 9/\
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M  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\
M_ 6/_"C_ (1/0_\ H#:?_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/
M_H#:?_X"Q_X5K44 9/\ PB>A_P#0&T__ ,!8_P#"C_A$]#_Z VG_ /@+'_A6
MM10!D_\ ")Z'_P! ;3__  %C_P */^$3T/\ Z VG_P#@+'_A6M10!D_\(GH?
M_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U% &3_PB>A_] ;3_P#P%C_P
MH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\ P%C_ ,*/^$3T/_H#:?\
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M_P#@+'_A6M10!D_\(GH?_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U%
M&3_PB>A_] ;3_P#P%C_PH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\
MP%C_ ,*/^$3T/_H#:?\ ^ L?^%:U% &3_P (GH?_ $!M/_\  6/_  H_X1/0
M_P#H#:?_ . L?^%:U% &3_PB>A_] ;3_ /P%C_PH_P"$3T/_ * VG_\ @+'_
M (5K44 9/_")Z'_T!M/_ / 6/_"C_A$]#_Z VG_^ L?^%:U% &3_ ,(GH?\
MT!M/_P# 6/\ PH_X1/0_^@-I_P#X"Q_X5K44 9/_  B>A_\ 0&T__P !8_\
M"C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\ _ 6/_"C_ (1/0_\ H#:?
M_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/_H#:?_X"Q_X5K44 9/\
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M  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\
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M  B>A_\ 0&T__P !8_\ "C_A$]#_ .@-I_\ X"Q_X5K44 9/_")Z'_T!M/\
M_ 6/_"C_ (1/0_\ H#:?_P" L?\ A6M10!D_\(GH?_0&T_\ \!8_\*/^$3T/
M_H#:?_X"Q_X5K44 9/\ PB>A_P#0&T__ ,!8_P#"C_A$]#_Z VG_ /@+'_A6
MM10!D_\ ")Z'_P! ;3__  %C_P */^$3T/\ Z VG_P#@+'_A6M10!D_\(GH?
M_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"%:U% &3_PB>A_] ;3_P#P%C_P
MH_X1/0_^@-I__@+'_A6M10!D_P#")Z'_ - ;3_\ P%C_ ,*/^$3T/_H#:?\
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M;#NU6#7J?)8C"8C"OEKP<?5%;_A$]#_Z VG_ /@+'_A1_P (GH?_ $!M/_\
M 6/_  K6HKF.0R?^$3T/_H#:?_X"Q_X4?\(GH?\ T!M/_P# 6/\ PK6HH R?
M^$3T/_H#:?\ ^ L?^%'_  B>A_\ 0&T__P !8_\ "M:B@#)_X1/0_P#H#:?_
M . L?^%'_")Z'_T!M/\ _ 6/_"M:B@#)_P"$3T/_ * VG_\ @+'_ (4?\(GH
M?_0&T_\ \!8_\*UJ* ,G_A$]#_Z VG_^ L?^%'_")Z'_ - ;3_\ P%C_ ,*U
MJ* ,G_A$]#_Z VG_ /@+'_A1_P (GH?_ $!M/_\  6/_  K6HH R?^$3T/\
MZ VG_P#@+'_A1_PB>A_] ;3_ /P%C_PK6HH R?\ A$]#_P"@-I__ ("Q_P"%
M'_")Z'_T!M/_ / 6/_"M:B@#)_X1/0_^@-I__@+'_A1_PB>A_P#0&T__ ,!8
M_P#"M:B@#)_X1/0_^@-I_P#X"Q_X4?\ ")Z'_P! ;3__  %C_P *UJ* ,G_A
M$]#_ .@-I_\ X"Q_X4?\(GH?_0&T_P#\!8_\*UJ* ,G_ (1/0_\ H#:?_P"
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MQ_X4?\(GH?\ T!M/_P# 6/\ PK6HH R?^$3T/_H#:?\ ^ L?^%'_  B>A_\
M0&T__P !8_\ "M:B@#)_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"M:
MB@#)_P"$3T/_ * VG_\ @+'_ (4?\(GH?_0&T_\ \!8_\*UJ* ,G_A$]#_Z
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M R?^$3T/_H#:?_X"Q_X4?\(GH?\ T!M/_P# 6/\ PK6HH R?^$3T/_H#:?\
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M1/0_^@-I_P#X"Q_X4?\ ")Z'_P! ;3__  %C_P *UJ* ,G_A$]#_ .@-I_\
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M ,!8_P#"M:B@#)_X1/0_^@-I_P#X"Q_X4?\ ")Z'_P! ;3__  %C_P *UJ*
M,G_A$]#_ .@-I_\ X"Q_X4?\(GH?_0&T_P#\!8_\*UJ* ,G_ (1/0_\ H#:?
M_P" L?\ A1_PB>A_] ;3_P#P%C_PK6HH R?^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PK6HH R?^$3T/_H#:?\ ^ L?^%'_  B>A_\ 0&T__P !8_\
M"M:B@#)_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"M:B@#)_P"$3T/_
M * VG_\ @+'_ (4?\(GH?_0&T_\ \!8_\*UJ* ,G_A$]#_Z VG_^ L?^%'_"
M)Z'_ - ;3_\ P%C_ ,*UJ* ,G_A$]#_Z VG_ /@+'_A1_P (GH?_ $!M/_\
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M<I)$Q5E/J".E>E^%?VH/BUX+"+I7Q"U^*)!A8;B]:YB4>R2[E'Y5YE3AJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!*\=^)?[(?PE^*WFR:SX.L;>_DY_M#2U^QS[O[Q:/ <_[X:O8Z
M*UIUJE&7-3DT_(WHUZN'ESTI.+\G8_.WXE?\$I95\VX\ >,ED'5-/\018/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?E7_ ,%SO^:)_P#<;_\ ;"OU4K\J_P#@N=_S1/\
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MVB_'_(_)#X;_ +''Q>^*7E2Z7X.O+&PDY%_JX^Q0[?[P\S#./]P-7U5\-_\
M@E'"GE3^/?&;2G@O8^'HMHS_ -=Y1R/^V8K]"**^<Q&?XNKI"T5Y;_>SY/%<
M3XZOI3M!>6_WO]+'D'PW_9)^$WPK\J31/!FGR7T>"+_4E-Y<;O[P:7=L/^YM
MKU^BBO J5:E9\U23;\SY:K6JUY<]63D_-W"BBBLC$**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O-OB3^SC\-/BYYC^*?!VFZA=R=;Z./R+K
M_O\ 1E7/T)Q7I-%:4ZDZ3YH-I^1K3JU*,N>G)I]UH? _Q*_X)4:->"6X\!^+
MKG3)>2MCKD8GB)]!+&%91]5<U\H?$O\ 8F^,'PO\Z6]\)W&L:?'S]OT(_;(R
M.[%5'F*/=D%?M/17OX?/L71TF^9>?^?_  Y]1A>)L?A]*C4UY[_>OUN?SS21
MO#(T<B,DBDJRL,$$=016EX=\4ZSX/U./4="U:^T74(_NW6GW#P2#Z,I!K]RO
MB-\!OA[\6HV'BWPCIFL3$;?M<D/EW*CT$R8D'X-VKY1^)7_!*WPQJGG7/@?Q
M3>Z#.?F6QU1!=09_NAQM=1[G>:^CH<086LN6LG'\5_7R/K<-Q3@L0N7$1<+_
M #7X?Y'SU\-/^"D7Q:\#^5;ZS/8^,[!>-NJ0[)POM-'M)/NX>OJ_X:?\%./A
MEXM,5OXGL]2\%WC8#23I]KM03V$D8W_B8P/>OB?XE?L(_&/X:F65_#+>([!,
M_P"F>'F-V#COY8 E ]RF*\"NK6:QN)+>XAD@GC;:\4JE64CJ"#R#71++<NQZ
MYJ=O6+_3;\#JGE.4YG'GHI>L'^FWX'[[>#?B!X9^(>FB_P##&OZ=KUIWET^Y
M28+[-M.5/L<&N@K^?+1==U+PWJ,6H:3J%UI=_$<QW5E.T,J?1E((KZ0^&G_!
M1/XO^ ?*@U#4[;QAIZ87R=;AW2@>TR%7)]W+?2O"Q'#E6.M":?D]'_7W'S6*
MX2K0UPU12\GH_P#+\C]?:*^,?AK_ ,%0OAYXE\JW\7:3J7@^[8X:=!]MM![[
MD D'T\L_6OJ;P+\4?"'Q,LOM?A7Q)IFOPA=SBQN5D>/_ 'T!W(?9@*^;KX+$
M87^+!K\OOV/D,3E^+P?\>FUY]/OV.HHHHKB//"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHIDTT=M"\LTBQ11J6>1R J@=22>@H
M?17A'Q)_;<^#OPQ\Z*[\6P:U?Q_\N.@C[9(3W&]?W:GV9Q7RK\2?^"K&K7?F
MV_@3P?;Z?'T6^UR4S2$>ODQE54_5V%>KA\KQF(UA!I=WI^9[>%R7'XO6G3:7
M=Z+\?T/TAKR;XD_M6?"GX4>;'K_C/3UO8R0UA8N;NY#?W3'$&*G_ 'L"OR.^
M)'[3OQ1^+'G1^)/&>I7-G+]ZPMI!;6I'H8H@JMCU8$^]>75]'A^&^N(J?)?Y
MO_(^NPO"/7%5?E'_ #?^1^C'Q(_X*M6</FV_@+P9)<MR%OO$$H1?^_$1)(_[
M: ^WI\J?$C]L[XP?%#S8M1\87>G6#Y'V'1<646T]5)CP[C_?9J\S\&_#OQ1\
M1+_[%X8\/:EK]R#\R:?:O-L]V*C"CW.!7T_\-_\ @F/\3_%GE3^)KO3?!=HV
M"R3R"[N@#W$<9V=.QD!]J]CZOEF6ZRLGYZO^O0]Y87)\H5Y\J?GJ_NU?W(^0
M9)&D=G=B[L<EF.23ZFM#0/#>K^*]2CT_1-+O=8OY/N6MA;O/*WT5037ZL?#?
M_@FK\)_!OESZZNH>,[U<$G4)S#;AO58HMO'LS-7TQX6\%Z!X'TX6'AW1-/T*
MR_Y]].M4@0GU(4#)]S7#B.(Z,-*$7+UT7^9YF*XLP]/3#P<GW>B_S_(_*#X;
M_P#!.7XO>.O*GU.PL_!U@^#YFL3CSBOM#'N8'V?;7U5\-_\ @EW\._#?E3^+
M=7U/QA=+@M A^Q6I]MJ$R?CY@^E?9U%?-XC.\97T4N5>7^>Y\EBN(\PQ.BGR
M+^[I^._XG*>!/A3X-^&-I]F\*>&=+T%"-K-96RI))_OOC<__  (FNKHHKPY2
ME-\TG=GS<YRJ2YIN[\PHHHJ2 HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSXA?!GP-\5K8P^+?
M"NF:X=NT37-N//0?[$HPZ_\  6%=G15QG*F^:#LRX5)TY<T'9^1\1?$S_@EG
MX*UTRW/@KQ#J'A:X;E;2\'VVV'^R"2LB_4LWTKY/^)7_  3_ /C'\.O-FAT!
M/%=@F3]I\/R?:&QV_<D"7/T0_6OV-HKW</GF,H:2?,O/_/<^FPO$F/P^DI<Z
M_O?Y[_?<_GMU'3;O1[V6SO[6:RNX3MDM[B,QR(?0J1D'ZT:;J=YH][%>6%W/
M8W<1S'<6TC1R(?4,""*_>CQU\*_!_P 3;/[+XK\-:9KT6W:K7ULKO&/]A\;D
M/NI%?+/Q*_X)=_#[Q)YMQX0UC4O!]TQ)6"0_;K4>P5R)!]?,/TKZ2AQ#AZFE
M:+C^*_S_  /KL+Q7A*WNXB+A^*_S_ ^1?AI_P4"^,7P[\F"?78_%FGQX'V;Q
M!'Y[D=_WP*RYQZL1[5]7_#7_ (*F>"->\JW\:>']0\*W!X:ZM#]MMO<G 61?
MH$;ZU\M?$O\ X)W_ !@\ >=/8:5;^,-/3GSM#FWRX]X7"N3[*&^M?..L:)J/
MAW4);#5;"ZTR^B.)+6\A:*5/JK $5URP.6Y@N:G:_>.C^[_-'?++<HS5<U)*
M_>+L_N_S1^[GP_\ C'X(^*EL)O"?BG2]=^7>T-K<*9D'^W$<.G_ @*[*OYZK
M2\GT^YBN;6:2VN(FW1S0N5=".A!'(->_?#7]O#XQ_#7RH5\3-XDL$/\ QY^(
M4-V#[>:2)1] ^*\/$<-S6M"=_)_Y_P##'S>*X1J1UPM2_D]/Q7^2/V7HKX7^
M&G_!5+PKJWE6WCCPQ?>'YR,->Z8XN[?/]XH=KJ/8;S7U9\.OCM\/OBS$K>$O
M%NF:S(PS]ECFV7('7)A?$B_BO:OF\1@,3A?XL&EWZ?>CY'%99C,'_&IM+ONO
MO6AWE%%%<!Y84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^5?_!<[_FB?_<;_ /;"OU4K\J_^"YW_ #1/_N-_^V%
M'W_^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM !1110 44
M44 ?RKT444 ?O]_P2X_Y,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9?]Q/_P!.
MEW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^*W_!%3_DZ;Q3_P!B9=?^EUC7[4U^*W_!%3_DZ;Q3_P!B9=?^
MEUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH@??_P".UY!XH^&OB[P2SKXA\+ZSH94X/]HV$L _-U%/ZAE>*^!1?H_\F/\
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M>"VV[L****0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /Q6_X(J?\ )TWBG_L3+K_TNL:_:FOQ6_X(
MJ?\ )TWBG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIF;R3,5_RY9]CT5\CK_P4]^#K, ;?Q*H)^\=/CP/_(M7_P#AY7\%?^?W6O\
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MT WU#HU5O%_<9O#UEO!_<SL**YT?$;PFQ 'B?1B3_P!1"+_XJM'_ (232?\
MH*67_@0G^-1R26Z,W3FMT:-%-1UD565@RL,AE.01ZTZH("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5F>(?#.C^+M-DT[7-*LM9T^3[]K?VZ3Q
M-]58$5IT4TW%W0TW%W6Y\K?$O_@F_P#"3QQYL^CVM[X,OVY#Z5,7@+>\,FX
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M_P#EQ?\ W+6B/^"L^E8&?AM> _\ 873_ .,U\2?\,Y_%C_HF'C+_ ,)^[_\
MC=9W_"E_B%_T(GB;_P $]Q_\11_965O9+_P)_P"8?V)DLMHK_P "?^9]]1_\
M%8?"S1J9/ 6KK)CYE6\B8 ^QP,_E5^W_ ."K?@-H5,_@WQ%'+W6-H'4?B7'\
MJ_.>3X;>+H9&1_"VM(ZG:RMITP((Z@C;5&?PIK=K,T4VCZA#*OWDDM75A]01
M1_8N7RV7XL/]7<JELO\ R9_YGZ:VO_!57X7O&3<^&?%T,F>%BMK608]<FX7W
M[5?L_P#@J1\(KG?YFE>++3;C'G6%N=WTVSG]:_*RZLY[&7R[B"2WDQG9*A4X
M]<&H:/[ P3V3^\7^J^7/9/[S]:+7_@IM\&KB0K)_PD-J ,[I=.4@^WRR$U?M
MO^"DOP2GF"/JFK6ZG_EI)IDA4?\ ?.3^E?D114/A[!^?W_\  (?"N7OK+[_^
M ?L-#_P44^!4DJHWBFZB4G!=])NL#W.(R?R%7U_X*!? -F 'CWD\<Z/?C_VA
M7XU45'^KF$_FE]Z_R,WPE@?YY_>O_D3]I?\ AN7X&?\ 10;+_P !;G_XU5]?
MVRO@HRAA\1='P1GEW!_]!K\2Z*C_ %;PW2<OP_R,WPCA.E27X?Y'[AP_M8?!
MR>)9%^)7AL*PR ]^BG\03D?C5^V_:5^$EU$)$^)WA!5/&)-<MHS^3.#7X6T5
MF^&Z'2H_P,WPAA^E67X'[PVGQW^&E^A>V^(?A2Y13@M#K=LP!].'J_:?%CP1
MJ&[[+XR\/W.W[WDZI V,],X>OP/HJ'PU3Z57]QF^#Z72L_N7^9^_]KXZ\-WT
MACMO$.E7$@&XK%>Q,<>N U7[?6M.O)EB@O[6:5ND<<RLQXSP :_GQHJ'PS'I
M5_#_ ()F^#X]*_\ Y+_P3^ANBOYYHI7AD62-VCD4[E93@@CN#5__ (235_\
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MOASXH75RT-E#FQU2&%IGD _Y9,%R<GL>GKBM7XD?\%7(4\VW\!>#&E/.R_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$%016O!^QG\;+B18U^'6KAF. 9%1!^)+ #\:/J&4QW4?_ O^"']F9%#=1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9SCJ,5U-%%4Y2DDF]BY3E))2=[;!1114D!1110 4444 %%%% !1110 4444
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M??\ X'YGR&?9\\4WAL,_<ZOO_P #\PHHHKY,^'"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH\=C*RG\0M:T'P5^(=TT8A\!^)IC)@((]'N&W9Z8PG.:_>BBLWQ+/I27W_\
M ,GQA4Z45]__  #\+;7]FGXMWDOEI\,?%RMC.9=$N8Q^;(!6I:?LB_&:\#&/
MX;Z^NWKYUJ8_RW8S^%?M]163XDK]*:_$Q?%V)Z4H_B?BK;_L1?'&ZA61/AYJ
M"JW0230(WY-("*UX/^"??Q[F:,'P*(E8CYY-7L<*#W($^?TS7[)T5F^(\5TA
M'\?\S%\78WI"/W/_ #/R!M?^"</QPN)-LFA:=;+C.^758"/I\K$_I6I:?\$R
MOC+<JQD'A^U(Z";42<_3:AK]:J*S?$.,?2/W?\$R?%68/917R?\ F?E5;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y5_\%SO^:)_]QO\
M]L*_52ORK_X+G?\ -$_^XW_[84 ??_[)W_)K/P;_ .Q,T;_TAAKU6O*OV3O^
M36?@W_V)FC?^D,->JT %%%% !1110!_*O1110!^_W_!+C_DQ/X9?]Q/_ -.E
MW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'XK?\$5/^3IO%/_ &)EU_Z7
M6-?M37XK?\$5/^3IO%/_ &)EU_Z76-?M30 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[K1["]
MU"TOKBQMI[VSW?9KF6%6DAW##;&(RN1P<=:N44[M;#3:V"BBBD(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\5>%=*\:Z#=Z-K5E'?Z==
M(4EAE&00>X]#7R9\*_\ @G'X;\"?%W4/$NJWL6M^'H9!+I&ER1G<C'D^=G@[
M3P,9SWQTK[)HKLHXNOAX2A2E92W._#X[$X6$Z=&;2EN-55C5550JJ,!0, #T
MIU%%<9P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7Y5_\%SO^:)_]QO_ -L*_52ORK_X+G?\T3_[
MC?\ [84 ??\ ^R=_R:S\&_\ L3-&_P#2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZ
MK0 4444 %%%% '\J]%%% '[_ '_!+C_DQ/X9?]Q/_P!.EW7U57RK_P $N/\
MDQ/X9?\ <3_].EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!^*W_  14_P"3IO%/_8F77_I=8U^U-?BM_P $
M5/\ DZ;Q3_V)EU_Z76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?E7_P7._YHG_W&_P#VPK]5*_*O_@N=_P T3_[C?_MA0!]__LG?\FL_
M!O\ [$S1O_2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4444 %%%% '\J]%%%
M'[_?\$N/^3$_AE_W$_\ TZ7=?55?*O\ P2X_Y,3^&7_<3_\ 3I=U]54 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?BM_P14_Y.F\4_\ 8F77_I=8U^U-?BM_P14_Y.F\4_\ 8F77_I=8U^U- !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5^5?_  7._P":)_\ <;_]
ML*_52ORK_P""YW_-$_\ N-_^V% 'W_\ LG?\FL_!O_L3-&_](8:]5KRK]D[_
M )-9^#?_ &)FC?\ I##7JM !1110 4444 ?RKT444 ?O]_P2X_Y,3^&7_<3_
M /3I=U]55\J_\$N/^3$_AE_W$_\ TZ7=?55 !1110 4444 %%%97B?Q5HO@G
M0[K6O$6L6&@:-:A3<:CJETEM;P[F"KOD<A5RS*HR>20.] &K17E7_#6/P0_Z
M+)\/_P#PJ+'_ ..UH>'_ -I#X2^+-9M-(T3XH^"]9U:\?R[:PT_Q#:3SS/\
MW4C20LQ]@* /1:**\F\>?M9?!OX9:U+I'B;XE>'-*U:%MDUB]\CSPMZ2(F2A
M_P!X#MZT >LT5@^"_'GAKXCZ''K/A77]-\1Z5(=JWFEW27$6[ )4LA(##(R#
MR*WJ "BBDSCD\"@!:*\9\0_MF? SPKK3Z3J?Q5\+V^H1R&*2%=123RW!P5=D
M)"D'KN(QSZ&O5?#_ (BTKQ9I%MJNB:G9ZSI=RNZ"^T^X2>"5<XRKH2K#/H:
M-&BBO)O'G[67P;^&6M2Z1XF^)7AS2M6A;9-8O?(\\+>DB)DH?]X#MZT >LT5
M@^"_'GAKXCZ''K/A77]-\1Z5(=JWFEW27$6[ )4LA(##(R#R*WJ "BBB@ HH
MHH _%;_@BI_R=-XI_P"Q,NO_ $NL:_:FOQ6_X(J?\G3>*?\ L3+K_P!+K&OV
MIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_P""YW_-$_\
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M1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\
M#0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"
M?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_H
MI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\
MP?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]
M:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:
M_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ]
M HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_
M /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\
MAH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#A
MH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12
M_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\
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M_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\
MQR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#Q
MR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS
M_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:
M$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X
M6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6
M?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__
M (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7
M_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_
M ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?
M\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/
M^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*
M7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7
MX/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P '
MUK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <
MH ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#
MT"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T
M"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X
M:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G
M_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\
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M /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\
M_!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\
M<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ]
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M1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\
M#0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"
M?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_H
MI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\
MP?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]
M:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:
M_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ]
M HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_
M /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\
MAH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#A
MH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12
M_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\
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M_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\
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M_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\
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M /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\
M_!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\
M<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ]
MHKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO
M/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/
M_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%
MG_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_
M!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!
M_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^
M#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY
M1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\
M#0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"
M?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_H
MI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\
MP?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]
M:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:
M_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ]
M HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_
M /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\
MAH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#A
MH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12
M_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\
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M_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\
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M_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\
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M /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\
M_!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\
M<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ]
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M1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\
M#0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"
M?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_H
MI?@__P 'UK_\<H ] HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\
MP?6O_P <H ] HKS_ /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]
M:_\ QR@#T"BO/_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:
M_P#QR@#T"BO/_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ]
M HKS_P#X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_
M /X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QR@#T"BO/_\
MAH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\ _!]:_P#QR@#T"BO/_P#A
MH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<H ] HKS_P#X:$^%G_12
M_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <H ] HKS_ /X:$^%G_12_!_\
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M[=_EL=N=K8SUVGTH _1_]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\
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M'N^AS6MX2_X*^^*/ ?AF'PQ\2?A%K%W\2+&(0/LD-D+V1<C?)"\1:)B!R%#
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MP$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\
MP4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/
MP$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\
MP4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4
M>*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z
M)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?
MX4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z
M)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?
MX5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\
M,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/
M_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\
M,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/
M_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[7
M10!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_
M3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!
M3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_
M3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!
M3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!X
MI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD
M/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A
M1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD
M/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A
M7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ
M3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__
M ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ
M3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__
M ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=%
M 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/
M^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,
M7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/
M^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,
M7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG
M_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^
M#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'
M_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^
M#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>
MUT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/
MP$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\
MP4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/
MP$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\
MP4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4
M>*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z
M)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?
MX4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z
M)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?
MX5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\
M,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/
M_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\
M,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/
M_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[7
M10!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_
M3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!
M3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_
M3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!
M3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!X
MI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD
M/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A
M1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD
M/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A
M7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ
M3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__
M ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ
M3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__
M ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=%
M 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/
M^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,
M7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/
M^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,
M7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG
M_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^
M#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'
M_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^
M#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>
MUT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/
MP$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\
MP4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/
MP$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\
MP4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4
M>*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z
M)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?
MX4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z
M)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?
MX5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\
M,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/
M_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\
M,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/
M_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[7
M10!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_
M3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!
M3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_
M3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!
M3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!X
MI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD
M/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A
M1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD
M/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A
M7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ
M3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__
M ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ
M3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__
M ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=%
M 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/
M^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,
M7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/
M^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,
M7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG
M_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^
M#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'
M_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^
M#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>
MUT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/
MP$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\
MP4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/
MP$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\
MP4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4
M>*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z
M)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?
MX4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z
M)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?
MX5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\
M,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/
M_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\
M,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/
M_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[7
M10!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_
M3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!
M3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_
M3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!
M3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!X
MI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD
M/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A
M1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD
M/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A
M7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ
M3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__
M ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ
M3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__
M ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=%
M 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/
M^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,
M7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/
M^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,
M7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG
M_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^
M#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'
M_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^
M#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>
MUT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/
MP$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\
MP4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/
MP$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\
MP4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4
M>*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z
M)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?
MX4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z
M)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?
MX5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^%>UT4 >*?\
M,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A7M=% 'BG_#%/P$_Z)#X/
M_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X5[710!XI_PQ3\!/^B0^#_\ P4Q?X4?\
M,4_ 3_HD/@__ ,%,7^%>UT4 >*?\,4_ 3_HD/@__ ,%,7^%'_#%/P$_Z)#X/
M_P#!3%_A7M=% 'BG_#%/P$_Z)#X/_P#!3%_A7YP_\%AO@IX"^#W_  J3_A!_
M"&C^%/[1_M?[9_9-HD'G^7]B\O?M'.WS'QGIN/K7[$U^5?\ P7._YHG_ -QO
M_P!L* /O_P#9._Y-9^#?_8F:-_Z0PUZK7E7[)W_)K/P;_P"Q,T;_ -(8:]5H
M **** "BBB@#^5>BBB@#]_O^"7'_ "8G\,O^XG_Z=+NOJJOE7_@EQ_R8G\,O
M^XG_ .G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _%;_@BI_R=-XI_[$RZ_P#2ZQK]J:_%;_@BI_R=-XI_
M[$RZ_P#2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\J
M_P#@N=_S1/\ [C?_ +85^JE?E7_P7._YHG_W&_\ VPH ^_\ ]D[_ )-9^#?_
M &)FC?\ I##7JM>5?LG?\FL_!O\ [$S1O_2&&O5: "BBB@ HHHH _E7HHHH
M_?[_ ()<?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_ "8G\,O^XG_Z=+NOJJ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\5O^"*G_ "=-XI_[$RZ_]+K&OVIK\5O^"*G_ "=-XI_[$RZ_]+K&OVIH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "ORK_X+G?\ -$_^XW_[85^JE?E7_P %SO\ FB?_ '&__;"@
M#[__ &3O^36?@W_V)FC?^D,->JUY5^R=_P FL_!O_L3-&_\ 2&&O5: "BBB@
M HHHH _E7HHHH _?[_@EQ_R8G\,O^XG_ .G2[KZJKY5_X)<?\F)_#+_N)_\
MITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /Q6_X(J?\G3>*?\ L3+K_P!+K&OVIK\5O^"*G_)TWBG_ +$R
MZ_\ 2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\J_\
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MOVIK\5O^"*G_ "=-XI_[$RZ_]+K&OVIH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "ORK_X+G?\T3_[C?\ [85^JE?E7_P7._YHG_W&_P#VPH ^
M_P#]D[_DUGX-_P#8F:-_Z0PUZK7E7[)W_)K/P;_[$S1O_2&&O5: "BBB@ HH
MHH _E7HHHH _?[_@EQ_R8G\,O^XG_P"G2[KZJKY5_P""7'_)B?PR_P"XG_Z=
M+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#\5O\ @BI_R=-XI_[$RZ_]+K&OVIK\5O\ @BI_R=-XI_[$RZ_]
M+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_X+G?\
M-$_^XW_[85^JE?E7_P %SO\ FB?_ '&__;"@#[__ &3O^36?@W_V)FC?^D,-
M>JUY5^R=_P FL_!O_L3-&_\ 2&&O5: "BBB@ HHHH _E7HHHH _?[_@EQ_R8
MG\,O^XG_ .G2[KZJKY5_X)<?\F)_#+_N)_\ ITNZ^JJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_X(J?\G3>
M*?\ L3+K_P!+K&OVIK\5O^"*G_)TWBG_ +$RZ_\ 2ZQK]J: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K\J_\ @N=_S1/_ +C?_MA7ZJ5^5?\
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M** "BBB@ K\J_P#@N=_S1/\ [C?_ +85^JE?E7_P7._YHG_W&_\ VPH ^_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^5?_!<[_FB?_<;_ /;"OU4K\J_^"YW_ #1/_N-_^V%
M'W_^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM !1110 44
M44 ?RKT444 ?O]_P2X_Y,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9?]Q/_P!.
MEW7U50 4444 %%%% !1110 4444 ?/\ ^W%^TO\ \,K_  "U7Q99I!<>(KJ5
M--T:WN.4:ZD!.]AW5$5W([[ N1NS7Q-^SW_P31O/VJ/ MG\6/CG\0/$UUKOB
MB!;ZQALKB-IDMG&Z%Y9)DD&&!#+&@4*I7GG"W?\ @N/X@FCT_P"$&B1R8MYI
M=4O9H_5D%LD9_ 22_G7Z<^&=#@\+^&])T:U54MM.M(K2)5& $C0(H [# % '
MY++_ ,)U_P $F_VCO#.E7/B:Z\2?!/Q3*=T<^0JQ!U69_+Y"7$)D1R4XD4@'
M&2%_7J.198U=&#HPRK*<@CU%?GA_P6RT6&?]GOP1J[*IN+7Q2EJC8Y"RVEPS
M 'TS OY"OL#]EKQ!-XI_9I^%>K7+;[F[\+Z;),V<YD^S1[C^>: /4:^!/^"F
MW[4WB_P3J/A#X*?"^[EL_'7C)HQ/>V<ICN;>&680P11.#\CRR!P7SE53C[V1
M]]U^4'B=QX^_X+=:5I]XRS6FE30BV5AD)]GT8W('U$VXT =IIG_!%'PI?>"M
M_B#XC>()O'MQ&9;B_MEA>P%PP);]VZ>;(-Q^\9%+8S@9P(_V ?CI\0/@Q^T1
MKW[+OQ8U235KBT\P:'>SS-*T;I'YPC1V^9H9(#YB!N5VA<#=@?I?7Y/?MP3?
M\('_ ,%5_@KK5IMCEOQH4UPP^7<K7\UL^3[QIC/IB@#[A_;B_:7_ .&5_@%J
MOBRS2"X\174J:;HUO<<HUU("=[#NJ(KN1WV!<C=FOB;]GO\ X)HWG[5'@6S^
M+'QS^('B:ZUWQ1 M]8PV5Q&TR6SC="\LDR2## AEC0*%4KSSA;O_  7'\031
MZ?\ "#1(Y,6\TNJ7LT?JR"V2,_@))?SK].?#.AP>%_#>DZ-:JJ6VG6D5I$JC
M "1H$4 =A@"@#\EE_P"$Z_X)-_M'>&=*N?$UUXD^"?BF4[HY\A5B#JLS^7R$
MN(3(CDIQ(I .,D+^O4<BRQJZ,'1AE64Y!'J*_/#_ (+9:+#/^SWX(U=E4W%K
MXI2U1L<A9;2X9@#Z9@7\A7V!^RUX@F\4_LT_"O5KEM]S=^%]-DF;.<R?9H]Q
M_/- 'J-%%% !1110!^*W_!%3_DZ;Q3_V)EU_Z76-?M37X;?\$B?B%X5^&O[2
M7B34_%WB71_"NFS>$KFVCO-;OXK.%Y3>6;",/(R@L51SMSG"D]C7ZZ?\-8_!
M#_HLGP__ /"HL?\ X[0!ZK17E7_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/P0_Z
M+)\/_P#PJ+'_ ..T >JT5Y5_PUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/^BR?
M#_\ \*BQ_P#CM 'JM%>5?\-8_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__
M /"HL?\ X[0!ZK17E7_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/P0_Z+)\/_P#P
MJ+'_ ..T >JT5Y5_PUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/^BR?#_\ \*BQ
M_P#CM 'JM%>5?\-8_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__ /"HL?\
MX[0!ZK17E7_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/P0_Z+)\/_P#PJ+'_ ..T
M >JT5Y5_PUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/^BR?#_\ \*BQ_P#CM 'J
MM%>5?\-8_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__ /"HL?\ X[0!ZK17
ME7_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/P0_Z+)\/_P#PJ+'_ ..T >JT5Y5_
MPUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/^BR?#_\ \*BQ_P#CM 'JM%>5?\-8
M_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__ /"HL?\ X[0!ZK17E7_#6/P0
M_P"BR?#_ /\ "HL?_CM'_#6/P0_Z+)\/_P#PJ+'_ ..T >JT5Y5_PUC\$/\
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M_P#': /5:*\J_P"&L?@A_P!%D^'_ /X5%C_\=H_X:Q^"'_19/A__ .%18_\
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M_P#^%18__':/^&L?@A_T63X?_P#A46/_ ,=H ]5HKRK_ (:Q^"'_ $63X?\
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M_P#A46/_ ,=H ]5HKRK_ (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\
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M_P"BR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\
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M_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\
MX[1_PUC\$/\ HLGP_P#_  J+'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T
M?\-8_!#_ *+)\/\ _P *BQ_^.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#
M6/P0_P"BR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\
M$/\ HLGP_P#_  J+'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_
M *+)\/\ _P *BQ_^.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"B
MR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\ HLGP
M_P#_  J+'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\
M_P *BQ_^.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\
M"HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\ HLGP_P#_  J+
M'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *BQ_^
M.T >JUDZEXLT/1=:TG1]0UG3[#5M7:1=-L+FZ2.>],:[Y!#&Q#2%5(9MH.!R
M:X#_ (:Q^"'_ $63X?\ _A46/_QVOFK]H/\ :$^%FM?M:?LQ:QI_Q+\'W^DZ
M1=^(&U*_MM>M9(+(26")&9I%D*QAF!5=Q&3P* /NJBO*O^&L?@A_T63X?_\
MA46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/
M_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =
MH_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:
MQ^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'
M_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/
MA_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\
M^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18
M_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#Q
MV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U
M6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*
MO^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L
M?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_
MT63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X
M?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\
MA46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/
M_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =
MH_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:
MQ^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'
M_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/
MA_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\
M^%18_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18
M_P#QV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#Q
MV@#U6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U
M6BO*O^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*
MO^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L
M?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_
MT63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X
M?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QV@#U6BO*O^&L?@A_T63X?_\
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M_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\
MX[1_PUC\$/\ HLGP_P#_  J+'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T
M?\-8_!#_ *+)\/\ _P *BQ_^.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#
M6/P0_P"BR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\
M$/\ HLGP_P#_  J+'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_
M *+)\/\ _P *BQ_^.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"B
MR?#_ /\ "HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\ HLGP
M_P#_  J+'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\
M_P *BQ_^.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\
M"HL?_CM 'JM%>5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\ HLGP_P#_  J+
M'_X[0!ZK17E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *BQ_^
M.T >JT5Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM
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MP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\
M_"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL
M?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM
M 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM
M%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?
M\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_
M!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_H
MLGP__P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP_
M_P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"
MHL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_
M ([1_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1
M_P -8_!#_HLGP_\ _"HL?_CM 'JM%>5?\-8_!#_HLGP__P#"HL?_ ([1_P -
M8_!#_HLGP_\ _"HL?_CM 'JM?E7_ ,%SO^:)_P#<;_\ ;"OO_P#X:Q^"'_19
M/A__ .%18_\ QVOS5_X+*?%CP1\4/^%0?\(;XR\/^+?L/]L?:_["U2"]^S[_
M +%L\SRG;;NV/C.,[6QT- 'Z5?LG?\FL_!O_ +$S1O\ TAAKU6O*OV3O^36?
M@W_V)FC?^D,->JT %%%% !1110!_*O1110!^_P!_P2X_Y,3^&7_<3_\ 3I=U
M]55\J_\ !+C_ ),3^&7_ '$__3I=U]54 %%%% !1110 4444 %%%% 'Y5_\
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M9T'X@/\ D:_4;0M7@\0:'I^J6QW6U];QW,1!SE74,.?H17SI_P %"OV:[O\
M::_9UU+1M%A6;Q5H\ZZOI$9P#-+&K*\ 8XQYD;N!DXW;,],CY=_9(_X*B>%?
MAE\,-/\ AW\:;'6?#WB7PI -,CNEL'E\^&)0L:2H,/',H 0@K@[02020 #K_
M /@MAJD,/[./@S36(^T7'BR*X09YVQV=TK<?65:^N?V5=%E\._LQ_"?39XC#
M<6_A73%FC88*R?98RX/T8FOS2\>>*M=_X*R?M.>%M#\-:)J.E?!_PI(7O-0N
MUV,(G9#/(Y4E5ED5%CCC!8C&X\;]OZ]VUO%9V\5O!&L4,2!$C48"J!@ >P%
M$M%%% 'G_P :O@+X$_:)\*VOAOXA:%_PD&BVMZFH0VWVN>VVSK')&K[H9$8X
M6608)Q\W3(&/%?\ AUQ^S%_T3/\ \K^J?_)-?55% 'Y<:W_P0YL+K6+V;2OC
M!-I^FR3,UM:7'AP7$D,9)*HT@NTWD# W;5SCH*I?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?
M\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE%
M'Y5_\.,?^JV?^6I_]VT?\.,?^JV?^6I_]VU^JE% 'Y5_\.,?^JV?^6I_]VTJ
M_P#!#$;AN^-9*YY \*8/_I;7ZIT4 <[\.?!5I\-?A[X8\(V$TMQ8Z!I=KI5O
M--CS'C@B6)6;'&2$!-=%110 4444 %%%% '\J]%%% '[_?\ !+C_ ),3^&7_
M '$__3I=U]55\J_\$N/^3$_AE_W$_P#TZ7=?55 !1110 4444 %%%% !1110
M 5Q7C+X(_#KXC:@E_P"+/ /A?Q1?(NU;K6=&MKN55XX#2(QQP/RKM:* ,SP[
MX9T?PCI<>FZ%I-CHNG1DE+/3K9((5).20B  9^E7;NT@U"UFM;J&.YMID:.6
M&9 R2(1@JP/!!!((-344 9>A^%]&\,1RQZ-I%CI*3$-(MC;)"'(Z$A0,_C6I
M110!YU=?LX_":^UE]7N?A?X,N-6D;>]]+X?M&G9L8R9#'N)QWS7H4,*6\211
M(L<2*%5$& H'  '84^B@ KBO&7P1^'7Q&U!+_P 6> ?"_BB^1=JW6LZ-;7<J
MKQP&D1CC@?E7:T4 9GAWPSH_A'2X]-T+2;'1=.C)*6>G6R00J2<DA$  S]*T
MZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXN>*_ /Q4\??LS>.=2_M2?PHT[Z-=/(6")!*L4L$9;DQD.DB+_" _; 'Z0T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6U+4K31]/N+Z_NH;&
MRMXVEFN;F01QQ(!DLS$@  =2:\%O?^"@7[.^GZI_9\OQ7T)I\XWPM)+#W_Y:
MHA3M_>KXZ_X*1>)/%?[0G[5'P]_9RT:_DTKPS<2VKZA,J-LDNI=SLSXX<10!
M75?[SMGL1]0>'?\ @F-^SGH/A6+1)O *:PXB"2ZGJ%]<&[F8 @N71U"$YSA
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MUI-G@11Q7<),T6P<!%<><JCA<+C@ 4 ?KE1110 4444 %%%% !1110 4444
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M ' _\%2-+CU+]AWXB,R@R6K:?<1D]B+^W!/_ 'RS#\:C_P""6>J2ZE^P_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJRQR$8\PMPAX4_6OR%_:9_:J\;?M;>//"_@7XL1#X"?#Q;L7<D5_IUW-)N
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M#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\ N)_^G2[KZJH **** "BBB@ HHHH
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MF;X;67@WPA^S@RVT1,MU?7'A_4S<WTQ^]+,RD;F[#C"J !P*]-_X>8?M3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_('_@K+>?%7XL_'*U\&Z+X.\3:IX)\,6T,D1TW2KB:W
MN;N:,222[T0JQ5'6,<G;M?NS"OU^HH _(CX>_MW?M#?"KP7I/A3PM^S/#I&A
M:7 L%M:P>'M5  '5F.[+,QRS,>6))))-=;I/_!2;]J&]U6RMY_V?O)@FF2.2
M3^P-4&U2P!.2W85^I5% '@W[:W[,T/[5?P)U/PA'-%9Z];RKJ.C7<Q(CCNXP
MP4.0"=CJ[H>#C?NP2H%?#'P>_;G^-?['GA6T^%GQ5^#&N>(KC1D%EI%]&[P.
M\2@+%"'6*2.=!C:LD;<  88BOU@HH _+'X2_!GXN_M\?M,:+\7?C)X8G\'_#
MGPZZRZ5H5["T8G6.3?';I&X#NK/AI)F4!P-HXP$^MO\ @HAX^\;^!/V9=:3X
M>Z7JFI>)M<N(]'C?1[62XN+6*57::4+&I*_NXV0-QM,BD'.*^F** /PB_9/^
M)?QF_9%35[CPW^SY>:UKFID)+K.K^']1:YCA&,01E-H1-PW' RQQDG:N/HG_
M (>8?M3?]&]?^6_JO_Q5?JI10!\;^&?VIOBWXJ_8C\>_$C5/A_=:#\1K&6>P
MTO0[/2[D2LS>3'#.() SOM:8L>,$1GWK\T/V;?$WQF_9Q^(6J^.8/@9J_C+Q
M9>AO+U/Q%H6H2R6S.299(]H7]Y)G!<Y;&0" S9_?>B@#\J_^'F'[4W_1O7_E
MOZK_ /%5]:?L._M'?$[]H?2O%UQ\2O /_""3Z7-;1V4?V"ZM?M*R+(7.)R=V
MTHOW>F[FOJ"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]L+]D!(/BEX=?PKJ7BVROK+4M+B@EMWM-MS-%$ZI-EE;;''(-V1D@]*^@:*
M/R0^$WBCX^?\$O\ 6=>\(:Y\.K[XE?#.\N7O+._TGS/*1N$\Y)4201;P$W0R
MJ#E05/4MH?&3]H+]H'_@H3I,?PV^&_PFU7P1X-U)D;4M8U1I5CN(@P8"2Y,:
M1QQ="8TWN^WC(RI_5^B@#QS]DS]G+3?V6?@GI'@:QN?[0NXV:\U+4 NT75W)
MCS' [* JHHZ[47/.:]CHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z*** /W^_
MX)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\ N)_^G2[KZJH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _E7HHHH _?[_ ()<?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_ "8G\,O^XG_Z
M=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\
MAD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.
M^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A
M_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\
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M_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\
M_A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2
M]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8_
M_&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\ _A+V/_QJ
MO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6
MB@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH
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M_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\
MQJC_ (9.^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H
M_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\
MAD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.
M^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A
M_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\
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M_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\
M_A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2
M]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8_
M_&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\ _A+V/_QJ
MO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6
MB@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH
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M_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\
MQJC_ (9.^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H
M_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\
MAD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.
M^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A
M_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\
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M_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\
M_A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2
M]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8_
M_&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\ _A+V/_QJ
MO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6
MB@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH
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M_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\
MQJC_ (9.^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H
M_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\
MAD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.
M^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A
M_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\
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M_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\
M_A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2
M]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8_
M_&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.^"'_ $1OX?\ _A+V/_QJ
MO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A_P!$;^'_ /X2]C_\:KU6
MB@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH
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M_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\
MQJC_ (9.^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H
M_P"&3O@A_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\
MAD[X(?\ 1&_A_P#^$O8__&J]5HH \J_X9.^"'_1&_A__ .$O8_\ QJC_ (9.
M^"'_ $1OX?\ _A+V/_QJO5:* /*O^&3O@A_T1OX?_P#A+V/_ ,:H_P"&3O@A
M_P!$;^'_ /X2]C_\:KU6B@#RK_AD[X(?]$;^'_\ X2]C_P#&J/\ AD[X(?\
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M2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /*OV3O\ DUGX-_\ 8F:-_P"D,->JUY5^R=_R:S\&_P#L
M3-&_](8:]5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKYM_; _; TK]G70#I>EF'4_'=]%FTL6
M.Y+1#P)Y@.W]U>K$>@)KHH4*F)J*E25VSJPV&JXRJJ-%7DSZ2HKX"_8K_;VG
M\1:A#X&^*&I*^HW,I&F>()]J"5V.1!-C !R<(W /"GG!/W[6N+P=7!5/9U5_
MDS?'8"ME]9T:R]'T?H%%%%<1YP4444 %?-'Q*_;N\)?#']IGP_\ !2_\/ZU=
M:_K5Q8V\.H6XA^RHUTX5"V7#8!/.%^F:^EZ_(O\ :U_Y2\?##_L)^'?_ $>M
M 'ZZ4444 ?.'QZ_;A\*?L_\ QN\&?#+6-!UG4=6\4):O;7EB(O(B\^Y>W7?N
M<-PR$G /!KZ/KYE_:#^(_P"SKX7^.W@C1_B?H^GWWQ'O$M#H5S<Z*]U+&K73
MI!MF"$)B8.1DC!YKZ:H **^6?B__ ,%+O@/\&_$%WH5_XEN->UBS<QW-KX?M
M&NA"X."C2DK'N!SD!B1@@X-:7A[_ (*)? CQ-\--;\;VGC C3=$$)U*RELY1
M?6PEE6)&,&W<ZEW0;TW*-PR10!]*45S'PS^)&A?%WP)H_C#PQ<O>:#JT1GM)
MY(6B9T#%<E& (Y4]17COQK_;_P#@?\!=;GT/Q'XP2ZU^W;9/I6CV[WDT# X*
MR%!LC8=U=@WM0!]$T5\<>"?^"LG[/7C'5(;&XUW5?#+S/Y:3:WIK)#DXQN>,
MR!1SU; &.2!7U_8:A;:K8V][97,-Y9W$:S0W%NX>.5&&596'!!!!!'!S0!8H
MKQ+1_P!LSX1ZQXR\=>&?^$JCL-1\$+,^NR:C!);6]H(IA"Y\UP$;]XP4;2<Y
M&,UXY>_\%<OV=[3Q!_9R:QKEU:[]IU6'1Y/LPYQNPQ$F/HF: /M"BN8^&_Q-
M\+?%[PC9^)_!NN6GB#0KO/E7EHQ(W#JK*0&1AW5@".XK.^+WQL\$? ?PJWB+
MQYXBM?#VE;O+C>XW-),^"=D4:@O(V 3A03@9H [BOG7X?_MM>%?B%^TYXD^"
M-EH6L6VOZ']I\[4)Q%]ED\DJ&VX<MSN&,K7$>"_^"K7[/?C+Q/!HI\0:EH33
MR+%#?:SI[0VK,V  9 6\L9/+.%4=2<<U\T_LO2I-_P %?/BK)&ZR1N-5974Y
M# M%@@^E 'ZKT444 ? 'BW_@LE\,O"'BK6=!N?!/BR:XTN]FL99(A:[':.1D
M)7,N<$KQFLG_ (?:?"S_ *$7QA_WS:__ !ZO$/\ @F[X>TKQ+_P4$^,MKJ^F
M6>JVR:?K,BPWUNDR!QJUJ P# C."1GW-?JE>?!GX?ZA"8;KP+X:N8LY\N;2+
M=USZX*4 ?/?P/_X*@?!#XX>)++P];ZAJ?A/6KUQ%:VWB2V2!)Y#P$66-WC!)
MX 9E)/ Y(%?2_C_QA;?#WP)XD\4WL,MS9Z'IMSJ<T,&/,D2&)I&5<D#<0I R
M<9K\S/\ @KI^RM\/_ /PYT#XE^#]!T[PGJYUA-+O;;2H%MH+Q)(I'5_+3"B1
M3">5 +!V)S@5].^"/'^J_%#_ ()BWOB37)))]7NOAYJ4=S<3$EYWBM9X3*Q[
ME_+WD]RU 'HG[)W[6/AW]KKP;K'B3PWH^J:-:Z9J']GR1:H(][/Y:2;AL9AC
M#@<GL:]QK\J?^"6OQ^\!?L\_LM>.-?\ 'WB*WT&QD\4-';QN&DGN7%I 2D42
M NYY&<# R"2!S7TAX-_X*Q?L]^+O$$6E2ZYJOA[S9?*CO=9TYHK9B3@$NA?8
MI_O.% [XH ^QJ*BM;J&^M8;FVFCN+:9%DBFB8,CJ1D,I'!!!R"*\6^.W[9_P
M?_9QN_[/\;>+[>UUHH'71[&)[J\P1D%HXP?+!'(,A4'L: /;J*^+-!_X*[?L
M\ZSJ@M+G4M>T6(OM%Y?Z0YA[\_NF=@/JO?ZU]>^%/%FB^.O#MAKWA[5+76M%
MOXQ-;7UE*)8I5/<,/?(([$$'D4 :U%>-ZM^US\+M!^,VI?"[4_$)T_Q;IMF]
M_=QW-M(EO! MM]I:1IROE@"+YC\WM7G7PY_X*8? KXI?$RR\$:)K>J'4]0NE
ML]/N+C2Y4M[R5CA51L%ER>\BJ/7% 'U317B>B_ME?";6_&7CWPRGB<6>H^!H
M[B;7GOK:2W@M$AE$4A\UU"MAR -I.<\9KQ[_ (>W?L[?\)%_9G]MZU]DW;?[
M6_L>7[+][&<?ZW&.?]7T]^* /LVBO*?'O[5'PJ^&OPSTWQ_KOC338?"VJ)OT
MZ\MW,[7W&=L,: LY'< ?+_%C!KQ_X;?\%1_@#\2O%-MH$/B&^T"\NIO(MI==
MLC;6\K$X7]Z"RH#V+E?PH ^MJ**^=OC7^W_\#_@+K<^A^(_&"76OV[;)]*T>
MW>\F@8'!60H-D;#NKL&]J /HFBOCCP3_ ,%9/V>O&.J0V-QKNJ^&7F?RTFUO
M362')QC<\9D"CGJV ,<D"OK^PU"VU6QM[VRN8;RSN(UFAN+=P\<J,,JRL.""
M""".#F@"Q17G7QI_:%^'O[/.@Q:OX_\ $]IX?MYRRV\4@:2>X8#)$<2 N^.,
MD# R,D9KYY\/_P#!6K]GC7=:2PFUO6-'1W5%O=0TJ00$G')*%F49/)90!].:
M /LNBL_P_P"(=+\6:+9:QHNHVNK:3>Q+-;7UE,LL,T9Z,CJ2&!]17F/QZ_:P
M^%W[--K _CWQ1!IM[<IOMM+MT:XO)UY&X1("0N01O;"Y&,YH ]>HKXZ\#_\
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M_BW^RK^VUXEBT?0KR;X+:@+FTDU:XO;<JUOL,MHYC\P.TB2!8B0F?G<X )H
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M>")M09-4^&FOV=CNPL]I?07$A7GDHP0 ].-QZGGCG[@^!/[1?@#]I'PJ^O>
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MA)_P4V^ _P 8/%EIX;L-?OM#U:]E$%G'KMD;>.XD)PJ+("R MV#%<D@#D@4
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MM\>%?'/P.\*W#_#Z:ZM[O4$@O8(8+2&21H[ZU"R2*2GE@NJX.-ZA<E0![O\
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M@CB@#O?AS\2O#'Q<\(6/BCP?K5KK^@WH)AO+5B5)!PRL#@JP/!5@"#U%>/\
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MHH **** "O*O#G_)TWQ#_P"Q,\,_^EVO5ZK7E7AS_DZ;XA_]B9X9_P#2[7J
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M_P"ZJX?[4RKNO_ 7_D>;_;.2?S+_ , ?_P B?&O_  T9\6/^BG^,O_"@N_\
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M8R &'0UI_P#!$?\ Y(O\0_\ L8(__29*]*_X*\_\F;:C_P!AJP_]#:@#TWX
MZYXO^*/["WA"ZT/5(K/QOJ7A!+6TU;4&8K'=B$PK<.0&)(9=_0Y->1_L6_\
M!-?0?@7I>M:O\5].\-^/?&EY=LT-U)&U[:6MMM&-JW$:_O68N68J>-H!ZYM?
M#'XXG]G'_@EMX5^($5FFHWFE^'H5M+60D))<2W'DQ;L<[0T@9L8.%.#FOF#]
MG+]CWQ__ ,%"O"<OQ2^+OQ:UL:+?7DL-EIMM^\:18W(=E5B(H$#@A55#D@GC
MN >O?\%)OA_^S9_PH77Y]-;P-H/Q&TU8Y-(AT.6UM[Z9A*@DB:*'#2+L+_>!
M"GD$=_7?^"4WBG4?$_[&/A==1N'N6TR\O-/@>0Y(A24E%SZ*'VCT  KYV_:N
M_P""=OP,_9A_99\<^+;-=8U;Q)!!#;Z;>ZYJ6YDN))XT&R.)8T9MI;AE; !/
M;(]R_P""0W_)FVG?]AJ__P#0UH ^2O@7X0M?^"C?[?'C?Q1XY9]3\#>'1)+;
MZ6TC*DEJDIBL[?Y2-JD;I7P1N8-_?-?HU\3OV+_@[\3OA[?>$Y_ 'A[1H)86
M2TO-'TN"TN+&0@[9(GC4$$'G'0XP017P7_P1]:#X?_M"?&CP#?R+#J\<*QQQ
M3?+*_P!DN9(I ,]QYJDC\>U?K'G')X% 'Q5^Q3\(?B5^Q!\!?B&/BCJFDZGX
M8T>";7M-M=+O99Y+5(H9)+I#OB545MB, I(W%R1D\_(O[!G@'PC^UE\8/'OQ
MD^/6KZ5J\T-Y&+32=9NTCMY[A\ODQLPW10HJ(L9!0AL$?+@_9MU^U5X/_;6^
M"/Q[\'?#JPUR;4]+\-:A:M)>VD:0SR20SQPB)DD?=YC1DKD XYQGBO@W_@FY
M^QW\)/VLO"_B^+QG>ZU#XGT6\C:.#2[^.$-:2)A6V-&Q)$B2 D''S*/J ?H/
M\=/V;_V:?C9X!OM!=? ?AS4C 5T_6M%>SM;FSD .PAHRN] >L;94CT."/$/^
M".?QFUG6/"?C;X3:W.MTO@^X2XTV;S-Y6&5Y%EA'^PLB;E/_ $V/8"NQD_X(
MX_ *&-I)+[Q<B*"S,VJP@ #J2?(K2_8%^%O[-7A/QEXHU?X%>--5\4ZF+%;/
M4XKV5VCAB:4,K8:"/DM&<')R ?K0!\]?L(_\I5OC_P#]=O$G_IWBK]7Z_*#]
MB)DTO_@J_P#'6"=PDES-XB$0/&XMJ<4F!_P$$_A7ZLW=W#86LUS<RI!;PHTD
MLLC!510,EB3T  S0!^6/_!('_DOWQY_[9_\ I5-7._\ !9#X=>%/!_C?X47F
M@>&-&T.[UJ;5+C5+C3=/BMY+^3S;4[YV1096R[G+9.7;U-:W_!&G4HM:^,_Q
MKU"'_4W<$$Z9_NM<S,/T-7/^"V_[KQ)\#Y7^2+_B:?.W X>R)Y]LB@#[?^,/
MPG\$?"_]FWXR_P#"&^#?#_A+[=X2U+[7_86EP67VC99S[/,\I%W;=[XSG&YL
M=37R_P#\$2_^2!>.O^QF/_I+!7V5^TU_R;;\5_\ L4M6_P#2.6OC7_@B7_R0
M+QU_V,Q_])8* /&_C-97'[>/_!39/AKJM[,G@/PC-+9R6L<A7$-LH:[QCH\L
MP\O>.0NS^Z*_1J\_9"^"M[X*D\)M\+_"\6BO#Y)CATR*.4<8WB8+YGF<9\S=
MNSSG-?GU^S2T'PS_ ."P'Q.TG5)%MYM<N=8%K]HX+/<.EZ@7/<H#CU''>OUD
MH ^)?V#?V/?B7^R7\2/B#:WVN:9??"S59)#I=DMY))>"1)0()WC\H1J6A+*^
M&R2$X(48PO#W_!.76O'/[7_BKXL_&S4- \:>&[N2:?2]#ADFDVG<%MHIXWB5
M#%%",;0QW, 2",Y][\!_MI^ /B-\?O%7PBT>WUI_$GAL7)O[R2UC^PA8&592
M)%D+8#N$Y4?,"/0G\\?!>L?%3_@JS\<O%=HOCN^\ _#'10LXTRS9V6*%F98$
M,2LHEF?8S,[G"_-@8PM 'W[\:_A3^R]:^%-1T?Q_I'PY\,6<L1#23)9:==0D
M@@-$XVNK^FWD].<XKXO_ ."*_B"YL?'GQ<\)VM^UYX?2*WO8.?D9UE>(2J,<
M%D*Y]=J^@KVKPA_P1\^ W@F(:EXFU+Q%XGCM4,URNI:@EK:;5&6)$*(ZK@'/
M[S\:\"_X(PR6<OQP^+CZ>GE6#:=&;=!GY8S<ML'//3'6@#1U/_E.<G_7:'_U
M'%JW_P %E-2N[?XH?!B/Q%;7MS\-H_-GNX;1ROVB03Q_:$!R )/)VA2>1O;'
M>JFI_P#*<Y/^NT/_ *CBU]Q_M$>/_@%XAUO2?@Y\6[S2[[5/$4UN+#0K^VG:
M1Y)7,4,D<L:_N6+;D$@=<?,,]: .2^$5]^R%\:/"=OX?\&Z=\.=1M+B%8QHD
MNGVT%[@J1S#(HFWC)^?!.23G/-8O[)7[ UY^RC\;/&?BG1/&XF\&:VDMO!X6
M^QNQCB\W? 7G:3EXAN4'8<AVY%>4_%3_ ((K_#SQ!YUQX#\8:SX1N6RRVNHH
MNHVH]%'*2*/<N_X]*\U_8Q^+'Q=_9D_;,'[-OCS7F\5:+<RM;KYMQ)=+:,;0
MW$$UL[?,J,FP-&>!N)P"#D _6.BBB@#\B_@3_P IF_%G_83UG_TEDKW_ /X+
M/?\ )J&B?]C;9_\ I+=UX!\"?^4S?BS_ +">L_\ I+)7O_\ P6>_Y-0T3_L;
M;/\ ]);N@"K_ ,$Y/V,?A_<? GP_\2/''AVP\;>,?$T9O1<^((!>):6X8I!'
M&DNY0=J*V_&[YL X KP#_@J]^SKX0_9^USX=_$;X;:3;^#;Z[O98I[;28U@M
MTGAV2P311J (V!W9V@#Y5X!!S^B?[%''[(_PAQ_T+-C_ .BEKY _X+>?\DL^
M&G_89N/_ $0* /=/VY/VBM7^%?[$,WBW3)SI_B;Q-:6>G6EQ 2#;RW4>^5T/
M4,L2S%3U#!3VKRO_ ()E?L4> K#X$Z+\1O&'AG2_%7BKQ,'O('U>V6ZCL;;>
M5B6-) 5#L%WEP-WS[<X',7_!3+PW/KO_  3O\$7L2N4T:YT6_EVC("M:R6^3
M[;KA?QQ7T?\ L"^)['Q7^QW\*KFQFBF2VT:+3Y1$1\DL&875AV.4/YY[T >'
M?MM?\$X+?XK77AOQ5\%M/T7P+X\L;]#<W%NYT^VDA"EEF_<H<31R*F&502&.
M2<+CD?\ @JI\</&?PN_9G^'_ ("O=3A@\6^+8?)\0W>E._E31V\,8N4C8JK"
M.265.H!*@J1@D5]F?M'_ +1_A/\ 9;^'B>,?&*7\VF27T.GQPZ9$DD\DL@8C
M:KN@("H['G.%. >E?FU_P5T\11_%'P+\ ?BCHMI>1^'-6M+QX%U"$1R()1;R
MP[U!(&] Q')R%H ^R/V3?V _AC\&?A3H::]X-T7Q/XSN[2*XU74]9LH[QEG9
M 7CA\Q2(XU)*C: 6QELDU\N_\%/?V2?#OP/T?0/C?\)[*'P+JNF:I#%?6VBK
M]FA5VY@N88U 6)E= I"@!MX.,@[OTX\%^+-.\>>$-%\2:3<1W>F:M9PWUM-&
M<J\<B!U(_ U\>_\ !7SQGI_A_P#9$N]%N9HEO]?U:SMK2%N7;RY!.[*/0",
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MNIQ?#_3[+PC/?W":'H\.CVR6L-E)<&26:2..,!4;8MPP( ^=@W6OF#1/W/\
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MO^"9(W''Q(P.V="_^Z:/^'9/_52?_*%_]TUY/L:_],_I/_6W@Y?;C_X*E_\
M('RI_P +V^)?_10_%?\ X.[G_P"+J"_^-'Q!U2QN+*]\=^)KRSN8VAGM[C5[
MAXY8V!#(RE\,I!((/!!KZR_X=D_]5)_\H7_W36%X\_X)X?\ "$^!_$7B+_A8
M'VW^R-.N+_[-_8WE^;Y432;-WV@[<[<9P<9Z&AT:]M?S-J7%7"52I&%.<>9M
M)?NY;]/L'QQ1117(?I@5U6A_%GQQX9TN'3='\9>(-*TZ#=Y5G8ZI/##'N8LV
MU%< 98DG ZDFN5KZK^"/["__  N3X8:+XP_X3;^R/[2\[_0_[)\_R_+GDB^_
MYZYSY>>@QG'O6E.,YNT-SP,YS'+<LP\:V:-*FW97BY:V;V2?1/4\-_X7M\2_
M^BA^*_\ P=W/_P 71_PO;XE_]%#\5_\ @[N?_BZ^J_\ AV3_ -5)_P#*%_\
M=-'_  [)_P"JD_\ E"_^Z:W]C7_IGQO^MW!W\\?_  5+_P"0/E3_ (7M\2_^
MBA^*_P#P=W/_ ,77M/[+?[5'CRQ^*GA[P_KNNWOB31=8NX["2+4I6GEB:1MB
M2)(V6&&(R"2",^Q'H7_#LG_JI/\ Y0O_ +IKTCX&_L+Z#\(_&%OXEU+7IO$^
MHV9WV2&T%M#"^"-Y7>Y9AGCD 'G&<8TIT:ZDG^IXV<<3<(8G 5J4.6<G%V2I
MR3O;2S<5:SZW)_\ @I#_ ,F2_%+_ *\K?_TK@KP7_@GM\'/#_P ??^"<M[X%
M\2P^9INJZEJ$8F4 R6TH=3'-'Z.C ,/7&#D$BO>O^"D/_)DOQ2_Z\K?_ -*X
M*\__ ."0W_)FVG?]AJ__ /0UKUC^9CY?_81^,/B#]B/]I/7OV>/B=-]FT'5-
M0$5E=2$B""\8 0SH3TAN$V#V;83MP]=7_P %RO\ D%?!O_KMJW_H-G7M'_!4
M;]C\_'CX8CQUX9LO,\>>$X&D"0K^\O[$9:2'CDNG,B?\#4<N*_-']I3]K*Y_
M:2^ GPAT?Q#-)<>-?"$NH6>H74F3]L@=+86]P6/5R(W5^Y9-W\>  ?OUX3_Y
M%71O^O*'_P!%K7Y6_M33-^VE_P %+/!WPGMR;OPGX1E6UU +S&0F+C4#G^$D
M(EO_ +T8K]&/B1\5+'X(_LZ:KXZU#:T&AZ"MTD;G FF\I1#%GU>0H@]V%?D=
M^QS_ ,$_=0_;>\->*_B-XG\9W7AT3:S)$DZ6"W+WT[#S;B0Y=<#=(HR,Y);T
MH _5[]KGX)Q_'S]G'QIX)B@5[^YL3-I@P!MNX<20 >@+H%/^RQKY'_X(S_')
MO$7PQ\1_"K5)B-2\+W)OK"*3(;[',Y\Q /\ IG-N)_Z[J*YO_AQSH?\ T5O4
M/_!''_\ 'Z\"TOPE>_\ !,/]OKPI;WFLR:IX3O(84GU26$0"YTZY_=3,Z!F
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MH;_@K/\ '#_A5G[,%SX<L[CRM:\:W']E1JK8<6B@/=/[@KLB/_7>OF#X)?\
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MT ?8?_"6:'_T&=/_ / J/_&M&WN8;R%)H)4GA<962-@RGZ$5^8O_  XYT/\
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M<<#. >]?<G_#FWX"?\_GC#_P:1?_ !B@#P;]B+7?^&6?^"@?BWX%Z)K:>(/
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M;>,?=CFD$T4Q'^\(8?\ OBOU&K\H/^"*'_(_?&C_ *XV/_HVYK]7Z "BBB@
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M=?\ QRC_ (7[\3O^BC^+?_!Y=?\ QROK3_AUS_U4S_R@?_=-'_#KG_JIG_E
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M8G\,O^XG_P"G2[KZJH _+_\ X+C6<#^%_A)=MM^TQWFI1)Z[62W+?JBU]_\
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M_P""JG@*VA_8/\-VVB/<7&D>%]3TJ6&67+.UNMO+:QM(<#D^<F20.3^%>_\
M[ OB>Q\5_L=_"JYL9HIDMM&BT^41$?)+!F%U8=CE#^>>] 'A_P"VU_P3AM_B
MQ=>&_%7P7L-%\"^/+&_0W-Q;L=/MI(0"RS?N4.)HW5,,JY(8YSM7'/\ _!6>
M#7;7]AWP/#XHFM+CQ+'KVFIJ<UBS-;R70LKH2M&653L+[B,J#@CBOKW]H_\
M:/\ "?[+?P\3QCXQ2_FTR2^AT^.'3(DDGDED#$;5=T! 5'8\YPIP#TKXV_X*
MH?$'3OBO^P?X%\8Z1;WEMI6N>(;"^M([^(13>4]I=E"R@D#(P1R>"* -S_@G
M#^P_\.]/^!'AWX@>,/#FG>,?%7B:W6^1]<M4NHK&WR1#'"D@*@[ K%\;OFQP
M *\&_P""M7[/?A#X&ZK\/?B+\.](MO!>I7EY+!<0Z+&+6$30A)()XXTPL;@[
MLE0,X4]<D_H=^Q3_ ,FC_"'_ +%FQ_\ 12U\@?\ !;S_ ))9\-/^PS<?^B!0
M![;^WQK[^*_^"<?BW6Y !)J6CZ3>,%& #)=VCG'_ 'U7SA_P2I_9!\$_$KX8
MW/Q/^(>C6WC.\:\?2]'L-:C^TVEI;0@;F$3Y1BSNPPRD+LR,%C7N_P"V-_RB
MTU'_ +%G0O\ T?9UJ_\ !)__ ),E\(_]?NH_^E<M '@7_!6?]DWX=>$?@U9_
M$?PCX8T[PKKEGJL-I>+H]LEM!=PS!@2\2 +O#JA# 9.YLYR"/K/X#_&BZLOV
M$?#7Q+\1.;RZTOP<VHW<C$EIS;0-EB?[S^5D^[&O-/\ @KS_ ,F;:C_V&K#_
M -#:CX8^';OQ9_P2;CTC3T:6^NO %ZD$2C)D?RIBJ#W)&/QH ^8/^";_ .SO
M8?MA>._'7QO^,4:^,WAU,6]O97^7@GNR@DD:6,\-'&CPJD9RN#@C"BONGX\?
ML&_"#XT?#W4-"A\$:#X8UC[.PTW6M%TZ*SFM)@I\LDQ*N^,$\QMD$9Z'!'SI
M_P $3_&&GWGP'\;>%UGB_M73_$3:A) #A_)GMH41R.XW6\@S[5^A]]?6^EV-
MQ>7D\=M:6\;3332L%2-%!+,Q/0  DGVH _-7_@CW\8]?BNO'OP1\1W#7)\,L
MU[IRNY;[,HF\FYA7/\ D:-@.Q=_6N1_81_Y2K?'_ /Z[>)/_ $[Q5%_P2@W>
M//VP_C?\0+&%CH]Q:W>)54JBF\U!9XEQV)6!\#'\)J7]A'_E*M\?_P#KMXD_
M].\5 $7[>&K:W^U?^WKX,_9YM=5FL?"^FS6R7<,1(7SG@-S<3XZ,Z6QVIG@$
M-TW-7W]X5_8U^"'@_P (P^'+/X6^%KG3XXA$\FHZ5#=7$^/XI)I%+NV><D\=
ML5^?7B2^B^$__!:RSU/772UT_5KN);>YGX5OM6E?9HR#V_?-Y>?8U^M= 'XY
M_&+PHO\ P33_ &[O!_B#P/<2V?@#Q*(Y)]*:9W5;1Y1'=6[%LE@IQ*A.2#LS
MG;D_0G_!9#XZ:C\/_@QX>\!:1<R6D_C.YF^W2QDAFLK<(7BSV#O+%GU564\$
MUXY_P5\OH?B1^TA\'_AUI!6\UQ(?*D@@YD62\N8TBC)'1CY60.N&![BNA_X+
M>>%;Q;?X2^+H(I'M+6:^T^>0@F-)&$,L(/8%A'-]=GM0!]2?LM_L$?"[X-_"
M71K'6_!6A>)_%=W9QRZQJ>LV$=X[SL@,D<?FJ=D2D[0J@9"@MD\U\ ?\%7OV
M1O#'P%U[PYXS\":?'H7AWQ)++;WNCVV5MX+R,;E>).BJZ,_R#A2AP &P/V(\
M"^,=-^(7@O0_$^CW"76E:Q90WUM,AR&CD0,/QYP1U!!%?G5_P6Y\;Z;#\/?A
MWX/%S"VKW&J2ZL;8<R)!'"T0<^BLTI ]2AZ[3@ ]F_:F^")^.G_!.O3M/M;?
M[1K6B^'-/U[30!EO.M[52ZJ.Y>$S(!ZN*B_X)-_&C_A:'[*]CH-W/YFK^#;E
MM(E5CEC;']Y;-_NA&,8_ZXFOIOX)J'^"O@)6 93X?L 0>A_T:.OS8_9@FB_8
MH_X*._$3X9ZC,NF>"_$MM/<63RG;$D2HUY:OGOLC\^'_ 'B: -7_ (*6ZK>_
MM'_M8?"7]G?0[A_*CFCN=4:$Y\J2XY9V'K#:HTGTE-?IWHNCV?AW1['2M.MT
MM-/L8([6VMXQ\L<2*%11[  #\*_,S_@F5H5W^T%^TY\7OVB];@<Q-=RV6E"8
M9\N2<[BJGUBMEBC^DU?J!0 5^1?_  6,_P"3DOA'_P!@Q?\ TL:OUTK\B_\
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M *&E?+W[$7A>]\;?\$J?'V@Z;&\VHZA9^(+>UAC^])*T+!$_X$V!^- 'F?\
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M'_V)GAG_ -+M>H ]5HHHH **** "BBB@#^5>BBB@#]_O^"7'_)B?PR_[B?\
MZ=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OV3O\ DUGX-_\
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M.ST7PE:3J+6[\6K<V4=QY9X+[X)78$C/,4089_A-7/V+_P!@'Q[^S%^U]?\
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MOE7D[D<= 6#$#]$?^"@G@W7?B#^Q_P#$/P_X:TF[US6[R*S%MI]C$99I2M[
M[;5')PJL?H#6)_P36\!^(_AK^R/X7T#Q5HM]X?UJWN[YY;#4(6BF16N9&4E3
MR,@@CZT ?+.I?LC?M3?MN>+M%E_:!U.S\"^!M-E$XTC3IH6D;(.3%#$TB^80
M=N^9\H"<*>5/Z1Z;\-_#6D_#N'P);Z1;KX3BTW^R!I;+F(VOE^68SZ@KD'/)
MR<UTM% 'Y=7'[#?[1?['?Q(U7Q!^S3K=OXC\,:HV'T'4;F&.39GY4F2=DBDV
M;CME5U?&1@9.Z/QI\!?VUOVT8[/PY\49M'^&O@;S4FNK>WFAV3X(()A@ED>5
ME(W*DCJN1G@@&OU)HH \\^ ?P-\-_LZ?"W1_ WA:%ET^P0M)<S8\Z[G;F2>0
MCJS'\   . !7R;^S%^R?\2?AG^WY\6?BCK^D6]KX-\0?VM_9]Y'?0R/)Y]]%
M-%F-6++E$8\CC&#7WK10!C^,/"NG^.O".M^&]6C:72M8L9].NXT;:6AFC:-P
M#V)5C7YA^ ?V7?VN?V&?&&O6_P &+?1?B+X,U299?L]]/"B/M)"-+%++"T<H
M7AC$Y4@C).!M_52B@#\\M4_9K_:D_;$FM]*^/7B32/AU\.DD6>[\->$V1Y[Q
M@VY5+!I%P"!R\C@$*0C$9'1?\$R?V9?BC^RW<?$70_'.B6MMHNJ36]SIVH6]
M]#-YCQ&1&!1&++N5D89 QM(/6ONNB@#\W/VT/V+?C9-^U%!\>?@/=0W'B*:.
M$R0?:+>"XM9X[<6Q91<$121O" "&/]X$$&OJGX.>"/'OQ1_9FN?"7[1-A;W/
MB75DO+/58[=K?;);R2,8BOD?NU9$90".08PQR>3[U10!^6'AO]DO]K7]B7Q)
MK$7P,U33_'O@K4)C/_9MY-!'TX#RP3O&%EVJ%+0O\P"YZ +)XL_9;_:]_;:U
MS2+'XUW^E_#WP/92K<-I]E- X)Z%TAADD+R[2<>=( N3C&2#^I=% ',?#'X;
MZ%\(? &A>#?#-I]BT+1K9;6VB9MS8&268]V9BS,>Y8FOS]^+G[ _Q<^!7QKO
MOBK^RWJ]O;?V@[RW?A6:>.  NVYXD67$,D!/(1RI0XVYP"/TIHH _,CQ!\"O
MVQOVQ[>/P_\ &.73?A[X!M_])N=,TJ:W$FIR)\T<>V.64GYU'^L8(I^?:Q51
M7M'_  3#_9K\>_LS_#7QAH_C_2X-+O\ 4=72[MHX+N*X#1B%4))C8@<@\&OL
M^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "LGQ9X;MO&7A76= O7EBL]5LIK&>2W($BQRQLC%200
M&PQQD$9[&M:B@N$Y4Y*<'9K5'RI_P[A^&O\ T'/%?_@7;?\ R/1_P[A^&O\
MT'/%?_@7;?\ R/7U716'L*?\I]=_KAG_ /T%R_#_ "/E3_AW#\-?^@YXK_\
M NV_^1Z^@/A;\-],^$?@33/">CSW=SIVG^;Y4M\ZO,?,E>5MQ55'WG., <8^
MM=715QIP@[Q1YF/S[,\TI*CC:[G%.]GWU5_Q84445H>"%%%% 'BG[:'PR\0?
M&3]F+QWX-\+6L=[K^JVT,=I;R3+$KLMQ$YR[$*/E5NIKD?\ @GA\$?%W[/O[
M-]GX1\;6$6G:['J5W<M!#<1SJ$=@5.Y"1VZ9KZ9HH *_(O\ ;,_X)4^.=<^-
M6I>(O@[HUE>^&-;S>S6$E[#:_8+IF/FQH'89C8_.N/N[BN  ,_KI10!\7?\
M!0WX)_%WXW? OPA\//ASHL-_$\\=QKLDNH0VX"P1J(HOWC#<&D8OQT,*^M>]
M_LL_!F/]G_\ 9_\ !/@78BWFF6"F_:,@A[R0F2X8'N/-=\>P%>K44 %?%?\
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M_@ES^RU\1/V8]!^(5K\0=)M]*FUBYLI+-8+V*YWK&DP?)C8XP77KZU]RT44
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MM+UJTGBL3<1VT4-K%;3Q *7(&%WH /3Z5]=T4 >9?LR^"-7^&O[/?P[\*Z_
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M^S\(^-K"+3M=CU*[N6@AN(YU".P*G<A([=,U],T4 ?FO\7OV!_B[\"_C9?\
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M_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\
M]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1/
M/A__ .%Y??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?
M_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\
MX7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y
M??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_
M ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*
M:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\ RFH
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M_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\
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M_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\
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M_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\
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M_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\
M]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1/
M/A__ .%Y??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?
M_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\
MX7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y
M??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_
M ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*
M:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\ RFH
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M_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\
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M_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\
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M_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\
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M_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\
M]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1/
M/A__ .%Y??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?
M_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\
MX7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y
M??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_
M ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*
M:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\ RFH
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M_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\
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M_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\
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M_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\
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M_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\
M]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1/
M/A__ .%Y??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?
M_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\
MX7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y
M??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_
M ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*
M:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\ RFH
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M_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\
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M_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\
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M_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\
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M_P#T3SX?_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\
M]$\^'_\ X7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1/
M/A__ .%Y??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?
M_P#A>7W_ ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\
MX7E]_P#*:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y
M??\ RFH ]5HKRK_A)/C?_P!$\^'_ /X7E]_\IJ/^$D^-_P#T3SX?_P#A>7W_
M ,IJ /5:*\J_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\ ]$\^'_\ X7E]_P#*
M:@#U6BO*O^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\ RFH
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M)_#+_N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _E7HHHH _;[_@G#^T)\+/ _[&/P\T3Q
M)\2_!_A_6K7^T?/T[5->M;:XAW:C=.N^-Y RY5E89'(8'H:^E?\ AK'X(?\
M19/A_P#^%18__':_F^\3_P#(R:M_U]S?^AFLV@#^E/\ X:Q^"'_19/A__P"%
M18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_FLHH _I3_X:Q^"'_19/A_\ ^%18
M_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/
M_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\
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M /A46/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\
MA46/_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X
M5%C_ /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%
MC_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18
M_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
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M_P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_FLHH _I3_X:Q^"'_19/A_\
M^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\
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M (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\
M^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/
M_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_
M /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\
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MH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH
M_I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /
MZ4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4
M_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K^:RB@#^E/
M_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K^:RB@#^E/\
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M_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\
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M /A46/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\
MA46/_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X
M5%C_ /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%
MC_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18
M_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
M\=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =
MK^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':
M_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_F
MLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK
M** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VOYK**
M /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K^:RB@
M#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K^:RB@#^
ME/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_FLHH _I
M3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH _I3_
M .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /Z4_^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4_P#A
MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K^:RB@#^E/_AK'
MX(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K^:RB@#^E/\ X:Q^
M"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_FLHH _I3_X:Q^"'
M_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH _I3_ .&L?@A_
MT63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /Z4_^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4_P#AK'X(?]%D
M^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K^:RB@#^E/_AK'X(?]%D^'
M_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K^:RB@#^E/\ X:Q^"'_19/A_
M_P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_FLHH _I3_X:Q^"'_19/A_\
M^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\
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M (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\
M^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A4
M6/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/
M_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_
M /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\
M':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#Q
MVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
MYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K^
M:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K^:R
MB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_FLH
MH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_FLHH
M_I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /
MZ4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4
M_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K^:RB@#^E/
M_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K^:RB@#^E/\
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M_P =H_X:Q^"'_19/A_\ ^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':
M/^&L?@A_T63X?_\ A46/_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC
M_AK'X(?]%D^'_P#X5%C_ /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_A
MK'X(?]%D^'__ (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:
MQ^"'_19/A_\ ^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@
MA_T63X?_ /A46/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_
MT63X?_\ A46/_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]
M%D^'_P#X5%C_ /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D
M^'__ (5%C_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/
MA_\ ^%18_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=K^:RB@#^E/_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\
MA46/_P =K^:RB@#^E/\ X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X
M5%C_ /':_FLHH _I3_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%
MC_\ ':_FLHH _I3_ .&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18
M_P#QVOYK** /Z4_^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VOYK** /Z4_P#AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\
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-9?\ 7%/_ $$44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308822272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Heritage Drive, Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,705,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the Registrant&#8217;s 2024 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2023 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308814032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306225920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,954<span></span>
</td>
<td class="nump">$ 45,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">147,355<span></span>
</td>
<td class="nump">166,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">32,917<span></span>
</td>
<td class="nump">30,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">23,969<span></span>
</td>
<td class="nump">13,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">6,395<span></span>
</td>
<td class="nump">4,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">237,429<span></span>
</td>
<td class="nump">263,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes, net</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">8,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">299,606<span></span>
</td>
<td class="nump">342,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">103,370<span></span>
</td>
<td class="nump">105,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Commercial license and other economic rights</a></td>
<td class="nump">67,291<span></span>
</td>
<td class="nump">10,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,607<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">6,062<span></span>
</td>
<td class="nump">10,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">4,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment in Primrose Bio</a></td>
<td class="nump">12,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">35,726<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,923<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">787,216<span></span>
</td>
<td class="nump">762,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">12,467<span></span>
</td>
<td class="nump">15,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights', window );">Current contingent liabilities</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">2023 convertible senior notes, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,782<span></span>
</td>
<td class="nump">98,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LiabilityForContingentValueRights', window );">Long-term contingent liabilities</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">31,622<span></span>
</td>
<td class="nump">30,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,755<span></span>
</td>
<td class="nump">10,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">27,758<span></span>
</td>
<td class="nump">21,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">86,303<span></span>
</td>
<td class="nump">165,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 60,000 shares authorized; 17,556 and 16,951 shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">198,696<span></span>
</td>
<td class="nump">147,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(817)<span></span>
</td>
<td class="num">(984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">503,016<span></span>
</td>
<td class="nump">450,862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">700,913<span></span>
</td>
<td class="nump">597,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 787,216<span></span>
</td>
<td class="nump">$ 762,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CurrentPortionOfLiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308741920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306080448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 131,314<span></span>
</td>
<td class="nump">$ 196,245<span></span>
</td>
<td class="nump">$ 241,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost of Captisol</a></td>
<td class="nump">10,512<span></span>
</td>
<td class="nump">52,827<span></span>
</td>
<td class="nump">62,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">33,654<span></span>
</td>
<td class="nump">34,237<span></span>
</td>
<td class="nump">34,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,537<span></span>
</td>
<td class="nump">36,082<span></span>
</td>
<td class="nump">32,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">52,790<span></span>
</td>
<td class="nump">70,062<span></span>
</td>
<td class="nump">46,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">121,493<span></span>
</td>
<td class="nump">193,208<span></span>
</td>
<td class="nump">137,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Pelican</a></td>
<td class="num">(2,121)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from continuing operations</a></td>
<td class="nump">11,942<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">103,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) from short-term investments</a></td>
<td class="nump">46,365<span></span>
</td>
<td class="nump">28,540<span></span>
</td>
<td class="num">(5,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,711<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(656)<span></span>
</td>
<td class="num">(1,799)<span></span>
</td>
<td class="num">(19,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain on derivative instruments</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,952)<span></span>
</td>
<td class="nump">4,187<span></span>
</td>
<td class="num">(7,650)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">51,718<span></span>
</td>
<td class="nump">32,974<span></span>
</td>
<td class="num">(31,646)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax from continuing operations</a></td>
<td class="nump">63,660<span></span>
</td>
<td class="nump">36,011<span></span>
</td>
<td class="nump">72,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(9,841)<span></span>
</td>
<td class="num">(41,230)<span></span>
</td>
<td class="nump">4,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income (loss) from continuing operations</a></td>
<td class="nump">53,819<span></span>
</td>
<td class="num">(5,219)<span></span>
</td>
<td class="nump">76,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss from discontinued operations</a></td>
<td class="num">(1,665)<span></span>
</td>
<td class="num">(28,142)<span></span>
</td>
<td class="num">(19,215)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss):</a></td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
<td class="nump">$ 57,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income (loss) from continuing operations (in USD per share)</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic net loss from discontinued operations (in USD per share)</a></td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(1.67)<span></span>
</td>
<td class="num">(1.16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (in USD per share)</a></td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="nump">$ 3.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic per share calculation (in shares)</a></td>
<td class="nump">17,298<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
<td class="nump">16,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income (loss) from continuing operations (in USD per share)</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted net loss from discontinued operations (in USD per share)</a></td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(1.67)<span></span>
</td>
<td class="num">(1.11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per share (in USD per share)</a></td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted per share calculation (in shares)</a></td>
<td class="nump">17,757<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
<td class="nump">17,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 83,910<span></span>
</td>
<td class="nump">$ 72,527<span></span>
</td>
<td class="nump">$ 48,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28,372<span></span>
</td>
<td class="nump">104,495<span></span>
</td>
<td class="nump">164,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 19,032<span></span>
</td>
<td class="nump">$ 19,223<span></span>
</td>
<td class="nump">$ 28,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308824416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
<td class="nump">$ 57,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="nump">167<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 52,321<span></span>
</td>
<td class="num">$ (33,428)<span></span>
</td>
<td class="nump">$ 57,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306257328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retain earnings</div></th>
<th class="th">
<div>Retain earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 709,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 318,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (801)<span></span>
</td>
<td class="nump">$ 391,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</a></td>
<td class="nump">27,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">27,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">38,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reacquisition of equity due to 2023 debt extinguishment, net of tax</a></td>
<td class="num">(12,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions', window );">Warrant and bond hedge unwind transactions</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">57,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 821,159<span></span>
</td>
<td class="num">$ (15,997)<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">372,969<span></span>
</td>
<td class="num">$ (51,130)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
<td class="nump">449,090<span></span>
</td>
<td class="nump">$ 35,133<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</a></td>
<td class="num">$ (5,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">60,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction', window );">Bond hedge transaction</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation', window );">Distribution of OmniAb</a></td>
<td class="num">(229,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(33,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 597,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">147,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(984)<span></span>
</td>
<td class="nump">450,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">16,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</a></td>
<td class="nump">$ 17,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">17,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">25,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation', window );">Final distribution of OmniAb</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision', window );">Final tax impact of OmniAb distribution</a></td>
<td class="nump">5,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">52,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 700,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 198,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (817)<span></span>
</td>
<td class="nump">$ 503,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Bond Hedge Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Decrease Due To Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid in Capital, Increase Due To Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Tax Return To Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303544416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
<td class="nump">$ 57,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Pelican</a></td>
<td class="num">(2,121)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights', window );">Change in estimated fair value of contingent liabilities</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(748)<span></span>
</td>
<td class="num">(36,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of fixed assets and amortization of intangible assets</a></td>
<td class="nump">36,521<span></span>
</td>
<td class="nump">51,534<span></span>
</td>
<td class="nump">51,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_GainLossOnShortTermInvestments', window );">Loss (gain) short-term investments</a></td>
<td class="num">(46,365)<span></span>
</td>
<td class="num">(28,540)<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion of premium (discount) on investments, net</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance fees</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">734<span></span>
</td>
<td class="nump">16,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain on derivative instruments</a></td>
<td class="num">(250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (gain) on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,192)<span></span>
</td>
<td class="nump">7,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights', window );">Amortization of commercial license and other economic rights</a></td>
<td class="num">(878)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights', window );">Adjustment to credit loss reserves of commercial license rights</a></td>
<td class="nump">3,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ImpairmentLossOnCommercialLicenseRights', window );">Impairment loss of commercial license rights</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization', window );">Lease amortization expense</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">5,521<span></span>
</td>
<td class="nump">4,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">25,743<span></span>
</td>
<td class="nump">60,285<span></span>
</td>
<td class="nump">38,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from equity method investment in Primrose Bio</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes, net</a></td>
<td class="nump">11,696<span></span>
</td>
<td class="nump">20,723<span></span>
</td>
<td class="num">(8,618)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">1,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions and dispositions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(2,601)<span></span>
</td>
<td class="nump">55,319<span></span>
</td>
<td class="num">(28,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(10,870)<span></span>
</td>
<td class="nump">12,058<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent', window );">Other economic rights</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(4,704)<span></span>
</td>
<td class="num">(3,340)<span></span>
</td>
<td class="nump">2,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable and payable</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
<td class="num">(3,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">419<span></span>
</td>
<td class="num">(6,281)<span></span>
</td>
<td class="num">(17,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities</a></td>
<td class="num">(9,865)<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
<td class="num">(8,925)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">49,577<span></span>
</td>
<td class="nump">137,850<span></span>
</td>
<td class="nump">78,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PurchaseforCommercialLicenseRights', window );">Purchase of commercial license rights</a></td>
<td class="num">(50,328)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,521)<span></span>
</td>
<td class="num">(17,923)<span></span>
</td>
<td class="num">(8,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(126,764)<span></span>
</td>
<td class="num">(51,226)<span></span>
</td>
<td class="num">(181,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ProceedsFromCommercialLicenseRights', window );">Proceeds from commercial license rights</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">148,765<span></span>
</td>
<td class="nump">209,561<span></span>
</td>
<td class="nump">154,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">45,402<span></span>
</td>
<td class="nump">24,830<span></span>
</td>
<td class="nump">67,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan acquisition, net of restricted cash received</a></td>
<td class="num">(10,405)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(960)<span></span>
</td>
<td class="num">(1,220)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used) provided in investing activities</a></td>
<td class="num">(11,682)<span></span>
</td>
<td class="nump">163,624<span></span>
</td>
<td class="nump">30,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsForSeparation', window );">Net cash transferred to OmniAb at separation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,840)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment at maturity/repurchase of 2023 Notes</a></td>
<td class="num">(76,854)<span></span>
</td>
<td class="num">(260,949)<span></span>
</td>
<td class="num">(155,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under finance lease obligations</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(9,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Cash paid for OmniAb transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cash paid for debt issuance costs</a></td>
<td class="num">(949)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeFinancingActivities', window );">Proceeds from bond hedge settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">18,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock option exercises and ESPP</a></td>
<td class="nump">22,448<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
<td class="nump">33,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(4,547)<span></span>
</td>
<td class="num">(8,236)<span></span>
</td>
<td class="num">(6,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(59,947)<span></span>
</td>
<td class="num">(275,990)<span></span>
</td>
<td class="num">(137,761)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(22,052)<span></span>
</td>
<td class="nump">25,484<span></span>
</td>
<td class="num">(28,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">45,006<span></span>
</td>
<td class="nump">19,522<span></span>
</td>
<td class="nump">47,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">22,954<span></span>
</td>
<td class="nump">45,006<span></span>
</td>
<td class="nump">19,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="nump">8,770<span></span>
</td>
<td class="nump">11,642<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract', window );"><strong>Acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">103,370<span></span>
</td>
<td class="nump">105,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for Novan</a></td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid', window );">Accrued Primrose transaction costs</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid', window );">Accrued royalty from commercial license rights</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid', window );">Accrued commercial license rights purchases</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid', window );">Accrued debt issuance costs</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued fixed asset purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on available-for-sale investments</a></td>
<td class="nump">212<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan acquisition, net of restricted cash received</a></td>
<td class="num">(10,405)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract', window );"><strong>Acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived', window );">Fair value of tangible assets acquired, net of cash and restricted cash received</a></td>
<td class="nump">17,101<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="num">(19,725)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for Novan</a></td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_NucorionMember', window );">Nucorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(750)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="num">$ (15,249)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Commercial License Rights Purchases Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Debt Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Credit Loss Reserves Of Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Commercial License and Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquisition Cost Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During the Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease And Operating Lease, Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_GainLossOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_GainLossOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ImpairmentLossOnCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss On Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ImpairmentLossOnCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsForSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsForSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProceedsFromCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProceedsFromCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseforCommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase for Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseforCommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_NucorionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_NucorionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308831952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. We operate in one reportable segment: development and licensing of biopharmaceutical assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the spin-off of the OmniAb antibody discovery business (the&#8220;OmniAb Business&#8221;) in November 2022 met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 205-20&#8221;). For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Spin-off of OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of other income (expense) within the consolidated statements of operations.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three&#160;months and less than twenty-five months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities consist of mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, Equity securities in Primrose Bio, or non-current other assets, based on the nature of the securities and their availability for use in current operations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the years ended December&#160;31, 2023, 2022 and 2021, we considered the current and expected future economic and market conditions and concluded an increase of $0.2&#160;million, a decrease of $0.3&#160;million, and an increase of $0.01&#160;million of allowance for credit losses, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. During the years ended December&#160;31, 2023 and 2022, we recorded an obsolete inventory charge of $0.2&#160;million and  $1.1&#160;million, respectively. There was no adjustment to inventory recorded for the year ended December&#160;31, 2021. As of December&#160;31, 2023 and 2022, inventory included prepayments of $4.6&#160;million and $5.9&#160;million, respectively, to our supplier for Captisol.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:f-532">one</span> to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (6), Fair Value Measurement and Note (9), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2023, noting no impairment. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For commercial license rights, we account them in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Receivables, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and are measured at amortized cost using the prospective effective interest method described in ASC 835-30,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If management determines it can reliably estimate future cash flows of the asset, we amortize the asset using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. If cash flows are not reliably estimable, the asset is accounted for using the non-accrual method. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate commercial license rights for impairment on an individual basis. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize an allowance for current expected credit losses under ASC 326 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments &#8211; Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our commercial license rights. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for changes in projected cash flows and credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other economic rights, which are characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce the asset as the funds are expended. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights are evaluated for impairment on an ongoing basis. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Commercial License and Other Economic Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments present equity securities that primarily include common stocks, preferred stocks we invested. Equity securities without readily determinable or estimable fair values are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Captisol Sales</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2023, the amount recognized as revenue that was previously deferred at December&#160;31, 2022 was $0.1 million. During the year ended December&#160;31, 2022, the amount recognized as revenue that was previously deferred at December&#160;31, 2021 was $0.4 million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teriparatide injection </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rylaze </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,527&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol - Core</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol - COVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,367&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (CRO) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. The 2023 Notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive. The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Updates, Recently Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, we adopted ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2021-08&#8221;). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic 606&#8221;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued updated accounting guidance related to annual and interim segment disclosures. The updated accounting guidance, among other things, requires disclosure of certain significant segment expenses. We will adopt the updated accounting guidance in our Annual Report on Form 10-K for the year ended December 31, 2024. We do not expect impact from the adoption of the new accounting guidance will have material impact to our segment disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313141136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Pelican Business and Investment in Primrose Bio</a></td>
<td class="text">Sale of Pelican Business and Investment in Primrose Bio<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#8220;Pelican&#8221;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received 2,146,957 common shares, 4,278,293 preferred shares and 474,746 restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $15.0 million in exchange for 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive 25% of sales revenue of PeliCRM197 above $3.0 million and 35% of all PeliCRM197 licensing revenue in perpetuity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#8217;s RYLAZE, Merck&#8217;s VAXNEUVANCE and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $4.1&#160;million, resulting in a $2.1&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $1.2&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we will receive 25% of sales revenue of PeliCRM197 above $3.0&#160;million and 35% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and thus, will be recognized as the underlying contingencies are resolved.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will receive 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of  $3.2&#160;million, at the disposition date, which was included under other long-term asset in our consolidated balance sheet. They </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are recognized as derivative assets under ASC 815,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and has been marked to fair value as of December&#160;31, 2023 with an adjustment of $0.3&#160;million. Any change in fair value is recorded to Other income (expense) in our consolidated statement of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Fair Value Measurement&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investment in Primrose Bio</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over its operating and financial results. In applying the equity method, we record the investment at fair value. Ligand's proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations for the year ended December&#160;31, 2023. Our equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Our share of the net loss of Primrose Bio since the divestiture date for year ended December&#160;31, 2023 was $1.8&#160;million, which reduced Ligand's equity method investment accordingly.  Any income of loss from our equity method investments are recorded to Other income (expense) in our consolidated statement of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the Series A preferred stock investment in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value. There have been no observable price changes or impairments identified since September 18, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, our President and Chief Operating Officer, Matt Korenberg, became a board member of Primrose Bio.</span></div>Spin-off of OmniAb<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the Separation Agreement to separate our OmniAb Business and the Merger Agreement, pursuant to which APAC would combine with OmniAb, and acquire Ligand's OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#8220;Transactions&#8221;).  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the closing date of the Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the Distribution. Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the Distribution, Ligand distributed on a pro rata basis to its shareholders as of October 26, 2022 shares of the common stock of OmniAb representing 100% of Ligand&#8217;s interest in OmniAb. Immediately following the Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#8220;OABI.&#8221; After the Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company determined its antibody discovery business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $1.7 million tax provision adjustment related to deferred taxes during the year ended December&#160;31, 2023 that was attributable to the discontinued operations. The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:76.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,956)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,215)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787311719552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition</a></td>
<td class="text">Acquisition<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novan</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2023, we closed the transaction to acquire certain assets of Novan, Inc. (&#8220;Novan&#8221;) pursuant to the agreement we entered into with Novan on July 17, 2023 for $15.0 million in cash (which agreement contemplated Novan filing for bankruptcy relief) and provided up to $15.0 million in debtor-in-possession (&#8220;DIP&#8221;) financing inclusive of a $3.0 million bridge loan funded on the same day. Novan filed for Chapter 11 reorganization on July 17, 2023. On September 27, 2023, the bankruptcy court approved our $12.2 million bid to purchase from Novan its lead product candidate berdazimer topical gel, 10.3%, all other assets related to the NITRICIL technology platform and the rights to one commercial stage asset. The remaining commercial assets of Novan will be sold to other parties. The approved $12.2 million bid was credited to the $15.0 million DIP financing, with the balance of $2.8 million and accrued interest repaid to us. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as business combination. We recorded $3.1 million of acquisition-related costs for legal, due diligence and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for the year ended December&#160;31, 2023. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for Novan, including restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DIP loan fees and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. Acquired intangible assets of $10.7&#160;million related to core technology. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 29%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired other liabilities of $13.7&#160;million related to a royalty and milestone payments purchase agreement, entered by Novan in 2019 and assumed as part of the acquisition, which previously provided Novan $25.0&#160;million of funding used primarily in the clinical development of berdazimer topical gel, 10.3%. Pursuant to the purchase agreement, Novan will pay ongoing quarterly payments, calculated based on an applicable percentage per product of any upfront fees, milestone payments, royalty payments or equivalent payments received by Novan pursuant to any out-license agreement, net of any upfront fees, milestone payments, royalty payments or equivalent payments paid by Novan to third parties pursuant to any agreements under which Novan has in-licensed intellectual property with respect to such products.  If Novan decides to commercialize any product on its own following regulatory approval, as opposed to commercializing through an out-license agreement or other third-party arrangement, Novan will be obligated to pay a low single digits royalty on net sales of such products. This contract liability was fair valued based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the related programs mentioned above, by applying a discount rate of 14.0% (revenue risk-adjusted discount rate).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired, liabilities assumed and purchased intangibles are provisional. Specifically, the provisional amounts include estimated projections on the completion of the clinical development process and projected revenue related to commercializing products based on the underlying technology as well as the assumed underlying contracts. The accounting for these amounts falls within the measurement period and, therefore, we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787311653072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin-off of OmniAb</a></td>
<td class="text">Sale of Pelican Business and Investment in Primrose Bio<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#8220;Pelican&#8221;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received 2,146,957 common shares, 4,278,293 preferred shares and 474,746 restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $15.0 million in exchange for 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive 25% of sales revenue of PeliCRM197 above $3.0 million and 35% of all PeliCRM197 licensing revenue in perpetuity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#8217;s RYLAZE, Merck&#8217;s VAXNEUVANCE and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $4.1&#160;million, resulting in a $2.1&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $1.2&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we will receive 25% of sales revenue of PeliCRM197 above $3.0&#160;million and 35% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and thus, will be recognized as the underlying contingencies are resolved.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will receive 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of  $3.2&#160;million, at the disposition date, which was included under other long-term asset in our consolidated balance sheet. They </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are recognized as derivative assets under ASC 815,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and has been marked to fair value as of December&#160;31, 2023 with an adjustment of $0.3&#160;million. Any change in fair value is recorded to Other income (expense) in our consolidated statement of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Fair Value Measurement&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investment in Primrose Bio</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over its operating and financial results. In applying the equity method, we record the investment at fair value. Ligand's proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations for the year ended December&#160;31, 2023. Our equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Our share of the net loss of Primrose Bio since the divestiture date for year ended December&#160;31, 2023 was $1.8&#160;million, which reduced Ligand's equity method investment accordingly.  Any income of loss from our equity method investments are recorded to Other income (expense) in our consolidated statement of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the Series A preferred stock investment in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value. There have been no observable price changes or impairments identified since September 18, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, our President and Chief Operating Officer, Matt Korenberg, became a board member of Primrose Bio.</span></div>Spin-off of OmniAb<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the Separation Agreement to separate our OmniAb Business and the Merger Agreement, pursuant to which APAC would combine with OmniAb, and acquire Ligand's OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#8220;Transactions&#8221;).  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the closing date of the Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the Distribution. Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the Distribution, Ligand distributed on a pro rata basis to its shareholders as of October 26, 2022 shares of the common stock of OmniAb representing 100% of Ligand&#8217;s interest in OmniAb. Immediately following the Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#8220;OABI.&#8221; After the Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, the Company determined its antibody discovery business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $1.7 million tax provision adjustment related to deferred taxes during the year ended December&#160;31, 2023 that was attributable to the discontinued operations. The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:76.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,956)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,215)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787311848992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commercial License and Other Economic Rights<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock', window );">Commercial License and Other Economic Rights</a></td>
<td class="text">Commercial License and Other Economic Rights<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, commercial license and other economic rights consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elutia and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ovid </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tolerance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,228)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,116)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $11.2 million, credit loss adjustments of $8.1 million, and impairment of $0.9 million as of December&#160;31, 2023. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(2) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December&#160;31, 2022. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis, S.A. (Selexis) in April 2013 and April 2015, CorMatrix Cardiovascular, Inc. (CorMatrix) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. ("Elutia") in September 2023) in 2017, Dianomi Therapeutics, Inc. in January 2019, Ovid Therapeutics Inc. in October 2023, Tolerance Therapeutics, Inc. in November 2023, and Palvella Therapeutics, Inc. in December 2023. Commercial license and other economic rights acquired are accounted for as financial assets as further discussed below. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively. We recorded a $0.9 million impairment loss for Selexis commercial license rights during the year ended December&#160;31, 2023 as a result of recently reduced programs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a royalty agreement with Elutia Inc. pursuant to which we will receive royalties from certain marketed products that Elutia acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Elutia to buydown the royalty rates on the products CorMatrix sold to Elutia. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Elutia (the &#8220;CorMatrix Asset Sale&#8221;). Per the agreement, we will receive a 5% royalty on the products Elutia acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#8220;Original Interest Purchase </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement&#8221;) between CorMatrix and us. In addition, Elutia has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Elutia acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#8220;Amended Interest Purchase Agreement&#8221;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Elutia in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Elutia commercial license right as a financial asset in accordance with ASC 310. During the year ended December&#160;31, 2023, we further considered the current and expected future economic and market conditions and recorded a $3.2 million credit loss adjustment to Elutia commercial license rights based on the assessment of current company performance and nonpayment by Elutia in recent quarters. This credit loss adjustment was recorded to General and administrative expense in our consolidated statement of operations. As of December 31, 2023, management is in process of modifying the payment terms with Elutia and has placed the loan on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2023 is 2.5%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2023 and 2022 were allocated accordingly between revenue and the amortization of the commercial license rights. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had accounted for commercial license rights related to Dianomi on a non-accrual basis and had fully reserved the credit loss as of December&#160;31, 2022. Dianomi Therapeutics, Inc. was dissolved in July 2023; therefore, we removed the related commercial license rights as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we made an investment of $30 million to acquire a 13% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. We performed predominant analysis and determined that the predominant characteristics of the underlyings are the sales-based milestones and royalties since the value of the projected cash flows tied to the underlyings are highly correlated with changes in the projected cash flows from royalties and commercial milestones and not the regulatory milestones. Therefore, the Ovid contract qualifies for the royalty scope exception under ASC815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and is accounted for as a financial asset in accordance with ASC 310. As soticlestat is in Phase 3 clinical trials, management has placed the investment on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we acquired Tolerance Therapeutics, Inc. (&#8220;Tolerance Therapeutics&#8221;) for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of TZIELD (teplizumab), that is owed a royalty of less than 1% on worldwide net sales. TZIELD is marketed by Sanofi in 2023. We account for the Tolerance commercial license right as a financial asset in accordance with ASC 310</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Due to the early stages of TZIELD's commercialization, management has placed the investment on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we announced the expansion of its strategic partnership with Palvella to accelerate Phase 3 development of QTORIN rapamycin for the treatment of Microcystic Lymphatic Malformations ("Microcystic LMs").  According to the terms of the second amendment to the development funding and royalties agreement, Palvella received an upfront payment of $5.0 million from Ligand. In return for the upfront payment, among other contractual changes, the tiered royalty payable by Palvella to Ligand was increased to between 8.0% and 9.8% based on annual aggregate worldwide net sales of QTORIN rapamycin. We are not obligated to provide additional funding to Palvella for development or commercialization of OTORIN. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce our asset as the funds are expended by Palvella. As of December 31, 2023, of the $5.0 million upfront funding related to the second amendment with Palvella, none of the funding to Palvella was expended, and we will reduce our asset as the funds are expended by Palvella in the future. Our CEO and director, Todd Davis, is a director of Palvella, who beneficially owns less than 2% of Palvella's outstanding equity. Mr. Davis recused himself from all of the board's consideration of the agreement between us and Palvella, including any financial analysis, the terms of the amendment and the vote to approve the purchase agreement and the related transactions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License And Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308825440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) In connection with the Purchase and Sale Agreement with Primrose Bio, we received 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under other </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">long-term asset in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The fair value of the derivative assets was determined using a discounted cash flow approach using a discount rate in line with the stages of the underlying contracts.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to equity security warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of derivative assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-878">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-882">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets and long-lived assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended December&#160;31, 2023. Other than the finance lease equipment discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (7), Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended and December&#160;31, 2022. There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued liabilities, deferred revenue, current operating lease liabilities, current financing lease liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license rights are measured and carried on the balance sheet at amortized cost using the effective interest method or on a non-accrual basis. Management calculates the fair value of commercial license rights using a forecasted royalty receipts.  The projected future cash flows derive from royalty payments and milestones, then discounted using appropriate individual discount rates. The fair value of commercial license and other economic rights assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair value and related carrying values of commercial license rights as of December&#160;31, 2023 were $75.9&#160;million and $62.3&#160;million, respectively.  The estimated fair value and related carrying value of the commercial license rights as of December&#160;31, 2022 were $13.1&#160;million and $10.2&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312989824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance lease</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the current COVID status, our forecast for COVID-related Captisol has been significantly reduced, which triggered an indicator of impairment of the right of use asset as of December&#160;31, 2022. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December&#160;31, 2022. As of December&#160;31, 2022 the remaining right of use asset balance is $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. In the year-ended December&#160;31, 2023, we recorded no impairment to this asset group as there have been no indicators of impairment, and as of December&#160;31, 2023, the remaining right of use asset balance is $3.4&#160;million.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating lease </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to nine years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-926"><span style="-sec-ix-hidden:f-927">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our operating leases have a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. As of December&#160;31, 2022, our operating leases have a weighted-average remaining lease term of 9.3 years and a weighted-average discount rate of 7.1%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.4 million and $1.7 million for the years ended December&#160;31, 2023 and 2022, respectively. Operating lease expense was $1.4 million (net of sublease income of $0.3 million) and $0.7 million (net of sublease income of $0.7 million) for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our finance leases have a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. As of December&#160;31, 2022, our finance leases have a weighted-average remaining lease term of 1.1 years and a weighted-average discount rate of 4.1%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December&#160;31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities were both $0.05&#160;million for the years ended December&#160;31, 2023 and 2022. Finance lease expense was $0.7 million and $2.3 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance lease</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the current COVID status, our forecast for COVID-related Captisol has been significantly reduced, which triggered an indicator of impairment of the right of use asset as of December&#160;31, 2022. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December&#160;31, 2022. As of December&#160;31, 2022 the remaining right of use asset balance is $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. In the year-ended December&#160;31, 2023, we recorded no impairment to this asset group as there have been no indicators of impairment, and as of December&#160;31, 2023, the remaining right of use asset balance is $3.4&#160;million.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating lease </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to nine years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-926"><span style="-sec-ix-hidden:f-927">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our operating leases have a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. As of December&#160;31, 2022, our operating leases have a weighted-average remaining lease term of 9.3 years and a weighted-average discount rate of 7.1%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.4 million and $1.7 million for the years ended December&#160;31, 2023 and 2022, respectively. Operating lease expense was $1.4 million (net of sublease income of $0.3 million) and $0.7 million (net of sublease income of $0.7 million) for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our finance leases have a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. As of December&#160;31, 2022, our finance leases have a weighted-average remaining lease term of 1.1 years and a weighted-average discount rate of 4.1%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December&#160;31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities were both $0.05&#160;million for the years ended December&#160;31, 2023 and 2022. Finance lease expense was $0.7 million and $2.3 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313058368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2023</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees and is being amortized to interest expense using the effective interest method over the five years expected life of the 2023 Notes. The effective interest rate for the year ended December&#160;31, 2023 is 0.5%. During the year ended December&#160;31, 2023 we recognized a total of $0.6 million in interest expense which includes $0.4 million in contractual interest expense and $0.2 million in amortized issuance costs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we repurchased $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million. We accounted for the repurchase as a debt extinguishment, which resulted in (1) a loss of $7.3&#160;million reflected in other income (expense), net, in our consolidated statement of operations for the year ended December&#160;31, 2021, (2) a $13.7&#160;million reduction in debt discount, and (3) a $10.2&#160;million reduction to additional paid in capital, related to the reacquisition of the equity component in our consolidated balance sheet as of December&#160;31, 2021. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we repurchased $266.4 million in principal amount of the 2023 Notes for $261.4 million in cash, including accrued interest of $0.5 million We accounted for the repurchase as a debt extinguishment, which resulted in a gain of $4.2 million reflected in other income (expense), net, in our consolidated statement of operations for the year ended December&#160;31, 2022, and a $1.3 million reduction in debt discount. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $206.65 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants did not have any rights with respect to the convertible bond hedges.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, in connection with the repurchases of approximately $20.3&#160;million in principal of the 2023 Notes for approximately $19.1&#160;million in cash, including accrued interest of $0.1&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, in connection with the repurchases of $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million, we entered into Warrant Early Unwind Agreements and Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. We paid $18.4&#160;million as part of the Warrant Early Unwind Agreements reducing the number of shares covered by the warrants from 3,018,327 to 2,559,254.  As of December 31, 2023, the number of warrants that remain outstanding is 545,000. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, in connection with the repurchases of $227.8&#160;million in principal of the 2023 Notes for $223.7&#160;million in cash, including accrued interest of $0.4&#160;million made during the six months ended June 30, 2022, we entered into Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the 2023 Notes (in thousands) as of December&#160;31, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:71.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, we entered into a $75.0 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (as defined in the Credit Agreement) entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make loans and other financial accommodations to us in an aggregate amount of up to $75.0 million. At our option, borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term Secured Overnight Financing Rate ("Term SOFR") or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from 1.75% to 2.50% per annum for Term SOFR loans and 0.75% to 1.50% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from 0.30% to 0.45%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $74.5&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.5&#160;million for letter of credit. The maturity date of the Revolving Credit Facility is October 12, 2026.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were no events of default or violation of any covenants under our financing obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313108048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account Details<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2023 and 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bond Fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,783)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bond fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,451)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,742&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 31 positions which were in an unrealized loss position with a total of $0.01 million unrealized losses as of December&#160;31, 2023. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments: Investment in Viking:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ownership in Viking was approximately 1.7% as of December&#160;31, 2023, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and December&#160;31, 2022, our investment in Viking is $32.2 million and $63.1 million, respectively, and included in short-term investments on the balance sheet. During the year ended December&#160;31, 2023, we sold 5.0 million shares of Viking common stock and recognized a realized gain of $44.4 million. During the year ended December&#160;31, 2021, we sold 0.6 million shares of Viking common stock and recognized a realized gain of $3.6 million. There were no sales of Viking common stock during the year ended December&#160;31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:f-1191">one</span> to nine years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $2.9 million, $3.8 million, and $2.4 million was recognized for the years ended December&#160;31, 2023, 2022, and 2021, respectively, and was included in operating expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Completed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $33.7 million, $34.2 million, and $34.2 million was recognized for the years ended December&#160;31, 2023, 2022, and 2021, respectively. Estimated amortization expense for the years ending December&#160;31, 2024 through 2028 is $32.8 million per year. For each of the years ended December&#160;31, 2023, 2022, and 2021, there was no material impairment of intangible assets with finite lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer deposit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novan contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:21.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(194)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312911104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense from continuing operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion and Modification of Equity Awards Outstanding at Separation Date</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the Merger Agreement to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-Distribution Ligand stock received a number of otherwise-similar awards either in post-Distribution Ligand stock or in a combination of post-Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the Merger Agreement that we entered into in connection with the Distribution. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the Separation; for OmniAb employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#8220;regular way&#8221; and &#8220;ex-distribution&#8221; markets during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five-trading day period prior to the closing of the business combination.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;). The amended and restated 2002 Plan, which is referred to herein as the &#8220;Restated Plan&#8221; was amended to increase the shares available for issuance by 1.0 million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, our board of directors (the &#8220;Board&#8221;) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the &#8220;2022 Inducement Plan&#8221;). The terms of the 2022 Inducement Plan are substantially similar to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved 300,000 shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there were 1.0 million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(619,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,952&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at October 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769,629&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of October 31, 2022, before Separation and Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation due to Separation, Before Regrant</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,987,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,584,760&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,559,662&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(399,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,784,209&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Options granted primarily relate to the modifications in connection with the Separation which resulted in new stock option grants at the modification date fair value. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2023, 2022 and 2021 was $36.65, $28.90, and $80.08 per share, respectively. The total intrinsic value of all options exercised during 2023, 2022 and 2021 was approximately $12.0 million, $4.6 million, and $77.3 million, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2023, 2022 and 2021 was $22.2 million, $2.6 million and $33.0 million, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$32.78-$49.99</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.36-$52.30</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$52.84-$52.84</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$54.81-$58.28</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$58.49-$66.54</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$66.70-$68.74</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$69.39-$75.09</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">484,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$78.56-$99.80</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$103.42-$103.42</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$114.15-$114.15</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,784,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7%-4.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49%-55%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-63%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7 to 5.3 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 to 6.5 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7 to 6.3 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $26.2 million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of 2.5 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $1.1 million of total unrecognized compensation cost related to non-vested OmniAb stock options received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of 0.9 years. </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at October 31, 2022, before Separation and Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited due to Separation, Before Regrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $15.2&#160;million. That cost is expected to be recognized over a weighted average period of 1.6 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $0.1&#160;million of total unrecognized compensation cost related to non-vested OmniAb stock awards received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of 0.1 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, 30,801 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a <span style="-sec-ix-hidden:f-1520">six</span> month offering period or purchase date, whichever is lower. There were 5,080, 8,479 and 8,448 shares issued under the ESPP in 2023, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, our Board of Directors has approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $50.0 million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. During the years ended December&#160;31, 2023, 2022 and 2021, we did not repurchase any common stock, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the Market Equity Offering Program</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we filed a registration statement on Form S-3 (the &#8220;Shelf Registration Statement&#8221;), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Stifel, Nicolaus &amp; Company, Incorporated (the &#8220;Agent&#8221;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100.0&#160;million in &#8220;at the market&#8221; offerings through the Agent (the &#8220;ATM Offering&#8221;). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $100.0&#160;million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. To date, we have not issued any shares of common stock in the ATM Offering.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308752976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies: Legal Proceedings</a></td>
<td class="text">Commitment and Contingencies: Legal Proceedings<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312923200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:66.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,148)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:66.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,628)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subpart F income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,148)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2023, 2022 and 2021. The valuation allowance amount in connection with the deferred taxes decreased $1.2&#160;million in 2023, increased $24.8 million in 2022 and increased $11.2 million in 2021.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(liabilities) are comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:76.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,470)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,085)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had federal net operating loss carryforwards set to expire through 2037 of $48.0 million and $165.1 million of state net operating loss carryforwards that begin to expire in 2028. We also have $8.5 million of federal research and development credit carryforwards, which expire through 2040. We have $29.4 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $95.5 million of non-U.S. net operating loss carryovers and approximately $16.5 million of non-U.S. capital loss carryovers that have no expiration date.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, we had federal net operating loss carryforwards set to expire through 2037 of $81.1 million and $168.3 million of state net operating loss carryforwards that begin to expire in 2028. We also had $8.5 million of federal research and development credit carryforwards, which expire through 2040. We had $29.0 million of California research and development credit carryforwards that have no expiration date. In addition, we had approximately $96.1 million of non-U.S. net operating loss carryovers and approximately $15.6 million of non-U.S. capital loss carryovers that have no expiration date. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2023 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2023, 2022 and 2021 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2023 is $20.6 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2023 and December&#160;31, 2022, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, and United Kingdom with varying statutes of limitations. The federal statute of limitation remains open for the 2020 tax year to the present.&#160;The state income tax returns generally remain open for the 2019 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.  The Company's 2019 and 2020 California tax returns are under examination by the California Franchise Tax Board. The Company does not anticipate that the examination will result in a material adjustment to its financial statements.  No other income tax returns are currently under examination. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303450080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
<td class="nump">$ 57,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312347536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308554064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. We operate in one reportable segment: development and licensing of biopharmaceutical assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued operations</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the spin-off of the OmniAb antibody discovery business (the&#8220;OmniAb Business&#8221;) in November 2022 met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span> (&#8220;ASC 205-20&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock', window );">Cash Equivalents &amp; Short-term Investments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of other income (expense) within the consolidated statements of operations.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three&#160;months and less than twenty-five months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div>Equity securities consist of mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, Equity securities in Primrose Bio, or non-current other assets, based on the nature of the securities and their availability for use in current operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses </span></div>Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div>Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:f-532">one</span> to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div>Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2023, noting no impairment. </span></div>Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsPolicyTextBlock', window );">Commercial license and other economic rights</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial license and other economic rights</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For commercial license rights, we account them in accordance with ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Receivables, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and are measured at amortized cost using the prospective effective interest method described in ASC 835-30,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If management determines it can reliably estimate future cash flows of the asset, we amortize the asset using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. If cash flows are not reliably estimable, the asset is accounted for using the non-accrual method. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate commercial license rights for impairment on an individual basis. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize an allowance for current expected credit losses under ASC 326 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments &#8211; Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our commercial license rights. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for changes in projected cash flows and credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.  </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other economic rights, which are characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reduce the asset as the funds are expended. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial license and other economic rights are evaluated for impairment on an ongoing basis. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (5), Commercial License and Other Economic Rights</span>&#8221;.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherInvestmentsPolicyPolicyTextBlock', window );">Other Investments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments present equity securities that primarily include common stocks, preferred stocks we invested. Equity securities without readily determinable or estimable fair values are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Deferred Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known, typically the following quarter. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Captisol Sales</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;D services.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For R&amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div>Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div>Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (CRO) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div>Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. The 2023 Notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span>, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Updates, Recently Adopted and Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Updates, Recently Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, we adopted ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2021-08&#8221;). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic 606&#8221;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued updated accounting guidance related to annual and interim segment disclosures. The updated accounting guidance, among other things, requires disclosure of certain significant segment expenses. We will adopt the updated accounting guidance in our Annual Report on Form 10-K for the year ended December 31, 2024. We do not expect impact from the adoption of the new accounting guidance will have material impact to our segment disclosures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Spin-Off And Migration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessSpinOffAndMigrationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Investments Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307644512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenue from Significant Partners</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teriparatide injection </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rylaze </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,527&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol - Core</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Captisol - COVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Service Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;License Fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,367&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,241&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313117920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:76.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,956)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,215)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock', window );">Schedule of Fair Value of the Consideration</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Fair Value Of The Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787309451152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for Novan, including restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DIP loan fees and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312952736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:76.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,956)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,215)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313017344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commercial License and Other Economic Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock', window );">Schedule of Commercial License and Other Economic Rights</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, commercial license and other economic rights consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elutia and CorMatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,882)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selexis and Dianomi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ovid </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tolerance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,228)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,298&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,116)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(1) Amounts represent accumulated amortization to principal of $11.2 million, credit loss adjustments of $8.1 million, and impairment of $0.9 million as of December&#160;31, 2023. </span></div>(2) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Commercial License And Other Economic Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313163872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for amounts owed to a former licensor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,557&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) In connection with the Purchase and Sale Agreement with Primrose Bio, we received 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under other </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">long-term asset in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The fair value of the derivative assets was determined using a discounted cash flow approach using a discount rate in line with the stages of the underlying contracts.</span></div>(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments, Assets</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to equity security warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of derivative assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-878">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-882">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments, Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to equity security warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of derivative assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-878">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-882">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments to contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312881360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Operating and Finance Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating and Finance Lease Assets and Liabilities (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-926"><span style="-sec-ix-hidden:f-927">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Finance Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787313108048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Equity and Liability Components of the Convertible Senior Notes</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the 2023 Notes (in thousands) as of December&#160;31, 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:71.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount of 2023 Notes outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized discount (including unamortized debt issuance cost)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total long-term portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of convertible senior notes outstanding (Level 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307601472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investment Categories</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2023 and 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bond Fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,783)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bond fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Bank deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,451)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,742&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bank deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Government Securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,301&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment are stated at cost and consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Other Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Completed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer deposit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long Term Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novan contract liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock', window );">Schedule of Contingent Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:21.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Repurchases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(194)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Contingent Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofContingentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312328896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense from continuing operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,561,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(619,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391,952&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at October 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769,629&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of October 31, 2022, before Separation and Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation due to Separation, Before Regrant</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,987,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,584,760&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(542,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,559,662&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(399,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,784,209&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Options granted primarily relate to the modifications in connection with the Separation which resulted in new stock option grants at the modification date fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Option Plan Activity by Exercise Price Range</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining&#160; life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$32.78-$49.99</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.36-$52.30</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$52.84-$52.84</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$54.81-$58.28</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$58.49-$66.54</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$66.70-$68.74</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$69.39-$75.09</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">484,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$78.56-$99.80</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$103.42-$103.42</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$114.15-$114.15</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,784,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Weighted-Average Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7%-4.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45%-54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49%-55%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-63%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7 to 5.3 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 to 6.5 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7 to 6.3 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at October 31, 2022, before Separation and Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited due to Separation, Before Regrant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(181,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310319744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:66.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,586)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,148)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:66.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,628)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subpart F income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,080)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,148)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Deferred tax assets <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(liabilities) are comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:76.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77,470)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,085)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2023, 2022 and 2021 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,072)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307842336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2007 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>right</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Increase (decrease) of allowance for credit loss</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="nump">$ 10,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs related to obsolete inventory</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">23,969,000<span></span>
</td>
<td class="nump">13,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Measurement input (as a percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2002 Stock Incentive Plan | Vest 1/8 on the six month anniversary of the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2002 Stock Incentive Plan | Vest 1/48 each month for forty-two months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsIssued', window );">Number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307911376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details) - Customer Concentration Risk - Revenue<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307760464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 131,314<span></span>
</td>
<td class="nump">$ 196,245<span></span>
</td>
<td class="nump">$ 241,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">83,910<span></span>
</td>
<td class="nump">72,527<span></span>
</td>
<td class="nump">48,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember', window );">Kyprolis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35,640<span></span>
</td>
<td class="nump">30,116<span></span>
</td>
<td class="nump">27,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember', window );">Evomela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,212<span></span>
</td>
<td class="nump">10,197<span></span>
</td>
<td class="nump">10,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyTeriparatideInjectionMember', window );">Teriparatide injection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,061<span></span>
</td>
<td class="nump">15,785<span></span>
</td>
<td class="nump">5,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyRylazeMember', window );">Rylaze</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,520<span></span>
</td>
<td class="nump">8,796<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,477<span></span>
</td>
<td class="nump">7,633<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28,372<span></span>
</td>
<td class="nump">104,495<span></span>
</td>
<td class="nump">164,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCoreMember', window );">Captisol - Core</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28,372<span></span>
</td>
<td class="nump">16,429<span></span>
</td>
<td class="nump">23,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCOVIDMember', window );">Captisol - COVID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">88,066<span></span>
</td>
<td class="nump">140,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">19,032<span></span>
</td>
<td class="nump">19,223<span></span>
</td>
<td class="nump">28,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember', window );">License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">2,849<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember', window );">Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">9,150<span></span>
</td>
<td class="nump">17,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 6,107<span></span>
</td>
<td class="nump">$ 6,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyTeriparatideInjectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyTeriparatideInjectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyRylazeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyRylazeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCOVIDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCOVIDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMilestonesAndOtherProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303201360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">17,298<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
<td class="nump">16,630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted income per share (in shares)</a></td>
<td class="nump">17,757<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
<td class="nump">17,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</a></td>
<td class="nump">4,357<span></span>
</td>
<td class="nump">6,241<span></span>
</td>
<td class="nump">4,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306281904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($) </div>
<div>contract </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,121<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative assets with fair value</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">consolidated balance sheet<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
<td class="nump">$ 28,142<span></span>
</td>
<td class="nump">$ 19,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Gain on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Consideration paid for an interest in potential development milestone</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business exit costs</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration', window );">Shares received as consideration | shares</a></td>
<td class="nump">474,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration', window );">Shares received as consideration | shares</a></td>
<td class="nump">2,146,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration', window );">Shares received as consideration | shares</a></td>
<td class="nump">4,278,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Consideration paid for an interest in potential development milestone</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_InterestInPotentialDevelopmentMilestone', window );">Interest in potential development milestone (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Primrose Bio | PeliCRM197</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesRevenueMilestone', window );">Sales revenue milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Primrose Bio | PeliCRM197 | Below 3 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Primrose Bio | PeliCRM197 | Above 3 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember', window );">Primordial Genetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Paid For An Interest In Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Share Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesContractInterestInSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Contract, Interest In Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesContractInterestInSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesRevenueMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesRevenueMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_PeliCRM197Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_PeliCRM197Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneAxis=lgnd_BelowMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneAxis=lgnd_BelowMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneAxis=lgnd_AboveMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneAxis=lgnd_AboveMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303189312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Pelican Technology Holdings, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">$ 8,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">19,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">8,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset', window );">Financing lease right-of-use assets</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities', window );">Long-term operating lease liabilities</a></td>
<td class="num">(8,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset', window );">Net assets sold</a></td>
<td class="nump">27,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Allocated goodwill</a></td>
<td class="nump">4,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Cash consideration paid</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions', window );">Total</a></td>
<td class="nump">$ 47,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Paid For An Interest In Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308500896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Pelican Technology Holdings, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">$ 49,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">13,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">32,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationClassficationAxis=lgnd_EquityMethodInvestmentsAllocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationClassficationAxis=lgnd_EquityMethodInvestmentsAllocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationClassficationAxis=lgnd_EquitySecuritiesAllocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationClassficationAxis=lgnd_EquitySecuritiesAllocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationClassficationAxis=lgnd_DerivativeAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationClassficationAxis=lgnd_DerivativeAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303418784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Narrative (Details) - Novan, Inc.<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments for acquisition</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationAcquiredPercentage', window );">Acquired (as a percent)</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average estimated useful life of finite-lived intangible assets acquired (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentMilestonePurchaseAgreement', window );">Research and development</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Discount Rate | Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent liability measurement input (as a percent)</a></td>
<td class="nump">0.140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAcquiredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquired Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAcquiredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentMilestonePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentMilestonePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306178864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,370<span></span>
</td>
<td class="nump">$ 105,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan, including restricted cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Restricted Cash</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">13,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets', window );">Other assets</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets acquired</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(2,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(3,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(13,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan, including restricted cash received</a></td>
<td class="nump">10,988<span></span>
</td>
<td class="nump">$ 10,405<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationLoanFeesAndInterest', window );">DIP loan fees and interest</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 12,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationLoanFeesAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Loan Fees And Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationLoanFeesAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310807152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DeferredTaxAssetsAdjustments', window );">Deferred tax asset adjustment</a></td>
<td class="num">$ (1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed', window );">Percentage of voting interests disposed (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxAssetsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxAssetsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303332608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss</a></td>
<td class="num">$ (1,665)<span></span>
</td>
<td class="num">$ (28,142)<span></span>
</td>
<td class="num">$ (19,215)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="nump">26,564<span></span>
</td>
<td class="nump">35,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">10,847<span></span>
</td>
<td class="nump">12,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">38,466<span></span>
</td>
<td class="nump">36,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,383<span></span>
</td>
<td class="nump">10,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating costs and expenses</a></td>
<td class="nump">62,696<span></span>
</td>
<td class="nump">60,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(36,132)<span></span>
</td>
<td class="num">(24,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments', window );">Gain from short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">554<span></span>
</td>
<td class="num">(1,210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income tax</a></td>
<td class="num">(35,578)<span></span>
</td>
<td class="num">(24,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax benefit</a></td>
<td class="nump">7,436<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss</a></td>
<td class="num">(28,142)<span></span>
</td>
<td class="num">(19,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations | Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="nump">$ 25,275<span></span>
</td>
<td class="nump">$ 35,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Costs and Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308476528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb - Schedule of non-cash items and capital expenditures of the discontinued operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,545)<span></span>
</td>
<td class="num">$ (1,050)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(554)<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,218<span></span>
</td>
<td class="nump">14,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,404<span></span>
</td>
<td class="nump">9,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchase of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,572)<span></span>
</td>
<td class="num">(4,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity', window );">Payments to CVR Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(960)<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by (Used in) Discontinued Operations, Investing Actives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by (Used in) Discontinued Operations, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Investing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersInvestingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308525328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commercial License and Other Economic Rights - Schedule of Commercial License and Other Economic Rights (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsGross', window );">Gross</a></td>
<td class="nump">$ 87,519<span></span>
</td>
<td class="nump">$ 28,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCumulativeAdjustments', window );">Adjustments</a></td>
<td class="num">(20,228)<span></span>
</td>
<td class="num">(18,116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Net</a></td>
<td class="nump">67,291<span></span>
</td>
<td class="nump">10,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCreditLossAdjustment', window );">Credit loss adjustment</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsImpairments', window );">Finite lived intangible asset accumulated impairment</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember', window );">Elutia and CorMatrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsGross', window );">Gross</a></td>
<td class="nump">17,696<span></span>
</td>
<td class="nump">17,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCumulativeAdjustments', window );">Adjustments</a></td>
<td class="num">(11,882)<span></span>
</td>
<td class="num">(9,538)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Net</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="nump">8,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCreditLossAdjustment', window );">Credit loss adjustment</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember', window );">Selexis and Dianomi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsGross', window );">Gross</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">10,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCumulativeAdjustments', window );">Adjustments</a></td>
<td class="num">(7,841)<span></span>
</td>
<td class="num">(8,578)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Net</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember', window );">Ovid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsGross', window );">Gross</a></td>
<td class="nump">30,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCumulativeAdjustments', window );">Adjustments</a></td>
<td class="num">(303)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Net</a></td>
<td class="nump">30,007<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember', window );">Tolerance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsGross', window );">Gross</a></td>
<td class="nump">25,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCumulativeAdjustments', window );">Adjustments</a></td>
<td class="num">(202)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Net</a></td>
<td class="nump">25,709<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaMember', window );">Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsGross', window );">Gross</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCumulativeAdjustments', window );">Adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRights', window );">Net</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Accumulated Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsCreditLossAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Credit Loss Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsCreditLossAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsCumulativeAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Cumulative Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsCumulativeAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Impairments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312037232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commercial License and Other Economic Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCreditLossAdjustment', window );">Credit loss adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember', window );">Tolerance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember', window );">Elutia and CorMatrix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCreditLossAdjustment', window );">Credit loss adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember', window );">Elutia and CorMatrix | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember', window );">Selexis and Dianomi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ImpairmentOfCommercialLicense', window );">Impairment of commercial license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember', window );">CorMatrix | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_RoyaltyAgreementExpirationPeriod', window );">Expiration period of royalty agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisMember', window );">Selexis | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent', window );">Effective interest rate of forecasted cash flows (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember', window );">Ovid | Soticlestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Consideration paid for an interest in potential development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage', window );">Beneficial ownership interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Royalties Receivable Under Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsCreditLossAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Credit Loss Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsCreditLossAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Paid For An Interest In Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ForecastedCashFlowsEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forecasted Cash Flows, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ForecastedCashFlowsEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ImpairmentOfCommercialLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Commercial License</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ImpairmentOfCommercialLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Beneficial Ownership In Reporting Entity, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProductRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProductRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltyAgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Agreement, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltyAgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesContractInterestInSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Contract, Interest In Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesContractInterestInSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisAndDianomiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_CorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_CorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_SoticlestatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_SoticlestatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787301813584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>cvr</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative assets(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsSeries', window );">Number of CVR Series | cvr</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_InterestInPotentialDevelopmentMilestone', window );">Interest in potential development milestone (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember', window );">Primordial Genetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time | Phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transferred over Time | Development, regulatory, &amp; commercial milestones and tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare', window );">Number of CVRs issued per acquiree share | cvr</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries', window );">Number of CVRs issued from each CVR series | cvr</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders', window );">Frequency of cash payments to CVR holders</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure', window );">Liability for amounts owed to a former licensor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,557,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,742,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,429,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,114,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure', window );">Liability for amounts owed to a former licensor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,992,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,615,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure', window );">Liability for amounts owed to a former licensor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,429,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,615,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,429,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure', window );">Liability for amounts owed to a former licensor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AmountsOwedToFormerLicensorFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Owed To Former Licensor, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AmountsOwedToFormerLicensorFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number of Contingent Value Rights Issued per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_InterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_InterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Series</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lgnd_ContingentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lgnd_ContingentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CyDexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CyDexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306238848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Fair value adjustments to equity security warrants</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Fair value of derivative assets</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Gain (loss) from short-term investments<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingency payments</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="nump">286<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310131168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Tangible asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangible asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsFairValueDisclosure', window );">Commercial license rights, fair value disclosure</a></td>
<td class="nump">75,900,000<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsFairValueDisclosure', window );">Commercial license rights, fair value disclosure</a></td>
<td class="nump">$ 62,300,000<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307714960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 3,393<span></span>
</td>
<td class="nump">$ 4,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification', window );">Increase in operating lease assets</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of operating leases</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of operating leases (as a percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of finance leases</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of finance leases (as a percent)</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for amounts included in finance lease liabilities</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease expense</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term of operating leases</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidToDate', window );">Consideration paid to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory', window );">Portion of consideration allocated to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use asset recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseImpairmentLoss', window );">Finance lease, impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid, Allocated to Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid to Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310646928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 10,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">4,095<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">9,455<span></span>
</td>
<td class="nump">15,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,755<span></span>
</td>
<td class="nump">10,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 6,184<span></span>
</td>
<td class="nump">$ 11,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306099456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating and Finance Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,912<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">8,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(2,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">6,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787300852688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>May 15, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss(gain) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,192,000<span></span>
</td>
<td class="num">$ (7,303,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reduction to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,407,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,854,000<span></span>
</td>
<td class="nump">260,949,000<span></span>
</td>
<td class="nump">155,760,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToUnwindWarrants', window );">Payments to unwind warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, interest rate (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, interest rate (as a percent)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Available borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member', window );">2023 Convertible Senior Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt instrument (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,400,000<span></span>
</td>
<td class="nump">152,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,400,000<span></span>
</td>
<td class="nump">156,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued interest portion of repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss(gain) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="num">(7,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInDebtDiscount', window );">Reduction in debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Reduction to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,559,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member', window );">2023 Convertible Senior Notes | Convertible Notes | Notes Repurchased During Current Period, Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod', window );">Repurchased amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchased Amount During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentRepurchasedAmountDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToUnwindWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Unwind Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToUnwindWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsforConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsforConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=lgnd_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=lgnd_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310820576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Equity and Liability Components of Financing Arrangements (Details) - Convertible Notes - 2023 Convertible Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract', window );"><strong>Notes Payable, Current and Noncurrent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 Notes outstanding</a></td>
<td class="nump">$ 76,854,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount (including unamortized debt issuance cost)</a></td>
<td class="num">(159,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term portion of notes payable</a></td>
<td class="nump">76,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible senior notes outstanding (Level 2)</a></td>
<td class="nump">$ 74,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312012864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Investment Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 120,874<span></span>
</td>
<td class="nump">$ 108,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(5,783)<span></span>
</td>
<td class="num">(5,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">115,170<span></span>
</td>
<td class="nump">103,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Bond Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">63,763<span></span>
</td>
<td class="nump">81,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(537)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">63,226<span></span>
</td>
<td class="nump">80,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">17,165<span></span>
</td>
<td class="nump">5,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">17,176<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">14,850<span></span>
</td>
<td class="nump">6,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">14,888<span></span>
</td>
<td class="nump">6,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">11,578<span></span>
</td>
<td class="nump">7,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">11,586<span></span>
</td>
<td class="nump">7,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">6,736<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">6,751<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">5,775<span></span>
</td>
<td class="nump">5,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(5,235)<span></span>
</td>
<td class="num">(4,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310181424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 55,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">13,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">68,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">55,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">13,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 68,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307964416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">17,809<span></span>
</td>
<td class="nump">12,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">20,758<span></span>
</td>
<td class="nump">13,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">4,175<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">4,175<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">4,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">10,222<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">10,222<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308285616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Narrative (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions in an unrealized loss position | position</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in Viking common stock</a></td>
<td class="nump">32,200,000<span></span>
</td>
<td class="nump">63,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) from short-term investments</a></td>
<td class="nump">46,365,000<span></span>
</td>
<td class="nump">28,540,000<span></span>
</td>
<td class="num">$ (5,263,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life (in years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">$ 33,654,000<span></span>
</td>
<td class="nump">34,237,000<span></span>
</td>
<td class="nump">34,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated amortization expense for 2024</a></td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated amortization expense for 2025</a></td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated amortization expense for 2026</a></td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated amortization expense for 2027</a></td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated amortization expense for 2028</a></td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss of commercial license rights</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightAgreements', window );">Number of CVR agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member', window );">Viking Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Ownership interest (as a percent)</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfSharesSoldOfEquityMethodInvestee', window );">Stock sold of equity method investee (in shares) | shares</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) from short-term investments</a></td>
<td class="nump">$ 44,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Contingent Value Right Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfSharesSoldOfEquityMethodInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Sold Of Equity Method Investee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfSharesSoldOfEquityMethodInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308095472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 22,262<span></span>
</td>
<td class="nump">$ 22,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(6,655)<span></span>
</td>
<td class="num">(10,125)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,607<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Lab and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">9,264<span></span>
</td>
<td class="nump">14,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">12,282<span></span>
</td>
<td class="nump">7,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 716<span></span>
</td>
<td class="nump">$ 989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307491536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 103,370<span></span>
</td>
<td class="nump">$ 105,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total goodwill and other identifiable intangible assets, net</a></td>
<td class="nump">402,976<span></span>
</td>
<td class="nump">448,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">42,911<span></span>
</td>
<td class="nump">55,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(20,894)<span></span>
</td>
<td class="num">(22,560)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">2,642<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(1,710)<span></span>
</td>
<td class="num">(1,577)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(19,161)<span></span>
</td>
<td class="num">(17,670)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contractual relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (93,782)<span></span>
</td>
<td class="num">$ (65,191)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310090480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 4,682<span></span>
</td>
<td class="nump">$ 6,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,394<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedCustomerDepositsCurrent', window );">Customer deposit</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LicenseeAccrualCurrent', window );">Amounts owed to former licensees</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties owed to third parties</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedSubcontractorExpensesCurrent', window );">Subcontractor</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedSupplierExpensesCurrent', window );">Supplier</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 12,467<span></span>
</td>
<td class="nump">$ 15,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedCustomerDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Customer Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedCustomerDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSubcontractorExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontractor Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSubcontractorExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSupplierExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Supplier Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSupplierExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LicenseeAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensee Accrual, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LicenseeAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310337248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Other Long-term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_UnrecognizedTaxBenefitsNoncurrent', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 14,039<span></span>
</td>
<td class="nump">$ 21,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Novan contract liability</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherMiscellaneousNonCurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 27,758<span></span>
</td>
<td class="nump">$ 21,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherMiscellaneousNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Non-current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherMiscellaneousNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_UnrecognizedTaxBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits - Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_UnrecognizedTaxBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303298864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, beginning of period</a></td>
<td class="nump">$ 3,513<span></span>
</td>
<td class="nump">$ 3,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, end of period</a></td>
<td class="nump">3,198<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember', window );">Cydex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, beginning of period</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">286<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, end of period</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, beginning of period</a></td>
<td class="nump">3,429<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="num">(551)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities', window );">Repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, end of period</a></td>
<td class="nump">$ 2,878<span></span>
</td>
<td class="nump">$ 3,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787309892240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 25,743<span></span>
</td>
<td class="nump">$ 50,881<span></span>
</td>
<td class="nump">$ 29,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">6,248<span></span>
</td>
<td class="nump">10,970<span></span>
</td>
<td class="nump">9,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 19,495<span></span>
</td>
<td class="nump">$ 39,911<span></span>
</td>
<td class="nump">$ 19,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306272304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgnd_AtTheMarketEquityOfferingMember', window );">At-The Market Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SaleOfStockAuthorizedOfferingAmount', window );">Sale of stock, authorized offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.65<span></span>
</td>
<td class="nump">$ 28.90<span></span>
</td>
<td class="nump">$ 80.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 77,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase the number of shares under the 2002 Stock Incentive Plan (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember', window );">Omniab Separation | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember', window );">Omniab Separation | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember', window );">Amended ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EmployeeStockPurchasePlanAbstract', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Shares allowed to purchase in employee stock purchase plan per employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ShareBasedCompensationInitialOfferingPeriod', window );">Initial Offering Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued under amended ESSP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,080<span></span>
</td>
<td class="nump">8,479<span></span>
</td>
<td class="nump">8,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CorporateShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CorporateShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EmployeeStockPurchasePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EmployeeStockPurchasePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SaleOfStockAuthorizedOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SaleOfStockAuthorizedOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ShareBasedCompensationInitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation, Initial Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ShareBasedCompensationInitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgnd_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgnd_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_AmendedESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303390928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period (in shares)</a></td>
<td class="nump">2,987,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,199,598<span></span>
</td>
<td class="nump">2,991,473<span></span>
</td>
<td class="nump">2,561,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,584,760<span></span>
</td>
<td class="nump">863,245<span></span>
</td>
<td class="nump">537,432<span></span>
</td>
<td class="nump">393,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,449)<span></span>
</td>
<td class="num">(34,941)<span></span>
</td>
<td class="num">(489,076)<span></span>
</td>
<td class="num">(619,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,987,833)<span></span>
</td>
<td class="num">(542,838)<span></span>
</td>
<td class="num">(40,069)<span></span>
</td>
<td class="num">(399,371)<span></span>
</td>
<td class="num">(136,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,473<span></span>
</td>
<td class="nump">2,987,833<span></span>
</td>
<td class="nump">2,640,458<span></span>
</td>
<td class="nump">2,199,598<span></span>
</td>
<td class="nump">2,561,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,559,662<span></span>
</td>
<td class="nump">1,769,629<span></span>
</td>
<td class="nump">1,784,209<span></span>
</td>
<td class="nump">1,391,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,473<span></span>
</td>
<td class="nump">2,987,833<span></span>
</td>
<td class="nump">2,640,458<span></span>
</td>
<td class="nump">2,199,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (in USD per share)</a></td>
<td class="nump">$ 102.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106.00<span></span>
</td>
<td class="nump">$ 61.31<span></span>
</td>
<td class="nump">$ 85.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.10<span></span>
</td>
<td class="nump">91.34<span></span>
</td>
<td class="nump">72.69<span></span>
</td>
<td class="nump">159.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.24<span></span>
</td>
<td class="nump">38.56<span></span>
</td>
<td class="nump">45.83<span></span>
</td>
<td class="nump">54.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.20<span></span>
</td>
<td class="nump">78.46<span></span>
</td>
<td class="nump">66.61<span></span>
</td>
<td class="nump">110.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.31<span></span>
</td>
<td class="nump">102.92<span></span>
</td>
<td class="nump">65.70<span></span>
</td>
<td class="nump">106.00<span></span>
</td>
<td class="nump">$ 85.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.83<span></span>
</td>
<td class="nump">102.38<span></span>
</td>
<td class="nump">64.90<span></span>
</td>
<td class="nump">98.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.31<span></span>
</td>
<td class="nump">$ 102.92<span></span>
</td>
<td class="nump">$ 65.70<span></span>
</td>
<td class="nump">$ 106.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">4 years 3 months 3 days<span></span>
</td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value (In thousands)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,477<span></span>
</td>
<td class="nump">$ 14,835<span></span>
</td>
<td class="nump">$ 8,784<span></span>
</td>
<td class="nump">$ 113,302<span></span>
</td>
<td class="nump">$ 59,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
<td class="nump">13,722<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">80,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,477<span></span>
</td>
<td class="nump">$ 14,835<span></span>
</td>
<td class="nump">$ 8,784<span></span>
</td>
<td class="nump">$ 113,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306291504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Breakdown of Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">2,640,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 65.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,784,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 64.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember', window );">$32.78-$49.99</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">32.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 49.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">301,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 42.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">290,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 42.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember', window );">$50.36-$52.30</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">50.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 52.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">99,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 52.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">42,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 52.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember', window );">$52.84-$52.84</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">52.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 52.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">357,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 52.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">221,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 52.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember', window );">$54.81-$58.28</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">54.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 58.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">270,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 55.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">244,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 55.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember', window );">$58.49-$66.54</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">58.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 66.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">283,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 62.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">160,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 61.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember', window );">$66.70-$68.74</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">66.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 68.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">450,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 67.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">380,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 68.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember', window );">69.39</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">69.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 75.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">484,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 72.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">109,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 72.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember', window );">$78.56-$99.80</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">78.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 99.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">209,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 89.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">192,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 90.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember', window );">$103.42-$103.42</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">103.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 103.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">170,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 103.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">128,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 103.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember', window );">$114.15-$114.15</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">114.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 114.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 114.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 114.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787306939200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310233488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Activity (Details) - Restricted stock - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">366,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">264,143<span></span>
</td>
<td class="nump">348,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,473<span></span>
</td>
<td class="nump">260,577<span></span>
</td>
<td class="nump">203,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,385)<span></span>
</td>
<td class="num">(138,867)<span></span>
</td>
<td class="num">(181,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(366,470)<span></span>
</td>
<td class="num">(2,635)<span></span>
</td>
<td class="num">(19,383)<span></span>
</td>
<td class="num">(20,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">348,453<span></span>
</td>
<td class="nump">366,470<span></span>
</td>
<td class="nump">350,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in USD per share)</a></td>
<td class="nump">$ 114.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138.21<span></span>
</td>
<td class="nump">$ 75.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.61<span></span>
</td>
<td class="nump">89.99<span></span>
</td>
<td class="nump">83.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.17<span></span>
</td>
<td class="nump">120.57<span></span>
</td>
<td class="nump">74.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.05<span></span>
</td>
<td class="nump">58.45<span></span>
</td>
<td class="nump">65.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.60<span></span>
</td>
<td class="nump">$ 114.83<span></span>
</td>
<td class="nump">$ 81.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787312343792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>complaint</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember', window );">US District Court for the Northern District of Ohio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of civil complaints filed against entity</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787310110688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (1,186)<span></span>
</td>
<td class="nump">$ 10,097<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense (benefit)</a></td>
<td class="num">(188)<span></span>
</td>
<td class="nump">10,742<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">9,374<span></span>
</td>
<td class="num">(3,656)<span></span>
</td>
<td class="num">(2,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">34,144<span></span>
</td>
<td class="num">(1,685)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred expense (benefit)</a></td>
<td class="nump">10,029<span></span>
</td>
<td class="nump">30,488<span></span>
</td>
<td class="num">(4,586)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 9,841<span></span>
</td>
<td class="nump">$ 41,230<span></span>
</td>
<td class="num">$ (4,148)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787307499008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">$ 13,448<span></span>
</td>
<td class="nump">$ 7,562<span></span>
</td>
<td class="nump">$ 15,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount', window );">FDII</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(2,395)<span></span>
</td>
<td class="num">(637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change for changes in federal, foreign or state law</a></td>
<td class="nump">342<span></span>
</td>
<td class="num">(535)<span></span>
</td>
<td class="num">(7,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="num">(7,206)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationContingentValueRights', window );">Contingent liabilities</a></td>
<td class="num">(116)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(7,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax differential on income/loss of foreign subsidiaries</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(405)<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount', window );">Debt repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome', window );">Subpart F income</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
<td class="num">(12,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount', window );">Provision to return adjustments</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
<td class="num">(1,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount', window );">Officer compensation</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">3,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">24,799<span></span>
</td>
<td class="nump">11,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="num">(3,823)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 9,841<span></span>
</td>
<td class="nump">$ 41,230<span></span>
</td>
<td class="num">$ (4,148)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Officer Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787303334016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) of valuation allowance, change in amount</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 24.8<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">48.0<span></span>
</td>
<td class="nump">81.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">165.1<span></span>
</td>
<td class="nump">168.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California and New Jersey Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Non-US | Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787311998784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 45,702<span></span>
</td>
<td class="nump">$ 53,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research credit carryforwards</a></td>
<td class="nump">26,611<span></span>
</td>
<td class="nump">26,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">4,550<span></span>
</td>
<td class="nump">4,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">11,886<span></span>
</td>
<td class="nump">11,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">15,012<span></span>
</td>
<td class="nump">14,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">103,761<span></span>
</td>
<td class="nump">110,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(57,699)<span></span>
</td>
<td class="num">(57,472)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">46,062<span></span>
</td>
<td class="nump">53,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets', window );">Identified intangibles</a></td>
<td class="num">(66,966)<span></span>
</td>
<td class="num">(64,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(10,504)<span></span>
</td>
<td class="num">(10,886)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(77,470)<span></span>
</td>
<td class="num">(75,582)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="num">$ (31,408)<span></span>
</td>
<td class="num">$ (22,085)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Finite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139787308008336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 29,096<span></span>
</td>
<td class="nump">$ 29,550<span></span>
</td>
<td class="nump">$ 31,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(6,783)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="num">(3,072)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 22,363<span></span>
</td>
<td class="nump">$ 29,096<span></span>
</td>
<td class="nump">$ 29,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF!TT9D&-MTJL>;E$XH=A92O -9BY@X,S,A$'&5$"B\L/XO*@N"]Z)90!PSB
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M5,>"]-97)S?@.D ]7S F-P-]-BC.@NX?4$L#!!0    (  ."75AAZO<OZ0<
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M'J'Q1-DC='H[C:(SU$!/48A.3\[0"2(4/:9L)3!-1->6*BA-;<=E (,B /=
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MO0?F]+!8I>4#ER,W;]I<3):B:=RG>>T]IL6V<R4:F&PBHL5Y19[>Y85UX&&
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M,P#\@T-?7WT!,DH)BO46!443O2&TM"D%2M@-2E_$8%6V5?T">H!(Q8^8SGJ
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MZDPLICM+\'%O)QJ=?-Y[SFC)7-'&!:D@BDYMK[5<]O"N,,&R U@HTCD"$*%
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M1<4FMZ!*8\:>808"H6J 9"^[R86"/&IK:S_(4MM6D"5'CS&^OW[/L_NT+,_
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M,TJS48@?"[X/7_!P7.,=%R,'IK/%R%C%,RP['U;UM9A>ZM#H!+!^4 \W.->
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M1#U1;(.&0,!X=:+MSI8EJT7@BK&N9\?NZ'KC'FOBAY,(4VW%D4=PFDK.1>(
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M;9;<9Q%%?)"8VXZ"5O8&$.1A.\@\,^5RJP01!Y050M-*AY69YI?6!:MCTLQ
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M4&#5"TC=@2=> N\KZKL\$V4FD6Y)_GAGNV01@18(W[V:8-\DOZGJY=>9*SE
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MKG!'%Y86X'UI4+K='W3 \/'WZC]02P,$%     @  X)=6&S5H:,#$   !BL
M !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULS5IK<]NX%?TK&-?=RC.,
M+%)/.X\9Q7ELVG7LQFG:;:<?(!*2T%"$EB"M*+^^YUZ #TF6=J?3SO2++8G
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MQ:Q(&4L) 0(Q"*+Q)(BN^CA%S55.QG?/F*_!>!",!R,00FSIN&B>'MCB0:^
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MK%PM9[EV2S!6+ZU2Q[FZ4;E8:F6E39=K41LB8RP$_EUA#1&N&IS4$/\XQ(M
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M'B]!#FPRG>,_1#O>O(VCXVDPG+P@Z% (5LFYI$9]U>X"6I4-Z%ZB7PDM&?=
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M0HQI+W3J]<";@C\,@_Z\R?CG&JVCLC0![Y?&^'I &S1?"M[^!U!+ P04
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M\WV'QG.'!\_&Z=_1H^\CK*[/OY<6)OVMV&C Y0;%BPI6(?1T2OK]!<_'Y3.
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MI^N>"R0*V !"+7DQL0)4G^EF*09?(X_=\\B=I6F!$\MCY+J=E476XT.R'BP
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M[&Q4NHP@0T>E:-E,KV#Q-\?59^T/J-S9*^M&Z$"O\\"?^ ,!D(#S.)@,E.!
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M >B?:]WT#5I@^ ..U_\%4$L#!!0    (  ."75CWS6#N^!   &\P   9
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M7$Y'X[\?ZUNE5J55QQ ]PK'A"=NFOLU;M@98H"?R#J+2JMLBJ5I#[*#:[#^
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M7HH63[1=TL(@ZA-2VR@QFJM*+74[%DAR;*E:776Z>A!(_492\A@A835IL*!
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M!Q/M::)QO290O+0^L.)*NXI=9OI# <(DZ/,UYVH7F +=IR?Z U!+ P04
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M9['+^X&>IE41:NH(R("I:-(V6[7-EEYK:)U^D>>$ZKD_JN=G"4WJB?1R[T2
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MT5=P%IA'V)=K^0/F3(0?ZG7)FD(2%#@GT;T*!21:I/! 8Y..4<UZ#536)Q:
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M:-J ZPN%)/0O=,#P5VCZ+U!+ P04    "  #@EU8FHS\C'<&  #+#@  &0
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MN;(&&%]*:;8O=H'A_GKY-U!+ P04    "  #@EU88+:6NW #  !C!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R-56UOVS80_BL'K1AB0(W>;-?-
M; .VLZT!VM5(LNW#L ^T=)*(4J1*4G':7[\C)3M.D1C[8O/(N^>>YW@\S?=*
M?S$UHH7'1DBS"&IKVZLH,GF-#3.7JD5))Z72#;-DZBHRK496^*!&1&D<3Z.&
M<1DLYWYOJY=SU5G!)6XUF*YIF/ZV1J'VBR )#ANWO*JMVXB6\Y95>(?VSW:K
MR8J.* 5O4!JN)&@L%\$JN5J/G;]W^(OCWIRLP2G9*?7%&3?%(H@=(1286X?
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M#M^,<-SB(RV,%T#^6FMWN'@'QV=_^@U02P,$%     @  X)=6+C(G5PJ"
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MX0U6E04B&G_L,+TNI0T\O-^C?W:U4RUSIO%&5K_RTJRG7N%!B4O65.:+W/Z
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MU,Z!SI>*LJ@W+L#^;R/^"U!+ P04    "  #@EU8U:53Y>L(  "S&0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU6=MRVS@2_164)C4E5S$1"=XS
MMJMLYS*IBG==<2X/6_L 49#$#4EH0-".]^OW-"A2E*70WMG9!YNX-AK=C=,'
MT.F]TM_KM92&_2B+JCZ;K(W9O)[-ZFPM2U&_4AM9H6>I="D,JGHUJS=:BH6=
M5!8S[KK1K!1Y-3D_M6TW^OQ4-:;(*WFC6=V4I= /E[)0]V<3;](U?,I7:T,-
ML_/3C5C)6VF^;&XT:K->RB(O957GJF):+L\F%][K2\].L".^YO*^'I09;66N
MU'>J?%B<35S22!8R,R1"X',GKV11D"3H\<=6Z*1?DR8.RYWT=W;SV,Q<U/)*
M%=_RA5F?39()6\BE: KS2=W_+K<;"DE>IHK:_F?W[=@8@[.F-JK<3H8&95ZU
M7_%C:XC!A,3]R02^G<"MWNU"5LLWPHCS4ZWNF:;1D$8%NU4[&\KE%7GEUFCT
MYIAGSB]%(:I,LEL; A=9IIK*L#?2B+RHV?2SF!>R/CF=&:Q%,V;95NYE*Y?_
M1*['V;6JS+IF;ZN%7.P+F$')7E/>:7K)1R6^D=DKYGL.XR[W1^3Y_<Y]*\__
MB;R_F[74;'__W;[_<3&OC4;$_//8SENYP7&Y=(Q>UQN1R;,)SDDM]9V<G/_Z
MBQ>YOXUH'?1:!V/2SV]Q+!=-(9E:L@_5G:P-CHAA5\+(E=*YK(\I/"KRN,)O
M?V1%L\BK%5.-9GF_4HTR^YI_1X_#8$&V5 5.-@TT%"O;XYW_6]:V^PYEU=0#
M"2SK=66"3)[)<@Y/=*YEHEI0@;,IEC)KS$9+??*:7:G:L/=:U35K*D!0@546
M; 7HJ0^;"]2QPMO:Y#B[:%B*7$.=HI%'UKQ=*VU>&JG+O;U>*NCRKL&_%RSR
MG3CR4?CUEX1[_#>4IJ$?G[1=G$>(I>H[$&&CZAQSO=CQHI#A($R]$UN+(VQ!
M;Y2&/FP.T1@4.$GHLL!E4WYB:TF"064I=9:+@FW$!FIZGA/&"4M;2:@D$?OR
MZO856ZD[J2MKU5IFC<X-635R8C]B7L*F_@E50H]=-U6>Y1M(W*[KN&[<[V0:
MG-@6?Z"?_*/)S<-0;.C$<;B;$SK<#T]8"-U?8)>ND\0!2G%J#>/$B4^F\;P0
M&W</3,Y'3;YL39YX3N*%^R;WW- EP8D+=X2'MHH=[GG,[Z=0/3BP.ZSB>LSS
MH6E"-HK"Q^X+'1>N@_-\&"=PTL0=,SF',?C.-C%4Y' _?\*@"9S ,6H:8'Y*
M3DA\EWT36@NR12?/\\.],LSJ)O!&@E)@#02#!Z%G#>XB3@/.1K F[+$F?#;6
M7-P!&.F OP03>'DK"CI%<\-N=]N9/V"WE87-!NZX%H9Z'HX!TNBZQP'I\SC6
M$$J)/1UKTG%!.M9[.F8#'<NMC@=0<X@0%R7"U2*+A:%WA"9?+9I\R\T:TU4E
MV8,4&CX(0\>/O&T!@7.Q1)CO!IBU5LUJS9;@([8%Y]%W K@3GY '[+,R4 ZX
MDB >TK:0NL&83Z/>I]%?Z5/L2U3LRPY6/Q+,WM 1 :<ZYMK1Y?^?KFU5?90!
MV&:KZH&'/\J:,A2FX)B7+579E91F*P@BM[7.://++IL\53\,H'UX>6&Q',<7
MZ+B/<$.LVXUX#& V$SB!YW:E(+8IA".?Q(>H:!'>19;:@=0>^+==C[-$EQ>"
MXY-LCP7%]SM0' 1/-SA-VU2$Q.5R6^(HN7V8 ],M<L7 0YL] JIR)PULS6NK
MP/LP.9)'#NSJ;Z<'L?LSPPZ''%B6PZ ^$C$,2ND])<M2ED!R]H-#TW9B,059
M][&A]GM'C-7G#._0V+NNG<EX:&W&'3\,[)8L$R%EJ3?BMM=W?*2Y$=B(>]B(
MGPT;-QIW0@W0)*+V%EEM0WLYA@6C,H]CP9YPV0EG0@,2C#U9X(P9(3 - );7
M>0VW0ZU],OHTH-O@^2CF5I!:+O-,#A:$*1T>D64].H 8*7'W6ZMBP?)RH^'"
MEJ[  3SA8!E!0.RNW#2$&0/%(;Q62W-/.XB]B*5)RC@F(>OC$X$ 6"026=:4
M36%WB&#6$A'67ELA0+2YIVV8$EN!\W%JG"X*0BO(AD.0C.;^I'=X\FR'OU=J
M<9\7A=6EO39]6&!S^3*W6/VA,J):Y52\ .DV1^\@H\L=CX6]=?/ABOEN16%7
M["+A3P?"!]Q2EWF5&_FR0%I>'%FB5Z<E6;Z%%]!1)XI]B'UB-L5&(<F]1F;K
M2A5J]< "@!S8*F@"D58*A-=T!^\C8=_QQ+%3(-<4@1-&P(3/6BPDJT0I 0\1
M2%_[_RDYGA,3XD[I5@'4N+*O#+"(EH4=4:_S#2AMBJ!RN\^3,E/")Q(:PQZ0
M/J2"^X+]R$7F</'E]ON4Z!2$-@&>32-<)5*LT8+@:A@=RD;E>(PXK))TL ,7
M5L==#*4@P1%*QLY+VI^7]/F\*LMT0UP)BN2%A?=C)V)4X/$3T4DN=I+_Y\BG
MP)15W1J;Z$8$! 'E=#A2!^!X"?>@"Q9?2GO3\=. 172UZ>)FFWQ9Q#W[!ZK<
M$#:J>XIVQ>CM$,,*(&Q5DXP@1#XD(/RD'D1A=]&-!976"V16;5M3A =(V6TS
M[U@[B!G"%[>U]O]ML]D4.>T)E]<(Z;F%)W1&-"1QHRTJ1O$6)Y/1?.BYNW<S
M]]D.;Q?]J&#TSW2??<+QXY*/>[Y=HL 2[97YKXP HO>96E66-1OQ@\UE!3BS
M; K9S[57$ Z."=_^3=V!,G?>Z-5X(*X1PUL=9QG3UTM9Z-+UB,>6TUGA*1_-
M6][@0=-[MF,(A& (2L1/^614Z)^ZMVATT74%J9\(AC7:5IFA-81E+__%,]CC
MH3BEXJ%E(X-;Z<7B7\WVP>V0,S\QX9/<-#I;"WI .U3LZF$A?\!IOJ7G U;-
M(\M&$LM'VU<:GD1[8WSNLFL)4PE$+$# A_O[EQH/#0%/!T],]*31U7"SP0VY
M(\ 4;?&CVU)J63VNT)Z_TZ#3:J #LLAQS)\-WM&!6"O[:P&=+\!9^Z3>M_:_
M2%RT[_"[X>W/&=="K^A=LI!+3'5?Q>&$Z?87@K9BU,:^RL^5 8K:XEHBG6L:
M@/ZE4J:KT +][S3G_P%02P,$%     @  X)=6.(Y$EQJ"   8A8  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&ULK5AM;]M&$OXK"]7N.0!%[_N2KFW
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M4!_[2A)>KPE2J^MWZ)\'FN:A3GDN*D<Q6%G)C6H:UYG7[)X:[3/&<YS\DGY
M1']&&$F0L[.R'!I07WK;+_N2EI6@ \1P'"B&$Z?#C5(&-7"<%!]AB.-/$> %
MB@0>TQK#PK$CI'$ W99=\9TKYXF79B&I) #54&=]DLHD<MF4TYC1S'$6^#KX
M?:1;3CX':ZDW[J,798?RVG\9CD_'[^JS_G/R<7K_4?Y&:"3 L$JNL=1_D>+P
MI_L/W?[&MCOW<;EJ+3Y5W7 K!0X4- 'OUVUK'V[(P/AOP^D_4$L#!!0    (
M  ."75B$@&$NQ@@  *=7   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;+6<:V_;.!J%_PKA'2Q:8!I;ESA)-S'06"2V"V0F:*8SGQF9MHG*HD>B<UGT
MQR]UB6G:,A.U9PNTE26^CR@>\:(CBI>/JOA6+H70Y&F5Y>758*GU^N-P6*9+
ML>+EB5J+W!R9JV+%M?E9+(;ENA!\5@>MLF$X&HV'*R[SP>2RWG=;3"[51F<R
M%[<%*3>K%2^>KT6F'J\&P>!EQQ>Y6.IJQW!RN>8+<2?TU_5M87X-MY297(F\
ME"HGA9A?#3X%'UE\5@74*?Z4XK'<V2;5I=PK]:WZ\7EV-1A5.1*92'6%X.:_
M!S$565:13#[^;J&#[3FKP-WM%SJK+]Y<S#TOQ51E?\F97EX-S@=D)N9\D^DO
MZO'?HKV@TXJ7JJRL_R6/;=K1@*2;4JM5&VQRL))Y\S]_:@MB)R Z%A"V >%>
M0!@>"8C:@.BM 7$;$.\'G!X).&T#3O<#CEW#N T8UV7?%%9=T@G7?')9J$=2
M5*D-K=JHY:JC30'+O+JS[G1ACDH3IR?7O)0E47-R6XA2Y)HW>N<S<M?<:]6Q
M.[G(Y5RF/-?D4YJJ3:YEOB"W*I.I%"7Y0'[C1<&K>X2\2X3F,BO?7PZUR5]U
MEF':YN6ZR4MX)"]!2&Y4KI<EH?E,S%S T%S8]NK"EZN[#KW$1*0G) I^)>$H
MC,C7NX2\^^4]*<7"U W=D<'IVW'A"ZX#D[P=$W@P],V8T1GYA0Q)N>1&Q0X2
M\Y/^P_,74C B1549/84?;6^MJ*9&?6ZMKKNBP<3=F*II_5BN>2JN!NL*5#R(
MP>2?_PC&HW]U*8B$)4@81<(8".8(&V^%C7WTR6^;U;TH*F4+L5:%YO>9>*E4
MY+NG>ETWW''-K?J\ATEP.7S8E<][YK[R(6$4"6,@F"/?Z5:^4Z]\G_/4C$%*
MTU3/1+/UOM*29V:4P?-4$#->(>; 3&J2J;*K/;ENSG"V(Z1IA,R?/34/DWV(
M.M(EA^F"PU34>UE]%0#!' 7&6P7&7@7^*J06'V;J,2]-%<JX%C.B%5'WI<J$
M%D3F#Z8"J>*YJ^C'!W6HL^@/DP5!5]&/#XI^O]B]U]*WV$$PI]C/ML5^]LJ-
M[RG6L\-BC2[&%X<%>Y@PB,*+^+!DO9GIV_H@80P$<T0XWXIP[A7ABS B;(2Y
M[U-E1I7_W1_G-6J<=S<(^UJ<'V@1=]WCWASU50()8R"8H\3%5HD+KQ*)?) S
M84;ZIAO(S,!Q1M[)O!Z.KDWO7H\EWYONW#NPO/:>HN_8#0E+D##:P"YV6X>3
M4_<N8Z 3.EH&(_L<-WJ;FL]29)UUR@_HJQ64ED!I%$IC*)HK[,X#>H!YC&HY
M*'V1M 1*HU :0]%<?4.K;^BMN#=F!+XI1/WP)//U1I-WO"2\:H13LZ_;1PD/
M.K[]KM%_UM[Z(6D42F,HFJN?=3D"[[/VY/;N:V?/Z _K71VAO@:41J$TAJ*Y
M<EIO(XA!S2W2$)A":0F41J$TAJ*Y^EKS(_"['Y\>>3$C#Z*L+6S3R$K5#'R?
M!2^.N-9^8M2$=JJ*M"P2*(U":0Q%<U6UADK@=U3H:IVI9R'(G5;I-_+[NGZ-
M\;VRQL-VW^>\ZDZK5Q2W&>^NT4BG8PJE)5 :A=(8BN9J;UV=X S48B--E"F4
MED!I%$IC*)JKKS6, K]CU+38XFDMB^;MY-L:;3\T&'E:;:3%DT!I%$IC*)JK
MK#6@ K\#U;O5-L?^-#TW"8;GQ*342T%*^416U5MCPO/<I"O*]J5U=7#&M:BV
M%P7O?B'ESV#O)@%J8$%I%$IC*)K[5M^:7>$(T^2'4,\+2DN@- JE,13-U==Z
M7J'7<_F10?HKQ''32'2V]_[0WK)"K2XHC:%HKJS6Z@K]5I<K:SW/Y UF5PL-
M@EVWZR0(]_SWJ?_DO66$.EY0&D/17!FMXQ7Z':^?Z+;C<R)XNFQ[[&JB@?FK
MGS_H1W6\@E[[\].[%8=::5 :A=(8BN;>)]9*"T%66@BUTJ"T!$JC4!I#T5Q]
MK946PJVT5XAQZ.NFH68:E$:A-(:BN;I:,RWTFVD_V$V/N[KI43@ZW^^GH<88
ME$:A-(:BN3I:8RSTSW?Z<O>UK*=R'WM%Y8_OW>Y"#3$HC4)I#$5S=;6&6'@.
MZE>19M$42DN@- JE,13-U=?:8J'?%ON1?M5/]+RB\D?V5A7J64%I#$5S/X:P
MGE7DGZ!U(S2_KVON'TM1\+78:)EV-LM^4.\/(J"F%91&H32&HKD"6],J DW4
MBJ 3M:"T!$JC4!I#T5Q]K7L5^=TK^]E+JNH/X*H96P\\JR8S5V/DDGSO^G:J
MU1QI $VAM 1*HU :BPYGNL7;YPE7R)WOTOS^U8W,Y6JSZI0)^RT:]F,T[-=H
MV,_1_A].4V2=I@CD-$50IPE*2Z T"J4Q%,W5USI-D=\7NBV4&0;KY_II5OR]
MD>MJNNRO9%.*^28CF9R+5P;(KYP@J$,[-8:Z3E :A=(8BN9J;%VGR.\ZM:VR
MZ42/V15^0._*"[6AH#0*I3$4S176VE 1:'Y6!+6CH+0$2J-0&D/17'VM'16]
M97Y67[NXA0;AKEV\YQ3[3]Q;0JCC!*4Q%,V5T#I.D=\?NN%/1T?$T!E24%H"
MI5$HC:%H[@H-UFV*03.D8JC9!*4E4!J%TAB*YNIKS:;8/Y_IYT?$KYS@XKAE
M[(_L+3+4<8+2&(KFBFP=I_B53P.;9MDS)/8#>M=>J*T$I5$HC:%HKK#6@8I!
M2R/%4#\*2DN@- JE,13-U7=G@22O'_*#0^(6Z@R)P_WUD:"6$Y1&H32&HKD2
M6LLI]CM"4[[6LE19IU!(WV4*I250&H72&(KF2FH=IG@,:G6A1A.4ED!I%$IC
M*)JKKS6:XI]8WZF-W5U2*!YWK2G4D?#THFM5(7]N>BL!M810M$:)X<[ZHBM1
M+.J58$M2+P3:+,:YW;M=;?93O<;JWO[KX"-MUHRUF&8)VQM>+&1>DDS,#7)T
M<F::BJ)9%;;YH=6Z7L7T7FFM5O7F4O"9**H$YOA<*?WRHSK!=FW>R?\ 4$L#
M!!0    (  ."75C'\]6'- ,  +4.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;*U7:V_:,!3]*U8F3:O4D0?AT0XB =FT?:B$8(_/;G(#7A,[LPUT
M_WZVDZ8$!48E?X'8N>?$Y_C>Q'=R8/Q); $D>BYR*J;.5LKRWG5%LH4"BQXK
M@:H[&>,%EFK(-ZXH.>#4@(K<#3QOZ!:84">:F+DECR9L)W-"8<F1V!4%YG_G
MD+/#U/&=EXD5V6REGG"C28DWL ;YHUQR-7(;EI040 5A%''(IL[,OX]] S 1
M/PD<Q-$UTE(>&7O2@V_IU/'TBB"'1&H*K/[VL( \UTQJ'7]J4J=YI@8>7[^P
M?S'BE9A'+&#!\E\DE=NI,W90"AG>Y7+%#E^A%C30? G+A?E%ASK6<U"R$Y(5
M-5BMH""T^L?/M1%' ']X!A#4@. 4$)X!]&M _UI 6 -"XTPEQ?@08XFC"6<'
MQ'6T8M,7QDR#5O()U?N^EES=)0HGHSD61""6H24' 53B:C=HBM95)NA[:[*A
M)",)IA+-DH3MJ"1T@Y8L)PD!@3ZB%>R![@!EG!6M\"7FD@(7Z$,,$I-<W*CH
MA=$%'"T83=1#>?74%1%/KUP35RI]>I5N4FN95UJ",UK\ #TP*K<"?:8II&T"
M5QG3N!.\N#,/+C+&D/10W[]%@1?T.Q:TN!X>=,#CZ^'^!37]9J_[AB\\PU?O
M!9IU67L1JM\^]Z+$"4R=4B<*WX,3O7_G#[U/7;;8)(LMD;4L"QO+0L/>/V-9
MG8NWZ '_9KQ)W"X#0YL&VB2++9&U#!PT!@XNYMQW)G&N/A#&1O46P )A5 +7
M97_396-%YU<UH;]:^\CK]57Q[8_]Z8P*!^VHN#MJU$2U% T;1<.KJFC>M?J+
MT+<F@4VRV!)9R[)18]G(5A6-;!IHDRRV1-8R<-P8.+9;1>.NS ].BJ@SR!^>
M%%%W5-!=1'>-H+NKBFC1M?B+T+?F@$VRV!)9RS+?>SVJ>;;*J&:RY*%5MM@6
M6]O%HP.O;[>6:K[3"C@IIJNBXO]%59K<H_.\VN"-Z8L$,@?OZO#:S#:]U\QT
M'"?S<]V3F3[AE:9JZ!XPWQ J4 Z9HO1Z(_6MY%6/5 TD*TW7\,BDRC)SN55]
M)7 =H.YGC,F7@7Y TZE&_P!02P,$%     @  X)=6"Q0[(R:!@  G#0  !D
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M[KO")XC([Y\Y(AIVKX\L8=AC;-+U<K:X@!%_Z%2D32EQF])G(:%7:"YS^SH
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M4[5^$=UZH9*+^L5I][*J9%%_G(LX%<IN8+Z?25D]+=@=;%X'./T+4$L#!!0
M   (  ."75CFL-;ONP,  /@*   9    >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;)56;8^;.!#^*Q97G5HI65[R0K*7("4;M5WIKHV:[=UG!R;!JK&I;9+N
MO[\QL"3; +W[ OAEYGF>83R>Q5FJ;SH%,.1'QH5>.JDQ^;WKZCB%C.H[F8/
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M5%=\%[#5>Y]).90'*7^6![?)S<@O>P0IQ*9$</MO W-(TY)D^_&X@XZ:-LO
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M[$0=NS.X[B4MH+W;'+/%" G6T9GZ[6;;=RH="AW+(C?$[K*!%-H*;239\+0
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MI]@B5O-K4C+WC;M.<'\.V_LXFU^7:(DK-)W?L.,WM/(;HS5B2F *^&J9QN&
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M;A&4*54&\OF:4O%VHSIHCQF7_P)02P,$%     @  X)=6.]#(UWT @  0 D
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M1<%U6:_JT?IY,'95T?]M7KXM[HA<4:Z 86I<VZV!V=VRK-=E1XO<E;RET*:
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M7?'C@=?Q0K!M=69TSX1@6?5Q0W!">!D@OU\S)IXNR@<TQX[+_P%02P,$%
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M#B>3G@0>(TNE2!A#PC@(YBCATT$)G[Q*H-G.*-$,>E>ZO!:F5(]] O!2A@H
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M:*D-CI1:U7%=UU6G'O67XSMG@_X/SYG\:DTPU'JAM Q*XRB:629MO<'9K3>
M6B^4ED%I'$4S:ZFM-Z"MUWZ864L"5=W IKJVS@LJNI:HQ&A<H"TWH"WWJ(Z+
M7%5 !W#.+G0F&DKC*)KY!44MRN'9%\6'4->&TC(HC:-H9BVUL8>TL1_?>=$@
MYY)8EJ^GB<48H6&Y)6P0^M.]_5>HK3NDK7NW_]J9%?6LJ83*-Y2606D<13.+
MHC4^//NZ]A#J_%!:!J5Q%,VLY<[WXDD//6UR@68Z5R<\=G(!&I=;XM*3"Z&V
M[Y"V[V,F%VB$<Q*']CO('E2W430SP]K(0]K(#TTKT,V=LQL/=]%IF%AF%:!Q
MN25NG'C>?C,(M2N']'IMP*0"'<$YQU 7AM)X.%QO3DPJA%IR0UIRCYI4H!G.
M:1Z:YF ?AJJM)2"5.ZVVX?%JNWMIZ#2W0,=PSBW4;J$TCJ*9-VW1=AN=W6XC
MJ-U":1F4QE$TLY;:;B/:;AWF%FB2<TV&GIGX4\L*"FA8;@D;3*?[KQ,CK;?1
M:7I[TC0#'<LYUU#_A=(XBF963?MO=';_C:#^"Z5E4!I'T<Q::O^-:/\]?J2.
M!CF79"B?@TX,:KMD0#-Y.[=BHS7WE.Z+G&R@XSGG&'MO-^S-W?X.?8ZT/D=G
M_^9U!#5P*"V#TCB*9M92FWQ$F[Q#%P85]F@HQ8,N#&KA9$ S>=K (]K ]W1A
MOC5]4!&'TC(HC:-H9E&TVD=G_X)U!!5_*"V#TCB*9MY'5(M_3*__/FF"@6:Z
M5B<>KLW^MJ."!N1D0#./6KIC6KJ/F5*@$<YI&VKO(&U0ST;1S QK&8^/6>&]
M?TJ!;NZ<W>$J:V^2I,ET.)H!#<PM@:?3V(OV#F?$6HSC ]];_O_G%.@(SDF&
MBB^4QC>T8SH);;,Q;;-'S2?0#.<4#[W2ON0$&I9;PI)+3F(MM?%)4NL[S2O0
M,9QS#!59*(VC:&:U=NY3?G:1C;$W.\?>[1Q[N_._0V1C+;+QT;<0.S2O0).<
M:S(4R[WG8JC16@(?.!=KL8U/$]N3IA;H6,[IAIHOE,91-+-JVGSCLYMO##5?
M*"V#TCB*9OY\@S;?A#;?X\?E:)!K29+#N@L-R,F 9O*T[B:T[I[2?9%3"W0\
MYQQ#OP$-I7$4S:R<UNC$/W<7ED!-'$K+H#2.HIFUU$*?T$+OT(5!O3T9NK%=
M*J%AN24L*96)%O.$%O,]W9GU[FXTRCF52%H&I7$4S2R*-OTD.GM/!1T'@-(R
M*(VC:&8M]3A 0J\'/VF:@68Z5V>X6'O074%UG0QHYG'G1\=H!S]FFH%&.*?-
M<B]OZVV1H&$YBF;F6>MY<LS*[_V3#71SYQQ;OM1LSS%4IBUAO6#_X$:B-3FA
MUWX#)AKH",X)AFHPE,:3X7W']A0@U6Z;'G-7KP/7A#3#-<7IT#*M7\R'1N4H
MFIEGK<'I21H<.$U&T#&<ZP!57RB-HVAFM;3ZIF=7WQ2JOE!:!J5Q%,VLI5;?
ME%9?A\D(FN1<$VI>>)-HJ/5: E)GZ51+;WJ:])XT!4''<DXRU(JA-(ZBF573
M5IR>W8I3J!5#:1F4QE$TLY;:BE/:BH\?OZ-!SB6Q?%_:>JT&]6%+5.(F2JEV
MXI1VXE/Z,7(N@H[GG&SH%Z>A-(ZBF97;^?'M].Q]&?8WN;$_R@VU>13-K*5V
M_I1V?H>^#*KV&UI"78]!?9T,N$[>N)U+V66B$Y<7I6P>Y+4LBO[G29>5:M/;
MY?95ULC[_B?-WO[HC\:JI7[[Y<5"/,@/HGG(JY85\EXUG;SIQW&;_&&^?=+5
MBQ[);NNNJ\O5P[D4=[+IWZ#^?E_7W<N3/L!3W7Q9;=[E_P!02P,$%     @
M X)=6'B!3?LV!   M0X  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL
MS5==4^LV$/TK&O=.ASL3\%>^H$EF2(!;9J!EH-"'3A\49Q.KUY9R)3F!?]^5
M[!@G<0SWEH>^)+:L79VSVCW2#M9"?E4Q@";/:<+5T(FU7IZYKHIB2*DZ$4O@
M^&4N9$HUOLJ%JY82Z,P:I8D;>%[732GCSFA@Q^[D:" RG3 .=Y*H+$VI?!E#
M(M9#QW<V _=L$6LSX(X&2[J !]"/RSN);V[I9<92X(H)3B3,A\ZY?S;QV\;
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M>%:"M0<98<4O?BB%V #XO1V H 0$3P&='8"P!(2O!71*0,<J4X1B=8BQPM%
M\!42QEJSF0<KID7K\ DS>;]10K\E&J>B"TP$NL-T >@2L%P(T$E5Z#.ZPD)@
MDQ.T%X/"A,I]/7M[$Z.]C_L#5^FU#8.;E.N,BG6"'>OX ;KD3,TE.F<II-L$
MKG:Z\CQ8>SX*&AEC2 Y1Z!^@P O"&H?.7@\/:N#QZ^%^0S1AE8?0\H4OYN$
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M!CW/3^WS"\E6V3GV"Y.2)=G')<'JA: +J._GC,G=A6Z@_.W$]#]02P,$%
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MLRH8&61,E$_Z4N5A)Z#=?2,@K +"OPWH5 $=)[1DYF2-J:')0,D-4=8;T>S
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MJ%W](HP3/.!HBB(A-+.,6I:1D^6?I4AE Y3T'FE:@#W-=L9[.=(N#F$(XV#
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M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6RM55U/VS 4_2M7&9I
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M59Z+)=<P1DTH4W *7W6)$FX$GY]JE!7<4#*EC&J*"HX;V(G!W4_&<'QT D=
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MX,O;WKWUG@[M(J L\5O(7[*]UZ0XE:<T_5:\^;BX[0V*%O&(S_,"P>2?9_[
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M3^.8?1K85;CF>CIKLZ*I-Q%-!]9A/H::,5":#Z4%4!I%T531M6:,8S9C#HS
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M,@FLD6.D-K*9VJ@H9([JD 3H2#]TIB@B(<57]K'5M=="3^&3 !N)QQ=S>0E
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MU(! .U-)T3Y$6.#EG-$]8JI:LJD#;:9&2_FD4,_]63!YE4B<6#X+&K^F-$N
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M&)@JD-?7E(JW$W6#9MI>_@]02P,$%     @  X)=6& OH!13!   VQ,  !D
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M%     @  X)=6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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MQ:-#&3>E=&RN#B?[O0 K0K B6JS)\FZ]7,RGX\ULRJ['B_'=9,;6'V:SS1H
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M&\/]^PUG=2H2S3J('8$&)Q\CB(DY(B)V!(X90TQ,%A&Q+- HJEN;F$4B8HN
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M X)=6">=YF?O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @  X)=6)E<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  #@EU8#H&'
MEC$(  !\,0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @  X)=6&3SDRD^ @  QP4  !@
M ("!=1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  ."
M75AH\. :IP<  )LB   8              " @>D2  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  #@EU8M_D.9/X"   7"@  &
M        @('&&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @  X)=6&'J]R_I!P  -2H  !@              ("!^AT  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  ."75A"6H_T#@,  '8(   8
M              " @1DF  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  #@EU8UT+\W],)  #Q6P  &               @(%=*0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @  X)=6*H9*A!K#@
M[%$  !@              ("!9C,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    (  ."75B57LP,RBH  )^%   8              " @0="
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  #@EU8T:?P
M-OP/  !0*P  &0              @($';0  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    (  ."75AL Z$P[P@   @6   9
M  " @3I]  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M X)=6&S5H:,#$   !BL  !D              ("!8(8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  #@EU8C-YQXNL-   N*0  &0
M            @(&:E@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    (  ."75A,MOH%TPT  &$I   9              " @;RD  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @  X)=6!CVA>8 "P
M-3@  !D              ("!QK(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  #@EU8-]*QC=$,  #5)@  &0              @(']
MO0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  ."75BY
M9+;L@@P  ,PA   9              " @07+  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @  X)=6/?-8.[X$   ;S   !D
M     ("!OM<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ."75A.[>L*^24  'I[   9              "
M@;__  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @  X)=
M6$@P7V>?!0  %@T  !D              ("![R4! 'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  #@EU8FHS\C'<&  #+#@  &0
M        @('%*P$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   (  ."75A@MI:[< ,  &,'   9              " @7,R 0!X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @  X)=6$>P,*4)!@  10T
M !D              ("!&C8! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  #@EU80$@8HI\#   ""   &0              @(%:/ $
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  ."75BXR)U<
M*@@  "8=   9              " @3!  0!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @  X)=6 QO@%20 P  )0L  !D
M ("!D4@! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  #
M@EU8+.92U.4"  !"!@  &0              @(%83 $ >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  ."75C5I5/EZP@  +,9   9
M          " @71/ 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#
M%     @  X)=6.(Y$EQJ"   8A8  !D              ("!EE@! 'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  #@EU8CZ8<*+8&  !Y
M$   &0              @($W80$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;%!+ 0(4 Q0    (  ."75B$@&$NQ@@  *=7   9              " @21H
M 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @  X)=6,?S
MU8<T P  M0X  !D              ("!(7$! 'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6Q02P$"% ,4    "  #@EU8+%#LC)H&  "<-   &0
M    @(&,= $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M  ."75C 4\6/5 0  .P3   9              " @5U[ 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @  X)=6&,Z)E6-"   &E   !D
M             ("!Z'\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  #@EU8YK#6[[L#  #X"@  &0              @(&LB $ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  ."75A>J^>I,@,
M )$+   9              " @9Z, 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @  X)=6.P<X]),!0  A"(  !D              ("!
M!Y ! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  #@EU8
M:0?,$O,$  !R'   &0              @(&*E0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    (  ."75CO0R-=] (  $ )   9
M      " @;2: 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @  X)=6$B>Z8.)!0  'Q\  !D              ("!WYT! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  #@EU86T7<$ZL$  !F%0
M&0              @(&?HP$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    (  ."75AUIFP8-P4  ((<   9              " @8&H 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @  X)=6'H<_,UJ
M"   _ED  !D              ("![ZT! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  #@EU8&5[QU9<,   ?C   &0
M@(&0M@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  ."
M75AX@4W[-@0  +4.   9              " @5[# 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @  X)=6)T1.!QH P  )0\  !D
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M=#4U+GAM;%!+ 0(4 Q0    (  ."75ALODP+_P(  $,(   9
M  " @1?G 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M X)=6$K><(YW!@  _BL  !D              ("!3>H! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  #@EU8#5#OC:<"  !0!P  &0
M            @('[\ $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    (  ."75B=3"M;3P8  /(J   9              " @=GS 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @  X)=6'"N'9UQ!@
MPRH  !D              ("!7_H! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    "  #@EU8(9VC:UT#  !]#@  &0              @($'
M 0( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (  ."75B(
MHBQC"@0  $43   9              " @9L$ @!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @  X)=6-V:NU@Q P  %0H  !D
M     ("!W @" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M"  #@EU8$LLNAIT"   H!P  &0              @(%$# ( >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (  ."75COL;+V"00  . 2   9
M              " @1@/ @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L!
M A0#%     @  X)=6$.\:;Q* P  \ T  !D              ("!6!," 'AL
M+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  #@EU8\R^\S/()
M   +:@  &0              @('9%@( >&PO=V]R:W-H965T<R]S:&5E=#8W
M+GAM;%!+ 0(4 Q0    (  ."75@E#"E4= <  +LL   9              "
M@0(A @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @  X)=
M6%"I0:+N"   FD$  !D              ("!K2@" 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    "  #@EU8'O'WM(4#  !Y#P  &0
M        @('2,0( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   (  ."75A@+Z 44P0  -L3   9              " @8XU @!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @  X)=6,I^#^]  @  !04
M !D              ("!&#H" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q0
M2P$"% ,4    "  #@EU83RR&N(\#  !(#0  &0              @(&// (
M>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (  ."75C[#JMT
M-P4  ",3   9              " @55  @!X;"]W;W)K<VAE971S+W-H965T
M-S0N>&UL4$L! A0#%     @  X)=6(VIVR+D!   @AT  !D
M ("!PT4" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  #
M@EU8$$":Z;D#   X#0  &0              @('>2@( >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (  ."75BG',X 3@,  &,*   9
M          " @<Y. @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#
M%     @  X)=6"+7P;A3 P  K!4   T              ( !4U(" 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  #@EU8EXJ[',     3 @  "P
M    @ '150( 7W)E;',O+G)E;'-02P$"% ,4    "  #@EU8E;+^6<<%  #,
M,@  #P              @ &Z5@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @  X)=6'KM3FU6 @  CBT  !H              ( !KEP" 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @  X)=6%6HN6<2 @  <RP
M !,              ( !/%\" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ %4 50!*%P  ?V$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>362</ContextCount>
  <ElementCount>583</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>129</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Acquisition</Role>
      <ShortName>Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Spin-off of OmniAb</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAb</Role>
      <ShortName>Spin-off of OmniAb</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commercial License and Other Economic Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights</Role>
      <ShortName>Commercial License and Other Economic Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitment and Contingencies: Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionTables</Role>
      <ShortName>Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Acquisition</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Spin-off of OmniAb (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbTables</Role>
      <ShortName>Spin-off of OmniAb (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SpinoffofOmniAb</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Commercial License and Other Economic Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsTables</Role>
      <ShortName>Commercial License and Other Economic Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FairValueMeasurement</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/StockholdersEquity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionNarrativeDetails</Role>
      <ShortName>Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Acquisition - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Spin-off of OmniAb - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails</Role>
      <ShortName>Spin-off of OmniAb - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails</Role>
      <ShortName>Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Spin-off of OmniAb - Schedule of non-cash items and capital expenditures of the discontinued operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails</Role>
      <ShortName>Spin-off of OmniAb - Schedule of non-cash items and capital expenditures of the discontinued operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Commercial License and Other Economic Rights - Schedule of Commercial License and Other Economic Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails</Role>
      <ShortName>Commercial License and Other Economic Rights - Schedule of Commercial License and Other Economic Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Commercial License and Other Economic Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails</Role>
      <ShortName>Commercial License and Other Economic Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Operating and Finance Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Debt - Equity and Liability Components of Financing Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails</Role>
      <ShortName>Debt - Equity and Liability Components of Financing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Investment Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Balance Sheet Account Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Account Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Account Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Balance Sheet Account Details - Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Breakdown of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Stockholders' Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="lgnd-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lgnd-20231231.htm">lgnd-20231231.htm</File>
    <File>lgnd-20231231.xsd</File>
    <File>lgnd-20231231_cal.xml</File>
    <File>lgnd-20231231_def.xml</File>
    <File>lgnd-20231231_lab.xml</File>
    <File>lgnd-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lgnd-20231231_g1.jpg</File>
    <File>lgnd-20231231_g2.jpg</File>
    <File>lgnd-20231231_g3.jpg</File>
    <File>lgnd-20231231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1326">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lgnd-20231231.htm": {
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "lgnd-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lgnd-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 464,
   "keyCustom": 119,
   "axisStandard": 39,
   "axisCustom": 2,
   "memberStandard": 58,
   "memberCustom": 66,
   "hidden": {
    "total": 14,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 9,
    "http://www.ligand.com/20231231": 1
   },
   "contextCount": 362,
   "entityCount": 1,
   "segmentCount": 129,
   "elementCount": 977,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1326,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.ligand.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ligand.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostDirectMaterial",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio",
     "longName": "0000010 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://www.ligand.com/role/Acquisition",
     "longName": "0000011 - Disclosure - Acquisition",
     "shortName": "Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAb",
     "longName": "0000012 - Disclosure - Spin-off of OmniAb",
     "shortName": "Spin-off of OmniAb",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights",
     "longName": "0000013 - Disclosure - Commercial License and Other Economic Rights",
     "shortName": "Commercial License and Other Economic Rights",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:CommercialLicenseAndOtherEconomicRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:CommercialLicenseAndOtherEconomicRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ligand.com/role/FairValueMeasurement",
     "longName": "0000014 - Disclosure - Fair Value Measurement",
     "shortName": "Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ligand.com/role/Leases",
     "longName": "0000015 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ligand.com/role/Debt",
     "longName": "0000016 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetails",
     "longName": "0000017 - Disclosure - Balance Sheet Account Details",
     "shortName": "Balance Sheet Account Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ligand.com/role/StockholdersEquity",
     "longName": "0000018 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings",
     "longName": "0000019 - Disclosure - Commitment and Contingencies: Legal Proceedings",
     "shortName": "Commitment and Contingencies: Legal Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ligand.com/role/IncomeTaxes",
     "longName": "0000020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-362",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-362",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:BusinessSpinOffAndMigrationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:BusinessSpinOffAndMigrationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables",
     "longName": "9954473 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio (Tables)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ligand.com/role/AcquisitionTables",
     "longName": "9954474 - Disclosure - Acquisition (Tables)",
     "shortName": "Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbTables",
     "longName": "9954475 - Disclosure - Spin-off of OmniAb (Tables)",
     "shortName": "Spin-off of OmniAb (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsTables",
     "longName": "9954476 - Disclosure - Commercial License and Other Economic Rights (Tables)",
     "shortName": "Commercial License and Other Economic Rights (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ligand.com/role/FairValueMeasurementTables",
     "longName": "9954477 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ligand.com/role/LeasesTables",
     "longName": "9954478 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ligand.com/role/DebtTables",
     "longName": "9954479 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsTables",
     "longName": "9954480 - Disclosure - Balance Sheet Account Details (Tables)",
     "shortName": "Balance Sheet Account Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ligand.com/role/StockholdersEquityTables",
     "longName": "9954481 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ligand.com/role/IncomeTaxesTables",
     "longName": "9954482 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954483 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "lgnd:BusinessSpinOffAndMigrationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "lgnd:BusinessSpinOffAndMigrationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
     "longName": "9954484 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
     "longName": "9954485 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
     "longName": "9954486 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
     "longName": "9954487 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:DerivativeAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
     "longName": "9954488 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
     "longName": "9954489 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ligand.com/role/AcquisitionNarrativeDetails",
     "longName": "9954490 - Disclosure - Acquisition - Narrative (Details)",
     "shortName": "Acquisition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9954491 - Disclosure - Acquisition - Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Acquisition - Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
     "longName": "9954492 - Disclosure - Spin-off of OmniAb - Narrative (Details)",
     "shortName": "Spin-off of OmniAb - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DeferredTaxAssetsAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DeferredTaxAssetsAdjustments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails",
     "longName": "9954493 - Disclosure - Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details)",
     "shortName": "Spin-off of OmniAb - Schedule of revenue and expenses of the discontinued operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails",
     "longName": "9954494 - Disclosure - Spin-off of OmniAb - Schedule of non-cash items and capital expenditures of the discontinued operations (Details)",
     "shortName": "Spin-off of OmniAb - Schedule of non-cash items and capital expenditures of the discontinued operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:PaymentsToContingentValueRightHoldersFinancingActivity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails",
     "longName": "9954495 - Disclosure - Commercial License and Other Economic Rights - Schedule of Commercial License and Other Economic Rights (Details)",
     "shortName": "Commercial License and Other Economic Rights - Schedule of Commercial License and Other Economic Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "lgnd:CommercialLicenseRightsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "lgnd:CommercialLicenseRightsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
     "longName": "9954496 - Disclosure - Commercial License and Other Economic Rights - Narrative (Details)",
     "shortName": "Commercial License and Other Economic Rights - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:CommercialLicenseRightsCreditLossAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "lgnd:ProductRoyaltyPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954497 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails",
     "longName": "9954498 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "shortName": "Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
     "longName": "9954499 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ligand.com/role/LeasesNarrativeDetails",
     "longName": "9954500 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails",
     "longName": "9954501 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "lgnd:LeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
     "longName": "9954502 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ligand.com/role/DebtNarrativeDetails",
     "longName": "9954503 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "lgnd:PaymentsToUnwindWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
     "longName": "9954504 - Disclosure - Debt - Equity and Liability Components of Financing Arrangements (Details)",
     "shortName": "Debt - Equity and Liability Components of Financing Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-228",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-228",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
     "longName": "9954505 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)",
     "shortName": "Balance Sheet Account Details - Investment Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "longName": "9954506 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
     "longName": "9954507 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
     "longName": "9954508 - Disclosure - Balance Sheet Account Details - Narrative (Details)",
     "shortName": "Balance Sheet Account Details - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
     "longName": "9954509 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)",
     "shortName": "Balance Sheet Account Details - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
     "longName": "9954510 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "shortName": "Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
     "longName": "9954511 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Account Details - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails",
     "longName": "9954512 - Disclosure - Balance Sheet Account Details - Other Long-term Liabilities (Details)",
     "shortName": "Balance Sheet Account Details - Other Long-term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "lgnd:UnrecognizedTaxBenefitsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "lgnd:UnrecognizedTaxBenefitsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
     "longName": "9954513 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)",
     "shortName": "Balance Sheet Account Details - Contingent Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails",
     "longName": "9954514 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)",
     "shortName": "Stockholders' Equity - Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954515 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-347",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails",
     "longName": "9954516 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)",
     "shortName": "Stockholders' Equity - Stock Option Plan Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-295",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-298",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
     "longName": "9954517 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "shortName": "Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
     "longName": "9954518 - Disclosure - Stockholders' Equity - Assumptions (Details)",
     "shortName": "Stockholders' Equity - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-322",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-322",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
     "longName": "9954519 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)",
     "shortName": "Stockholders' Equity - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-332",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-330",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails",
     "longName": "9954520 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "shortName": "Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-349",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "complaint",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-349",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "complaint",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9954521 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
     "longName": "9954522 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.ligand.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954523 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails",
     "longName": "9954524 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "longName": "9954525 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "lgnd_AboveMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AboveMilestoneMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Above 3 million",
        "label": "Above Milestone [Member]",
        "documentation": "Above Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update [Extensible List]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r321",
      "r322",
      "r323",
      "r371",
      "r372",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r445",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r615",
      "r616",
      "r617",
      "r625",
      "r626",
      "r627",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r658",
      "r659",
      "r664",
      "r665",
      "r666",
      "r667",
      "r674",
      "r675",
      "r679",
      "r680",
      "r681",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r1140"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r1003"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization/accretion of premium (discount) on investments, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued commercial license rights purchases",
        "label": "Accrued Commercial License Rights Purchases Incurred But Not Yet Paid",
        "documentation": "Accrued Commercial License Rights Purchases Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedCustomerDepositsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedCustomerDepositsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer deposit",
        "label": "Accrued Customer Deposits, Current",
        "documentation": "Accrued Customer Deposits, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedDebtIssuanceCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued debt issuance costs",
        "label": "Accrued Debt Issuance Costs Incurred But Not Yet Paid",
        "documentation": "Accrued Debt Issuance Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued inventory purchases",
        "label": "Accrued Inventory Purchases",
        "documentation": "Accrued Inventory Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties owed to third parties",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalty from commercial license rights",
        "label": "Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid",
        "documentation": "Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedSubcontractorExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedSubcontractorExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractor",
        "label": "Accrued Subcontractor Expenses, Current",
        "documentation": "Accrued Subcontractor Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedSupplierExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AccruedSupplierExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier",
        "label": "Accrued Supplier Expenses, Current",
        "documentation": "Accrued Supplier Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r274",
      "r761"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r173",
      "r283",
      "r757",
      "r784",
      "r788"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r19",
      "r46",
      "r629",
      "r632",
      "r703",
      "r779",
      "r780",
      "r1124",
      "r1125",
      "r1126",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average estimated useful life of finite-lived intangible assets acquired (in years)",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r1003",
      "r1244"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r798",
      "r1137",
      "r1138",
      "r1139",
      "r1217",
      "r1246"
     ]
    },
    "lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdditionalRoyaltiesReceivableUnderSalesbasedMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional royalties receivable under sales-based milestones",
        "label": "Additional Royalties Receivable Under Sales-based Milestones",
        "documentation": "Additional Royalties Receivable Under Sales-based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "lgnd_AdjustmentToCreditLossReservesOfCommercialLicenseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdjustmentToCreditLossReservesOfCommercialLicenseRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to credit loss reserves of commercial license rights",
        "label": "Adjustment To Credit Loss Reserves Of Commercial License Rights",
        "documentation": "Adjustment To Credit Loss Reserves Of Commercial License Rights"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond hedge transaction",
        "label": "Adjustments to Additional Paid In Capital, Bond Hedge Transaction",
        "documentation": "Adjustments to Additional Paid In Capital, Bond Hedge Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Distribution of OmniAb",
        "label": "Adjustments to Additional Paid in Capital, Decrease Due To Separation",
        "documentation": "Adjustments to Additional Paid in Capital, Decrease Due To Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reacquisition of equity due to 2023 debt extinguishment, net of tax",
        "negatedTerseLabel": "Reduction to additional paid in capital",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Final distribution of OmniAb",
        "label": "Adjustments To Additional Paid in Capital, Increase Due To Separation",
        "documentation": "Adjustments To Additional Paid in Capital, Increase Due To Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r536"
     ]
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final tax impact of OmniAb distribution",
        "label": "Adjustments To Additional Paid In Capital, Tax Return To Provision",
        "documentation": "Adjustments To Additional Paid In Capital, Tax Return To Provision"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant and bond hedge unwind transactions",
        "label": "Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions",
        "documentation": "Adjustments to Additional Paid in Capital, Warrant and Bond Hedge Unwind Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant derivative",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r85",
      "r213"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1045",
      "r1055",
      "r1081"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1046",
      "r1056",
      "r1073",
      "r1082",
      "r1086",
      "r1094"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) of allowance for credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "lgnd_AmendedESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AmendedESPPMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended ESPP",
        "label": "Amended ESPP [Member]",
        "documentation": "Amended ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AmortizationOfCommercialLicenseAndOtherEconomicRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AmortizationOfCommercialLicenseAndOtherEconomicRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of commercial license and other economic rights",
        "label": "Amortization of Commercial License and Other Economic Rights",
        "documentation": "Amortization of Commercial License and Other Economic Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r486",
      "r677",
      "r1131"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and issuance fees",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r677",
      "r983",
      "r984",
      "r1131"
     ]
    },
    "lgnd_AmountsOwedToFormerLicensorFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AmountsOwedToFormerLicensorFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for amounts owed to a former licensor",
        "label": "Amounts Owed To Former Licensor, Fair Value Disclosure",
        "documentation": "Amounts Owed To Former Licensor, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r278",
      "r312",
      "r349",
      "r360",
      "r364",
      "r405",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r620",
      "r623",
      "r663",
      "r752",
      "r842",
      "r1003",
      "r1019",
      "r1175",
      "r1176",
      "r1224"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating and Finance Lease Assets and Liabilities",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets and Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r288",
      "r312",
      "r405",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r620",
      "r623",
      "r663",
      "r1003",
      "r1175",
      "r1176",
      "r1224"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "lgnd_AtTheMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AtTheMarketEquityOfferingMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The Market Equity Offering",
        "label": "At-The Market Equity Offering [Member]",
        "documentation": "At-The Market Equity Offering"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1038"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1038"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1038"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r421",
      "r751"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r978"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r747"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1151",
      "r1152",
      "r1236"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r746"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r421",
      "r742",
      "r1145"
     ]
    },
    "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Presentation [Line Items]",
        "documentation": "Basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation [Table]",
        "label": "Basis of Presentation [Table]",
        "documentation": "Basis of Presentation."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BelowMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BelowMilestoneMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below 3 million",
        "label": "Below Milestone [Member]",
        "documentation": "Below Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan",
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]",
        "documentation": "Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r996",
      "r997"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r613",
      "r996",
      "r997"
     ]
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Commercial rights, beginning of period",
        "periodEndLabel": "Commercial rights, end of period",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period",
        "documentation": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "lgnd_BusinessCombinationAcquiredPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationAcquiredPercentage",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired (as a percent)",
        "label": "Business Combination, Acquired Percentage",
        "documentation": "Business Combination, Acquired Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationAcquisitionCostIncurredButNotYetPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Primrose transaction costs",
        "label": "Business Combination, Acquisition Cost Incurred But Not Yet Paid",
        "documentation": "Business Combination, Acquisition Cost Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r16"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities incurred",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r118",
      "r619"
     ]
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent liabilities",
        "label": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure",
        "documentation": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liability measurement input (as a percent)",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Acquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r614"
     ]
    },
    "lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Frequency of cash payments to CVR holders",
        "label": "Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders",
        "documentation": "Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationLoanFeesAndInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationLoanFeesAndInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DIP loan fees and interest",
        "label": "Business Combination, Loan Fees And Interest",
        "documentation": "Business Combination, Loan Fees And Interest"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVRs issued from each CVR series",
        "label": "Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series",
        "documentation": "Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVRs issued per acquiree share",
        "label": "Business Combination, Number of Contingent Value Rights Issued per Acquiree Share",
        "documentation": "Business Combination, Number of Contingent Value Rights Issued per Acquiree Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred revenue",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate used to value intangible assets acquired (as a percent)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "netLabel": "Intangible assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "negatedLabel": "Other liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of tangible assets acquired, net of cash and restricted cash received",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business exit costs",
        "label": "Business Exit Costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "lgnd_BusinessSpinOffAndMigrationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "BusinessSpinOffAndMigrationPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business",
        "label": "Business Spin-Off And Migration [Policy Text Block]",
        "documentation": "Business Spin-Off And Migration"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California and New Jersey Research Tax Credit Carryforward",
        "label": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "documentation": "California and New Jersey Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property, plant and equipment",
        "label": "Capital Expenditure, Discontinued Operations",
        "documentation": "Amount of capital expenditure attributable to discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued fixed asset purchases",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLossCarryforwardMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Loss Carryforward",
        "label": "Capital Loss Carryforward [Member]",
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reported Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired from acquisition",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r272",
      "r965"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r191",
      "r309"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r191"
     ]
    },
    "lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Equivalents &amp; Short-term Investments",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "documentation": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CashPaidDuringTheYearAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CashPaidDuringTheYearAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the year:",
        "label": "Cash Paid During the Year [Abstract]",
        "documentation": "Cash Paid During the Year"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r280",
      "r281",
      "r282",
      "r312",
      "r335",
      "r339",
      "r341",
      "r343",
      "r347",
      "r348",
      "r405",
      "r455",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r494",
      "r495",
      "r498",
      "r501",
      "r508",
      "r663",
      "r792",
      "r793",
      "r794",
      "r795",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r830",
      "r851",
      "r870",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1102",
      "r1133",
      "r1142"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in USD per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued in public offering (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "lgnd_CommercialLicenseAndOtherEconomicRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseAndOtherEconomicRightsTextBlock",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRights"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial License and Other Economic Rights",
        "label": "Commercial License And Other Economic Rights [Text Block]",
        "documentation": "Commercial License And Other Economic Rights"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial license and other economic rights",
        "totalLabel": "Net",
        "label": "Commercial License Rights",
        "documentation": "Commercial License Rights"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Commercial License Rights, Accumulated Amortization",
        "documentation": "Commercial License Rights, Accumulated Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsCreditLossAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsCreditLossAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit loss adjustment",
        "label": "Commercial License Rights, Credit Loss Adjustment",
        "documentation": "Commercial License Rights, Credit Loss Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsCumulativeAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsCumulativeAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails": {
       "parentTag": "lgnd_CommercialLicenseRights",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustments",
        "label": "Commercial License Rights, Cumulative Adjustments",
        "documentation": "Commercial License Rights, Cumulative Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial license rights, fair value disclosure",
        "label": "Commercial License Rights, Fair Value Disclosure",
        "documentation": "Commercial License Rights, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails": {
       "parentTag": "lgnd_CommercialLicenseRights",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross",
        "label": "Commercial License Rights, Gross",
        "documentation": "Commercial License Rights, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsImpairments",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite lived intangible asset accumulated impairment",
        "label": "Commercial License Rights, Impairments",
        "documentation": "Commercial License Rights, Impairments"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CommercialLicenseRightsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial license and other economic rights",
        "label": "Commercial License Rights [Policy Text Block]",
        "documentation": "Commercial License Rights [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r134",
      "r754",
      "r829"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies: Legal Proceedings",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r447",
      "r448",
      "r959",
      "r1170"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend declared (in USD per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007",
      "r1008",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1137",
      "r1138",
      "r1217",
      "r1242",
      "r1246"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r830"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r167",
      "r830",
      "r848",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; 17,556 and 16,951 shares issued and outstanding at December\u00a031, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r756",
      "r1003"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r292",
      "r294",
      "r300",
      "r743",
      "r767"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer equipment and software",
        "label": "Computer Equipment And Software [Member]",
        "documentation": "Computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r125",
      "r126",
      "r368",
      "r958"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r125",
      "r126",
      "r368",
      "r789",
      "r958"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r125",
      "r126",
      "r368",
      "r958",
      "r1107"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentrations of Business Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r251"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues (as a percent)",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r125",
      "r126",
      "r368"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r125",
      "r126",
      "r368",
      "r958"
     ]
    },
    "lgnd_ConsiderationClassficationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ConsiderationClassficationAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration Classfication [Axis]",
        "label": "Consideration Classfication [Axis]",
        "documentation": "Consideration Classfication"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ConsiderationClassficationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ConsiderationClassficationDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration Classfication [Domain]",
        "label": "Consideration Classfication [Domain]",
        "documentation": "Consideration Classfication [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid for an interest in potential development milestone",
        "verboseLabel": "Cash consideration paid",
        "label": "Consideration Paid For An Interest In Potential Development Milestone",
        "documentation": "Consideration Paid For An Interest In Potential Development Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ContingentLiabilitiesMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Contingent Liabilities [Member]",
        "documentation": "Contingent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContingentLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ContingentLiabilityRollForward",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Liability",
        "label": "Contingent Liability [Roll Forward]",
        "documentation": "Contingent Liability [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContingentMilestonePurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ContingentMilestonePurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Contingent Milestone Purchase Agreement",
        "documentation": "Contingent Milestone Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContractRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ContractRevenueMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract",
        "label": "Contract Revenue [Member]",
        "documentation": "Contract Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross contract asset",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r418",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r523"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novan contract liability",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512",
      "r523"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_ContractualRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualRightsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual relationships",
        "label": "Contractual Rights [Member]",
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements)."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 convertible senior notes, net",
        "label": "Convertible Debt, Current",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of convertible senior notes outstanding (Level 2)",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt Securities",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r229"
     ]
    },
    "lgnd_ConvertibleSeniorNotesDue2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ConvertibleSeniorNotesDue2023Member",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Convertible Senior Notes",
        "label": "Convertible Senior Notes due 2023 [Member]",
        "documentation": "Convertible Senior Notes due 2023"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CorMatrixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CorMatrixMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CorMatrix",
        "label": "CorMatrix [Member]",
        "documentation": "CorMatrix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r995",
      "r1241"
     ]
    },
    "lgnd_CorporateShareRepurchaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CorporateShareRepurchaseAbstract",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Share Repurchase",
        "label": "Corporate Share Repurchase [Abstract]",
        "documentation": "Corporate Share Repurchase [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostDirectMaterial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostDirectMaterial",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Captisol",
        "label": "Cost, Direct Material",
        "documentation": "Cost of material used for good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles",
        "label": "Cost, Amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r468",
      "r496",
      "r704",
      "r969",
      "r971"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r320",
      "r326",
      "r332",
      "r409",
      "r415",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r640",
      "r643",
      "r645",
      "r646",
      "r701"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r320",
      "r326",
      "r332",
      "r409",
      "r415",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r640",
      "r643",
      "r645",
      "r646",
      "r701"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r320",
      "r326",
      "r332",
      "r409",
      "r415",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r640",
      "r643",
      "r645",
      "r646",
      "r701"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1136",
      "r1216"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1136"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r602",
      "r608",
      "r1136"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current expense (benefit):",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CurrentPortionOfLiabilityForContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CurrentPortionOfLiabilityForContingentValueRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contingent liabilities",
        "label": "Current Portion of Liability for Contingent Value Rights",
        "documentation": "Current portion of liability for contingent value rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1136",
      "r1216"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r368"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "lgnd_CyDexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CyDexMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CyDex",
        "label": "CyDex [Member]",
        "documentation": "CyDex"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CydexPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "CydexPharmaceuticalsIncMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cydex",
        "label": "Cydex Pharmaceuticals, Inc [Member]",
        "documentation": "Cydex Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r310",
      "r464",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r480",
      "r487",
      "r488",
      "r490"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r162",
      "r163",
      "r229",
      "r231",
      "r316",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r678",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1134"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion price per share (in USD per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r467"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of 2023 Notes outstanding",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r131",
      "r465",
      "r678",
      "r981",
      "r982"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r129",
      "r491",
      "r678"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on debt instrument (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r466"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r678",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1134"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r316",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r678",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1134"
     ]
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased amount of debt instrument",
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DebtInstrumentRepurchasedAmountDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DebtInstrumentRepurchasedAmountDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased amount",
        "label": "Debt Instrument, Repurchased Amount During Period",
        "documentation": "Debt Instrument, Repurchased Amount During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r90",
      "r91",
      "r128",
      "r129",
      "r131",
      "r135",
      "r211",
      "r212",
      "r316",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r678",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1134"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of debt instrument (in years)",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails": {
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized discount (including unamortized debt issuance cost)",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r131",
      "r1178"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r427",
      "r978"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "12 months or greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r427"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r427",
      "r978"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r427"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Debt Securities by Contractual Maturity",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1158"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r424",
      "r978"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "terseLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r425"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r978"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r978",
      "r1165"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of positions in an unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r426"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1215",
      "r1216"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r585"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r220",
      "r257",
      "r607",
      "r608",
      "r1136"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred expense (benefit):",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r230",
      "r596"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r585",
      "r753"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term deferred revenue",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1215",
      "r1216"
     ]
    },
    "lgnd_DeferredTaxAssetsAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DeferredTaxAssetsAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "label": "Deferred Tax Assets Adjustments",
        "documentation": "Deferred Tax Assets Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D",
        "label": "Deferred Tax Assets, Capitalized Research And Development",
        "documentation": "Deferred Tax Assets, Capitalized Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1214"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1214"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r1214"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1214"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred income taxes, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r1213"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DeferredTaxLiabilitiesFiniteLivedIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Identified intangibles",
        "label": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "documentation": "Deferred Tax Liabilities, Finite-Lived Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1214"
     ]
    },
    "us-gaap_DemandDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DemandDepositsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank deposits",
        "label": "Demand Deposits [Member]",
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r82"
     ]
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r1131"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation of fixed assets and amortization of intangible assets",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r354"
     ]
    },
    "lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "label": "Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "documentation": "Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "label": "Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "documentation": "Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r662",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821",
      "r836",
      "r837",
      "r923",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r971",
      "r1008",
      "r1243"
     ]
    },
    "lgnd_DerivativeAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DerivativeAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets",
        "label": "Derivative Assets [Member]",
        "documentation": "Derivative Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets with fair value",
        "label": "Derivative Asset, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development, regulatory, &amp; commercial milestones and tiered royalties",
        "label": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]",
        "documentation": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1181"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Expense",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r154",
      "r177",
      "r1237"
     ]
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax benefit",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r154",
      "r159",
      "r586",
      "r606",
      "r610"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r34"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r27"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "label": "Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration paid",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred revenue",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue",
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Disposal Group, Including Discontinued Operation, Financing Activities [Abstract]",
        "documentation": "Disposal Group, Including Discontinued Operation, Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease right-of-use assets",
        "label": "Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain from short-term investments",
        "label": "Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments",
        "documentation": "Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated goodwill",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r34",
      "r155"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Long-term operating lease liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets sold",
        "label": "Disposal Group, Including Discontinued Operation, Net Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Net Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetContributions",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Disposal Group, Including Discontinued Operation, Net Contributions",
        "documentation": "Disposal Group, Including Discontinued Operation, Net Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)",
        "documentation": "Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating costs and expenses:",
        "label": "Disposal Group, Including Discontinued Operation, Operating Costs and Expenses [Abstract]",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Costs and Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs and expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)",
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for acquisition, net of cash acquired",
        "label": "Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting interests disposed (as a percent)",
        "label": "Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed",
        "documentation": "Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r140",
      "r157",
      "r204"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Disposal Group, Including Discontinued Operation, Research and Development",
        "documentation": "Disposal Group, Including Discontinued Operation, Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r268"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense",
        "documentation": "Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationShareConsideration",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares received as consideration",
        "label": "Disposal Group, Including Discontinued Operation, Share Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Share Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued expenses",
        "label": "Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio",
      "http://www.ligand.com/role/SpinoffofOmniAb"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of Pelican Business and Investment in Primrose Bio",
        "terseLabel": "Spin-off of OmniAb",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r201"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1038"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1038",
      "r1074"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Basic net income (loss) per share (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r333",
      "r335",
      "r341",
      "r342",
      "r343",
      "r345",
      "r646",
      "r647",
      "r744",
      "r768",
      "r973"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted net income (loss) per share (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r335",
      "r341",
      "r342",
      "r343",
      "r345",
      "r646",
      "r647",
      "r744",
      "r768",
      "r973"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r339",
      "r341"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions",
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt repurchases",
        "label": "Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research",
        "documentation": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "FDII",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Amount",
        "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer compensation",
        "label": "Effective Income Tax Rate Reconciliation, Officer Compensation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Officer Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subpart F income",
        "label": "Effective Income Tax Rate Reconciliation, Other Income",
        "documentation": "Effective Income Tax Rate Reconciliation, Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provision to return adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ElutiaAndCorMatrixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ElutiaAndCorMatrixMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elutia and CorMatrix",
        "label": "Elutia and CorMatrix [Member]",
        "documentation": "Elutia and CorMatrix"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average period in which cost is expected to be recognized (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation cost, restricted stock",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1210"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1210"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EmployeeStockPurchasePlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EmployeeStockPurchasePlanAbstract",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Abstract]",
        "documentation": "Employee Stock Purchase Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-Known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Major Customer",
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r263",
      "r296",
      "r297",
      "r298",
      "r317",
      "r318",
      "r319",
      "r322",
      "r329",
      "r331",
      "r346",
      "r409",
      "r415",
      "r510",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r634",
      "r645",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r703",
      "r779",
      "r780",
      "r781",
      "r798",
      "r870"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment in Primrose Bio",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r403",
      "r1119",
      "r1162"
     ]
    },
    "lgnd_EquityMethodInvestmentsAllocationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EquityMethodInvestmentsAllocationMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment",
        "label": "Equity Method Investments Allocation [Member]",
        "documentation": "Equity Method Investments Allocation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r127",
      "r404"
     ]
    },
    "lgnd_EquitySecuritiesAllocationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "EquitySecuritiesAllocationMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities Allocation [Member]",
        "documentation": "Equity Securities Allocation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesByIndustryAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector [Axis]",
        "label": "Industry Sector [Axis]",
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r815",
      "r818",
      "r884",
      "r898",
      "r919",
      "r945",
      "r977",
      "r1008"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Viking common stock",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r660",
      "r967"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Viking common stock",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r660",
      "r749"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input (as a percent)",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesIndustryMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector [Domain]",
        "label": "Industry Sector [Domain]",
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r815",
      "r818",
      "r884",
      "r898",
      "r919",
      "r945",
      "r1008"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate equity securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r1014",
      "r1015",
      "r1016",
      "r1248"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1039",
      "r1049",
      "r1075"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of Fair Value",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r662",
      "r981",
      "r982"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "lgnd_ExercisePriceRangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeEightMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$78.56-$99.80",
        "label": "Exercise Price Range Eight [Member]",
        "documentation": "Exercise Price Range Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$58.49-$66.54",
        "label": "Exercise Price Range Five [Member]",
        "documentation": "Exercise Price Range Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$54.81-$58.28",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeNineMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$103.42-$103.42",
        "label": "Exercise Price Range Nine [Member]",
        "documentation": "Exercise Price Range Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$32.78-$49.99",
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise Price Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeSevenMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "69.39",
        "label": "Exercise Price Range Seven [Member]",
        "documentation": "Exercise Price Range Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeSixMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$66.70-$68.74",
        "label": "Exercise Price Range Six [Member]",
        "documentation": "Exercise Price Range Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeTenMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$114.15-$114.15",
        "label": "Exercise Price Range Ten [Member]",
        "documentation": "Exercise Price Range Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$52.84-$52.84",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$50.36-$52.30",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of Debt [Axis]",
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of Debt, Type [Domain]",
        "label": "Extinguishment of Debt, Type [Domain]",
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r656"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r656"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r120",
      "r122",
      "r226"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments, Assets",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r122"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r651",
      "r708",
      "r709",
      "r710",
      "r981",
      "r982",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r120",
      "r478",
      "r981",
      "r982"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r651",
      "r653",
      "r654",
      "r657"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r981",
      "r982"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r526",
      "r531",
      "r651",
      "r708",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r526",
      "r531",
      "r651",
      "r709",
      "r981",
      "r982",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level\u00a03",
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r651",
      "r710",
      "r981",
      "r982",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments, Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r122"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments to equity security warrants",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of derivative assets",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments to contingent liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Repurchases, Contingent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r708",
      "r709",
      "r710",
      "r981",
      "r982",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r657"
     ]
    },
    "lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Adjustment",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease amortization expense",
        "label": "Finance Lease And Operating Lease, Right-of-Use Asset, Amortization",
        "documentation": "Finance Lease And Operating Lease, Right-of-Use Asset, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, impairment charges",
        "label": "Finance Lease, Impairment Loss",
        "documentation": "Amount of impairment loss from right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease expense",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r692",
      "r1002"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in finance lease liabilities",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r694"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Finance Lease Liabilities",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1223"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "lgnd_FinanceLeaseLiabilityTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "FinanceLeaseLiabilityTenantImprovementAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less tenant improvement allowance",
        "label": "Finance Lease, Liability, Tenant Improvement Allowance",
        "documentation": "Finance Lease, Liability, Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments under finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r694"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate of finance leases (as a percent)",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r1002"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term of finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r1002"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r428",
      "r429",
      "r489",
      "r506",
      "r635",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r766",
      "r978",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finite-lived intangible asset, useful life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r442"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated amortization expense for 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r739",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81"
     ]
    },
    "lgnd_ForecastedCashFlowsEffectiveInterestRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ForecastedCashFlowsEffectiveInterestRatePercent",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate of forecasted cash flows (as a percent)",
        "label": "Forecasted Cash Flows, Effective Interest Rate, Percent",
        "documentation": "Forecasted Cash Flows, Effective Interest Rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1046",
      "r1056",
      "r1082"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1046",
      "r1056",
      "r1082"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1046",
      "r1056",
      "r1082"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1046",
      "r1056",
      "r1082"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1046",
      "r1056",
      "r1082"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) from short-term investments",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r1101"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of Pelican",
        "verboseLabel": "Gain on sale of business",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1131"
     ]
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivative instruments",
        "label": "Gain (Loss) on Sale of Derivatives",
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r240",
      "r858",
      "r859",
      "r860",
      "r861"
     ]
    },
    "lgnd_GainLossOnShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "GainLossOnShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss (gain) short-term investments",
        "label": "Gain (Loss) on Short-Term Investments",
        "documentation": "Gain (Loss) on Short-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss (gain) on debt extinguishment",
        "terseLabel": "Loss(gain) on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r87",
      "r88"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r853"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r437",
      "r741",
      "r979",
      "r1003",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and intangible asset impairment",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r439",
      "r979"
     ]
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill written off",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r979"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Held-to-Maturity, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1235"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1038"
     ]
    },
    "lgnd_ImpairmentLossOnCommercialLicenseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ImpairmentLossOnCommercialLicenseRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss of commercial license rights",
        "label": "Impairment Loss On Commercial License Rights",
        "documentation": "Impairment Loss On Commercial License Rights"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ImpairmentOfCommercialLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ImpairmentOfCommercialLicense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of commercial license rights",
        "label": "Impairment of Commercial License",
        "documentation": "Impairment of Commercial License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss of commercial license rights",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1168"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r181",
      "r193",
      "r324",
      "r325",
      "r326",
      "r327",
      "r340",
      "r343"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income tax from continuing operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r175",
      "r237",
      "r349",
      "r359",
      "r363",
      "r365",
      "r745",
      "r764",
      "r975"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income (loss) from continuing operations (in USD per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r235",
      "r238",
      "r301",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r335",
      "r341",
      "r342",
      "r647",
      "r744",
      "r1238"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income (loss) from continuing operations (in USD per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r301",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r335",
      "r341",
      "r342",
      "r343",
      "r647",
      "r744",
      "r1238"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss from discontinued operations",
        "negatedLabel": "Net loss from discontinued operations",
        "totalLabel": "Net loss",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r154",
      "r159",
      "r224"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net loss from discontinued operations (in USD per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r301",
      "r339",
      "r341",
      "r342",
      "r1233",
      "r1238"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net loss from discontinued operations (in USD per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r339",
      "r341",
      "r342"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Losses from equity method investment in Primrose Bio",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r176",
      "r236",
      "r355",
      "r403",
      "r763"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statement of Operations:",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r27",
      "r33",
      "r140",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r160",
      "r161",
      "r205"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446",
      "r854"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r854"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r579",
      "r588",
      "r593",
      "r600",
      "r605",
      "r609",
      "r611",
      "r612",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "totalLabel": "Total income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r258",
      "r330",
      "r331",
      "r356",
      "r586",
      "r606",
      "r769"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r582",
      "r583",
      "r593",
      "r594",
      "r599",
      "r601",
      "r791"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate change for changes in federal, foreign or state law",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r587"
     ]
    },
    "lgnd_IncomeTaxReconciliationContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "IncomeTaxReconciliationContingentValueRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Income Tax Reconciliation, Contingent Value Rights",
        "documentation": "Income Tax Reconciliation, Contingent Value Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax differential on income/loss of foreign subsidiaries",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r1122"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r1130"
     ]
    },
    "lgnd_IncreaseDecreaseInDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "IncreaseDecreaseInDebtDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction in debt discount",
        "label": "Increase (Decrease) in Debt Discount",
        "documentation": "Increase (Decrease) in Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income taxes, net",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes receivable and payable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIntangibleAssetsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other economic rights",
        "label": "Increase (Decrease) in Intangible Assets, Current",
        "documentation": "The increase (decrease) during the reporting period in intangible assets (for example patents and licenses)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and dispositions:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1130"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets and liabilities",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive potential common shares (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r343",
      "r538"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1046",
      "r1056",
      "r1073",
      "r1082",
      "r1086",
      "r1094"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1098"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1098"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1098"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total goodwill and other identifiable intangible assets, net",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r241",
      "r299",
      "r353",
      "r676",
      "r855",
      "r1017",
      "r1245"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r484",
      "r492",
      "r983",
      "r984"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r485",
      "r983",
      "r984"
     ]
    },
    "lgnd_InterestInPotentialDevelopmentMilestone": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "InterestInPotentialDevelopmentMilestone",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest in potential development milestone (as a percent)",
        "label": "Interest in Potential Development Milestone",
        "documentation": "Interest in Potential Development Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest portion of repurchased amount of debt instrument",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r306",
      "r308"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal Revenue Service (IRS)",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r966",
      "r1003"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r271",
      "r284",
      "r430",
      "r431",
      "r433",
      "r737",
      "r972"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-downs related to obsolete inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r352"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, fair value",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "lgnd_LeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Lease, Liability",
        "documentation": "Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current lease liabilities",
        "label": "Lease, Liability, Current",
        "documentation": "Lease, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease assets",
        "label": "Lease, Right-of-Use Asset",
        "documentation": "Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term of finance leases",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1221"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease assets",
        "label": "Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification",
        "documentation": "Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1223"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term of operating leases",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1221"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r312",
      "r405",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r621",
      "r623",
      "r624",
      "r663",
      "r828",
      "r974",
      "r1019",
      "r1175",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r232",
      "r759",
      "r1003",
      "r1135",
      "r1163",
      "r1219"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r270",
      "r312",
      "r405",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r621",
      "r623",
      "r624",
      "r663",
      "r1003",
      "r1175",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LiabilityForContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LiabilityForContingentValueRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term contingent liabilities",
        "label": "Liability For Contingent Value Rights",
        "documentation": "Liability for contingent value rights."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LicenseFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LicenseFeesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fees",
        "label": "License Fees [Member]",
        "documentation": "License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LicenseFeesMilestonesAndOtherProductOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LicenseFeesMilestonesAndOtherProductOtherMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "License Fees, Milestones, and Other Product, Other [Member]",
        "documentation": "License Fees, Milestones, and Other Product, Other"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LicenseeAccrualCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "LicenseeAccrualCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts owed to former licensees",
        "label": "Licensee Accrual, Current",
        "documentation": "Licensee Accrual, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest (as a percent)",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available borrowing",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, interest rate (as a percent)",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term portion of notes payable",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r84"
     ]
    },
    "us-gaap_LongtermNotesPayableCurrentAndNoncurrentTotalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermNotesPayableCurrentAndNoncurrentTotalAbstract",
     "presentation": [
      "http://www.ligand.com/role/DebtEquityandLiabilityComponentsofFinancingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable, Current and Noncurrent",
        "label": "Notes Payable, Current and Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r454",
      "r1171",
      "r1172"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r454",
      "r1171",
      "r1172"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of civil complaints filed against entity",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1172"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r988",
      "r1181",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investment Categories",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaterialSalesCaptisolCOVIDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MaterialSalesCaptisolCOVIDMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captisol - COVID",
        "label": "Material Sales, Captisol, COVID [Member]",
        "documentation": "Material Sales, Captisol, COVID"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaterialSalesCaptisolCoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MaterialSalesCaptisolCoreMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captisol - Core",
        "label": "Material Sales, Captisol, Core [Member]",
        "documentation": "Material Sales, Captisol, Core"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaterialSalesCaptisolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MaterialSalesCaptisolMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captisol",
        "label": "Material Sales, Captisol [Member]",
        "documentation": "Material Sales, Captisol [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r532",
      "r735",
      "r776",
      "r820",
      "r821",
      "r878",
      "r897",
      "r902",
      "r903",
      "r939",
      "r960",
      "r961",
      "r976",
      "r985",
      "r998",
      "r1005",
      "r1177",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MetabasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MetabasisMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Metabasis",
        "label": "Metabasis [Member]",
        "documentation": "Metabasis"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MetabasisTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MetabasisTherapeuticsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Metabasis Therapeutics",
        "verboseLabel": "Metabasis",
        "label": "Metabasis Therapeutics [Member]",
        "documentation": "Metabasis Therapeutics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "documentation": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Domain]",
        "label": "Milestone [Domain]",
        "documentation": "Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MilestoneMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone",
        "label": "Milestone [Member]",
        "documentation": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MinimumBeneficialOwnershipInReportingEntityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "MinimumBeneficialOwnershipInReportingEntityPercentage",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial ownership interest (as a percent)",
        "label": "Minimum Beneficial Ownership In Reporting Entity, Percentage",
        "documentation": "Minimum Beneficial Ownership In Reporting Entity, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r532",
      "r735",
      "r776",
      "r820",
      "r821",
      "r878",
      "r897",
      "r902",
      "r903",
      "r939",
      "r960",
      "r961",
      "r976",
      "r985",
      "r998",
      "r1005",
      "r1177",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal bonds",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MutualFundMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond Fund",
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r988",
      "r1181",
      "r1239",
      "r1240"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Discontinued Operations, Investing Actives [Abstract]",
        "documentation": "Net Cash Provided by (Used in) Discontinued Operations, Investing Actives"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Discontinued Operations, Operating Activities [Abstract]",
        "documentation": "Net Cash Provided by (Used in) Discontinued Operations, Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used) provided in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss):",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r193",
      "r239",
      "r268",
      "r291",
      "r293",
      "r298",
      "r312",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r340",
      "r349",
      "r359",
      "r363",
      "r365",
      "r405",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r647",
      "r663",
      "r765",
      "r850",
      "r868",
      "r869",
      "r975",
      "r1017",
      "r1175"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Updates, Recently Adopted and Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NonCashChangeInEstimatedFairValueOfContingentValueRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in estimated fair value of contingent liabilities",
        "label": "Non-Cash Change In Estimated Fair Value Of Contingent Value Rights",
        "documentation": "Non-Cash Change In Estimated Fair Value Of Contingent Value Rights."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1046",
      "r1056",
      "r1073",
      "r1082"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition:",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NotesRepurchasedDuringCurrentPeriodTwoMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Repurchased During Current Period, Two",
        "label": "Notes Repurchased During Current Period, Two [Member]",
        "documentation": "Notes Repurchased During Current Period, Two"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NovanIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NovanIncMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novan, Inc.",
        "label": "Novan, Inc. [Member]",
        "documentation": "Novan, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NucorionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NucorionMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nucorion",
        "label": "Nucorion [Member]",
        "documentation": "Nucorion"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContingentValueRightAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NumberOfContingentValueRightAgreements",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVR agreements",
        "label": "Number Of Contingent Value Right Agreements",
        "documentation": "Number Of Contingent Value Right Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContingentValueRightsIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NumberOfContingentValueRightsIssued",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of contingent value rights",
        "label": "Number of Contingent Value Rights Issued",
        "documentation": "Number of Contingent Value Rights Issued"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContingentValueRightsSeries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NumberOfContingentValueRightsSeries",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVR Series",
        "label": "Number of Contingent Value Rights Series",
        "documentation": "Number of Contingent Value Rights Series"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContracts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NumberOfContracts",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of contracts",
        "label": "Number of Contracts",
        "documentation": "Number of Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "lgnd_NumberOfSharesSoldOfEquityMethodInvestee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "NumberOfSharesSoldOfEquityMethodInvestee",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sold of equity method investee (in shares)",
        "label": "Number Of Shares Sold Of Equity Method Investee",
        "documentation": "Number Of Shares Sold Of Equity Method Investee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lab and office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_OmniabSeparationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "OmniabSeparationMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniab Separation",
        "label": "Omniab Separation [Member]",
        "documentation": "Omniab Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs and expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating costs and expenses:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from continuing operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r359",
      "r363",
      "r365",
      "r975"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "lgnd_OperatingLeaseLiabilityTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "OperatingLeaseLiabilityTenantImprovementAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less tenant improvement allowance",
        "label": "Operating Lease, Liability, Tenant Improvement Allowance",
        "documentation": "Operating Lease, Liability, Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate of operating leases (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r1002"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term of operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r1002"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforward",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r194",
      "r195",
      "r223"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r1003"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "lgnd_OtherBalanceSheetDetailsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "OtherBalanceSheetDetailsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Balance Sheet Details [Abstract]",
        "documentation": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized net gain (loss) on available-for-sale securities, net of tax",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r18",
      "r224"
     ]
    },
    "us-gaap_OtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Other Investments",
        "documentation": "Amount of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "lgnd_OtherInvestmentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "OtherInvestmentsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investments",
        "label": "Other Investments Policy [Policy Text Block]",
        "documentation": "Other Investments Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "totalLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "lgnd_OtherMiscellaneousNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "OtherMiscellaneousNonCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Miscellaneous Non-current Liabilities",
        "documentation": "Other Miscellaneous Non-current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Long Term Liabilities",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other operating income",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1044",
      "r1054",
      "r1080"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1047",
      "r1057",
      "r1083"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1047",
      "r1057",
      "r1083"
     ]
    },
    "lgnd_OvidTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "OvidTherapeuticsMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ovid",
        "label": "Ovid Therapeutics [Member]",
        "documentation": "Ovid Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PalvellaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PalvellaMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Palvella",
        "label": "Palvella [Member]",
        "documentation": "Palvella"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PalvellaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PalvellaTherapeuticsIncMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Palvella",
        "label": "Palvella Therapeutics, Inc. [Member]",
        "documentation": "Palvella Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PartnerAMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner A",
        "label": "Partner A [Member]",
        "documentation": "Partner A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PartnerBMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner B",
        "label": "Partner B [Member]",
        "documentation": "Partner B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PartnerCMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner C",
        "label": "Partner C [Member]",
        "documentation": "Partner C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentedTechnologyMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Completed technology",
        "label": "Patented Technology [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1128"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of warrants",
        "label": "Payments for Repurchase of Warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "lgnd_PaymentsForSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PaymentsForSeparation",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net cash transferred to OmniAb at separation",
        "label": "Payments For Separation",
        "documentation": "Payments For Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for OmniAb transaction costs",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments for acquisition",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r618"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for Novan acquisition, net of restricted cash received",
        "terseLabel": "Net cash paid for Novan",
        "totalLabel": "Cash paid for Novan, including restricted cash received",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for equity method investment",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "lgnd_PaymentsToContingentValueRightHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PaymentsToContingentValueRightHolders",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments to CVR holders and other contingency payments",
        "negatedTerseLabel": "Payments",
        "label": "Payments to Contingent Value Right Holders",
        "documentation": "Payments to contingent value right holders"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsToContingentValueRightHoldersFinancingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PaymentsToContingentValueRightHoldersFinancingActivity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments to CVR Holders",
        "negatedTerseLabel": "Payments to CVR Holders",
        "label": "Payments to Contingent Value Right Holders, Financing Activity",
        "documentation": "Payments to Contingent Value Right Holders, Financing Activity"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsToContingentValueRightHoldersInvestingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PaymentsToContingentValueRightHoldersInvestingActivity",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments to CVR Holders",
        "label": "Payments to Contingent Value Right Holders, Investing Activity",
        "documentation": "Payments to Contingent Value Right Holders, Investing Activity"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsToUnwindWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PaymentsToUnwindWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to unwind warrants",
        "label": "Payments to Unwind Warrants",
        "documentation": "Payments to Unwind Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsforConvertibleBondHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PaymentsforConvertibleBondHedges",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for convertible bond hedges",
        "label": "Payments for Convertible Bond Hedges",
        "documentation": "Payments for Convertible Bond Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "lgnd_PeliCRM197Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PeliCRM197Member",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PeliCRM197",
        "label": "PeliCRM197 [Member]",
        "documentation": "PeliCRM197"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PelicanTechnologyHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PelicanTechnologyHoldingsIncMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pelican Technology Holdings, Inc.",
        "label": "Pelican Technology Holdings, Inc. [Member]",
        "documentation": "Pelican Technology Holdings, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_Phase3ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "Phase3ClinicalTrialMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 clinical trial",
        "label": "Phase 3 Clinical Trial [Member]",
        "documentation": "Phase 3 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1242",
      "r1246"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r494"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r830"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r494"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r830",
      "r848",
      "r1246",
      "r1247"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r755",
      "r1003"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r434",
      "r435",
      "r968"
     ]
    },
    "lgnd_PrimordialGeneticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PrimordialGeneticsMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Primordial Genetics",
        "label": "Primordial Genetics [Member]",
        "documentation": "Primordial Genetics"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PrimroseBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PrimroseBioMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Primrose Bio",
        "label": "Primrose Bio [Member]",
        "documentation": "Primrose Bio"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ProceedsFromCommercialLicenseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ProceedsFromCommercialLicenseRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from commercial license rights",
        "label": "Proceeds from Commercial License Rights",
        "documentation": "Proceeds from Commercial License Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from debt issuance",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ProceedsFromHedgeFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromHedgeFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from bond hedge settlement",
        "label": "Proceeds from Hedge, Financing Activities",
        "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r1129"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash received from options exercised",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturity of short-term investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r189"
     ]
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRoyaltiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from royalties received",
        "label": "Proceeds from Royalties Received",
        "documentation": "Cash received for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of short-term investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from stock option exercises and ESPP",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r366",
      "r738",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r963",
      "r986",
      "r1004",
      "r1109",
      "r1173",
      "r1174",
      "r1181",
      "r1239"
     ]
    },
    "lgnd_ProductRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ProductRoyaltyPercentage",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product royalty (as a percent)",
        "label": "Product Royalty Percentage",
        "documentation": "Product Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r366",
      "r738",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r963",
      "r986",
      "r1004",
      "r1109",
      "r1173",
      "r1174",
      "r1181",
      "r1239"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment , gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r273",
      "r762"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r748",
      "r762",
      "r1003"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r252",
      "r255",
      "r760"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PurchaseCommitmentConsiderationPaidAllocatedToInventory",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion of consideration allocated to inventory",
        "label": "Purchase Commitment, Consideration Paid, Allocated to Inventory",
        "documentation": "Purchase Commitment, Consideration Paid, Allocated to Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PurchaseCommitmentConsiderationPaidToDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PurchaseCommitmentConsiderationPaidToDate",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid to date",
        "label": "Purchase Commitment, Consideration Paid to Date",
        "documentation": "Purchase Commitment, Consideration Paid to Date"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PurchaseforCommercialLicenseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "PurchaseforCommercialLicenseRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of commercial license rights",
        "label": "Purchase for Commercial License Rights",
        "documentation": "Purchase for Commercial License Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r525",
      "r532",
      "r564",
      "r565",
      "r566",
      "r711",
      "r735",
      "r776",
      "r820",
      "r821",
      "r878",
      "r897",
      "r902",
      "r903",
      "r939",
      "r960",
      "r961",
      "r976",
      "r985",
      "r998",
      "r1005",
      "r1008",
      "r1169",
      "r1177",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r525",
      "r532",
      "r564",
      "r565",
      "r566",
      "r711",
      "r735",
      "r776",
      "r820",
      "r821",
      "r878",
      "r897",
      "r902",
      "r903",
      "r939",
      "r960",
      "r961",
      "r976",
      "r985",
      "r998",
      "r1005",
      "r1008",
      "r1169",
      "r1177",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1039",
      "r1049",
      "r1075"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment at maturity/repurchase of 2023 Notes",
        "terseLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r795"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of notes",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r468",
      "r496",
      "r704",
      "r970",
      "r971"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r577",
      "r1232"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1040",
      "r1050",
      "r1076"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1041",
      "r1051",
      "r1077"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1048",
      "r1058",
      "r1084"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "lgnd_RestrictedStockUnitsAndPerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RestrictedStockUnitsAndPerformanceSharesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs and PSUs",
        "label": "Restricted Stock Units and Performance Shares [Member]",
        "documentation": "Restricted Stock Units and Performance Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r213",
      "r758",
      "r783",
      "r788",
      "r796",
      "r831",
      "r1003"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retain earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r317",
      "r318",
      "r319",
      "r322",
      "r329",
      "r331",
      "r409",
      "r415",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r628",
      "r630",
      "r631",
      "r634",
      "r645",
      "r779",
      "r781",
      "r798",
      "r1246"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r358",
      "r361",
      "r362",
      "r366",
      "r367",
      "r368",
      "r521",
      "r522",
      "r738"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue Recognition and Deferred Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r962"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r1002"
     ]
    },
    "lgnd_RoyaltyAgreementExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RoyaltyAgreementExpirationPeriod",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period of royalty agreement",
        "label": "Royalty Agreement, Expiration Period",
        "documentation": "Royalty Agreement, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyAgreementsMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Agreements",
        "label": "Royalty Agreements [Member]",
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r578",
      "r1211"
     ]
    },
    "lgnd_RoyaltyEvomelaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RoyaltyEvomelaMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evomela",
        "label": "Royalty, Evomela [Member]",
        "documentation": "Royalty, Evomela"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyKyprolisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RoyaltyKyprolisMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kyprolis",
        "label": "Royalty, Kyprolis [Member]",
        "documentation": "Royalty, Kyprolis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1182"
     ]
    },
    "lgnd_RoyaltyOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RoyaltyOtherMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Royalty, Other [Member]",
        "documentation": "Royalty, Other"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyRylazeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RoyaltyRylazeMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rylaze",
        "label": "Royalty, Rylaze [Member]",
        "documentation": "Royalty, Rylaze"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyTeriparatideInjectionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "RoyaltyTeriparatideInjectionMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Teriparatide injection",
        "label": "Royalty, Teriparatide Injection [Member]",
        "documentation": "Royalty, Teriparatide Injection"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "lgnd_SaleOfStockAuthorizedOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SaleOfStockAuthorizedOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, authorized offering amount",
        "label": "Sale Of Stock, Authorized Offering Amount",
        "documentation": "Sale Of Stock, Authorized Offering Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_SalesContractInterestInSalesRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SalesContractInterestInSalesRevenue",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest in sales revenue (as a percent)",
        "label": "Sales Contract, Interest In Sales Revenue",
        "documentation": "Sales Contract, Interest In Sales Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_SalesRevenueMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SalesRevenueMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales revenue milestone",
        "label": "Sales Revenue Milestone",
        "documentation": "Sales Revenue Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r1106"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r533",
      "r1141"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r533",
      "r1103",
      "r1141"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r613"
     ]
    },
    "lgnd_ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Commercial License and Other Economic Rights",
        "label": "Schedule Of Commercial License And Other Economic Rights [Table Text Block]",
        "documentation": "Schedule Of Commercial License And Other Economic Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Benefit",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity and Liability Components of the Convertible Senior Notes",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables",
      "http://www.ligand.com/role/SpinoffofOmniAbTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r27",
      "r33",
      "r140",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r160",
      "r161",
      "r205"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r335",
      "r339",
      "r341"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ScheduleOfFairValueOfTheConsiderationTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Consideration",
        "label": "Schedule Of Fair Value Of The Consideration [Table Text Block]",
        "documentation": "Schedule Of Fair Value Of The Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r739"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Goodwill and Other Identifiable Intangible Assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r930",
      "r931",
      "r932",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Restricted Stock Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r537",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Plan Activity by Exercise Price Range",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Stock Option Plan Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits, excluding amounts pertaining to examined tax returns."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "lgnd_ScheduleofContingentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ScheduleofContingentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contingent Liabilities",
        "label": "Schedule of Contingent Liabilities [Table Text Block]",
        "documentation": "Schedule of Contingent Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from Significant Partners",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r70",
      "r71",
      "r125",
      "r227"
     ]
    },
    "lgnd_SecuredOvernightFinancingRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofnoncashitemsandcapitalexpendituresofthediscontinuedoperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofrevenueandexpensesofthediscontinuedoperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r141",
      "r142",
      "r143"
     ]
    },
    "lgnd_SelexisAndDianomiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SelexisAndDianomiMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selexis and Dianomi",
        "label": "Selexis and Dianomi [Member]",
        "documentation": "Selexis and Dianomi"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_SelexisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SelexisMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selexis",
        "label": "Selexis [Member]",
        "documentation": "Selexis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Revenue",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in USD per share)",
        "periodEndLabel": "Outstanding at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant\u00a0Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r537",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares allowed to purchase in employee stock purchase plan per employee (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase the number of shares under the 2002 Stock Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for future option grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value per share of stock options (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value (In thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in USD per share)",
        "periodEndLabel": "Balance at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options vested and expected to vest at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options vested and expected to vest at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued under amended ESSP (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "lgnd_ShareBasedCompensationInitialOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ShareBasedCompensationInitialOfferingPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Offering Period",
        "label": "Share Based Compensation, Initial Offering Period",
        "documentation": "Share Based Compensation, Initial Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r542",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r572",
      "r573",
      "r574",
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Axis]",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lower range of exercise prices (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upper range of exercise prices (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting right (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, vested and expected to vest (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life in years",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r1123"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r964"
     ]
    },
    "lgnd_SoticlestatMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "SoticlestatMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soticlestat",
        "label": "Soticlestat [Member]",
        "documentation": "Soticlestat"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r280",
      "r281",
      "r282",
      "r312",
      "r335",
      "r339",
      "r341",
      "r343",
      "r347",
      "r348",
      "r405",
      "r455",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r494",
      "r495",
      "r498",
      "r501",
      "r508",
      "r663",
      "r792",
      "r793",
      "r794",
      "r795",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r830",
      "r851",
      "r870",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1102",
      "r1133",
      "r1142"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r44",
      "r263",
      "r296",
      "r297",
      "r298",
      "r317",
      "r318",
      "r319",
      "r322",
      "r329",
      "r331",
      "r346",
      "r409",
      "r415",
      "r510",
      "r569",
      "r570",
      "r571",
      "r603",
      "r604",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r634",
      "r645",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r703",
      "r779",
      "r780",
      "r781",
      "r798",
      "r870"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r346",
      "r738",
      "r790",
      "r809",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r830",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r849",
      "r852",
      "r853",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r870",
      "r1009"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Balance Sheet:",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r533",
      "r1103",
      "r1104",
      "r1141"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r346",
      "r738",
      "r790",
      "r809",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r830",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r849",
      "r852",
      "r853",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r870",
      "r1009"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1043",
      "r1053",
      "r1079"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r166",
      "r167",
      "r213"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r166",
      "r167",
      "r213",
      "r548"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r166",
      "r167",
      "r213"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased in period",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r166",
      "r167",
      "r213",
      "r798",
      "r870",
      "r955",
      "r1018"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r170",
      "r171",
      "r197",
      "r832",
      "r848",
      "r871",
      "r872",
      "r1003",
      "r1019",
      "r1135",
      "r1163",
      "r1219",
      "r1246"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r311",
      "r493",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r636",
      "r873",
      "r874",
      "r957"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r1002"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Account Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tangible asset impairment charges",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r203"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Core Technology",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1181"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1181"
     ]
    },
    "lgnd_ToleranceTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "ToleranceTherapeuticsMember",
     "presentation": [
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsNarrativeDetails",
      "http://www.ligand.com/role/CommercialLicenseandOtherEconomicRightsScheduleofCommercialLicenseandOtherEconomicRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tolerance",
        "label": "Tolerance Therapeutics [Member]",
        "documentation": "Tolerance Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade name",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred over Time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r489",
      "r506",
      "r635",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r766",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "lgnd_TwoThousandTwoStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "TwoThousandTwoStockIncentivePlanMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2002 Stock Incentive Plan",
        "label": "Two thousand Two Stock Incentive Plan [Member]",
        "documentation": "Two thousand two Stock Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "USDistrictCourtForTheNorthernDistrictOfOhioMember",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US District Court for the Northern District of Ohio",
        "label": "US District Court for the Northern District of Ohio [Member]",
        "documentation": "US District Court for the Northern District of Ohio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1234"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivative instruments",
        "negatedTerseLabel": "Gain on derivative instruments",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r864",
      "r865",
      "r866",
      "r867",
      "r925"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r589"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reductions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "lgnd_UnrecognizedTaxBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "UnrecognizedTaxBenefitsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits - Noncurrent",
        "documentation": "Unrecognized Tax Benefits - Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r249",
      "r250",
      "r253",
      "r254"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) of valuation allowance, change in amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Technique, Discounted Cash Flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209"
     ]
    },
    "lgnd_VestingPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "VestingPeriodOneMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest 1/8 on the six month anniversary of the date of grant",
        "label": "Vesting Period One [Member]",
        "documentation": "Vesting Period One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_VestingPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "VestingPeriodTwoMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest 1/48 each month for forty-two months",
        "label": "Vesting Period Two [Member]",
        "documentation": "Vesting Period Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_VikingTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20231231",
     "localname": "VikingTherapeuticsInc.Member",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Viking Therapeutics, Inc.",
        "label": "Viking Therapeutics, Inc. [Member]",
        "documentation": "Viking Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in diluted per share calculation (in shares)",
        "totalLabel": "Shares used to compute diluted income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r343"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Shares used in basic per share calculation (in shares)",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r343"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-22"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0000886163-24-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-24-000009-xbrl.zip
M4$L#!!0    (  2"75@[6@P7M00  'T6   >    97AH:6)I=#$P,3)?86UE
M;F1M96YT=&]L:6<N:'1MW5AM<^(V$/[>7[%-IG>]&4.P"9<$.&8HN V=!!C@
MFNFGCFS)6!?;\DARB._7=^47 M.F3=*7,&$&L"VMM?OL[K-:]4,=1X-^R @=
M?-/_MM& L?"SF"4:?,F(9A0RQ9,UW%"F;J'1J&:-1)I+O@XU."WG%&Z$O.5W
MI!S77$=L4+^G?U+>]T^*1?J>H/F@3_D=</KIB)\Z'TF;!#Z]N&B=$B<XMRGM
MM#L7SBFA=CLX^\T^0E&<7LHHG4?LTU',DT;(S/K=,R?5O0VG.NS:K=9W1WOS
M-+O7#1+Q==(MM,710*!MU; O(B&[QZWBTS,CC8#$/,J[[T<HY4G^WE(D40W%
M) _*"8I_95W;QD6+VTVE!<I'/&&U5J4J[GW(/:[!;C5MIW]B!&IC_F@2D6NT
MRA-:B[AK&ZMVM/<122:?KOZ*QTS!E&U@(6*2_#,SAM?N=(S?%:QF<#7Y:3@=
MP_QRN+@>CMS/J\EH>+6$R70T6\QGB^'*'9N8<,"]GE_-?BW$)M/QYY%;7,ZO
MAM-]))Z,P9=,:1[DY2.>4(2DV_Z8/L.I+T3E]$]165U.EK 'S>K2_3?@@>]U
MR!6\.SYWG%:O!NO_-[$$FC)?2**Y2+H98B[-+ P)3&U:IO=KJ7<T*!"R>Q\L
M8$' ?,WO&! %(H"?29(1F4.[914$90$"&A.*XPD%0D5JF,W+X8JOS9-Y2&1,
M?)9I[I-(P21!HU-C-Z,6$!BSB&R(9% _1CB,F]AA>VDDXI0D^2'XJ DP(BG7
MF,I?$7HDLUAA:3%>R#0D0H- ..6&*P:4!?@>"GC/> (J)%$$(4'O&L1C1A*L
M2 I=[4ONF9<),Q #SC43YA%!YV @U._Q6"0V'YHOI)U7I=Z%.YJLD$#>!F7>
M7+H+=[BT"C=5P8EIR1.-7U4\?4)"5OP9IY'(BYW*)*&9SXK+K>^)(2B<&T@1
M@T8CBBC!_W+Q@TY;8\0AY.R[X\Y%SS#F&XN^-),J(Z@ AL108H1%#);\WH*E
M*2+([)/)Q%21FDRL!UJ)28YTLHTNK"!FZ =!) 4C,N82WR&DJN7K*#_\8E$8
M<0AA!T2#@<QDZTM)^\!";SJ[L<SV<.'^.%NXEJE4OD@41_#+O405+8&0;"VP
MNED[<67*( 9:$7/J(121Y (18653F*?GO>< E1)*<9%&Q(*J@?H;Z!JOB)W=
M?,5\V4/*.6N>=0P.-4_4Y#%+V -Y_-(<[I*'V7GN>A!9PQ0XR90NBAF& M<*
M$&6D#IT;3L+&F_[7[GTE9U8,N,R\+PB7,990HU%1O'=YN6B!MI"6Z9!DL<>D
M 1>WA B@N4)^C7'&4@O_%C8A]\.:H[E2&>(K)&B)&@=,2KS=XW[<TF-&%1RX
MYZ^.T[$0AVJ99D5,;S;#G,/+L)5Q_[;)K%H KVS?'A**[^X*,9',*%(H=A8$
M4B+U;AYB _)F'=@^/ >Z]SY+M6$Q=I]B$JDHAU2*.TZWC1TVUNC4HNVK^D'C
MOV*2PJQ7>RQ:1H!DIEO C/5#DJPK*L4'08:#Z'F_C)#R.."O/'XH_=U38_)\
M&UN#OB<'CTKM'HJF0O%BDR=91,SAR*/'I-4BK0<1XBD19?IQD6>HM_=;'O^>
M%,?.OP-02P,$%     @ !()=6*6.:.T3"P  E$@  !X   !E>&AI8FET,3 T
M-%]P86QV96QL82UF:7)S="YH=&WM7&U3V[@6_GY_A2[L[;8SB1OG/< RDT)H
M,Y<&+DG;V4]W%%M.M#A65I*39G_]/4>R0U[9T (Q<V$&)K8E67K.VW..%$Z&
M>A2>G@P9]4__<?+/?)Z<"R\>L4@33S*JF4]BQ:,!^>8S=4OR^:35F1C/)!\,
M-2D6BF7R3<A;/J'VN>8Z9*?I."?O[?7)>_.2D[[P9Z<G/I\0[O]VP(-BM50-
M/-<K!X5R)7#[M6K=;=1=W_,:-:]4^:][ %VAN>VC]"QDOQV,>)0?,GS_4;7F
M5.MC?3SEOAX>N87"OPY,T].30$0:WB>AO_TX'^9'GZ6OU^R[SM.0#Z(C \*!
M[90^]D0HY-%AP?P<XY-\0$<\G!W]VN,CIDB'3<F-&-'HUYRBD<HK)GE@&RK^
M%SMR75B0N9S:1=9@G)!'+%VT76;K^Y#WN29NP2F7ER>[CAB5 P!-B_%1R6E4
M8/PQ]7V0;#YD 0Q8JSAN<>&NM.]);R^LV .A,OGH2R[NM.2+]DVW1YJ?6YUS
M^.V1WM56(2VMK^@4:FNK2VYF96WGK:^MRZMKLZZ++YWS=N<C:7;.R<W5[\W+
M7KO5)<V/-ZT6/M^ZZ 4Q+XG3"KFP!D'%J5>6(?@C5IH',WN+1SX@<E2J&)5Y
M<ES*&W'I#;DB%UPJ39K@47SCG;0@YVS"0C$VEQ=QA*LB-/+AE3,::@X3: XD
M8^;Y6XV#O#FL%XN%XQ2]YU^,1=5GGI!4<Q$=P;29Q%8'I_.U[6]Z!Z<&(??X
M'0&T1M1GA 4!\S2?,$(5$0'Y3&>D6,RAVR\@JNR%@$I:\X6<0UC+!,;]F='7
M/M-3QB)RR0=X>3VD<D0]%FONT5"1=@0+&^/:F)\C%-0^I%,J&4EOPY)?@"3L
MZK* >\Z@?DU#<!\A);TADW1LX%8Y1-O9CG*F$4Y7E &,$>$<^.@! [V49,KU
M,%%ON)MU3;VF$J-'1F DC'I# H&83[@?TS $IY%]_&890.^=LQM-<@KK='@3
M4VIDARAM)I#?/K5N6LWN/J&WYIU8$$'_.4X^ V'30PII)9.:\N@A["U'#"V'
M7)1',(PQBA5:<LX\-NJ#JW%+R$W<^@N(B//U9<%6WAQ6&L>/EE947TUE!U,!
M*_!$%*$B [DP09*2_X"/YP$'9;_@$8T\M(O6!*T$VJ!.^T $"415)H+<'8L!
MOLZ5BK&U @+)C%5T86;PZ8Q<2Q8PB1;4U<*[16/DT80I+218J8;7CF/I#:D"
M>Y7<8]CYEXI3K-<:9 Q6989\9!5QW QEGAG6$I",BJE->2%8N2X*!Q5AP3\N
M74+B-@-E :+0!_>("1#(74@R$KY5+,P[R%1RK2'KX)'2TE;\%$C!/EYPXD;J
M9(&Z/TSRY>K_M_06PZ'/%(>(B"$,I;(B-0ADBFD2" E^ .V;1X]*8*JV6:8-
MKG/U+4=Z*+>+JYM69B270ZF0@1"^(1\3&L:T'V)N&"D.\=R$=MM# A'A8VW:
MJ3@(N,=9Y,W09J=##DP>.1%*%XW0NXW$-&3^P&3VD>$WS%(A4!*PWI -#./O
MBQA3I[0?ZLP]:A2(,!13M-SZ=G^]9J5+:I O/8?=;H;>==X<NM7"\?K?C/*X
M+!3NMKN*)4%7G/*&S*9661%_":+S'N6_70.Z"5DJ.\6U,(@<*+60).JAC6C3
MRMI$8EEX RT'1E QV.3"J/<;S;VAKKZ^?U*K+6"[Y'3WA&V2$'6$1KJI-$V\
M#0!"^V+"<B0> Q#WT- <N8H8^<S#$!&[, 55P)8BD01(>T,.V7_^0L22G$%S
M1=[^XN9@4?!;<4KE=ZG88 3DGQ$ZV9D1WYC.C%<%^<UI[=_-9HD=F1K_HH8@
M$0(OJL!DE>EM.#:^';DRC+/\,A@BJ<'"''&5G\#*D32W$,%9O@-PP@)%K+#-
M8H/>E,$8Y*U;;^1<M_AN@8.GHR/R;NU8;2?EN_)PAUQ -/( <JYG:=0904Z-
MJ"P*Q\PWG2)>K*UA4PLCND61=OEWN U_%P3::#3@M^Q4JV:M88@XCRGW35)#
M%5:L(+Z!N_0-S GPR_)Q2'L] UJ2SIV!;L8LEPIL/@?)_HRYM*;/OC,OAF0)
MA]R*^G4*^ *=ACD*&+29>!%3E@!E-=OA[7G>=(-:H7;M]U5HE,]":X/M/3W,
M^ B!W?NZ80$(+31MSD2^2\.E.9LR89_A.Y)JR58OEGB$4MVIX\[Y6"AN8IID
M(<6:RMI>>MJQ+[06HZ/"71?:5R($C'???E_=G][M%$!Y?@I@*.\"VX#E^Y+1
MVSP-8,5'-)S2F3IX/2GPE"<%-D2Y:L.I[F][V-8$1P(4?^[):4*+4V\J[RV'
M.$D1[ 5RY>(+X\J?N?)00A&#"/1"^?(NQ<U]\N?B/?SYC(ZYAGG_A1&2R9$B
MD=#$9P&/3'G=QNB[7?,AG9CXR25$5C5.:NXC1I%L*$PVE_HN1*2? 1C!RSC$
MVPVON9:%V%K >!P:8)B_6J^SY,5R.,0QB.$R$!((T-U>AR%+)G&QQ>  R")P
MAR#DGIX?(<#G5JRV0#QWA$NUPB4)VY?#2%J*$*BE%"/3RX14VW?+&0ID,#-B
M7"E#LI8D5JOKPB+D?:U AU*@+&X_7O7:K$P[E;WVJTVEK=K46Y96DM$DS-9:
MW538ZJXYK! C]\,]-Y50PGGA:2X-'X%'K81N'/"D88[T8Q $/)ZWGN_=S_4#
M0-/(IC%E2]5*@>06*L@.'J8@ ?44!Y@83HN%H#%21-PSY66J8VEH/:J.V2A>
M?P$./ %16</I<YNBVB5CFI"H-AB8R0W,*#]5_LB^0R]OU8^VA7(LQ80K1&>]
M*A)Y89QD^4NZQ+%2&$=^4FODD0$]1R![Q+(C2B^.6&0<$2;F.8@51!BE6'D=
MC&0<"/46C=XXB\3]&=U:[JKNFB8O\5/G8!P@H)\X.KP5TNGC^H7=]O/W*_;*
MKFYACN1 3)BTFSBY.:PVU9QRV\18FHRM\UA/T0W4*H6]BZDH7N":?A<2,NXO
M$=>&.<,397H)<!X25$;:@ANH8Q."'?=,->>23G-$QM8;C"5H(X= :,\"3$4<
M^D@LXE"G!(+:KGI!E],)X<A6B?Z()5<^-V6#=;5XRH1N0=6*J%4'NW1:.8I<
M7$^ADIO/?Q1Y6YFPX1[?&$("U-V6L08,& B:)&!N-B4N837D W#Y6Y(GW;ES
M-RTO[!8$Z&^CM)Y7/86 7I\]W[,-QE PV_D[6<-2KPU;E_B=@\J:A<QO9\5&
MBG]77RN7G.(+*:_57LMK&2FOF8W[[&S(MSOD6[O7:76[Q!RGN+K(S*:\K4W,
M,Z$5<DOG%&9;^OHPWK"):A;0OA]. -Q&P[B]O8CTWB/Z[8_-SOE^3R/^\.YK
MBNIJV'#K3FE_Q6D+*;G^U+SYW#QK?>FUSYJ77=+NG%W=7%_=-'NM\Y]5P[I3
MWC7R+O/0DFMZ;B[FKU2X%[GN<V/X86;4XF45NK?-]LUAN7:LS%]R-J0RA,E\
M8/(6II*]!1Z<D@X=,0/_ZFP?IF3[^NH@?O783A]^G@;(PDXSZ;*(0P+\%3?U
MKR'CY;XIQGYD$9,T)&<BCA0+R9O#$LRURSS)-)6SG5RAZSP2\RX6"N;KH)D+
M3-?-RZ^MR\OF"PU-SX;KYIFGZ)F#E<UK$X2Z.8Q!/TV!ZC]8 BE5[?>.5T)/
MV2F^AIYG"3W?F K9C'QRR+]I/(9N68\^ZQ-^F*KM/0!MW9$=<A:0EMW=@-3D
M"L\,,[GW&L_KL]=G^WZV(>*4%U/G!U7=W0U%]Y5S!D]43]R-(9J:^TH978N?
M_,<7F^OOF3L(^-[^5Z#WYK\1_0]02P,$%     @ !()=6.M^I;19$@  ?FH
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M&Y_Z%+R/FEO]Z<#+[D>NL$6H_#?+$4.T/7P/^%&&J/F=R XO90>L2V'SUKT
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M[MF#(9/?)V.+U+!.-WRZX N[SS%C SBD9RJOHB'QX.$5T08)C>O1(],DKM>
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M1> _ ]W(![[KG Y'$NQ=?*XXP:(=8WUIPY&P4$XPUJN>"PGZWL1P%(5<)D_
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M8_=  H)%<<$"A_UE?77]+C@:JOG1/,[75'2PEG=XL&#F_LN-P/Y\1J AY[L
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MQCL(>/5 3>*PKB)I#YB^UZ!^G&GJOU8?JT(\);)9=]8"K0 TN;MQ\/]=<]C
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M.8V4\'A0NA3>%7-ON>N60%),''<=ZCNX.OIV4I9@WY7D@2W%B"0&1?V^!=B
ME7.K99>NN_I5#T1=6=JKJ\.6D\-[\&Q9)C^KPY;3U[\:^-P3]]:-P/$@96'L
MB4-;UWS$Q!NOWA:0ZCNO:\97P)-RV</Y7YZ-ET>P.V/DB=*I[FNJ37C=58I"
MG9;\^FL><";M@6K5Q<%R]T</!EZ5@,NO^:WOWJ*'JV=@G3!;N"(LRW18[,PB
M$QC8"@8]#0.0 S@A"SW\)P>CE4$Z=+Z]+ME3P*/R()3"QJ8KB](&Q>.+#NN7
MX(YV<M2%!VV*1_8=YOF]LLQ44(>U.JW2\77KNBQS4CK<5<%WJ^4YTN]S#SPY
M[+CE2^O<=["Q4JD:*BF@'+?+PN+<CJ0(!2R(-O[QO3V@9%;;'^)H]Q*V7>]P
MQR]+S([..KM<9].";ZXOCXX[)57T')S=LA3IJ<.N<W*D#>]?69M9V--NOMG"
M*R+%RZ'OB;(DX>+C/I3U9^5KKM8Y/2T-@\MH"((\"$48A=SR>_"',S4L;K6Y
MG>+8G?\+Y_;\VX>7C$IRYI)J\\@+!O"I=<:^<RWZRL+Y,XY>RF)<E;\ (#AE
M*;%3AWW0/T5WUB]KD>X-NW]0:K;"IQUP"T_<CD(5V/G-[P9E++6[X;>EX7LX
MZ@.N_]9IQ?&<&=^C-1AA'@\V@7J!2 6HA-T*Y1I8I1,3V%=.EB6IIT];R@#?
MS?76(2]-.YV;P5CZPK$&/@8"L)I#YWBZTS H 9/_3MU"2Q/FBX]KC5R[;%P.
M9_>]LC"Y.FSL[;T9VP6D=/$==EH6MJ;#3B1MUIWTUYWT"]9)OWA2]M_B)WCG
MOX47^J^4-04_LW7.'6%C<#&N#R^;GOGO&-QFJ\T<\<J+N\4^LO4K9VXXL)GD
M%$]^@=J9%*I/Z '\C7!^V1".TZWV=AN[.]6NO=VK[7?M:H\W]K?W=ZL]I]GH
M_6^MNC'C12_1.;G];*V$GU/"C^UZ8=1?JTZ1_^XT^=?I]E/K^L8Z-1J1<X"D
M)05S7RL&" ZUQPGE!1S;V,B7NIYDSJ41&*WX682 ._M94"M=X'#;5QV5/M,M
M&WQJXZ#-(IIM(\?6A1^B&NXS2<WP3WQY!__<.O-]<@YH'B[>Q$E< Q/.MG'P
MV7J4E3(:HCEM=N\F*B/_(_S'CZQ@X$>N8TD<2(KWGWI@\_MW"'C)1[X,K=#O
M<_A"6G<B'- C0U]RR^$A$RYW+.'1G4IJBR 3+/J1!#."TG6;\1]#[)E"%VTP
M1H\?]H3'<%2>"Y_'6*8O/:") %X-[_,#/O'M:,2QI7K?XF[ [P88^Z4!RB*P
M'-^.\*G*XZAY!!?SZ$83,7B#Q]:(LN%I)KP 4*@XR-4<E(%>.& A@ NOP7&+
M65Y$P\C]GB5%\%V!/O)L,-E@(:RHKE@ML)+\J#]0^'I\9<E[6(5/!-+W?<?J
M,:27/R.GCP_@.W %@ $(2?QD$Q^=Q*T-(/4]=VQU>=IE!^<AJYVIR<CP6"0E
M/ _/???\.P][\T2PT[;O!?ROB+Z)%W]BPXP(!^F'E@JB[I^T?_\Q6&S21["'
M".A5\B!R];[\* 3J!C0/V=AR1*_'\9P@_P5-_^Y)?SC[>7"K[2@(B(DT\SVV
MW4I9*/KD<8PA>0!EZ&Y-(NW*% 54%S8-O3M?.@$@%B__!M8_?]BKUZM?NMP5
M_!:P27_7OL2?\_L1H/_!QX#2Z8_NA.M.?S9RF3?]&5 -]YR'+\)AWSCB_<&Z
M*(BG/T2F%E[$IS\/./_^8(61]"T2QLD7OHR_8[".+483+X9O?1+M@0#<,JDA
M]B&=3 /?"DGPU13J\3Y9@Q^IN+X[CFD8&R82#J(P L:" P+]I\!78IQ,24 ;
M\!A)$_5LS!HH(9+FBXKA$_40FY:;EO3'X+C%ESU@VP!/WX,_U15>(#(.8L!B
M\?U=8-LV&X4"+-*$*:V N<C/NLT7Z++D6KAB\O@+T&?J]A!PL0!:[:NWJJY@
M5'N*?R)< *<:7I+[/7 I:0+03P'1+WB=  -F#8#.M\"+O@/!F"A'^.:.NR[^
MKT;&E+A&007Z$'X-)Y7H2U>LC.8&CF!W^ P]C'OQ;24A;>(*+)B!_\$O<+1<
MF!4[Z;5GFZG&1II:KD$$X@UQE+<QM=CTNI@ 0+ Q:GI&J)P'AT#*#B$Q!9ID
MCIJ$(]1><2FR$$HC[FX(]HDMG,']D#FI9:-5O-)9*%84%R'N5>MYC.+"!Z!P
M$BY[0O>1V72K4#\FM:7,JJGW5:P_0+C*/K?&0&](@_ *$'6 +*"<B!A:4#<-
MWWM6X6["6P5(@P!>]%VI>1;$E.DP5=H[\?+C>TSPXE,2]+J02N"[[ Z6@H,'
M 1A[L"O+[[IZ5";N+QJIQ9XT5S:)%RS1 WJ^FS!ANUSI9G8+YBV!-=;-)*TJ
M%IE<&F66T'A*&0F; EH#)KL@'E%*B$0T=O"2HN_]\X?:3O5+O78<GSUS?RVY
MN]:RR6*J[3>V24*P(>&\N&SQ)!-<\QXG>44FOQ9!9W/,4)O2?^HGR:<(7/V-
MKAQ\H'(?Z%4@F_@3?+O^-$J$H%*-W)IC=XF7<S< GVJ\!:8J=AK(S'I[B,Y\
MO/K'PD94A'W%9.@!<9^F3/*R;9M#;'2>TYG^ZDB=DCN9WI_*$.A+-@PL)13(
ME,]*BQ%U$051!I*0D\<"$@IQKM=3JVBCI" (OP&MS(=,?@_>CN?&3BYXKL>N
M<<OS(AJJ2^H3$ ;NQ="J5;?^%7-R0%:(.N^F^K?EL:&V+P,UA=>BKRW%P<K=
M7$XPJC[7T2QKR:&P)]^N1!^HL=WM+YO6X?&5]$$Z;N_5OZ2F=OQM>WS$[^,_
MSFZN,O^T;K@]\&#/_7'\Z<7IS?5I^_1L*:?;J6SOSG&^&8%OC.-M-2K;>P]3
MW!BE4 '-F_,\<:(<D?\>GW6^_7Y^6DSXY4K4:%F#L \YM0-2YES&M$:CV\7X
M%DH3> Y\G)!,4>T02F5PQM]@V,S5[MS\XB5QNS>M;A22O>VJFPYH%EUQW(P'
M-N((O"VT*F=P$#[4OCY/_E2-2Y_\B1ILH/ZR_C6&([@BB+\\O@6]Y[+XS]_Y
M=S>2R4_/Q*W?%[?)UX< 9N['?_TW<O&M?IZ24NTE7\Z\'KOL;YZ L/7OB^-O
MO[<NVL>)U+SR>#0$MDG$YKGP/-Z5"2@/V;V30<,%:%BLDTL6O?#O62_]^5'$
M;GGR9:Z:*D_0GYR>=:Y:U\L1AX4AP$1 H3N4B"[E>PJ*W(QT]QPT;V10L3J^
MB^$=L'(Q9@-^LD#?;/,%DDRB0R>5W)H*862"#9A0\J-0^VF*6#5/8'"QB%JL
MDZL58 7C8=?'L"3J#XJ]RM2UCN.(V0 2F.DX!('C-'**%-XQRIVP$$,L&.FF
MG[  =H09&U^'0EP,NUHHAKSPH;:D$ V%!7%S 2(3?T9_Q5&/[./D'N%#OMKT
MW(16P1[LN+PN4%2V.4422?>B%P9^-CKOM=TO,]9U4$-9*E2CO#Z@U&D@X6L=
MG^LOAB.,7*DH&X9V!F)$E$P!<?B-+P.N,E[2"D8^'HR>P:@P[$VG+)*M$'"R
M>U%,^!I'<>%?EJXTI%ZD&J+W+=W=WZWL[^V]M')W'TZ^F,+=O;U*]9FEGJG:
M?&&E(LC[]R_4(MHX#?E018EKDU?:"GZNPR@0L^?C/%IK^<JBQ$GZQNWE5'-W
M>8OJBM_-N=.==ZT6>E(4_L')8&!65_BCR1NW.G4)R@ZP1GD56ZB4O&TQYQ83
M0J0 PX&DRI$@&J'II_.CE@V_H74R:5=4V90=O65N!,I=5V>#@M>!=M*_9$>"
M J6\"H5M=781769E1<2U1V'LYV):!3/58!!4K$OXIJNIT!KZX%-9E$A'+=\'
M5QGC]I;: EJ_E(H<^*Z#@5QXKPU"GX[!P.  S :J"@$/UP.OV<=3/ 17FDP&
M4SI"B0W+##/)70T?%5H$3/,>0!(AJH+'_IV5)!7@7V!WP0JP(&6C\$1]']XB
MZ! ^%9\(,-H#*I7!@AI:'%L;CRE]AR:1*@2(,UNPP:$(>&R9P0D0>F@;XL7J
M,9F&^%!/*)5#^,B<'V@-0#<3NCW?C@+$@ =&HZ>3O3JD#LL.A;.%F\*$Y580
M8G]>FK^5I0R!87HXK$<HX>"1P&YM;5IN6J-(V@-&>%>E >/8ZH0?9M=1R_NJ
M$HU+2DD_BJQLW/X!21$<!]P=I5%^3*G[F% EV*BW9JD8N$D_J\KHM'DZBZ^$
MRH*YF)_%'=_IM/X8>,#JHMG](0NN;.E"IEPAK;.B+:5G%G^3V?H1P4,VPP3M
MJUP^T:G"9U([ 49$B'F/+!@$%C78 S[$[8-5##A7%&&/;1?P?Q]*> L=F*5$
M"WL.0*#K.I 15D[\K;Q3- V[JB$[F?I ;NHOH$RD"P7( 0-?E>.7K@@&2'^1
M&XH1$J:KTM%!+ VTSZ"@G9!FUG0/TK+&.U^ZCG85 H"_JDUX3/PAFM(ZF=80
M0+AIG0.,OV/83<V1^8W]_?>FI9J9;%I?!:YI=6RA_3'8V2'#2(YUBJK-HTTQ
M]_$DK['*XC(E&PP9!"((=6I?<I0O8HC%#=Q5R??/F2(>RJAEJ3.3@=M4=3IQ
M8<C#,AXMSI #-S69>^!+960M+1_7!/7XPZJA$1NK^KI%E8SFD[/KA,B^_;'N
M@,OMZ/5Y6F.I[ F3)!;]K-_'G"Z(P$VM>ZB&5"E$9%14"E2AB08+9>DSPA3#
M''&-IJIB2K7*EI:19&L(KR=9(M"V7 IL/)205$#;$50@$Y&;[RDW6 52T)B9
M5)>PNWJUNDOU+23F'#YR_3$> I7+CS4X.L@X6 !XPF8C+#.B.J!(N*K60.EE
MGMHD%>LDJ>@F&3L"W(*9D+"5GGN,]8%=WQDGJFR<;@ZV=0$?4:UPO5JO)P5<
M3^8DTE(',B$Z?!0F2S0V=:V7)EMEO<3%COAO?C^*ZR=&8D3A-3*/-()GZ_M9
M]D3&!)C4A"D9923.W0!D T@80;74RM8#L>U-H9R6(H-5<4L"JR?DB+%\-<-N
M WS@Z=SQ-+>00&6J<D^IJ]A>U$B/G0. 24 FC&M]YQ17!-B<"!F$*77'V:TI
MV.IJK[A0*_8R(J*1&#56''RBC6;X58$9&0]M18?>AC1*ZTS2@[+8K*[T02^K
M";C*!HYOHZ.\84H@Z.)C3;'X%7S892[:&X[%NG$@&P$?LY82.[J4T[>8/<#2
M8UT(2K"=X410A9ET%(-,H07 A95NY KI@]_Z" 9E,P6!;RLTD5%#4D&1<+(.
MHSN<:([!%R[9P\$0JP;3JP!*"H*II0PCH:?@PNY3S%$$5QMGB!2]+_I<  &H
M\K6NH*+&Q.%+"M^UX_%0CL<^QZ:JI 6&UR-Z%&YM%@RL'DBSC/=$MU%&.+7'
M)O<$J<Q#<S3!? @4P>?'#AX63!8\#MX$F#"E;>D'"O@IOHK'\"WE&$KPK+4[
M0+#J2D4LFCJQ(EZ2K0K"'CS6J7)>=&.]/I(("FNT.*@,-"O6*]39@<?2Q,*(
MM^>HQ))67K&'J\LM$W,_D09.\J@FFH G%TIFTQ!&U3GYC:K@%$ZFI /?3#UX
M]$ P8 %J#[8%OT*JFO"5<9<J^%"QOGFN^$[+>%MZ>911X3BU+#:13L8S:0O;
M5R95L\!C;=_KJ4L,\-XC4+>N'Z#<2V9.!=:']E$K^+B)'HU2W5A";MO(P92U
MV0+# %,.%&Y!/>='Z(2"(4)EW[&%'"@GKH<]LE490[RM%, J,93UR1)NIHLP
M^MJ+&VB?%[:!5[FHR#91#LJV853@FETZN<63K8G[B2(6RIG3US%F";M4!P6
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M>?9'4LWI3-^31@D1.UM(A$O.Q;ZP"7;X('*1!_A2=DS2XR32-4NJ_-,:>,\
M;S-6+W$#Y"G)MJD5*Z@8=^)*/4TF4;I'10>!D;6=""I%V9H1WG3Z.YV7,7VY
M;]+%HJ"GCH)ZH<K\Q-ER[1 54(<\?><RU239.K!-A(7*'&D=#H\%UO9^9?\?
MCZL:8P7=S;-73R>M..EW([QW> L@=I@**(+)NY4DNI0W'E<K)#^FFIB'%)2)
M+>B2!XQ6H&E&=AG5YP61T#WXR;X"TM_4H0=\#4^(L6)]50&M3,P$7!5]^3=C
M8^EK]71U1V?PDHA#LN%DL,)$CX8TY.9'H0XAJ*TEG1,RWGRF@P7RE2X=BD6B
MDH(8TX]O'>J$9[('M Z[G.(1F>VGK4;BJ Q&^\E=PB8>?$26ZV;F&C*0QBU9
M-+J\Q0-:Y)220%/98RIMF\+Q)KN)M+@YF)V??GAM+"M+$@4 ?!0,L#<+707&
M<!-28WS] 8ZBRFRPW<'T[<N)?$MV\3ACG8'Y [F5N8.J7G;+;-U*Y*O R06/
MW)M$OP\M^="GM#%17,9Y4P:^CI4Y2;1<-[5 ^:P&'3U_MSO+8$3PL56I_5.N
M+ER"^,'[67@J0)Y#<U#@F9AHT/%482(^P.2-YD2*]**'$\]@V,P "SY/^'@&
M1V:B$YKF8M@L?"J8*0E+*CO-Y'M_Q5MS9/853[2?/FP4@.4L'CB-ZB+J0!48
MQH'$F$KCLC&=>B%2TD0V'R'K:XY N< R5,$=_XZ8!K6I+QUDUJ]<NZFAFK9$
M88*[=*!/5O%6K%9 8?*'=2'QC" LP&3"TV=+JO@RTB&-NV8&*+V 12?U/1UM
M8HMQ5)A</)+5E'U-[M6I4+6;&:J4P@17V53S9+KCM @*5OFQUL1&*ZZNC>;Q
M:!,J>*'$C=8"=.PI=X4,;])D=WX6)G$]HS[#-$8(A5ZZ6K8N/BTJ2^9.4=0Y
M2+H?.>EKI\FJ,HFLN 07M/D(2V@G&U$\6&4F?K))PAG>&O8.2C)ZU_\Y:_WW
M6/<72G.):2MI.OGOM=I.HB@VK99[ZV=SC-E[!)O 93(:@M10]QR)64X]@&;R
M>'(+@=8^Y]X)\E2Z/!MBH1:U5HK[,F&@1_15M6OJBLZ"9Z($J0P@4T6/B%57
M+?3U"N"@'I5;>7;4C<M.L>PO)705U\).0U3.1Q+#\^^4$=7#73]@IG'2A2U!
MUJ0@2&PK1+#?ZRGW@F0#K:_H@/HHI-:%OHT1A%3M]8?NA11/!II]3&(NW9,E
M*W4RC/RK3VT<X&"GGEV)YSY9U*,E4PB;O8*M"H)'>B!C>B&3:OBR;5:2SE_9
M<R2<$4<,]?B<8F8U+^W0?T2;,"\CD!'Z/S:JB="BGA"J9)I9M<8_IF76HY/H
M_#LEHB]OA3.1-I^6WZE(>KKFE$I??%@!7\%"[-"=_*$\'%UPNJGJ8P'N6Y0X
MV=1^]I"C\!7!D&I'%8G$5B$0DYJ-!:)(>8ZJ81F93R!])8U&X" :P**V+3Z"
M@XX"@3>\SSA \G[K*X.-8,/IL>< -W'KP]G7SD<ZRA$&?--O*LG:$V8@=5[[
M*>VY]D3#-5"UD=1%\RB.J7=!$BB']V9?2UW/X0C$*9A<$G#@4.=&DG%TP6:F
MMC[RAO##I*96&:W@F8S G4.!HI)-6#H\65FLJMO1[0&'43E;<5E(<FCJ7! J
M=RBT,@,99\T9I&+8+)J!5%&W"/0?2= A06]7K-/9Q<L 87!A/.WL3A,4P2ZA
M7R!'K=YL/5*P3[*-WH(46\CTSNEDURK%^]AK@RK<?JRGG#XEF6^ ,R1EP;+,
MNXD7T94D3IH<)<&6V+2C/@*TQG]/C\^.K \A'P'0HR'K?JS$'PIE/JA2=DV\
M6Y2V',<S)-DHI9\TG9<452OM-![QK1HLP+H<B>C#3>T(7G*J14+[J+'E4"J*
M!)UVJ^.&[[0J%OBHO>/HW%#U7<&(>L."M:COIY-,K<7<SD"X#CB88 ABB)FZ
MGJD*>C(QL4^JVII:I8ZK)*?&F@Y-D532]SUC M!Y5<66GL(WCDLI=.W'OM+*
M+$C!,OG,1(.R+*B35"G&(!GH<I&9<8TL]6.]LI_T59M6TO@JC_X"4SF^XU>)
M%TIY/5$IE(W%,OO$L-!;N;J^O#ENWR1W T+,D"1#$0>D--2CB0F6Z@<LR,$&
M-3J&TH_-R1AC5H(Q>#]UEF)]CR@]Q1G:Q@Z0=F GURFP*:*@-"1Z\2CGHTS)
M#;[,K)GKN/"QUW?Q++^!^X?MQP $Y[K1:IX!\(0F5,L*%7),.E?$\>J85V&'
M-I_X">F.'F<Z!J2)9B)<(E2/%9<!I0WB:$[6;NNZOOT=WXLU;6D_'"W;A;9,
M6&(#P[*N,L8!7K5_8%D/J>([=>\K3*_RJ>T\-I7@'0,>N]O_B"_?ME)6+:1R
MFHYS4#>KI&D+JF(9IM(.-%:M7JDG.JLKM+NJL8MW;F*'/:X@B7NW]"R"F/(?
MLGXGO-QA?\.Y)#@"+K6;BG\T9:K&H]GB^2RS*B;BZ'/JQ"+M9GRO3)?-"OKO
M:N0'[>VG('-V79&>)=6L)Y_9=>C372RU^UJUTOA'Q3I\ZNNG5,AOS(NP@@GM
MJLVXHK@KJ9J"#8D+XPEK1;2'XKW'*/R0PO'C+$B1%3'I3R2/46MKI:IC'Y%,
ME-B/ N?"C0([4I%XUA=^$ VG#(K4ITCL&J07,CK135'=NLFJ4-%]1%."NO@T
M:KHXUXX.5=H\LR/A]9(+8,DJ$S8963,XH#@^+H9O;"G4B.S,V9,RMDQU%O:G
MU^?9Q-"?^@>UO ,[G:Y#6.@P@#N$/1Y##!"H2ZVCP3@ /4;,X*.SPC?3$>WJ
MK=BO/HSK0Y512-$0W2@M!G846+<"P_K!=^&E!U[?YCK865>5O%!LM/3=5@J_
M<45NRLA,(GQI\)U4!6EGZJQ''6WTM'C@(6SZI"^DSKA7VTXSG,D5S,F6@,G5
M5N[U@<RQ4%QD6_]-%"7'M>E4+7F?WO](QSMHS1D,8,EXRD.87)]*.[UF FOS
M1L"6,G)DNM7!(_>!)E.Y[3B4T2'E>Y5<[+J*KTX8/+!YZ@:Y2F=.C-O0UDJ:
MXD[;=$\%Z'34/R46'>7,-/9.\KY9&XEJU_>:-/1LO(4M-1Y.>5YR:A$QGU-N
M\3I;\Y\AK2L=_7K!"4P1:*J/0-H47=5\Q/<2L3&N'MH3YQ@U<4T27D)<\_89
MU$A\YZE=C4JMVGCIU"YP-!KUYD+&=M4:E>;.8B: U78JU?K^HG:UM[.@I?8J
M>]7=A2U5>].(,TU/U*FJ-@KU)2YDJ2_Z*YQB.?7-$_/#E'WV8-PE45A.0\2T
MX)EC+MK*G%@IF1*=.!-VMUI@AI?HZ-<ZWG$-MF>)CDTE3,G9]?">#S31@\)=
MF0L1SP)#JG574_P=!ZJ%C*.:#6II&(.,C$HU.O)QX#VG0YC]O4]3(K;TH6R;
M\U[ORZ*5RZSAE.\$VP>&(<$VOH0_#ZD] Z2"0X*:$WRZ]/Q/AQQ'"LPEBE8;
M)&U,",^EA%<;#K5*\Q_6EM4 &_;=@9&K/)X-CA\;S<K. @"Q(DKK$2#5-IM5
M\$3?IH9Z])^GU%"1^$@U>WX5Y6A %.FT6,U:EK.^05,4\+1G_ET\2\P1?3&7
M8_Z*<QLIU1J5YEN.^Y3H+Q@H&ON[4[!8@I=1)+;(%MN_Q3PHTIGUA8.R'/</
M?\@Q5?\KM;4MRZGKS7]L;5?_\<\?:GO-+TLZM(D2KE:;LE\7:.<7#!2-W4I]
M;<IG8G*JGV)9++ZX\^0G[#%9ED.7RZBOOS*X4U [OCHES\IKQS=KE>K:C$\!
MDIG/518#C^X8E^6PI[HT-@IP$#->Q"K+R1<2MRFF*;^]MN0U)'::C<K^VI3/
MU-K$30_*8NE-M8$HR[$7)/<+>/(2Q^NWU^'ZV./9WUN'Z[,0>3"2?,6M/SV2
MO2S'/>VW8*G10/HC%@[&93GV_IM*= HFT^J5W;55KR"Q_U;AOEI&?3(UJ2PV
MGIHA59;3MIETA'_+ IQ649I3E]B.KZWM^#A<7WUK^&92^\57%6>6H19=#="L
MMP68"+.!5"1(_*XF0:QAL8:%*; P4;I6%^)1/"E35T$)U1M3-R!("7VB.^NY
MM#;8FZL-P(?:1PM[]&(//^P1' HU[QBG7874%$3WXJ\WJ3/:7Q&3(4XZUH\$
MF=YI/S8JNTFWZTVK\=@O^C1@6<[XD=6-PNR"NY7T*^Q>L5V=:\G,SZ@S:&:.
M '4GOF4N#8RDQBP#P6^Q/>CTHI;JU$VM4YI5:AC^X+WS-D+!KCR:GI4!T9AN
M;;/5R*]S_K_X.-,19;*]!34">667KW<YTN.S4=+F%LD@"\FQAQ5VL1!#[&.1
M:?.<;8!"L^ \U8OKD>87%>O$EQ,S2UG7C\*IELAQ#^1(=;*-.]*I1H8!SW1:
M"3BWL.-EO?HE:39"?]>^J-ZSJGDB4&S2#"AXK)V5:6,;:,7Y1_O$%U"M#W0!
M<].Z]/Q-ZY +;'!?P#D](%V#:#1RQYE1MKZ:?$U4@:,/J8-3>G";R9YP__:'
MHJLZ2,<M8]6O& T2T/,== ?F=/RFGFVC1M+K!CW43TIW)(SGLJB^Z.F W4JZ
M 4'T.HS<=)"+:A.5-&5-CY*V0-3M-9/F=+K=YS>/A@!U0FKR'+>E2[ASWLXQ
M.\_+T-K>2Y#\5!NU!UVF9J.6.'0G*0!_?^J:A @V=$$(G-)@8AS71)*)\.?P
M>X9#O%E @]-! 0([.D!A#C;]CX+I!QR\MA$-L6?SS.]QBFKF$9J("7(KDKXG
M'&SEW!.#/_74G^D?B@!^=R_BWTT\,+MOX63/9^S'-PK4W%?)>S@, ]O+)G.<
MAF/N F2MNX$>\JRM&X=:*U(O3YR3H(88)7.&7M38?TV)<U%B*Z#A$!2@8WU$
MYM+1BP.]?/DV[!JB.2Y!=D]-FU$* ,<H=W' F1PBDZM6;%Q0BTSLQI:T6D;;
M1C7^1!L";3ILZ&@/$$K93K.HACQ!A@:-+8'EU)M4:T%J4GLG10AZQ/*P'S\P
M<A!U_]0J)#9L@DC>"IH.X'?!)V.ZOVBK2S879V@ZQYLF'X$F@F1.Z+KIH:P(
MC#"<WR$DRTZ<2)>F=K\ BL3@JH"R48-&4 _%ZV8:)H8B=)5)%CL\VOQ37823
MB0>3 RA2;9> 4?6$GAP@0$Z*%]' A$S7Z$2K=FG<&!XDT<EZ6(^:84S04BV'
MX]ZF.'4D.TB>K-*)157G=#P=X$5/.U$G),C%\[KKU4:CB+."U05QZP->G<:F
M\9F)&$^,!S:6HT$S_Q:YU%RYMDG3C::F>GVK="JZMSFB68T\LCXPK,O 9I_8
MV)I+L)L$#GN78]A,B#/?K0^9$8T?M^3XSONXB=U&;S&6!6\$0<JE5)3! NNW
M_UYM-_<JR4PE149/M86.0+:J;:MIDIF)D/&&UHUU=R=!8'!CW9P88(*0(QI"
M@M0T(=N84O5;RF"P@;S]; 0'^T</^2,MMYF-8[S<\7 T #W! OR!RZ/OP"(,
M',JS,^5/33U ?X%%\>'L$!Z(&W0_U9][""<=))VY4U,D'?L[&(^X#'">(U X
M#L0"QCNN8.Q4;-%83SI["HW*<FRW^<Q':]DC+EXZ!N"!:&0JMG(,#L:(,]6%
M5:CQ'Q^.VQ^I47[L):MA)S2D* H'OHSG_2#%Q )/S0]+QJ( %1Y[DI3-/W^H
M[6Y_J:@M=#FXO=2!W\6)1+%HUN95@"/K -7,I:EEN/4\L5C)%8LM1TV20@-2
M(Q TA1I6328A6#T/YM5-3J_&63,GN]M-T/?_O6ILUS[BN"'7!Z\"&T_#&L=:
MTTR(D9F" %A==; GHQAD" OQO:IO/ZD'YMED,M).<?A(.O4CG=V@=_=@(AE7
M&RV@4W&6S$'A  6!?7@SYG TPK]^K#7KV;&5R5@W-+>'B=VJDP6N?[>5+<+(
MF,2)R?O(1!4<'Y6,$),\0+F/O='5U""<VHR]@+N^U/Y"VI!:&89%-&GC*EOK
M@ZX__5C ,1H@LI4[5Z_6ZLD0UV2L=C+/;FN*G_#DZ PR<MXT "8FC%623Y.Y
M4HE_?S)+OCU:XO)>L,"!'+;-73T^-1D^AW+IY/2L<]6Z/K4^I"?_.%MBB>$P
M\OR^ZW<C>(?5 DY):G6M#Z?]UL7'2KK>[%$=#GJ?W'-0ZN$B:A1L7V"[=V!1
MZ_24@#D*<?PL3LGP/:'&R63%,$U\1Y?RNW \/DY&"\81WO3%.(1<[1M#W#2/
MZS9[K'30&JZ)9TC1FQW]A_Z$:C8^ OF>CCXC+1^&7 EY/>$JTWB=/OXU A1:
MWT 3?&C_>G[UT?*]QP9+TCS!E 1GX@%WB1!1ID:LZM5Y=090*_OMBC6I].*C
MT6!'G)A@?R>BC[I#G'6H\@ 4DX"](/4=X:265NK^ YE<'+52 @'S D>E9&<$
MQV. R5.<27>(9SP#3F:.W/3T+U96RHOZ,X(7]L:F2)Z$?'!8LQK8CJ?/3'^D
MN1@JHD1&GQH8T]=@!P8#+1ZY?F #Y,"M#*P/)QT<U0EP4VYP[/:BPH^\>%)@
M;(+&H^N.OEV='?_;PI&A8ZV[@)!=U))Q.":(<("-H'GW/F'?QVE6 #/ LB(+
M9<+2.&C/PGW$/!-_G)(KC=%F^E4IL8U<YI%L15L4V^"RA"9A3>:. Z5K:7$:
MRJ>">O'/)-]2$)L<-HC3GXC?AYID:?Q6.@]$<E^"T(]MZYA-<%[78(I/&FI(
MN!WAS!0FMS#$A\> 9VT5-U/3%_L^$G8BXE);FP3'XI1D[AKC6Y*: \;/TV:G
M1.%4B%G3U9-14QH'\F.SFC424W'[T%S<1 ?KCM-@-:"B_7^DT_<\,@+U7)+4
M3"03L8CF7;;GF77J_:FR]$F/Z@_@-U3W/EH?=)^P3RV'P;\*&,O\@T].-P^S
M!Q?)P;5YG\X2?W30>69$=;4R,:@]LQP%'VG V:1M<:NJ]C"F%&3<A ?:W0]"
M[H,8)L&/TUQUZB*)[N!4,C@EV*S!=UJ9$E! G(]N":.F:=P'RS.4L_ODX/OG
M)KG2M%>TX&S;EP[-X4T@V*PV/W0_?JA_S&H]M!/OV%B/[#NYO+XYOHS'PE'P
METJ>-#8J%N:6'DY$UJ-\-BU-G9OQG$TG'KI*N,S$@ZLST_Q%G QXF8XRRIP?
M P-)L058V!,N3NK73,8&:!0Z\Z*>HIQYV&,6%"DL#UZU$A&TE:?>JI<X_K:9
M4+4-2BZ4>F@X?GDN' =6/&;::[CP45VW>A(HU?IP?GS1^KB9CK#$49/ ,R25
MK0_7EW]\Q&-( 02':W[ AX#\4-,[O"<\'<YUW<R+,\/]XMTITQ5>@N_;5. E
M;CV'/=-8V_8 S/Q-ZU>P":Q_P7]M6AWXG@'?@EXZ9RX;!Q@%\G"R/!/X$YSY
M#$Y3U,>!LTB7FX^& ?5TL[A<Z_@;\6'B9$8ZA8B"@V'  J=>G@F@!W'+XB'0
M1_!T'*XD%N@P.(+5DJP+&TN7H!\? NUQGS:8_$Y91G72LID\+DO*=Z:T\B$7
M?^)1_@7N'/ C36*.XUD9J=+V*^"-AT[%^A _^9$RX+R+1FK__['WIMUM&UNZ
M\%_!RCW=1[XO28O4'/?-NK(LVSKQH+84)YTO=Q7!HH@8!'@P4&)^_;NG*A1
M4*(F6Q31JX]CDT2AAEU[WL^&#39LD<AHGHI(/N&*[G$8I 9?F.:A:"06^4K.
M:UE==2U/ZI,79$*P:0[J7T%)U<0EFNDJ<IJ3>;8>NZ%^6:KE0481J_'7B0L.
MM-DTK<G:[>OL$ELJ8_:N3:"M2625$#_&!B.3AWAH\@\7I<\ZK<I- !$$;\*N
M AS*&P)SH.398%@WL*1;.FFX*^A/77"8R.>0O=&V ^></UUBZG2XDLY1=[Z.
M+9=/ADD<,=NN<<C"L6)-6"E?&@<F.WG!Z.SMW66B*-&0B5"1)];(*"?I 4Q
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M.";B)V&+CN>2$.T=[JF[@47ZE!/7[2V[?91Z;[9JF<T,(O*33 -,@7/VP6Z
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MA*/D&F)O3)^TK;!T6C6JXW$8P%91/BIV8.78N@U%'[WY=?OEKN,?5GT]5GX
M[^]3EM+?.@IBSD9[(4E@K(0-\Q W*%%RONZ#:$@GFAMBSW6YY*Q)L;##F)F3
M&DP5L<VRCGS\Y?][^?[X2Z]=;B)GP]7'9U^ZWCCG1+HE^QXO\B%1:_)_;!<Y
MIX&K*]XJ$NEXE*Y7/6WP<15]=TZ[(HS4.)>OD()!5LT!X=Q"]/N6;SCN:N%$
M6=!:^[V.PB O6L\7JIO<[);3JEU73@J6MK8:4Y5-'(V 22QS8<R.4\JRN2K%
M.<D!<$R[+Z=&!U)Z(UE!&3)6C,)<QO."I&UC+!MPZ5_4WGK'AC(JAV&U,XE3
M61),-*;YD0Z#_6](^%R$<1^O,LW9X<R8;T-SOHR3;V5"0Y+UP4;'H ?W';:<
MN2)+:MDX53ZT@7>P8)C/M:=S0**E[.#2GMGR 7(@PN^HXX]1N8"UI#$[KXOV
M5R<ETP(5T^)*<A!&\@_Z8.2":A<E< 6M=FQG7=?*>Q6-U@)\QMLHP;*LH/6*
M6HXA KEFH*V45N5]U' _T.-DO3<;17<ERL I)[+">%.3G.93?I *TQ?5RJ")
MW47T=HK.1 GW&6P6IZ.#7D]MWN0>O'_]U7OSZ1 H,P2)B&F^+]&;FF"/+(Q:
M^DDPR10Y:JW>8=]Q0R$,CAU$0^Y(U_&<,\:L59DWD&V.>9FB)%IUY[V>O D2
M*MJPW4H[E5UL\E^ZO2;_Y8;\E[Q/D7?V)!4WA+*G@7U^5#-AP.0MI70-[LX^
M20+*'\;P0@"3$>^KN=KH+-CX]/'T\$5MZ$+9ENS, Y#$W?3OH31Z?Z81"0%C
M77UN7N7D-S)RM,.Q[Y[#EV4S6F3FHNV23K0?@&78<MB<PYC]688%/#@LJ 0Q
M5V* :+^1XU*-98R!"NQC",H8:-,1[ '3-O;XY2I,G])G,$TRMK_IF&G.%61*
M>9>CC*X!O5]/W=:0/!5#\JGWZ237BRF49/YF##>N 2M<,RDEN'#SWZRVQR6F
M^*>8.%MZ"@@1G4$Z077^]C6@-_:8Y)RJ*PRN%4T]<09S,RS:C2+/MNI#JZ[U
M:&3;E&*?9.-12%_8YI3?N8WA?J>WMW/;-H;=@\[6[L/T'NQN=7:Z![<::O'G
M.UOU+_D.D_HNZSO8_6&36CC4?F=S9__VO2-W+8K&@[9ZO#MCJRK ]9T>S^WM
M_M]+ (28I6WBPF2+5GT'SI"/K>OBI7-V>?GW1-IZY :.#[8C"V \0?#YZB%P
MIVZW#^2J>TH;\9\7V:M_= ]V.IOWV8MK+\W:T!08*.(/;>@*Z<K[1[<AJWOO
MY(,AJZXX1?WC8&>S0DYWA<9;H=,W>;J/A)#ZY$Y9^,9>]:CON.1;<XX5I)#[
MR)R5I9#]AD"6W;!_J;__7A?B0 R(^PJ)IX2CN]RJ/YR?OGRO)Q[[R%^^/CY-
MXD>"$'YR)\[L8&OKKOS@@53-%:*6+];-O%XTLK_9T,BR.W:.T!G)8S5.?7($
M\H]U-"T^'1V__(QY9.NB'(AMT>K=F1&LG_)X9(.0ZT4E!PV-++UC:\=$_K&W
MCE;&.8)R-7Y(CIBT[LX@UE";;"BGH9R&<AZ!<D3L5#*ZN]N40?>#-);F^2?R
M?'U'F_HL4:SY>C3:7I@579^%^;\/PY 3&P6&:* )MEHR9P5!>:BE4-4OE=U9
ME)LX*24R8BG4LBFS!S\L9?9M#DL_C9-L"(PJ]MY@T5?XY--F?]?>2"&:8)KJ
M,<%!.0!_(1;5I!DU$*%5454>=J8HU>G0PT7I/2PJ3[-DYEV. G]40%AS%7.<
M<*)K3*C4>20HU9BB*A"=%D PB#&UM31>B.FZ7 DMY<KF6UM7DZ>"]*\QP;NH
M<\-29!@D"=)O!B[?'I8?1VF0,FZO+(8G7Z2)VW1A0Z6F4KR4[^TD_F*Z>^Z7
M*W M=).@_-8^0+5SIH0;]P:6F6J9%Y4-\XEAE6.:*4XOMPG!Y>XT)@F8UT0X
M$#5+(CA,K%/%@6P.M(% M,G'#-0@5>QXA2FQ6A+;G4QWN+[%IE"E=SUBE23[
MQUA+6,[<QJ1G^Y!3'G7;VW1#\Z^:I[YS,G2OL]_=O6TR]-9N9W/G=IF\"X?:
M[&SUMA]NJ)W;Y^4>_%39[KK.AM>UL+N3GO@],SUO%B"D*1X*),FMG!,W;MG*
M;XMDP'J?U'BIH,9S639SQ.57_*SOAM,WP#M,M%K"DMJ_SI"ZS[6Y2<E_H 'N
M>)YE$V)]VS$?^@FICR^/#L].UJ4I\_$T'NM0/8#79>6;Q3+0XT.V8U[Y&Q%.
M$>;DY>% P=\>*>CSY%9]#H]AM\ ,;- 'Z+"\\O?B=^ 0T3\1?@(,M-%#EA4]
ME_OQ/O@V5B\_J>@O]#'\"G^TWR:!C@;K(D6^QDG@QY'Z.P[OE4;T7*[,B4"\
MY*EI7-J(%>?:C/'2O(:/=*1??H[61K+\.@-[/0S21JH\C+;UO*3):W65W3&U
M9@5%QB>-JXVC1E[094@&03Q5J8\@-8VL<"X%PO'<38]:00%QKOOX8",?2(6R
MG;%??M29ZL,Z_$9>.*Z;(%7!NHB+M_]S]/GCZ6$C+$!88/]D%<)PR10MC+-9
MFNEQ(S2<FX%=K^_FTUQ!H7%\]+%(3&A$QT^_$  A8QP'OG[)RA5F S32PZ&:
M*QT&5T'Z\HT* G\4M,]4]&WV6)6D3V[Y'X,HTOW[5<X^E_O26!^+=N9=@-TT
MUD60?-7?POR.A<+/3(0\M /W><F.D^A"1_G=W)BK*"L^M+O;W492-"'R[XJW
M\N36^F46JK^;D'@3O*BUN>"S[%YY1*NTW-?J:M"D336Q[B7N181]UN_FIUU!
M&?$V 4,RHPXY=P/<?6Z2XA&<M<]+<KQ5B9ZNC>#X%%^I81"V3[XVLJ.1'3?)
MCL3_MBZ"XZNZBG1.?50;N=$XH&[BHM/[X?FOTF+/7O<V=QMIL=R=6(B L#[]
M#[>>:O_#IGCZ"11/KX_ZA$("9G.O;.M56N]'_2V(@C1KU*?&05M;%+\N"M-I
MG*JF&JFQLI>DEB'\^+$039_<:M_D:JH;"[M),'_<F[&"4N/K4,/\&[]L(S%N
M=,B [;PN\N+//$QTFC9YY4TL;ZF;$<7#M:E).O\[T.&],!Z>R\VPZI/7R GG
M-NA!G+S\D$^">Z5"K-:2TW_G ?#)1EXT\F(9<DGRL7<2I5F0Y1E!T9Y$@SN6
M[JV@!#F-=#Z.T^ A4.]7_KHT1L=WNRHK*%D^Z@BF&ONQ?\_VM\UU60?)\K@]
M#9_<<M\&N*[D7J;7<[D8#^3+?5[BX\_9(,=N H/@CE4+*R@RO@;3 !3P1E@T
M\?!'N! K*"5>)[.K3+W\<_9:3QM)T92S-F*"] 65Q), V^(TDJ)Q6C628P%:
MT'AR5TRM9R8U'B-QI)$BJRY%OF)ONJM[U?FNWP6I%&=T=V[NP//CV^S<HI7.
M;=9WNTF83I[W6<B28S0]V/CT%G3=&JE4>ULO3X,IMB_VXL3[HB_RD*C?.\O[
MXR!-L2WC659-&VHZM36=VII.;7?IU+:$G+C;M6DZM:V"@G$8#O3LCH[=%32^
MONA)$E^I4$T:\^NG7SYGP"]>_A8-@M0/X_26W4^?N>7U6D<#]>5J78PN6NXX
M3[/@CGU$GIGE]3G"-S5 UQ7W;K!&8*7O5*1 5F#W]::6I6F7T. ,5?UTW>[=
MP%2>F:C@U%-.I_/4( ^S1F@X@G2D$N6=PI]CY9-IJL*U$2'_.GW?V]QJ9$>3
M(%!S,29@?JU-4.?SZ7E[:[/7R L\^%$V4N&XL2^J&Y-G81Q_\QPWYMI(BL^?
MSMH[F]W-1E8T?JD;T(?"J0[7)QO@]/R/]F:O$1P/?R^>E_ XT\DXCH*[.6Q7
M4&!\4&D\C*^"H6X:/S<&1NV-^&_O)(JPB4 0KTW9_-%Q^VV> ',<!X,FD#'7
MDM ;- 6.<_<DC](1?.I]4-_6ILSQ:Q"JO^-!W B/)K*Q5!4PW(W!VA@=9S%,
M)=1IIII*EJ:291EVJI,X6ILTJN,H1;LC2U!J;GPY_;"SL_VBD2.87Y9.@H03
MEAODE;GM^2/X)[STCR#*XNAB763)::(&>AA/@WLA(S^7&[(<ULJ:5;-L-<4L
MSRT5GXM9>K?B_DV5RJTOUHHLNZE2N5^5RFY3I;+.UM6AGP33._JP5]"\.CSZ
MTM[:W6\,JB:J4T,<D>[GX;U0Y%=JN9^.7[<W-[N-[=2XX9;8H3B9KD^!RE$P
MC-&Y$-T5<*D1%L]<6!SER1_K(BF.CMOG,7I?QRIK(O^-N%C&-3N*=11<>>=!
MFN9K$_H_/?_2OJ-"]<P$QCL=:?1"-*&:NOKG3"?1_0#B5VG!?P9AC/,!\=%O
MI$>#<US7DBN[F]F]@C+B['5O<]?;^)>"=S>1_27CEB\SU0\U_'<03'_Y+_BC
MXL7>[G7V=N!MDS@-,"?WYT2'*@NF^I4TJ*<WN0]**&ZS>$3U80/S;/$C<[[_
MY3?L, E4N&";#F[:I1Y.I+MM=X7VP/US9)WZ$W6AV_U$JV]M-809_JS"2S5+
MT='M+&0<1.W*QE77S"O[Y;_Z"?K(YU]<W98@ F,Y^[FWQ^$$/*V*HQYV)U23
M5/]L_O)J$*234,U^#B):+CWT:JR2"YB>' ].K4*K]#K^6F9]T.OL=W=QXL)!
MY<6RI@ZLZ>7\YUN[G<V=;NU7FYWZSQ<.M=G9ZFT_W% [UPZUYNK3>J5+GA_^
MVC[8;WRTC=KTL%=A!14GN@J]G49E:I+J'S5K> 6EA)LUW(B*GWXY3+/1N#;[
M95U%Q?IFT3?R N0%R(? ]]X&_02LW;01%&ZUWK=@?3+FO_ZZT^LVUL0C-4AY
M9B+C[C=C!47&UU][^YL'C;!XD)OQ/"[ ;6NJ5FEM'U]O[G6WEL)/?"9DO=A]
M]"-*HNHK@9[,Z$T%TLT52-T'8HG/9E>:"J2F ND.%4C[U[';.UB?]V>B-[ST
M\49NBIGNY_:;Q#"]=;%8/NHPOH+)+,5ZGKO1\C$ )ESU]JVY:^LP\748KDV?
MG<.C#W\T]4Q-K/SA+\,*"@>Y#'<#]WUFLJ$I7IK;D5$0*>^+3N,<KD7JO8ES
M3-@[2M3]XL<KM0=_]+J;W<-&6L!6?/YZ\L;K'C3RPMF3LP_K(BM@J>VMWG8C
M*G[ZY60\SJ/X_MU#GI>X^)?Z^^]U$0O_^O.TO;7=&!&(@Q]'%]ZAG\%\O>/D
M,H@"Y1W"1!)U >I#@W1=(IM\$F0Z\5X'\5@/<%:H7FF5^*-U$2-? Z+X1HPT
M%D>-?^[X1#H5KHL@^7@,<N1N2M4SDR.-,^KAFMFNHESH=O<:H5!N9MN(AF)?
M/L53!;.Y&[;4*@J&DU_;N[MWJV-J),,SEPR?<C].[MI4:@6%PZ??CMK=ICEG
M%0CA07I)/2\Q\45/@Q1NQOU[V*Z@S(#%PR6YVRUY9C*CZ?&\$$3G8FV ULX.
MWQVW=_>;>HVF&'R)'5H_R)#>]E*E'<]=5C3VQ9PS1EU=J;6!<?ZDHGBBLOO%
M8)[+95BN/]1=><6U)4<K?VON722^5 .HE=B*7]N;O>Y#Q#6NI9B5OVTW N N
MA#2LP=/C9^>Q^%Q,OQ)NWJY][.'6W;NI *C'+9_',)69%P^]5(? </3 FW")
M5.JIJ0I"P@8<QHD7!KZ.G*VY<4FO%FS-C13W'0Z]QRS60Q)%.$DOB[T_=9CF
MTW'00G^.GZ<I[(7JQU/=\BZU-U)3[2DORL=]G>!^Y=&$2^C<+1O&\"!\ ",J
M[S(8Z':BH@N-O\=JER@+0/6'+0&ZQ]>F7FP[D:?P^VSD92/M_!0W?I@G\"'\
M3D]U&$_&\)5GSP,OV/V.Y/NB/^[O=S;WMF^+_KB]W=G<W[L59./BS[=W>@\"
M_M@]Z!QLWPY'<O'G>WO[#X-("5]L'=P+D?*!:U]_(*]_H!+0QVR;M@H;]L9A
M/&?9DGZK']LP[HEO:W>'_!S)A4:!>V+E ?+U!]'VGY<9?'3</HE'^BJ^&PA_
MQ12^==7O"IK2=5U7O_-V/1?3X$V@+J(XG8M?K;F7]D,^AL_22=!_^3Z='&P"
M%QL%_2"+[]7=^[Z5^:NT@_>YHP^T7<_ECGZ._"; ."\TSV ZB<*O6MYG##H=
MQ9%/\:<[-@9;6TEZKRY1C20U=L0DT6E:S9=:<T%Z=/2EZQU&8%?%49#>K2!C
M':5GHGWX-*BFYS82M)&@#R=!7^=I'@[5@R1XKH6TO.>M;"3F(]S*9R8OC]M'
M.@N2X&_X"JS.ORA,?K<;VLC-1F[>$[DG#'72B,VJX0FCCE421!3 Q&[4/@<S
MQWFH[GQ;&WG:R--[)B+GD3=0XVH(:\TEZML/YUO>KP0247AQ'Z18HQ&HC4!]
M H;HL\YV?'=T]M;[HGT]@5OK'=[#B[3,ICV0)%G]S,H'DLP_;K.?"\-X'<;Q
M )/H:#TU,=JF&W5WIYPB^..[43^1)-D;$W5H^SZJ*!\J/\L3-ZW\WOFOW^&"
MT/1_U\ T,.CG9YQBJKQL%"2#-N:OSKRQ79U.6M[[> KTK%MDN!VI20;W*L3\
MUD%.;I:.^8473S3&$5/O[9M#6&4ZX>QAN!#P&5A^F,CZ6Q3@9V<9_K#E?52^
MREO>"5ZP:.#A_T[C),LO5-CQ2KLLHU.*;&DF*M$>?(6F).7=!FAFAC-/969B
M_TSMH/0&\S88.PCAMNJTX\&6]'48Z*G&U-ZQ"J(,_N>I@?YW#E.%Z4_AT&).
MC+;OSF)OK'7FQ7GB^7F28#Z<Y ![D=:#E-Z7C13_Q#[GJPF\&[;Z,@A#>+&7
MYL-AX ?XO!ESF.,!E(?KK!ZMG?"YZRDE*0^!U.PNI/ED @<5(/-+\@F>+256
MRXF.@PQ)!?9CH%-@DW@,L)TM)EDYV__\7_N][MXKV.@T!2T'Z\5:'AQ9& SA
MJ) H$V\<PX JA+?0&/3:  1#QSL9TN1J)D(7)(ARV(B^GL5(F\4T!CB](!ZT
MF%9F7H:SI<%Q.'61:(VYD?""(J&\Y05#>U5\%45Q9EZ,M)$ H04)/9:6:&R0
M:]P#.+D\ AJ#EP.I^_C>OS02".VLG8D*T]B+^T2\=HAA$H_-'??XCB-=4@+[
M)-%3K"G"]2.M!,, [VSNC^B7>#E6C^C.X13,?<2SP0TMG4R)AKP@A6]!7;H8
M>6] ;:9\_MYF;[N#6 6EA^"VJAP6JTC9@3V#5\"4D2'!EOD8RX8]S2[C]DRK
MA+\%KH-S2.'\0OB!IP-*WN=SN(#?I]YE@K0>>4 3@4^U 4&6$CU&IA9A 8G!
M(QZ-"DPFPA=[^.(4^2#,"9_#RW<U"1)))^6- #65J@EX<\H3K5!M:;K7$#MM
M GYBR!0V2:.BXJ$& >0$7_=5] TOF#\S$XF=P>$'L :@( T$5$OFQ*=OFH,=
MH):_)/H"/8[(R17)+X^4.V8T]L; ,#PS%&)\)6@"+"GHXL3118QR">81C/.Q
M-\D3GS)#_'@,K(LO,FC@.JDPA2>OW1S%XXG.@I)7=F6N_ED\UH:X!DE^D9)$
M 6Z'3%8JEC3+91&M*0D<J:6A$P4"\VD/-/,)?06B!;_)"+H$>&)!(/P.X+9N
M,4Y_)M_B,"HB#>,M%^V@,&H!Z8%F,0Y\>!!&SG+2:UK>10QV5$1#@.H=^8',
M5&Y)WH<%\-238(K4'R<7,/S?HA>!S"*E#&::"'@I+096_ U6FY%ZDL09Q\=X
M;?!#U-.0^FV146C6CR.)ID=+AB='!*]L)H:CZQ3-J2 =H24:*K BR5:"7:5*
M)[X(]"Y2DX2XXF05!<MG5XOKYRDFO*:T"Z!,:KLXW%T2NL)$C,9!574!S MD
M@S_SPW@ R\*@B+[R@TG LM]05FFS28=$.E7!F'E5$/D)E@6@E9[W49$E#HJ'
M(?\8>H>G)T!YJ[G-=B]121&KFM6;@9X @P?F.D&!!C\U*\ZLZC-/[&9;+X/4
M7G;\'FZ2SK#@T:5S^#O*<KJV*)5,_9\C09,@_49:9^P')#Z(PAT":.&U0Z,B
MOA0Q8,[A87?4EG72B#\'&>B^_A)[C)IS;_/5XTQJ\XZ3.LGTV.L>=KPOL+W>
M6Y#0R"=HJMU7*R XDPER/Q8X[XB9HT7BO8<?A?C#=/7NXN]LD+%6(WK2!#L*
M&QDP03]"@&U(G%I7'4V#)"91IM#22_%:RCUMR7V&.PC:&0A(%EEXD^DVA?2R
M/ K$3C'6./X(_^WG88;B#_]]@:X^W^[[A=WSCO=ZQA.BL2,V:8[/WBV8/%E0
MC@L +#1/#1%Q :[_6"M\^S!G!X*9O@<*'];R!I$1;36SIJ]BX%BMBGPL9HT+
M AV7=$NR,8SQ2<\",\(YPA/I"$YB%(?(3/ 5>CP)XQEP&1U=*):T.!<R71Z9
MV5Q+,H_$Z994 &$_+B\O.W#?8(\Z<"AD%001>HC8"((SR-DCLY@>T*UU";20
MM- JTRR V70J!L)SPJYU1/(XWJ7NH[L++4JT[\F"&_"=Z;,OA^4'?#^$NQ!=
M+*L#;?TPIG;LWN26]UZK$#V&L%=G:JB!V#>.WY^]>"9\+8FGP8#XC)?"ZMA-
M0BN>>9=Q\FT2*G0PP>_&,?&?,I\#-4Z'H4:67^$) 7(88EZ@(80S?)0]KW#;
MP0#54P5W5VQ3TN7QM[!)P#A!-T''UD E S8_"X6;^$P<H39=( [ .L#\SGU4
MF\(P9UT$W3S,'O[*$SL9RZ-H5@')*IX6*JP^X0 XDZKGJ;=EH:U;\D]E3P _
MIF-Q=KWCO6'_,'"]+9H!;80FL 8<]1^]S@X8Z6&(%Q9T9960,S?-V,S*O%^!
MB%2*GFFX[2F^_B2*XBG?\%.5?'L%<QEHKW(1SEA4523]!G"4%]:E .M+ H93
M&,01;^(K9MW3.)S"+Z)\K!.$]"D (\AN8-[4MA(US]B)8LA5?-;ZRAAO)9&A
MA\"C,G8^(S4,,3&2QGQ_MDAX&\'A?41WJ<OEA+?-/<M.I(P\6($+#E)AAK#'
M98;\Q'CKCU,8WQ7V_A=[S5:/E:*7U#H<D#(<7TC+"2<9!0X6\HV="XB"0ETE
M?,*#56%AAB%S3O/^7T+?!1M"[XJ]-H7'1)%K=A0GQ&QKXTV.+\6/\RA+3.C'
M^(>,1Z@E-J9A<^P$],EC..7Q;<BI59TIC)]6V.9);?"KO/(;5@RG/O*&&E0_
M83I38"VX VE&!D>Q]!:Z!L)\( XKC,:Q(_NM//TVQM#%FR3GTSB*TS%!'1WZ
MPC+@MZ?L:Q)I?Z:3*3JF\1>\XVP#+SQS6!^>KWOX)BZ#^G]*FD,+^10LW8>_
M >/0(3V1@C #918]M: A#[QO6D_H"Y!)()Z1]:H!I1NDAIY$'+-QOH">: O@
M7)PCK.RW<7FKL"2(V?-"GF3A4KSC(:Z71DU8DS".'?=AE&QE>O,4>B3#D#T+
M=*H2J0AG<C$8/DAN0>3\H^QE;'E#8+CH&R?VCVK%(N&-WNY2@ F7%,V\#+B
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MRB 20#,Q<_HZNT2^#22R3<LCB;2"+.!4H_R+/##D$!,/J>+<(A]ZIR"VL4'
MZO&"DWGD0D(CU,D%(QB;A3/<>3!.0/BTO-,AR*PK-!+ S*?+?D'(D_-T0I#<
MJ>G(3.35V]PLHXS3ASO78F("YY&9$*6'6A@-XPBB,')'3(.K:T<;!(E5F!S
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M8IU<$KVL"GHK/=,!V[V7UG@;+;'RSM74$!]5:?-R*J0P&S5?LX$'ZM8[VHR
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M*#1**_F;<OF!H&\/OODA^ZN'R;"ATE'3[;>,N33$\$5;;J1 $ (3 *,7A,E
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M'<B.)^Z.Z$E1N_1UTW.NAAB'7-KV(+(<UDF)@"("/('RE65;]JD&7494;$:
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M>]IR(B9#&^S8P4C.(.JT7I7=RAJPT#J%5W#<IUC*AUWF63_9%>R/T% [#^_
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M[Z0!@PXC4D\MW,<OPW;=*@0ZNDZJ_!E.$SGJDR_V4&A90'[[Q &)8%DTA_*
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M#FW'[C8JH2DI<5JO@<Z^CZ?V_CG7NP-YR=^*5*7YS[\_I9:DK? K=KY'Y4X
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M?,3_P&L!T&A)+NJ@UI4I._2Q$A'(WM'Z%;JEO5<V(^A6#^_0#!5"6I&6C+M
MC^*3X&../3-<#!QNM"I&S 4OPM7[$L%!?Q-F,A"+M+<6'+3;<9/4%!*?ZM67
MJU/0."1H$SE)#13QP%'R2#!G],-T/*#A^WTQIDR!P3ZR_,429UWGN+WI-&NM
MN2!XIG3TD;6>^J&8KJ0'Q0;KLZ,/Z82:U3G,Z;EPXTHUB@?"C"G6WD./_Q_8
MUFOL"[SF1XTB?OJ4.,+Y S()1J6L#.;254A$U2LR&9.X&UVR/M<NA$;^">H:
M$#$P(!*2'2Q:B(>/I. XS0(I]!!&/TA3<)[G._47$_U!PB%0ZD-TC[>FIOOU
MSLJ2UBDUH"^4X"W$N1!#^#:^.@T1_\0GX)"\+P^_S(PUG1\")B4\C0HOIB#U
MV*/Z:C(SP8WB] 6Z613Y #G,ER]79*JC>L%,*#A<V6_4W#G11]@;*M$3?$U*
M7>/EJ0,.AN0[,!TXH8H4>!R'<(H@=VH[/[>U\CX89'[,IODP)0;B\-&2,-UV
MV=FKZEE*4ZRR,)WQA=L*=VNM1G>+ML*-WO*&LILTN=U-@V+'J;5;O6I2ZTVJ
MW=S[?L#=5<4+C%>[;1_@_>B=NMXF'&2[X+67?GCM@M=>NI-;^@MU_H"S]KD7
MO+CMQUQ:\"D%@_S@[.U6&*/K 'VO\?[JEI3;CES-;.?GU:LQ,)ODB_Y[79#@
MOJ5J*]B75^Z7L-X&+>J74(;.!^NMH-FS6RNZ2#Y/#X.*#<JT J?1L;NMY;VY
M*SXX?#[H=.U.;WDCE*>RP:%;?<L/S2M5C;?9H;G3GD4'(U?KK;#4 G?J.':[
MZ[YL YN7:8U5L5EYEN:T&W;;W;2[1\5K%:]MOK1&W6ZYC==AM:-PO#]E5ZB5
MX[VOEO9IJV?WFIU%!W_E;!T!"[B=EMWKU2L>.&(>P,A+I[VP@^5.#L15W;G*
MES6BFPL]""/C: %*CBI.D4W5QV.A4DPY2S8AD!0&X<"-B*G^A>YA>,10P97D
MSU1S:(EPJ9-_5.6^B"AK4<%U$#5BV_H2WF.&<Y9Z,H,7A*DG7V'T")M _8;9
MS5,OPC2C,785&L8BH:Q/O5[*E$7,! -LA?L/+<.2P>4P#HBLZLEE"#, V(/<
MB:ILO#6#OEZ5C<_ND):688$%:J:SR43;+,-UHSKM= H_-9E\IA;\D.NX=2NS
MYU-\1<.N4G];Z* ENF8C/M(%[#,-T8!>\ CHUSO%9"J9/&.5O64 9S,&,!IZ
M:=1PV CLT,8@WL=&^"7GJ0;CXO4KJ)A9)!Y.,A>3Z3A\%$+^$--Y6?\0KMJ=
M&(Q4-BFA #V=W9X(W-M; MQ+B0O-5X/MO<1:3S!1K8M^']4\DOEK"(:3JKSX
M"'R(U81K@J(WMT_"+8FH?R?T(C@F(UVADM7!Q!GT!)YF(0%LZ$K-OUY<?,VZ
M)@JU<YQK#RP]F<I\9\SCYX:@ZE &D14#LS>I;!W(('PZEQIKP:BYH4KLI\:#
MLA)'220"PH_#.-505CI'V\S*EC4T?1,;HW"ALE* H=<(HI*4.%5DW'R\)(A-
M559)57?X'"%J=-[%5E\QF)<QV%0S&->RAH%",\'J@TF(ML($M\3 ^<)_1MYC
M!G<S^Z%L[KH(7.X* OLQ;I36TKQA7% J"68.JLL_L9L#S6?@8[=0JF[".@"N
MHL,"JC_3P4ABC89@>0:S:(+<$=:H*,W8@LK6J2@[6[P?8*%1D("&3 .I06O6
M;ZKP/;GSY6;[7#*J@,Q\%!L)N(CK6+KKL (];:PD@]D25C)CPN:P0[B0XH=X
M+!I)M<:%8R8<W_,.IEQ-KE=IFSM4+ A85 ?.!6%7,L%)S6-1')=5II&B(N/:
M%./L,YI-><OW7Q+#QCFSD6E\8K*O1FF=_!I5$^#O;HR-+S@"RH !8%V,,3=[
M1)B.N5(H@H'(&,W@+'N6R:F"THN!9\#BIKKQ1_HA0TJ0;V.B)<EJ1,3'4:5N
M-42Z2 E$@A4*%AJB6@#Y,-C7,,]B4]C9<N'G&3K4F*RI1"(#Q&(#TZ4T12NJ
M^^XW[B:ZM"-1:8T U($$C\2]E[ /&97<@<:'_1!3A+<5XR)<E8N;2ZM=;^?0
M=36@B3SM:8/>6J?^F=;;_5PY[!0XR$?&'(7A($:>D"5TYK$-QV$_>0>C^&?Z
M"WJ4ASLAT;.7CB8Q?(GQR=XVP<$RP]\8C<5F0 6%_<2<#E N.YN-V<'T)B!Z
M:23,N(.!_*(P6O*.!AHF\)"/KP3</QR+GG)E9CC^_1GUB<MOX-SHVHPH7BQ7
M#9["6%'&MER+R-P,.Q!8IWCVQ&=<>RPM!:Z/Q&.5(":*Q]]#C_<?&B#9BD(P
MNY)'O1?HC1%8ZRV7A:)3%Z 5 _L%O(98 A)OEI/KIUZ2 UX.HYG7'@)+E58S
MWZ":U<!D'!\9A%35349)5AY81,NL$CD6.@1,Y>0C8SQVN]$3-2M<#2PS!(+'
M$G2*7U$0!V<%ZX//XF903%FA20@RYG&SS-)DM9R:];?P 4$AR%[+%$NVL1G/
M&6RO2_ZSTFJ$WZ;UHKM.1) =QGBH# U;>R&>_@I76>J>8T%HQ2%8WA)AGS$Q
MX#MCLO$9"KC?3R.V]".!'>ALXSN:"_)45\%W:B,]RR"JZ9GL,BV5QS]3^'VF
MJW D O,(QP.&9M?O9T1CETG.P#RY&8<%#1UT*_388X\@B-.8P7CDL2PC%Q(M
M3FV4QJ[5>%-X:P#6YJ,TJ.XTUCV]'/E"(2A3K-.?(!=X>=QY<QDY1>?#+U)@
MNSX:&T$0HMG/4,P8LY'V NIJA6"GY /]/[F.P:R,QK*.&[MF9ALMX=C\((/2
M08QEZB?W(P Q!,/H<2K+H?,GG]S'?:QUODXSQ2+QC1D8@U46^FR$/*:0_HN/
M&K6'R&DS7K6&BY>RJ$)DI&?4J$7/6_GGU2<RJLX?8W0.^20?P%ZW-$\OYSXA
M!T0QN49<::TAB/KI))4- Y0J-X21]@!5+$F]POLW@AC:6H;)%$H &MW@=?I3
MYDAI)E,Y/C9KP"L 9>A:$AX=H?!JUE6F+I=O$:F%3.MMIDXY&(#:+W^J%VD^
MC&E@UX( @XM]F*+I)V5NQ03X")6J B519IB&^YFCWU >?EIU%IXNX/&+OB==
M:5J:'__@\U.K6OI<AHU ?)W3,IJ@$5DFYL.\J7J38\8^D:>]&"&7A(@:0YB)
MWM@(>[/NE4Q#F.D&U3)46SKI%4Z*C(.#6B8_BR(^R&.DU]0*S>EEU*=YS<UG
M'[60<HO(.=3(JO+\BG."B$Q)"BND8)=^6(.ZT<UXD5&2O_#&<8D#X0B),@2O
M3/E)M#)6$$0S..9QT%A;X)G^>S#!*16S\.7'[*!"84/R!7T8ZW,])JCX0KL-
M9ZN^R$%,]C#X$^1^F$8>(<$JM:[5HF[.XZENK,KP5Q-4D&CXP81M3YQD.&(/
MA\6(_AJIWG59F HD:>";08&YT<D( "7%\6/L"V=$YF9\-PYFS9&7I$WM!(OT
MP@U3WL> P=^FH<]9#-SH(B2O5$8(34XPN,LPNFSTT[3NTDNZDU%:HT,2:B;2
MZ[=TPX._5=LMAZP2%UJ-*G%A5;>V[10;V579(:0.<W:)E#PL<@[# &22U,6#
MR =F(@9K#\(L\DZ.#D(Y1F2M*RL$7Z(S4\F4,@A!IFJRD0GV9\Z0B.!?##TD
M\P'P:3X!Y<DM%W'.HCAS\XO3 IW*75U('\K'C0Y18XUXG>T,*QL&]A]&M/6R
M8Z,_G<JXCG'4(&;S/$U(_/.G2%[C$6RDO(E"W7,IOZB&TKC&_/L^QX'HGB:6
M]S*D1FC1LRJ==VF N,<Y7PT.K2CQ_R6CM1IFFO04WISI8 -;(;1'IN<9DW=(
M2.(A(C;&3,_,7H8G_(G:!(Y ^ /N%X-S(M-G_<4,LKMW"6JD+_WV,S8$!IP7
MR]Y<O+MQ>GNNQ-04."-/P S",(R8:M6D[ DUP%!@0-\P4,EX5[$'YBC&?Q;2
M>IR)?XXB[(]-=W%9)A,Z1FE,"1C,M=Z(&RE1\QJ@C_9OR&*&C08)'.2"42NI
MA??Y96IX_M<P') G0+#/P*K!R$?#Y8+OE^6MD74UF7I^1-H-?Q/'N7ZT>K%+
MK_9+<-OFN,:2-YM]Z:5.4Q(['$CF'Q!<+@DAY<MF5$3HNY$R=CV,W\!IEK#W
M#T\B0+#ZIPIMU2SS$^#S4TI ?EC/S%A@V$<P^A#Q=FPKX_<VNZT64MB(UW H
M$JS\VV;@?V1RJY]Q*X]0LW(SQ%Y_HX!52^&X9+B2<R7O\]B0'8</&(N@2?,Y
M05$"/TD3]AP4;*!<#[U##^.10BK+ *5G_S32_0]E2H.&X= WU]^-6P-IG<2S
ME-%11B:?1[D<>![I-"U$@^/+I\RZR)#P$]&_"_Q_IM1D,N4F:F0:4)-'_BA_
MLX#Z"-.JKM;MC!0Y=IMA!SRD!?5Z"!2Z*\6,Z1K3A+:UI$=H1 90O?99@<//
M.*8%ISH> C\$A71@4#QPZ?<4>\MA#WJS7 COTT%.+Z)SUX<#AV(Z?*;7K(\2
MJW9V<O0%W"N9M\&.L;%.)FT6S*/%D!,Z\?I1"(9%$$[\?J[_ *P/;*3H42;H
MJ?X$F4N-X)UH*\GV S998-B7(4ME,:Q86[NEP(L8AD*W,GD\EUC"?0G$:ULS
M/Y")1D8"L+EG:#/#+#W*WE%MLW%=1O>$/;104-98,QI\G)$3=1OUHY'[BW<L
M4N"*1,-268Q(26XZ<K'@07/(VT?26W%L8BK+SJ?4]%?1/=-_8/[_R0:N9)@P
M3<9A^(.>!YOF 5T%SG; ^QA0"8ELCBAO!3B@1*I!:R 8%#US)A:\J72*&DDS
M*MY:V(9>T:QFKE4WR^  \?QZN!,K*CIV%WA$=2C8RD;724 2>HM^3KE6: SR
M1PL48[:]"XX35K1&UI>\8IHA%NQ29M!+1>3I3"VE*@OGL(_A1YW!+CT15&_R
MKDIZ3RH;>/9$TM8@;7CN@&9],E9\H97S1"1WH?1%Y=V\R-Y453O7D\"_N,V?
MMI_!;2"X;[QL4+\P\J@C$4;PA'+\)'4O9U(!LS>!T]-8\E>Y4L)>J[M9\\RV
M;L#Y/P^'0]P_IL)LOY778-$=2%7)'9,Y]^O /)1_",,:5BI46\5F'A2VL<I9
MC'14*"O,L Q%9L21;C$ZF<\X!YP^2V<\XO%?#=4P(6>F&,<_X:'SY2%I-ZE:
M*&5%1;E5,(F,)YC<. Q&YV/9+YR^=_LH3SF<7(&Y24OVN>=>@14?ZWM/_0UC
M(7QO)V<T%O-9"WE;6,>]8O.:,V_#CC$B(N-H^4W%X"(E/.0'KB&4/FW?/&4R
M!';C"\H\SE](@U5)W7E\+G^2-1MT&VI:Q@P@KS2[83^0"WF+1A#-RLX-;ECB
MYAT% =RK2&"H:VPLOCO OA>:#/HDFU(N-ATJW*! GS$>UZWTD;-YT#TTB:^,
MA,0EG*2NJ^AV:T[(YOE0>M;9 #(YR]A@F0^+UX#*CT<3C9+*9Y/!V0I1O++,
M^Y49^T876=ELSL@^'Q3,AM.@LJJKVT<C:APJ7_9G0EWLS- R=NTC2YM[$E%R
M( P>9"$$?\"Y_(951!?WR$+].U_<Z[LU/1U;IT%D.S@) _%HVN%#4PP]NMC'
MD:3D,&_Z4Q0']JS57(K3%OBZ.>LFDR-GX7;.;^*<]5>T3B2XJ>[V3V8N#/8T
M\ZW@7[?@F:F-D2<3:UY53@ML/$RQ!OU>9"[16,A;(4H[RLI(2"*P%"Z@QC+J
M0$ /DO*1!.NT H\1.37"2@C%)-1KW8OSX0<=H&!WS<Z2U8I>-90J9>XH<UJV
MOWC4.3W9"-(9E04:XJ>':Z5VE?B<W*>YH)C*ZIP(/ 'D?9@>BZX#ARKQ0&79
MY>,5YLE2?))P="DVNTJR"I!G&05$.9HDNV#-M[G@"I1\<%'UZ,JW9I(GKURP
M<3;"GD8CV9H[:^M=$.*\FG^'.PZIRRBL+%6!&F-SL[)2H^P)EX+A3GEL:1M*
M$M8;T_UH?">6'6G'<V7?K*[L-[U?NF*6^TX7W%;)G&QK;_^W?V<E)6IC^E6L
MVGA);42Y#]@F42408&;$@NI6J;E$="]591H8M_;XILPSBE6J6I9;:D2JBDQ
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M6K3:(LJ2QG1JJ6$%RUG*7$P9MH"!'Q7T'+XA?RM^G@^,=:LGV%R(3?OW>>[
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M<S%T+WM7 HXI3.<A> FR5X9^A/0>Y0W*#YNCY1K,2.@ ^O38TU' /VHW-6N
MYAR&!*[U=H@,?33&]!>9S\J I0]A-!Z =41<+N="0IB?L#'V# RJ+U/A] P9
M"DVA-JODGAEQRPXKHZQ%(U32N;6G.6JJC"0#;:-E_BV\!WH+V^+">^*/SWY\
MB]H-CX9TA(!F7W4N5*C>D.E#&2L0!W@^C6"2_)UUI_#,.1?+-U(T]&3DG78\
M<]G.Q4:J<\P,6A#>-*BBLR)9T2#8=!?]$'+QF^I&)*2!,>3*5WD59CGU7U0:
M@!_H<?,L(-.2-<2\EP'@J>2_V50_K9+M8G.&8&;RAHLL=Y)Y98B<1KW*3$,F
M+M03PW&*^!Y[>P!<*3OQ&Q)D/[7_O#EL*)090UB%/[.>?3(N4V2\L ;-_09V
M]5$F=:F2NPCS)/JI(2SR7EA?7LK"-]FA:JJ2;?BT JM\X!,X-B7>9P#EA.4Z
M>P^J"_NXRYC\AX%ZA?'CGV#B)&)V66K&-'@&)\]/X%;=P9YB*A-GVF@SR<YN
M-'G7X"C37;:P*M8/_(G_+XUC)%-),W0_K&]?M)5F!I5LC& 8:*H>4+\UHA:=
M7/,P\25LF &D'H%F27*^!P;=4852#DR4X7)F0.GP;74U1K?9*K*+'2BP8R.8
MJC#%D<AZ.2JL\"*>L56NK4K;]ZR[QRD>I=SW"YQ;F:S&F,#> "_/\,[B7A3P
M*X)88?[N>*P^[^=THI$G:Q2*4*Z<-%!SMWJF7:[NY%4VV-:AIM9)%51?%%1O
MESJH/K,M59#PX(.$W8.*$:Z\35AP*_'4".%.(O3=%<UG>_F=SRFO]2*7JT9Y
MZ1O:JR\?/OX_UO=KZ_+ZR\WUYZL/%]\_?K ^77VY^')Y=?'9NOD./_C]XY?O
M-\]]I;R>]F:147/9"^W8K-7;Q6IP4_78J'4:O5UHQSKJ$#G.9LJ&F75VKWB;
M=LW"W;44SE<XJ>>5QXY/B&7L/AP^CR,%J^/)#1 G@]R-M]Q[!YZ".7FEF8MU
M%XGA7T[^;;6&;3N8%$+MR,#\O0JRA/UO8@3F/R5P?J467^:E\2<_FOSGK][[
M5[HS)CZS3K]>7ES_9EU]>&O]I__S;1 &7U*L&^RKCH[?<!/ZY\Z)%7@3F-E
M^&\O4O!^P@@7<#4XH7-H>-YHG[QONO_Y:VZ4]V<SYN%B8T!J.FJ'/DTL.F\M
MM0,;\K<6W6)#E.IF%@MVQ?N;\7ZK:[*Q0>A*:968<,T9L_8WB05T@UA \0**
M[H20E72^))%;O4HZ2S*7#0C7F9%.P]5$S%Y]QU#)Z:&0NUVOY+0D<UF?<)WZ
M4CG%.MU(W&&>P+VP)%+:Z><PCL\JP3T4^K>=2G!+,I<-"-=8*K@W6=%\+*OL
M98ET);>'0OYVHY+;DLQE \*UEQ^XF&[S"=-M*CD]%')7<EJ:N6Q N-[)^_6+
ML2IA/12:MUO+A'6[^ICCR>+I+,[B6?_"'T/RY4G]D6F;C?;*@L.G4V#'9=Y;
MWNB5J8)]O@U5"\L8&(C!='(TT.MOH1<1;-D'5?)O8&=\O?.BB=<7*2G8F"(:
M$HEML$$^KY$V0J@6!LDQ2]P?/KX2S:^G?B!AH' OBH^JS=*67W99"Q.7.:<=
M[VW%0$*A]1E$C@N:C ,ZUQ1B7>I;IP8NW1FBXR$+R2(N2]5OZ?Z9=@;2(@;Y
MS\<Y@]XLI^GGHFD2$_44LW[/;"LN\-@5XD2N@#"#8U*(=ADT\PQX'W< FEM%
MAHJL%A"$A+E^BMDYG+!,B<8*SCF4J(ZJVGYE;;XLY3XC=&R"$6/&M->$65<]
MF3 _%S%"_$!E]G)% _QZ"O.4<$%&MUD%4ISOJXCH/,MHF6V'KH(@X.&L$H)
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MRL?SH\$YAC<>K1B6UY?;)T,9^$V>J"'6 T.0S:$I#-8/HRB\#;D+ 66U!=1
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MI$E[9YZX8!,[NVH8M6>79X?-&^LKAX6\T4;E6A+>.)J$KPN8+^ZS-P:+S!^
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M.LX@41MZ55KO9"MGF0#3CP^P%@%,TPHWJDF 51!@&YO/]P^P-G=2.N?HPI]
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M7[C_KK,?9_\"#-\M[5Y.?V2;O(JZVP"+MZGV6V5E1"O1[KYO?^L"D+>MNU\
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M0'4N4\LT;58V>;HI\F0G/[X8MN&,F&($B]VY6D-KE#! <9>4V0$31-M2*>\
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MH#:XY7M!%*9GFVI;/Z/TK$34MF[Z7A#5)T0UNE6141?CMF/ 1?GP8F"&QI_
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M(R+T06R!'?@R 5DR0QF(GR0!"M^AYYCLE=GNC#X+ )W VZ]>#7O.E"DS 91
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M%<9JC71UI]8XU<)8I(62((92>9:\62Z""&M!1%<&, TO'DB6?O "B43A 55
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MAE)_Z7/:[!=^\G,JG9]"LCLK6S+T-HUH)C;Y=UJM*J#X(D8.S(/0+OZ8$!%
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M2AJ01KGSEPHX0SX\GG"121(XLO.:+0D$[BG?SG?R_5$6/CGN0NFT+_\[,?%
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MG\$0]C ^[[A\AJ!<]B?&=67-X;!S<=5N%8&'"'/84J;V2@Z:!HL6HX3I);)
M_'*:S 6)@6YOI15,V)QP]@M2)TH5M7!L6^ASTK0COB,.V,Q8S0:+B=$-8&MA
MP\.WJD(]9-0<IWSAP1=N4LQTJ(7#O_T..P,* 8IG@QQ_,YM087%NU2HGKT4I
M2[DQFM\I!R?XCOXG#_$<X=2E/AA.#J-L-FE5U_3^%%//GW$Z(\@*2A*LVD/G
M6@Q@ F6$PSM\C2(26)9GPJ8UEP]CC*?:3*X]^6\8"R&*XVM$Q']TVOCHKG 6
M0KC\],B U/,3Z/ZH[K1H<4]X*?NO0&+A\J<SFO5H^E(?%VY%ZO20F*D<HDGV
M")[I)+0S6H54?G$5L_:];N?$I$<$T!'O7"JBX^<NV_%39Q&*3<'E:CS_;--,
M%:6JDJ)' UV$-X)CY.A&+<TM9#_0#X"OQ\>#@@$ 98J<CIDNFO$6(0C01+UP
MGABON0B4?Q1\"3R>6("<! -\%Y,RSIYQ%Z$EJE;_R6?3."Y9))\)<0*SA4/W
M* V7&L:1,(MKC9^7M'XE"B7*+3RT*%<O/9\GDSTSFCD(?S1P?I_CTBMQ/)OI
MRCTS#6):EP:GTK0W&ME'M,7'R%J=X3S;*4>(#RQTR0^ EQG\F! ZF\@"6^>?
M(_T'GR%]>@D_V1 D+^!]FKOB.PEIR@>K%M#5"S6>@=X.(KFCUXF'@GO<2+5*
M:HW(G/"OM%?&,=C1+_OD.HM\G/:O#*+W>^W'U.?W(JA9WODN*?^1)GB6]N&Z
M6.PIZD<+4QH\<P$V(M"9$;%V<;F'YEG#JBPX(O( A5\'AT*'PXM\6W!AI?[A
M*6C,/"CZ.T;#4*<96[U&@Z;F?;M,,V"]X>/IQD \+.'9?V%9F<5T.6%\$7FB
MBF;!MVT>)L$+A6W%TT&+#F?)9T,6*D@L>JJ*Q2O[JY@F\51E:04TRA$6!__@
M$8,7*X5SEH&WN$^T^"4X*"S\'+*!2V%??' 75XJH6ZCQ A\OG8TXJPG5X>'$
M-)IKZ;:4/QY9(EJ9,60\+T% =;=%J<2Q,<J$%9><@)'"4U?8/ HK;:?XC;C;
MB*ABYS3/EJN_;,Q:?Z'X /Z.L,5S!P?^*G\%FHMS8.'<>-B-]/P&K$+[)5Z^
M?C397(E 2V_GX!+@,*LOFN\K_PU,;@,5'M1H4-Z,9J,O.'72$[*:#&8Z@SFH
M8A3HI%_%)% Y>/4,AH'V2@\#E0T?U\YBAODL!"];,_)SV,LF=8>][*"6J0Z&
MF7/B3F,\Z9FUB[/RB?[5>=+LVJO!Q*#1[B@V:)27:=)#*RDSH--L\K!**5*;
MH-UHSZD9HO2[<()H?#HIQ5K1A+_4/$#*6M*7,77[SP#,74>LC^QOR7I>=WT&
M\YN86W[O3/GNI 0P[Q?0U^73F/TMIOK1.)XWW V."$$K7RSY6%-.@#D?3X_;
MGFGVGVZP]'4:?0KFB&?"(1[$:,=0@B62MEKBY&B#Y!5;Y _N0L;PJ&YXG= H
M3;K!%J0SV PBQTL0(3!MGICS)5GNP\VWD.'F(38RE4<]FB4_+]W_V"_H/SH2
MB88;9M7-7--XP(X<9)Z XD]1_R!WU- @@@I92\3CUX_:$OV?3@<XRW$A&C/_
M%J.G4O(' 7*^VL 7Q!A41\<*\Q[ G+B"H+34]DM3_7M8K;L1;JH6CL00HFU,
M[?@AP-_ !AGI^1D4&=Z#!RQ[=TL?$EY@[.94]J-3,LDM7\JYI^3W\V/!I)(%
MT14*-L3'H!5 RBD0!=_2-;2_P0A@;G-)$<@#L]8,UBUH?ND/BMO2<@@KB?>-
MN>@8@CN5U_HR',.F\^HW/ZG4F.;$)E[$9S<CYWR]N?]^<WWS.3[>&=4@DEV&
MDK'Q?%B4BU7J/%P2?S(OOD%T"=:)]SN%GTK9JC!($C/4Q/IP8C-P!G].R+^O
MB7<GV_ NYJYT6),9.\13MCRC]B;+ Y8ELBAJ--18]JN4[[S>0 !$=Y)'CUF\
MF ==>G<=;*W/9N42 TXU 9)NBNXW3,)J7$T%( ^U]V=)8",:$8N*<H$P<UA'
MEQ=!](BM6LH?L<Q@J4,<;+@;4:1,^1+%11!JJR]]I%WT [*W)<(C14\G>M6E
M5+C\F@!2PV(/&M@.(\ $-D3]E"]'1N"*D'^0]^;:C),B9/H$G>&7F)@*4R,B
ME>J52:66*394,M(TJW!!P6Y6MP60,J/>*4#*W"< 8@3("^/L(/I$^ 4,P3^B
MFFN9F)YT5Y&WPG.$0NV;,8.E1//?;-(DR7%P,G[D]9P8;C#^'<D;TZOLA\Z\
M9$='.-#T_+%MAJW^J%<-MDVGU>N.7CNVS?>H 0'M:@-I\TH@;?H;;C57Z8J3
MP\8'ECZ!M;9SY\R-^A=7@_'>$[)J@D1P I)08CQQ W%S%+FI;.+O:$"X4>U!
M%CJ@P<,YE&'%?R<&SC6 .*6EJBCQMK-(I4;0E<8['6&661TV=NKE&&GO@<"O
MVS!5+D+KQP6/1B @P\;.O/S<.E_[T=B9&GEO\F"PD[106L9X*_I<X-=.0%IN
MBC-OC6VIA=A45+>+R1C6[=KJZ&P&2IR F/W2S";:5Z9V9?<Q%FS5<7?2&)63
M&AU\LI:DW+#'%\T[<TR.V!\RTX9+RA:V"ZB]?K8'I!FB>H!AQ)4,'CY9:U*-
M7%4>_N\[B'C<+<J@G<,(UKK)4#6#B%^Y;3I,"FT?&>J).2#9D.94#1&]MSNH
MMS317$GJ_<.N+'&SPY20WW$P![K&("=1[6.W7NW<XU07:,917',[A2YPQ[M$
M2\M7GU(&D_'>\T-*G>(1;=A)B!]V&O/K&TS 4\F6W-=EU2J1HR*C]AD(_ GH
M"X9+PGV6%A]L-U [P[U''C<FJC1OW#N^9J7@B(\R:_4LFP'/:33*"]CH$E=5
M2L]5'P_Q.H[:R0$5/KOQKS5LF?^*5\U$*WS8?FXB:@=>S:,"&]U<T'Y@=_S2
M\?#JF/3'<AK@R]\2&ISP7;+QB*X$CC8@Z\<N ^J(%A-= N37\+)S75(?H[L^
M"51Y R&/^,T?BE'FEO,<PNTA# X"-BTTB4FS!/N/=U(2+XGPNEUGI5E(*#4&
M'*H*B%++TD!JY%!>CK,/ 1+3%@(R%F\?X?5. LH/(?G%2\*]R\W(RX=TS<+Y
M-],3>Q XV+'MX2W2Q.H#>KP6?D9Q\>HHO*[T+=$U<R,.R78?Q,*_P[KS+IJ.
MQQ=7.76?G[9E%A/A5(E&"X2Z^IMSC8:'IE$W(ZH!9"<$"7N2L'$AOP0>FP<6
MG.0\3M6""TC];EI@PRM])I"??4;V2!/@#]) 0"UXN?; ?J,7?H;W98'9C<#%
M&U,1;; */$AK5KI5=0IW^$+-Z:03>M5ISIJDN2(M.<%29J^,EM2$1N)-[1%0
M\5(D"Z*;6B&VA!I";,Q6\J*YK73;G0F__,FW@E<D\0:T%)W8/3\)VA:#\@^1
M)_CS*CR><,!&-&WAF]C25.ZH-)FQJI5WQ3=)9M@YPB:@?@C0H"Q=>)Z+4&<"
M"%4'MJ6K]W$\:?A6K2_G3[I%E_-;RK<4,$L>\\2NS .3@;Y\<)!" C@+>4&P
MG@JVRM(#2V#Y"Y.L<0Q,( I!C(5+Q7^&. =X8]5>*<$2K"5"?+*$O8V]03)_
MR.X.Q_WCMVZB7\O$9,3R<0P:?)<3H+9'DYS8+6(^5KX:2JB&*R%:FZXA 0<R
M2PN7(V'FN?CQ;S_2S >Y=)X@LA!C+P"N6\H;+W27$GR#)?R!8^J1_!*UP1HH
M-Q(* =G-8!YWP"1@ FA"6DAX/!R: H$WHTND+GO LW;<E0!+P"O%"$F^7'(,
MH>03.>X:A"4/=-TTE_Q(/Z[^B4"72"!XNNLB(EV&&V=@A&<0:DC5B-R)B)_/
M"%#W8*&K](#+EJ<$N\#3Y4.J<%I5DB;WCZ87SBT)[0]W,"//PC@-9U-:#-C>
M@XN?0.K!-Z/18K-5A$U;QF,$9F59Q34LF#*S/DX6BCX1,4MKNHK!EM_8R\#/
MU6U8)NKG*/:?E#>21@B*?<E1\&'WB8V^K3]BX7W" 8WXD#@XU>"IYMVKYD!1
M0J_'XU(.BTJ&''&4-*NEW(&Z(+QCRUJI@F'#/Z//''#L<9HX$UN6B%;H-K\0
M#!#]I<7BU\ESC2=\4Y?#.:.8)SRZ>'285"52;I/B&!O7$//Z">D9AXORF5B2
M,*G96#2N2("_<.P(B;[E4T@FMS\'ZG@2^B"-:AIA%JL1!BHAJRU0.Q$7BN?E
MD18V"E]!;0ZJZCD^= !4'<*N<?D-$!\:-T^:P73U8($8Z+H$@V<_3&)VS<OQ
MY@BG>!L4RF+,PTU_3.%72E#%,X:P'%8!88G1;:TA+#<<=UV0+_LM9<THHAS4
M2OAM_^+J;@F+QTG (#.W"]N<SG+D8AO 2GI<WDL&]00'N;65+QH8" 71W+KM
M;E?-X#)RZ&CPQ_A&PTB,?$O^>T:(+YQPBK3W(8+7%^8^X B%R-..>[W<P9U^
MFUXKSTY@&0*CAW$_EC]3%5!%'(8R! Y/O5#E<XZQ_=$%)?O%<<'^*_<NZ=T8
MHN4;=*C09H$M$K9.X C&)NMZ$E 0H53KP_4%"134#L+2.I0(-(0OA[^+[PJM
M)?C1 KQ9'CE^"EQ@<.C)2F?&&41B$0.0%M:J8+Y ](S8I $<IQ5#I8\C ?%H
MYY?I]!L';<*0DPRJ)SUG\J-Y$$'N=VR''TR/H]D3KE,ZLHW/2PZ9$+A%3 0G
M!P"_+ #B^3[)I8^/9O2$@Q1Z7BDL&]P]3@/P)<ITBCNSZXJO.ER-(7\I\Y/@
M*Z##JHG4)$Z-@;?3L()'QP*B><+6W^J^0^B,0WZL_#->E ^-S<R(SM-E@KRX
M[-))B]&Z"9,?:'2A9OT"A[:\D8U$N6,)HC3&[?QW!]<BR_,>?PJVN>3$ -3*
M4C!XDQ,T'%P3 IS!6?*]MY0;<"P-$QC)6L4ADC)G(S3873 #CP_^:<@16T)%
M2BT54UG2!E",Q9U/\!2?S">!3[@DY'H[KB!Y1@Z._!D.%E8$,3="9P4SB)!,
M1&)"$$-0&'+U%!_ 2]PD8"^!]'$7G/-05MYI9DEBOWP):NSYF#"G=&$X40WU
M-@3=.L>A-PA6C.\#%NRE.(P^P=7-].[#]']BLUB\U6+F6%+GWD[?W[2$LE4B
M198\ +!)AD.#"&;,9B"%?.0/9B7P_1&GIR;#R+W@AFV'9F.RA*(*-XO'B$HL
MJ_M0'4E5Q'B*D+RQ#%WKD6DOB5K](5\?UV$GF\8"YT'423[&?U\+[HS-PC!)
M<?OFS#%6W!31Z.H0'_"O ,A&@P[PU(ML52Q&Q"1,.#F#SRLA7$A:$ ZVZ+8'
ME]UV"#8HYTKN.8TO-0!&C&U-7<F=AN/_RA<GL,DIIS81X@Q2Z5M&L?%!@[&X
MW8A=WL:1%]$ ALU3<BB6)2S'V)P::3@+SJ78]>]UD81IK[R'LTGSX?&"!6;_
M_XY-M"<<(0EQ*$QJ$7_$40V]U#X5L<4N/1'^T<GBVNT4>?1R)ZWVPDFK+XV!
M-QFW!KUQ60B\T;#5F4RJ@<!KMT;#<H\J_OV@7^X;A1!_K<ED_9,V]//)AIPV
MMN.(YX0?FURDCC?;T9/3U/-S)G_R,CU;XTT1/>4O_H6ZXF.^KDAT0>U#N-YF
MPIT6U5##%/8-E]GMJR%7IPPS574#$>AVG V+.Z+>NVV8I'3C?QD&VD3)7;]?
M;G%5WC3H]&IQ\ 7(;;+.N$^?^I'[G[?;Z?;]SWD[/%(?\W9;*]=R,U[?QUPB
M3;/CS?()=C.KW?'>J T579G84<;CFJB1EG.5ELEAI65N_F#&Y=_,=?($9<3'
MN7>Z/]=$5*J\751KNW@MNW_V@3FI(1S# 41DT#ZZ0<%>\(':'0UJ@@-4I6_;
M,-B@<W0&FUQ<]0;J8'^7I5YH'EO?\CR:'N97/(42W@O08^L4V#E*T(:[BP>7
MH%&[#2IZJ XJ0\LMD]$\1D30L.:6K-D[.FMVJE+N+\&:YYZ)C(:K\]EC\4);
MDYU\9=G)*;^;&<XBB[6LGPL*2KVM_0=L!]--?L?,-N+G45K-TN4S==PONN)X
M@FF_AND.8<>K9+H> 6=,^GMG!IH$6LG"$O,8=9)3%VMTSZ=)I)76VV6[9R7I
M078^1(0O+3I]<(O':G\XK$G.HTFJO82^/A*S#7"2CCII[^T<U##!5FL]_0NS
MX20MWFUN+$P;&ZWI2E[C8;^$ARWHCWY.@OH?><Q;6I"&A);;VW]H6^-EUY'Q
MJO.RJV8\0OE2AY.Z,-Y+ V$>N43BK,F;G3\F<[UU?)C3W%6VQA=7PR[(5E6N
M^.$ 'E_827^]W%F=(=B;.R? G6UUL'^.Y50 Q&MK"CX[GL>1?W*N[C4U\W(3
M,K(&('7-;A]9@X\Y"X;G55;<.FT*E3N]"@8S-47T<^'5C#FH!Z\BVF)?G0RR
MCDN]>/7LJ^H$I6?202IO1%SPMJFGO[)Z^B^(7$+^@??HN/XE7H0'KGABXEYX
MD_([>'$&CP!5Z:U]AT=P#R=P$QW ]I<#1IUNW2X'-*F^.A9HRC#<%A:]1W>W
M]B\*UC#+5VO5+0&09%*OJ:._1.9.4CTW-;)>/?<K4\]-_?PT0J[JN"S+38.+
MJVQI_%2'R-9?V^;'2X0)W_C(!_>1B?H\Z[!&)(875X-!5==)&M^WYLHU%^)L
M/Y8JZ?F.R//MG,\8XMIJ7U'1)ATL=._NJK=,1NATQ.DH>OFK8SO)I/ :]3RN
M1#V7/;T3<(Q?-2=6E-0HQ8F3BZM^51>WZU6%.,7R](P&84C?VM=^- 7J%RA0
MYP6=LJKWR746N1]Y3T?%/WBO_2CK,77;_&+M*#M9OE[5OZ9272//_MA,*TK6
M.3<1ZL6TYQX$W(0&0H"\-U?'#F4*0$P^SN=,]V_GN7\O+4/=BZN1VN\U-\?.
MDM?VTN"5\UH/XDQU.,EVPYWTQ;$:J.7\3J*OS%<LL+\[VD(!&=\#RAI.@ #T
MU-B[1Q_WR2-G5D*96JN7 X4U6SB#'K#K[1Q'8,3F1MP[W]D2,07LAX_P!7]5
M6N?TP4<<JYU^=2VX>YU^34%O&Y%O1+YBE^)X(H\3<"9JMY.]Y'(R(D^NR3^(
M'F7'M]9ES-.&Z3PT3@PV39.+;5^!8[JDR7VFSQ8TE7Z)D[!X4<DP_2 V$*]@
M>H^8CL;'@.&L+QP4R4?\T5 BC><R<0RR(0>X)28?QN8=XD R.1I\_[% \:/*
MF1&4-\=7'M?KF<8[*I[&>X3!NL6SFGH7ZV;(#HXSLPDVUFKSS94:VM1O3;J]
MJH8V#2:#JH8V]?)?LL.B^H-N,[6IF=IT8*HU4YN:J4W;8:5&7DESI^N5W>FZ
M?M3L!_1!E;EFNLJ39@6,C[ZED:0XA!/]4=,0'FTSZ.ET1]<<N8F2L]J-/5W@
MO-O;^77(8M=Q#LL+GPN:=5^\=;*9]?2J!*:<O/2K:4[;6DQ*IJ *&Y";JW<'
M9:(X'C''28PA$C=-";O?D"K&><[/[):6F#&!(78[V0:TIA'A#/BK0%^_'']-
M@+_ZZF"P-^9AO9H/ZJ^2[WQ'__-RIGD,-[K UF^NGO>Y'7VR=ZN.TH)_]ZBY
M[#V>P#=MA?6-J>NBWX/_W/&*5:]]<351^^WF4M]9,EY%[O4A&*]#C#>HRV@2
MH<=3Y;I.E^JN+YQVJ]WWS[W#CJ.S5)'5W48O'>/[+YJ7CU5PQ?<O\<-2FHZ1
ML<4>@*5F&M0"H.E_!28OIM,EU[!+@/[@,B-52-[!E3RS+%3>#L_(3%;DGPGC
MZ-T[4\Y([P,/5N9YC'=((1>*OQ@E<&UZU<&.U2>H;H3I7(6I(I_S4,+4JYLP
MO9H,PK? U1\AB$!SNW2QW\]?J<K2PK9!FIT A[G[P+*3C>BJQ<"ZYOV6'Z-V
MRVH2;[T^7OH9C"KHOV]R!/7BJ TYW8-QU.#BJJ^V1^>#[G,"*E@85<5WE.O?
MORN_.I;!W+VFU9R]>*P+#B(G):HX_X[M0-_Q?8*Z879ARI,+JSQA&%Y<38;[
MB$)]7/N&>[;TAJOCGM'%U:A; ^ZI)(M:UQS:2>7@CI!%_91S8V>OWMASS8.?
MC9_0].6=3A+GI;V>4!M$=JMD?("M1+DSSDXQXFQ$Y6Q%96\7;W]1P:XHM3VH
M3RC=U-%?8QW]+E@N+>H*T:SHWC7=\[8<#Z]^-U7UT\P;B=2]MS%WG[B9K^DZ
M]N-[RE);T35J:N76=1<O_!>-2FXJ@Z=C*8]29O>R&6D/OA&X+C/>!_Y7Q_\7
M\[]IIE'6C/;;%U==M;?_=8_ZY.(:83I78:JHS'XX8>K0W:E>IR;"E /%LR6$
MRUJXGO58/D@+TS!F[?FH-QJV9WI_WIG,]/:<]2;]R:@]-P:]^?].@%1U  #*
M.'4$Z#)H*8I@S:_! IZAIWDQP7O7S@(^I)N:]=G4T<!/;8-&@7R$;SD+4Z?(
MQ[N'[[^W'/W/B&&Z%TK(GU-?_ Z?SH"YEO!\'_R&BZOH!8IX [D5?'Z0?(G"
MWR)Y3RP\=4+YZ"_BI3E+Z88RN@TA[O1'9@06P]N(VY&$8+.R=.GE+*:7I4L=
MP:.FY#!F\$<07JDG<9:Z*MXGD4=JQ8Y4C".11TH"[O&K]9XO0:0B;*JU<$VG
M@^73[;=ZO7'] 'AJB0K4+*I95-6+&K9'!T.:VO)CG4'F<R>!!Y0&T^MMD>YY
M%81(@DJ]  >='=04Q#)9".R=MGL(>JT-DZN!9JR2F%/CWT%J 'VEJQBTNENL
M(P<%$ZE^V6V-L_X5WCS&!UQ<O>F\S;^@4QMNJ)_T?%TSRJ_1*(U&>>4:I=MH
ME'TUR@MUMQTS0?O1"GQ3H]3$M>-^T7S7+!ZE=Z"$_:O$\"^W]S-*\@_6)/DS
M646>122K5CI9W[^XZHS4X:2J^5''GZ+1R-BKE;&2_5L["-EUL BX?Q'S>TH+
M'0ZXZ*CC\3YWZAIYJQ7KO4IY.[BXE98LQ+Y5QYV#ST)OI*N1KGI)U_"E/,91
MXS$V,G8N,E;28]Q!R*KQ&,<(FC?H[3/=O1&W6G'>JQ2W@TM;:<&:7%R-U<Z@
M*M3J T\4//P5DF-RQQVSV _3HSSK!U/#YJ^#W1HY2_R7<N(U>B&/<=!&&1NV
M]QX;7I]+G>?-1B6=HAWXJ!*G:-"YN!JIXWZVT?P4[PF?-TL=G*/R^*,+_#'<
M^QI"PR)U9)'Q2QFOWL55I]U8K]/AHY+6:P=&JL9Z]=$K&HSV">D;ECH3U52:
M>09X8;7=K<OTCI?N 0KOW[TP(]P^03B_?<=8 YZWFP1-7LJX#R^N>NWSNOA]
MWGQ4TKCOP$@%QCW+.R/DG>PTL@:XLVX\<W"6*:UVQJ1VVNV]9R U+%1#%AJV
M*S%?:Z<9 )O6;)I!PT/'YJ$MPM*U/ 7O;'BJX:DUIFT]^W3JQCZOH&1Z[UC,
MU6R=*4VE]'""TWFA>'38O;CJ#M1)IRE:G @?E8M'=V&D;>/180]X)Z=*T623
MZ\8S!V>9TFJG3VIGU)XT:N<<6:A[^'AT.*C,^6MXZ$QX:.]X=-CP5,-3N\>C
MH[JQSRM 2OBF64_,LK2#3?]ITCC#=6C:E4:C8[Q,"1NO23JG8:-CL]'>%KVI
M6C0\M6>P.FHW6NF,.6@=NGU%L>JH=H6*AH>.S4/[6K91M^&IAJ=VCE5'O;JQ
MSRNHG7+"%OWWWO$UJ^JBZJ;OB.O#8MA #\[-< (<74!7B%_E[?<J*7,V^J@:
M+VD+9QLOJ8S40:>JRE 5QWBDS&TCNXWL5M(&<!CW= MAQDM#;;7;K>#*62/'
MC1R?H1P?6(Q+2^SPXFHX4KN3JOK!&K%MQ/:5B^U+(6N/1F!MQR"[>T-+-;+;
MR.[YRFXIU_E8B-VC\<559ZQV.EG0T\9U;N2XD>.#V^#2$CLAW)Y.#L;^:9G?
MG/'5&Z=/B[V(5U^B]+SK'6 8<,@9],!W.$[<U-?S2F?P$PUR4Z8+(++O*2Y;
MNLP#I:QHNLYU-3,4;>$ /?[FXYE]1UFZIJV;2\W"Z;__L7N8-MB&UZ;10J:Q
M=6S'@L.0!<=M'//0RC*@ C2VX!^JHKO,,'W% O]2T2+S5'J3G?*;O*97?X8W
M1W:Q] X[%U?C5C8XC3:(4)[F8JF9+C[_)?9U$[YM2YT1VT[WXJK=RJ:ZY784
M;<U4ZU8:%R8U@/P4Y+)P,#I.'<=A:2\FM8/C26V/I#;KZ$5< #Q=F>#NL-%*
M)+=_<35L#79B]6Z+OA9GE"NEM!':8+OJ,L@^.H,M)M3'I$)9 @O.P0UPD([S
MP ]<AL1EGN_8_!FNL](L?Z4LM14I1_$03?\K,.&(E;GK+!2!B:PJ=ZUI2WDC
M?GRKF+8R!?&RX$ Z/7I<^.- C:;4*=>::YC.D^;I(!JNJMS8.CPF_#L]Z(NV
MPN\-5>7YT=0?E6<X?)0C-UK+;*5,_S97CO*&_Y_^J-D/\'L3%JP[+FP6/D^\
MBW(OYN7Q=UWPGR[H57=LZ?/YR*@SZ5?PYI$J\9Z5>Z"KMF3P#=T3JX7/_%,#
M1G-IE1-5(12N^ ?#S]WJOB,?KBK1Y>C\IWYUGJ*U<%LE^]<+OA%.=^8:OQ1S
MA+34@!- :Z(BQ5-V7!2VN6G#2O%)FN<Q_#C\+G#I288)IP>_A6-@EO.<MC0U
ME)I/L"D]2QQ."6 SICQJ3TP!9M;);H"E<+PE_ !ANJ(MX2<-^! X2=")J,1Y
MSL-S "D"Q89?U37O49D#53ALN!<]<L'\1X?3UV# S O3!CT$+,Y0A<>]DF<G
ML)"V(+^Z\V##/@UZV*/SC&M8,,U#Z?4?-3_VM19PA:*;+E@=ST<N\_#9\#DG
M<!4;Z"@7B0J _5CR=<76:WK*@\M(SN#1-M" /9E.X%FK\.-$JF=0R4JP-.A1
M\.R5R6"Y,8I9JRK6 JK)*UP(T8.XCQ[IP$D"PUJQ@^"K>N9$=(TDB6%]$;E-
M+TYHT"P@%(&.9P/<GA8$8@(;/0MD SJ"4,MZ] 6I<I\T*Z#]X0(7CH<?Q.FI
M&_>.XB6$$1:#CXRV-Y\+IC1Q#"O#A\*36MP>'ICFJC(+?,5V_"T(3XRRB4?^
MD(=#\E'.3QFN<U2BP[V=9YR6TJ[)8(,7'I-<\K]0PN7H@$*EHQB!*UELQ310
MSS:2(=^71^6K :V\P**8A3.2)3B5$6$?7&WAG8 JO@GM^XB8A.8)H^6V4;)"
M)T0#5<2X-C3]QX0%7P:N%V@VB:)P$(120KJ@</"'F+!H\EETYOH::&D@P9_,
MY^0"NI&\@OS*:;H)/R?T2%K*M]C[\+C"I:E"O> [C;+\.\SGW\"[?-"TY;MO
MKJ,S9GB?8#'?Y7:^BW>59N$A)I]:V2L*$0]SOX?O71 $MCL+5H;S;-.VY<F@
MP@%GW!;*3E R\O \!R0]=+I:Z+G$3E,'$0%B.9P+.(,C)\ "@$(VXZ2C,\?G
MX\=13(#IB?2D@CW87NJ48E[>&_P@-J]VVS]'?Y_2-^_@F_2GSL]OX6#)TJ4/
M-,%)FE)XJD!V$-3LP2; XF^^?DIHIF^<7OQ$5[  %&3M@86'=MF-3FUT<96-
MB'X*#R)]!&D^-OG?\VB@AIJ#R)BP,:4W/*YLPV-L"%JSX]29+U."&;-9:$,Y
MIX6&$CX-'IN7.&Z#+!9Q(C'B,,$]MY(D-_(9W^0SLKF51/@95[Q"^_6[K=$
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M]=+>K6/J:>5#P*0!!Y4'FLO# X^QY']Z64^FT;35:=I$RRC7M+8- B#IR7[
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M_??+____F_2'/\/N'-OT1  >Q;"8A\,4RY(R8P90D^*T^'L>5TMP3RBC >2
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MECSDDR8Y<<SD1&A]BO-X>;(WN;CJCH>OU":=NB.[(5>Q85!@_B72XAND9^T
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M;E^4A &R1WJN#KM;*QO7$6JN0$16* W'.6T1;HHDQW5-'D@B/R58"'>M+3!
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M5) F4?0@SN=:TF4+S;1Y>P=/+I05ET[!04C_@YS9V_EO'J\0W,YPDC!U=_Z
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M2-'@?[OZ=0?GPWXA'T(43E9!Q8L)'"V:+<Q+S0;=8&$VYA[,!@;12]?1&3/
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M6K,L9KQ?B<]YXH-;)J#:$<-#&-A3D1J];D[?#-\%61RR1XN%@\?JZ'^B![X
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M5>U,>NI>[+_V^/B(K6C=A;!TER3DSL=JVC$OK#[J&M"0(AI68QKBEOWP\-5
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M:.T23M2<J+LGZM/M D<=C?76:M5Q0N:$/$!"KN7;9]*S[] S2MTH9MZ>VBV
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MSQ_:0/3G%5:X_S++_MY()3F'8JQ?7$2PD TT$I[GWF0.JQ,27!$7)Y-]35C
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M,G<R]\@3R=HJK#\!TT2PT4&$Y %;WP8P:%@^$L6!#\.D!1A(.J]H[H9D'BP
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M<@A85UO&.J>(WLRK XI@;Y+?R'(53N9NM.<P_FJ(72LA]BL(T'C[,B4_6PM
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MEU?Z+]GZ5H\C>?_<14/'2W<JM>BG]?G(UK'<Q\\?6F<DI[$/.<<^L*2Y+(M
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M'1*%B]DP'MWPP?-ODL=O32"[KI!#7WCKQ3#>R7XLJ1F6$#&>OZ);GZVWZEC
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MXOYQ*3##3.D_<N[]I,]]=?"T4ZJ-MTJB.RG_5$BB>%S[YTL)%#NV:+:DMM5
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ME\ON=37L+H3*NH!NCBO49PC*:&SA>4PQV>+4\KF]+G;-*>P:*.Q(B=L.A:E
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MAY/:<K#G7)?SXDWG19C&2E&;ITH[M3P2BIXU]^"J'WD^I!.%0LS'/$R$W*?
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M0)_%QOF8A3?<\+'34YC&46#T.0Q\P56IUO;711T.@RQ154BX%D7@L[6-V#X
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M3PS,*TY5R>885&4=N!"P:<+/\@_OAWXR#=CLS ^)++KI/7#T!D8AYP9'L+"
MB=OBYW)PIB4&*(&@?+/\V82?3I>_[Y@=UU[YBV6N_G[=DQI-TW6[.WE4RVQW
MW9T\J6NV[<Y.GF2[9JNS&_(Z9G-'C.J83FOU+_F3M&6@!CZV+;O3Z38%/K8+
MR\ Y M-@%>F.JI9!658W&AE/-Q-:A)QL;29H,T%Y,Z%AB\6N%HGZN.\X%;X,
MHK%=_-QLGQ:5Y?^*1O<W0B'<>[?Q/3L*$+ M.QH:&%2!@<0%V-/=L4A,NKN
M!'ACAD%,8Q9S!4-^- XX#+)H73MB7:M%F5;_6OTOZ;LTOA^ I-;J?RT[W*-0
M_QN'"+V&^J]I_;__!&G]?V"4Z4B@X]3_I=.["?]TI=/;LHY"VS],O,KU@A^F
M'$O>.NY[5;'-.9NF?A(%__ZSW7;?&_UL.@UFRX<;>3T9&1Q">,9R\B..\]E'
M?I]#EM^B6Y@7+J[\\N6\^,;XC'E3YSX//9^)G_MFK[Q#)E8E'E[!C2_^Q,\3
MSO,K+C"X(:2)9T%QA6K:1P.@@R#K*P.Q8C3T 8A&0(JKPF.+>5A%_(&5$=XA
MY8HC(#M)C;F&RAM"HM^S((^5I8+S5E/#(0V'-!Q2% Y9&A!I0)1K1N>8 9%3
MK32L("!PPJ%0QT]!!20%Q>T4&F>U7P,5U#0L.'B*-"PX--((%NB3(@T+<LW8
M.&98T*A6Y3U&RA7WDS3B9\"B^=QB:DI@=30RTLA((R-ED=$VTZ61D=HJTCUF
M9.2J7W[X8<H51T9N.GXZ,NKS:2HJIXJ2*U9W#A8M5AO6QTH:)6F4I 9IA))T
MFTN-DG)UV3RFJH.K:6]81TNZXBCIB^_Q,.$/("!94J)FV-TN_)NWJA0XZ(MY
M;HJ.E&-N_!D"D^/$3V>8DO4'#(HE&J#L.44:H!P::010=&M*#5!R3=4Z8H B
M:6\H6QCYLQ\OAL*NU=EE2UZ7U'5G05W+CD8/Z6O51*56UP=!ENKJNJ75M5;7
M4F6U"W7=.#Y]W:Y6*SU&RA7W)_2!DP O-L,KHK&C<#!02V#+W1ZQ: _#GE.D
M(<NAD4:0I:TABX8L0G?9]A%#EISXXZ5<<<C2\WZ$T5T C!$5XAYPJSAYB*P&
M*1JD' )9BH.4K6C2($5I;65UCABDY,2[1TNYXB#ET[T79 DP9[TWY?<LCSP5
MIS^M$J9<C>!-<4W\JL'*H5.DP<JAD48>E8X&*QJL2-/:.F*P8A]M^5K[.,K7
M]H9#'@ZS"1[^?(M"_CAVF:]D:XLB+?9Z/\LRH%%-7VC,<A!D*8Y9M'_E""%+
MWF*F@9]="U8 ]](XFP1">K-<>-?Y48"8;=FA<DW:;7FA.-!9@6<&,P(H\VDR
M*].%Z;J^9."ZC&(!CUB"WAFA:R@?V6ZH!WC^4RV*E 4\LWP)JD68[B^DT4Y5
MI254&J*BT>Z/&NVL8T=;\Z+@A>)H9[E8B@8[&NQHL'. A DEIL&. F G>9)*
MZ^(91;-U*@FR+1MF!&1TG?H)'RK2>3E>'%@!W9=CA.(8)S^ZJE4;18M^NMT"
M[XA*<%^(-XM8!J%,%$]Q=K#.[8/EXO#VGA='*0>H\\&/IG29\>7+N?$.4%"2
M>1Y/DBBN^R'\/^4Q3RBAZF$<=5+#:](Q2PT/&,O\</G<K8!L&Q"Q!72; VVJ
M:4R-V0Z"+)%4*!=A5RW:GM4!\C1E@X#GXAK^R2^7KW =L]V$84RCQ"?-$O,
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M09@>RTV1JKA\]G:?RT!!,CFFX:1$)*-S,@ZA3DK($92.B+%]]U\1"8C! ;P
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MFM-+R*9KGD8P6P\2&B\:)L7^X%G3[(ATR N)U?@L=;&47<S;.^;[5_$1J"$
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M58G(DCVQJH[10_LZ1AFZW/ES>%VE9^F/M0NL+SYZV!M.)Q/%TQ3EAE8LLG)
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MWN/A^F;\(EX,YW$TX**(:JMGA4?=&"A8+,8P)X5",SIF$:AUV08H?7)6B2E
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M)ZYE%JDX:HVT(T02FZ^=Y7'4LC@FX^43;D_F_''1>E7&_;PU?OT,5SK %]0
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M[X!.PF>#P2G33*(32!WNWS("\D5ZYF)0HK,:_8\=]1W@RDL,M!DPZ9J9$F@
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MK'1Q8"Z(DG(BP*"E@^B3I#D0X4.KJ2\;-'?KH?NUCP\6^ZB&S"J;P%_=CQM
M=-)><ZZ!B^:VFW(PC 60:)6-B%Z3=H6TFY1W\Z%/4'D/EEF'Y38W4F>:347Y
M0$E, 8@JOIJ.%&S, H@1+/"0#4^UVR*L@?+T?9V:LNZP^. FK%GF9IH[[FT
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M<>8I_L(V:KWYX4]=CP\65.VF0W,\)]-O:;Q8F\:E6:-!JHP[O3,"#$$/(/I
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M#9'54:7D"1BNBS<6,UBM"= 0K,[121EL[5.2Y]U7;BL6;=E7;AMM'J0]6!N
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M!5Y]S#>'?>O ;\'7R[LI$#V7HZ&RS(O59:*'"NB:!LXPS(D^*F)%UK4O"BO
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M\Y*.1))MY-[Z!O7WBZO9,)!3\VH\^3/,)L._ETFP"JUCCC-@B650R12(AG-
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M9S]/:Z*))AJV79Y?->.WJTFJ5O+U&)/[$)<V>!>0+3-?N@([?-!J?QV.#Z6
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MU@WH#[:X7[S_&5AU0A& QX\5'11G46E(5M&Q(A'KY)I$'@>MDDDOO&S=M>D
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MF#,UN60L)Z;FVF=8,42(C"3$1 PU':]8T2FQ=QMWH0'NGYM=1]-@'S,/;EM
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M:LF^A0OH\W ,<?1E./AO<YC]"D.4]W3RZ:N?_GMT<Y7>77_S<?HF9RB#<TK
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MW#36FCPP70-2Q;27OXW?_U!^\M:8G[Q)TS"KODL@'N^XW/#N5XJ$^87+OCT
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MGT*(&2B0]EWLC=I<0-<4(?^Y.)E)%\,ZGEI)*L!44 %?$OF.[N??.ECK>V<
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MDS+;8DJVI_>OK./7/2G EK*=<BPOJ6[;F +8DF69ZK/$&A$)WGU(7@Q;HYY
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MEW$R_/]EH?\?H 61L;&6LKY9DXO[W^GU;=W^WUG[A0/DOX26OXJB[_\]0<^
MIA\^/KX,__]^\O\C&OS_8A_Z[-]<17^2^7_"\?_G2?[C[[;.:"?W07OS]0R@
M"(!P<'!QL$&X.+AX(! > =DM-,8$%"2DA&34%+0TU!345'2,['?H&.XR4%&S
M\+'<Y>#DYN&F9>87YN<28N?BYKH1@@'"PR/ )P#?N@7FHJ>FY_J_?5QW &1X
MF$B<2BP,%@"3# .+#..Z&V!"YP4<C#_'/P$2 Q,+&P<7A(=/< L]H)84P,3
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M#9-."7P-M#-=:)Q#@6?H91)VK-Y64P(D.ZAM+\K[3PK'4N,+S(IT?SO4 $<
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M"JNT4G'JR7?:.7RQ;6Y/YQ7!DV5";GN=@ 7NWR 4(G6SV&D.4EUEB6^ 70'
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MM%[2&,+U?1W$<AG%&04UI"9_O]%U*:M0QC4MI =UM)94ZIF"KF2&A<Y"U9,
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M]+C%85V-6<@@85WU;50(['.Q?"O'8K$]04';LU2RE_*_'6=0LK[I9L/LP]=
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MIL$B:# Q.@U.5/KQ""Q,]=Z2F7AA]H6Q+!\3DD/V9+(7?L;6=ON\YQK(Y<Y
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M^@F/,'9;F K$0BE,;C8V/ *(TB[*^PM'=Z6]3[[;8W#^ :JRL1"K]I/4B#R
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M@X5VALXVKA,6N(7OF=]:9B+:8KP]F9!66N;H&?;DE4O#TP/)@I=N:OH!A=>
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M]<RGDYQ+\*F+1W =M4!C&4HCLJQ1%<+F55=I&]>\!;D(MU'/H)1XS?-3*:X
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M^6UH)CB'O8%D_;@A)ZC3X#N!]U"6?\QO0.RXP=^@-$7C6CE:V\]7S%(NV1J
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M1I3=+H=M90Z5'EK?455?TNZB!J1&2(PKM[#1LH)HZLKF<<=:$_UXK?U.QT,
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M&LBSXPM.[_"?EDX+F,-UG0+5TB=EW=/'M"9X5XU"N&YR1*FM]R+. <+UL9Q
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M4OJODR\F\++6K.&0%!9\LY)1^SK4Q<V(348ST.J2JE$.%Y(V?1UVF,;B^\+
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M@6OU;UR9F&]J[$ Y%IM1;-D[]6^F_*XA!;V*JR\6[RI&4J'MU.M]^<5.2[X
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MTUFC\GG/#^H\OT 7:@Y.V9'=Y;L3S2+3<SM0BOV]X@]6)7;<3R+9IXKXS '
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M#YACBM.GN@N/K=O;NX;&)-(3#.+V5)CMD:)]8&$[3&7&]L"5$5'B"KU E>,
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M#3H3I4^L=,?B#JGQ4<:&JJN(5T(L91OD#GKWA3@V[5XE[?YJVU&(:D[(V>.
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MJ'@ >/N>IL;W];;25QC:E'@,O)VJ3($(K]#J<L-"V*NW!E*)B=>C7KZC<<7
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MT<]@OX_/]>CW3:W3'J/NHFTX["">+Z%]^8=)Q[5>^WQ)&N<<S6S?7<-S(NU
M,4,1B08IHTX>XK%7RY?>CC3KC:T?N$^&! P]'?EJZQ+, =1T903?^P:M=Q@X
M)X4XG6]V33XU#E(<?WY8PDE3$L%V:U;)ZQ$X,UE)N#V4O20@]9]90$/[*F\J
M([@#NU(X^C[KEV_ZWW,0<H,8HE?5(KNMSO44(KZ4R?.-I9K'Q4\$5;JS-2-9
MB_+;C>OJI;5<7[_]?N4X6>/#C0_J":7871Q@B[Q'9\  ?-8_:J-G5?V*]ZG<
M=)Z;O'AT>ERJ[^37L?-8"]4LJVI@.B5V,J;C4G:Y_+6IZ;4&>C'T"2R-?V/E
M\%5C@J^T!!E[NZ .7!'N*=2^77^6E2-O4I%A:[J6Q6Z<T9.CC&6?I!NH1T1S
M[)M-U_;\[*'WUHS3JUT9+2M;NL5HVZB/Z19Z['6L/W\:,1'8IU++\%1W?XZO
M87M7 VXP;.)0 5<>46ZBMO95 #9.&(HTQRF:4.FSZ_OI ,]+E+UTMR4]L46J
M.(!CRQDX79=1#T%>Z04=9J9UER=ESG\<-274M[@S5?\MQ$AU(^33[2/V;K\
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M/@'^LNN=@Z.+40T]<U\YB%1*).<8S4=?4P9\[)]"?O@'8B7&_V)*0PI!KR=
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MTGNM</.*;L42N[^*_(&]_:,^$I!,><<-%8FAKHETZ-#DP'&L53<:"^ S 0"
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M3%\L*;7?A'P/'C8@EG+B>]Q;/QURI4A( <-WQ_5LWW-<C9?.,MA]@Z5?TL3
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M5J,,\3=+XAN%A$BXM]6HS$Q4[;K71 26>$.T2GH9L.J:<-NGDYG3G'/Q]8S
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MB$NG\H\8?8I:,/'(G.8D2P(*^0"?6E04[93WP;5;S^7^EI_+%T_? #D4OK
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M%EY<QJ[>'L6;G3-2UHK5(5HF$R<2^\NDTUP&(P2UF!MCO!)3#+A79 1''>[
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MIR6PI9PVO[S/!STS?"I+6 2URR*M'7=A;0-%PF2U,M\H^?NS7@C&KE  V*\
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M'ENRZN/B^"/ 0Z7MM.'ZUJGC.T!$$'/#N%!D <(Y"#SI+Q_^CK;SC-$=- G
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MPX#]3I>4)_DOAFM,!UPV!]S8;Y9+%.\IJ!ZE!:1Q9]Z>AJ:";CP;9\=-ZK[
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MY$JV_92-AI=IO<_-5%SC[P"=0F*4)-:5VU7A6P>\'AENP!+[003Z)AA(*2)
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MV XK]ZDUP%\9BO:;Z44N)L(<U/Q)"Z(TG%C'"J:2+[X]$7(+43#1H\>WIV/
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MX*),HEQ-3ANPM.2"IQM3PR5[7#%R.Y7*V/ML+@8QA/**)=Y1HGGDI]T"=V^
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MFK/8-\&%C=MB#/^X-ZD2V7@@"[/F<C)=0Z>H&[.=O,H)HMI.5)Z*UFX^_8T
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M&:S$$_Y@;]D4[@AQ.8H]F*PKAB@NZMP] GYO-*M:E,JMTM(_2>= :$!GK8Q
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M'D_?VMT!?VFRXEU%UL/:IXB=00F%_; 3Y6_OWU)'_Y!RE3C.2LY52A::3%E
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M0OCG,D/_Y&"HO,'BA^<:33Z5:*:(RIBSL@6#KD]QJJ$C7@)*H'64(&34M<7
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M->V<QED!'X&>=> ];[(@_+VG_F'EJ&UEXI8M=I,TM85?OQ-K88L=*E7$#A-
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MWQ!3S]G#Z_+'=_9X%<#2EB[Z\))<;ALZ2T^;Y\-X=D*31=+"/CJ\EU\G/.X
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MW1 XWQYRM0F' "(@JV%'R9_W]T6$5Z8F('0%WTZ$0QE>/H@?CI!X0R/N(KY
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MU$[!O'^W+OAU^44ZE+CC/ I7O4N,0L&O?)LTR44HL%B._F?61S* N90&Q<>
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M;J62=@UK)U-[$^-N]+&7M*IU31ZH>"I*&/:Z=/"_;C7RCU;;1^8; /&?EWG
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MKW-5S6<GE4W"9 7:7@UC^OI&ZJTR?A!L@2?W'+Q5?G*P+B]@"$CJ.=$& 7N
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M3)2^.!8 4GFGX[;L'/DVD34O?MYM._<CR4H@8<[EC;\(>!)$NZ0.4C-*5 E
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MRF%1^6QOZ[]2&A1 X^79.8O!;C'&P5&\PVCI704B?_>8X0=TP,>O,.*$^&4
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MOF:>,H_#P//FV?&NZ?+/"A;9L =14J0!U)U=?5SH;/JH->\5,11*!N#%,DC
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M[_?(G]D',,G=-T7O+\K?($ #-9P%&13D=.1?_R1J8X6$BW4X:9^RX>_? -&
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MB85MVZYFVHEC?^O64.',*-(A0DIZ=D6C@*7C]1?'R[K:GQ<MQD8(7[_ZO#/
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MYB![U_F,8G[P9=U<R-7H6?AD)64QRT[+ U87#7N)3QTP^XW9HP>--T!KV U
MOG[)-0^C0+2W'QS*U=5[V2MP<$PQ)\_^>:R&O3N&<X2Y3]!&<8:1Y9I5J;7*
M1(CVA6_G[12>F5?WHN9+J\AT! 545#Y-ZSN?O;;_YY_$7NK^+M"1K^[,C%:R
M1A*18+K/RQQ2#R+V/(.K'"DV3P4?NDK'=>;L,-0FI0]@D_::P:&=A\]<8?8(
MV1>U5<]V*K]O>D*8X^GEIWTCS#W!LP1>8>I[S748A=FJRR_:?2,*2]U-ILE/
M( %,?D+[3466W0844S.9;WB_\,%F>>5E%W]%#U2EI#(DZ\D[J\=9-_ ZAD@1
M(I'X8-,5 >OD%&![5>V--B(O1$M*H1]%2GFZTIC5[:-3$W;I7F1]0GI?SJ6=
MD:8U+S6 K'O>$,[\#8:*X%)*GI@?#^]:L>B&,UCH2;SG(]J.5DM<\*RI(8^\
M/$V*(W-@CNFE3ROJ7$KN2WC^927+PK%QQ$49SN;I*=$U3[YXHOJ^E^*$Y56W
M,,IJ\I[/T6XHG'AN+S=1,F1!C*1E>(5=FR[4ZM1_F;430VN"QK#N"PV1 !S5
MIOI$:<Z>HVCE&5D)1<]!!PH&IM:L@,9*GJ[RI-+,TD5%'I6[<K?#ORCU]41.
M3:?$(TDL./I5VM$&?5'#@]X;X.6*^Y^T5/^9JI4OW_0)]90YU++\]7-'7Y.8
M_9&RA)VA>L&O?\/6N S!LUY7MJ.2)'Y/AB_O613)?GD^\\,="*6W>]OF1$JY
M8W*UZW/(ZZ)*^/[D,$D^:8FMU(+TN$&"9DX%]FVD4NL&$&>BGUH2R"C<+/=R
M/$F":]79ERGX%+#!W*EI7U^#OB+TF/<FO@D:XN\7D7?E$7=6[W^C(Z[1L?S.
MB8D6=/X32F5;W<RT7YU59+W?_Y>_U"E-_O*79HC[:'5J<0#=^ZO1EX[GU+'[
MLRKC;K.$<J7KIWJR3YO>$2:3?61W 44Y.?%R*Y0*+!,4;WS)D*K<Y15Q/ K=
M7!]O(FF=)1N(S8J\]^V$67?DIWBE\9<1.IA;H=/F>BKA[O/9O1@_@BC7?,Z8
M02DCYJV#6/CI/6_W!)'\$B7Y=;OARN3"7>973@9&KR^=BQ#*JYV"GB3R7;BK
M/QK,K<&X7UF8T14FUI-A;; SMF2I<<<KHN.\?<Q%XL%PM\,L*\$PE>$]XB1:
M)=:H<.EYO:M8>*G-BB05(GBB?4:L;%P :R5N<NH'9QD+QP^[1A3I#06?2<H=
M7A?=>H^+B+R^HOBZPOV\:^7QTAO KN5(<P)+=$)E_UZG1QK[_K>3KWD*_!ZG
M%(+L&ZB1^6"DKS0V7RQ9KDS^H0C9WM61$1X)]R>B>I6C4>E;LPVZ >BB0R6+
M;ZM)V0U@*8_:31X>Q^MV&+1YT5FT&RZ%;-;(K7PDHI+L?7&KT<YR5_C5 ]2%
M)[M'F]FB]V#AI>(4"[;^IFVZ\M%L#$^=&&5_*ETWO26.9'4YT7R_Z3P6UVBP
M[O@COFM8/$!X@DB'C<ZH/\;_7AS!YF4A2M/WEXC8O<'.>O^?V]=!W.,,0;'/
MMA.JKVHU]06Q,"F3]\:[%FOR;.J)DKC8$XN($[SK,D_%!D.N>:!8B-]XFUNC
MN_$]M:9>:BXE 6%'3/4$D33X)4?;IHY$:WM574D>?K\;,^!?ZY;BH^<E7#>@
M5=Y,6TR86N--;*U&Y )0[$F%7)LRF(VUE6 FGZFBWC#4>0O&(V?@LJ+SJ/Y2
MO:#_K@U,A#T9.B8@M!E:KY?[.OWBAQ.Q HY8N43@CNT4-%(2=V/ICPTY^7.U
M,\Y28QGFV>\]S#,I[OLI[9*DHQ8AK9+4&O3.*_QT6+W'PF<IU(CSL0OOK?0=
M*0N:%5V1Z'<W -X1 :J7HVH<GKS'SQ6<:!!M=C9!FK1H_N!$E1OL7LM2(.+K
MYM]2Z=A)_6CL$EJD4K"IQ^'LS$RVEM^4J& LP5:W9]2IRM9Q ]P['L0WG)KI
M]?9?)4T#RY+O1JJ;?\#,EP MY+IM^&*2B=5<6XRF$GM592HDZS7X<0@C4!<J
M1$/O'I\9/C",GQM\6P\-"R"U#:!LJFF*.U3G\X;B//I/6VZP0+>LE'-E8_E8
M6<!TIALN4^5H'!\8*L<\E68[>0-8DZ;"\7^ /Y[\:&BP7!(NQ==M?51/,S11
MB8 MDH2Y0^]-K<$)W3XT"FX06Q)BZYQ$8-#&Z)1/6TJ.%<KK12R4]LTN@%.U
MXOPUEI+QT]TB?;JU 7CY"P5!S'W[VUI7_7]2ZY;21%J&W&G *D*OB\E'57YE
M"H?;G06>1?'Z)*\'4%V^;-QSKSG1+7"\RLGB$7Y/[R>R62-^'U8/X]'2Y,W/
MTF33&8XB4H]_[\,7>CWULV6-V?L&""*X%AA%&+5?"^V_>;.\\M[5;6\RRN!Y
M-52@I?YUZH/9?.+9EK<!6$;*7#O\'J&+NZ1RC?EWU<_<:W#Q\0LKV"])S-&!
MV+P*.]YM;?^TMX7M(9MQ 8F<V4O%6,_.MC1?:S7FY"T8^U$?8G:I<@TRYLQ*
M'CQG@$,.!WTLN^!G; 8M5Q7(X*@\HR%HE+.>AU+^LA6-<%5QM%]QU >3B,4F
M&!-A:FU"$6\6** /O49.GX^:I8G9?@[2=0>U:>.X@.AKBFU96AS)W*I:B,P8
MMY8BI8)O@ /=(\<+>R2D#*O]?,WP\RZ>5,/=H^DV=L;)9(3[*M+IZ@C"9N@J
M]^!1=@*?Y45RJJL/A8IP[GWNZ>/&1BTX+A!W7\@75]A'V>PDYZZM42(7"AL
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ME)#JX/MHQYE@?FAJWC_F!U&!;SLRM43I1TD[-?13DX%D:I'UA?[C5Q+KE>J
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MA\9 &8MV;@CULO1D]/H\3P&+XY W1H26,EY#'5L32YCN0]:0GNF._C%_PAE
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MB:Z6/X2O$/O(CR1*71%'/:-U.YTU, <BD]PH^0!MV+?7Y\"-5^*!#_P5A?D
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MWDUA?H8HMBG2^\23S] [^BOO_CV!)/\FD7ZK@-QH,I661 =93G3_FC\Q@VU
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M#\[4.J$.E<";-K:,EUX06JI2E-#*IG%$9ET?*3M TYJUZYZ[8$N  81H3=!
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MGRK[_MDS*W@BAS./5HZW/#><%5WM/Z:B"I7YW$_X:OJJ>O+81APQUS_K7T6
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MJDY9\7)D37BUH2'-7SE$5#H(BRB6]WM"=.VZ$//RD+)2\BAL36X-?,UBA/T
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M=(+7ZE+ 23LW;H3/5GF%_0Q'=YY_;$^$.#EOM?&<IW!IP-;%H7X92_UY#VD
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MKJ=B U;HB_KFS?@,DVS+H8I( +X6BW"<?DD8U<%'  #P +"-\C%9IW\O?O[
MK%-8K\33G+.:!QC@\7EOQ>MJY:J';TQ'X"(XS4[V2B+RP4VJ28HQ\:=;@8+X
MSKGMV>LWQ!=^!:<O*_I/#EN=/54O2^B]L1_^(+SHU-WSQ#H^^EKA$$HSN_J>
M;?/@YTOX11VPV%&8"#'&LQ&@8YCZ3-Y;5#@(AJYX=2==L[(E)E];M=)>[>Y
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M!#Q*=";S>9W$F!F(>U,XNEVH]*+&H YT"'DP!31>$,$=3M\]UL+.8(IF>RO
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MG=H@F-OL[GRC4!?[8*Z)NWSPK [^P1\S:(VE0EK #LCUBQ1JE.HE!<88W;Y
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MHI?F?5**=ZW N^?18"]\'NI]SSW\(_19J7?,=\1DLT:>58S]T8NB&K*?KQX
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M!#H"G,R[9DU0ZSZP>N@LSWI%<^ &HMRCZ>V\E%0Z7K0U4#08K:N'&0Z4X"(
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M3+;"+XS*#AMRK]*W.T>?[C&P8EP<RO;LH[R84IW>STOK?!*]PC*TB$#I_*6
MP>]*,*FJT;2E2)^5FK<X/JIF+PBP=G3O JLE"5#,*QW^Q/$=^HFQ175PVY->
MHEHGLX$116RHW*.SW;YAD;7AC7-&''38,QF:?4MU\_H:]CN]_1@74YPT;Y(*
MFP8-Q>$%99Z+>&H)6;>_=,=I<D>_MZO@;F":1IFK2]S\E"_]8:RFC]OGM,-5
M)[1DI,_4!<UR-E\OP3!Q/W<.<*Y P5ZYA%KKIBJR3?WU?//J:)8\@H?9X9N
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MT[]+K/_'5\30C<(](,X:07*%BK_4438<_8\Q8&R##+]5(#V&41%C:OJYPMB
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MKVK:/!A12+[KT$O-!+K55"\ -1LQX$IS<,TT>@<%>O1GT=/EMS=[U)ENBEP
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MZI#/U)UZ;!_")L9*3-; ^G*=3MNB$,J(VTM<:KKN<'"ME4!QWG.(H*:/_?4
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M[2Z^<+L$+JJ-BJ_4O'U'STB@9G&&_!?=L&.Q5P;=3@L^L#W,'&*'2[H&@J8
MZ!"IPP-6Z,T6ZRN]!X%.#5-!,#-T=Y7\*P,^:F_ZSCNTFRL6IJJW!]!U4G^T
M36<CEF;^]/E=73-FLYNSGD-S^%ASBP/@\+JKD540!<!VID*?P$V>\72AXT >
MX%MUQ/MCJ]WO>*S*6&)L!'&D(/F3W2FQ-.??B\?;#+/EA6T6?/9)>.I!'\U,
MCG:#/VH9T '%'YR.75=,6^UMU7D>?MA5V ;<3IN$LZS<;X:7M_DD0HLNI_0Q
MB\DS?J'*;D8S2NN2_H+6"NI'_NH_<\CWBUR8P]D0G4;49$@BXR.</( W\P#M
M/GA 3SH1\<$."1<D'2*WI,SAXF+V2-KVM62CT#C7@0Y1_*]NM.?7W&]E09:Y
M$T[R)X,VI6G>S;G"+?<J%F(O>O0[AF9EKMTW&H)Y94K/&6(_/83!>!),6]T_
MVY]#94=FTP(YG4H9M%K3Y)._F%M/0:240\)^5,5>]%^D=@QOG.H_\3#H#[)&
M'84172SO>]#,7^&%0-IY>9X::.(;[0,C@RK6^;JJJQ]Z9#-FSI!9@]=[,+;5
M5"!% 4F.\0%A>/,VW>8J!7#QCR'2;OI/?.=_!R:)4Y,BSVU/FY]1S6NE'05:
MU)RYD!_AEH(BQ$YN?K-#_I22E>=$T;YP7I.J+-XX;;/F9H3T=!L(?\-A]HX5
MZWV .IH$;_INXW(9[:2<#E4N;IOOD/PD'$N\.R\6KMVKPJS./@5JML@/Z%R=
MOC%J/^26&Y,7PGUC1YS(,+1.#\E23CPRZ=3M.+ =G784VCBC ,H;"7<#O4'O
MSIZ*EX46HC[QWWBH_)&V;5W)/6S9[OWD91[P,1K+!QW!&[RK4R&@%=-A(H>/
M0SH)\5\M!!/4GY\3E< [+I]Q=5PP&'_9R5!7\=0:_8Q+*G&,WJ^IM23QO='F
M:)H]/VVL 34FS+OV6.ZJO2(F Y0L=I/1[KCB5=?XSUYE8^-('1],'_GJ9\6J
MB4U$<G8WKF&K+*)P64NK>A!&;O[^HB6<RS'GL3++JFCFZ"P$'J%Z,41\X@;D
MAW6WV:P&H.-N=A$J\5<6J+Z2W#T<Y"AT8GYLSV(NYLL&.N0U])L+N=>!+IFA
M%^X+]P+JBB:R.G7=+A6&I-[_;%"GKRFUF68$U24=GJ4<FGR+WYHAOXP[Y9;
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MPG]NPL+*O(:-G8N=G4N8CX=/^']Z,=H  <[#'_@R6%GD@4,"+*P"+(PN  P
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ML^N%N=MH=OH< V!!ROD,>\XH=_,=\;UXCTM8]S*IP$<H\LWH217-\X!B+I5
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M]#,$I>BE"%NPR-R,>5CYC>(M1?DO@X_=GMTY[A&8:J]-RN]=-R%P_Q*+IPO
M+51XA62?2^KB!EC CS#]F*E2.K<) ^ -)V#L"#"J"I9LA9ROM*J@-5!@ZTZZ
M[6RNKD,U_2_").8;(];=D] H&%G=O3HK%8?^ G<F5QB0EM>=OW+DHMHM(7<'
M.4CGB).1K0J(8Q\^$*I_B654W^CT'R1)]7%;9+1]MO*]U7OR@3!&6F?X8).
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M)^@2NT.LO_PO-NQ!/?D50T+5ZI44_'EOB,Y=#M$H 2($& "?!*&9SL^%"&
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M.J;7K&_]SXL>"W3RH']9.W_UZ9*3)CHG7@+90WA(YNBD"*\6>73V6?<<8%U
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MA1GIPT!CR@T",1I?WZXY%0<UA3;Y1Q;8J4TL###Z?R8"7OZ\ [C7+\W0CQA
MS:JPPMS )(6 3@2O^U>B*$RPOV@>K.CY=GAV);T'O=1X[G8T-3^G=AV(MT6\
MM;+E;D.Q0&[-ND5JZY?5[)\39;3VRE^HC'[QVY0O^.Y=%OF"D 5@K17.Y.O3
M*12#KI ',>1TY;NN^LR,].UJAD^JOTS%#/IZ_XZ:.'0JON0,0%;[4/A]NS/
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M]-W1D(V'4),H/!OD$%HG35"VUYR/-'6KVJFJR_8,>S%-(-!;E@WU>5_M4-T
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M!OX(<'_D>-VR&.F3@;2ZA.2$=&(;.H3P?['WGE%-M>N^=Q 5:4;I3:(40:J
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MV4#I1SN)[$^96KU'X2QF60!19YZEW]MC;U)#2,*4N Q":E2-O!VUC+ ]L'#
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MQ3^\4QK^8[_N1KXO254(X'^]\%F\3C5*S/0979^M+Z6B\1I/O/' V$D!71:
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MAK11V..3WE0-8+2&&IV?5%2O/%3:YZ]*-#'NM"F/4NY=KWK$$*9ZXZ51X2P
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M7;Q"11/ 0@N3O ;&BO7#QG[!NC]??4NNM5'?J1B55YYL;6\=L.3"-5%)PS1
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MZ"Z4SD"_!-#3.VNQ-.%CWHQ#8=]L'O,I9_T-</*CWT<4%I<*6KV)$L N*[$
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MY>^L\D44^AQU7B*WTGZ^GMVU6U]R _@82[K(+@%,<7EC+#]!/&R#!9!P670
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M4AY>L*);)&(A?79DN5BNU<"G_%JDM;4\3R6WSYQ=G.H8\A#\<#/!]C'B(O[
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M2<:0K9/>(K^WLO)GF\$!79H5]$_/_L,7Y_!78ZFST_+'V0\QB? =C\6BR"Q
M!+0TMX[==IBW;&L4PZUJ+AO59[.+]V)"GU#N3<R=&U M^EEVE8V'V3+9S9NN
M[YUSWE>,9HTRNO<H8I O=\')1KCHLG3QDF_'_HYBQPNAN[.8?=_ZJ0M,<PSB
MI[9CPVK;HHP[OT[E]RLG$X/XR-X1T#+-NLEPY#U+ZA/_T?46FFS$KO9;_KMJ
M]X=D-CXI^NDMRQ[/RQOFT^@6!$>&I78 OUO2[:J7LW**=<#OMI).5DW@3^@!
MWTY^C[.]/_(KP3-AT2S CD?82M!U^CGVC<;",VS6/.F@-P[N1V5"JVO =RLH
MUZOE,#=E:]S)S8U0<;IYQ5JU!4']G-U6N9JM,.@(D*85(\<$6+,  (0@>;9Q
M]SE\D0!T06S)AU(/2O8"$_/Q8(%?-1G4(+;A'>\KK,Y'2U'3I26V2^-B,N^]
M6->NX,N=^VBXR&_S,1A=@K^\W\8I/IVX ME(W!H&B0Z^H1LR,$:'$%?<)^N9
MXM\J2I"I@[S3CJY]%ZA6ZY:04F0*PI"18B2)T%U]VXO0\@P,!LG1KH'N9@1L
M/D$E VE/8 .J61+@6;>&.\@CQBZ2=V19@ D,"R"'W=),(&'K.ZF'QWH";67U
MR&<;3JC?R#H\M:YC=A38#1SX?<LT7?H)JNM,:Q;<Y<?$NSW8;R"/BA;FP957
MX8PQOO4%U3*1&X()6T9NC?9-GOZ1#4:V%-?EYF4;; ?>6,2FN37T/RH.8I8\
M13E"2FU$ERQ4'437U1Q&5%:4HQE2,U5,RJ&N)#HLI,/,*WG]MJC0LSL%"H_2
M'GK$M,$^FO!E/ZNNVM(M=KE$]Z3FDMP:L;LWBI96A.<M'7@4S@2".CWO\\"G
M963'9(ZVM(AV4-T:I; A_AG!CN?ZO!X47!C[=2K#GN_$AN2!,\M GF_(+GA2
MW38DI@06J^346U#J?!QW\R+L?7WV(QG99P_EXP-%29O-:*H2<2*#\LH-_[$@
M^)[VRNMQ<]KT 1^!\!4TQ?'75+ZLZH^\T.>&<W=1YV_)'KI>;/;QL*?H9>^+
MC,A'D_BM^=FN.28[I*X]_7$#4CPW*91E8;2$%W8N16_N1<V7N"Z#**FJG<:B
ME,NO\AQ@8D==AL;/!;F=Y)6K*(\WEXEZI/T)A_:!1IY,20O,6A 7.QGZ<<"V
M;-DU?8*@(Y/P:4$2<I !ZZX10'9GZE!!B-QS6)I)8F=5L"PIM2S)T$RR38]V
M,:177\8J)\JGQPV\#^X7UJ04U3KR++,:>WL;7+SU"%1TS#8*(<#X:"!)KCIQ
M#X^A 1N>(;8-UQYW!&UI?H\//CKFF_6M\-N)5G,7->:CYNM:]IYNX8V]]]/G
MV&'AXD]W]M!T]?M?/Q/R?Q'K ][.O=6Z.6-W'4HW:C)R1PNWO IS]C>%]'T^
M(4HN:@92E:U+,2/',&%E6<M>5TM'YUHB@_$1JY,K1CR@!W$PE61Y"Y=+VS*8
M0S]TVFHZ=UU>_%@6M8%ZQTB8A?[1XC@P5<@/2Z=B[P9#H7W+_IX7O+$^_H<>
M-M^6C=*IB^$:LC&&^RMVZLG3I!7:9Y-OEQRU2M5Y=F]D2#DKZL<FL!*,2P.O
M6:*6V=%_N?6F(H)M 7:VLAU$$@MP?Y)1552I.E:/XD4Y0Z8FC%B Q"11%L +
M-5_!;J?.2K/_U.P,9T:"P[\&+C R/R6.ZD_"_D0[DXW379IK/Y5XESC-=C6E
MJ;('^>^;16E&AU"UYL 5=?I^/.*A(]&'!7BNA>G#XNTZ2@Y]-2I2P]^;.EY<
M?V-2E0891T\04<F=E;"VFD/(/K"@D51@PMT:Y=**&LB63R]DY%WG&][X<,:J
MZAJ$($[<3Q8FA&?(8@G1P_>F%UWOU4V,RH8=^^Z=?XLV^-)6A(QI^=L<@EC2
M#S*(L@3>8EOZ%GIG*9-]/V8KA0;MJ)W4FZ>.&:A32IBN4R,*![DW'LKVKRDU
M ..81M37/<#]U,SM[>'M8?FMXY.;\T<QD9*;'[$[$>KD@(;H(OEZ(]D^W13!
MTK=ESU[$LYO^H2U;YD[C8'72)I.WG? *VE9!#JMTP]/\G@ZDG"/:RBY ]N2.
MB1<&#7P,KLNN>ZE0I&%F$;"9N]V*^(B.AWTB@6I7I.B7TZSJ9:7Z=&\I>53$
MJ7\Z,A^6_"F:6HI\SG8DL35B=,/5&8N=L,W6SI&-)G$EHRR#/<U]&L&+([BG
MI^PL)5SMLF)VF4U=^?#Z 6#OT_(P0489 NE&2)9PD?3D4:+W=J-PJK:;V3A(
M.)9T^4#0U=5E@]L$54]9^=;B7F&B<##_2Q7,.S+T,MO=)##%$?JK,R6D,8>"
M553[\A=D_^'@LY^&<L>OV7[N=O[TYK*T_.J]SNBUCP/D N<FS:7F<6A8T:^A
M/NM8:VNV6=UU]3%/SDEV&#YU]O\O5-6B_J2=I.I,A3YQ?EC?TG_U>&W^\.-4
MK4<[AK8&&2DMTU,\Z70R=9YVF-J)>YGDTLI#60E[3J]J3#SP_E1@:VO,^O1,
M(!Y]@>'TKE7*0MI4+C][Q\>/VGL,SXC^M'EV%U9LM!E>T:[5(I4K3E1F 12P
ME$$*2E.>M*SO(BED-IZ=L.?V[1,'XYZ!'+:_XDR)\P3@3@;&C-QF00@6O1^-
M?"L]QU.I)(3>C/"FH"]0,&C0)[?P:A]*+/0[$1BF6]9>&KG3;DSODTP#:GP7
M:O@ #(>11>B30?4''EF &D8LFI(0E2K%FJURL]()S6V+RV^CUISNXL>[:4SI
MHRTG9OF75!2F:]I[?-:B&3:O:*!/+MS42'QG9)7 H^8P?UBP0RU5G1_17:93
MVD5OF?C!51B'%:OF(0LWH 1*YS;0 @N#4A:K]QW$MFXYS<+>;#D'O]@/?43G
M87PS $]Y%\_+ZMLAM K*]GO7RC7Y+9O_4&(0;!EO>K[FW<PV5,P&RQ T@3[#
M4%W$KD5+%J!U\,/B0HT'R.ZJ1=SY=-W$X[8F7,G/I_<]VN?1/X*\])?[@?_C
MN)B3LRF9)--:Y5OAUVJ878/'?QE*?0_')-0B?23FVV6F7NMJ)T95IXV&U-[T
MXVL'AKZ;U>MF=W$7.UT'TI[FW3D(T#8G0G7HWHPJ@T.D2:*46Q@"*PY;3#X\
M 5D_(<VH-)V4I^5ASK;!IB9C)TO+8YG'CE$LG5B ZU2?2&[SWK%0__4TJG;P
M7G%&@HL"UTV I.ZOOL;U=\C->J;46;&BEVTK6W+K['XF9[ [>&FYY@C]'AG=
M9&%%S%3JG_D::5=R7(NY/ #<E)?ACM.3^;QLX7OR>/1[>+15>6_)5]58$R:^
M[!P,)FRN$#LG(I"^+8T+7SHU!8K$NO55GP;5&<DB3B0N&(QW8-<[Y&-?HPD(
M_YV[BVJ,1.B")._:6+VE&LD>RXF *\4+PH2+>2S 9'S,5$UWZ('''_/PL]9K
M9MN7IF)]XP[D;!C4J/C%11W]$A/LT#M=2!NBMY A2]_(IG5^=N=\<#]=F([Y
MUE7R%XM3R-?;M;=\#>Y>,U]=5N']?KO3R4:3KHR)1*U##&S90>%%#%,.ZSI7
MB,EKKB2)T*V:FXY @+L9#F 9,/X\_2(+D!5(P-*%V ^0+(*JBZ2FL@#GUQI1
M5(5*%H"@2C&*,LJ5_84ABVIAUP5!WS!L(U1K8,!+@.YD >I0+ "O>+B_)P\1
M.LPTI;QZ7C;A-5FR//K-9,G+:>H=?A%ZZZKQ0ZOPXJ@HL$K'FOUL8.BENK?7
MG(A9HV;OF4_8859XV#]3RSBS2QS^0D0;J+0IR!.F>--/@K>PG4?BDX2[/8&I
M H99ERKI^;^\(U D2T&YYI_E)&C8;-^,)']P/CA)+/@\+.7&AC+L2/\SH\/!
M&H[U@67>;L_>*(E3,A-HXZECP1@7%)EG:O*QD?C':(*FB-WPN)*C,J:CLC/W
M>=J-C8/ 1_0^:BC-#@&A)OPR1A'LUQ?%6VA[$YC18D!K1:2;[(^FZM@7Q6(W
M+PHG0JR<K)I0<F"[=@/UEP4&'=^P7X%,<Q9@5;./5DX T47B>D#')VN-)!)G
MJM29)31AHRP1A80-G_6B%\Q#R%Z,4,WAP(0%IG)56"/UN%0@[9@$<_Y:K0]S
MZRZ>KHK#[(-/7:&)AY<X$N\N5C\\3CQR=6$(I+QI8-L]"43A,I$&9*5D'X+C
M*(AW1$]=6&^D\#.3<""$C$!?^/6KP-%UQ365E,N;<_+#_O1%I9_@:Z4H*I]I
MVT87%8Q?B:PYZ,)(JG\DR"P]?G_2]<DK*P:EJ5]VZ711#S@<^ZFSC@7@WO*;
MF%^#?]BZCR#>M"!S3^Y[O\>T>/?VX#>/*N?,:%?13(S'KMB7Y^X]I'2K^;Q>
MYWO-Y7AN]V1#9\H/^M6ZGFKM!0WOZF_]FZKE["@2DXEAW_(KI,Y@=27=]L,P
MW&4(EP%']2P'U_*=!1:NK1?E&LDBV1T!/V+7C,7QN E%["50"0PRJQ&<!3!%
M?TA:<5DS?E@/_-\V+E:GNH><YURG^=:P?[, ^O.+]*E3P48#IV!V\F7E$9YF
M-TY'A'1Q?1?5%;$]0Q8L6_[]U\J9_VZTZC0;QY2%^Q'NA!Q&$SP/3]I\0I[]
M@3WFR9B^L28?E+>[ZN01W6#) I5290OK'"5)]?3N(A.D'QW.>$H_@\.4W&7N
M\JBVR"IT+J$ )D\;/B9<9<X),EL7H<JMTO7RS7+'? ^IM-7OW-^W?Q%:T4_
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MG:(?ESFN&4C+S=+@BI_\UO(#L=0.+QVMJ9R<E+[N/5W^]G2 /%MT\Q?#AR\
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MCZ 4M<Z42:L%_H7MBI8;3AL, -YNQ89)0W3D/S4-D8 A'Z;M=_WB-"&[C@R
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M;?UB:C7JB<3 30C);RC)F'VPI'N*[-7XT<,YN"M!FOZR!(ZS4#5*N4/D>L4
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M-:"*V/"E)3LE/A0PSGD(.8D^06"5;[F@;AK50^7JOYS,T3!R$>P2!24MZ64
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ML4C=8>UY::08H6*5!@43RK)QNL<6CRTHBR<\'S+V2F ]S.-X13=;]96 V#N
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MQS3-AV8N5669P@;A!&,7KG;LB/4 ]=HTO+CUTI?GV-0QZ\3$!DYV6H$>OVC
M'55.IZPBYI=M3?\).M5K0[ -I&B.CU!!CQ^8:LHO']#0&@^8>"J9<_.:GOAA
ME=VA(6 1<-EJ>FJ$M7XHWE>HS\GR3'_9)VU(=:2^"8DVW*,!_?ZZ]7",FYO)
MM\O[-A*H)V.QGZ;>[I4=-BO$S[IB/YFD5MH<^)"_^NZ\^\JL.CO-W'@(4K36
M-"&-#ZF%'"2C[M4$$U=?#HNB[XQ?-9L4<RQNQ&?9O/#=.B#RQM@'QP"PS=-!
M!'0NMOO8([4<^X\95:.3)EU78IKQ1SBOB32Z<;*=#J,N5S+_H4=4'2;S<-;
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M)*K"JP]RB+1O_CM.;[/!3Z1T_>G/5F>Y=YVGU"\\T\-[G(E[7<<TLX*T)I0
M>88B1;Z*AUZ9L#!C$D#O\.<G3 IOB$E\B_.]"\(H"EU&@0IX51V0WPEK;^7M
MU[$;<9W .3,4\1(Z%R+>_8I^B#Z0<I4L*F=4-@0<LQ0ZFM"#2GZOEW)/MS5T
M:R&NM=4 \H7).S$.P$/0%\5Z:1#_V$</)Q00WK?,ORK'">SMHTP9J<-A%-%R
M]$[T5;*P=XM)(<4RHKM,^$D'7SDTA47(5H$!L"E<22F=-1(,&DSP.3H3US'H
M]4(I1CK<Z[S8,^4KW_;64?[\VSK*Q'+VI^,F_\8Z2CGC6N0?36K&N^"13?A;
M;E#FT\MO"\Q.4VY;TS]^QMVD]V*_SS<.C:/YB+:1>.>34\8_/:2=S722;:\G
MF;!D;['^7[91OJ2_["*[R_Z0<K,^LUJ37AJ^"4\K7I?/2@T;WGGUG],,UDK4
M#-N$'YSO6QPE93JG+WQ#I,PNW@CC>GRU/Z76S4^O\,6;'*U;["O+\;.E+Q@
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M7$>!X'Y?;&@[[9@LRI<<SE0\._W5BH3)UFKI<RWA5+MSU"=+V]]&S9J<9WY
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MB4$H=[ZY@R IR3U]\8&0:DV_C=DPXH$?]SL_P0DRA!C8A&0M_9+M#3&,:?V
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MN/JNTW?'-7$\N)EO+\R^2V,8GVQH]^ZP?!-*0;RRO&.#V'&3_'D[M*D[RUI
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M"N 1HSL+:M%O,",R:&K<-T:7E1^PB 4@U6"$6(!.35(6DW<12ZT$X_U@\BQ
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MM0<\X_MI6[P8R52$1ATVP<Z?EMX4I[( []!;H^$L ,J%CFAG>+$ 0>U4619
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M>7/W,34=@KZ1A7*+WG!YE""C5_(1$V J#_6E2C+WA>W<=*56-47K,FA6!P=
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MQ0"\P[:5;B'&!QM%@8-/!K<P00B^K>5C B],RNN/^<[>6N S/01!$ A3@@Q
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M>5A2T!0=A_!G -X)S4B/!)5!=EIE-T#F+Z'CMOB^BE=I\N$##Q8#[-VY5!B
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M<&E$HR[]- 7<+$,NM ?K7VPBZ]TTT_/37TD\<EWE&"'FJ<0WV[3XA>OUQQF
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M!IKZXR:G6>#GQF FE!MXC,#H@XJKRT+Z98-RY:O?%6Q[;B-JT54Z*T;AQ:0
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M^ (FS*NS2(;%!0D.VC$IWK-1Q,?0YKH#<"R<<A;W8^Y&B1<U&I\\U0,&')K
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M0)6?[TYV5;4%,:\+;ZUN,QP'%"+, 24*!B\HD?BNDCPU]$I'H$S>:U\X()+
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MVIDU/<N>Q7=JL\;3JE%H75D/9_NY7\_CRIAZ/(KDK6DC5DG> [,VUS'2U@4
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M:=94V>&AFR3]X.=^PK6-:37V#^3WX 8)>1AJ:X5FL.L0?&4Y<8L[;L?1/)$
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M]Y"6_,]J@S=YB;\3F@B I&0#](1W[ZRQ2>J!/DCTV6B5AZ-SCV)=_1>29:;
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MLD3P/B99'2[MI)0[W%U0NTGRC)9S"A /-#YYX&IC,RD*\1%!72;WQ;-"W3&
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M\#.B#JQ= ?2I^*9X':I-^#IM287'X,88G5 I>OTE;&'79^5_[!G#I))(G*)
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MU[R(F-S X<^:3/XA7?<I/G\>SL?0*,%).>/TN\SD?4;4=%J9:Y!>U)9$R#E
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M2[UHW:5@Z/1V(3WP#CU<=.IQ=O@[RY&YIO!TKA;A1RAOFB)K;QBULS[9HS$
M[Z&X:ZA8KU& ^:5-8%8L"(.X!EK#OX9*8VK46 H N 6G6_R%EO0"-;"2]>*F
M\)"(:K3?JRITF8'5$/A"PZWVYK?>L\""WPGAX(+]IR)1L_1^UD66S/+B"'C_
MK 1?5UIG48O<N@X!&U1$*$%*([+S=A=0WLZ/7WO@&7GE7M/4DSN1FESY>/*B
M(%+Q$JTGH=\KN/ &S#+_/!NDV^44[;YS?=OSFG4QT@_,%O=(@.UCV$P,(OV*
M>'<A3C<Q Q'0 :^LT,OPX<\?JN-YZ^[(I"-+-^T)/S;G%(7NS_B6OCE7/6O$
MPKRE8HGP ;=1WEHV2 X"%VS)G:;1UL21?E_.<&F68=^D]EF8=)-Y8,/9_=+K
M,4ZCK7LM[0RIN9@/WTX=E^FJ&[^KV_Z.%/Q'\MMCQAVJ2Z(K9:V3X?"@[*AI
M\YIO4G7&R3W@%Q6B&V'U5MPD!G>6:M*(@L"M-GP\;&HSHN#KV('ATR(2HZ$+
M2(N",R8!B4OM;)#5QY4A7ID6DHH*9P&O2-W +^O.DXF(?@BEI+Y&%#!I$'5.
M=V?*F\%/S+(8WP39H(-*5EA$JUR^\4XQOF_'JU(IF?-8FA<%$7L@=I2[>1X*
MW8W+88,RM$KHJ3^:C[)!KG&5%KH\5=3E#=@R8@RU!GGYL*BV:T.?0=H %]\Q
MF5PD(@"Y[M<L(P*V4EPZAW\' D##E:#55](.<A6&^U6A\8 =_1;C%% TUDAI
M/3S=2=:OG5Z'KSE\VMR3UM^R>DNWBN-LI^KO>V1Q.=/Q7S?V&]^.J)DU3BSQ
MR*:WS[@;:'MGOOIGQ\A_O]WZ]8MH[:#0\B-K)]]);ZE7%"-=J9A+ @96>ZF3
M:QV %TUY)#!W..G"?V/OO>.:ZK9UX2@J790JB$0%04%Z4RE1$1$1(RJ]1*6#
M@(@(""0JTDM41!"4"((@+=)[0D>:2!<00@)(AX2Z@)2[>,_^]N^[[W[_..?<
M<^\^]^[\\>075@9SC;76F&,\8ZXYQUS[6%GL5A(?OX=-_MLV27F6!VN36KU8
MDGTYG;7-1,U1][Z6E<H;5]W&:F\.,-"=K?O/CFC\>6Z:P-871!R*;+6TF8K:
M.,R #'- ML%LZCH#$FL.@ +W'*(9D#2%@:R!..0_)%-_C[UTXVGPDT;_BWK;
MFZ9T=D\&1%**W$8GH;8>56*S,O^C?H>%8DEG^\* 2!F2,-M\<OC5BB:\B^M?
M'73ZI[O(?P_2[+G2#K[T/=K==5Z4)P*Y*T"-DO^XG\I.I%UT.*O<DG%)<@J[
MM#N$YMJ\DQ;N(0)2)-FF'KW>*@UQ1_GT627OM=T>BGICB@AXE_4;2D($K#YS
MH./#JB=0 :W+/K'B.+7S\F$L-O%^"J$>=< ]]PKT]+F\Y$+'N>/G;$$B/T[_
MMS=+5EWJN#BOC[X1,**!95/(K37>U$P&!!>-_&IDDZZY<03N)[7SVJ=8+]Q+
MVK+#H$^^NYD(M@RSPT?9["?0TLES5O87=?1M/=8;#BU5\(Z+;3;ZN:=\'IE1
MEW4+=%7]4+<60E(^C,X45Z6QFR +B33Y!I//PR8]]]<T[K$IC)[_MRE^3]X
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M]+(-+"S1XJGG=M];Y4TEEAMDW[CJ4X'M'9- 8[7P'RW<3ZV*Z%PO!Y0#\6W
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M(P D&?RX$=U:6BK]6I].<O0"N_(%;+RV!*K62/L(X-$15&=Q.6.<,_V;^:_
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MXHU;$4%ANQ6SVBZF3#73J@"DHF&N'I'X T66N>(VE.JUWTG>](K1,RG/K)Y
M9870[G$3QHOVY2)UG4,DD5A+2X];,THQA\W.)0_S]Z:5&-A/86\V83)_S:C_
ML!F$GRCNW2\1X_1=V.S1T8%9^+S^MJM%P.W\4K)IE/O-SL;^:<'^V<N[M70A
MTSS.^[27/+\MLDYZF_6L<7Z0W.(</CLZ-#O2\,I0N%Z<Y>4%K.N19QDQ&2U:
M6V!*YN!G+_H=7?@E[6UG*95EBR\5=YL6A'*.MAW'O,"J1*/@Y>?R(D7V];T5
M7_=_(0417#BZNJCD;]KGO6DBSJ,I:V[TI0+&VTATN3-W-=CZ!QB VQ\RUV_^
MD]9O_F^#%2H"N1_@:_IC3>7'.;DI2<N1<\(2G9D/RUE_B<R?S(I*9_6M%&)O
M3:HZ@GFU'-K$ T@AZGD.^3ZF5$E] JF)#.D 9ZU6;OMG(8]%%??VC]#U\UL#
MD\T-B-!$0AU!" %X-0AZ.&8.:?>;B"K,M_H'S2%P?41\L?I\Y4=ZU^A!Q381
M<]_4QD,S0ZDG]VML7D>%\Z1,^QU96=UT\+KY@I8L>=THT"875:/=)D7B*+-(
M;A.2.JF--<&/02/Z9'.+2N,/6M8>-M3,.2A^X:V#%&37G+5Z#%((0!.7HC/(
M>=@,P_U849R%SM??5N]/(6ZXKMJN'Z.%C0'>W/$Q5$_[(\WA(P%MG.QOE'X^
M/_.01\SA',I'NW@]H;TN9C^ZV'UCT =VL5WYFC8+S\+$$BI8#D_6['RCL@1(
MH9LZ;ND6]]XETQ(C@_>7]+@<U%/Z(KPW+HQEYOV*OB=HE O  M?I&:*!9<@1
M<;1)$9??0L5YF 4M+!4G3[O72""B?S$@[=05VOUFQ-^^.\6O[P(VN.XOC$E*
M?Y)RS[W33-X=@*G+1-5S4\%<)S70GP%Y9D*@/L0[9V8Q(&84Z[O09FJ;E77T
M'!NM$\R78+PH8HRV*JKK;#]^:8@!H1A?A \:C/.[MR)%@)=Q9S0>;;)1V40'
M%F4%4'.2XCE")*>R2H'^]RCH"HQCBI:$E+5L[2JMAQX2M&%'7ZSP! Z\$$GQ
M)LN3#*-PULWU! '+EJCY>-WR6V@K?NSH.>D!WKXYP\#Y/L] 9%'\:&?-,#[8
M1K5GT&2N=FNM4.$;GW/L%]BUW!N59'A8CH#A]V=9EB'$:_T/Y9#O+.A/G7*%
M>#MSY9OINURCI+U3_QCR62%X?R+\;/QM96YEV?S>XZVD$>;:*V.9K<.94Z41
MLX(13MU.24O_-CVFN&%DF@&9()"YA0YMI( . +6>L=*EB[K ZVM[.5%-K_N^
M]2$W>U>[HT&]!R/ WSFFZE"K,M-X0#Z4 0G/9D#,/_7'CS,@D"[/%^=^," M
MH$4][35=@E-/H4()J\=]'<%GN,Z 4'4=6[8UJ-*)EU_#0VSV^QUZZ^"V^\=K
M^$UXO"F]H'O.D/8[.W)Z+96^BN0S0I2;0@NFZCC?)>H!CL0[';UZZ1<C@;TW
M]MZHH+W$<=E<$8.'BG"4*&YG>YQ&7CV?;:6ODZL.B,C)U7NGR]=0+Z7B7=T9
MD'NHYT+IUS \*GW#/2VOG1@0K3QEH(\3_U-]3'<VJV6,C?_4MV5OSF^=OPNY
M^O(DZM9>X'E65*RL@^:N(T(W,5$JIO.!G52^X;'3%'[XGA9WPDJWE@V H3ZY
M![N:HD[EBQ^[GZ\D'XHEWE.0,#09%Y]Y*[XBX!KV%=,F7XYZETIJ9]E6VH[?
MQ*!73><B4;4J=$ZEEZ?7TB5L'_0FB1/BLJ#D>6@0866%Y$$]I,> -&4-'+A#
MI2\!DI$1!0S(4B"!#&\9JMY?^<7R4KY.IK6N2)2T1#MD"^*ZQHT?BR.P#X:+
M':6\1E_P=VZF&QBSX\?>,"#[$R\K^A8VLHLAC7U*[K&6+X>@I/$+\YPC^#+\
M6I+LVP5:\^^.TABJ@:-0O ?IB G;RH=7HZV?EKE-%[1E?<?A)I8(8>#YH-E$
MSKFT6?8UXMSJ\7$ZN\[8[W=18F<&Q",+6CPXOU+/0ULS1U"UDJM"+P][A#UY
MHQ]C8JVF?G8K%#&IM_[=6I9 OPJR!%@_UV?+-@;D!&HBX)0C98[DD&PV1+U$
ML<_WJ)Z8\]''Y(EAA^C=!,'YB15QX /I]WU;WCD?)9Z6]Q';:BMT=AFG;>TV
MBK;3D\65(D7)0,7(X&:418H/:$^QY5=J2X!/_)W))FY[FA37A+BIF?3>UO1*
M!,#)@!RE#[:<J(JG0QB03;Y)3M10\_B1JK;C ?H48?MI"9P/HD'M0C:%/H@0
M(;VR1AZ?V_LFY/"[0YZS'&,T[D#Q'9^3." HJ!"@VS,17]#R^4H$ZN QNO%%
M!'""-4I031&8NN2GN)QM>>TCQNL[3%J[^DU;#HH,!7;1TE\9_/&--015__ /
M5Q,$NIJG)02J2Q&*.(:"PJ8#&9!6;0SXL&5ZA^GLAA0>Y^;(*B7X_>(:!F3(
M&/QA?RZ0SX#H\ 2AR&I+#,@KIZTFN/P$:$:L_07LCS+ YK#+9\! /9:*.<*K
M>HL4J<]VZ/2081Z\O,&7FK4*)=_TB'Y9E[F5'*N\OT#_\^5#-,]G6R:%('60
MIRO(* @A#SW8SR*7(L>#5^@#3281)G(O[I7;H[-OQ"0,KT"0[VZ@%/74P#-2
M69*.QE.WMU_=&Z!S>%)>CVH5\/!8E7CAK,\^VPHHV+5EO T'I.&-;?9W)6.)
M,JE/A'/<]VDGN>_U,H61K\-B%*X:J1S1)J*FTI[D0%#C[3PSM^5 K9-18FZ#
MEY!<$=,'7_^873_/XY%X5Z^P99**><+C^-* 'DB;HW;J%(%$/SO@^F6/8E_;
MNEMR9PX,CUS6&U N<:&54@6\FEWEW#4/$P=MFT>B,W0VXV&M54]6UCD RCW^
MEC'V)!^XU,W"V)5AQ>;QVW+X>X@80<_06.+OU+;WR%DS.]CK;X90D]83I5+T
MO>"3ULYXV>8.I[*CWBV14;5F53<*OB35G+OT"L7;["\=NRHABC1&P@"9RYE'
M#*BJA7:=Q[Q]]J!M)R@(12MD,P,B(@MF1L2F,C S&MM/>+HG]K8$[2U20?>P
M1H *Y2P'YY$*NQS?U5T/D<_1F?9*@V OWPU>&G303[3$"$QX\&,8:P:D?A@_
M"W;=R4:0V!6GPL9RMDSV(0_;L# @=Q\Q(..J%"FJ,J81O24II@02!21H%=']
M/J![#4. [A7DX'LVH%1=Z*"YY: \E9T!24#=LRL8D@%/A?H=N :E"H36=8B\
MT]R;G9.P&>=Q_ Y/?DWGI.D"^#"RD2Q.MSO'" ?UY+VC/WI#PSVIV2O)\)!1
MN9#+>N22HI@,5QGGGMULLVS#MQW)GTM=E775T)DZTK2)UWU]H;T']=;E$++Q
MI'J:=6LZZ+%:,)N8SR5XLC$B>$E875N8\DC),3ABJ/\"VBHI>&/!=!X\Y1<H
M6Y[/9J)II*S:N)AW</G(ZO!9FNMRP>QW?^& RC")TECA06F!,VNUF4[TFEJM
MV.U&>O9DIQU]92T5M$,WL@OI8@&J3L<%\GWFT>31[8 "/M,%_%@:?D]&@OAL
M8G$%9M-9\MTQ\-X&3-#C-@_JZA#GH1@"&)Y"Z\K]Y^3Q]%W;W#Q4_EMCMU]G
MJ4>XI]Y\8+V:E,/C%=9"#48@@)-"-6IW6-%^FEZ?"&A:"B+Z]FU4=@+\=_PH
M_EL'^2WKYM0&EGZ)ELZ A$P"P@R([C[0O^UR1P%]",2PS-BGDW<I0GJUPI._
MH+1]>-[I3 ;$A#PB)5]/C2*P$<_=CB?2]19%8<6AM2TD<R&2:4C=UV\\R C4
M@>MZX^!U."->Q!NQ\Y%\7@C #\5:E431KXT-$-T$DH@51Z1A-1WD$&BZ.9)U
MB3NC&142/VTS3((&RQE=Y]3)'59@[0G-7L<(:A[,=-^6CZJ">94N^9U+XXY:
M_2Z&9YG.#%"%IYMN".-XTKL+=V(2?AUWCCRR&J+A<6#&E'=768YIOF)S'HOQ
M=J#K]:IW]Y[3^YTMTSS;<YJCR+NP4TT1H?6*,Z9DT'8= &TMT+8F\&3XM'L$
MW2\UCOC*+GKH+/^BR:WG;(O<B)VA>].=H?LE^AX8T(O*ED_WH,;3V9/&IKKQ
M= ,&9!CZPUA@QT]S'F[$K"K/P0"%> 8D(I>-KAQP/EJ KUE;XI+1T^SL7Q#6
MCYNSL+XOJUDX,"C"@V8?Y8!?I&9+%YYM(YQAA4NAW^,^&XJEC+M.=P[.#_P6
M!)^%EOVJ6-"7J1^)U!B*>J2JQR$@8LFJ7_YS=9][NK*!E_B1QL)D+<7A[BR7
MQ$9Z9>")Q71_STP;_8U%N71G.X]L18F^JUOW\7(93S.<YJ0JZ150^SA[E8(*
MJ_Q^N _MD3:-%HL:2WDKQD?^A1,%4KP?_AC423IR\Y"%XTN>3;O:AP_]Q9++
M<A'A4++QMUL=I62A()%;WT&U#K05.=+++OE!UW\$RJR4% 5H$$<,&A-'WJ(_
M#1IDSOH4Y*BM?Y6ST9/:=3[',7;L@YZ%YR9")_'SA?BK1?D"QW EU?'8M90Y
M*"_L/BJ2P%_ULQA^:-3<3+_V:S?/3^(PK6>2^!Z%LZBR3J@4O&<>WB+U!?L5
MM[.$1H$NZ9O=BFD4&G(,DCU\^-,K^N CULP8Y<*5EU"7+>S.!BN.1/GG55_6
M,CVHC@%IBF[7O41WA:89N7U;?]CW8L6J<D_Y*?--760E4DKKVIQTVZ>6RYVM
MG&M=2*E)^=  ^1P ?],0=K';HSA[8[ND(K"P\]B6]&[7&?F=#4ZN0R-Q9Y8S
M^G+FJP[?^2EI:/&@1V ]1*L!ZG@*D3TJ3 X)'LM5!5T<SW2_R)&(U9*>A==L
M],K;NS!/!K"<!QN\T]/93F[-,B!M*]J. HW%4Y]%.&0J^^B1*]HJ@!OH]W"
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M%$IVBKJVVH][ >3C(7[[M---T+GV!X=CP0P0M%>HU;>[I5+TW?AOFZWCZ_E
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M'LRB'\QD#2B[$F$:C721Z.OJ"?0?#4_&%:/H<5LH7;L5JNLL;ERH83-R2#\
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MP/:T&!"/?0 T<\Y4!%O?>:A*YL[&(4C56*1^W:JY9J/:4M2^.73<>9H]MH4
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M?[@WY=RBHK2GD-WC4-VQY_]10'J_$OL^[=/_"OK?K1([@@:0?)&C-(#P@08
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M=, '"T-A+6RC9+D% P4QD=.?;G,Y3K>>$NM7U:]4[;NC(YULWH?Y: 4J<"<
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MOWC"MA-2*5N;#^N7WGDL\$RV]KV;OBEODK'Z.8.P!"G4S'G2ZO^1"[@5OV+
MXYAX??\%U%39HBD8F']W[VTM'CX^ZBT]4BI3ES$]D.>?U9.67S9?S&_EX<AT
M5/&'@SPCH8?>#7W$RAWCX6T+&!MUR-_A[;LBBY8-^W%]:&'UIV[5BJ-7W>W:
M^EI%D\V'!']CP,#(=4L:8+)- ]*HQ32@RW;U#2\#'E8QU(GAI0[#&.8G#:5
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MN4KD#R^TD*G4D;67FA;XG>QV<-!1" @90.,>RS-N8JCBMTA742/-J&_8(AI
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M(Q>].Q=80'C7).94"Z:>* 4)+)J:FFJVZSOT95@9+>*Y,_E44>3S7,TF&QL
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M*!?([$6<VL:@LB CM"K-KO/E]PDF.W#>F^>79?JB\-T><OZ.J*@C45>\$K_
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M?LS#-,; Z!@K,Y">\H1-)-)!C*T-58NF%"[A8JC/*(RP6S"!-:?Q4"2'=-A
M-G-"9HQ$BL>Y0$TSS<,9P7=_++\(8WH8"@  &V#UDVV3L:8S0> #1O(%XZ$#
MO_;0@Q>4BC5&TP5<ZO/^7%?R^_A05H-CR',Z&%KQ\J:!KZCS#S8*/YIV2XS
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MGO%X7[K@>,\HEV[QK.56T#&I"OZ@2PZ33G@[O<6,"K]/_<R:US/S;=WQN99
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MHUH]:9(%K*Y3IZ)1, H+?HG*2B4A-K]I"_FN!O$$H+K$N$W=YHSBYW, ';8
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M]N**E=?4PA_3SJ/U#+QVWVDC]07^BYY[ONFPA3(Y$"5<-&:+Y,2!]-]?X%Z
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M!QQQB@EAG$4/8F7P/M\"^$[H3U2[.K[T[DX/JOV$O5Z2I<[.<%[DA4CMR("
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MN:U6N>)%N&:=^$4VQ5?%LVEO?@XK_XSA.Z=48_9C2Z==<4<M2@'X+#^/#G_
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MU(J-@%[8''4CB3#?6-*3U.OFHZ0DNUEOQ)2H$:?>W"L==DI? KN?NZ>!;*1
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M>EP\2Y1RFD_3=M./>W5'?17Q"?)5OTS7NO?/VR$^QPH4TI1IWVF*",&@S,&
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MQRVS]0BN\NC@JSO7'C!_Y9UI\RVQ4&YVZW&M,W#<68XB5T8!LTA/0I8)^)&
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M^1'.()F';?U+5_G^F9'[OVXN5V?[_^KZ1:!)1X,@=7Z^8N6WP[_M2+C$\FG
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MN<PER(5<4 01(QS&W(T@3AQ&'11%S"$FFZ FPI=&J*V>@'2* MIJ:N:,&DV
MGO<Y%:P3<[!26_F&C>*@T_P*=%!OE0>OST%M[#".P<R2AV@D>E:7< PHSWW
M46.,X[+/O.3RIOOKC+WAW_@Z?U0?OK<_U($37V&&8H>[/D1AA.427&!(N$^A
MSQT<!E2$B1.;D->@M*6Q5:=LO5!C.W7-N&H88#URL@;;Q&RTAUA/4]"J:H]Z
MM!"QQ#7#LF8E%RVSG[.)WDVC]_<*CDO^AC?_?Y^UJ]2:H-(*KZ])61685JM8
M#A#Z*(:A<*0C)"2AQ(GG0=<)* KB1 34,^$2?=%+(Y;7]\H;+4&:=3MT\O.,
MRY)7S:;0NK\5GC6;/YC^]R8MT]W.$:MWCII?_-EX+T]WTK2W[B:8BNEWZFIE
MP4^=VC^K&=EJ#EK5P==.>8LGR.:(V=M:TQ4\]TZ:(2!'-LY,1QBQ3_:&%^DW
M.>@W?JU>V(_2NN:@Y$N%JSIN[$:\2S.<T12O/[4OZ%N5B5.F9,W?9IN'=A?O
M8UZIW;UU7G+V;HWO5B$+79^S",8L)A Y@?PIXA%TJ$^<,!:QY_O:VVS3Z;DT
M-MU9"FI3P<[6*["U%MP(L+47= :KV+[.9-"S^4H.4H&MV4#9;;";->%#HK%[
MN(RIGYB]__\UZP9;H,N8_9EV4%_\*3#;B)U^;@;W<2<4/]\V\/08[NTBSR!N
M9!RN.O$CS\.#>_'KKYYVE[3A[=??<<'DPB]M-&J2NU>,)M3%)(&(1T35GW"D
M!\(=2&(1.E'HH 11HS!=6YHMS=.HE01\JZ4*II!JUK$53W*);9P&9VT*]99I
M+S(Q$_L!_22.OE7]3 Z5I',TV4/9ICX#VPEMS+,8*&P;<5MQQ-;TFC?,V#:<
M!U'(U@5<0.X'N1\]/<I6D5?/%:G_N)52KS.F<D$^RG?G3?Z TVP5.;Y#7<X@
M3SS)\[['(8X\# 7S.?&CB*/(+"=P B672?E*5?"UT5 SJF'2F32@^Q><GXF9
MWV1JQA'W1-C9Y'#;*LY/YQ.!?)39IY)E1O*<LE4]Z&]2>/5&+B/>X;3X"UYO
MM*+H!FY?&GLJQ4"M&<"E.L6H509*9ST6'8)JF 0MH30+A^U0 3O$+N<R#0B.
M4%')Z2]W^;=?Y=TM"U&V(Y^A,6?A#@VCNE=?Y]*Q01.4I]]45EIY6V"FF.&F
MNN?%-:7Y1E+)[M^OU^O\NZJ/^"XOWN0;4HG-NKOJ4[Y.Z=.*($IY& L8$]^#
MB% /$E]@& 4LP YFH4A<LQ@+>\HMC5 Z[<#.B/HP=&L)$'G1!4.I&&K3C"NK
M,ZL;W/$R\S5Y+,C6K"M0&U;/5&T:.#*/5\\FL3-P>^T5:&P$7]O_3Y+:.\5L
M6(M#L:C:S&$K]D$]C'*90,:XST/K/9:W^;6*VI ^Y:9,,Z[8Z+="DM**^31R
M"$&0>J&D_% E5$2$P# *!'4BQT-^8D+YYP0NC<9?X_(>/+9*UV][+[S%C+#/
M8JU'PC81G)A8.U5!E8-66;#3]@K4^MHC1%UD+)'<67&S$I>N\<_)2/N^2VNP
M2%;+[S)5".8]DP)3D7)6'U25K6 F>;"7U2O_;?/ V;,R(31V'9]0'[HJOQ:%
MT@^-8U6HW TBXC@)C4(C/K*LW]+H:Z_TR'K=5CNOP_#SK$Q9>^ '?@4[\\'.
M_N:HNNQ>7E;[1?W2)2T(8ZO"V'DF-/<87VZFISY8ZDWR1=,X4R4:J_A;+U=C
M1[L7JFEC%=K3A6_LBAD1V]A]I*YWSMBNGNX>M7W**Z4A7BM/KMLLK=Y*EUNT
M)](X#BGSL8#$IP%$+I=?$\Q#*%P6DY@GL1^SU>.SS@C#D4T6U3/AF>=*3N@6
MYP\/*F<1KT'=5D0Z<X3?I5FFHI$E#3T.GTY/.Z$T03@)PQ#ZR*^;F<00!W+A
MXL0^B[W$CUPBV@GMV@4L>#J/-T^8>#*Y_$"\]#0.?]9?<F(F_IYW5H&>6:!7
M@7W?==M:!NJU:A<Q@BOPMIG$,Y$BTTZB03CH"TWF3/&?\TZJ6;#G!,@/1G?:
ME#=?..<$*.W%;TXQ_IBTD;;.CUS];Q[?9W2]47W(CE9WV6:M?%!9+'7I\1OQ
M1]G$GZYB'V/B^C%$L1=!%(0!C#''\EN,D\0G/ J)5CD!JUHM;8&^R^%:UQE>
M]0<8Y@)N2MXFVIG$]=N:.XUO[TO,R,0?WFV)J]JF*["UZD3!JZM>"EYMVE73
M*$'-GS2O67:_Q/29)&&\P#3.E7(QZW0:YE=8AGTXF\*6L!ES)RSCLY\I87OP
M<7OC;[C@1<%94T?M%O_H[9A\E&\QB8($!Y3#()*+623B$":Q2Z%'$N2().:.
MATSVNL_(6]JGL5,7I$VAP@K_:+/,S;:;S\&LMWUL$;RIOV(=;FV!1ZGK?LG:
MCS98S! 72]NTYZ3-NNVJ:?KS;53=V\:1REM<J$VX4BX$ZB#1MNKB![FT>%_Q
MAW(5!9P3X3%5U)I!Y&,.B1.IS;+825A"N4>,8NO/"5P:K73ZUO5):XVONC*E
M5RK]1NV&J:7Y6GK??9_A]GO>_!+\SJM[W0T5[6G18R&;8$],0[9P!E^5=: V
MS^)QE"Z2EHCKK+A9F4O7^.?4I7W?..[:!KW^+IVM35$'N_\UK>[_R')2\J(.
MB7J?/6[J$"EIJ23-VDF3?]L4A53L%2[3LG;-FL!K$5&:!!S#2*BC'40=B*/
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M&<^9]LXOQM5L.]P I,&=;IUQYMO$-K!J;W_:Y#[SA-[WS4FR2CV1@]=I)'+
M3T5.=7<C-$=9$$VTVH)67=#I6T?"*J4YDQ_(TO)>@R%.HU)<=<:?+=W5P-A^
MZJO);1-5*3F54M^TJBW;#@W*8VI>SA4*./5]A"'"0O[A,PQCU^<0$3<1<IF*
M(Q*:M?RRKJ/)^S=/([">BBJ6:2_*L*Y-5??[&E6<RNKDZBU37W3")B9,"\6J
M6BNW3<F;U-G&TAG+GXR=A+EJGQCKMZS")V/A-:YZ,EJ0N8?T>;/FKD,"5XJ_
M+1ZRJBEMJEGQY/C=2UML*BV!4A.Z>^_T+2\>T@Q7NDE= WB==R(OAVIB&CR/
M$OBJ5+;D+ [C,<H_/#'D;"[AL$E]+_#,E6,Z!0K!J2J(NCUJ_RRG;'^SJRZ'
MIU*3?C2U.,JN!\6*,!+X@8NAF_BA]/ 0@CB,0QAPZ=M1KF)9M;I 7*[*XKCC
M1+L90!N]3;KI731%&MM9LP$_]7%Z9T<_K$>9<G!"T%I37]#:HXX-&HMFFQJ3
M5HAS3=%<S1(GGBK#EHHVT!UNNGB1A!G;,MI 8K]QHY411T:/2F?W[J[@=TV<
MJO@L>3C;\-T>7NAA(H0K/UBQ= J0P!C&,0\@$R@,,/,"FAAU,3HG<&E?J7U]
MF^3X6F/#\-%S..MM%MA$;^)/S4G@)@K%TH7&5@SI.7'S!I%J&G\01:I[W\C&
ML:H"#-^/?N_B5)^ZFC%O-OP_)96]DP2X2GS!HTAQ#*+26W:B""8H"*'K> E%
MS.-1;!16:JK TMA'/G:Q8:M84\CUB&=*("<FHD;U(VDY6_VO5&DIPL$GG+(K
MH$P R@:+C6-'HF>K>:RI^'D;R(X$YZ")[-AQIDUO+=MF;'7_2>FYJ1/"]TU3
M%?9J4WW,J__DE7KR5@(G*.&$0A8B%6?J1# 6/H4AH[[P<1*RQ-$[#)I,Q^4=
M!GV2 ]W+F:[++3\6JK^D>J$?UZK$L-I9X/^]29M]A;3&H$X% K@KR/F(G[95
M5>4O"Y7+QYM6H1/ES.H_$!H;$R\]R=,[D4;)EW+AVW6Q[)L).CL!V51UNZLG
M7M5T_])3/$V.[213O=!\6WM3/EGNK?%TV,K#U1>\R)Q<8]S&YN>:"QIQ',C+
MKH/:FYR7<LS/O*YRIC9ZY+?R:5>*4/>(4'O$I2UK>IH#)E4'F7P_BT9YT&EO
M<'*H#ZW&:>(DJ$Y]PM@#5&E=$][G9X""KU9+,HX#:]SQH[Z8^8XDC4W?.Z8T
MOWMDS%HEQ[C/U_*.\JV44#U)6;QMS"AY;O=JQ#&. D0]Z"'!(')4NRP><SD3
MG 21XU$OX8:Q:+JRE[>LZ*O^OT"CO&$\F3;P>CLPDX Y]7%CK:=EWAD-B*U8
M+&VY\\98F<)Q$#ME/,#+1-'^15)G71I6>6M4_GB;JU_=;"I)J76:XG6[I<W?
M9U619F5*F[S!R",X(=B!OH@X1)+88)(X#$81PUP@+H*8S1MM.]J6Y3'F5E&0
M=IJ";TV*XK?:RF8WIK53[;BJ7\\;HSO^T='DZ'^$QV%BSK<9\_N7W8/SMO?@
MJ%_+JW:H7('=T[<%QG8VZXM/[D)BB<?;\0\5<WSQ=-F.3;Y<H<NZ^[S+B\_\
ML=UNOQ%_Q4KSJER%+@^I&R0PQ-R#"-,0DL C,"$)3T(A M<CJZS62[.@PAF)
M6F27-&37ESOE\KO34IU"?&_U'-?8YQ3,>E\@&]#-W-9'M4/:!_"OYP <W=3G
M#"R6>_J<DO8B+7W.F'ZJH\^YV\9QROOLFQP\+Y[^6J1RC9%_SU;4XZ$(1 Q1
M&#D0L2B&1'4+PV&"0LX2$;NQ2>C'H8BE[8+6BD$F-2M!P=>X]6YR4DH-:C^Z
MM<",2(Y@J\<=ER$V,5ULE0,[V.SQPVG3+5'"$0&SLL!I Y^_^ -7FKWK95&M
M;KYG\D6Z3Q^O?Z3EBD2Q$PB70.ZY(42$19 D@L XB>/0#W%(A59'Z(.1E_9F
M;Y4#7Y5ZIS>]S@ V_-Y>!,/$KZLV MJOZDEKA]Y0>5/O[91_V[V9A^/-\D*>
M-*-[#T]?,").Z9JQN@4 7G_.G_!:%0?=]07](Y.C?,%K7A*UY/@]E3]5><;+
M%>?,BU%,H:_:WB OB.4[ZLIO,<4A<Z6O'[E:89@7Z+"T5WIG!2@Z,^17>]N5
M>:,, :6R!-:F@(>M+09!)B,G;)@H9IJ&B2FE-P-;"_I]L6L;P)?>#/P^XPP8
M!/),/Q,SA>I,,B-F43B783D89S-RZ/DB:2ZS?2]6YL*AS!W#W_%_Y<7KC1SG
M09)W[>PP&C)!!(:,^P0B01WYT4$<A@%S>>@X$:%,USL\''YIWY-..6,/\0AR
MY]W$R_"8F-AUH3!R%4];?(&_>&30V9S&TP;U/<>!JT:F\.S*RK]6\7!9=4W*
MJL!4=98(78>C!#J8J60=G\(DB@GTG2@B/@E"N=XS.TX]+6QYYYVM@F"]T_G/
MAJDZIZ%U$DQPPAATL8\E%W(.$Q0Z, D<+&DP(1XW:E!M!]AY>'%"6/7VP>R
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M-?B@K,'Y.\:1Q1]9P?%:':'_AM/L@_Q^WF0]$2NFCKY"&D W$762$I+.A>=
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M@9BQ"ZC]V9NK[Z=%S9?5Z=/^E!CW]IQ A7&?1+57T:[%V#L)9?US63=_6)'
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MP/G%EQY7X/WB7^9Q[; <Y6^-0N@EO"VIJ!U?:P?819[6*.!>TL_2 O!2+^L
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MJ_)WCM4) +O)/DM912%I0K%#^4>6DY(7]7'7^TQ^V?=[S_7<(]63*7$Q#(E
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MYT>?K>J5MJ']"ECZ-\U<SZ0IB' CFG((U]]PNE;'N._RHNZ7M^*.[WM!0F!
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M+=&S'9UF96ZK,#XG=;N#C^3[[[A@M_+>ZQ]IN>+<CY(HBB'AH0,1Y3XD8>S
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M;\A4[JI/,;F:]#Q?P @)"I'P/4B0HX(T$IY0(01.C#)#AH0M[?5OU!OCGIP
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M>=]$<62\4I=7^(=AS1L;,TLCY,4B\6" ?*:V%4,8!RB GA?Z013XV F%0>#
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M89J8 LO)&:,/XTY?T"H,/D\!HT&4L64X9PHSOA16LVAC XP&PXUUQIDOWMC
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M9]+8ACE6YE>/&U]NUJ8^*.A/F#(-UK:!UCA06W>U-Y?E%=B:V)_&F7KMV)P
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M(CS;<DK6*(Q>BNDK+*EL5E!KU"#?P@9XC=O"*V:_,@9NRW&(?J=B(AWG52,
MZ$@ KB?AW,+I."KW$_D7G:^!G1]Q,(6]+D/[4:?S#@Z6>,<1.'R481;F-UZK
M,-R='#=GG'UX^Z-250&;2[D[T;H%]A'W T9@$@F5=H,03+T@@D$0I6$<Q!E3
M?1?+&B_-3$[SJ:ULT V \=XMB1Q0%8'^Y45"_A4\MR*HFV+Y&C[ &_QV]JG%
MDI@9K.,0/?(>HCC64?XU;$#>P"\*N:3X5[ !WTD+<&?@VC/FR.*UF'A2$]B>
MD'V;>, ( XSDMO_CG;IO6Q:W8ALM*5?;@(H^HG_/'QYK>9"._3@DQ(-^[&-I
M)$<<$IPE,$JR""<!)20U[P!G/?W<3M>M (!>&M^W7P@#FWA4>L?V[[7,MN#5
MX7P#7Q?#[H1^&W]?(\*HG%O8Q*-R/Y%-O%Z#Y^T:+'?6H/.U;[S9*RV*J]9R
M@SGL-8KM1YW.*!XL\8Y1/'P4=W?I%E[D"1$F$:0H4%4322HWB@!!C$62Q30*
MP\2J5LRQ2>:V'4S08OR"RW$STNZG+\.UW]UQK\ YMD*/3O'N5]Q.69:]GQU:
M28K4G<XCKSA?JO9L4MTHA^X?Q8KC9?X_G'TMJ^JNK'*EEKZ]J%N\MV+]<[5(
MI%V)48)APN(,HA1E$(>,0>:3*":8>8'9/16GJ.:F8AJ NC#E&J+2-;@ +QN!
MP%)*M/F[;1DJ%TMIIJ0F7Z"1M9JN^M[5:1N1H+26H!+J"FS% DHNL!;D"FR7
M=B.<RU)6#KEV5M[*!::)2UXYI/&P#);+P8>K\INBJE?Z@*'#O+$7!X0E 22^
M%T"$20!3G_LP#D(O\SR1I=RRZM_^%'-3LOI%WD(<%#8_0J2Y5AQ.SQ0JSIR9
M06KJN/ .=<[>!),KD.,"'M,&)SYY2;ZR4AY?)*SF(/@B3RB=DI(^E2)Y/H99
M$OD0!4D"29!DT,,)"@3.& ZH3<SB_)1SC%7D31+L+\J,^A6H-6P]'2^Z#/OY
M0I-#Z3=3$&Y)'5EAM G%OWS=<KE%W"G:*<V?)A'\'O\E#:>Z7N7DI=8MONM2
MY?<Y/12:4^@T][AWPG=(-S8AX'B&L=&3 P(2:W-&C;O"M*X6F* D"CT/(B],
M(8J05$DI$=+ZH%S$%"4^\8P##@?#S\WRV)X!Z!JBA4?[D#V#*,%%G(P=U=S0
M\=$)'18._(MHF<A!;T./G>O]I/2]KO7#IZ9SG9]$O.,:/_TI^TJ+G58*UP\/
M]>?5ZF/Y]'S]5)M67CPYP-RT4@<HD$A7.N\02+QEP<L7?2=3];YL*@Z=N31D
M06._\G+&X,@ZS"5Y5@4@SY(SJ"#DZ5$G*Q!Y5K!NP<CS'QYBII2ON)"64%MR
M%*5A%G,_@0%##"*"0H@3@6&:^4GF41I[?F)NH^R,/3=5H-'I"L:GH[QG^3*Q
M2@:S,+9)LB7@?,'6LTS8&"2#&9G*&C'X:EA:(4=%[C=!=A^9T/XXBG77^#C^
MD:&.6L%7*\[D>?GK-N7HFE3:KEDD*0\%C064:BF&B$?RV)00!$./LB3D<<B8
M536I_NGFIJ76:$&-_^IF9/V7K0^WEV-3?ZXKYD;W[;:DJ=OB':A7X+>5BE3]
MN<;LU-]K0HXSWV_O9!/[@4T$/_0)&STU3*/LU[6]E\-\*I]P7BQBAF(>A0*F
M0I>NB"G,2)9!'V=9PA*1\=!*FYR>:FZ:Y* X,U!8P9\-6LN84 _#9KK$#6\C
MZY&AE%DKC_-L.%(</1--JC3."[RO, R>&%CZ05>J_8*I3BS4X4U?X"@."88T
MXDQ5RX\@X;X'!<6>)Q+LL9A9]4D^F&)NRJ$MJ[R&."A.?(1(,UUP&3TCZP!+
M9NPK,9P4WE7AA<,)IJVS<%+ @[(*IS\Y[-7N6!8+SR-1Y$41#&*F.C[&'*8)
M$RH.0Y#P$/-I:A,0[HP]M\COO9K#_OK&,=;,7N"!7(S\YGXU(,#Z=3TBJJ/W
MM#ORI"_H$9'VW\QC'QFXVS99T9O*39__4BYC_J$IEK:(N"^XQV/H![Y\2Y,D
M@ED04LB(X#AB(B2$V;RE_=/-\\6E[645WF %O[25Y&SK*?4S;;@U.^-O[&VZ
M):U3)N[SFK\/Y_BSW[2-:'&U@?=/-NUF;B3XP<9N]M3 4DFJW-('7''6C3]=
MKU;RZZ&/"Q_>MA^YPV\Z!^TG7K%-'<WKJGIY>M89'PH95;6<RJ4<1IDAJMC@
M(O$C+H(@A4G I5K",84ISP3,U'\C@B-"0JNB2^-CGML)8XT2O&Y@7M1_:XIE
M-].1,UO,D16M%@5J6?8"OEN!U8W][N=:H8&6>J>,<4?R*[#YBFR%U[4^'=:O
MFFZI7%7"F@#QM#6UIEN"@^I<$TX]W?4S:3,SN?T@KLJS^/(\&W@0TSB  I'
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M#O.;A":T]FO>$1@=^_!H2*;-A6ZKRX86= VZ=6@R_F37#RV$[=Y#M'GLH@9
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M22SUHN&"&.I"]R2/K?^Z["K(0&$&'="CE FW),J5;C.<=5I]9D?%@0ZS?'Q
M+L^=_+(]XHK+03^63T\JQ1DOO^94^72_J_SG:A&(@&=IR&#L)1BB2&4-HE#
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M[A:I[[+2K52O>RD?*V:ON+D"[1W1#CU \].TAFH9N@(-1ZH05</2D:+V^B-
M406V\3C'M>WGM/XN"]O/0J[IJ]K/0NQ3-SYF!W!@<E!>Y#7_FK]R>2RH)7A5
M^["I/W+]5*[J_'^T8*TG_;\Y7GV1GUT$89@QGD20$"Q->YY%$*>>W,])FOE^
M@JAE5ZUA,.:V^7ZNZOP)ZP8R'=";>*!*^9<ON&&/[ M7R##U8W3>Q\[MT )
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MIM//&&<?WOZHE">W58'%PS6M\U==(W>1)8E'0N)!@AB&** 8DC#QH9=%F-*
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MH5Z!!BR0:(&":WN)_BBS_2^M.[Y&?H&'4C7@#GT?$Q=<H3\Z[,0WZ/M$.[Q
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M?) >--Y,%^X6_3CTQ'\4):GXZE7-?U,\O]2[)6ZW.@3A@(<)"V 82G,4<9'
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MZ$:B=3J1% G\DA?@CQ^?@/Q-$V__=4BS7)MU,].)HZ[&R&JQ/?+]\G5+_E:
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M?=4G?*_6.OK@=+JK#_>.!NO]H'T\_'-1Y_7;G;X>^&59XGJ!.?>$\&-(PE1
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MA#Z;3+#T9:)VCZF1/WVTB9J0WY6 ->[[4S4B^@$+/;68$H@91>I#4<LIE32
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M^]./*_72UKFP3?_C95X*_FE)?BR2Q",)9Q(F3-G*2'NX*%;[R81A74F<LB1
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MN;%E75YUF:]^0-U\<&#R@2GB!EPZ HXC\VH-X9[(0!>49$WUI\^C0FK!MR-
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M@":?.$>VT'1R3VH633X=AQ;2] (,,Y8^*RM.B&VOX:H[S5>A/7OMW^Y%\;C
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MC!7ZP[HKLL="]P]0N^95J3;.VBW,E!8VA2J'3DP_H4T%]\CD=CS:L*,$T%J
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MB )E&5$L4LAC285'0^G)Q(90+A5H;J33D=W0<>-L:HP/<28#?/RS'BV]^@"
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MNWFGBVXV/2VKDIN+0/(@DHG:%C/%\RB1"%),/&758IYZA'(/67EF)Y%Z;HM
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MD'!&[W=:O]^O1!SO':]$!INMS$ GP]H>7KN9O6$>QO$F8TZ>Q9U:H)ZQG6)
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MGI2EN]QP9>!6/IR5,G453=\^-<6$F[*?B\ 788I8"&5 ?8AHR"%-)(=1%+&
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MVTI@T+ARP+6.J?_1+!>-Z%> 2#77NIN$.U8?AIHC8K8<?%)N'0;,(3T.?,J
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MB3+B9+KTD6)JELWW1[F6U$CH:,GT&@)+0V=H8(>V@TKY9Z#E4VI4.'":VJP
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MG(4<\DSH75' L$FE06 <IB%)L29#[':N,JKX4SNJ,8<+>9,'_1=1*_!G<X/
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M^EX_(<8MN'<34"<U]FYKK<^=HM1<2RL+;;58/;R8$V/=9Z%[;\IYDS0201C
MA)G$L#@+("%A!+,DQI0JFA)JGPSN>G]3H[I:8K 7&30RE_/S+RYW5-?1MKD3
M](KAT/=_U^#KDVG. D>7>SVO>(YUA]?[LW2\IK,&I_M*[GHS(UZ_6>MT>-5F
M_]JP*7C^1O.E\2SYLOSVN%IOOLOU4^L8;AZ@("49#6$0LT 3=LH@58+ $$ND
MPDRBB-L3MC>QIL;K1EI@/@Q0&&FA[O,)Y*YG\YZ'SH+]7V5 )F?VEJ-7U2P
M7Y:@U \:!=VO5SP/X3!I>/P-Y63S\-PVI(-EXK%#WE<JGBN]33(7CQU"?9/Q
M6+;>*^^UJ>Y0?/E#BN^K#ZOUDUQ_RKE<%JOUN;K8%"F2(!5#%9@;[$0RB .D
M()$8$2;"F JK&^P>?4]M[=RE%2D+=U55,@JP^J,J^4;-;[5"8%%KY)1#VFE,
M+-;+X9 >>%&L!0=&<O!]!2K902.\:UGSF[%V2N8]%.:C9?KVBKUK*O ^Z%W)
M$^[4Y)A)Q/OH>I1AO%<3/;V<-BO^/Q^+0J]0[[9KO695:5K+3LX'ALYCG,DH
MIAA24\ 9Q5D$280S*(E0H4 HTI^@D^>3LPA36SZ,\&7^L94"?/7TM%J"PB@%
MMDMS-R?KHGSU+WD[MOQ9-U3,P+*J4E88=0OP1[YY?)2+JHSD,WW1BBS AOZT
M37ASP^#:W4L,.V0#KT/?*I K\6<5Z<W.1_6W:X!2I3\E0YQ*YALOY'@[FK[\
MM]P%&->GJS= )WY>_5OJ&0:YO]9XNUV;<H-SDO",T$3!6&("$5$!I&& (5<9
MYW$@6,8="SF?=N(RW<8IMES=Z_%*O%XWK6>@M&.KV^ 9F(W:]YTS4,OG,;CQ
MHNZ^@AI/.Q@WF/&B@B=!C)>?]).'XL-:_N]6+OG+%V5RWW='LA1U*,N<2$%5
M1@AD8<(@0BF'.$*1-J<B(>,D(#&VSS#O2ZJI65@[)4H3R]3.>#X*<GQT#G+T
M-H(6F_;7&)>!B>M\(H>#@2J+G%P/SBMZ1*AZ&[S;4FX,/HBOFI5CF,&\.7_'
M3:"[IOCHU]FK9@&Y"9]KB4)N:_R6\,SO]*=)Z;CD^2(O1=G]^OU/8Z[+-W(I
M5;ZYVWR0NFVZ,!%A6_UIO>S?IQLYYZDIZL(0Q"@0$&4IACA#'*8XSN* 8(JY
M4W)$K])-;>'58@&Z :J2&12-T&"MA>T3!>IK%.U,_U<;FX$7WZI"4JO<O1FG
MLB38H:)F[&J=P$ZIXW=FH#IR]!VKZAEVKQ&NOF1[A;A8S[">CZ;UW<DMQ45R
MNOBXJU1?[(^^O\N?FS<:G_^9!RI,<! *& MEZOM&(63(>'A2B:6(TR1(G.+T
M+?N=&EFW+G%^E=2(^M1UF' 3Y';\.P"0 S/K3F+0$KEU)P9^-U*#4FR/(7>.
M0'DM('*]UU>H&V(-Q?ER(?:O]V,F4]AP\_*KW#R:FH9[;RFN""<X$3#@FG\0
M$:EFHHC +* DP0D1B;(ZS;G2S]28IQ(3/)5RMKP.327<^W7^M%X5$KS)5VY<
M= ED.^[Q -W05ER%6B6B7Z\P2Q \\<BE7D;EC2NJ'O/$M<?[;E5_Z%:T&?19
M;N:4)K&( @0)BR1$,::09C&#)$PQ4IQ1RE*WFYYV\].[X]E)Y[HQ;&$6Q#1*
M413 . DT9DHRR.)(P93&8<0(12:[G]/NO!]BXT1!WXZ7[3ZX'PH#$^!.K!GX
M[*,J99>ZWK:/K:9'WOV=*G6Z>3OSS"T6SC?)M^NR"LH;O;,36VU2O92Y-;C2
M=);$,0Q3$5775HRQ3)L\,4]$FA#,K#*LVW4WO9E;R0:TP!KN7DE+K@#L8N3X
M@&WPJ>Z$6$]#YQH07NV=BYV]@MES3?'SUL_5M[P=VY2?-&,XX:F0>C<D$LT9
ML;:,4A+"-,-2,A:1@(H;CVFF2!;GCA1Z,<8E7'N?Q4R,(_H Y>.D90"&N-3+
M:Y^D=''"M<<]Y"DINF-CSIXTLBAF,@D3B!E)-6N@$&).! Q50'G$$I,.W&T7
M=:M(T]MY?:-58L$FBGIWGV_2 'WT=!QS\TCB+(@B3"7$28@@2D("*=,F)$$)
MEI2B)$!.GN-CCN,H636?\R5<*54FVWU:YG=LY &R6TC&A'W@%><PJK.X'M:I
M'QG\+L 7OD.DK>DCSNLEL+D!O,Y4-K>TZYXF\/MJ0Q>E=WKEY/AUL[Q[VMCF
M!CS_]M2HKY02M,0$7^5FNUY><TVP!:N;V?S@-#!7]87(*:=?-PJ]$OE=:'*T
M['W=*K53]EUYTF?YWRH(Z6Z[>5RM38GBWTRD6!F=4E55O#=Q88?U$TTHTN>M
M2<OR1=5_,06-ZRJ,\T!D+(RB$$:("8@BQK1=I2TL0N(LD5)%49;=7O/7N]Q3
M(Z):+"#WDH)?M-E<A>99UD\<>^SM[+8)CNC E'DUJ*\2>79<D;?4L(X)+$!+
MQ:$+] XV&(-6Y?4O]01*\0XV%';U=X?K?O!TL_?KE?YQ\V)$W-PMA3EK?C;S
M;<Z2A$HD(Y@B7AX "$AY%$"1ID@D:8@2YG2YZT.HJ2U C:#ET8ULI"Q#Q ?+
M3'MYQ'J<"(PP#J.>"MCD>FJTTC\9O<JQVVGV*FELK^(\?E+;RR)--<7M51!O
M2'A[O6TWHA8RG[_7G6Q>WI8I*,JUHEI%6A7:]38A4F$@!!0*)Q!E%$%,*88*
M\S!$7"H26253M.MN:N1:20PJD4$I\\[,:XEM1[26B'=3J'\<!R;'6R&T)CTW
M9#J.)G1#%9/I'_8$9MG\*-3DIFI#.HYON1\\WHE_?5_=RY6Q2S\L]]<$EB>/
M%UZ?&B=H,;?U]=CW%;A__P6T[? 9^+!:;98KVVBW+MRN'T)Z@&S@Z6^+EN>[
M$0MP>AU.7FISM-/)*TJUCR>O/=IO8V>B>#\L5G]\UK+J'_>E59>B=@C8E5G-
M9>MF8U?%DR<*!UF&88PHAT@;%Y E,H5<<"ZS-%81=0IYN%6@J?'+M^WS\Z(\
M;S(!M*TJ@,O5$I:Y+/)=36*S;U"-DH#NM'0LN'KSF-IM^\8<J8%IK<QN8'29
M@5J;5J5H,RH[A<!>HX.KX %*OOK"U]-6[V9Q1MWF^0+O>(OGK=V>OI5-"L@W
M+[L?_SO7>\HU?WSY)']H3(U+8*QW<Q(E"!*:I! )$D.6A0$481RF"A,>NY&R
M7;=3H]Y60.Q.V'(V?[[[>S\/3#OT[>C3/Z8#D^0M<+K[:3JAX\MMTZ[3<;TX
MG8 X<>IT>WO80A]?92%-QYHKWYFN5]4ALTAP%&7,Q)(H;4'*,(*8D 2*("09
MCI0, ZN,+'[$F1J)-5*6,TWLY1RF&L2%(>IFM/&!G]P-P,$HO7NE41JF5L?M
MHS79&AW.HS9868YND'V5X[C0RR3+<'0CTK?\QI56^QGE7^6&YDLIWM/UTA30
MNN/Z>]\NZ$;J3E3.\\T\H@2'BF50(2(A8@F!^K\,9J:&%1,)DC%RBV*XWJG+
M%!TG3J&1&<A::#?SVP)G.]/;+W8#+T8[T!IIP2\M>4$M\&77-&?3VQX=3V:W
M18>CFMSV !R;VPYO]JGPP_E:D]G7U0M=;%X^:+G-S8_Q]*&+JD9$G7=1<Z!)
M<2S>;#>?5YM_RLT]S<4<XP@1EA(8&^9!G#)( YK .(I)J*@,0F05L^U!EJD9
MV;4V8%VI4Q72XSN%ZM(_$JQ+E5R*TMPV9!9V]W@#,?354CT&M2; J +VNM35
M:G9Y9AMU@-8':(6 U@@8E<8;'9<20J.-TE@EA88>+<<B0U[P[2XZ=%L7(Q8A
M\H+%85$B/TWV,Z_OURLNI2A,MR;2]8LZ6ZF21"0F+*90"JX@BCB%C(@(9C1D
M<6@2_::.Z9;L.IZ>F=W(7=>#K8.#;ZD+ZS@4=E:X?W@'7J$.<6V"KH>J[-D/
M)D\FN66GHYKE;D <F^:.;X\>[?7FY=2=O[Q-"@(3PA4$,(T1U;R& \UK2$)"
MTBC&,0YY$(\4V75)QJF9\^?B>7I=^ TQGG;D^,JC-#"3]AF@,6.LKD'X^O%4
M%R7\=XF=N@:QQSBIJUWUC(F2;+//E?-!?^E5*/8\D7&H2)9 F40)- >\D"*!
M8*@DPHK0+(N<O"\N=30UVM7H+GG^K'=_50UE8QV9;]YL^&0!5JX>]E>!MJ-2
M'_ -?>&H16QEO3(%>34M^J[+< T(7S%!E[H9-\[GBK(GL3O7GN]'$@<5YW8.
MEEDJ.-8&'&11P""*:08IIRG,0D%2A4S>8.ZV5SW;S_2VIF\/*D Z^K6>Q]*.
M!&[&9^C3S\,2D(,XE'9BX&GRG^]CU)G?J>;QM.]^N-^<_R2UF5(X?J"'+TWH
MRZP$&^2#/*^SIR_QJ/%1/\'SBAU_>Q>>ZAOX>2>$'O?"E.*17];WZ]4/;8[)
M.0HS'H4IU6N-"""220!)E#*(.:<H30*]^#"WD,_S'4W-&JTC%6MA9V4!+*DA
M!8W KF&>%_#MGMX^41MZ4]X;L!Y!G=UHW!#.>:'AD0,YN]4[#>&\\KQ[\*;9
M)-_QS98N%B_F#N;OQ9GT5LXQG6ZM3HT1V@<'H%&CO(4$/XJ_@$L9UNPC/QU!
M[V:.8?$>F$MZ0CU V&@_"'M%DSIV-5J0:3\(VK&G/5L8/-?0WU8K\4>^6(3S
M%&<,TS"!*$BUE8,%ABP1"0PD22GA890BI[*N?828&M_=+<JI(05XJ$4<+(70
M?B LS^0&AG?H\SIG5_._71N!(;,!G4 X?O:?O0A3S?9S M(-V7U.V[JEE(8L
M-XJ?<LKRA;85FZ+;[[926Y!IDDE*((^ET-PG TA5(B!C21*),(YEG,PWAJOM
M:.]:ATX4M^MVN(E8&1(+(RYXKL7L4U6C V([0O,)W,#D58L*2EEG8"?M#&Q6
M@$E/;GFNP'BMO-'1W2N4X+BN_/E:'!;O]:.5SW)CXMC+;::0XLW+;X44'Y<U
M?;4#V'>'F'$2QFDL(TB8Q! E:0JQ3"B, QS'*DM#I"*W&PMW(:9WG;$3MI6L
MPXU^>@R%'2$-"^_ %*6%!V5.CD9\P%[ +T8#D"__#/:PM[)Q#'% W1]$3W36
M0X!1":X_0,>4=T-+_4-IOFV9,=Y,:ZMU7=J^N0R:DPR))-%L)V3,(4I9"%G*
M,Y@$6,A(I2DG5@?GMAU.;?MX(*M[5$4GMMT<-@1B0]_?UO$0!^*"1M[=O:YG
M&-TC4'S!.7*825]8>T61V&!D$RK2V<[H\2 V6IT+^K!ZKV^Y;+YZDI]615&%
ME)3;:,WU^U(Z]W+]AA8Y+T\:YR3%6"4T@"A&H39":0Q9%,8P5"P25*@4">Y6
M'=JI_ZD1="F9R0RNC2*C"/AEH57Y<Q.]V&@#5CMUREH6OWU[!_1OJIH6CB4M
M7$?,SE8=<!P&IOV/-?"?]L#OQ3^H&Z8U -6 E3KXK';="SQO!;'=>A^Y9G8O
M:$[+:O=KQH=;L>Y-;V4W.5O(ZL>B3!Z><QG.!5*$)C2"-..F"#='D"J<0HI0
M$ >)5"AQJOECW?/4B+!TG^4[(<%S&56PX[B;6<]^2"QO/X8 >N@KCV,7Y9;8
MS3]*\$O)AW):ML!J$"_FKGY?T:W9 HYN/V>;!D8H_/M9?WCO5D\TUYN83.%8
MJAAB$E*(0I) (HG>=6=Q$&.>98R'@U6)W<LQ.8H[N'$$1E#P>R6J8TQ;WX'I
M<;$[#-RCWNU:(CULE==3G%ZCN&M+BNG6=#V%ZJ92KF>:ZW'::(J[;%Y^E9O'
ME6@%&]?^&;J?7Z6IVS7',8U9* *H<*0@DAA#(JB"*N(ABR).I%W@F$NG4R.Z
M2FSP5,K=RE3@<')F"[?%(>0 ( Y,7S5^E<CMC 1@+S3XO1+;<N5P M7A2'(
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ML1MT\V4XU6078<,@Z-Z+#1QAF.[29(8T7:4>R*^FV_D[GG&A*M53)XQC%,#
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MO3DZ.M,<+W]:0L&3I!3*CSVI:36]M#D.K>Z]R\5PC7YULL5)D2AE);@^@].
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MNH'8TL'4DW:="Z6!1R#R?09CA%PHX@@Y5#@(1UKW6+H3SFV[*I)5VE.IB%X
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M)MJPKLN[BQD@OBN0GR"(F0@A\I$/B:\\;)1B[#&?<=W^6I<18B)\)FJD)=D
M'3Y U<X:5+S JM!9AQL#[\OPM=)PI4V"_\C"7]&OFBOOP[^HFZ8<1=^H KC-
M%3'P>$VR,A/YM$9>(3.WU<7 ]CJFAH\^G>OI8@3VG$N7CS;,VMH%>3;^JKM"
MM7E>ORB5706J*(+J[O,1]D+LQSZ,B$<APM*,H@(3:4:%C.$0"0<G;4*5GOFD
M/[G6=MS/GAKYH+J3 _TD36SC4T-WM1=Y2[29E6.P$GI&BV5TIP]\;\@&+=V+
MRHY<UQ+OPUF4C8T)<\ LV08&$T^JZIL#<JBY#QC!O$S1=?Z5KW@B]WR3V7KU
MN-:M0G3LW;FY7I310S)I=S>4MHGI34B*?DFAHT#U"Q,;&(VMN0Z$QZCB3Q\&
M@PKZ'!UPLGH]?>QTR_'T/C? 9&X-\ETT3)5"?J\JFEW]*'C=EF(IA.?3*(FA
M0X4/D<,P)"I?(PQB%*/ IT&B50#<8,ZY;?J=)^WZ;_> ;.DTL+ TP=8P<.U#
M.+),:-"[W0O6JRMO5$2#JQ$!-;!/[0,[D3%J V SB],,JE[S4G.HZ6Q),][V
M#$?#5R^XDZ.'#MA#7^HW=0E47?W</JF_*QVO_/"+%TE:2L4O3?B]<MAV:E/6
MSY6GJK KGE3%MPU9J5KLWE*XCN,*%L$H"1V(@L2!U.,Q)($O')<[2>0;A2_,
MA*^YG3W;&K)'.DZDHHJ&5@VO#5M,S 1LDRN_MZ=V1F?JT6N_W1W, M2LJ7J<
M-?^@ @!4""SVRP[W=-3H(&"YK\;,EM3FQ>(,N)K^$G(&3/==6,Z(O &6VB<Y
M?59R?I4DA1SONNX8M12^X[MA[*MJ):I%'V*J-5,"0T810HGC.XY6)GW/'',[
M#;=)[7_4<6PB+QZEZKMJB#<Q($Z JF&!70[5R*=#2R!H*%R AL;+X3&PIRZ'
M:2+[R1PN,VNI'XA>Z^C$J]-90_VT[UD_9QX=(/?N\Q>R6K]\>,X?^8HT?7F=
MF#'.70(3Y B(',P@]GT*!4<\"%V$/<_1EGK'9IB;S&N(,]B[1W'3$&R7HC&R
M6&O(DTIM3>#Y_L6:T!@(M4LAFDBD'4)E29+U<=\KQXZ^.)T4ZZ-[3X;U/CC,
M7].DAB$:,]\5#HP"$4!$> 1IX(4PC@CR*?(]@ER3GD0#4B\G:#54]:HS2KT\
M@$G/(3"[]$9;:6C'&;1DG4Z9$7:<D4/;[**L*W4G5D66EM>KO.0/^>?L*57Y
MWS<9^R+72O?:N6^,N>D"BB;].^9>=,[?-=L"9NR]5Y$)*CJ5._0A50TL<_#Y
MR]T-Z%3T424F6/J<,N7-Z@72Z#9:!Z5!M]*] T]V.ZW#7O>66NOYRSM7;TN?
MMU$M[S?\2L@M^-^<%!_39[YD84Q]+XQ@%%*57NF'D+C$@XAZ(N!>$/DX'-JX
M^NSL<Y,;#S]YP8FB<'@KZO.0ZQW>HP$YLIPY:$3=Z24AA0WE567J!:A !HI\
MH.@?IQ.U-FPC-*(^/_>;]:'6AJ6O#;7^( /M 8W"U\=]UO<JFK5,U_PK+Y[3
MA-_Q(LU9D_>N'JANFY<NCJ@7NP3&W)7BCOD!Q ZGD(0$1PP'B<NT G:F(GAN
MLK*^6ZN8J7JEMMP8VC-C+[.FI32CQ1M;#[R[N5X<3XCLWHQNDV=56=OKO%R#
M#D\6+;B)@+=E&XY-[K16YT3@O[)GIYIWW%JDS0_J$K-<ERHR_)<BE)=7M*PN
M-9?"<YD?(0P1PARB.$&JG#>'0>SX.(DQ]9%KD#1IDS83B31-'N669'F<E$W9
M;=Y0_5_C%*4\OX(:UP%OM2HCGQ/FA2=W"WB]7<"60?"]9='D&L+J4HY36=3J
MDLZVIFC?TDY?0U0;<UO50\]/.,NZH=HX#:T8JC_!Y:ZLFTQ:-;Q<-]KJ;;:U
M0)=N'$>>XW*8"$>>M6'(5)4"!F,',;7N/&1&,;9ZT\[-(*O2K)]4WR^ELI,F
M!"BM%I!7S<!$XYI958K]RK0UK.&JF+NY[& ]K7^KI7EK1>79SN<UCEOK/$PC
M^+-Z)GTS1]9Y(/H\6!IO3UP.3&66KE]N,BD[*S6@K&HN/OPD61-%^3=)+I<V
M4FWV',14_JY:';TG:[YM<[H,"(]=+R#0BZ( (A_[$#M!#)DCD*!AS$G ]>R/
MV?$V/_NE9J"J&?;MZWL@C\:Z=MA4I<.L?SUZ GPV],[HC+!0EJQ&!W3@:4KY
MKB5 3=Y"N0#-1R>_N1JE(WD*%5) 0=7IYCV#>F9CK?];5S^SSM>?HU;:6,MI
MK;+:: 2:Q^-\R;,O/"^;N$K- )R]E^9F?$CBX)</MYJ6Q&L,SH?9#&9_9%G?
M<GX^S-8H7N8HNX,"9/9'FBPBYB@#W1"8XP\,=!2TF[(.E6LJ/[!;5>Y\4Q1I
M]D.*@[3\EN6TY,6S*GE^DSUMUNKF($NDTE\W0"&K9+.J+QKRU>IC7BBYL8RB
MA'@DYC!@3@11Y'@PIGX,:2(8C=S Q5PKBFX*8N<F%TQZ3DRRF)I>B9DLT=B^
MC*T^N&@[2K2L*C_&EEE0<;L 77Y!Q3#8YU@5^]OR#+XKKD'#ML5FF%.LCBT7
MRIBD3NMXF0#T5^Z:*>8<<$G<QCR)O+C.,ZD@KE,Y];L\8W_E[ <OEXG Q'>9
M@()Q 5$8(1CS,(&<.T&8^#A 2#_G]-QL<Y/YVX)XR@^=["@&5)(,?E8T#V@)
M?Q)LC3M:FQ".+)/WT.L0"Q2UX*_6T3.X%K6)XD17G1>A:7:!J8M.[Z7DV4&F
MNVC4Y6?O\E#[I6%Z_A>^5M=<=T7^G#+.WKU\*Y7%7KOUY7%PE:S3Y[IK47OM
M'\6!$\8!AS3B,428Q1 C-X*$,AP[',>$.68^<',BYN>LWA(+R)9:,RU]P%+H
MZ=[CPCNV-X"OZWK7+?G*S?N;X@"DV5_ #O8=%SJA,<8J\G 0+2F^ PB85)T=
M#M"ADGK!2 -4S_;6\B:[R]=2TJ9D]9X_\U5>E:3]G*[DW_*,+]TD3N+0=R 5
MS(6(A2[$4< @QR+VL&#R0];/_]><=&Z*Z/9N/LW 4TLX8#O*P6-+.OB-E("H
M2SO5 $CSRLYH032TU!%@'EG<=1'>T@PZ1(,MU2- :J"ZC@#M1!JL#8C-%%E#
MK'KU6=VQIE-K#;G;TVY-WQUT,W3'\R\\-[X;ZKXV-T&L[DCN/MR"+Q]NC2Z(
M]J#0NB(:BL($ET0- /;OB8[Q//2F:&^L*>^*CC%Q<%MT])'+6M!>95)36\N5
M2MLFN#>/3R0MJIX5//&)2(0'J:NR-[CJNL@<^9,;1 P3/PR\9$CGV;Y)Y[9S
MMPUG5<1WNJ6ZKET"TBW=PYK0]L*O9RW:!G5D0;"'YX[@^O8%W)S'<W"361V
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M'8<-,M"^U*^$]CO/Y$_JCOB*/:99J@)]U^DS;PJB+9,@H$*:G3!*?"D5HY!
MFOA$FJ288Q>%#L9F)JDUTN8F,AMRJP )LD>PH0UK;_$TS=XW69*Q+67C4I'=
M]=OGKJT8:='"M@ZY+:/<'F'3VO'6 7UE^MN?89APOU:(9.MZJONT_.>[EW<\
M2WX^DN*?E?$;N:' 3'50Y)&0(COR(74\!%T>.ERP(*:.D<@^-^'<!/$>O4 1
M#+;T&OD7M!'7D[,V<1Q9>EX"H;$PU,7%DH@[.]VD@DN7^4-QI/W>,"%SSY^Y
ME&F[%,B8! Y-'!\2GV.(8E_^A#P7AJ$?BBA.:."'9MFHAU.8?/[3Y)JV%&I&
M_YW$3D\\7(+'R.*@)6V4C,]3?%O:[J^&GW1[GV+N<#N??&Y IN4'(;A*W>12
M2\D?N0K+(&N^7UKD5H@TX<5>);HJLF.)8^(F41) &HL0(NJZ, YB#CW/=3U'
M1$*X^A5 +B)E;GI%0^B ID$6EJ5?ADP+]LC29LL'J!FIX^-4&=##FDWMBG39
M6331=I.MC$$RYV0K-%&*Y\@K99;]:07<WIS0RV:8+E/4"A)[^:-V1AQPELG1
M'GF1I&3U20XNC>=[Y44MKS>/U>W0,^^T9%HRYL><103Z 9*&K\=4UR(<2^N7
M^I1'CL,07F;\AR2=:1Q>)G.;7:[M*!AO;W:(,Q"%1GAKG$G6,9S*_FW)!@W=
MH"9\ 7:D@PD@-CA<QH)ZHK/$'N1FQ\80V'I/":,!ISL4AO"Y=P8,&F"8]^&N
MR!/.6?E1LG!3EAO5^J*]*ON6R7%N*N>'FC-CQ^MJW\F/J]RZ:;^N\^2?3;7L
M980]-XZ\"$9^*(\)%CF0A#&!H2O_$[*(^8B:N3)&I7=^?I&J3E3!$RX98D!]
M9R"O:07\E_I$)&]F+I-Q%US/_S*;11SY;&OY7("6RUUT@5Y_U>8BK68-?#B[
MY,8NH4F6PI)_:5Q:)W5630+[H>=KFDG-T]OOGI^JW"7=S/;V^;EYK>0F!L]5
MZJ'(B\=JNZM+RU6N*A+KI[5OX>@7ID.1&%OF]8'0I%E:2F@_Y'Y0+OMVD,G2
MV _)[F:PO_K;,*WN4YK)G7U=<):N/Y*DZECV+5,1H-=$KIO\EU(QTTJ#_,A5
MBV2U\<D/OL0L2%R:>##T/1\BAPM(1.##)(@XIS'%'&N%PU],R=PVMV)$G=Y)
MQ0H0#2\+5?&F+KY6*&_<D!J!EZ^:GMHUR5J,+%[:9:BY !^WRU S EI.%F#'
M"Y#,@!TW]I2GBP&UI!@-IV-2I>=BN X5FLL''%@;I$UN^+1->R.A-&===7E'
ML,J!)A3B4$30I[[O$.P&&!GE0+^>8FX"<4OA!4F$1X#4$V67P3.RC#)$QKR>
MQ$GF;55^>#W!M#4:3C+XJIK"Z2>';6V=ZY>/+$V;&\D8DSBDA$$6"@<B'GI0
MI:] ^6L2)SARA>OJW8,,(V!^ER$?W]_<F D!0\CU!,0(,,[M2EXA;>]B]S+@
M+ D>P\DG%4K#@#D46 -'F;C+]%ZWRZN,J7#J1/[XD*M?=5)HZMR:I>M*JS'!
M/@QP(JU&GTFKD;@8)JZ01F. (A$&$S61-B1]?B[_A@'P7+?M53D2O.%!E;)2
MOP9D#;C\O;2#GJI&I,,S B?[1#3UNADN^]C:XN6-H ];/:MOYD/GFU&_7NRG
M,]8PS*#%\\"%>^L.SJ9D_SD:- ]<#&O]EX?./Z0_G]R_/^7\.P_!M9PY94UB
MT1U)Y:RJF?.2,^8'<1S (.%2QQ=. HDK3?O )4+X! 4T"/4;]>E..S=S?X],
M\"3I5)*%24I-.LUI@]Y_7(P'Y=BW(PW-'>^D\E1VH;UKH'T_%K0FW?S&@'BJ
MMGZ6H#;L\&>*6'^K/^W1)NSY9\KA?O,_X[<O+=^L"DD=E-LE!+DQ=SQ(8A*J
M3'L7DB"A$"//XT$HJ'Q@6,GEUY/-38YW*^I^^-<F7;]4ZN*GE-#*?U[IH'FF
M0LO4(^N??*\GYE>>I7D!ON1KTV: O2NB:1U8PGELC;X#<55&;IKBPJ<QL5X0
M^,A4;U3$]S33IPOO]KPSO,CD5]5NNF[A]TS2E1K^8UY\)7*6_4_=]T,?(TX@
M)2Z!B%(*J1MX,$F<V./(QP[V32M/ZDX^9V&TI1R*O("*]GKS['A35K"41576
MWH:LP&>R5G]Y,2]<J;U8>G)IK"4864X=P+LXM@1CBJXAL%FLB*D]]>1E,DU!
M.58[TWB,8:+O</#=M(J(9H<J(AYSJ4'\6WD$RO4V7=M-I&GM1!BZ'O<@0H$O
MI2)"D$<D$2$.6.R[)K+P(FKF)ARW1 )%I9F0NVQ9]*3>9&"_O1BLKMDZB[$
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M7_A=I6#<_&8+?=^^Z=M;PB,&:ZOENDY$R*=I38$ +K].$S[[-EU-K)*1>6Z
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M=U,R;@>%]D!J(.^1IQ.^V&Z$VH&V/NU;O\?E=)&/RK.\^++12W4<7<S6Y!+
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M8%CAP*SQQ&[0V^:4VA29/'/9EG;V\1XB1NY8VQ4L6^CI3P1+BAH_X/IT.:=
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M!%TPI-;%#L-S-6[IT5."_FD!T*D=OWI 734#-86_U7IM0++]V@V3P*6TH3X
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M>(-7X=!GE\&1:"E*1$?G0>' A(DF*)-S'.Y&\/'TCAO@#P_6@378%5I?GA%
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M"J\,2-Q,];GP;3#;R+/__]A[T^6V<F1=](DR O/PTW;9O1VWJNQPN7?'^<7
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M1HQL[Q+\"U6_G\:[.1 3A^:6?QYC'?RV(73;<@*3= 5E'3O&;+T/B1 *UT
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MZ;1OB&[J"5![9A*3$'Q-0K)<@4=RO%(N4:#57 MU.I#V4(G3% +#X;6'/CH
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M%P*?B\?=!F3[CG([EL;[R=UZ<Y$I\?8J4^(!WRQR+IF)BD**3+L7Q1= \K?
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ME5*TB\"?34I1,)%[*PPX5T(]3R:FM"_@M+#D?*C8)C'MN:84[:3SO5**=E'
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MVKK$I4S%\:/E$CU"5R=P; &$AT#62BL=(.WC?+%6S>J2N7NXW%0KA2*S4L%
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M6B]<K-BJ]6&7]*P!W=L!]*1NR(^NSGZ0?#M<K,-!/ET.!YGXX#1&HT#(NB6
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MK8N]X454Q/EPY0._A;,Z5_SC%\35B[3VQI?/Y*]) !?M12_);7Z>+Z9X2-7
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MK0L$/C3?H#@,V0L$FV* >ML P? "W#MG:DU&D:T[RO8?0G$:8T\.0]RA2NH
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M+?H!E\U4FHL04^' '1)+3&<((23(09GD#%/>M5Y0M@59X^*M.12VA=J>>ND
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MMNZ8WNZBZM'/](>1 _0Y'T2XXX],_I.._QB6T^4GB@O"MS4[5UVGO.@LR7"
MDU.FY)4[RF2R R&<,R+5]D.[%4P>^<BX;4X#@J258+OH$7] 3F^N&R"8*%:Q
M9,"Z$NKN%P4AL #:J8"2TW_JUONT'Z.GEP;><4*@_=0R^G'U2W+\\\/\[.S5
M?/%W6.2)C"(7Y)RX6%=%>#)'18F)=4Q0FN)CPNV2U<>_T]V!M:<RY\-(=FR0
M/""@&^[HGY934M#%P-MYG1XT#6<OP_++^_!S/:%^]<<LOROO<3&=YXG/7 2E
M''!<-_'Q G4R5GU.*M%)'X5,6R&J(5$CW@JT1,F\ Y7M#=5OZV]]7(7%ZG#
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M.B0 3\-$&P7\4M0]8$:#9(X""^XXA.(=9/)GJ*UTJKN)H2WSRU-X ^O"($>
MV_-[-7M4-,B)]V 46!(%*)4=Q!(5L""Y1!M54;U9XI:LC6N)'5V+#@&%9W%:
M/?W4\JB\B@ZUZ<Q#25)0 *XC!+0!A/0L*24Q^]8=(>-R/.X\WXXLZHC Z<?0
M]ID'\^0Y_0'K]CWZ_9?SV5JOY^'L$RZ^B@G7S#A/0K*>U;H;I\ ;%)"MCX;^
MO[#FHWQ'8'/<P;ZM3:ICB#P+.]I\DF\2$I\D'R4K*0(7M9J&%0?!E S%!6VR
MS**(09[RCLOFN,-[.[*CH2'R+.QHY_-[L^Q4X(R'%$";NF\S10V1\E\PZ(3R
M)5ITW0RT:\[]N/-Z.[*ZD0#5CS&VN<2YMQXFA<!*W<EL3-UNAA$A9I& &X-*
MV" 4ZZU]<",S(T\*[BAY:J/O?J#?YK"^*PH^*9EEESRY 926-)0MN"P\>(O!
MY1!,BH,LKAN$FY%'L75T4#32>#_H'_06Y<7GSXMUU]8]1V&"49XK!)2!@[+!
M@XN4 FKOG/72NEQZV^JX-[/;V<Y_0J?(<?#2T+0&GO7TVP+#O_/\[]F\_'JT
M-IWXM-67!IG[M#N/PTQ_0BNU*F@H(*E7MMPJB%HZ\M"<JU!,\<WO^AM/?TI?
M,)^?7:V@VZL*XE,]MB;1!"UDR1"RIP1%< ,^9Y*,]-X)4XSSS3/>5L1W->-I
M%TS]XDM'46>W'1#KW[VU07Z]8/'>S#B2P]TBABJ@%S^FRTE63CB*M2"(^O I
M> 0OO8+">3$F\6##<?9S',3&R)T-XP!RJQ#C>.@X;0/Y50"_S^LUU427$K-A
MQ+/C) *>"P2F(U#LY&7A.<3F.\@&8*/'UI\C0K.=J33!R=AC>']EXMT,_\1U
M:VW)Y&BL*N!C(1=D3 17'$(N.CDK2O!HGXJBG_K(R:*QC?;G ZBB/TA]^GM^
MR4>V1JC(+"7.15,*&BT00QJ*EMQF9[CA8D](77^DQSZJ;B"UGRHZA!2AX\HX
M7!*\*!W ESH>6XA"G @&IN1HN?!2Q+0OJ&X^TV,34#^PVE,=_0'KU?Q\<<D(
M,Y'<+0_5Z?KJ=*N%9 8:;4DFR(QA7V=U\Y4>6U>Z@=6>RN@05=/O5^;AF2W$
M C$B:Z< 8P$<"0:,P;IJR7(3M]O\\]A7>NR_Z =5^RFC/U1]G/ZXY",$Y;TI
M J1F%!_R%"$RQH!GZY072D:O]P35]4?&K7ON'%/[J:)#2.%WG%UR(J.6Z$-=
MT5I;:Q$SQ$C)-0K!$BNBN.+W!=7-9\:M_>T=5GNJHS]@_5$+ORXY058' ,NZ
MR\\;4%)F\KID+)HI5XQ-KN"^ ?NMSXQ;#-LYL/951W_ >CN]OB4QG"MAHX D
MZWHU0:[7,Y(4^6#NM R4>CSY[/OD5\:M]NP<5GLJHS]4?;IVN\PJ%"P82#86
M4%8)<+S>F'@E-.I@"MO[=F&G,W"XLLC.0;6?+KI]A-II^2GCR<I@#6@=U453
M0C0D )DY0Z>UTKR;@=C75(]\ ]OQ&^Q@NN\6[7MZD3?SOW%Q\4_3K]/5))9D
MN>*6C@]+[L20%CQW"BQGT7B'0?OCU#JVX:?'9Z_AL#GDF^LA0'EN1O/7MV]W
M9&%-,JA-!%/HY%71:O HZ\'I3-11JB1XST9SCY\>'_9.TV@. <IS,YJ+.>+O
MRJV*VLL:VPF3R%'$.E8NUL(20>%F59HN:#0Z3W_>=<'/9M9Z?,P\35-J!)]>
MK.J7IIX]Q?*K.+:>9R"PQ,@-N2 ZK4$%%B"0?P+.A#$\<8END#K4\5GO\2WX
MN%8YO@YV@M]_G-7>^5=^P\_3697A;X%^7$(^X2E'J[*'G.K]#$$!7+8.T#I5
MG,IQH$G G?#?XZO[,[7?AD#LQ8A;1R2WFFRO(I+(%!-"!T#A*2QAM>O&(8>8
M??5YF4=QG"WUS5GKL3CAM /: ^'3BU6U\DB_BN,QC\0G)98L#9++,20AQ2F,
M\$E),-(;J3W';(XS<.HX_/98Q7&:1]^00&MFE /W=+]8+L^_7C#?M(/[@9\[
M2+_V4_0/TYU=@O"\1 8Z!0%*6 [.\ !2Y<"%ST*5UM%WK]W9/ FO:Q)'T9X#
MI;2$X*T%DH.*6IK$VX_[>Y;=V;M@:KCN[%W4.6+@L5RL)C=MB9(.#86<@7<J
M@$*)$&PQD*4HSBM?.-]J;A?]U%OXHU_=8._.!Y]+Y_-.RIX?*OD>X')5C%Y<
M8CX:X,G5FZ?$("CAP/+HG).9&32M #-F]^4!RKJO[CTD-[+"_YS.IE_/OU[U
M2@ENR85*8(+5D3PY$-8)^M%9F:+B/+*M!JH\H?(['QU9Z?NH;-Y"?F,K/ORX
M13@OR:HH!!3K*_O60V!9058&0PY.ZMSB<+CST7'>SYLI?F_Y]7(5<5B"JE*2
M#G5M 3>2CD4"?=#U+L9;D;-2*8;_K03L*2892?>GC/978;I8SZJ[E4!_F"[_
M_6J!=9@=$GY6'\(**6C Q&T,E)9H50M65-WZ[DD@,<9LLQ-RD+4(0S)U\C6!
M.Z&TE9$, IG3'BSZD$BNAD7^<WY&/^:,4ORU4&+Q.N6H0202A6**A**5!"<*
MJ:Q@<?ULH-N>K9,O%.S&DAK II?S:)]QQ8^)Y&).?1 R):4,8%("5'8<?%T0
MK4MB3+$H31QD./L@W)Q\5>#!=C,^2$[EB>8#G:N+:>5Q_6<OTFKZG7Z[Z7/-
M$]\8Y.EF%[Z&><;Q 9G6,0+&N+YR3^"DB,!=,,)Z-,;]ISSC**>+M2Z#]C+7
MU586HN,:9+0E)R,QM&]@>);/.+M@:KAGG%W4V4'8<$$Y_>7U/;7(1*2K#^LZ
MU2YY2V>+4AQD\!9]\2ZDUEB\0\!S>=[9"03S5AKI $[["^Z&[5FN52-OP]>K
M-FMTW(;()"1MR+ #UHLIQB"4F%D2*3I_] 1N#S[&!?<!L-HU^1I:QQW@_%X$
M=7EA'XWCQ$BN*\<9*,T$>)$T<(K_C/)%6-T:J \2TODMV^#XF+=65@>(:Y Y
M6ALL&D=)HS:VODK9.D.Z'E+)YXA"H9#']J/_,:\KAX0$1];]*:/](B=X/2.+
M/U]KY=WJ"RX^?0FSRT+3M_/9]_5VH0_SL[-7\T7]ER8V*ZMEL5"D(E_ ZKVY
M]KK*"8WF+G'7S9:IO3CL_$1HC-]6YC,\F$[[$69[^5PT7$RRLQADG944:[>P
MS B!20?2H?&H!*FQFR?-79D[41,[ L:/;XY[P&UO2_R&B^F<(LNP6'5NC?^@
M'[%:OIZ]7U,\L=)ZE[P$EG.@B(02P9@RQ28BV"2,"^[^A,J.C?$N;R?Z./J<
M;/$ L#WS0_%BN>6U9 0:J7FNX[F1,MOBZV8?Q2G1]05Y\"GQ0=;*'X&W$WUK
M?4YF> #8=C=#?V&&L_5BUMRY&9+>"DYO"\<8'FT4INZY]:"4#1"%*F Y9P6#
M,T$?IW-\$/9.=/#*<S+&PR#WS.WQ?O"N#7DCU D$,D>N"BT$FPMHE@.WT0@I
MW,E8XSZY8G]#5)Z3+1X"MP-SQ3]F)V.+]]KRUT'][^1,KNO![B@Z*8V12S#9
M6U!^/0V]KG&0/F,N)N6T56]?7Q:[BPA.-.\\F6O6P>#XG_'D\:3X)DQ%QJ51
M@+'Z:B\%^+IU-KG,"1LJJ^WZN4_,A)_]W>UPAM.A$]@)Q?]Q][Y/BT]GU,7S
M*KXZ7MPG0^*+"9AR4KLD4>M!AI/VP/R)GN#_49Y@2#P_ZT#@[F7@TX)S/,L2
M8X2DJ])=$>!\4""S)/?J6,KV5*^FVSB"4[Z[?@:.8$@\/_-'J,NKR'/"]=-R
M0RV9SMQ#( R LH%!Q,PAB_5 "RU=\VZ=/CA_]G?FS\ )#(;D9^X!=LBG2.M:
M""N!.6- %:8A%,5!8+9*!5DRZZ:#_MBW J=\2_\,K'\@%#>]X6_:I4P"_#I=
M55G0;]?%#E,2X2Q-<?D&/X>S]XMY0JPSY9=O \EW-?V.!_0K'_"U!IW+K7AM
MU,-\0\[RQ3UZ?I\NT]E\28?0=3MJ8E(D8Q!R=+6_Q'((TM1ARYHQ[CPJT_H6
M92<"#SV9WLR7RSN?N.ASR-S*.D<:(JMNPH0"7NE(!ZZ6F3&TV;0NI7^8DG'O
M=(?#RGW?VD /(T\-?#-=D>%7S;PD_[_N3Z2S)IMB"Q@AZD R;\!'1+#18];!
M^U*V:E5Z8G3@KU\>%S4M=#EO)MBN8%'; B][ 0-)PV>MP$2!H%0T$ 3]DTS&
M!:64];+%7,E-WQ]OMNBA^MP(C3V%._9*\[\^DB]=MW:^G)\O5A2I?OJ";^>+
M&B/.KO[H77GW93J_;/K4V85<4-<@M@ Q5Q<)! THT%9I91OR4S'1?I_N!37[
MJGI^-+EW< 7_BQ^^J9#(!J,L29*4R.H4'=C@'&5%(:<B4@R:\]8M3)NI&?>U
MJN%IU5CPW4'HYUO\^^59F'Y=OIJ>7=><><6URIB <Z- H1 4]H4 662> \O!
MZ];5%EN0U5D(M"<"'@76X>KH<X39ZQG](WX*/W!9+UKFLYI_S,OU;]>1;;,E
M_H8S+-/5 ?<"^WVHP95  PX;W09<?_*A?*Y0XA;H?).,DPN46D!TBER@LM(Y
MS7#+M1@[&/8CY!SJREZ>+ZKE;I#QA56=K[<8XF*MT.6U((PR/*#3('A.H(1A
MX*R(P&)TADD>?6Q=Q+T_M>,ZOE9XNN_YCJ2]#H[<2TY?(2DJG/W"ZB2%2 *S
M$K1+C.)=5!!<"5#06T[./7+;_$;N<9)&OJ,Z$C(>!F03-?6#NH^DMSJWZ W]
M"P\PI:V))28+R>NZK-4DRK6" .&%EUEGY*KU$]I6A(V;08R+P(8JZP>'E(SC
M]//L5W:P>!F#\\"<=Z "963.: .E#A2.M0^[>;+Q!$GCEEB-[/U:J*D?U&V0
MXB0G883P"9BEF(58T.!9-H!1H]!.694& MT&BL:MZ!D7<RV4M#_DYJMPU@1R
MOU]^=A\I"N9,*<J"CXQ8_?_;N[;FMG$E_;[_!;L$ 1+ RU9YG&1.3N4DKL0S
M6_ODPM7A&5GT4))GO+]^ 4JR+9FD> $%Y/*229Q,L[N_1J.[T6CD5+@Q% @D
M2!$CE#:<^0X!)[ ;=G.>*R$Y%WX1>,>]J+M8MVT!TARR+$,<*&V7'6:9=GVI
M J0YU<I0DQJN9[+*;L["YB=G,Y06 _6(6D2V>!#UMLE&5(H%RBE(5$;=@]O&
M3<Y"P,TK4(J(Q"C?Z<H0_L(ZQM!VZ1W!B*RS31R!W<T]ID JMH]@NL$US$9#
M"<',& ,SZ'LVRPF6PF8OH6W0!TX1Q))M8J22*9T(!"1V#ZDE3+OG=FRDH]*<
M02%Y0GV?\D9I9G/%@#[T[LU\YCJ"^ZQEN93%HJA)SGP,-_!C?H_BIDAZAN.X
MW%H/RE$*%%+,);@8"(@I@(;86,VFOH;/MIK]'\<-</E/__00H.<EC'.K#&/]
M/]5VD:4, D89!G8+R+G6E$#J.\SSQWV\QW5#[*VG9YP;W0A"P!9Q6A1RL3]
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MED!C;#<=S1%@J2(@EQKF)N64>A]QVI.U?I;[O9ZGS8EC3.9YU#.?L%RP-.>
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M4_1N/1VW1JJ]=O<D/&I=*HD!LK=_5_*J*J2']?5,JA<X$1RMO1(^!D1^M3O
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MJITQLT=H@3YQ**,D!_E$U1=#-=BMLO8<"8^*O,[="X[(-)P+4:.C.^=H+>+
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M.R AKGXAXKA--K@! $H^ETKZ-::4=<,B?(E,!)W S3M5]U;/2'S>5A,J2EL
M]!REP'$,N"$#:!UM(31DM@K8!R6B0*ABE5+[P#> KRQ _S6$:PCW]6,Y;@A7
MXQ6QY*HDO8/A+])4Q%XN(7!=S?+3F3M&N87#^K4H0ADT!-7EPHK7W)3^X;&/
MT99\6UO@<E[Z^*(]FV\6"HG.E0_ 'B(1#M#0J*'1UU46#8WJO!+"_1 ;N+=8
M+1M12>TBVA-4%B:+)HY+BW#8R\QJ>LV-\W ^QG7^%.R#COXJ(;&#KL\?:)("
MY4#_W*M=&1X#>VA;%'=,Z9F)8-?K8%7&W3:-1>5$5!0)24KR1R7WUDS)&Z&J
M/=)[]5M?[*+OFX3-QL$+WC@8-AL'CVX<G#VZ94"/:&UYVMI)'E1@^TS;J1^D
MTA-RW(/E-#"*EXGTQKIM0DDGH+,\E]X+4:LIYP:252Q))-A$S<^!=B#A'$I$
M^(^+>1M$B[]*"283CDL=T\;IZV8WH!%MS6[ ,WE%*8;+51+P@SMTN-<72P&\
MJ)+![:K\2O ;S.["<A'E=[3018^$;9Z">!*%J@7TL#]:HXQX @V=V JC&F)5
M"V-0&> #)&B%Y-)!9NG*'*X#N(*F44G1VB=%OF^YU##HY41;LU!?RR#(#U,+
M8J,%1!"DC( I]'!G!9]62*^D7AJU%)AC:;ZHGE&UE9@2>:',6D#I*C-!0?$[
M: ,4U22@9T_(J^JT[4. ^&<=V7O,D?1J$-O[>_Y7@\BD=W %2=^].HU&W>KS
M5S&WD%>OPU%OVJ)7PS86?UNTCON=X7#\=\@ZG72FW>= 8+#_2>$>#5YRTOCJ
M=#"^=/1Y]T6RA^+M85=6]PO@< :>9/1$ -O,X/_=SU_HVV_@OMH?ZY?BOK>9
M%"E[?ROB$K<ZV.\A9V\<^51'GO\1MH_AM_7 FW4*Z7._L35O[NZY:?_-W\(X
M>GY[%IXI6HJ#=X%W$"&O=G=-^!Q(4OK#)H^\/EQ]AC>9+^@-ZO\!4$L#!!0
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MT(Y( @E*-$.!DD@$]&=XI+9'(O/"8G<#'2,!EP:(9'"9(/N)<H* F3%P+PF
M2]A0=PJ*Q%PS-%N&"[$Z/P!-.;NCJCP)+,XPI<4SII!VN2J[+Q(U=[($,SW^
M L$ZQ4N.*&1F0&40H"R%$44F$=)8NA'_VS+ZV?#\&![A:5=&_TAE] M/0IS
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M6/4^<N'#_*<?A_HG)_\!4$L#!!0    (  2"75C=%+V.<"L  *IU 0 >
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M^/+3U>CV[/;LMQ'#S[+;RXVF<7;*KCY_/#\[AI%.SFZ.SR]O1B?M/$*\*BK
M"0Q_?NSWY-#]3OLH/_+KG*C-<&ST3=A)[ 8^^TV$$?R[R:(&[1(8K</V_F%I
MK?IJ74[4$,[&"9X/0-$VZP*ZK5QN:765BZO1VDY&OXW.+Z]H=:>?+T[.+OY%
M9^_Z\O?A^>W9Z(8-_W4]&N']3?;8ZK4'Q4WNPTRVM#JB;N7M8P^N>K,-WF\?
ME3<83NH@O\%_)%'L3I;;PEZ]?TPOZG5GT:^<Q4X\<R-@*H-NM_/A;2:R AP@
M&#E2.-H>- @.UH==!C"9<T<P[CN,R  (?:X?!PQ$,F''[AW<BE@P81?!G9B/
M1<BZ1RV4^WH,("IJ!5 V2N=\ M)K'>#;8N,EP78LXGLA_#<Z M6 JA916BBC
MM+<)K!;C[$1X_)Z'@MG!?,'])9OQ.U0].%MXW!:(@6-41D04,1ZSWI%EL9L@
M# 7BZF_<\\22?0P23]SQT&FQF\2-!;.L#OS*?7;BBFG08L= #B=!Z+N<'76M
MKM5BG]LW[6&[Q79J@,?G[A0PI1Y8BRB[35A<#<^!09X/452_'EX1KGZ?F&IU
M]]E-'/()()[#AG?"3X3&SQ]Z!X"@7_C2ATM70V8==0:'$OAN'+'A9.)Z+E"R
MJ!;X><6].^%YO#X8RI'R1RR> 9QM$<;<A:,N8)+!@OC!:>([M#7P['6PY%[L
MPE2&TU (O-\J,;D384LF9_60R5F#VC"Y^K$V!!EM $@,13A^XDO6[9*<T"FQ
M0$GGZ))&J=J .<6-.D"XG<$'@:7@-@?8C@4+Q42$**T!_YN!V :H[P*VW[E.
M MQP2;M3!XA>\3!>U@":+ B!8H.<0'@J 503I$,0 6':)I#:"DH;J=C=*BM*
MW>T,UZ/CLUL0=TLKW,0RMIG2O5^I=<M+<#9A]>][!ULS17P!26HTO-FN^*1H
M&&B=PI_R*2F;= P=@VWC$R!<S45HNP#*_W R] %;6<QX. <9*XE=FWML$09.
M8L?1WW_8/WHBYC9[^?2]3)E3<.]'2%X#V,CPWHU0-/;C,/"B5"ISX>03[4WD
MOBW@^I(1N"/:[U!,$X_'0;AD*/3ZTP@NP044WX##(8J@O!V 1 >X$L&>D'\*
MB/C5[?_L=;I=M@._.V("$T51PPON04B\G[GV#+$-WX^2\1\P T0D&[Y *&2@
M78-%6\&B11)&"8<OJUTVI'-%+ B9W'$22V$''YHHP1ZVLD@\X)+&", [\<V>
M<7\*;P!^XJ/2;PG#A"#JH\ Z2>($E+D%7^+K$1OS"+X3/((JJ<\1_C!#@W\9
M'#IL<.A!',*M4D(4 _HSP_TEU22/47AYA^\"Z^%C3] ]7_!P#X22.2"+&[OI
MGM*(,T %UF,+]RZ(@5:D1".*$V=90+1/KAT&]A+VQF;GRSEP*OSM$_< \>8T
M;-1B.V/X^+<%5Q.+;*"#^FNY6;J^[24.8&40PQ47/PZB*Q\'H1P*\1,1!?_(
M&"&S8637(8/!5/@B)!(Y"8-Y2JM1S+,./T1$@T-7Q!P([O^[O;P^NX!;_4'W
M UHQ8IRT5+%W[%T%2DW*B<HSA%E4FGLK);+JH,K'U"F6\XU8)&(\C_%,,G\@
MSZD)=R-GJ&7ES\K:\W-4Z^-S<?FE13:NT>GE]6B[IP@V S8I<AT1YLX!;)68
M!MJ.HB[.$V+E=G 'IPGIIM)!D5ASY,'Y4XEWT0R B(),>P+H'-RCY#;X:_%<
MZXWLEU5?+T006.W./L(A/7P1GMI:6$! ';4..A_*/V]SE-+-$$L9HGA&DU9X
MA5X9^QY&OL/M>:/Y%HWG*Y#OEJ2L"7%?27)J8)"Y  9UP[WMFF2TW:J,Y/@K
MP5+#BMLV*$9QI(1:DFYXZ%+L'K)_92WW/,6\E=X%IUV)O0#WEOX>GP#3UB/C
M/[W.A[G@*+_<N\"S0Q$M%(='[\>5E#W4@VJ0S=CX$VCZ]L_0N#YGJ-/N#6I[
MAFY%&+JHS]?K##G"$V0X()L#>>S(!H7^-A2U0Q$O)9Y+T0<9!4"\FE4\,JBN
M0S0OOXF'AX^26U\=Z=? 49WN!JU2M"*R2"IED3*2[*O,DT W@]!S[D&P5CK5
MN/J%RP6=W^P]O/@93C6@Z$U,:AV<;1!L0E!#6TI)1!J/R!LKP*"TC1]9!%$D
M(@R-C!XT[JO%[1^V#Q 5@X@(R7MI@+L3*\.KQT$<!_/WG>P5/HX"+XG+K_S\
M4TQL*7TS!#5CC[3:123>ZU\^.&X$AW+YWO4)[/32!W6&U.?PN-R!,HJZN#H=
M=%#D;?7E;ON@V\5OQW V8T=_5TVK3=/Z,7;*]XX&[:/.ZMN=MI7>^Y'&EN/#
M B)0[/_YKO>NX#1XWUU\8U;^-./1+ZY!3O_=:N)1HAV]-V""U0>@6PAB3Z'Q
M(VU8B42^V/P&&YY/J]O_\/EF[^3R^.;O/QQU/UC]P5&_W[>.VI:\F?ZL5#/D
M7<98IS<X[%M[G<Y!WWRO*H9?_IR%V?9/Q=XX%/SK'HE4[[EWSY?1N[]F+L/W
M*>S9]1'VK/9A3PM["!W#B@8\8[A8@&[@?F/#DAW]M82?C39YI7BSPJR]7?DF
MM>=B[(0?W D/&?9LZ81! NPXY L^7]IHM P69 F>"@_W8(ZN*V3=/":=R Y\
M]'4K,QJ?HW*&K#L=H)T+4^)HG7#)3H9N"CV+L4#>CG93D 8VLVTD$2A^K-<^
M^EMA#OF/GRIG"+\+7(?[,FC-"9)QW$J_'LU07]2&:%S5JD6;8Z^  . ;K@SO
M8)"*39<-":;%QDD,$(^9Y\Y=Z>AI5:SCF6$*5D]BHTE=]K9H#'3J0UX.VKV4
MO*0'/_6G*C-^*%)3A.-(;]P091B0ZRR%F^6=V2S3KU^5Z9>RPG:GQ X+@N+8
M"^RO);$P6"AVVC]J=X^*0U2PHRW1GY18/XK4KD[J*KU9":TY_[:G!6+8GK]]
M0&E$B[ETH0S/JFUZPE9T4[7@80TZMTT')68RZ!,S>?.=ZUJ'&>?8CDHLIU"O
M_ <#+*F&7,H=:6_70E6$VY6T@M8!8#,5EHB 0PJ<\Y7>X.X"/^VWK=46UN)Q
MV:Y(M4U;T4=N?]W[O$"P):$+HNT9)3A%=0CNW72C>VUK9[S[1'MZF5AN+S>P
MQECB?PV316POV3F_KX7+1[E;S'!ED)#3>:+@' 7>G?#Q]U $X11PZ#]*J)YC
MD$@0NLF\Q28A3YS$HXH.@7\GEBCLYRZ#8.U'$R#-.GZ/12"!>SQD'@"#<<E1
M, @/<%7X@*&VT'%6=B@<-#E&*JI$^Y5D[(GG+5\,;?_R/+Z@YWV/#*L.+%]:
MV+\GL'4V9/25UC3KZ*]\9I0[Y1AC-GU%M2X"4$IJ(1EOC@!U.CIL] WC7R/Q
M74*RN[G4O'%@V5]7<,J[*VLC-Y&5D8RWJ<6R%!^+*0LRD"9+8I#F21!K"JFW
ME%WJFA&U\!I*2SX;BQGW)A0)_. P3PW#W3@B]ID!Y0T>*R2Y2D*;(K^OPJT1
MN$IU  WIK4*0P-YXN5>8_YA'KHH=6.BE+' I:0[$:N]E$Q/0Q 0\%5M[34S
MBE/5Q 2\G4_G3\$4"Q3]6E#5$)E,8;L+Z52]QA=61 &<,A['W)Z!L((..PH)
MD%),)-"D)(48HQ #QJ&Y$S?+Q^6+A0=01_)<+?F_=(AOG>!?/Z%D#0K43$+Q
MBQ(*6RFB4$#ZI"P4$U* !(.E8V4Q'&6WAU]:,N[<88GOB+ B;#(K]&)&2%:F
M?I9?_AZ]J(W\ULAO+W&6^XW\MD8KVBR*Y?!=(_,]/3_"ZK9[^^O"6AZ15C&H
MO9!A\*G[F2#7FQ_<*\L4:.KBFQN1YPU^1R%.YF7IM"ZT,]G_3MR0,FV#J1R
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M%*.*S0+S-RKE@!#:*,))?^LOP$_7(Y))-6HQ,,,&!@3O9722HK2_+=PPY\/
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M[.HR7T,T),?+@H<H#Z3^E^<E<?0&A CY'([M517Q:A/]WSUJ'QSF$CA.GY#
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MV])#YI&N:>(4/4E,>!N&_Y H\]?A23^. V<)_\SBN??S_P=02P$"% ,4
M"  $@EU8.UH,%[4$  !]%@  '@              @ $     97AH:6)I=#$P
M,3)?86UE;F1M96YT=&]L:6<N:'1M4$L! A0#%     @ !()=6*6.:.T3"P
ME$@  !X              ( !\00  &5X:&EB:70Q,#0T7W!A;'9E;&QA+69I
M<G-T+FAT;5!+ 0(4 Q0    (  2"75CK?J6T61(  'YJ   >
M  "  4 0  !E>&AI8FET.3=?;&EG86YD+6-L87=B86-K<"YH=&U02P$"% ,4
M    "  $@EU8+^!  2!6 P";^R8 $0              @ '5(@  ;&=N9"TR
M,#(S,3(S,2YH=&U02P$"% ,4    "  $@EU8AM*L^28=  !"7P$ $0
M        @ $D>0, ;&=N9"TR,#(S,3(S,2YX<V102P$"% ,4    "  $@EU8
M3WO5L9<\   N;0( %0              @ %YE@, ;&=N9"TR,#(S,3(S,5]C
M86PN>&UL4$L! A0#%     @ !()=6&#Q&:IBM0  _",( !4
M ( !0],# &QG;F0M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    (  2"75AG
M 4#FB#H   ^;   4              "  =B(! !L9VYD+3(P,C,Q,C,Q7V<Q
M+FIP9U!+ 0(4 Q0    (  2"75CL_E)<(M4! ",= @ 4              "
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M2P$"% ,4    "  $@EU8*C#@ I\# 0!F1PP %0              @ %,!PT
M;&=N9"TR,#(S,3(S,5]P<F4N>&UL4$L! A0#%     @ !()=6*6L8Z>; P
M^BX  !H              ( !'@L. &QG;F1?,3(S,3(S>&5X:&EB:70R,3$N
M:'1M4$L! A0#%     @ !()=6.$"[5BL P  XA4  !H              ( !
M\0X. &QG;F1?,3(S,3(S>&5X:&EB:70R,S$N:'1M4$L! A0#%     @ !()=
M6/C6<[@ "   2#T  !H              ( !U1(. &QG;F1?,3(S,3(S>&5X
M:&EB:70S,3$N:'1M4$L! A0#%     @ !()=6)UK;[C7!P  [SP  !H
M         ( !#1L. &QG;F1?,3(S,3(S>&5X:&EB:70S,3(N:'1M4$L! A0#
M%     @ !()=6&A&AI^_!@  >3(  !H              ( !'",. &QG;F1?
M,3(S,3(S>&5X:&EB:70S,C$N:'1M4$L! A0#%     @ !()=6-T4O8YP*P
MJG4! !X              ( !$RH. &QI9V%N9"UE>#$P-#5X<&%L=F5L;&%X
=86UE+FAT;5!+!08     $P 3 "H%  "_50X    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>lgnd-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lgnd="http://www.ligand.com/20231231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lgnd-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMilestonesAndOtherProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:BelowMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:AboveMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquityMethodInvestmentsAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquitySecuritiesAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:DerivativeAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-27</startDate>
            <endDate>2023-09-27</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-27</startDate>
            <endDate>2023-09-27</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-27</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-27</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-27</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisAndDianomiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-01</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:CorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:SoticlestatMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-01-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-01-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">lgnd:NotesRepurchasedDuringCurrentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">lgnd:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">lgnd:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgnd:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>lgnd:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lgnd:right</measure>
    </unit>
    <unit id="contract">
        <measure>lgnd:contract</measure>
    </unit>
    <unit id="pure">
        <measure>lgnd:pure</measure>
    </unit>
    <unit id="cvr">
        <measure>lgnd:cvr</measure>
    </unit>
    <unit id="position">
        <measure>lgnd:position</measure>
    </unit>
    <unit id="agreement">
        <measure>lgnd:agreement</measure>
    </unit>
    <unit id="complaint">
        <measure>lgnd:complaint</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0000886163</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="c-16" id="f-265">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-532">P1Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-114" decimals="4" id="f-620" unitRef="number">0.1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-115" decimals="4" id="f-621" unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-878">http://www.ligand.com/20231231#NonCashChangeInEstimatedFairValueOfContingentValueRights</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList contextRef="c-15" id="f-882">http://fasb.org/us-gaap/2023#GainLossOnInvestments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-926">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-927">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-1191">P1Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <lgnd:ShareBasedCompensationInitialOfferingPeriod contextRef="c-344" id="f-1520">P6M</lgnd:ShareBasedCompensationInitialOfferingPeriod>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33093</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">555 Heritage Drive, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">33458</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">550-7500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-29" unitRef="usd">900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">17705287</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Portions of the Proxy Statement for the Registrant&#x2019;s 2024 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2023 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-36">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-37">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-38">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">22954000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">45006000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">147355000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">166864000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">32917000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">30424000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">23969000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">13294000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">6395000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">4614000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">1182000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">1132000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">2657000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">2267000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">237429000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">263601000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">214000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">8530000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">299606000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">342455000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">103370000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">105673000</us-gaap:Goodwill>
    <lgnd:CommercialLicenseRights contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">67291000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRights contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">10182000</lgnd:CommercialLicenseRights>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">15607000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">12482000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">6062000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">10914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">3393000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">4095000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">12595000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherInvestments contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">35726000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">3000000</us-gaap:OtherInvestments>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">5923000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">1736000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">787216000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">762668000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">2427000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">5307000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">12467000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">15681000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">256000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">57000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">1222000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">355000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">670000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">45000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">76695000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">16782000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">98810000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">1444000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">44000</us-gaap:DeferredRevenueNoncurrent>
    <lgnd:LiabilityForContingentValueRights contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">2942000</lgnd:LiabilityForContingentValueRights>
    <lgnd:LiabilityForContingentValueRights contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">3456000</lgnd:LiabilityForContingentValueRights>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">31622000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">30615000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">5755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">10336000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">27758000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">21922000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">86303000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">165183000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-105" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-106" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-107"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-108"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-109" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-110" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-111" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="-3" id="f-112" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-113" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-114" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-117"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-118"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-119" unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-120" unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-121" unitRef="shares">17556000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-122" unitRef="shares">17556000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-123" unitRef="shares">16951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-124" unitRef="shares">16951000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-125" unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-127" unitRef="usd">198696000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">147590000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-129" unitRef="usd">-817000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">-984000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-131" unitRef="usd">503016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">450862000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-133" unitRef="usd">700913000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">597485000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-135" unitRef="usd">787216000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-136" unitRef="usd">762668000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">83910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">72527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-139" unitRef="usd">48927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-140" unitRef="usd">28372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-141" unitRef="usd">104495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-142" unitRef="usd">164250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-143" unitRef="usd">19032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-144" unitRef="usd">19223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-145" unitRef="usd">28367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">131314000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-147" unitRef="usd">196245000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-148" unitRef="usd">241544000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostDirectMaterial contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">10512000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial contextRef="c-15" decimals="-3" id="f-150" unitRef="usd">52827000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial contextRef="c-16" decimals="-3" id="f-151" unitRef="usd">62176000</us-gaap:CostDirectMaterial>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">33654000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">34237000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-16" decimals="-3" id="f-154" unitRef="usd">34222000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">24537000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-156" unitRef="usd">36082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-157" unitRef="usd">32105000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">52790000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-159" unitRef="usd">70062000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-160" unitRef="usd">46790000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-15" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-16" decimals="-3" id="f-163" unitRef="usd">37600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">121493000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-15" decimals="-3" id="f-165" unitRef="usd">193208000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-16" decimals="-3" id="f-166" unitRef="usd">137693000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">2121000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-15" decimals="-3" id="f-168" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-16" decimals="-3" id="f-169" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">11942000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-171" unitRef="usd">3037000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-172" unitRef="usd">103851000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">46365000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-15" decimals="-3" id="f-174" unitRef="usd">28540000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-16" decimals="-3" id="f-175" unitRef="usd">-5263000</us-gaap:GainLossOnInvestments>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">7711000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-3" id="f-177" unitRef="usd">2046000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-16" decimals="-3" id="f-178" unitRef="usd">886000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">656000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-15" decimals="-3" id="f-180" unitRef="usd">1799000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-3" id="f-181" unitRef="usd">19619000</us-gaap:InterestExpense>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">250000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-15" decimals="-3" id="f-183" unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-16" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-1952000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-186" unitRef="usd">4187000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-187" unitRef="usd">-7650000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">51718000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-189" unitRef="usd">32974000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-190" unitRef="usd">-31646000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">63660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-192" unitRef="usd">36011000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-193" unitRef="usd">72205000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">9841000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-195" unitRef="usd">41230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-196" unitRef="usd">-4148000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">53819000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-15" decimals="-3" id="f-198" unitRef="usd">-5219000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-16" decimals="-3" id="f-199" unitRef="usd">76353000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">-1665000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-15" decimals="-3" id="f-201" unitRef="usd">-28142000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-16" decimals="-3" id="f-202" unitRef="usd">-19215000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-204" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-205" unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">3.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-15"
      decimals="2"
      id="f-207"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-16"
      decimals="2"
      id="f-208"
      unitRef="usdPerShare">4.59</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-209"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-15"
      decimals="2"
      id="f-210"
      unitRef="usdPerShare">-1.67</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-16"
      decimals="2"
      id="f-211"
      unitRef="usdPerShare">-1.16</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-212"
      unitRef="usdPerShare">3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-213"
      unitRef="usdPerShare">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-214"
      unitRef="usdPerShare">3.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-215" unitRef="shares">17298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-216" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-3" id="f-217" unitRef="shares">16630000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-218"
      unitRef="usdPerShare">3.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-15"
      decimals="2"
      id="f-219"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-16"
      decimals="2"
      id="f-220"
      unitRef="usdPerShare">4.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-221"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-15"
      decimals="2"
      id="f-222"
      unitRef="usdPerShare">-1.67</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-16"
      decimals="2"
      id="f-223"
      unitRef="usdPerShare">-1.11</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-224"
      unitRef="usdPerShare">2.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-225"
      unitRef="usdPerShare">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-226"
      unitRef="usdPerShare">3.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-227" unitRef="shares">17757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-228" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-3" id="f-229" unitRef="shares">17246000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-231" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-232" unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">167000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-234" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-3" id="f-235" unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">52321000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-237" unitRef="usd">-33428000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-238" unitRef="usd">57022000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-17" decimals="-3" id="f-239" unitRef="shares">16080000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-240" unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-241" unitRef="usd">318358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-242" unitRef="usd">-801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-243" unitRef="usd">391952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-244" unitRef="usd">709525000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-22" decimals="-3" id="f-245" unitRef="shares">687000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-22" decimals="-3" id="f-246" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-247" unitRef="usd">27744000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-16" decimals="-3" id="f-248" unitRef="usd">27745000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-249" unitRef="usd">38783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-250" unitRef="usd">38783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-24" decimals="-3" id="f-251" unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-16" decimals="-3" id="f-252" unitRef="usd">-116000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c-23" decimals="-3" id="f-253" unitRef="usd">-12407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c-16" decimals="-3" id="f-254" unitRef="usd">-12407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions contextRef="c-23" decimals="-3" id="f-255" unitRef="usd">491000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions contextRef="c-16" decimals="-3" id="f-256" unitRef="usd">491000</lgnd:AdjustmentsToAdditionalPaidInCapitalWarrantAndBondHedgeUnwindTransactions>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-257" unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-258" unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="-3" id="f-259" unitRef="shares">16767000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-260" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-261" unitRef="usd">372969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-262" unitRef="usd">-917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-263" unitRef="usd">449090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-264" unitRef="usd">821159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-266" unitRef="usd">-51130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-267" unitRef="usd">35133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-268" unitRef="usd">-15997000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-34" decimals="-3" id="f-269" unitRef="shares">184000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-35" decimals="-3" id="f-270" unitRef="usd">-5004000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-15" decimals="-3" id="f-271" unitRef="usd">-5004000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-272" unitRef="usd">60285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-273" unitRef="usd">60285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-36" decimals="-3" id="f-274" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-275" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction contextRef="c-35" decimals="-3" id="f-276" unitRef="usd">202000</lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction contextRef="c-15" decimals="-3" id="f-277" unitRef="usd">202000</lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation contextRef="c-35" decimals="-3" id="f-278" unitRef="usd">229732000</lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation contextRef="c-15" decimals="-3" id="f-279" unitRef="usd">229732000</lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-280" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-281" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-38" decimals="-3" id="f-282" unitRef="shares">16951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-283" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-284" unitRef="usd">147590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-285" unitRef="usd">-984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-286" unitRef="usd">450862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-287" unitRef="usd">597485000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-42" decimals="-3" id="f-288" unitRef="shares">605000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-42" decimals="-3" id="f-289" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-43" decimals="-3" id="f-290" unitRef="usd">17901000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">17902000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-292" unitRef="usd">25743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">25743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-44" decimals="-3" id="f-294" unitRef="usd">167000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">167000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation contextRef="c-43" decimals="-3" id="f-296" unitRef="usd">-1665000</lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-1665000</lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision contextRef="c-43" decimals="-3" id="f-298" unitRef="usd">5797000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">5797000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-300" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-302" unitRef="shares">17556000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-303" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-304" unitRef="usd">198696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-305" unitRef="usd">-817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-306" unitRef="usd">503016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-307" unitRef="usd">700913000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-309" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-310" unitRef="usd">57138000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">2121000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-15" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-16" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">265000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights contextRef="c-15" decimals="-3" id="f-315" unitRef="usd">748000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights contextRef="c-16" decimals="-3" id="f-316" unitRef="usd">36962000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">36521000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-15" decimals="-3" id="f-318" unitRef="usd">51534000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-16" decimals="-3" id="f-319" unitRef="usd">51071000</us-gaap:DepreciationDepletionAndAmortization>
    <lgnd:GainLossOnShortTermInvestments contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">46365000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments contextRef="c-15" decimals="-3" id="f-321" unitRef="usd">28540000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments contextRef="c-16" decimals="-3" id="f-322" unitRef="usd">-3997000</lgnd:GainLossOnShortTermInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">1318000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-15" decimals="-3" id="f-324" unitRef="usd">-16000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-16" decimals="-3" id="f-325" unitRef="usd">-111000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">240000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-15" decimals="-3" id="f-327" unitRef="usd">734000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-16" decimals="-3" id="f-328" unitRef="usd">16692000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">250000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-15" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-16" decimals="-3" id="f-331" unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-3" id="f-333" unitRef="usd">4192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-16" decimals="-3" id="f-334" unitRef="usd">-7303000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">-878000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights contextRef="c-15" decimals="-3" id="f-336" unitRef="usd">-164000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights contextRef="c-16" decimals="-3" id="f-337" unitRef="usd">-125000</lgnd:AmortizationOfCommercialLicenseAndOtherEconomicRights>
    <lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">3595000</lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights>
    <lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights contextRef="c-15" decimals="-3" id="f-339" unitRef="usd">0</lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights>
    <lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights contextRef="c-16" decimals="-3" id="f-340" unitRef="usd">0</lgnd:AdjustmentToCreditLossReservesOfCommercialLicenseRights>
    <lgnd:ImpairmentLossOnCommercialLicenseRights contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">924000</lgnd:ImpairmentLossOnCommercialLicenseRights>
    <lgnd:ImpairmentLossOnCommercialLicenseRights contextRef="c-15" decimals="-3" id="f-342" unitRef="usd">0</lgnd:ImpairmentLossOnCommercialLicenseRights>
    <lgnd:ImpairmentLossOnCommercialLicenseRights contextRef="c-16" decimals="-3" id="f-343" unitRef="usd">0</lgnd:ImpairmentLossOnCommercialLicenseRights>
    <lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">1735000</lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization>
    <lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization contextRef="c-15" decimals="-3" id="f-345" unitRef="usd">5521000</lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization>
    <lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization contextRef="c-16" decimals="-3" id="f-346" unitRef="usd">4840000</lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">25743000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-348" unitRef="usd">60285000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-16" decimals="-3" id="f-349" unitRef="usd">38783000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">-1829000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-15" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-16" decimals="-3" id="f-352" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-11696000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-15" decimals="-3" id="f-354" unitRef="usd">-20723000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-16" decimals="-3" id="f-355" unitRef="usd">8618000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">739000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-15" decimals="-3" id="f-357" unitRef="usd">365000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-16" decimals="-3" id="f-358" unitRef="usd">1572000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">2601000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-360" unitRef="usd">-55319000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-16" decimals="-3" id="f-361" unitRef="usd">28616000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">10870000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-3" id="f-363" unitRef="usd">-12058000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-16" decimals="-3" id="f-364" unitRef="usd">427000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">5000000</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent contextRef="c-15" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent contextRef="c-16" decimals="-3" id="f-367" unitRef="usd">0</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">-4704000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-15" decimals="-3" id="f-369" unitRef="usd">-3340000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-16" decimals="-3" id="f-370" unitRef="usd">2810000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">1781000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-15" decimals="-3" id="f-372" unitRef="usd">-1579000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-16" decimals="-3" id="f-373" unitRef="usd">3976000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">419000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-15" decimals="-3" id="f-375" unitRef="usd">-6281000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-16" decimals="-3" id="f-376" unitRef="usd">-17870000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">9865000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-15" decimals="-3" id="f-378" unitRef="usd">-6342000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-16" decimals="-3" id="f-379" unitRef="usd">8925000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">49577000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-381" unitRef="usd">137850000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-16" decimals="-3" id="f-382" unitRef="usd">78798000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <lgnd:PurchaseforCommercialLicenseRights contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">50328000</lgnd:PurchaseforCommercialLicenseRights>
    <lgnd:PurchaseforCommercialLicenseRights contextRef="c-15" decimals="-3" id="f-384" unitRef="usd">0</lgnd:PurchaseforCommercialLicenseRights>
    <lgnd:PurchaseforCommercialLicenseRights contextRef="c-16" decimals="-3" id="f-385" unitRef="usd">0</lgnd:PurchaseforCommercialLicenseRights>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">3521000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-387" unitRef="usd">17923000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-16" decimals="-3" id="f-388" unitRef="usd">8761000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">126764000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-15" decimals="-3" id="f-390" unitRef="usd">51226000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-16" decimals="-3" id="f-391" unitRef="usd">181325000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <lgnd:ProceedsFromCommercialLicenseRights contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">418000</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights contextRef="c-15" decimals="-3" id="f-393" unitRef="usd">92000</lgnd:ProceedsFromCommercialLicenseRights>
    <lgnd:ProceedsFromCommercialLicenseRights contextRef="c-16" decimals="-3" id="f-394" unitRef="usd">494000</lgnd:ProceedsFromCommercialLicenseRights>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">148765000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-15" decimals="-3" id="f-396" unitRef="usd">209561000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-16" decimals="-3" id="f-397" unitRef="usd">154230000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">45402000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="c-15" decimals="-3" id="f-399" unitRef="usd">24830000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="c-16" decimals="-3" id="f-400" unitRef="usd">67105000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-50" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-51" decimals="-3" id="f-402" unitRef="usd">750000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-52" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-53" decimals="-3" id="f-404" unitRef="usd">15249000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-54" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-55" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">10405000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-15" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-16" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-15" decimals="-3" id="f-411" unitRef="usd">960000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-16" decimals="-3" id="f-412" unitRef="usd">1220000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-413" unitRef="usd">-11682000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-414" unitRef="usd">163624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-16" decimals="-3" id="f-415" unitRef="usd">30523000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <lgnd:PaymentsForSeparation contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">0</lgnd:PaymentsForSeparation>
    <lgnd:PaymentsForSeparation contextRef="c-15" decimals="-3" id="f-417" unitRef="usd">1840000</lgnd:PaymentsForSeparation>
    <lgnd:PaymentsForSeparation contextRef="c-16" decimals="-3" id="f-418" unitRef="usd">0</lgnd:PaymentsForSeparation>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">76854000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-15" decimals="-3" id="f-420" unitRef="usd">260949000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-16" decimals="-3" id="f-421" unitRef="usd">155760000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">45000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-15" decimals="-3" id="f-423" unitRef="usd">54000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-16" decimals="-3" id="f-424" unitRef="usd">9188000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-15" decimals="-3" id="f-426" unitRef="usd">6800000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-16" decimals="-3" id="f-427" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">949000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-15" decimals="-3" id="f-429" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-16" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromHedgeFinancingActivities contextRef="c-1" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities contextRef="c-15" decimals="-3" id="f-432" unitRef="usd">202000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities contextRef="c-16" decimals="-3" id="f-433" unitRef="usd">18938000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">22448000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-15" decimals="-3" id="f-435" unitRef="usd">3232000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-16" decimals="-3" id="f-436" unitRef="usd">33763000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-437" unitRef="usd">4547000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-15" decimals="-3" id="f-438" unitRef="usd">8236000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-16" decimals="-3" id="f-439" unitRef="usd">6018000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c-1" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c-15" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c-16" decimals="-3" id="f-442" unitRef="usd">18446000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-15" decimals="-3" id="f-444" unitRef="usd">1545000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-16" decimals="-3" id="f-445" unitRef="usd">1050000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">-59947000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-447" unitRef="usd">-275990000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-16" decimals="-3" id="f-448" unitRef="usd">-137761000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">-22052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-450" unitRef="usd">25484000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-16" decimals="-3" id="f-451" unitRef="usd">-28440000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-452" unitRef="usd">45006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-30" decimals="-3" id="f-453" unitRef="usd">19522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-21" decimals="-3" id="f-454" unitRef="usd">47962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">22954000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-456" unitRef="usd">45006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-30" decimals="-3" id="f-457" unitRef="usd">19522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">288000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-15" decimals="-3" id="f-459" unitRef="usd">1428000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-16" decimals="-3" id="f-460" unitRef="usd">3028000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-461" unitRef="usd">8770000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-15" decimals="-3" id="f-462" unitRef="usd">11642000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-16" decimals="-3" id="f-463" unitRef="usd">3722000</us-gaap:IncomeTaxesPaid>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived contextRef="c-56" decimals="-3" id="f-464" unitRef="usd">17101000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived contextRef="c-57" decimals="-3" id="f-465" unitRef="usd">0</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived contextRef="c-58" decimals="-3" id="f-466" unitRef="usd">0</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets contextRef="c-56" decimals="-3" id="f-467" unitRef="usd">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets contextRef="c-57" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets contextRef="c-58" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:Goodwill contextRef="c-56" decimals="-3" id="f-470" unitRef="usd">1829000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-57" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-58" decimals="-3" id="f-472" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-56" decimals="-3" id="f-473" unitRef="usd">10700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-57" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-58" decimals="-3" id="f-475" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-56" decimals="-3" id="f-476" unitRef="usd">19725000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-57" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-58" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-59" decimals="-3" id="f-479" unitRef="usd">10405000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-60" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-61" decimals="-3" id="f-481" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-482" unitRef="usd">998000</lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid>
    <lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-483" unitRef="usd">0</lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid>
    <lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-484" unitRef="usd">0</lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid>
    <lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-485" unitRef="usd">52000</lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid>
    <lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-486" unitRef="usd">0</lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid>
    <lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-487" unitRef="usd">0</lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid>
    <lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-488" unitRef="usd">347000</lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid>
    <lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-489" unitRef="usd">0</lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid>
    <lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-490" unitRef="usd">0</lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid>
    <lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-491" unitRef="usd">41000</lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid>
    <lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-492" unitRef="usd">0</lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid>
    <lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-493" unitRef="usd">0</lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-495" unitRef="usd">2333000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-496" unitRef="usd">1567000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <lgnd:AccruedInventoryPurchases contextRef="c-1" decimals="-3" id="f-497" unitRef="usd">0</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases contextRef="c-15" decimals="-3" id="f-498" unitRef="usd">0</lgnd:AccruedInventoryPurchases>
    <lgnd:AccruedInventoryPurchases contextRef="c-16" decimals="-3" id="f-499" unitRef="usd">1974000</lgnd:AccruedInventoryPurchases>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-500" unitRef="usd">212000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-15" decimals="-3" id="f-501" unitRef="usd">-85000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-16" decimals="-3" id="f-502" unitRef="usd">-221000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-503">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. We operate in one reportable segment: development and licensing of biopharmaceutical assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the spin-off of the OmniAb antibody discovery business (the&#x201c;OmniAb Business&#x201d;) in November 2022 met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 205-20&#x201d;). For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (4), Spin-off of OmniAb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#x201c;available-for-sale&#x201d;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of other income (expense) within the consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three&#160;months and less than twenty-five months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities consist of mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, Equity securities in Primrose Bio, or non-current other assets, based on the nature of the securities and their availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the years ended December&#160;31, 2023, 2022 and 2021, we considered the current and expected future economic and market conditions and concluded an increase of $0.2&#160;million, a decrease of $0.3&#160;million, and an increase of $0.01&#160;million of allowance for credit losses, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. During the years ended December&#160;31, 2023 and 2022, we recorded an obsolete inventory charge of $0.2&#160;million and  $1.1&#160;million, respectively. There was no adjustment to inventory recorded for the year ended December&#160;31, 2021. As of December&#160;31, 2023 and 2022, inventory included prepayments of $4.6&#160;million and $5.9&#160;million, respectively, to our supplier for Captisol.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:f-532"&gt;one&lt;/span&gt; to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any change in fair value is recorded in our consolidated statement of operations. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (6), Fair Value Measurement and Note (9), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2023, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For commercial license rights, we account them in accordance with ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Receivables, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and are measured at amortized cost using the prospective effective interest method described in ASC 835-30,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. If management determines it can reliably estimate future cash flows of the asset, we amortize the asset using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. If cash flows are not reliably estimable, the asset is accounted for using the non-accrual method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate commercial license rights for impairment on an individual basis. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize an allowance for current expected credit losses under ASC 326 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments &#x2013; Credit Losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on our commercial license rights. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for changes in projected cash flows and credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For other economic rights, which are characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and reduce the asset as the funds are expended. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights are evaluated for impairment on an ongoing basis. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (5), Commercial License and Other Economic Rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments present equity securities that primarily include common stocks, preferred stocks we invested. Equity securities without readily determinable or estimable fair values are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the following five-step model in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;amp;D services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For R&amp;amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2023, the amount recognized as revenue that was previously deferred at December&#160;31, 2022 was $0.1 million. During the year ended December&#160;31, 2022, the amount recognized as revenue that was previously deferred at December&#160;31, 2021 was $0.4 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Teriparatide injection &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rylaze &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Captisol - Core&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Captisol - COVID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;License Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (CRO) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#x2019;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. The 2023 Notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive. The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2023 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Updates, Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2023, we adopted ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2021-08&#x201d;). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC Topic 606&#x201d;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued updated accounting guidance related to annual and interim segment disclosures. The updated accounting guidance, among other things, requires disclosure of certain significant segment expenses. We will adopt the updated accounting guidance in our Annual Report on Form 10-K for the year ended December 31, 2024. We do not expect impact from the adoption of the new accounting guidance will have material impact to our segment disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <lgnd:BusinessSpinOffAndMigrationPolicyTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. We operate in one reportable segment: development and licensing of biopharmaceutical assets.&lt;/span&gt;&lt;/div&gt;</lgnd:BusinessSpinOffAndMigrationPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-505"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the spin-off of the OmniAb antibody discovery business (the&#x201c;OmniAb Business&#x201d;) in November 2022 met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt; (&#x201c;ASC 205-20&#x201d;).</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-508">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-509">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="2" id="f-511" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-512" unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-513" unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-65" decimals="2" id="f-514" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-66" decimals="2" id="f-515" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-67" decimals="2" id="f-516" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-68" decimals="2" id="f-517" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="2" id="f-518" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="2" id="f-519" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock contextRef="c-1" id="f-520">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#x201c;available-for-sale&#x201d;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statement of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statement of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of other income (expense) within the consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three&#160;months and less than twenty-five months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;Equity securities consist of mutual funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Mutual funds are valued at their publicly quoted net asset value (NAV) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, Equity securities in Primrose Bio, or non-current other assets, based on the nature of the securities and their availability for use in current operations.</lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="c-1" id="f-521">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses &lt;/span&gt;&lt;/div&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c-1" decimals="-5" id="f-522" unitRef="usd">200000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c-15" decimals="-5" id="f-523" unitRef="usd">-300000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c-16" decimals="-4" id="f-524" unitRef="usd">10000.00</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-525">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;Inventory, which consists of finished goods, is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-526" unitRef="usd">200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-15" decimals="-5" id="f-527" unitRef="usd">1100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-16" decimals="INF" id="f-528" unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryNet contextRef="c-71" decimals="-5" id="f-529" unitRef="usd">4600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-72" decimals="-5" id="f-530" unitRef="usd">5900000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:f-532"&gt;one&lt;/span&gt; to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-74" id="f-533">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-534">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</us-gaap:BusinessCombinationsPolicy>
    <lgnd:NumberOfContingentValueRightsIssued contextRef="c-75" decimals="INF" id="f-535" unitRef="right">4</lgnd:NumberOfContingentValueRightsIssued>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-536">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2023, noting no impairment. &lt;/span&gt;&lt;/div&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <lgnd:CommercialLicenseRightsPolicyTextBlock contextRef="c-1" id="f-537">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial license and other economic rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For commercial license rights, we account them in accordance with ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Receivables, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and are measured at amortized cost using the prospective effective interest method described in ASC 835-30,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. If management determines it can reliably estimate future cash flows of the asset, we amortize the asset using the effective interest method whereby we forecast expected cash flows over the term of the arrangement to arrive at an annualized effective interest. If cash flows are not reliably estimable, the asset is accounted for using the non-accrual method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate commercial license rights for impairment on an individual basis. If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize an allowance for current expected credit losses under ASC 326 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments &#x2013; Credit Losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on our commercial license rights. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for changes in projected cash flows and credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For other economic rights, which are characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and reduce the asset as the funds are expended. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights are evaluated for impairment on an ongoing basis. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (5), Commercial License and Other Economic Rights&lt;/span&gt;&#x201d;.</lgnd:CommercialLicenseRightsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-538">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <lgnd:OtherInvestmentsPolicyPolicyTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments present equity securities that primarily include common stocks, preferred stocks we invested. Equity securities without readily determinable or estimable fair values are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;</lgnd:OtherInvestmentsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-540">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, and contract revenue for services, license fees and development, regulatory and sales based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the following five-step model in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues are adjusted in the period in which they become known, typically the following quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Captisol sales is recognized when control of Captisol material or intellectual property license rights is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material, we consider our performance obligation is satisfied at a point in time, once we have transferred control of the product, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in Cost of Captisol. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers often will include variable consideration in the form of contingent milestone-based payments. We include contingent milestone based payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone based payment is sales-based, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development based milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation, which typically occurs with our contracts for R&amp;amp;D services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For R&amp;amp;D services we recognize revenue over time and we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time it will take us to complete the activities, or the costs we may incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally have sub-license obligations related to arrangements for which we receive license fees, milestones and royalties. We evaluate the determination of gross as a principal versus net as an agent reporting based on each individual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-541" unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-15" decimals="-5" id="f-542" unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-543">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue for 2023, 2022 and 2021 for continuing operations are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Teriparatide injection &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rylaze &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Captisol and contract revenue for continuing operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Captisol - Core&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Captisol - COVID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;License Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-544" unitRef="usd">35640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-545" unitRef="usd">30116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-546" unitRef="usd">27472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-3" id="f-547" unitRef="usd">10212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-548" unitRef="usd">10197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-549" unitRef="usd">10079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-550" unitRef="usd">11061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-551" unitRef="usd">15785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-552" unitRef="usd">5260000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-553" unitRef="usd">13520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-3" id="f-554" unitRef="usd">8796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-555" unitRef="usd">2420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-556" unitRef="usd">13477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-557" unitRef="usd">7633000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-3" id="f-558" unitRef="usd">3696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-559" unitRef="usd">83910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-560" unitRef="usd">72527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-561" unitRef="usd">48927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-562" unitRef="usd">28372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-3" id="f-563" unitRef="usd">16429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-564" unitRef="usd">23423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-566" unitRef="usd">88066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-3" id="f-567" unitRef="usd">140827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-568" unitRef="usd">28372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-569" unitRef="usd">104495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-570" unitRef="usd">164250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-571" unitRef="usd">615000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-572" unitRef="usd">1117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-573" unitRef="usd">3737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-574" unitRef="usd">217000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-575" unitRef="usd">2849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-576" unitRef="usd">634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-577" unitRef="usd">16800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-578" unitRef="usd">9150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-579" unitRef="usd">17584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-3" id="f-580" unitRef="usd">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-581" unitRef="usd">6107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-582" unitRef="usd">6412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-583" unitRef="usd">19032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-584" unitRef="usd">19223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-585" unitRef="usd">28367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-586">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (CRO) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-587">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (RSU) and performance stock unit (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#x2019;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-109" id="f-588">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-110"
      decimals="INF"
      id="f-589"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-111"
      decimals="INF"
      id="f-590"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput contextRef="c-112" decimals="2" id="f-591" unitRef="number">0</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-113"
      decimals="INF"
      id="f-592"
      unitRef="usdPerShare">2.50</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-114" id="f-593">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-115" id="f-594">P42M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-116" id="f-595">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-117" id="f-596">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-597">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. The 2023 Notes have a dilutive impact when the average market price of the Company&#x2019;s common stock exceeds the applicable conversion price of the respective notes. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Share&lt;/span&gt;, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-599">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2023 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-600" unitRef="shares">17298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-601" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="-3" id="f-602" unitRef="shares">16630000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-118"
      decimals="-3"
      id="f-603"
      unitRef="shares">85000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-119"
      decimals="-3"
      id="f-604"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-120"
      decimals="-3"
      id="f-605"
      unitRef="shares">96000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-121"
      decimals="-3"
      id="f-606"
      unitRef="shares">255000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-122"
      decimals="-3"
      id="f-607"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-123"
      decimals="-3"
      id="f-608"
      unitRef="shares">520000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-124"
      decimals="-3"
      id="f-609"
      unitRef="shares">119000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-125"
      decimals="-3"
      id="f-610"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-126"
      decimals="-3"
      id="f-611"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-612" unitRef="shares">17757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-613" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="-3" id="f-614" unitRef="shares">17246000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-615" unitRef="shares">4357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-15" decimals="-3" id="f-616" unitRef="shares">6241000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-16" decimals="-3" id="f-617" unitRef="shares">4793000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale debt securities, foreign currency translation adjustments, and reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-619">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Updates, Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2023, we adopted ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2021-08&#x201d;). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC Topic 606&#x201d;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued updated accounting guidance related to annual and interim segment disclosures. The updated accounting guidance, among other things, requires disclosure of certain significant segment expenses. We will adopt the updated accounting guidance in our Annual Report on Form 10-K for the year ended December 31, 2024. We do not expect impact from the adoption of the new accounting guidance will have material impact to our segment disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-622">Sale of Pelican Business and Investment in Primrose Bio&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#x201c;Pelican&#x201d;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received 2,146,957 common shares, 4,278,293 preferred shares and 474,746 restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $15.0 million in exchange for 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive 25% of sales revenue of PeliCRM197 above $3.0 million and 35% of all PeliCRM197 licensing revenue in perpetuity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#x2019;s RYLAZE, Merck&#x2019;s VAXNEUVANCE and V116 vaccines, Alvogen&#x2019;s Teriparatide, Serum Institute of India&#x2019;s vaccine programs, including Pneumosil and MenFive vaccines, among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net assets sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allocated goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the consideration received includes the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;49,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $4.1&#160;million, resulting in a $2.1&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs of $1.2&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described above, we will receive 25% of sales revenue of PeliCRM197 above $3.0&#160;million and 35% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and thus, will be recognized as the underlying contingencies are resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we will receive 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of  $3.2&#160;million, at the disposition date, which was included under other long-term asset in our consolidated balance sheet. They &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are recognized as derivative assets under ASC 815,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and has been marked to fair value as of December&#160;31, 2023 with an adjustment of $0.3&#160;million. Any change in fair value is recorded to Other income (expense) in our consolidated statement of operations. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (6), Fair Value Measurement&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Investment in Primrose Bio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over its operating and financial results. In applying the equity method, we record the investment at fair value. Ligand's proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations for the year ended December&#160;31, 2023. Our equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary. Our share of the net loss of Primrose Bio since the divestiture date for year ended December&#160;31, 2023 was $1.8&#160;million, which reduced Ligand's equity method investment accordingly.  Any income of loss from our equity method investments are recorded to Other income (expense) in our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the Series A preferred stock investment in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value. There have been no observable price changes or impairments identified since September 18, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2023, our President and Chief Operating Officer, Matt Korenberg, became a board member of Primrose Bio.&lt;/span&gt;&lt;/div&gt;Spin-off of OmniAb&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2022, we entered into the Separation Agreement to separate our OmniAb Business and the Merger Agreement, pursuant to which APAC would combine with OmniAb, and acquire Ligand's OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#x201c;Transactions&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the closing date of the Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the Distribution. Pursuant to the Transaction Agreements, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the Distribution, Ligand distributed on a pro rata basis to its shareholders as of October 26, 2022 shares of the common stock of OmniAb representing 100% of Ligand&#x2019;s interest in OmniAb. Immediately following the Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#x201c;OABI.&#x201d; After the Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, the Company determined its antibody discovery business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $1.7 million tax provision adjustment related to deferred taxes during the year ended December&#160;31, 2023 that was attributable to the discontinued operations. The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income (expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain from short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss before income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for acquisition, net of cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental cash flow disclosures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration
      contextRef="c-127"
      decimals="INF"
      id="f-623"
      unitRef="shares">2146957</lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration
      contextRef="c-128"
      decimals="INF"
      id="f-624"
      unitRef="shares">4278293</lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration
      contextRef="c-129"
      decimals="INF"
      id="f-625"
      unitRef="shares">474746</lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration>
    <lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone contextRef="c-130" decimals="-5" id="f-626" unitRef="usd">15000000</lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone>
    <lgnd:InterestInPotentialDevelopmentMilestone contextRef="c-130" decimals="2" id="f-627" unitRef="number">0.50</lgnd:InterestInPotentialDevelopmentMilestone>
    <lgnd:NumberOfContracts
      contextRef="c-131"
      decimals="INF"
      id="f-628"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-132" decimals="3" id="f-629" unitRef="number">0.25</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:SalesRevenueMilestone contextRef="c-133" decimals="-5" id="f-630" unitRef="usd">3000000</lgnd:SalesRevenueMilestone>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-134" decimals="3" id="f-631" unitRef="number">0.35</lgnd:SalesContractInterestInSalesRevenue>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-632">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net assets sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allocated goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes revenue and expenses of the discontinued operations for the years ended December 31, 2022 and 2021 (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other income (expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain from short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss before income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the years ended December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for acquisition, net of cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental cash flow disclosures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="c-135" decimals="-3" id="f-633" unitRef="usd">8250000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="c-135" decimals="-3" id="f-634" unitRef="usd">19895000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="c-135" decimals="-3" id="f-635" unitRef="usd">717000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset contextRef="c-135" decimals="-3" id="f-636" unitRef="usd">8693000</lgnd:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset contextRef="c-135" decimals="-3" id="f-637" unitRef="usd">20000</lgnd:DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="c-135" decimals="-3" id="f-638" unitRef="usd">630000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue contextRef="c-135" decimals="-3" id="f-639" unitRef="usd">495000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities contextRef="c-135" decimals="-3" id="f-640" unitRef="usd">8445000</lgnd:DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="c-135" decimals="-3" id="f-641" unitRef="usd">74000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNetAsset contextRef="c-135" decimals="-3" id="f-642" unitRef="usd">27931000</lgnd:DisposalGroupIncludingDiscontinuedOperationNetAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="c-135" decimals="-3" id="f-643" unitRef="usd">4132000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone contextRef="c-135" decimals="-3" id="f-644" unitRef="usd">15000000</lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNetContributions contextRef="c-135" decimals="-3" id="f-645" unitRef="usd">47063000</lgnd:DisposalGroupIncludingDiscontinuedOperationNetContributions>
    <lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock contextRef="c-1" id="f-646">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the consideration received includes the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;49,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-136" decimals="-3" id="f-647" unitRef="usd">13706000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-137" decimals="-3" id="f-648" unitRef="usd">32278000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-138" decimals="-3" id="f-649" unitRef="usd">3200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-135" decimals="-3" id="f-650" unitRef="usd">49184000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-139" decimals="-5" id="f-651" unitRef="usd">4100000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-139" decimals="-5" id="f-652" unitRef="usd">2100000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:BusinessExitCosts1 contextRef="c-140" decimals="-5" id="f-653" unitRef="usd">1200000</us-gaap:BusinessExitCosts1>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-132" decimals="3" id="f-654" unitRef="number">0.25</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:SalesRevenueMilestone contextRef="c-133" decimals="-5" id="f-655" unitRef="usd">3000000</lgnd:SalesRevenueMilestone>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-134" decimals="3" id="f-656" unitRef="number">0.35</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:InterestInPotentialDevelopmentMilestone contextRef="c-130" decimals="2" id="f-657" unitRef="number">0.50</lgnd:InterestInPotentialDevelopmentMilestone>
    <lgnd:NumberOfContracts
      contextRef="c-131"
      decimals="INF"
      id="f-658"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-141" decimals="-5" id="f-659" unitRef="usd">3200000</us-gaap:DerivativeAssetsNoncurrent>
    <lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-660">consolidated balance sheet</lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="c-1" decimals="-5" id="f-661" unitRef="usd">300000</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-139" decimals="-5" id="f-662" unitRef="usd">-1800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-663">Acquisition&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 27, 2023, we closed the transaction to acquire certain assets of Novan, Inc. (&#x201c;Novan&#x201d;) pursuant to the agreement we entered into with Novan on July 17, 2023 for $15.0 million in cash (which agreement contemplated Novan filing for bankruptcy relief) and provided up to $15.0 million in debtor-in-possession (&#x201c;DIP&#x201d;) financing inclusive of a $3.0 million bridge loan funded on the same day. Novan filed for Chapter 11 reorganization on July 17, 2023. On September 27, 2023, the bankruptcy court approved our $12.2 million bid to purchase from Novan its lead product candidate berdazimer topical gel, 10.3%, all other assets related to the NITRICIL technology platform and the rights to one commercial stage asset. The remaining commercial assets of Novan will be sold to other parties. The approved $12.2 million bid was credited to the $15.0 million DIP financing, with the balance of $2.8 million and accrued interest repaid to us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was accounted for as business combination. We recorded $3.1 million of acquisition-related costs for legal, due diligence and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for Novan, including restricted cash received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DIP loan fees and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the goodwill is deductible for tax purposes. Acquired intangible assets of $10.7&#160;million related to core technology. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 29%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired other liabilities of $13.7&#160;million related to a royalty and milestone payments purchase agreement, entered by Novan in 2019 and assumed as part of the acquisition, which previously provided Novan $25.0&#160;million of funding used primarily in the clinical development of berdazimer topical gel, 10.3%. Pursuant to the purchase agreement, Novan will pay ongoing quarterly payments, calculated based on an applicable percentage per product of any upfront fees, milestone payments, royalty payments or equivalent payments received by Novan pursuant to any out-license agreement, net of any upfront fees, milestone payments, royalty payments or equivalent payments paid by Novan to third parties pursuant to any agreements under which Novan has in-licensed intellectual property with respect to such products.  If Novan decides to commercialize any product on its own following regulatory approval, as opposed to commercializing through an out-license agreement or other third-party arrangement, Novan will be obligated to pay a low single digits royalty on net sales of such products. This contract liability was fair valued based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the related programs mentioned above, by applying a discount rate of 14.0% (revenue risk-adjusted discount rate).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of assets acquired, liabilities assumed and purchased intangibles are provisional. Specifically, the provisional amounts include estimated projections on the completion of the clinical development process and projected revenue related to commercializing products based on the underlying technology as well as the assumed underlying contracts. The accounting for these amounts falls within the measurement period and, therefore, we may adjust these provisional amounts to reflect new information obtained about facts and circumstances that existed as of the acquisition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-142" decimals="-5" id="f-664" unitRef="usd">15000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-142" decimals="-5" id="f-665" unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-143" decimals="-5" id="f-666" unitRef="usd">3000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-144" decimals="-5" id="f-667" unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationAcquiredPercentage contextRef="c-145" decimals="3" id="f-668" unitRef="number">0.103</lgnd:BusinessCombinationAcquiredPercentage>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-144" decimals="-5" id="f-669" unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-142" decimals="-5" id="f-670" unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c-142" decimals="-5" id="f-671" unitRef="usd">2800000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-59" decimals="-5" id="f-672" unitRef="usd">3100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-673">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth an allocation of the preliminary purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for Novan, including restricted cash received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DIP loan fees and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-145" decimals="-3" id="f-674" unitRef="usd">583000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-145" decimals="-3" id="f-675" unitRef="usd">13054000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets contextRef="c-145" decimals="-3" id="f-676" unitRef="usd">3683000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets contextRef="c-145" decimals="-3" id="f-677" unitRef="usd">364000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets contextRef="c-145" decimals="-3" id="f-678" unitRef="usd">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-145" decimals="-3" id="f-679" unitRef="usd">10700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill contextRef="c-145" decimals="-3" id="f-680" unitRef="usd">1829000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c-145" decimals="-3" id="f-681" unitRef="usd">2342000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities contextRef="c-145" decimals="-3" id="f-682" unitRef="usd">3683000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseLiabilities>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities contextRef="c-145" decimals="-3" id="f-683" unitRef="usd">13700000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-142" decimals="-3" id="f-684" unitRef="usd">10988000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lgnd:BusinessCombinationLoanFeesAndInterest contextRef="c-142" decimals="-3" id="f-685" unitRef="usd">1162000</lgnd:BusinessCombinationLoanFeesAndInterest>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-142" decimals="-3" id="f-686" unitRef="usd">12150000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-145" decimals="-5" id="f-687" unitRef="usd">10700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate contextRef="c-142" decimals="3" id="f-688" unitRef="number">0.29</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-142" id="f-689">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities contextRef="c-145" decimals="-5" id="f-690" unitRef="usd">13700000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities>
    <lgnd:ContingentMilestonePurchaseAgreement contextRef="c-145" decimals="-5" id="f-691" unitRef="usd">25000000</lgnd:ContingentMilestonePurchaseAgreement>
    <lgnd:BusinessCombinationAcquiredPercentage contextRef="c-145" decimals="3" id="f-692" unitRef="number">0.103</lgnd:BusinessCombinationAcquiredPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-146" decimals="INF" id="f-693" unitRef="pure">0.140</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed
      contextRef="c-147"
      decimals="INF"
      id="f-694"
      unitRef="number">1</lgnd:DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed>
    <lgnd:DeferredTaxAssetsAdjustments contextRef="c-1" decimals="-5" id="f-695" unitRef="usd">-1700000</lgnd:DeferredTaxAssetsAdjustments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-148" decimals="-3" id="f-696" unitRef="usd">1289000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-149" decimals="-3" id="f-697" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-150" decimals="-3" id="f-698" unitRef="usd">25275000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-151" decimals="-3" id="f-699" unitRef="usd">35589000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-152" decimals="-3" id="f-700" unitRef="usd">26564000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-153" decimals="-3" id="f-701" unitRef="usd">35589000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="c-152" decimals="-3" id="f-702" unitRef="usd">10847000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="c-153" decimals="-3" id="f-703" unitRef="usd">12945000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment contextRef="c-152" decimals="-3" id="f-704" unitRef="usd">38466000</lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment contextRef="c-153" decimals="-3" id="f-705" unitRef="usd">36907000</lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-152" decimals="-3" id="f-706" unitRef="usd">13383000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-153" decimals="-3" id="f-707" unitRef="usd">10693000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c-152" decimals="-3" id="f-708" unitRef="usd">62696000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c-153" decimals="-3" id="f-709" unitRef="usd">60545000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-152" decimals="-3" id="f-710" unitRef="usd">-36132000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-153" decimals="-3" id="f-711" unitRef="usd">-24956000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments contextRef="c-152" decimals="-3" id="f-712" unitRef="usd">0</lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments contextRef="c-153" decimals="-3" id="f-713" unitRef="usd">1266000</lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-152" decimals="-3" id="f-714" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-153" decimals="-3" id="f-715" unitRef="usd">7000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense contextRef="c-152" decimals="-3" id="f-716" unitRef="usd">554000</lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense contextRef="c-153" decimals="-3" id="f-717" unitRef="usd">-1210000</lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense contextRef="c-152" decimals="-3" id="f-718" unitRef="usd">554000</lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense contextRef="c-153" decimals="-3" id="f-719" unitRef="usd">49000</lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-152" decimals="-3" id="f-720" unitRef="usd">-35578000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-153" decimals="-3" id="f-721" unitRef="usd">-24907000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-152" decimals="-3" id="f-722" unitRef="usd">-7436000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-153" decimals="-3" id="f-723" unitRef="usd">-5692000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-152" decimals="-3" id="f-724" unitRef="usd">-28142000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-153" decimals="-3" id="f-725" unitRef="usd">-19215000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration contextRef="c-153" decimals="-3" id="f-726" unitRef="usd">-554000</lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration contextRef="c-154" decimals="-3" id="f-727" unitRef="usd">1210000</lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations contextRef="c-153" decimals="-3" id="f-728" unitRef="usd">13218000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations contextRef="c-154" decimals="-3" id="f-729" unitRef="usd">14553000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense contextRef="c-153" decimals="-3" id="f-730" unitRef="usd">9404000</lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense contextRef="c-154" decimals="-3" id="f-731" unitRef="usd">9457000</lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-153" decimals="-3" id="f-732" unitRef="usd">0</lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-154" decimals="-3" id="f-733" unitRef="usd">0</lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c-153" decimals="-3" id="f-734" unitRef="usd">5572000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c-154" decimals="-3" id="f-735" unitRef="usd">4070000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <lgnd:PaymentsToContingentValueRightHoldersInvestingActivity contextRef="c-153" decimals="-3" id="f-736" unitRef="usd">960000</lgnd:PaymentsToContingentValueRightHoldersInvestingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersInvestingActivity contextRef="c-154" decimals="-3" id="f-737" unitRef="usd">720000</lgnd:PaymentsToContingentValueRightHoldersInvestingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-153" decimals="-3" id="f-738" unitRef="usd">1545000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-154" decimals="-3" id="f-739" unitRef="usd">1050000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid contextRef="c-153" decimals="-3" id="f-740" unitRef="usd">2310000</lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid contextRef="c-154" decimals="-3" id="f-741" unitRef="usd">1231000</lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid>
    <lgnd:CommercialLicenseAndOtherEconomicRightsTextBlock contextRef="c-1" id="f-742">Commercial License and Other Economic Rights&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Elutia and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ovid &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tolerance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Amounts represent accumulated amortization to principal of $11.2 million, credit loss adjustments of $8.1 million, and impairment of $0.9 million as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license and other economic rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis, S.A. (Selexis) in April 2013 and April 2015, CorMatrix Cardiovascular, Inc. (CorMatrix) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. ("Elutia") in September 2023) in 2017, Dianomi Therapeutics, Inc. in January 2019, Ovid Therapeutics Inc. in October 2023, Tolerance Therapeutics, Inc. in November 2023, and Palvella Therapeutics, Inc. in December 2023. Commercial license and other economic rights acquired are accounted for as financial assets as further discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For commercial license rights, we have elected a prospective approach to account for changes in estimated cash flows and selected a method for determining when an impairment would be recognized and how to measure that impairment. In circumstances where our new estimate of expected cash flows is greater than previously expected, we will update our yield prospectively. In circumstances where our new estimate of expected cash flows is less than previously expected and below our original estimated yield we record an impairment. Impairment is recognized by reducing the financial asset to an amount that represents the present value of our most recent estimate of expected cash flows discounted by the original effective interest rate.&#160;In circumstances where our new estimate of expected cash flows is less than previously expected, but not below our original estimated yield, we update our yield prospectively. We recorded a $0.9 million impairment loss for Selexis commercial license rights during the year ended December&#160;31, 2023 as a result of recently reduced programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a royalty agreement with Elutia Inc. pursuant to which we will receive royalties from certain marketed products that Elutia acquired from CorMatrix. Pursuant to the agreement, we received $10.0 million in 2017 from Elutia to buydown the royalty rates on the products CorMatrix sold to Elutia. The agreement closed on May 31, 2017, in connection with the closing of the asset sale from CorMatrix to Elutia (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the agreement, we will receive a 5% royalty on the products Elutia acquired in the CorMatrix Asset Sale, reduced from the original 20% royalty from CorMatrix pursuant to the previously disclosed interest purchase agreement, dated May 3, 2016 (the &#x201c;Original Interest Purchase &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement&#x201d;) between CorMatrix and us. In addition, Elutia has agreed to pay us up to $10.0 million of additional milestones tied to cumulative net sales of the products Elutia acquired in the CorMatrix Asset Sale and to extend the term on these royalties by one year. The royalty agreement will terminate on May 31, 2027. In addition, in May 2017, we entered into an amended and restated interest purchase agreement (the &#x201c;Amended Interest Purchase Agreement&#x201d;) with CorMatrix, which supersedes in its entirety the Original Interest Purchase Agreement. Other than removing the commercial products sold to Elutia in the CorMatrix Sale, the terms of the Amended Interest Purchase Agreement remain unchanged with respect to the CorMatrix developmental pipeline products, including the royalty rate of 5% on such pipeline products. The Amended Interest Purchase Agreement will terminate 10 years from the date of the first commercial sale of such products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Elutia commercial license right as a financial asset in accordance with ASC 310. During the year ended December&#160;31, 2023, we further considered the current and expected future economic and market conditions and recorded a $3.2 million credit loss adjustment to Elutia commercial license rights based on the assessment of current company performance and nonpayment by Elutia in recent quarters. This credit loss adjustment was recorded to General and administrative expense in our consolidated statement of operations. As of December 31, 2023, management is in process of modifying the payment terms with Elutia and has placed the loan on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the Selexis commercial license right as a financial asset in accordance with ASC 310, and amortize the commercial license right using the effective interest method. The annual effective interest associated with the forecasted cash flows from the royalty agreement with Selexis as of December&#160;31, 2023 is 2.5%. Revenue is calculated by multiplying the carrying value of the commercial license right by the effective interest. The payments received in the year ended December&#160;31, 2023 and 2022 were allocated accordingly between revenue and the amortization of the commercial license rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had accounted for commercial license rights related to Dianomi on a non-accrual basis and had fully reserved the credit loss as of December&#160;31, 2022. Dianomi Therapeutics, Inc. was dissolved in July 2023; therefore, we removed the related commercial license rights as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, we made an investment of $30 million to acquire a 13% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. We performed predominant analysis and determined that the predominant characteristics of the underlyings are the sales-based milestones and royalties since the value of the projected cash flows tied to the underlyings are highly correlated with changes in the projected cash flows from royalties and commercial milestones and not the regulatory milestones. Therefore, the Ovid contract qualifies for the royalty scope exception under ASC815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and is accounted for as a financial asset in accordance with ASC 310. As soticlestat is in Phase 3 clinical trials, management has placed the investment on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, we acquired Tolerance Therapeutics, Inc. (&#x201c;Tolerance Therapeutics&#x201d;) for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of TZIELD (teplizumab), that is owed a royalty of less than 1% on worldwide net sales. TZIELD is marketed by Sanofi in 2023. We account for the Tolerance commercial license right as a financial asset in accordance with ASC 310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Due to the early stages of TZIELD's commercialization, management has placed the investment on the non-accrual method during the year ended December&#160;31, 2023 until we are able to reliably estimate future cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, we announced the expansion of its strategic partnership with Palvella to accelerate Phase 3 development of QTORIN rapamycin for the treatment of Microcystic Lymphatic Malformations ("Microcystic LMs").  According to the terms of the second amendment to the development funding and royalties agreement, Palvella received an upfront payment of $5.0 million from Ligand. In return for the upfront payment, among other contractual changes, the tiered royalty payable by Palvella to Ligand was increased to between 8.0% and 9.8% based on annual aggregate worldwide net sales of QTORIN rapamycin. We are not obligated to provide additional funding to Palvella for development or commercialization of OTORIN. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, thus we account for them in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and reduce our asset as the funds are expended by Palvella. As of December 31, 2023, of the $5.0 million upfront funding related to the second amendment with Palvella, none of the funding to Palvella was expended, and we will reduce our asset as the funds are expended by Palvella in the future. Our CEO and director, Todd Davis, is a director of Palvella, who beneficially owns less than 2% of Palvella's outstanding equity. Mr. Davis recused himself from all of the board's consideration of the agreement between us and Palvella, including any financial analysis, the terms of the amendment and the vote to approve the purchase agreement and the related transactions.&lt;/span&gt;&lt;/div&gt;</lgnd:CommercialLicenseAndOtherEconomicRightsTextBlock>
    <lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock contextRef="c-1" id="f-743">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, commercial license and other economic rights consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Elutia and CorMatrix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selexis and Dianomi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ovid &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tolerance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Palvella&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;(1) Amounts represent accumulated amortization to principal of $11.2 million, credit loss adjustments of $8.1 million, and impairment of $0.9 million as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;(2) Amounts represent accumulated amortization to principal of $11.6 million and credit loss adjustments of $6.5 million as of December&#160;31, 2022.</lgnd:ScheduleOfCommercialLicenseAndOtherEconomicRightsTableTextBlock>
    <lgnd:CommercialLicenseRightsGross contextRef="c-155" decimals="-3" id="f-744" unitRef="usd">17696000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-155" decimals="-3" id="f-745" unitRef="usd">11882000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-155" decimals="-3" id="f-746" unitRef="usd">5814000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-156" decimals="-3" id="f-747" unitRef="usd">17696000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-156" decimals="-3" id="f-748" unitRef="usd">9538000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-156" decimals="-3" id="f-749" unitRef="usd">8158000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-157" decimals="-3" id="f-750" unitRef="usd">8602000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-157" decimals="-3" id="f-751" unitRef="usd">7841000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-157" decimals="-3" id="f-752" unitRef="usd">761000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-158" decimals="-3" id="f-753" unitRef="usd">10602000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-158" decimals="-3" id="f-754" unitRef="usd">8578000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-158" decimals="-3" id="f-755" unitRef="usd">2024000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-159" decimals="-3" id="f-756" unitRef="usd">30310000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-159" decimals="-3" id="f-757" unitRef="usd">303000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-159" decimals="-3" id="f-758" unitRef="usd">30007000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-160" decimals="-3" id="f-759" unitRef="usd">0</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-160" decimals="-3" id="f-760" unitRef="usd">0</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-160" decimals="-3" id="f-761" unitRef="usd">0</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-161" decimals="-3" id="f-762" unitRef="usd">25911000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-161" decimals="-3" id="f-763" unitRef="usd">202000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-161" decimals="-3" id="f-764" unitRef="usd">25709000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-162" decimals="-3" id="f-765" unitRef="usd">0</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-162" decimals="-3" id="f-766" unitRef="usd">0</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-162" decimals="-3" id="f-767" unitRef="usd">0</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-163" decimals="-3" id="f-768" unitRef="usd">5000000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-163" decimals="-3" id="f-769" unitRef="usd">0</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-163" decimals="-3" id="f-770" unitRef="usd">5000000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-164" decimals="-3" id="f-771" unitRef="usd">0</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-164" decimals="-3" id="f-772" unitRef="usd">0</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-164" decimals="-3" id="f-773" unitRef="usd">0</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-4" decimals="-3" id="f-774" unitRef="usd">87519000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-4" decimals="-3" id="f-775" unitRef="usd">20228000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-4" decimals="-3" id="f-776" unitRef="usd">67291000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsGross contextRef="c-5" decimals="-3" id="f-777" unitRef="usd">28298000</lgnd:CommercialLicenseRightsGross>
    <lgnd:CommercialLicenseRightsCumulativeAdjustments contextRef="c-5" decimals="-3" id="f-778" unitRef="usd">18116000</lgnd:CommercialLicenseRightsCumulativeAdjustments>
    <lgnd:CommercialLicenseRights contextRef="c-5" decimals="-3" id="f-779" unitRef="usd">10182000</lgnd:CommercialLicenseRights>
    <lgnd:CommercialLicenseRightsAccumulatedAmortization contextRef="c-4" decimals="-5" id="f-780" unitRef="usd">11200000</lgnd:CommercialLicenseRightsAccumulatedAmortization>
    <lgnd:CommercialLicenseRightsCreditLossAdjustment contextRef="c-1" decimals="-5" id="f-781" unitRef="usd">8100000</lgnd:CommercialLicenseRightsCreditLossAdjustment>
    <lgnd:CommercialLicenseRightsImpairments contextRef="c-1" decimals="-5" id="f-782" unitRef="usd">900000</lgnd:CommercialLicenseRightsImpairments>
    <lgnd:CommercialLicenseRightsAccumulatedAmortization contextRef="c-5" decimals="-5" id="f-783" unitRef="usd">11600000</lgnd:CommercialLicenseRightsAccumulatedAmortization>
    <lgnd:CommercialLicenseRightsCreditLossAdjustment contextRef="c-15" decimals="-5" id="f-784" unitRef="usd">6500000</lgnd:CommercialLicenseRightsCreditLossAdjustment>
    <lgnd:ImpairmentOfCommercialLicense contextRef="c-165" decimals="-5" id="f-785" unitRef="usd">900000</lgnd:ImpairmentOfCommercialLicense>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c-166" decimals="-5" id="f-786" unitRef="usd">10000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <lgnd:ProductRoyaltyPercentage
      contextRef="c-167"
      decimals="INF"
      id="f-787"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:ProductRoyaltyPercentage
      contextRef="c-168"
      decimals="INF"
      id="f-788"
      unitRef="number">0.20</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones contextRef="c-169" decimals="INF" id="f-789" unitRef="usd">10000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:ProductRoyaltyPercentage
      contextRef="c-167"
      decimals="INF"
      id="f-790"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:RoyaltyAgreementExpirationPeriod contextRef="c-170" id="f-791">P10Y</lgnd:RoyaltyAgreementExpirationPeriod>
    <lgnd:CommercialLicenseRightsCreditLossAdjustment contextRef="c-171" decimals="-5" id="f-792" unitRef="usd">3200000</lgnd:CommercialLicenseRightsCreditLossAdjustment>
    <lgnd:ForecastedCashFlowsEffectiveInterestRatePercent contextRef="c-172" decimals="3" id="f-793" unitRef="number">0.025</lgnd:ForecastedCashFlowsEffectiveInterestRatePercent>
    <lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone contextRef="c-173" decimals="-5" id="f-794" unitRef="usd">30000000</lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-173" decimals="2" id="f-795" unitRef="number">0.13</lgnd:SalesContractInterestInSalesRevenue>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-174" decimals="-6" id="f-796" unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:ProductRoyaltyPercentage contextRef="c-175" decimals="2" id="f-797" unitRef="number">0.01</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones contextRef="c-176" decimals="INF" id="f-798" unitRef="usd">5000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-177" decimals="3" id="f-799" unitRef="number">0.080</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-178" decimals="3" id="f-800" unitRef="number">0.098</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones contextRef="c-176" decimals="INF" id="f-801" unitRef="usd">5000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:MinimumBeneficialOwnershipInReportingEntityPercentage contextRef="c-179" decimals="2" id="f-802" unitRef="number">0.02</lgnd:MinimumBeneficialOwnershipInReportingEntityPercentage>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-803">Fair Value Measurement&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs such as quoted prices in active markets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) In connection with the Purchase and Sale Agreement with Primrose Bio, we received 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;long-term asset in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The fair value of the derivative assets was determined using a discounted cash flow approach using a discount rate in line with the stages of the underlying contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of derivative assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingent payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-878"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-882"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Measured on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, indefinite-lived intangible assets and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. We determine the fair value of our indefinite-lived intangible assets using the income approach based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended December&#160;31, 2023. Other than the finance lease equipment discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (7), Leases&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended and December&#160;31, 2022. There was no impairment of our goodwill, indefinite-lived assets, or long-lived assets recorded during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued liabilities, deferred revenue, current operating lease liabilities, current financing lease liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Not Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial license rights are measured and carried on the balance sheet at amortized cost using the effective interest method or on a non-accrual basis. Management calculates the fair value of commercial license rights using a forecasted royalty receipts.  The projected future cash flows derive from royalty payments and milestones, then discounted using appropriate individual discount rates. The fair value of commercial license and other economic rights assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair value and related carrying values of commercial license rights as of December&#160;31, 2023 were $75.9&#160;million and $62.3&#160;million, respectively.  The estimated fair value and related carrying value of the commercial license rights as of December&#160;31, 2022 were $13.1&#160;million and $10.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-804">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for amounts owed to a former licensor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Excluding our investment in Viking, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we have investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and are at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) In connection with the Purchase and Sale Agreement with Primrose Bio, we received 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;long-term asset in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The fair value of the derivative assets was determined using a discounted cash flow approach using a discount rate in line with the stages of the underlying contracts.&lt;/span&gt;&lt;/div&gt;(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375.0 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10.0 million payment upon initiation of a Phase 3 clinical trial.</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-180" decimals="-3" id="f-805" unitRef="usd">115170000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-181" decimals="-3" id="f-806" unitRef="usd">7291000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-182" decimals="-3" id="f-807" unitRef="usd">107879000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-183" decimals="-3" id="f-808" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-184" decimals="-3" id="f-809" unitRef="usd">32185000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-185" decimals="-3" id="f-810" unitRef="usd">32185000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-186" decimals="-3" id="f-811" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-187" decimals="-3" id="f-812" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-813">Derivative assets(2)</lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeAssets contextRef="c-184" decimals="-3" id="f-814" unitRef="usd">3531000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-185" decimals="-3" id="f-815" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-186" decimals="-3" id="f-816" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-187" decimals="-3" id="f-817" unitRef="usd">3531000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-184" decimals="-3" id="f-818" unitRef="usd">150886000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-185" decimals="-3" id="f-819" unitRef="usd">39476000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-186" decimals="-3" id="f-820" unitRef="usd">107879000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-187" decimals="-3" id="f-821" unitRef="usd">3531000</us-gaap:AssetsFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-188" decimals="-3" id="f-822" unitRef="usd">320000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-189" decimals="-3" id="f-823" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-190" decimals="-3" id="f-824" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-191" decimals="-3" id="f-825" unitRef="usd">320000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-192" decimals="-3" id="f-826" unitRef="usd">2878000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-193" decimals="-3" id="f-827" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-194" decimals="-3" id="f-828" unitRef="usd">2878000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-195" decimals="-3" id="f-829" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-184" decimals="-3" id="f-830" unitRef="usd">3198000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-185" decimals="-3" id="f-831" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-186" decimals="-3" id="f-832" unitRef="usd">2878000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-187" decimals="-3" id="f-833" unitRef="usd">320000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-196" decimals="-3" id="f-834" unitRef="usd">103742000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-197" decimals="-3" id="f-835" unitRef="usd">3992000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-198" decimals="-3" id="f-836" unitRef="usd">99615000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-199" decimals="-3" id="f-837" unitRef="usd">135000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-200" decimals="-3" id="f-838" unitRef="usd">63122000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-201" decimals="-3" id="f-839" unitRef="usd">63122000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-202" decimals="-3" id="f-840" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-203" decimals="-3" id="f-841" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-200" decimals="-3" id="f-842" unitRef="usd">166864000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-201" decimals="-3" id="f-843" unitRef="usd">67114000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-202" decimals="-3" id="f-844" unitRef="usd">99615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-203" decimals="-3" id="f-845" unitRef="usd">135000</us-gaap:AssetsFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-204" decimals="-3" id="f-846" unitRef="usd">84000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-205" decimals="-3" id="f-847" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-206" decimals="-3" id="f-848" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-207" decimals="-3" id="f-849" unitRef="usd">84000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-208" decimals="-3" id="f-850" unitRef="usd">3429000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-209" decimals="-3" id="f-851" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-210" decimals="-3" id="f-852" unitRef="usd">3429000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-211" decimals="-3" id="f-853" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:AmountsOwedToFormerLicensorFairValueDisclosure contextRef="c-200" decimals="-3" id="f-854" unitRef="usd">44000</lgnd:AmountsOwedToFormerLicensorFairValueDisclosure>
    <lgnd:AmountsOwedToFormerLicensorFairValueDisclosure contextRef="c-201" decimals="-3" id="f-855" unitRef="usd">44000</lgnd:AmountsOwedToFormerLicensorFairValueDisclosure>
    <lgnd:AmountsOwedToFormerLicensorFairValueDisclosure contextRef="c-202" decimals="-3" id="f-856" unitRef="usd">0</lgnd:AmountsOwedToFormerLicensorFairValueDisclosure>
    <lgnd:AmountsOwedToFormerLicensorFairValueDisclosure contextRef="c-203" decimals="-3" id="f-857" unitRef="usd">0</lgnd:AmountsOwedToFormerLicensorFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-200" decimals="-3" id="f-858" unitRef="usd">3557000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-201" decimals="-3" id="f-859" unitRef="usd">44000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-202" decimals="-3" id="f-860" unitRef="usd">3429000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-212" decimals="-3" id="f-861" unitRef="usd">84000</us-gaap:LiabilitiesFairValueDisclosure>
    <lgnd:InterestInPotentialDevelopmentMilestone contextRef="c-130" decimals="2" id="f-862" unitRef="number">0.50</lgnd:InterestInPotentialDevelopmentMilestone>
    <lgnd:NumberOfContracts
      contextRef="c-131"
      decimals="INF"
      id="f-863"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare contextRef="c-213" decimals="INF" id="f-864" unitRef="cvr">4</lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare>
    <lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries contextRef="c-213" decimals="INF" id="f-865" unitRef="cvr">1</lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries>
    <lgnd:NumberOfContingentValueRightsSeries contextRef="c-214" decimals="INF" id="f-866" unitRef="cvr">4</lgnd:NumberOfContingentValueRightsSeries>
    <lgnd:BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders contextRef="c-213" id="f-867">P6M</lgnd:BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders>
    <us-gaap:Investments contextRef="c-215" decimals="INF" id="f-868" unitRef="usd">375000000</us-gaap:Investments>
    <us-gaap:ContractWithCustomerAssetGross contextRef="c-216" decimals="-5" id="f-869" unitRef="usd">10000000</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-871">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of derivative assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingent payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-878"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-882"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-870">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of derivative assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingent payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-878"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-882"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-5" decimals="-3" id="f-872" unitRef="usd">135000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-1" decimals="-3" id="f-873" unitRef="usd">-135000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-1" decimals="-3" id="f-874" unitRef="usd">3531000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-4" decimals="-3" id="f-875" unitRef="usd">3531000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-876" unitRef="usd">84000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-1" decimals="-3" id="f-877" unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-879" unitRef="usd">286000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-4" decimals="-3" id="f-880" unitRef="usd">320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-30" decimals="-3" id="f-881" unitRef="usd">409000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-15" decimals="-3" id="f-883" unitRef="usd">-274000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-5" decimals="-3" id="f-884" unitRef="usd">135000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-30" decimals="-3" id="f-885" unitRef="usd">349000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-15" decimals="-3" id="f-886" unitRef="usd">-265000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-887" unitRef="usd">84000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-888" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="INF" id="f-889" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-15" decimals="INF" id="f-890" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-15" decimals="INF" id="f-891" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-16" decimals="INF" id="f-892" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-16" decimals="INF" id="f-893" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <lgnd:CommercialLicenseRightsFairValueDisclosure contextRef="c-217" decimals="-5" id="f-894" unitRef="usd">75900000</lgnd:CommercialLicenseRightsFairValueDisclosure>
    <lgnd:CommercialLicenseRightsFairValueDisclosure contextRef="c-218" decimals="-5" id="f-895" unitRef="usd">62300000</lgnd:CommercialLicenseRightsFairValueDisclosure>
    <lgnd:CommercialLicenseRightsFairValueDisclosure contextRef="c-219" decimals="-5" id="f-896" unitRef="usd">13100000</lgnd:CommercialLicenseRightsFairValueDisclosure>
    <lgnd:CommercialLicenseRightsFairValueDisclosure contextRef="c-220" decimals="-5" id="f-897" unitRef="usd">10200000</lgnd:CommercialLicenseRightsFairValueDisclosure>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-899">Leases&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the current COVID status, our forecast for COVID-related Captisol has been significantly reduced, which triggered an indicator of impairment of the right of use asset as of December&#160;31, 2022. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December&#160;31, 2022. As of December&#160;31, 2022 the remaining right of use asset balance is $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. In the year-ended December&#160;31, 2023, we recorded no impairment to this asset group as there have been no indicators of impairment, and as of December&#160;31, 2023, the remaining right of use asset balance is $3.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to nine years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-926"&gt;&lt;span style="-sec-ix-hidden:f-927"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our operating leases have a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. As of December&#160;31, 2022, our operating leases have a weighted-average remaining lease term of 9.3 years and a weighted-average discount rate of 7.1%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.4 million and $1.7 million for the years ended December&#160;31, 2023 and 2022, respectively. Operating lease expense was $1.4 million (net of sublease income of $0.3 million) and $0.7 million (net of sublease income of $0.7 million) for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our finance leases have a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. As of December&#160;31, 2022, our finance leases have a weighted-average remaining lease term of 1.1 years and a weighted-average discount rate of 4.1%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December&#160;31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities were both $0.05&#160;million for the years ended December&#160;31, 2023 and 2022. Finance lease expense was $0.7 million and $2.3 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-898">Leases&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December&#160;31, 2021, we have fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the current COVID status, our forecast for COVID-related Captisol has been significantly reduced, which triggered an indicator of impairment of the right of use asset as of December&#160;31, 2022. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December&#160;31, 2022. As of December&#160;31, 2022 the remaining right of use asset balance is $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. In the year-ended December&#160;31, 2023, we recorded no impairment to this asset group as there have been no indicators of impairment, and as of December&#160;31, 2023, the remaining right of use asset balance is $3.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to nine years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-926"&gt;&lt;span style="-sec-ix-hidden:f-927"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our operating leases have a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. As of December&#160;31, 2022, our operating leases have a weighted-average remaining lease term of 9.3 years and a weighted-average discount rate of 7.1%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.4 million and $1.7 million for the years ended December&#160;31, 2023 and 2022, respectively. Operating lease expense was $1.4 million (net of sublease income of $0.3 million) and $0.7 million (net of sublease income of $0.7 million) for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our finance leases have a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. As of December&#160;31, 2022, our finance leases have a weighted-average remaining lease term of 1.1 years and a weighted-average discount rate of 4.1%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December&#160;31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities were both $0.05&#160;million for the years ended December&#160;31, 2023 and 2022. Finance lease expense was $0.7 million and $2.3 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <lgnd:PurchaseCommitmentConsiderationPaidToDate contextRef="c-221" decimals="-5" id="f-900" unitRef="usd">69100000</lgnd:PurchaseCommitmentConsiderationPaidToDate>
    <lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory contextRef="c-221" decimals="-5" id="f-901" unitRef="usd">50200000</lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-11" decimals="-5" id="f-902" unitRef="usd">18900000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:FinanceLeaseImpairmentLoss contextRef="c-10" decimals="-5" id="f-903" unitRef="usd">9800000</us-gaap:FinanceLeaseImpairmentLoss>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-72" decimals="-5" id="f-904" unitRef="usd">4000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm contextRef="c-72" id="f-905">P6Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-71" decimals="-5" id="f-906" unitRef="usd">3400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-74" id="f-907">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-74" id="f-908">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification contextRef="c-1" decimals="-5" id="f-909" unitRef="usd">1100000</lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-910" unitRef="usd">1100000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <lgnd:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-911">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating and Finance Lease Assets and Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-926"&gt;&lt;span style="-sec-ix-hidden:f-927"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-912" unitRef="usd">6062000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-913" unitRef="usd">10914000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-914" unitRef="usd">3393000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-915" unitRef="usd">4095000</us-gaap:FinanceLeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-916" unitRef="usd">9455000</lgnd:LeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-917" unitRef="usd">15009000</lgnd:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-918" unitRef="usd">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-919" unitRef="usd">670000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-920" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-921" unitRef="usd">45000</us-gaap:FinanceLeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-922" unitRef="usd">410000</lgnd:LeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-923" unitRef="usd">715000</lgnd:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-924" unitRef="usd">5755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-925" unitRef="usd">10336000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-928" unitRef="usd">19000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-929" unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <lgnd:LeaseLiability contextRef="c-4" decimals="-3" id="f-930" unitRef="usd">6184000</lgnd:LeaseLiability>
    <lgnd:LeaseLiability contextRef="c-5" decimals="-3" id="f-931" unitRef="usd">11056000</lgnd:LeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-933">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-932">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity of Operating and Finance Lease Liabilities as of December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-934" unitRef="usd">1046000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-935" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-936" unitRef="usd">1193000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-937" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-938" unitRef="usd">1226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-939" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-940" unitRef="usd">1260000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-941" unitRef="usd">6000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-942" unitRef="usd">1178000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-943" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-944" unitRef="usd">2912000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-945" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-946" unitRef="usd">8815000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-947" unitRef="usd">31000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <lgnd:OperatingLeaseLiabilityTenantImprovementAllowance contextRef="c-4" decimals="-3" id="f-948" unitRef="usd">419000</lgnd:OperatingLeaseLiabilityTenantImprovementAllowance>
    <lgnd:FinanceLeaseLiabilityTenantImprovementAllowance contextRef="c-4" decimals="-3" id="f-949" unitRef="usd">0</lgnd:FinanceLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-950" unitRef="usd">2238000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-951" unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-952" unitRef="usd">6158000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-3" id="f-953" unitRef="usd">26000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-954">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-955" unitRef="number">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-956">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-957" unitRef="number">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-958" unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-15" decimals="-5" id="f-959" unitRef="usd">1700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-960" unitRef="usd">1400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-5" id="f-961" unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseExpense contextRef="c-15" decimals="-5" id="f-962" unitRef="usd">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome contextRef="c-15" decimals="-5" id="f-963" unitRef="usd">700000</us-gaap:SubleaseIncome>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-964">P3Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-965" unitRef="number">0.068</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-966">P1Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-967" unitRef="number">0.041</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-4" id="f-968" unitRef="usd">50000.00</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-5" id="f-969" unitRef="usd">700000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-15" decimals="-5" id="f-970" unitRef="usd">2300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-971">Debt&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.75% Convertible Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees and is being amortized to interest expense using the effective interest method over the five years expected life of the 2023 Notes. The effective interest rate for the year ended December&#160;31, 2023 is 0.5%. During the year ended December&#160;31, 2023 we recognized a total of $0.6 million in interest expense which includes $0.4 million in contractual interest expense and $0.2 million in amortized issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we repurchased $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million. We accounted for the repurchase as a debt extinguishment, which resulted in (1) a loss of $7.3&#160;million reflected in other income (expense), net, in our consolidated statement of operations for the year ended December&#160;31, 2021, (2) a $13.7&#160;million reduction in debt discount, and (3) a $10.2&#160;million reduction to additional paid in capital, related to the reacquisition of the equity component in our consolidated balance sheet as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, we repurchased $266.4 million in principal amount of the 2023 Notes for $261.4 million in cash, including accrued interest of $0.5 million We accounted for the repurchase as a debt extinguishment, which resulted in a gain of $4.2 million reflected in other income (expense), net, in our consolidated statement of operations for the year ended December&#160;31, 2022, and a $1.3 million reduction in debt discount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $206.65 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants did not have any rights with respect to the convertible bond hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, in connection with the repurchases of approximately $20.3&#160;million in principal of the 2023 Notes for approximately $19.1&#160;million in cash, including accrued interest of $0.1&#160;million, during the quarter ended December 31, 2020, we entered into amendments with Barclays Bank PLC, Deutsche Bank AG, London Branch, and Goldman Sachs &amp;amp; Co. LLC to the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. The amendments provide that the options under the convertible note hedges corresponding to such repurchased 2023 Notes will remain outstanding notwithstanding such repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, in connection with the repurchases of $152.0&#160;million in principal of the 2023 Notes for $156.0&#160;million in cash, including accrued interest of $0.3&#160;million, we entered into Warrant Early Unwind Agreements and Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp;amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. We paid $18.4&#160;million as part of the Warrant Early Unwind Agreements reducing the number of shares covered by the warrants from 3,018,327 to 2,559,254.  As of December 31, 2023, the number of warrants that remain outstanding is 545,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, in connection with the repurchases of $227.8&#160;million in principal of the 2023 Notes for $223.7&#160;million in cash, including accrued interest of $0.4&#160;million made during the six months ended June 30, 2022, we entered into Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp;amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the 2023 Notes (in thousands) as of December&#160;31, 2022.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 12, 2023, we entered into a $75.0 million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (as defined in the Credit Agreement) entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make loans and other financial accommodations to us in an aggregate amount of up to $75.0 million. At our option, borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term Secured Overnight Financing Rate ("Term SOFR") or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from 1.75% to 2.50% per annum for Term SOFR loans and 0.75% to 1.50% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from 0.30% to 0.45%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had $74.5&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.5&#160;million for letter of credit. The maturity date of the Revolving Credit Facility is October 12, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there were no events of default or violation of any covenants under our financing obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-222"
      decimals="INF"
      id="f-972"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-222" decimals="INF" id="f-973" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-222"
      decimals="INF"
      id="f-974"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-223" decimals="-5" id="f-975" unitRef="usd">733100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-222" decimals="-5" id="f-976" unitRef="usd">16900000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm contextRef="c-223" id="f-977">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-224" decimals="4" id="f-978" unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt contextRef="c-225" decimals="-5" id="f-979" unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-225" decimals="-5" id="f-980" unitRef="usd">400000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-225" decimals="-5" id="f-981" unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-226" decimals="-5" id="f-982" unitRef="usd">152000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-227" decimals="-5" id="f-983" unitRef="usd">156000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-227" decimals="-5" id="f-984" unitRef="usd">300000</us-gaap:InterestPaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-227" decimals="-5" id="f-985" unitRef="usd">-7300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:IncreaseDecreaseInDebtDiscount contextRef="c-227" decimals="-5" id="f-986" unitRef="usd">-13700000</lgnd:IncreaseDecreaseInDebtDiscount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="c-227" decimals="-5" id="f-987" unitRef="usd">-10200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-228" decimals="-5" id="f-988" unitRef="usd">266400000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-229" decimals="-5" id="f-989" unitRef="usd">261400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-229" decimals="-5" id="f-990" unitRef="usd">500000</us-gaap:InterestPaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-229" decimals="-5" id="f-991" unitRef="usd">4200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:IncreaseDecreaseInDebtDiscount contextRef="c-229" decimals="-5" id="f-992" unitRef="usd">-1300000</lgnd:IncreaseDecreaseInDebtDiscount>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-230" decimals="-5" id="f-993" unitRef="usd">76900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:InterestPaid contextRef="c-230" decimals="-5" id="f-994" unitRef="usd">300000</us-gaap:InterestPaid>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-222"
      decimals="INF"
      id="f-995"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-222"
      decimals="2"
      id="f-996"
      unitRef="usdPerShare">206.65</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <lgnd:PaymentsforConvertibleBondHedges contextRef="c-223" decimals="-5" id="f-997" unitRef="usd">140300000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-222"
      decimals="INF"
      id="f-998"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-222"
      decimals="2"
      id="f-999"
      unitRef="usdPerShare">315.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-223" decimals="-5" id="f-1000" unitRef="usd">90000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-231" decimals="-5" id="f-1001" unitRef="usd">20300000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-232" decimals="-5" id="f-1002" unitRef="usd">19100000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-232" decimals="-5" id="f-1003" unitRef="usd">100000</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-226" decimals="-5" id="f-1004" unitRef="usd">152000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-227" decimals="-5" id="f-1005" unitRef="usd">156000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-227" decimals="-5" id="f-1006" unitRef="usd">300000</us-gaap:InterestPaid>
    <lgnd:PaymentsToUnwindWarrants contextRef="c-16" decimals="-5" id="f-1007" unitRef="usd">18400000</lgnd:PaymentsToUnwindWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-222"
      decimals="INF"
      id="f-1008"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-226"
      decimals="INF"
      id="f-1009"
      unitRef="shares">2559254</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-224"
      decimals="INF"
      id="f-1010"
      unitRef="shares">545000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <lgnd:DebtInstrumentRepurchasedAmountDuringPeriod contextRef="c-233" decimals="-5" id="f-1011" unitRef="usd">227800000</lgnd:DebtInstrumentRepurchasedAmountDuringPeriod>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-233" decimals="-5" id="f-1012" unitRef="usd">223700000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-234" decimals="-5" id="f-1013" unitRef="usd">400000</us-gaap:InterestPaid>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-1014">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the 2023 Notes (in thousands) as of December&#160;31, 2022.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal amount of 2023 Notes outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized discount (including unamortized debt issuance cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of convertible senior notes outstanding (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-228" decimals="-3" id="f-1015" unitRef="usd">76854000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-228" decimals="-3" id="f-1016" unitRef="usd">159000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable contextRef="c-228" decimals="-3" id="f-1017" unitRef="usd">76695000</us-gaap:LongTermNotesPayable>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-228" decimals="-3" id="f-1018" unitRef="usd">74789000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-235" decimals="INF" id="f-1019" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-235" decimals="INF" id="f-1020" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-236"
      decimals="INF"
      id="f-1021"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-237"
      decimals="INF"
      id="f-1022"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-238"
      decimals="INF"
      id="f-1023"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-239"
      decimals="INF"
      id="f-1024"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-240"
      decimals="INF"
      id="f-1025"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-241"
      decimals="INF"
      id="f-1026"
      unitRef="number">0.0045</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-242" decimals="-5" id="f-1027" unitRef="usd">74500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-242" decimals="-5" id="f-1028" unitRef="usd">500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-1029">Balance Sheet Account Details&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bond Fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bond fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 31 positions which were in an unrealized loss position with a total of $0.01 million unrealized losses as of December&#160;31, 2023. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. We do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of the amortized cost basis. Accordingly, no credit losses were recognized for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments: Investment in Viking:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ownership in Viking was approximately 1.7% as of December&#160;31, 2023, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and December&#160;31, 2022, our investment in Viking is $32.2 million and $63.1 million, respectively, and included in short-term investments on the balance sheet. During the year ended December&#160;31, 2023, we sold 5.0 million shares of Viking common stock and recognized a realized gain of $44.4 million. During the year ended December&#160;31, 2021, we sold 0.6 million shares of Viking common stock and recognized a realized gain of $3.6 million. There were no sales of Viking common stock during the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from &lt;span style="-sec-ix-hidden:f-1191"&gt;one&lt;/span&gt; to nine years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $2.9 million, $3.8 million, and $2.4 million was recognized for the years ended December&#160;31, 2023, 2022, and 2021, respectively, and was included in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $33.7 million, $34.2 million, and $34.2 million was recognized for the years ended December&#160;31, 2023, 2022, and 2021, respectively. Estimated amortization expense for the years ending December&#160;31, 2024 through 2028 is $32.8 million per year. For each of the years ended December&#160;31, 2023, 2022, and 2021, there was no material impairment of intangible assets with finite lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer deposit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other long-term liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Novan contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-1030">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bond Fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bond fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-243" decimals="-3" id="f-1031" unitRef="usd">63763000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-243" decimals="-3" id="f-1032" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-243" decimals="-3" id="f-1033" unitRef="usd">537000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-243" decimals="-3" id="f-1034" unitRef="usd">63226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-244" decimals="-3" id="f-1035" unitRef="usd">17165000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-244" decimals="-3" id="f-1036" unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-244" decimals="-3" id="f-1037" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-244" decimals="-3" id="f-1038" unitRef="usd">17176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-245" decimals="-3" id="f-1039" unitRef="usd">14850000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-245" decimals="-3" id="f-1040" unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-245" decimals="-3" id="f-1041" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-245" decimals="-3" id="f-1042" unitRef="usd">14888000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-246" decimals="-3" id="f-1043" unitRef="usd">11578000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-246" decimals="-3" id="f-1044" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-246" decimals="-3" id="f-1045" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-246" decimals="-3" id="f-1046" unitRef="usd">11586000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-247" decimals="-3" id="f-1047" unitRef="usd">6736000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-247" decimals="-3" id="f-1048" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-247" decimals="-3" id="f-1049" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-247" decimals="-3" id="f-1050" unitRef="usd">6751000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-248" decimals="-3" id="f-1051" unitRef="usd">1007000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-248" decimals="-3" id="f-1052" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-248" decimals="-3" id="f-1053" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-248" decimals="-3" id="f-1054" unitRef="usd">1003000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-249" decimals="-3" id="f-1055" unitRef="usd">5775000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-249" decimals="-3" id="f-1056" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-249" decimals="-3" id="f-1057" unitRef="usd">5235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-249" decimals="-3" id="f-1058" unitRef="usd">540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-1059" unitRef="usd">120874000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-1060" unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-1061" unitRef="usd">5783000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-1062" unitRef="usd">115170000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-250" decimals="-3" id="f-1063" unitRef="usd">81815000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-250" decimals="-3" id="f-1064" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-250" decimals="-3" id="f-1065" unitRef="usd">1050000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-250" decimals="-3" id="f-1066" unitRef="usd">80765000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-251" decimals="-3" id="f-1067" unitRef="usd">7211000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-251" decimals="-3" id="f-1068" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-251" decimals="-3" id="f-1069" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-251" decimals="-3" id="f-1070" unitRef="usd">7214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-252" decimals="-3" id="f-1071" unitRef="usd">6701000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-252" decimals="-3" id="f-1072" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-252" decimals="-3" id="f-1073" unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-252" decimals="-3" id="f-1074" unitRef="usd">6656000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-253" decimals="-3" id="f-1075" unitRef="usd">5012000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-253" decimals="-3" id="f-1076" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-253" decimals="-3" id="f-1077" unitRef="usd">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-253" decimals="-3" id="f-1078" unitRef="usd">4980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-254" decimals="-3" id="f-1079" unitRef="usd">2232000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-254" decimals="-3" id="f-1080" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-254" decimals="-3" id="f-1081" unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-254" decimals="-3" id="f-1082" unitRef="usd">2162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-255" decimals="-3" id="f-1083" unitRef="usd">5807000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-255" decimals="-3" id="f-1084" unitRef="usd">262000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-255" decimals="-3" id="f-1085" unitRef="usd">4239000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-255" decimals="-3" id="f-1086" unitRef="usd">1830000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-256" decimals="-3" id="f-1087" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-256" decimals="-3" id="f-1088" unitRef="usd">135000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-256" decimals="-3" id="f-1089" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-256" decimals="-3" id="f-1090" unitRef="usd">135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-1091" unitRef="usd">108778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-1092" unitRef="usd">415000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-1093" unitRef="usd">5451000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-1094" unitRef="usd">103742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-1095">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-4" decimals="-3" id="f-1096" unitRef="usd">55361000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-3" id="f-1097" unitRef="usd">55380000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-4" decimals="-3" id="f-1098" unitRef="usd">13478000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="-3" id="f-1099" unitRef="usd">13524000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-1100" unitRef="usd">68839000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-4" decimals="-3" id="f-1101" unitRef="usd">68904000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-1102">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Government Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-244" decimals="-3" id="f-1103" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-244" decimals="-3" id="f-1104" unitRef="usd">4175000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-244" decimals="-3" id="f-1105" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-244" decimals="-3" id="f-1106" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-244" decimals="-3" id="f-1107" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-244" decimals="-3" id="f-1108" unitRef="usd">4175000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-245" decimals="-3" id="f-1109" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-245" decimals="-3" id="f-1110" unitRef="usd">1410000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-245" decimals="-3" id="f-1111" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-245" decimals="-3" id="f-1112" unitRef="usd">1447000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-245" decimals="-3" id="f-1113" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-245" decimals="-3" id="f-1114" unitRef="usd">2857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-246" decimals="-3" id="f-1115" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-246" decimals="-3" id="f-1116" unitRef="usd">10222000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-246" decimals="-3" id="f-1117" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-246" decimals="-3" id="f-1118" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-246" decimals="-3" id="f-1119" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-246" decimals="-3" id="f-1120" unitRef="usd">10222000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-248" decimals="-3" id="f-1121" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-248" decimals="-3" id="f-1122" unitRef="usd">1004000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-248" decimals="-3" id="f-1123" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-248" decimals="-3" id="f-1124" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-248" decimals="-3" id="f-1125" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-248" decimals="-3" id="f-1126" unitRef="usd">1004000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-247" decimals="-3" id="f-1127" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-247" decimals="-3" id="f-1128" unitRef="usd">998000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-247" decimals="-3" id="f-1129" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-247" decimals="-3" id="f-1130" unitRef="usd">1502000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-247" decimals="-3" id="f-1131" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-247" decimals="-3" id="f-1132" unitRef="usd">2500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-3" id="f-1133" unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-3" id="f-1134" unitRef="usd">17809000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-3" id="f-1135" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-3" id="f-1136" unitRef="usd">2949000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-3" id="f-1137" unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-3" id="f-1138" unitRef="usd">20758000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-253" decimals="-3" id="f-1139" unitRef="usd">34000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-253" decimals="-3" id="f-1140" unitRef="usd">2470000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-253" decimals="-3" id="f-1141" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-253" decimals="-3" id="f-1142" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-253" decimals="-3" id="f-1143" unitRef="usd">34000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-253" decimals="-3" id="f-1144" unitRef="usd">2470000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-252" decimals="-3" id="f-1145" unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-252" decimals="-3" id="f-1146" unitRef="usd">3887000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-252" decimals="-3" id="f-1147" unitRef="usd">37000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-252" decimals="-3" id="f-1148" unitRef="usd">947000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-252" decimals="-3" id="f-1149" unitRef="usd">58000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-252" decimals="-3" id="f-1150" unitRef="usd">4834000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-251" decimals="-3" id="f-1151" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-251" decimals="-3" id="f-1152" unitRef="usd">3836000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-251" decimals="-3" id="f-1153" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-251" decimals="-3" id="f-1154" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-251" decimals="-3" id="f-1155" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-251" decimals="-3" id="f-1156" unitRef="usd">3836000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-254" decimals="-3" id="f-1157" unitRef="usd">70000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-254" decimals="-3" id="f-1158" unitRef="usd">2161000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-254" decimals="-3" id="f-1159" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-254" decimals="-3" id="f-1160" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-254" decimals="-3" id="f-1161" unitRef="usd">70000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-254" decimals="-3" id="f-1162" unitRef="usd">2161000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-5" decimals="-3" id="f-1163" unitRef="usd">125000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-5" decimals="-3" id="f-1164" unitRef="usd">12354000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-5" decimals="-3" id="f-1165" unitRef="usd">37000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-5" decimals="-3" id="f-1166" unitRef="usd">947000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-5" decimals="-3" id="f-1167" unitRef="usd">162000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-5" decimals="-3" id="f-1168" unitRef="usd">13301000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-4"
      decimals="INF"
      id="f-1169"
      unitRef="position">31</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-4" id="f-1170" unitRef="usd">10000.00</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="c-257"
      decimals="3"
      id="f-1171"
      unitRef="number">0.017</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-4" decimals="-5" id="f-1172" unitRef="usd">32200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-5" decimals="-5" id="f-1173" unitRef="usd">63100000</us-gaap:EquitySecuritiesFvNi>
    <lgnd:NumberOfSharesSoldOfEquityMethodInvestee
      contextRef="c-257"
      decimals="-5"
      id="f-1174"
      unitRef="shares">5000000</lgnd:NumberOfSharesSoldOfEquityMethodInvestee>
    <us-gaap:GainLossOnInvestments contextRef="c-257" decimals="-5" id="f-1175" unitRef="usd">44400000</us-gaap:GainLossOnInvestments>
    <lgnd:NumberOfSharesSoldOfEquityMethodInvestee
      contextRef="c-258"
      decimals="-5"
      id="f-1176"
      unitRef="shares">600000</lgnd:NumberOfSharesSoldOfEquityMethodInvestee>
    <us-gaap:GainLossOnInvestments contextRef="c-258" decimals="-5" id="f-1177" unitRef="usd">3600000</us-gaap:GainLossOnInvestments>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-1178">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment are stated at cost and consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-259" decimals="-3" id="f-1179" unitRef="usd">9264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-260" decimals="-3" id="f-1180" unitRef="usd">14172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-261" decimals="-3" id="f-1181" unitRef="usd">12282000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-262" decimals="-3" id="f-1182" unitRef="usd">7446000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-263" decimals="-3" id="f-1183" unitRef="usd">716000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-264" decimals="-3" id="f-1184" unitRef="usd">989000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-1185" unitRef="usd">22262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-1186" unitRef="usd">22607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-1187" unitRef="usd">6655000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1188" unitRef="usd">10125000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-1189" unitRef="usd">15607000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-1190" unitRef="usd">12482000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-74" id="f-1192">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1193" unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-1194" unitRef="usd">3800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-1195" unitRef="usd">2400000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-1196">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-1197" unitRef="usd">103370000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-1198" unitRef="usd">105673000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-265" decimals="-3" id="f-1199" unitRef="usd">42911000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-266" decimals="-3" id="f-1200" unitRef="usd">55211000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-265" decimals="-3" id="f-1201" unitRef="usd">20894000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-266" decimals="-3" id="f-1202" unitRef="usd">22560000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-267" decimals="-3" id="f-1203" unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-268" decimals="-3" id="f-1204" unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-267" decimals="-3" id="f-1205" unitRef="usd">1710000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-268" decimals="-3" id="f-1206" unitRef="usd">1577000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-269" decimals="-3" id="f-1207" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-270" decimals="-3" id="f-1208" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-269" decimals="-3" id="f-1209" unitRef="usd">19161000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-270" decimals="-3" id="f-1210" unitRef="usd">17670000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-271" decimals="-3" id="f-1211" unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-272" decimals="-3" id="f-1212" unitRef="usd">362000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-271" decimals="-3" id="f-1213" unitRef="usd">93782000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-272" decimals="-3" id="f-1214" unitRef="usd">65191000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-4" decimals="-3" id="f-1215" unitRef="usd">402976000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-5" decimals="-3" id="f-1216" unitRef="usd">448128000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-4" id="f-1217">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-5" id="f-1218" unitRef="usd">33700000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-15" decimals="-5" id="f-1219" unitRef="usd">34200000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-16" decimals="-5" id="f-1220" unitRef="usd">34200000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-5" id="f-1221" unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-5" id="f-1222" unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-5" id="f-1223" unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-5" id="f-1224" unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-5" id="f-1225" unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-15" decimals="INF" id="f-1226" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-16" decimals="INF" id="f-1227" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-1228" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1229">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer deposit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-1230" unitRef="usd">4682000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1231" unitRef="usd">6201000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-1232" unitRef="usd">2394000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-1233" unitRef="usd">662000</us-gaap:AccruedProfessionalFeesCurrent>
    <lgnd:AccruedCustomerDepositsCurrent contextRef="c-4" decimals="-3" id="f-1234" unitRef="usd">621000</lgnd:AccruedCustomerDepositsCurrent>
    <lgnd:AccruedCustomerDepositsCurrent contextRef="c-5" decimals="-3" id="f-1235" unitRef="usd">621000</lgnd:AccruedCustomerDepositsCurrent>
    <lgnd:LicenseeAccrualCurrent contextRef="c-4" decimals="-3" id="f-1236" unitRef="usd">45000</lgnd:LicenseeAccrualCurrent>
    <lgnd:LicenseeAccrualCurrent contextRef="c-5" decimals="-3" id="f-1237" unitRef="usd">3989000</lgnd:LicenseeAccrualCurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-1238" unitRef="usd">900000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-1239" unitRef="usd">12000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent contextRef="c-4" decimals="-3" id="f-1240" unitRef="usd">1756000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent contextRef="c-5" decimals="-3" id="f-1241" unitRef="usd">1756000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent contextRef="c-4" decimals="-3" id="f-1242" unitRef="usd">303000</lgnd:AccruedSupplierExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent contextRef="c-5" decimals="-3" id="f-1243" unitRef="usd">634000</lgnd:AccruedSupplierExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-1244" unitRef="usd">1766000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1245" unitRef="usd">1806000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-1246" unitRef="usd">12467000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1247" unitRef="usd">15681000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-1248">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other long-term liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Novan contract liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <lgnd:UnrecognizedTaxBenefitsNoncurrent contextRef="c-4" decimals="-3" id="f-1249" unitRef="usd">14039000</lgnd:UnrecognizedTaxBenefitsNoncurrent>
    <lgnd:UnrecognizedTaxBenefitsNoncurrent contextRef="c-5" decimals="-3" id="f-1250" unitRef="usd">21421000</lgnd:UnrecognizedTaxBenefitsNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-1251" unitRef="usd">13700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1252" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <lgnd:OtherMiscellaneousNonCurrentLiabilities contextRef="c-4" decimals="-3" id="f-1253" unitRef="usd">19000</lgnd:OtherMiscellaneousNonCurrentLiabilities>
    <lgnd:OtherMiscellaneousNonCurrentLiabilities contextRef="c-5" decimals="-3" id="f-1254" unitRef="usd">501000</lgnd:OtherMiscellaneousNonCurrentLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-1255" unitRef="usd">27758000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-1256" unitRef="usd">21922000</us-gaap:OtherLiabilitiesNoncurrent>
    <lgnd:NumberOfContingentValueRightAgreements
      contextRef="c-273"
      decimals="INF"
      id="f-1257"
      unitRef="agreement">4</lgnd:NumberOfContingentValueRightAgreements>
    <lgnd:ScheduleofContingentLiabilitiesTableTextBlock contextRef="c-1" id="f-1258">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofContingentLiabilitiesTableTextBlock>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-274" decimals="-3" id="f-1259" unitRef="usd">349000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-275" decimals="-3" id="f-1260" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-275" decimals="-3" id="f-1261" unitRef="usd">-265000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-276" decimals="-3" id="f-1262" unitRef="usd">84000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-277" decimals="-3" id="f-1263" unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-277" decimals="-3" id="f-1264" unitRef="usd">286000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities contextRef="c-277" decimals="-3" id="f-1265" unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-278" decimals="-3" id="f-1266" unitRef="usd">320000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-279" decimals="-3" id="f-1267" unitRef="usd">3358000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-280" decimals="-3" id="f-1268" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-280" decimals="-3" id="f-1269" unitRef="usd">71000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-281" decimals="-3" id="f-1270" unitRef="usd">3429000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-282" decimals="-3" id="f-1271" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-282" decimals="-3" id="f-1272" unitRef="usd">-551000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities contextRef="c-282" decimals="-3" id="f-1273" unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-283" decimals="-3" id="f-1274" unitRef="usd">2878000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-30" decimals="-3" id="f-1275" unitRef="usd">3707000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-15" decimals="-3" id="f-1276" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-15" decimals="-3" id="f-1277" unitRef="usd">-194000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-5" decimals="-3" id="f-1278" unitRef="usd">3513000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-1" decimals="-3" id="f-1279" unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-1" decimals="-3" id="f-1280" unitRef="usd">-265000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities contextRef="c-1" decimals="-3" id="f-1281" unitRef="usd">0</lgnd:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepurchasesContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-4" decimals="-3" id="f-1282" unitRef="usd">3198000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1283">Stockholders&#x2019; Equity&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense from continuing operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion and Modification of Equity Awards Outstanding at Separation Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the Merger Agreement to preserve the intrinsic value of the awards immediately before and after the Distribution. Upon the Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-Distribution Ligand stock received a number of otherwise-similar awards either in post-Distribution Ligand stock or in a combination of post-Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the Merger Agreement that we entered into in connection with the Distribution. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the Separation; for OmniAb employees, the number of awards that were outstanding at the Separation were proportionately adjusted into post-Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#x201c;regular way&#x201d; and &#x201c;ex-distribution&#x201d; markets during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;five-trading day period prior to the closing of the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the &#x201c;2002 Plan&#x201d;). The amended and restated 2002 Plan, which is referred to herein as the &#x201c;Restated Plan&#x201d; was amended to increase the shares available for issuance by 1.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2022, our board of directors (the &#x201c;Board&#x201d;) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the &#x201c;2022 Inducement Plan&#x201d;). The terms of the 2022 Inducement Plan are substantially similar to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved 300,000 shares of the Company&#x2019;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there were 1.0 million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;393,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(619,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;863,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of October 31, 2022, before Separation and Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cancellation due to Separation, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,987,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at November 1, 2022, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,584,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(542,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,559,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(489,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(399,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,784,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Options granted primarily relate to the modifications in connection with the Separation which resulted in new stock option grants at the modification date fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all stock options granted during 2023, 2022 and 2021 was $36.65, $28.90, and $80.08 per share, respectively. The total intrinsic value of all options exercised during 2023, 2022 and 2021 was approximately $12.0 million, $4.6 million, and $77.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from options exercised, net of fees paid, in 2023, 2022 and 2021 was $22.2 million, $2.6 million and $33.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$32.78-$49.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.36-$52.30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$52.84-$52.84&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$54.81-$58.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$58.49-$66.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$66.70-$68.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$69.39-$75.09&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;484,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$78.56-$99.80&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$103.42-$103.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$114.15-$114.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,784,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7%-4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49%-55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7 to 5.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0 to 6.5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7 to 6.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $26.2 million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $1.1 million of total unrecognized compensation cost related to non-vested OmniAb stock options received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of 0.9 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at October 31, 2022, before Separation and Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited due to Separation, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(366,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at November 1, 2022, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(181,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $15.2&#160;million. That cost is expected to be recognized over a weighted average period of 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $0.1&#160;million of total unrecognized compensation cost related to non-vested OmniAb stock awards received upon aforementioned spin-off conversion. That cost is expected to be recognized over a weighted average period of 0.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, 30,801 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a &lt;span style="-sec-ix-hidden:f-1520"&gt;six&lt;/span&gt; month offering period or purchase date, whichever is lower. There were 5,080, 8,479 and 8,448 shares issued under the ESPP in 2023, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, our Board of Directors has approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $50.0 million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. During the years ended December&#160;31, 2023, 2022 and 2021, we did not repurchase any common stock, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the Market Equity Offering Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, we filed a registration statement on Form S-3 (the &#x201c;Shelf Registration Statement&#x201d;), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Stifel, Nicolaus &amp;amp; Company, Incorporated (the &#x201c;Agent&#x201d;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100.0&#160;million in &#x201c;at the market&#x201d; offerings through the Agent (the &#x201c;ATM Offering&#x201d;). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $100.0&#160;million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. To date, we have not issued any shares of common stock in the ATM Offering.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-1284">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense from continuing operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-284" decimals="-3" id="f-1285" unitRef="usd">6248000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-285" decimals="-3" id="f-1286" unitRef="usd">10970000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-286" decimals="-3" id="f-1287" unitRef="usd">9341000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-287" decimals="-3" id="f-1288" unitRef="usd">19495000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-288" decimals="-3" id="f-1289" unitRef="usd">39911000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-289" decimals="-3" id="f-1290" unitRef="usd">19985000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-3" id="f-1291" unitRef="usd">25743000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-15" decimals="-3" id="f-1292" unitRef="usd">50881000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-16" decimals="-3" id="f-1293" unitRef="usd">29326000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-290"
      decimals="-5"
      id="f-1294"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-291"
      decimals="INF"
      id="f-1295"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-292"
      decimals="-5"
      id="f-1296"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1297">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,561,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;393,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(619,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;863,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of October 31, 2022, before Separation and Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cancellation due to Separation, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,987,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at November 1, 2022, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,584,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(542,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,559,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(489,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(399,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,784,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Options granted primarily relate to the modifications in connection with the Separation which resulted in new stock option grants at the modification date fair value.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-21"
      decimals="INF"
      id="f-1298"
      unitRef="shares">2561822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-21"
      decimals="2"
      id="f-1299"
      unitRef="usdPerShare">85.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-293" id="f-1300">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-21" decimals="-3" id="f-1301" unitRef="usd">59033000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-16"
      decimals="INF"
      id="f-1302"
      unitRef="shares">393589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-16"
      decimals="2"
      id="f-1303"
      unitRef="usdPerShare">159.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-16"
      decimals="INF"
      id="f-1304"
      unitRef="shares">619731</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-16"
      decimals="2"
      id="f-1305"
      unitRef="usdPerShare">54.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-16"
      decimals="INF"
      id="f-1306"
      unitRef="shares">136082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-16"
      decimals="2"
      id="f-1307"
      unitRef="usdPerShare">110.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-30"
      decimals="INF"
      id="f-1308"
      unitRef="shares">2199598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-30"
      decimals="2"
      id="f-1309"
      unitRef="usdPerShare">106.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-16" id="f-1310">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-30" decimals="-3" id="f-1311" unitRef="usd">113302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-30"
      decimals="INF"
      id="f-1312"
      unitRef="shares">1391952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-30"
      decimals="2"
      id="f-1313"
      unitRef="usdPerShare">98.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-16" id="f-1314">P5Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-30" decimals="-3" id="f-1315" unitRef="usd">80849000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-30"
      decimals="INF"
      id="f-1316"
      unitRef="shares">2199598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-30"
      decimals="2"
      id="f-1317"
      unitRef="usdPerShare">106.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-16" id="f-1318">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-30" decimals="-3" id="f-1319" unitRef="usd">113302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-294"
      decimals="INF"
      id="f-1320"
      unitRef="shares">863245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1321"
      unitRef="usdPerShare">91.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-294"
      decimals="INF"
      id="f-1322"
      unitRef="shares">34941</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1323"
      unitRef="usdPerShare">38.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-294"
      decimals="INF"
      id="f-1324"
      unitRef="shares">40069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1325"
      unitRef="usdPerShare">78.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-295"
      decimals="INF"
      id="f-1326"
      unitRef="shares">2987833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-295"
      decimals="2"
      id="f-1327"
      unitRef="usdPerShare">102.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-294" id="f-1328">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-295" decimals="-3" id="f-1329" unitRef="usd">14835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-295"
      decimals="INF"
      id="f-1330"
      unitRef="shares">1769629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-295"
      decimals="2"
      id="f-1331"
      unitRef="usdPerShare">102.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-294" id="f-1332">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-295" decimals="-3" id="f-1333" unitRef="usd">13722000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-295"
      decimals="INF"
      id="f-1334"
      unitRef="shares">2987833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-295"
      decimals="2"
      id="f-1335"
      unitRef="usdPerShare">102.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-294" id="f-1336">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-295" decimals="-3" id="f-1337" unitRef="usd">14835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-296"
      decimals="INF"
      id="f-1338"
      unitRef="shares">2987833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-297"
      decimals="INF"
      id="f-1339"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-298"
      decimals="INF"
      id="f-1340"
      unitRef="shares">3584760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-298"
      decimals="2"
      id="f-1341"
      unitRef="usdPerShare">60.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-298"
      decimals="INF"
      id="f-1342"
      unitRef="shares">50449</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-298"
      decimals="2"
      id="f-1343"
      unitRef="usdPerShare">30.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-298"
      decimals="INF"
      id="f-1344"
      unitRef="shares">542838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-298"
      decimals="2"
      id="f-1345"
      unitRef="usdPerShare">56.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1346"
      unitRef="shares">2991473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1347"
      unitRef="usdPerShare">61.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-298" id="f-1348">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-1349" unitRef="usd">30477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1350"
      unitRef="shares">1559662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1351"
      unitRef="usdPerShare">60.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-298" id="f-1352">P4Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-1353" unitRef="usd">17951000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1354"
      unitRef="shares">2991473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1355"
      unitRef="usdPerShare">61.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-298" id="f-1356">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-1357" unitRef="usd">30477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-1"
      decimals="INF"
      id="f-1358"
      unitRef="shares">537432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1359"
      unitRef="usdPerShare">72.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-1"
      decimals="INF"
      id="f-1360"
      unitRef="shares">489076</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1361"
      unitRef="usdPerShare">45.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-1"
      decimals="INF"
      id="f-1362"
      unitRef="shares">399371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1363"
      unitRef="usdPerShare">66.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-4"
      decimals="INF"
      id="f-1364"
      unitRef="shares">2640458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1365"
      unitRef="usdPerShare">65.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1366">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-1367" unitRef="usd">8784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-4"
      decimals="INF"
      id="f-1368"
      unitRef="shares">1784209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1369"
      unitRef="usdPerShare">64.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1370">P4Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-1371" unitRef="usd">7300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-4"
      decimals="INF"
      id="f-1372"
      unitRef="shares">2640458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1373"
      unitRef="usdPerShare">65.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1374">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-1375" unitRef="usd">8784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-299"
      decimals="2"
      id="f-1376"
      unitRef="usdPerShare">36.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-300"
      decimals="2"
      id="f-1377"
      unitRef="usdPerShare">28.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-301"
      decimals="2"
      id="f-1378"
      unitRef="usdPerShare">80.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-299" decimals="-5" id="f-1379" unitRef="usd">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-300" decimals="-5" id="f-1380" unitRef="usd">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-301" decimals="-5" id="f-1381" unitRef="usd">77300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-299" decimals="-5" id="f-1382" unitRef="usd">22200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-300" decimals="-5" id="f-1383" unitRef="usd">2600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-301" decimals="-5" id="f-1384" unitRef="usd">33000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-1385">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&#160; life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$32.78-$49.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.36-$52.30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$52.84-$52.84&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$54.81-$58.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$58.49-$66.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$66.70-$68.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$69.39-$75.09&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;484,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$78.56-$99.80&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$103.42-$103.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$114.15-$114.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,784,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-302"
      decimals="2"
      id="f-1386"
      unitRef="usdPerShare">32.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-302"
      decimals="2"
      id="f-1387"
      unitRef="usdPerShare">49.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-303"
      decimals="INF"
      id="f-1388"
      unitRef="shares">301757</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-302" id="f-1389">P3Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-303"
      decimals="2"
      id="f-1390"
      unitRef="usdPerShare">42.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-303"
      decimals="INF"
      id="f-1391"
      unitRef="shares">290880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-303"
      decimals="2"
      id="f-1392"
      unitRef="usdPerShare">42.35</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-304"
      decimals="2"
      id="f-1393"
      unitRef="usdPerShare">50.36</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-304"
      decimals="2"
      id="f-1394"
      unitRef="usdPerShare">52.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-305"
      decimals="INF"
      id="f-1395"
      unitRef="shares">99385</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-304" id="f-1396">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-305"
      decimals="2"
      id="f-1397"
      unitRef="usdPerShare">52.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-305"
      decimals="INF"
      id="f-1398"
      unitRef="shares">42782</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-305"
      decimals="2"
      id="f-1399"
      unitRef="usdPerShare">52.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-306"
      decimals="2"
      id="f-1400"
      unitRef="usdPerShare">52.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-306"
      decimals="2"
      id="f-1401"
      unitRef="usdPerShare">52.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-307"
      decimals="INF"
      id="f-1402"
      unitRef="shares">357661</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-306" id="f-1403">P5Y1M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-307"
      decimals="2"
      id="f-1404"
      unitRef="usdPerShare">52.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-307"
      decimals="INF"
      id="f-1405"
      unitRef="shares">221056</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-307"
      decimals="2"
      id="f-1406"
      unitRef="usdPerShare">52.84</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-308"
      decimals="2"
      id="f-1407"
      unitRef="usdPerShare">54.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-308"
      decimals="2"
      id="f-1408"
      unitRef="usdPerShare">58.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-309"
      decimals="INF"
      id="f-1409"
      unitRef="shares">270544</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-308" id="f-1410">P5Y21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-309"
      decimals="2"
      id="f-1411"
      unitRef="usdPerShare">55.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-309"
      decimals="INF"
      id="f-1412"
      unitRef="shares">244342</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-309"
      decimals="2"
      id="f-1413"
      unitRef="usdPerShare">55.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-310"
      decimals="2"
      id="f-1414"
      unitRef="usdPerShare">58.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-310"
      decimals="2"
      id="f-1415"
      unitRef="usdPerShare">66.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-311"
      decimals="INF"
      id="f-1416"
      unitRef="shares">283007</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-310" id="f-1417">P5Y10M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-311"
      decimals="2"
      id="f-1418"
      unitRef="usdPerShare">62.27</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-311"
      decimals="INF"
      id="f-1419"
      unitRef="shares">160772</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-311"
      decimals="2"
      id="f-1420"
      unitRef="usdPerShare">61.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-312"
      decimals="2"
      id="f-1421"
      unitRef="usdPerShare">66.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-312"
      decimals="2"
      id="f-1422"
      unitRef="usdPerShare">68.74</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-313"
      decimals="INF"
      id="f-1423"
      unitRef="shares">450234</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-312" id="f-1424">P4Y9M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-313"
      decimals="2"
      id="f-1425"
      unitRef="usdPerShare">67.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-313"
      decimals="INF"
      id="f-1426"
      unitRef="shares">380713</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-313"
      decimals="2"
      id="f-1427"
      unitRef="usdPerShare">68.03</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-314"
      decimals="2"
      id="f-1428"
      unitRef="usdPerShare">69.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-314"
      decimals="2"
      id="f-1429"
      unitRef="usdPerShare">75.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-315"
      decimals="INF"
      id="f-1430"
      unitRef="shares">484258</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-314" id="f-1431">P8Y6M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-315"
      decimals="2"
      id="f-1432"
      unitRef="usdPerShare">72.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-315"
      decimals="INF"
      id="f-1433"
      unitRef="shares">109410</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-315"
      decimals="2"
      id="f-1434"
      unitRef="usdPerShare">72.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-316"
      decimals="2"
      id="f-1435"
      unitRef="usdPerShare">78.56</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-316"
      decimals="2"
      id="f-1436"
      unitRef="usdPerShare">99.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-317"
      decimals="INF"
      id="f-1437"
      unitRef="shares">209945</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-316" id="f-1438">P4Y1M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-317"
      decimals="2"
      id="f-1439"
      unitRef="usdPerShare">89.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-317"
      decimals="INF"
      id="f-1440"
      unitRef="shares">192904</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-317"
      decimals="2"
      id="f-1441"
      unitRef="usdPerShare">90.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-318"
      decimals="2"
      id="f-1442"
      unitRef="usdPerShare">103.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-318"
      decimals="2"
      id="f-1443"
      unitRef="usdPerShare">103.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-319"
      decimals="INF"
      id="f-1444"
      unitRef="shares">170701</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-318" id="f-1445">P6Y25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-319"
      decimals="2"
      id="f-1446"
      unitRef="usdPerShare">103.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-319"
      decimals="INF"
      id="f-1447"
      unitRef="shares">128384</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-319"
      decimals="2"
      id="f-1448"
      unitRef="usdPerShare">103.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-320"
      decimals="2"
      id="f-1449"
      unitRef="usdPerShare">114.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-320"
      decimals="2"
      id="f-1450"
      unitRef="usdPerShare">114.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-321"
      decimals="INF"
      id="f-1451"
      unitRef="shares">12966</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-320" id="f-1452">P4Y1M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-321"
      decimals="2"
      id="f-1453"
      unitRef="usdPerShare">114.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-321"
      decimals="INF"
      id="f-1454"
      unitRef="shares">12966</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-321"
      decimals="2"
      id="f-1455"
      unitRef="usdPerShare">114.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-4"
      decimals="INF"
      id="f-1456"
      unitRef="shares">2640458</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1457">P5Y7M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-4"
      decimals="2"
      id="f-1458"
      unitRef="usdPerShare">65.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-4"
      decimals="INF"
      id="f-1459"
      unitRef="shares">1784209</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-4"
      decimals="2"
      id="f-1460"
      unitRef="usdPerShare">64.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1461">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7%-4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45%-54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49%-55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-63%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7 to 5.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0 to 6.5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7 to 6.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-322"
      decimals="3"
      id="f-1462"
      unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-323"
      decimals="3"
      id="f-1463"
      unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-324"
      decimals="3"
      id="f-1464"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-325"
      decimals="3"
      id="f-1465"
      unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-326"
      decimals="3"
      id="f-1466"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-327"
      decimals="3"
      id="f-1467"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-322"
      decimals="2"
      id="f-1468"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-323"
      decimals="2"
      id="f-1469"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-324"
      decimals="2"
      id="f-1470"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-325"
      decimals="2"
      id="f-1471"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-326"
      decimals="2"
      id="f-1472"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-327"
      decimals="2"
      id="f-1473"
      unitRef="number">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-322" id="f-1474">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-323" id="f-1475">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-324" id="f-1476">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-325" id="f-1477">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-326" id="f-1478">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-327" id="f-1479">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-292" decimals="-5" id="f-1480" unitRef="usd">26200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-117" id="f-1481">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-328" decimals="-5" id="f-1482" unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-329" id="f-1483">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-1484">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at October 31, 2022, before Separation and Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited due to Separation, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(366,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at November 1, 2022, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(181,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-330"
      decimals="INF"
      id="f-1485"
      unitRef="shares">264143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-330"
      decimals="2"
      id="f-1486"
      unitRef="usdPerShare">138.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-331"
      decimals="INF"
      id="f-1487"
      unitRef="shares">260577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-331"
      decimals="2"
      id="f-1488"
      unitRef="usdPerShare">89.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-331"
      decimals="INF"
      id="f-1489"
      unitRef="shares">138867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-331"
      decimals="2"
      id="f-1490"
      unitRef="usdPerShare">120.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-331"
      decimals="INF"
      id="f-1491"
      unitRef="shares">19383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-331"
      decimals="2"
      id="f-1492"
      unitRef="usdPerShare">58.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-332"
      decimals="INF"
      id="f-1493"
      unitRef="shares">366470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-332"
      decimals="2"
      id="f-1494"
      unitRef="usdPerShare">114.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-333"
      decimals="INF"
      id="f-1495"
      unitRef="shares">366470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-334"
      decimals="INF"
      id="f-1496"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-335"
      decimals="INF"
      id="f-1497"
      unitRef="shares">424473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-335"
      decimals="2"
      id="f-1498"
      unitRef="usdPerShare">75.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-335"
      decimals="INF"
      id="f-1499"
      unitRef="shares">73385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-335"
      decimals="2"
      id="f-1500"
      unitRef="usdPerShare">75.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-335"
      decimals="INF"
      id="f-1501"
      unitRef="shares">2635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-335"
      decimals="2"
      id="f-1502"
      unitRef="usdPerShare">89.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-336"
      decimals="INF"
      id="f-1503"
      unitRef="shares">348453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-336"
      decimals="2"
      id="f-1504"
      unitRef="usdPerShare">75.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-337"
      decimals="INF"
      id="f-1505"
      unitRef="shares">203752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-337"
      decimals="2"
      id="f-1506"
      unitRef="usdPerShare">83.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-337"
      decimals="INF"
      id="f-1507"
      unitRef="shares">181246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-337"
      decimals="2"
      id="f-1508"
      unitRef="usdPerShare">74.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-337"
      decimals="INF"
      id="f-1509"
      unitRef="shares">20054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-337"
      decimals="2"
      id="f-1510"
      unitRef="usdPerShare">65.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-338"
      decimals="INF"
      id="f-1511"
      unitRef="shares">350905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-338"
      decimals="2"
      id="f-1512"
      unitRef="usdPerShare">81.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-339" decimals="-5" id="f-1513" unitRef="usd">15200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-340" id="f-1514">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-341" decimals="-5" id="f-1515" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-342" id="f-1516">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-343"
      decimals="INF"
      id="f-1517"
      unitRef="shares">30801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-344"
      decimals="INF"
      id="f-1518"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-344"
      decimals="INF"
      id="f-1519"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-344"
      decimals="INF"
      id="f-1521"
      unitRef="shares">5080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-345"
      decimals="INF"
      id="f-1522"
      unitRef="shares">8479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-346"
      decimals="INF"
      id="f-1523"
      unitRef="shares">8448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-347" decimals="INF" id="f-1524" unitRef="usd">50000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="INF" id="f-1525" unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-15" decimals="INF" id="f-1526" unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <lgnd:SaleOfStockAuthorizedOfferingAmount contextRef="c-348" decimals="-5" id="f-1527" unitRef="usd">100000000</lgnd:SaleOfStockAuthorizedOfferingAmount>
    <lgnd:SaleOfStockAuthorizedOfferingAmount contextRef="c-348" decimals="-5" id="f-1528" unitRef="usd">100000000</lgnd:SaleOfStockAuthorizedOfferingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1529">Commitment and Contingencies: Legal Proceedings&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#x201c;JPML&#x201d;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#x201c;MDL&#x201d;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-349"
      decimals="INF"
      id="f-1530"
      unitRef="complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-349"
      decimals="INF"
      id="f-1531"
      unitRef="complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1532">Income Taxes&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.686%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.941%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal, foreign or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subpart F income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2023, 2022 and 2021. The valuation allowance amount in connection with the deferred taxes decreased $1.2&#160;million in 2023, increased $24.8 million in 2022 and increased $11.2 million in 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(liabilities) are comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, we had federal net operating loss carryforwards set to expire through 2037 of $48.0 million and $165.1 million of state net operating loss carryforwards that begin to expire in 2028. We also have $8.5 million of federal research and development credit carryforwards, which expire through 2040. We have $29.4 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $95.5 million of non-U.S. net operating loss carryovers and approximately $16.5 million of non-U.S. capital loss carryovers that have no expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, we had federal net operating loss carryforwards set to expire through 2037 of $81.1 million and $168.3 million of state net operating loss carryforwards that begin to expire in 2028. We also had $8.5 million of federal research and development credit carryforwards, which expire through 2040. We had $29.0 million of California research and development credit carryforwards that have no expiration date. In addition, we had approximately $96.1 million of non-U.S. net operating loss carryovers and approximately $15.6 million of non-U.S. capital loss carryovers that have no expiration date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2023 are net of any previous limitations due to Section 382 and 383.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2023, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2023 is $20.6 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2023 and December&#160;31, 2022, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, and United Kingdom with varying statutes of limitations. The federal statute of limitation remains open for the 2020 tax year to the present.&#160;The state income tax returns generally remain open for the 2019 tax year through the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.  The Company's 2019 and 2020 California tax returns are under examination by the California Franchise Tax Board. The Company does not anticipate that the examination will result in a material adjustment to its financial statements.  No other income tax returns are currently under examination. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1533">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.686%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1534" unitRef="usd">-1186000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1535" unitRef="usd">10097000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1536" unitRef="usd">460000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1537" unitRef="usd">218000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1538" unitRef="usd">193000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1539" unitRef="usd">-22000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1540" unitRef="usd">780000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1541" unitRef="usd">452000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1542" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1543" unitRef="usd">-188000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1544" unitRef="usd">10742000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1545" unitRef="usd">438000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1546" unitRef="usd">9374000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1547" unitRef="usd">-3656000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1548" unitRef="usd">-2901000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1549" unitRef="usd">655000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1550" unitRef="usd">34144000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1551" unitRef="usd">-1685000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1552" unitRef="usd">10029000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1553" unitRef="usd">30488000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1554" unitRef="usd">-4586000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1555" unitRef="usd">9841000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1556" unitRef="usd">41230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1557" unitRef="usd">-4148000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1558">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.941%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal, foreign or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subpart F income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1559" unitRef="usd">13448000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-15" decimals="-3" id="f-1560" unitRef="usd">7562000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-16" decimals="-3" id="f-1561" unitRef="usd">15163000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1562" unitRef="usd">397000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="-3" id="f-1563" unitRef="usd">264000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-16" decimals="-3" id="f-1564" unitRef="usd">-82000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-1" decimals="-3" id="f-1565" unitRef="usd">1037000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-15" decimals="-3" id="f-1566" unitRef="usd">2395000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-16" decimals="-3" id="f-1567" unitRef="usd">637000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-1568" unitRef="usd">342000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-15" decimals="-3" id="f-1569" unitRef="usd">-535000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-16" decimals="-3" id="f-1570" unitRef="usd">-7963000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-1" decimals="-3" id="f-1571" unitRef="usd">7206000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-15" decimals="-3" id="f-1572" unitRef="usd">158000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-16" decimals="-3" id="f-1573" unitRef="usd">-480000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:IncomeTaxReconciliationContingentValueRights contextRef="c-1" decimals="-3" id="f-1574" unitRef="usd">-116000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights contextRef="c-15" decimals="-3" id="f-1575" unitRef="usd">15000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights contextRef="c-16" decimals="-3" id="f-1576" unitRef="usd">-7993000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-1577" unitRef="usd">-38000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-15" decimals="-3" id="f-1578" unitRef="usd">103000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-16" decimals="-3" id="f-1579" unitRef="usd">-114000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-1580" unitRef="usd">-405000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch contextRef="c-15" decimals="-3" id="f-1581" unitRef="usd">256000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch contextRef="c-16" decimals="-3" id="f-1582" unitRef="usd">-1628000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount contextRef="c-1" decimals="-3" id="f-1583" unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount contextRef="c-15" decimals="-3" id="f-1584" unitRef="usd">626000</lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount contextRef="c-16" decimals="-3" id="f-1585" unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome contextRef="c-1" decimals="-3" id="f-1586" unitRef="usd">479000</lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome>
    <lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome contextRef="c-15" decimals="-3" id="f-1587" unitRef="usd">853000</lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome>
    <lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome contextRef="c-16" decimals="-3" id="f-1588" unitRef="usd">1392000</lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1589" unitRef="usd">1241000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-15" decimals="-3" id="f-1590" unitRef="usd">1279000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-16" decimals="-3" id="f-1591" unitRef="usd">-12080000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount contextRef="c-1" decimals="-3" id="f-1592" unitRef="usd">-2200000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount contextRef="c-15" decimals="-3" id="f-1593" unitRef="usd">-2232000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount contextRef="c-16" decimals="-3" id="f-1594" unitRef="usd">1347000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount contextRef="c-1" decimals="-3" id="f-1595" unitRef="usd">844000</lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount contextRef="c-15" decimals="-3" id="f-1596" unitRef="usd">5869000</lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount contextRef="c-16" decimals="-3" id="f-1597" unitRef="usd">3239000</lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-1598" unitRef="usd">-1184000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-15" decimals="-3" id="f-1599" unitRef="usd">24799000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-16" decimals="-3" id="f-1600" unitRef="usd">11245000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-1601" unitRef="usd">876000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-15" decimals="-3" id="f-1602" unitRef="usd">460000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-16" decimals="-3" id="f-1603" unitRef="usd">-3823000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1604" unitRef="usd">9841000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1605" unitRef="usd">41230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1606" unitRef="usd">-4148000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-1607" unitRef="usd">1200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-15" decimals="-5" id="f-1608" unitRef="usd">24800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-16" decimals="-5" id="f-1609" unitRef="usd">11200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1610">Deferred tax assets &lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(liabilities) are comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(75,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-1611" unitRef="usd">45702000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-1612" unitRef="usd">53960000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-1613" unitRef="usd">26611000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-1614" unitRef="usd">26309000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-1615" unitRef="usd">4550000</lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-1616" unitRef="usd">4693000</lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-1617" unitRef="usd">11886000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-1618" unitRef="usd">11158000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-1619" unitRef="usd">15012000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-1620" unitRef="usd">14849000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-1621" unitRef="usd">103761000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1622" unitRef="usd">110969000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-1623" unitRef="usd">57699000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1624" unitRef="usd">57472000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-1625" unitRef="usd">46062000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1626" unitRef="usd">53497000</us-gaap:DeferredTaxAssetsNet>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets contextRef="c-4" decimals="-3" id="f-1627" unitRef="usd">66966000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets contextRef="c-5" decimals="-3" id="f-1628" unitRef="usd">64696000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-3" id="f-1629" unitRef="usd">10504000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-3" id="f-1630" unitRef="usd">10886000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-1631" unitRef="usd">77470000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-1632" unitRef="usd">75582000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-1633" unitRef="usd">31408000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-1634" unitRef="usd">22085000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-350" decimals="-5" id="f-1635" unitRef="usd">48000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-351" decimals="-5" id="f-1636" unitRef="usd">165100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-352" decimals="-5" id="f-1637" unitRef="usd">8500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-353" decimals="-5" id="f-1638" unitRef="usd">29400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-354" decimals="-5" id="f-1639" unitRef="usd">95500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-355" decimals="-5" id="f-1640" unitRef="usd">16500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-356" decimals="-5" id="f-1641" unitRef="usd">81100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-357" decimals="-5" id="f-1642" unitRef="usd">168300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-358" decimals="-5" id="f-1643" unitRef="usd">8500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-359" decimals="-5" id="f-1644" unitRef="usd">29000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-360" decimals="-5" id="f-1645" unitRef="usd">96100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-361" decimals="-5" id="f-1646" unitRef="usd">15600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock contextRef="c-1" id="f-1647">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2023, 2022 and 2021 is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-1648" unitRef="usd">29096000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-30" decimals="-3" id="f-1649" unitRef="usd">29550000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-21" decimals="-3" id="f-1650" unitRef="usd">31619000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1651" unitRef="usd">47000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-15" decimals="-3" id="f-1652" unitRef="usd">58000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-16" decimals="-3" id="f-1653" unitRef="usd">252000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1654" unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-15" decimals="-3" id="f-1655" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-16" decimals="-3" id="f-1656" unitRef="usd">751000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1657" unitRef="usd">6783000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-15" decimals="-3" id="f-1658" unitRef="usd">512000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-16" decimals="-3" id="f-1659" unitRef="usd">3072000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-1660" unitRef="usd">22363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-1661" unitRef="usd">29096000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-30" decimals="-3" id="f-1662" unitRef="usd">29550000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-4" decimals="-5" id="f-1663" unitRef="usd">20600000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-362" id="f-1664">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-362" id="f-1665">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-362" id="f-1666">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-362" id="f-1667">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
